<SEC-DOCUMENT>0000950170-22-003292.txt : 20220310
<SEC-HEADER>0000950170-22-003292.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310073338
ACCESSION NUMBER:		0000950170-22-003292
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001563577
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461454898
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39114
		FILM NUMBER:		22727412

	BUSINESS ADDRESS:	
		STREET 1:		2 WEST LIBERTY BLVD #100
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		610-725-1500

	MAIL ADDRESS:	
		STREET 1:		2 WEST LIBERTY BLVD #100
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>grtx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-09T14:02:47.6763+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:grtx="http://www.galeratx.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_c795c78f-8be7-43ca-9734-bcb7657f60da" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_fee3e958-b0d8-4163-ada6-e3c148fc641f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_02e529b0-9177-4d0a-8d45-26a8684d2f9c" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_82ec9d38-55d6-49a7-9b4c-1f328cfde640" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_2650ce90-b6ea-4ce6-a377-81d00bcbaa95" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonNumeric id="F_93963c3e-bc42-4daa-b8ec-a0c05063cb3d" name="dei:EntityCentralIndexKey" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9">0001563577</ix:nonNumeric><ix:nonNumeric id="F_6609fc12-0319-49c0-95cd-2a3e1d272227" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_02423d12-894b-44ac-a7a0-9a6e1fd4800c" format="ixt-sec:durwordsen">three years</ix:nonNumeric><ix:nonFraction id="F_39ac49a9-a08d-470b-9d8e-441479f7cc65" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_66dcf313-c339-4433-a31f-7b050bd059e0" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_4b016ec7-c9de-4004-9397-7645b2c3a792" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_70b71d11-f6c2-4c62-8626-bd6d1fd6cb30" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_ac483134-1335-48d8-8e13-9abac8dd12bf" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_688f27b3-4933-4708-aa8f-2bbc99b732be" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5722ee67-25cb-4023-b75d-50b07da9f90a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_40b56f53-5ecf-4153-8f63-fdba1f4dd223" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_cccfab26-cd38-4711-a8ad-904460dbbf06" name="dei:CurrentFiscalYearEndDate" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9">--12-31</ix:nonNumeric><ix:nonFraction id="F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_6225d527-e4ef-4f35-a66b-7bda00076a37" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_e9728d70-5cb0-41f9-97d9-56322b96a0a9" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonNumeric id="F_7b746d64-60bb-4bcd-b1e3-d69984c4454f" name="dei:DocumentFiscalPeriodFocus" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9">FY</ix:nonNumeric><ix:nonFraction id="F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_e0b87fd6-cc11-47a8-ac63-63b4dcfcc465" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c89274bf-8d90-49f0-888d-378fdc6d56bc" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_b00efb57-83ef-4313-8979-7bdb93bd618a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f1fec276-850c-48f5-82e0-7c1f144c9d23" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_bf370159-17d8-430c-bf51-32824e192bad" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_71db6aad-ca49-4c24-a01f-b7baac31ab94" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0de6ffc2-2137-46dc-ae46-12e3c0e17006" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonNumeric id="F_fdfad8e8-00e1-4249-a04e-ba654390c002" name="dei:AmendmentFlag" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9">false</ix:nonNumeric><ix:nonFraction id="F_90fe34be-68f6-4f3e-996c-414d28713b22" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_15ffa14d-8ab6-4a7a-87e0-32c2877a3d2e" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_b5ca7b31-6e3b-4277-a915-633d3b089c9c" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="C_3df4a5dc-c1ad-4043-a5a8-530371ef0c5c" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="grtx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91adba5e-65f4-4e18-bcd7-f7c48f289acd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b00efb57-83ef-4313-8979-7bdb93bd618a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15ffa14d-8ab6-4a7a-87e0-32c2877a3d2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0de6ffc2-2137-46dc-ae46-12e3c0e17006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efe17399-273f-425a-8f72-453a258c293e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6225d527-e4ef-4f35-a66b-7bda00076a37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bf5e8de-1ddb-476f-8d38-35c1b5ab97dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:NewMilestoneWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d891bfc-c9b7-4664-aa86-cb70d7dca47d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_593a8fd2-e876-4c36-8f67-ec70818d7144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99780757-769e-45eb-9aeb-da23f499cad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ef0432b-dbc1-49fa-b25a-eee0df54a3d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grtx:LaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_283a587d-af22-4372-b32e-6522c523cb6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a550fef5-0f03-494a-a55a-4b38cad970c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cdbba6c-4c21-4368-9002-fbaec59111a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c71d8cd3-e5bd-471e-b060-cec87aa74c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8002ece0-6266-462e-8ed6-a5bfe859d9a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">grtx:IntellectMapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5e004bf-3018-4d7e-9906-d7992b1097fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FifthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2b24743-77df-4859-afed-60ec1f89419a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a54c939-736d-4e51-b6f0-2b61907375c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba6ef8ac-9f4f-4b23-bbad-8188c1047172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36d53670-b4ec-458a-b3e8-080466455ca0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b49a26cc-28b3-4484-a6c0-28d5227aaace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10927f54-f772-42ac-8e0e-6713aa190f61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_747599dd-834b-4762-88a4-e8ce71446162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb9a312e-caf8-4908-aa1d-2b259e84c87a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_161a7224-4479-4a28-b4d5-77a29763ab5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6796aa74-9221-4cd7-bee7-288036afa9bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe1042c2-2d5c-47e5-8b71-e66bdb49c74b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f6342f9-c1df-4acb-9bdb-a02055460487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5282f06-c797-4fe4-b19a-c3d0534f9f5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grtx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e58e8310-2bcc-41d3-91b9-08c841d3541d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">grtx:IntellectMapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4d49bf1-a218-4aaa-a336-133680ab18c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_230365fe-9c24-4694-9fc3-5ece4ab88972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90454ea7-bd37-4277-92c9-e6be357b98f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c9a6f1f-9227-4c02-9d86-d4296da459d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1065604f-6672-47c1-8be6-5334d0edc400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff4d9ca7-3a8c-4c0e-91f3-4d20825252ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e00e7a20-1841-49e0-bf38-357903c57486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9c572bf-158b-4aaa-b672-6edd20fde598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">grtx:AmendedRoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_373e0480-111d-42c8-8898-a0604bcd9d8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d65dbd3-c5d4-4b15-adcd-9b943970247a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a526bee0-eb97-448d-b843-ed2b8330aa57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8e23883-6f88-4b3e-8a59-993c4b0a8e68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_362fa296-c948-48d8-8633-02f4c1279301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bd9d8bb-1771-4a1a-9624-32a8d3f04ef8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c71197f-876f-45b6-af5b-bb409d6b1c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3286eeb2-2aa4-477b-b07d-a1e64579ceed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_722e6ba2-bc11-4290-88a5-e542358ad8a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d9a581f-e062-40fd-b896-d6dce0738d15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02423d12-894b-44ac-a7a0-9a6e1fd4800c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52a132bc-811e-41a6-8227-721ecf66a245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3513012-929a-445a-a467-3e5db3bbe70d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f568e62-0715-4e4c-a97a-e44b2148e476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3ba5c9b-58df-4b65-82e0-7c06fcb7e9e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2650ce90-b6ea-4ce6-a377-81d00bcbaa95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d2525df-46a5-40bb-8481-d3306638d529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d6f0a55-359d-403b-a434-44702e4affb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd22c5c9-25d5-4067-8c16-626d9550cb64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">grtx:AmendedRoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FifthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0749fd21-5c0d-4d48-bf75-581475061ab8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3df4a5dc-c1ad-4043-a5a8-530371ef0c5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c572ee6-0f00-49f1-a14c-f6c0a3c80911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f40e1447-029f-430d-b180-94abe2cbf70c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66dcf313-c339-4433-a31f-7b050bd059e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3841438-e11c-4976-96af-f274931b7060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45be0985-0b88-45c8-908b-dfddf0179f67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grtx:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a9a3126-74c3-4629-800e-3c042fa2b51f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bda9d35-0891-4ab3-af62-f84219914e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9728d70-5cb0-41f9-97d9-56322b96a0a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:NewMilestoneWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acafa9c5-1a78-4420-88f9-7764339aa6cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbe44deb-cd48-49e6-b9b3-3243f04236e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87179a00-f82d-4ea2-a1dd-b16211dad274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6dfbed4-0d76-449c-8163-dee538b8360e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a54c4234-e2dc-4d64-9b15-6d41a7216e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9d64566-02c3-4d28-9715-ba795d3bd45a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57afcb19-5891-4994-9bdc-91438deda211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a84419a9-fda0-4f1c-b1a3-4f9270aa2e0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_305118ea-acc7-41f9-8491-7c1c62482e6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad6a9a6d-8f04-4896-b2eb-e94cb204175f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d323ff0-f330-4ed0-8d21-499632ec29a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7306d50-8a8a-4d6c-a10f-596f186d7d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grtx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef60c426-c561-4135-a8f9-593afe49a453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caca5273-7404-4350-bcc4-e533ba016ded"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5872ee23-7a9b-4c65-8dcc-db0a2b7bf7b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d1b5e52-e6b7-4acf-ae56-9c937aa16f4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32d0e2d4-86a8-4678-8bc2-8f2c07f319d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02e529b0-9177-4d0a-8d45-26a8684d2f9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f5fa676-9ecf-47ef-9aa5-1a0b787f12a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8372daa2-ef3f-464f-9b15-3e1083aa76c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70b71d11-f6c2-4c62-8626-bd6d1fd6cb30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c7d9157-dcfd-4f05-9f1d-325119845497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_976e5af6-a09b-4243-b493-8a6bf08de5c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb27f37f-1cab-4e5e-87cb-015e4b21b863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1539b5e-d51f-4a4e-95e6-8cccb7631150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:FourthMilestoneWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61bbf69e-e94a-42b1-8fab-75d4e9b55dcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf370159-17d8-430c-bf51-32824e192bad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c795c78f-8be7-43ca-9734-bcb7657f60da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_688f27b3-4933-4708-aa8f-2bbc99b732be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25712525-0b37-43f7-91fa-c953260ec5ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9a832f5-9650-4043-bd50-c48a5692f4e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36e5cf66-783f-49af-adeb-a81f9fe9b685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0b87fd6-cc11-47a8-ac63-63b4dcfcc465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_959739eb-48eb-46c2-beb8-069b0136e9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89c8d8d2-8951-4199-b591-7a7a075b63cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fffc937-6507-4e45-b94f-02243159331f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93f1c71c-423d-48c2-972d-165e521b4a2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50484754-2125-4a69-bac3-8fcfeb669f39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f6a782f-8c22-436d-9355-d84bb1aec291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8b04265-e6c4-456e-b08c-93fe2b0c7f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cc167f7-0366-47b7-bbfd-33156a4567b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:FourthMilestoneWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3097c236-8fd6-46ae-9c61-fb91d2b9fe52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9df347f3-5a56-4f15-95db-ac9ca27ed0ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grtx:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11baed89-bceb-4f0a-b7cf-02d6f3284e9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_434d1ba1-6f87-483a-9518-2b7eea1ec42f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FourthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a70b00b9-2347-4b6b-81cc-9944932bfaf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001563577</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Claim"><xbrli:measure>grtx:Claim</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95631a1d-c806-4121-86ab-99f45a85dbfc" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:5.0pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55dc246a-5d30-46e7-a28b-bb7377e290c7" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7319fd9a-f8a1-4b97-a9b2-9ace26b3dcc6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c2434c7-d096-4cfe-ad94-43ef5c86f78c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">or</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14ec26fe-f14b-4011-a8f5-31ef5dc11127" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">For the transition period from                     to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">  </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10264376-b01d-450f-b472-0727fcd6f7af" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">001-39114</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:14.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b03d28ea-1dd7-4ec2-9e81-bcf35c8075f8" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b4c27bc-674f-4357-8c19-584ee89460c5" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74189663-54b1-4a77-abf4-8652dca72d11" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">46-1454898</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b019b888-30b5-4f54-89d7-5d4e0f686d37" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2 W. Liberty Blvd #100</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_061a7b60-5410-40e8-a4ef-7b9e3a837df6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Malvern</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de093d3f-25ef-432c-91e6-798774560542" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Pennsylvania </span></ix:nonNumeric></span><span style="font-size:9.0pt;font-family:Times New Roman;"></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d3c8658-fb34-4cba-a058-85e7309c83d2" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">19355</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2878af02-05af-49c6-bb93-3a7a6601a31e" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">610</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">) </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d74fd9af-3cad-447c-ba60-ab745f4f7d69" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">725-1500</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.7%;"></td>
    <td style="width:28.581%;"></td>
    <td style="width:35.719%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:17.3pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span><ix:nonNumeric id="F_422fd3ba-4400-4998-b8af-9df21517537a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:Security12bTitle" continuedAt="F_422fd3ba-4400-4998-b8af-9df21517537a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Common Stock,</span></ix:nonNumeric></span></p><div><ix:continuation id="F_422fd3ba-4400-4998-b8af-9df21517537a_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">$0.001 par value per share</span></p></ix:continuation></div></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fbda40a-e9a7-40f5-af08-a363f58bb998" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">GRTX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">The </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8887dc8a-bdc1-467b-a4df-8530812105a7" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Nasdaq</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#160;Stock Market LLC (Nasdaq Global Market)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744; </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a455d377-777f-41a3-83f3-ed6618c515fd" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES &#9744; </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a472e894-be57-4ed3-bff7-6d1db1d42a29" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32d2c216-6be7-4f30-ac58-0a7d3f9f8fdf" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> &#9746; NO &#9744;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_108e9a01-816f-4942-b51e-7de221267831" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> &#9746; NO &#9744;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.087%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:56.214%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.143%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.556%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35babd04-1857-449d-826a-372393754c56" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf0c09cd-91e8-4090-826b-ce487ba49379" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_763088d9-304e-44a5-bdb0-f689e90ea54d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5fc9f76a-4484-409c-a81e-398f8d300a6f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> &#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15-U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0a5c23b-0a5e-4ded-a12d-49b06c490c6b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4ab76b4-ca90-4af6-b556-0237c6333808" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> NO &#9746;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">At June 30, 2021, the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_91d8d37a-a6d8-40e1-929f-8ecc600f9941" contextRef="C_91adba5e-65f4-4e18-bcd7-f7c48f289acd" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">161.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> million. Solely for purposes of this disclosure, shares of common stock held by executive officers, directors and certain stockholders of the registrant as of such date have been excluded because such holders may be deemed to be affiliates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">The number of shares of registrant&#x2019;s Common Stock outstanding as of March 4, 2022 wa</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">s </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba2775cb-8611-46ab-9520-936cbab5bef0" contextRef="C_caca5273-7404-4350-bcc4-e533ba016ded" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,795,172</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c956c03-0212-4c64-96bb-a2bf3e6c6b64" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Portions of the registrant&#x2019;s definitive Proxy Statement, relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;could,&#x201d; &#x201c;intend,&#x201d; &#x201c;target,&#x201d; &#x201c;project,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Annual Report on Form 10-K, including without limitation statements regarding our plans to develop and commercialize our product candidates, the timing of our ongoing or planned clinical trials and data readouts, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency of our cash, cash equivalents and short-term investments, the anticipated impact of the COVID-19 pandemic on our business, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#x201c;Summary Risk Factors,&#x201d; &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Annual Report on Form 10-K to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are heavily dependent on the success of our lead product candidate, avasopasem manganese (GC4419, also referred to as avasopasem) and if avasopasem does not successfully complete clinical development or receive regulatory approval, our business may be harmed. </span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may need substantial funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations. </span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely, and will continue to rely, on third parties to conduct our clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to establish our own sales, marketing and distribution capabilities, or enter into agreements with third parties to sell and market avasopasem or any other product candidates, we may not be successful in commercializing our product candidates if and when they are approved, and we may not be able to generate any revenue.</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have our own manufacturing capabilities and will rely on third parties to produce additional clinical supplies, if needed, and commercial supplies of avasopasem and our other product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be materially adversely affected.</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The successful commercialization of avasopasem or any other product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do. </span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic caused by the novel strain of coronavirus has adversely impacted and could continue to adversely impact, our business, including our preclinical studies and clinical trials, results of operations and financial condition.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.101%;"></td>
    <td style="width:82.816%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item6"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">]</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_foreign_juridiction"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Avasopasem manganese (GC4419, also referred to as avasopasem) is a highly selective small molecule dismutase mimetic in development for the reduction of severe oral mucositis, or SOM, in patients with head and neck cancer, or HNC, and for the reduction of esophagitis in patients with lung cancer. SOM is a common, debilitating complication of radiotherapy in patients with HNC. In February 2018, the U.S. Food and Drug Administration, or FDA, granted Breakthrough Therapy Designation to avasopasem for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Our second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy, or SBRT, in patients with non-small cell lung cancer, or NSCLC, and locally advanced pancreatic cancer, or LAPC.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we announced corrected topline efficacy results from a Phase 3 trial of avasopasem for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC, which we refer to as the Reduction in Oral Mucositis with Avasopasem Manganese trial, or ROMAN trial. We had previously announced topline results from the ROMAN trial in October 2021. Upon further analysis following the October topline data announcement, an error by the contract research organization was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints. The corrected results demonstrated efficacy across multiple SOM endpoints with a statistically significant reduction on the primary endpoint of reduction in the incidence of SOM and a statistically significant reduction on the secondary endpoint of number of days of SOM, with a median of 18 days in the placebo arm versus 8 days in the avasopasem arm. Exploratory analyses, such as time to SOM onset and SOM incidence at various landmarks of radiotherapy delivered, also demonstrated clinical efficacy of avasopasem in reducing the burden of SOM. Avasopasem appeared to be generally well tolerated compared to placebo. The ROMAN trial is our second randomized trial conducted in patients with HNC to achieve statistical significance and demonstrate improved clinical benefit in reducing SOM. We plan to meet with the FDA in 2022 to discuss the results from the ROMAN trial together with the previously completed randomized Phase 2b trial with respect to the potential submission of a New Drug Application, or NDA.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we also announced topline results from a Phase 2a multi-center trial in Europe assessing the safety and efficacy of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, which we refer to as the EUSOM trial. Avasopasem appeared to be generally well tolerated, and the incidence of SOM and median number of days of SOM observed in the EUSOM trial were in line with the ROMAN trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Avasopasem is also being studied in a Phase 2a trial for its ability to reduce the incidence of radiotherapy-induced esophagitis in patients with lung cancer, which we refer to as the AESOP trial. We expect to report topline data from the AESOP trial in the first half of 2022.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to developing avasopasem for the reduction of normal tissue toxicity from radiotherapy, we are developing our dismutase mimetics to increase the anti-cancer efficacy of higher daily doses of radiotherapy, or SBRT. SBRT typically involves a patient receiving one to five large doses of radiotherapy, in contrast to the 30 to 35 small daily doses typical of intensity modulated radiation therapy, or IMRT. Clinically, SBRT is increasingly used in patients with certain tumors, such as LAPC and NSCLC, that are less responsive to the small daily doses typical of IMRT. Even with the use of SBRT, there is need for improvement in treatment outcomes for certain tumors. Our second dismutase mimetic product candidate, rucosopasem, is being developed to increase the anti-cancer efficacy of SBRT, and we have successfully completed Phase 1 trials of intravenous rucosopasem in healthy volunteers. In September 2021, in support of rucosopasem, we also announced final results from our pilot Phase 1/2 safety and anti-cancer efficacy trial of avasopasem in combination with SBRT in patients with unresectable or borderline resectable LAPC. In this proof-of-concept trial, improvements were observed with avasopasem plus SBRT in overall survival, progression-free survival, local tumor control and time to distant metastases relative to patients treated with placebo plus SBRT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We used our observations from the pilot LAPC trial to inform the design of our rucosopasem clinical trials in combination with SBRT. We initiated a Phase 1/2 trial in patients with NSCLC in October 2020, which we refer to as the GRECO-1 trial. The GRECO-1 trial is supported in part by a Small Business Innovation Research grant from the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, for the investigation of our dismutase mimetics in combination with SBRT for the treatment of lung cancer. We intend for this trial to assess the anti-cancer efficacy and safety of rucosopasem in combination with SBRT. We also initiated a Phase 2b trial of rucosopasem in combination with SBRT in patients with LAPC in May 2021, which we refer to as the GRECO-2 trial. In the future, we intend to assess the anti-cancer efficacy and safety of rucosopasem in combination with SBRT and a checkpoint inhibitor in patients with NSCLC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management team has extensive drug development and commercialization experience ranging from discovery through market registrational and commercial launches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our product candidates:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_0.jpg" alt="img187335194_0.jpg" style="width:624px;height:265px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our mission is to transform cancer therapy by reducing normal tissue toxicity induced by radiotherapy and increasing the anti-cancer efficacy of radiotherapy with the use of our dismutase mimetics. By doing this we seek to improve the lives of patients with cancer. Key elements of our strategy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Complete development and obtain FDA approval of avasopasem for the reduction of radiotherapy-induced toxicities.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Avasopasem has received Breakthrough Therapy Designation from the FDA for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Avasopasem has achieved statistical significance and demonstrated improved clinical benefit in reducing SOM in our Phase 3 ROMAN trial and randomized Phase 2b trial. We plan to meet with the FDA in 2022 to discuss the results from these trials with respect to the potential submission of an NDA. We are also evaluating avasopasem in a Phase 2a trial to reduce the incidence of esophagitis in patients receiving radiotherapy for lung cancer, and we may initiate additional clinical trials for avasopasem to reduce radiotherapy-induced toxicities in other cancer indications. We may also pursue a strategy for avasopasem, if approved for reduction in the incidence of SOM, of presenting clinical data to entities like the National Comprehensive Cancer Network, or NCCN, to support the use of avasopasem to reduce esophagitis and/or other radiotherapy-induced toxicities as medically accepted indications in published drug compendia, notwithstanding that these indications may not be approved by the FDA.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Build a commercial infrastructure in the United States.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We intend to commercialize avasopasem, if approved, by building a specialized sales and marketing organization in the United States focused on radiation oncologists. We believe a scientifically oriented, customer-focused team of approximately 40 sales representatives would allow us to effectively reach the concentrated prescribing base of approximately 5,000 radiation oncologists in the United States, who we believe are among the physicians most likely to use avasopasem. We also expect to leverage this sales organization to commercialize rucosopasem, if approved, and any of our future product candidates in the United States. Outside the United States, we may seek to establish collaborations for the commercialization of avasopasem, rucosopasem, and our other product candidates. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Advance the development of rucosopasem in combination with SBRT to increase the anti-cancer efficacy of radiotherapy.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Based on extensive preclinical research results with avasopasem and rucosopasem and positive data from our pilot LAPC trial, we believe that rucosopasem has the potential to increase the anti-cancer efficacy and safety profile of SBRT. We successfully completed Phase 1 trials with rucosopasem in healthy volunteers and initiated a Phase 1/2 trial with rucosopasem in combination with SBRT in patients with NSCLC in October 2020 and initiated a Phase 2b trial with rucosopasem in combination with SBRT in patients with LAPC in May 2021. We may seek new applications for our dismutase mimetics for other cancer therapy indications.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Develop additional novel dismutase mimetics and formulations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We intend to leverage our expertise in superoxide dismutase mimetics to continue to develop novel compounds that are intended to reduce normal tissue toxicity from radiotherapy and increase the anti-cancer efficacy of radiotherapy. Additionally, we believe we can broaden the utility of our novel dismutase mimetics by formulating them for oral delivery or other routes of administration. We have evaluated alternative formulations of rucosopasem and other novel compounds in our portfolio and will consider them for potential development. In addition, we intend to seek new applications for our dismutase mimetics, including other potential combinations in cancer therapy. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Seek strategic collaborative relationships.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We intend to seek strategic collaborations to facilitate the capital-efficient development of our dismutase mimetics. We believe these collaborations could potentially provide significant funding to advance our dismutase mimetics candidate pipeline while allowing us to benefit from the development and commercial expertise of our collaborators. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Background on Superoxide and Superoxide Dismutase</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0685416666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Superoxide is similar to the molecular oxygen, O2, that is essential to breathing and life, except it carries one more electron. This extra electron, shown in the chemical formula O2&#149;-, makes superoxide a reactive oxygen species that can react with a variety of biological molecules. Superoxide is produced constantly in every living cell by normal activities such as mitochondrial respiration, and if not removed rapidly, it causes damage to lipids, proteins, DNA and other critical biological molecules. As a result, it can harm or kill cells and has been implicated in a variety of biological disorders, including cancer. As protection, human cells produce superoxide dismutase enzymes, or SODs, to eliminate superoxide by rapidly and selectively converting it to hydrogen peroxide at rates of 107 molecules per second or higher. Hydrogen peroxide is much less toxic than superoxide to normal cells and is subsequently broken down by various enzymes, such as catalase (the natural disposal enzyme for hydrogen peroxide), to molecular oxygen and water. The SOD pathway is depicted below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_1.jpg" alt="img187335194_1.jpg" style="width:620px;height:208px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Radiotherapy induces bursts of superoxide in the irradiated tissues well in excess of normal amounts, which can overwhelm native SOD activity. It generates superoxide directly, by splitting water molecules immediately, and indirectly, by activating enzymes that produce large amounts of superoxide following radiation. In addition, once tissue damage has begun, inflammatory cells attracted to the irradiated region also produce superoxide prodigiously. The resulting high levels of superoxide can induce significant damage in normal cells, and, depending on which organs fall within the irradiated field, can drive a variety of normal tissue toxicities. A condition referred to as mucositis occurs when the cells lining the gastro-intestinal tract, known as the mucosa, are damaged or killed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scientific literature suggests that metabolic differences make cancer cells much less sensitive than normal cells to elevated superoxide; elevated superoxide levels may even be typical of some cancers. As a result, the removal of the excess superoxide generated by radiotherapy does not decrease the anti-cancer efficacy of radiotherapy. Meanwhile, scientific literature also suggests that cancer cells are much more sensitive than normal cells to elevated hydrogen peroxide, so the conversion of excess superoxide to hydrogen peroxide by SODs may contribute to the anti-cancer efficacy of radiotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Artificially increasing SOD levels, by gene overexpression or administering recombinant SOD enzyme, has been shown in third-party preclinical and clinical studies to reduce radiotherapy-induced normal tissue toxicities, including mucositis. The preclinical studies have also suggested that increasing SOD levels can increase the anti-cancer efficacy of radiotherapy. Current therapeutic applications of the SODs themselves, however, have been limited by their following characteristics:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">large size and inability to enter cells and mitochondria, where superoxide is predominantly produced; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immunogenicity, particularly when derived from non-human sources; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">short half-lives in circulation; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inactivation or inhibition by various reactive oxygen species, including hydrogen peroxide. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Superoxide Dismutase Mimetics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe low molecular weight drugs that can mimic native SODs can overcome the limitations of using the native enzymes therapeutically. The challenge has been finding small molecule dismutase mimetics with similarly fast catalytic rates and high selectivity for superoxide that are also stable, safe and suitable for manufacturing. We are developing our dismutase mimetics to address this challenge.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our class of dismutase mimetics are based on a common core structure, where a macrocyclic ring positions five nitrogen atoms to tightly hold a manganese atom in the ring&#x2019;s center. These pentaaza macrocycles are manufactured with the manganese in the +2 oxidation state, or Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In solution, this Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reacts rapidly with the protonated form of superoxide, which has the chemical formula HO2&#149; and is constantly in equilibrium with regular superoxide. In this reaction, Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> gives up an electron and is oxidized to Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, making hydrogen peroxide. Then, as quickly as superoxide can reach the Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, it takes superoxide&#x2019;s extra electron, reducing back to Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, making molecular oxygen and bringing the dismutase mimetic full circle back to where it started.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Dismutase Mimetics Core Structure:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pentaaza Macrocycles</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_2.jpg" alt="img187335194_2.jpg" style="width:149px;height:139px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have designed, and are developing, our dismutase mimetics to have each of the following essential features:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Speed.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our dismutase mimetics catalyze the conversion of superoxide to hydrogen peroxide and molecular oxygen at a rapid rate of 2 &#xd7; 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> molecules per second or more, comparable to native SODs. Their structures hold the manganese such that it can rapidly shift back and forth between Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, meaning that their catalytic rate, or the speed that they convert superoxide, is mostly dependent on how fast superoxide can get to the manganese. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Selectivity. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our dismutase mimetics are designed to interact only with superoxide. Central to this selectivity are three key attributes: (1) the Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will not react with reducing agents; (2) oxidizing Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> requires a powerful oxidizing agent, so it will not react with nitric oxide and molecular oxygen; and (3) the Mn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">+2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> oxidizes rapidly via a single-electron pathway, excluding many other biologically relevant reactive oxygen species, including peroxynitrite, hypochlorite and hydrogen peroxide, that operate as two-electron oxidizing agents. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stability. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our dismutase mimetics hold on tightly to the manganese at the center of the macrocyclic ring, allowing them to maintain their functionality as dismutase mimetics while they remain in the body. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Safety.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We have observed our dismutase mimetics to be well-tolerated in our preclinical studies and clinical trials in patients. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Synthesis.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We have developed an efficient and cost-effective manufacturing process. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In radiotherapy, we believe our dismutase mimetics have the potential to reduce normal tissue toxicity by removing excessive superoxide. We have demonstrated this in preclinical models not only of mucositis, but also radiotherapy damage to the lungs, liver and other organs. Importantly, our dismutase mimetics do not interfere with the anti-cancer efficacy of radiotherapy, as demonstrated in preclinical tumor models and in our placebo-controlled Phase 2b SOM trial in patients with HNC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is also the potential to increase the anti-cancer efficacy of SBRT, where our dismutase mimetics generate high daily doses of hydrogen peroxide. Preclinically, we have shown this effect in a variety of cancer types, including head and neck, pancreatic, lung and breast cancer and, when SBRT is combined with immune checkpoint inhibitor therapy. Given the combination of reduced normal tissue toxicity and increased anti-cancer efficacy of radiotherapy, we believe that our dismutase mimetics can transform radiotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have two dismutase mimetic candidates in clinical development, avasopasem and rucosopasem. We also believe the technology is amenable to development of additional candidates for intravenous or other routes of administration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Disease Overview and Our Product Pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reducing Radiotherapy-Induced Toxicities in Patients with Cancer (Radioprotection)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Over 50% of patients with cancer will be treated with radiotherapy at some time in their treatment cycle. While radiotherapy has variable success depending on the cancer being treated, the toxicity or side effects associated with its use can limit its effectiveness. Radiotherapy causes acute and late toxicities that affect various organs and functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One of the most common radiotherapy-induced toxicities results in a condition referred to as mucositis which occurs when cells lining the gastro-intestinal tract, known as the mucosa, are damaged or killed. The oral mucosa is a common location for mucositis to occur, particularly for patients with HNC receiving radiotherapy. Another common location for mucositis to occur in patients receiving radiotherapy is the esophagus, referred to as esophagitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Oral Mucositis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">OM occurs when radiotherapy induces the production of superoxide that attacks and breaks down the epithelial cells lining the mouth. The severity of OM is commonly measured using the WHO scale, which is also used by the FDA as a basis for product approvals. The scale consists of five Grades: Grade 0 through Grade 4. SOM is commonly defined as Grade 3 or Grade 4 OM.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:85.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">WHO Scale Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.4pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No OM</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.4pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Erythema (redness) and soreness</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.4pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Erythema and ulcers but patients can swallow solid food</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.4pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ulcers with extensive erythema and patients cannot swallow solid food</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.4pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Oral alimentation (solid or liquid) is not possible</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SOM can lead to devastating complications, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pain. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A majority of patients experience severe pain, often requiring opioids to manage the pain. A publication describing 191 patients being treated for HNC noted that of the 157 patients reporting the greatest amount of mouth and throat soreness, 70% were taking opioids to alleviate their pain. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dehydration and malnutrition.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Approximately 70% of patients with HNC receiving radiotherapy become unable to eat, drink, or both, often requiring nutrition through a gastrostomy tube or intravenous line. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Treatment interruption. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SOM can be dose-limiting, requiring a reduction or delay in radiotherapy, leading to poorer clinical outcomes. Approximately 11% of patients experience unplanned breaks of a week or more in radiotherapy, with each week of treatment delay decreasing tumor control by over 10%. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Increased economic burden.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Approximately 16% of patients receiving radiotherapy for HNC are hospitalized due to SOM. Based on a third-party analysis of medical insurance claims covering 40 million patient years, patients with HNC and treated with radiotherapy who developed OM incurred, on average, approximately $40,000 in additional medical expenses in the first six months from the start of radiotherapy compared to such patients who did not develop OM. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each year in the United States, approximately 65,000 patients are diagnosed with HNC, according to the American Cancer Society. In the five largest European markets, approximately 68,000 patients are diagnosed annually with HNC, and an additional 23,000 in Japan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the patients with locally advanced HNC being treated with standard-of-care radiotherapy are at risk for developing SOM and based on observations from multiple studies, we estimate that approximately 70% will develop SOM and between 20% to 30% will develop Grade 4 OM.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a survey we conducted in 2018 of 150 U.S. radiation oncologists, OM was identified as the most burdensome side effect caused by radiotherapy in patients being treated for HNC. OM was also characterized as the side effect most likely to cause treatment interruptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Current Treatment Landscape and Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no FDA-approved drugs for the treatment of OM in patients with HNC. In 2020, the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology, or MASCC / ISOO, published an update to the leading clinical practice guidelines for the management of OM. These guidelines, which are summarized below, underscore how limited the existing approaches are for the management of OM in patients with HNC, and that these approaches have been largely palliative to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basic oral care. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The guidelines suggest the use of basic oral care protocols to prevent OM across all cancer modalities; however, the guidelines indicate the clinical evidence is weak in supporting the effectiveness of this approach. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-inflammatory agents. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The guidelines recommend the use of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">benzydamine mouthwash to prevent OM in patients with HNC receiving radiotherapy doses up to 50 gray without concomitant chemotherapy and suggest the use of benzydamine for patients with HNC receiving radiotherapy with chemotherapy. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Antimicrobials, coating agents, anesthetics, and analgesics.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The guidelines suggest the use of 0.2% morphine mouthwash to treat pain associated with OM in patients with HNC. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Laser and other light therapy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The guidelines recommend the use of low-level laser therapy to prevent OM in patients with HNC receiving radiotherapy. However, some evidence suggests that low-level laser therapy may have long-term carcinogenic effects, so MASCC / ISOO advices the clinician to inform patients about the expected benefits and potential risks of this therapy. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cryotherapy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The guidelines recommend the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">use of 30 minutes of oral cryotherapy to prevent OM in certain cancer patients, not including those receiving radiotherapy for HNC. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Natural and other miscellaneous agents.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The guidelines suggest oral glutamine to prevent OM in patients with HNC receiving radiotherapy. The suggestion is with caution because of the higher mortality rate seen in patients undergoing hematopoietic stem cell transplantation who receive parenteral glutamine. The guidelines also suggest the use of honey to prevent OM in patients with HNC receiving radiotherapy, with or without chemotherapy. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These MASCC / ISOO guidelines demonstrate that there is a high unmet need for the treatment or prevention of OM in patients with HNC, driven by the lack of clear efficacy of the existing treatment options. This unmet need is further demonstrated by the findings from our survey of 150 U.S. radiation oncologists, where only 19% and 21% of physicians, respectively, stated that topical agents are effective in preventing or reducing the incidence of SOM and in treating or reducing the duration of SOM in patients with HNC. The respondents also stated that effectiveness in preventing or reducing the incidence of SOM was the most important product attribute. The FDA has also acknowledged this unmet need and the lack of effective therapies for the reduction of the duration, incidence and severity of SOM induced by radiotherapy by granting avasopasem Fast Track and Breakthrough Therapy Designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Solution: Avasopasem for Radiotherapy-Induced Severe Oral Mucositis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Avasopasem is a highly selective small molecule dismutase mimetic we are developing for the reduction of SOM in patients with HNC. We believe avasopasem, which to date is not approved for any indication, has the potential to address shortcomings associated with current approaches and become the standard of care treatment for SOM in patients with locally advanced HNC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Potential Benefits of Avasopasem for Severe Oral Mucositis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that avasopasem has the potential to be the first FDA-approved drug and the standard of care for the reduction of SOM in patients with HNC receiving radiotherapy, with the following benefits:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mechanism of action designed to address the root cause of OM:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Unlike existing treatment options that are largely symptomatic and reactive in nature, we believe avasopasem has the potential to address and mitigate the root cause of OM. Avasopasem is designed to rapidly convert superoxide to hydrogen peroxide, reducing mucosal damage and thereby the incidence and severity of mucositis. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Compelling Phase 3 and randomized Phase 2b clinical data:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Results from our Phase 3 ROMAN trial and randomized Phase 2b trial demonstrate the potential benefits of avasopasem across multiple parameters of SOM. Avasopasem has received Fast Track and Breakthrough Therapy Designation from the FDA. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Maintenance of anti-cancer efficacy of radiotherapy:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Two-year follow-up clinical data from our Phase 2b trial for avasopasem in patients with locally advanced HNC showed similar rates of tumor control and survival between avasopasem and placebo with no observed decrease in the anti-cancer efficacy of radiotherapy. We believe this is significant as maintenance of anti-cancer efficacy of radiotherapy is of key importance to physicians when considering new drugs to manage side effects of radiotherapy. Long-term follow-up from our Phase 3 ROMAN trial is ongoing.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Higher patient adherence:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The intravenous formulation of avasopasem, administered in a clinical setting by a health care provider, promotes higher patient adherence, optimizing clinical outcomes. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development of Avasopasem for Severe Oral Mucositis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ROMAN Trial (Phase 3)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2018, avasopasem was granted Breakthrough Therapy Designation by the FDA for the reduction of SOM induced by radiotherapy, with or without systemic therapy. As part of our correspondence with the FDA, we received the following guidance:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One pivotal trial is required to support an NDA filing; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Phase 2b trial will be considered supportive to the Phase 3 pivotal trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reduction in the incidence of SOM through the radiotherapy treatment period should be the primary endpoint of the Phase 3 registrational trial; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All available tumor outcome data at the time of the NDA submission, including survival data, should be included in the NDA submission.  </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we announced positive corrected topline efficacy results from the ROMAN trial. We had previously announced topline results from the ROMAN trial in October 2021. Upon further analysis following the October topline data announcement, an error by the contract research organization was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints. The trial was a randomized, double-blinded, multicenter, placebo-controlled trial assessing the effects of avasopasem on the incidence, duration and severity of SOM. 455 patients were enrolled in the trial and randomized 3:2 in favor of the avasopasem 90 mg treatment arm. Like our Phase 1b/2a and Phase 2b trials, the eligible population was patients with locally advanced, squamous cell HNC who were eligible for seven weeks of standard-of-care radiotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ROMAN Trial Design (n=455 patients)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_3.jpg" alt="img187335194_3.jpg" style="width:624px;height:189px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoint of the ROMAN trial was the reduction in the incidence of SOM through the radiotherapy period for patients being treated with 90 mg of avasopasem as compared to placebo received as a 60-minute intravenous infusion less than 60 minutes before radiation, Monday to Friday, for seven weeks. All patients were assessed twice weekly for OM by trained evaluators during the course of their radiotherapy treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional endpoints included, among others, reduction in the number of days of SOM experienced by all patients and reduction in the severity of SOM, as well as the effect of treatment on tumor outcomes measured by overall survival, or OS, progression-free survival, or PFS, locoregional control, or LRC, and distant metastasis-free, or DMF, rates. Adverse events were monitored during the trial period. One-year tumor outcomes and two-year survival rates will be collected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In this trial, avasopasem demonstrated efficacy across SOM endpoints with a statistically significant 16% relative reduction on the primary endpoint of reduction in the incidence of SOM (p=0.045) and a statistically significant 56% relative reduction in the number of days of SOM (p=0.002), with a median of 18 days in the placebo arm versus 8 days in the avasopasem arm. The severity of SOM (incidence of Grade 4 OM) was reduced by 27% in the avasopasem arm compared to placebo (p=0.052).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Relative Reduction Across SOM Endpoints</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_4.jpg" alt="img187335194_4.jpg" style="width:624px;height:321px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exploratory analyses, such as time to SOM onset and SOM incidence at various landmarks of radiotherapy delivered, also demonstrated clinical efficacy of avasopasem in reducing the burden of SOM. The median time to onset of SOM for all patients was delayed by 11 days, from 38 days in the placebo arm to 49 days in the avasopasem arm. The incidence of SOM at all radiotherapy landmarks for patients on avasopasem was reduced compared to placebo, with the relative reductions greater than the primary endpoint both earlier during the course of therapy and during the two-week observation period after radiotherapy, as summarized in the following chart. The gray, or Gy, is the International System of Units unit of absorbed radiation dose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Incidence of SOM Reduced at All Landmarks of Radiation Therapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_5.jpg" alt="img187335194_5.jpg" style="width:624px;height:297px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe the data in the above chart further demonstrate the potential clinical activity of avasopasem and the potential benefit to patients over the course of their radiotherapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Avasopasem appeared to be generally well tolerated compared to placebo. No difference was observed in the severity of adverse events and the most frequent adverse events were similar between the treatment and placebo arms. The percentage of patients with the most common adverse events in the ROMAN trial are shown in the table below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Most Frequent Adverse Events Similar</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Across Active and Placebo Arms</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_6.jpg" alt="img187335194_6.jpg" style="width:274px;height:272px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2a Trial in Patients with HNC in Europe (EUSOM)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we announced topline results from EUSOM, a Phase 2a multi-center trial of avasopasem in Europe evaluating avasopasem in combination with IMRT and concurrent cisplatin in patients with locally advanced HNC. This trial was conducted in twelve centers across six countries in Europe and enrolled 38 patients, of which 33 completed full treatment.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary objective of this trial was to assess the safety of avasopasem in combination with IMRT and concurrent cisplatin. Secondary objectives included, among others, the reduction in the incidence of SOM through the radiotherapy period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Avasopasem appeared to be generally well tolerated. The incidence of SOM was 54.5% and the median number of days of SOM was 9 days for patients who completed treatment in the EUSOM trial, in line with the ROMAN trial in which the incidence of SOM in the avasopasem arm was 54% and the median number of days of SOM was 8 days.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2b Trial in Patients with HNC</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2017, we announced positive topline data from a Phase 2b trial in 223 patients with locally advanced HNC being treated with IMRT and concurrent cisplatin at multiple sites in the United States and Canada. The trial was a randomized, double-blinded, placebo-controlled trial assessing the effects of avasopasem on the median duration, incidence and severity of SOM. Patients received 30 mg of avasopasem, 90 mg of avasopasem or placebo as a 60-minute infusion less than 60 minutes before radiation, Monday to Friday, for seven weeks. All patients were assessed twice weekly for OM by trained evaluators during the course of their radiotherapy treatment. If SOM was present in a patient at the end of the course of his or her radiotherapy treatment, that patient continued to be evaluated weekly for up to eight additional weeks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase 2b Trial Design (n=223)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_7.jpg" alt="img187335194_7.jpg" style="width:624px;height:211px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoints of the trial were reduction in the duration of SOM in the 90 mg and 30 mg treatment arms. Duration was defined as the number of days from when a patient was first assessed with SOM until the first day that patient was assessed with Grade 2 or less OM, with no subsequent occurrences of SOM.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In this trial, the 90 mg treatment arm of avasopasem demonstrated a statistically significant reduction compared to placebo on the primary endpoint (p=0.024). The median duration of SOM in this arm was 1.5 days, a 92% reduction compared to placebo.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Secondary endpoints included reduction in the incidence and severity of SOM in each of the 90 mg and 30 mg treatment arms. For these purposes, we define the severity of SOM as the incidence of Grade 4 OM. The incidence of SOM in the 90 mg treatment arm was reduced by 36% through 60 Gy and 34% through the full course of radiotherapy treatment compared to placebo and the severity of SOM in the 90 mg treatment arm was reduced by 47% through the full course of radiotherapy treatment compared to placebo.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the 30 mg treatment arm, intermediate reductions compared to placebo were observed in median duration of SOM (58%), incidence of SOM through 60 Gy (31%) and through the full course of radiotherapy treatment (8%), and in severity of SOM (30%) through the full course of radiotherapy treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Relative Reduction Across SOM Endpoints</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_8.jpg" alt="img187335194_8.jpg" style="width:624px;height:319px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the trial, we also observed an apparent delay in the onset of SOM in the 90 mg treatment arm compared to placebo, reduced usage of opioids in both the 30 mg and 90 mg treatment arms compared to placebo, and reduced placement and use of gastrostomy tubes in the 90 mg treatment arm compared to placebo.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following chart depicts the course of SOM in each patient in the 90 mg treatment arm or the placebo arm who experienced at least one episode of SOM during the course of his or her treatment and follow-up. Each bar represents a single patient and illustrates the length of time between that patient&#x2019;s first evaluated instance of SOM and his or her last evaluated instance of SOM, along with the severity of his or her SOM during that interval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_9.jpg" alt="img187335194_9.jpg" style="width:624px;height:289px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This chart demonstrates that (1) fewer patients in the 90 mg treatment arm developed SOM than in the placebo arm, (2) fewer patients in the 90 mg treatment arm developed Grade 4 OM than in the placebo arm, and (3) on average, SOM did not last as long for patients in the 90 mg treatment arm. This is consistent with the observed reductions in the individual numerical endpoints of median duration, incidence and severity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We followed patients from this trial for tumor outcomes out to two years following radiotherapy. In the two-year assessment of tumor outcomes, we observed similar outcomes among the three arms in OS, PFS, LRC and DMF rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.695pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tumor Outcomes Maintained through 2 Years</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_10.jpg" alt="img187335194_10.jpg" style="width:514px;height:231px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No difference was observed in the severity of adverse events among the three arms in the trial and the most frequent adverse events were similar among the three arms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Safety Profile of Both Avasopasem Doses was Comparable to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Standard-of-Care Chemoradiotherapy (Placebo Arm)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_11.jpg" alt="img187335194_11.jpg" style="width:489px;height:212px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The percentage of patients with the most common adverse events in the Phase 2b trial are shown in the table below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Most Frequent Adverse Events Similar</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Across Active and Placebo Arms</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_12.jpg" alt="img187335194_12.jpg" style="width:334px;height:243px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1b/2a Trial in Patients with HNC</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2016, we completed a Phase 1b/2a, open-label, multi-center, dose escalation trial of the safety, tolerability, pharmacodynamic and pharmacokinetic properties of avasopasem in combination with radiotherapy and concurrent cisplatin in 46 patients with locally advanced HNC. Doses ranged from 15 mg to 112 mg. The objectives of this trial were to evaluate the safety and tolerability of avasopasem in combination with IMRT and cisplatin, to determine a maximum tolerated dose and to assess the potential of avasopasem to reduce the duration, incidence and severity of SOM.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In this trial, patients were assigned to treatment duration groups based upon the dose and duration of dosing of avasopasem received and we observed that the incidence, duration, and severity of SOM through six weeks of radiotherapy (with patients receiving a cumulative radiotherapy dose of 60 Gy) decreased for patients who received six to seven weeks of avasopasem. In the group receiving six to seven weeks of avasopasem, 29% of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patients experienced SOM, with a median duration of 2.5 days, and no patients experienced Grade 4 OM. Avasopasem was well tolerated and a maximum tolerated dose was not reached.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients in the trial were followed for tumor outcomes at one-year post-radiotherapy. The observed LRC, DM-free, PFS, and OS rates in 44 patients evaluable for tumor outcome at one year were 93%, 93%, 84% and 93%, respectively. We believe these outcomes are similar to the outcomes observed in historical control studies, suggesting that avasopasem does not decrease the anti-cancer efficacy of radiotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Radiotherapy-Induced Esophagitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Radiotherapy-induced esophagitis is a common and debilitating adverse effect that develops in patients receiving radiotherapy, most commonly for lung, esophageal, breast or head and neck cancers or for lymphoma. Radiotherapy-induced esophagitis is inflammation, edema, erythema, and erosion of the mucosal surface of the esophagus caused by radiotherapy. Esophagitis can be life-threatening, and symptoms include an inability to swallow, severe pain, ulceration, infection, bleeding and weight loss and may require hospitalization. The severity of esophagitis is graded using the National Cancer Institute, or NCI, Common Terminology Criteria for Adverse Events, which is a five-point grading scale:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:85.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Grade</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.65pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients are asymptomatic with only clinical observations</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.65pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients are symptomatic with altered eating or swallowing, with oral supplements indicated</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.65pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients exhibit severely altered eating or swallowing requiring tube feeding, total parenteral nutrition or hospitalization</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.65pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patient requires urgent operative intervention; condition is life-threatening</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.65pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.65pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results in death</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Radiotherapy-induced esophagitis potentially represents a larger market opportunity than OM. In lung cancer (our first target market for esophagitis), there are approximately 230,000 new patients annually in the United States, of which approximately 50,000 are treated with radiotherapy. The overall frequency of Grade 2 or higher esophagitis in patients receiving radiotherapy for the treatment of lung cancer is approximately 50%. The results of our survey of 150 U.S. radiation oncologists suggested that they view OM data as being representative of potential efficacy in esophagitis, which we believe supports the feasibility of exploring the use of avasopasem for the reduction of esophagitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Current Treatment Landscape and its Limitations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are currently no FDA-approved drugs and no established guidelines for the treatment of radiotherapy-induced esophagitis. Treatment options are not only ineffective but also largely symptomatic in nature, with medications being administered in conjunction with a focus on adequate hydration and nutrition. These approaches, which include various analgesics such as topical lidocaine and opioids, and tube or intravenous feeding, do not treat the underlying cause of radiotherapy-induced esophagitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Solution: Avasopasem for Radiotherapy-Induced Esophagitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unlike existing treatment options that are largely palliative in nature, we believe avasopasem has the potential to address and mitigate the root cause of radiotherapy-induced esophagitis. By removing superoxide, avasopasem is designed to reduce the damage radiotherapy ordinarily causes to the patient&#x2019;s esophageal mucosa, and thereby reduce the incidence of radiotherapy-induced esophagitis. We believe avasopasem has the potential to become the standard of care for the reduction in the incidence of radiotherapy-induced esophagitis in patients with lung cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development of Avasopasem for Esophagitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ongoing Phase 2a Trial in Patients with Lung Cancer (AESOP Trial)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2020, we announced the initiation of a Phase 2a trial of avasopasem in combination with radiotherapy with concurrent chemotherapy in up to 60 patients with lung cancer, which we refer to as the AESOP trial. In the AESOP trial, 90 mg of avasopasem were given to patients before each of typically 30 radiotherapy fractions.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoint of the trial is to assess the efficacy of avasopasem in reducing the incidence of Grade 2 or higher esophagitis in these patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to report topline data from the AESOP trial in the first half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Increasing Anti-Cancer Efficacy of Radiotherapy (Radiosensitization)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As cancer cells are much more sensitive than normal cells to elevated hydrogen peroxide, we believe the conversion of excess superoxide to hydrogen peroxide by our dismutase mimetics has the potential to increase the anti-cancer efficacy of radiotherapy. We are developing rucosopasem with the goal to increase the anti-cancer efficacy of high daily doses of radiotherapy, which we have demonstrated in our preclinical studies. A preclinical research article was published in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Science Translational Medicine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in May 2021 describing the synergy of our selective dismutase mimetics in combination with SBRT in killing tumors. This increased efficacy could be particularly important in settings where the current anti-cancer efficacy of radiotherapy alone is insufficient to achieve the desired outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Locally Advanced Pancreatic Cancer Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pancreatic cancer is a disease in which solid tumors form in the tissues of the pancreas. It is a particularly aggressive form of cancer and represents the third-leading cause of cancer deaths in the United States with approximately 60,000 new diagnoses and 48,000 deaths estimated in 2021. Globally, pancreatic cancer accounted for almost as many deaths (446,000) as new diagnoses (496,000) in 2020. Over 30% of newly diagnosed patients have non-metastatic disease that is unresectable due to the location of the primary tumor or its relationship to the surrounding vasculature. The first line of treatment for patients with unresectable tumors is chemotherapy. For those patients whose tumors remain unresectable following chemotherapy, SBRT is an emerging treatment option. Even with SBRT as an option, patients with pancreatic cancer often have a poor prognosis, with a five-year survival rate of only approximately 10%. As a result, there remains a large unmet need to increase the effectiveness of disease management and ultimately improve outcomes for patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Small Cell Lung Cancer Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">According to the NCI, lung cancer is the leading cause of cancer-related mortality in the United States. The NCI estimates that in 2021 there were approximately 236,000 new cases of lung cancer (both NSCLC and small cell lung cancer) in the United States and approximately 132,000 deaths. Approximately 175,000 patients are diagnosed with NSCLC each year in the United States and are typically treated with some combination of surgery, radiotherapy, chemotherapy and immunotherapy, depending on the severity of their disease, and SBRT is an established radiotherapy treatment for some forms of NSCLC. Even with all these current treatment options, NSCLC remains the leading cause of cancer deaths in the United States. As such, improving the effectiveness of lung cancer treatment and improving patient outcomes represents a significant unmet need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Solution: Rucosopasem (GC4711) for Increasing Anti-Cancer Efficacy in Patients Receiving SBRT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rucosopasem is our second dismutase mimetic product candidate. We are specifically developing rucosopasem, an analog of avasopasem, with the goal of increasing the anti-cancer efficacy of SBRT. Based on our extensive preclinical data and positive data from our proof-of-concept pilot LAPC trial, we believe rucosopasem has the potential to increase the anti-cancer efficacy of radiotherapy. By adding rucosopasem to an SBRT regimen, we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">believe that our dismutase mimetics&#x2019; conversion of superoxide to hydrogen peroxide may increase the anti-cancer efficacy of radiotherapy at current doses.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 Trials</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2017, we completed a Phase 1 single-dose trial of intravenously administered rucosopasem in Australia. In March 2020, we completed a second Phase 1 single-ascending dose and multiple-dose trial of rucosopasem administered by 15-minute intravenous infusions to healthy volunteers in Australia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In these trials, rucosopasem was observed to be well tolerated. There were no Grade 3, 4, or 5 adverse events, and no adverse events led to withdrawal from these trials. We used the results of these trials to identify the dose and schedule of rucosopasem to be studied in future trials and to support an Investigative New Drug Application, or IND, filing for intravenous rucosopasem delivered via 15-minute infusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have observed in multiple xenograft and syngeneic tumor mouse models a strong correlation between the daily dose of radiation and the increase in anti-cancer efficacy with our selective dismutase mimetics. Notably, we observed that many of the mice at the highest daily dose of radiotherapy with a dismutase mimetic became tumor-free. The results of one such study, in which mice bearing NSCLC xenograft tumors received 24 mg/kg of avasopasem daily for five days concurrent with one of four different radiotherapy dosage regimens, are depicted below. For example, 5 Gy x 5 RT indicates that the mice received five daily doses of five Gy each. These radiotherapy regimens were selected because, without the addition of our dismutase mimetic, each should produce an equivalent reduction in tumor growth. The data reflects that expected result, but the increase in anti-cancer efficacy with addition of the dismutase mimetic increases significantly at the higher daily doses of radiotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">H1299 Human NSCLC Tumors in Mice</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_13.jpg" alt="img187335194_13.jpg" style="width:624px;height:161px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In another preclinical study, mice bearing pancreatic cancer xenograft tumors treated with a single 12 Gy dose demonstrated a meaningful decrease in tumor volume when avasopasem was added, as depicted below. We believe that this result shows that our dismutase mimetics have the potential to synergize with SBRT to rapidly convert superoxide to hydrogen peroxide and exploit cancer cells&#x2019; increased sensitivity to hydrogen peroxide to promote cancer cell death.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_14.jpg" alt="img187335194_14.jpg" style="width:420px;height:297px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional preclinical studies have provided further evidence supporting our dismutase mimetics&#x2019; biological mechanism in combination with radiotherapy in solid tumors. To test the hypothesis that our dismutase mimetics&#x2019; conversion of superoxide to hydrogen peroxide increases the anti-cancer efficacy of radiotherapy, we genetically engineered NSCLC tumors to overexpress catalase enzyme when triggered. This overexpression of catalase, a native enzyme that rapidly removes hydrogen peroxide, blocked the dismutase mimetic&#x2019;s synergy with radiotherapy in an experiment similar to the ones described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_15.jpg" alt="img187335194_15.jpg" style="width:472px;height:267px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe the results of our studies represent significant potential in the treatment of cancer, particularly as recent advances in radiotherapy, such as SBRT, are capable of administering targeted, high daily doses of radiotherapy to solid tumors. SBRT utilizes several beams of various intensities aimed at different angles to precisely target the tumor, with the goal of delivering the highest possible dose of radiotherapy to kill cancer cells while minimizing exposure to normal cells. For example, SBRT is an established radiotherapy treatment for NSCLC, used increasingly for small, peripheral lung tumors. Data to date suggest that SBRT could also increase the anti-cancer efficacy and safety of radiotherapy for many other patients with NSCLC, LAPC and other cancers. SBRT application for large or centrally located NSCLC tumors, however, faces unique challenges, as lung and other toxicities limit the amount of radiotherapy patients can tolerate. As such, the most suitable patients for this procedure currently are those with smaller, well-defined tumors who are ineligible for or cannot tolerate surgery.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in anti-cancer efficacy of SBRT with our dismutase mimetics has been shown in a variety of models of lung, pancreatic, head and neck, breast and other cancers. In addition, because low oxygen levels typically found deep in larger tumors can interfere with the anti-cancer efficacy of radiotherapy, it is important that our dismutase mimetics appear to also increase anti-cancer efficacy in hypoxic tumor models. Further, they may also reduce the normal tissue toxicities that restrict the patients now eligible for SBRT. Because of this we believe that the combination of rucosopasem and SBRT has the potential to further increase the anti-cancer efficacy of and to broaden the group of patients who can benefit from SBRT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical research community is also exploring the possibility of increasing the anti-cancer efficacy of SBRT by combining it with checkpoint inhibitor immunotherapy, merging the targeted efficacy of radiotherapy with the demonstrated durability of checkpoint therapy. In preclinical models combining our dismutase mimetics with SBRT and anti-PD-1, anti-PD-L1 or anti-CTLA4 checkpoint therapy, this triple combination was more effective than combinations of SBRT combined with checkpoint therapy or SBRT combined with dismutase mimetic. The triple combination increased control of the irradiated primary tumors and also appeared to reduce the metastatic spread of the cancer and even controlled pre-existing tumors outside the radiation field. Based upon these data, we believe there is an opportunity to assess the combination of SBRT, checkpoint therapy and rucosopasem as a novel approach to treating various cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development for Increasing Anti-Cancer Efficacy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1/2 Pilot Trial of Avasopasem in Patients with LAPC</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, we announced final results from a pilot Phase 1/2 safety and anti-cancer efficacy trial of avasopasem in combination with SBRT in patients with unresectable or borderline resectable LAPC. The primary objective of this trial was to determine the maximum tolerated daily dose of SBRT in conjunction with our dismutase mimetic, with secondary measures assessing, among others, OS, PFS, resectability and overall response rate compared to placebo. The trial was designed to evaluate three dose levels of SBRT, with each patient receiving five doses of SBRT. SBRT daily dose levels ranged from 10 Gy/dose to 12 Gy/dose.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The results included a minimum follow up of one year on all 42 patients enrolled in the trial. In this proof-of-concept trial, relative improvements were observed in OS, PFS, local tumor control and time to distant metastases. 46% of patients in the active arm were alive at last follow-up (11 out of 24) compared to 33% in the placebo arm (6 out of 18). 29% of patients in the active arm achieved a 30% or greater decrease in primary tumor size (partial response) compared to 11% of patients in the placebo arm. Avasopasem was well tolerated, with similar rates of early and late adverse events in the active and placebo arms. The data from this trial enabled us to select the SBRT regimen for our subsequent trial in this indication, the GRECO-2 trial, of five daily doses at 10 Gy/dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Improvements Across All Efficacy Parameters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img187335194_16.jpg" alt="img187335194_16.jpg" style="width:624px;height:328px;" />&#160;</p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ongoing Phase 1/2 Trial of rucosopasem in Patients with NSCLC (GRECO-1 Trial)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, we initiated a Phase 1/2 trial of rucosopasem in combination with SBRT in patients with NSCLC, which we refer to as the GRECO-1 trial. We intend for this trial to assess the anti-cancer efficacy and safety of rucosopasem in combination with SBRT. Subsequently, in a separate trial, we intend to assess the anti-cancer efficacy and safety of rucosopasem in combination with SBRT and a checkpoint inhibitor.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approximately 5 patients with locally advanced NSCLC will receive 100 mg of rucosopasem with SBRT over five consecutive weekdays as part of the Phase 1 open-label safety run-in portion of the trial. Following the safety run-in cohort, up to 66 NSCLC patients with locally advanced disease will receive 100 mg of rucosopasem with SBRT or placebo with SBRT over five consecutive weekdays in the randomized, blinded, placebo-controlled Phase 2 portion of trial.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary objective of the trial is to assess safety with secondary measures assessing, among others, objective response rate, PFS and OS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GRECO-1 trial is supported in part by a Small Business Innovation Research grant from the NCI for the investigation of our dismutase mimetics in combination with SBRT for the treatment of lung cancer. We expect to report initial data from the GRECO-1 trial in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ongoing Phase 2b Trial of rucosopasem in Patients with LAPC (GRECO-2 Trial)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, we initiated a randomized, double-blinded, multicenter, placebo-controlled Phase 2b trial of rucosopasem in combination with SBRT in patients with LAPC, which we refer to as the GRECO-2 trial. We expect to enroll approximately 160 patients in this trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary objective of this trial is to determine the impact on OS of adding 100 mg of rucosopasem to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic pancreatic cancer. Key secondary objectives, among others, will include PFS, locoregional tumor control, time to distant metastases, surgical resection outcomes, and objective response rate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Oral and Other Formulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical studies conducted by us suggest that rucosopasem and other novel dismutase mimetics in our portfolio can also be delivered by other routes of administration beyond intravenous, and one or more of these may be considered for future development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Development of Avasopasem for COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2 Pilot Trial in Critically Ill Patients with COVID-19</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, we initiated a randomized, double-blinded, multicenter, placebo-controlled Phase 2 pilot trial of avasopasem in up to 50 hospitalized patients who were critically ill with COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary endpoint of the trial was to assess the efficacy of avasopasem in improving 28-day mortality compared to placebo. Patients received 90 mg of avasopasem or placebo as a 3-hour intravenous infusion twice daily for seven days. In June 2021, we ceased enrolling subjects in this trial. Enrollment in the trial was limited at the three centers that participated, and due to the overall decline in COVID-related hospitalizations in the United States at the time, we determined that it was not feasible to complete the trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to rely, on third party contract manufacturing organizations, or CMOs, for the supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our product candidates and products, if approved. We require all of our CMOs to conduct manufacturing activities in compliance with cGMP requirements, and we maintain our product candidates in refrigerated conditions prior to intravenous infusion. We have assembled a team of experienced employees and consultants to provide the necessary technical, quality and regulatory oversight of our CMOs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that these CMOs will have the capacity to support both clinical supply and commercial-scale production. We have a formal agreement with Patheon Manufacturing Services LLC, or Patheon, for commercial production of avasopasem, if approved. See &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources-Patheon Manufacturing Agreements&#x201d; in Part II, Item 7 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also may elect to pursue additional CMOs for manufacturing supplies of drug substance and finished drug product in the future. We believe that our standardized manufacturing process can be transferred to a number of other CMOs for the production of clinical and commercial supplies of our product candidates in the ordinary course of business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our aim is to become a fully integrated biopharmaceutical company. At our current stage, we have a small commercial organization but have not yet established sales or distribution capabilities. We intend to commercialize avasopasem, if successfully developed and approved, by expanding our commercial organization by building a specialized sales and marketing organization in the United States focused on radiation oncologists. We believe a scientifically oriented, customer-focused team of approximately 40 sales representatives would allow us to effectively reach the approximately 5,000 radiation oncologists in the United States, who treat patients using an even smaller number of radiation machines. There are approximately 2,500 radiotherapy treatment sites in the United States. Based on a third-party claims database, we estimate that over 80% of radiotherapy treatments for HNC patients are performed at approximately 700 sites. Because of the limited number of physicians concentrated around a smaller number of radiation machines, we believe we can effectively commercialize avasopasem, if approved, in the United States with a small, focused commercial organization. We also expect to leverage this sales organization to commercialize rucosopasem, if approved, and any of our future product candidates in the United States. Outside</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the United States, we may seek to establish collaborations for the commercialization of avasopasem, rucosopasem, and our other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries put significant emphasis and resources into the development of novel and proprietary therapies for cancer treatment. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing treatment options and new therapies that may become available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our potential competitors may have significantly greater financial resources, a more established presence in the market, and more expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These potential competitors may also compete with us in recruiting and retaining top qualified scientific, sales, marketing and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The key competitive factors affecting the success of avasopasem, rucosopasem and any of our other product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. There are currently no FDA-approved drugs for the treatment of OM in patients with HNC and no FDA-approved drugs or established guidelines for the treatment of radiotherapy-induced esophagitis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A number of large pharmaceutical and biotechnology companies that currently market and sell drugs or biologics are pursuing the development of therapies in the fields in which we are interested. Our commercial opportunity for any of our product candidates could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects, than any products that we may develop. Because our product candidates are designed to reduce the side effects, or to increase the anti-cancer efficacy, of radiotherapy, our commercial opportunities could also be reduced or eliminated if radiotherapy methods are improved in a way that reduces the incidence of such side effects or increases anti-cancer efficacy, or if new therapies are developed which effectively treat cancer without causing such side effects. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for avasopasem, rucosopasem and any of our other product candidates, manufacturing methods and processes, novel discoveries, and other know-how; to operate without infringing on or otherwise violating the proprietary rights of others; and to prevent others from infringing or otherwise violating our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to our product candidates and other proprietary technologies, inventions and improvements, including claims related to composition of matter and methods of use, that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. For more information, please see &#x201c;Risk Factors&#x2014;Risks Related to Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patents and Patent Applications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our owned and currently pending and/or in-force patent portfolio consisted of approximately 21 issued U.S. patents, 11 pending U.S. patent applications, 125 issued foreign patents including 7 issued European patents that have been validated in many European countries, and 104 pending foreign applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#x2019;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO, in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier expiring patent. In some instances, such a patent term adjustment may result in the term of a United States patent extending beyond 20 years from the earliest filing date of a non-provisional patent application. In the United States, the term of a patent that covers a drug product may also be eligible for patent term extension when regulatory approval is granted, provided the legal requirements are met. This permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to a maximum of five years beyond the expiration of the patent if the patent is eligible for such an extension under the Hatch-Waxman Act. The length of the patent term extension is related to the length of time the drug is under regulatory review; however, it cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted. Only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and certain other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each drug and other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The two most advanced product candidates in our portfolio, avasopasem and rucosopasem, are protected by issued patents with claims directed to composition of matter and method of use. Avasopasem is covered by a composition of matter patent in the United States that has a natural expiration date in March 2022. The U.S. patent family covering the method of treating OM has a natural expiration date in late 2027, and if we are successful in obtaining a patent term extension of approximately two and a half years which we believe should be available, the extension would result in an expiration date in 2031. The U.S. patent family covering treating tissue damage resulting from radiation therapy, chemotherapy or a combination thereof by administering high doses of avasopasem, including that tested in the ROMAN Phase 3 trial, has a natural expiration date in 2032, and if we are successful in obtaining a patent term extension which we believe should be available, the extension would result in an expiration date in late 2034 to early 2035. In any event, we can only extend one applicable patent for each approved drug. Rucosopasem is covered by a composition of matter patent in the United States, which also covers oral bioavailability of the product candidate, and has a natural expiration date in 2036. However, we believe the rucosopasem composition of matter patent may be eligible for a patent term extension of at least about two years which, if granted, would result in an expiration date in 2038. When including only current issued patents and related potential patent term extensions, our product candidate patent portfolio is projected to expire between 2031 and 2038 in the United States. Additional pending or future patent applications may supplement or extend this patent portfolio.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">However, there can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents. The applicable authorities, including the FDA in the United States, may not agree with our assessment of whether such patent term extensions should be granted, and if granted, they may grant more limited extensions than we request.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also have pending patent families in the United States that cover certain combinations of our product candidates with several oncology products and therapies that may provide protection for the use of our product candidates in connection with those oncology products and therapies, which, if granted, are projected to expire between 2037 and 2041.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Trademarks and Trade Secrets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our owned and currently pending and/or in-force trademark portfolio consisted of 2 registered U.S. trademarks, 8 pending U.S. trademark applications, 18 registered foreign trademarks, and 4 pending foreign trademark applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, we rely upon trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees, and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with an employee or a third party. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Royalty Agreement with Blackstone Life Sciences (Formerly Known as Clarus Ventures)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, we entered into the Royalty Agreement with Blackstone Life Sciences. Pursuant to the Royalty Agreement, Blackstone agreed to pay us, in the aggregate, up to $80.0 million, or the Royalty Purchase Price, in four tranches of $20.0 million each upon the achievement of specified clinical milestones in our ROMAN trial. We agreed to apply the proceeds from such payments primarily to support clinical development and regulatory activities for avasopasem, rucosopasem and any pharmaceutical product comprising or containing avasopasem or rucosopasem, or, collectively, the Products, as well as to satisfy working capital obligations and for general corporate expenses. We received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively, under the Royalty Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, we entered into Amendment No. 1 to the Royalty Agreement, or the Amendment, with Clarus IV Galera Royalty AIV, L.P., or the Blackstone Purchaser. The Blackstone Purchaser is affiliated with Blackstone Life Sciences, successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $37.5 million to $117.5 million by increasing the fourth tranche from $20.0 million to $37.5 million and adding a new $20.0 million tranche upon the achievement of an additional clinical enrollment milestone. We received the new $20.0 million tranche of the Amendment in June 2021, in connection with the enrollment of the first patient in the GRECO-2 trial. Also in June 2021, we completed enrollment in the ROMAN trial, thereby achieving the milestone associated with the fourth tranche, and received the associated $37.5 million in July 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the amended Royalty Agreement, in connection with the payment of each tranche of the Royalty Purchase Price, we have agreed to sell, convey, transfer and assign to Blackstone all of our right, title and interest in a high single-digit percentage of (i) worldwide net sales of the Products and (ii) all amounts received by us or our affiliates, licensees and sublicensees with respect to Product-related damages (collectively, the Product Payments) during the Royalty Period. The Royalty Period means, on a Product-by-Product and country-by-country basis, the period of time commencing on the commercial launch of such Product in such country and ending on the latest to occur of (i) the 12th anniversary of such commercial launch, (ii) the expiration of all valid claims of our patents covering such Product in such country, and (iii) the expiration of regulatory data protection or market exclusivity or similar regulatory protection afforded by the health authorities in such country, to the extent such protection or exclusivity effectively prevents generic versions of such Product from entering the market in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amended Royalty Agreement will remain in effect until the date on which the aggregate amount of the Product Payments paid to Blackstone exceeds a fixed single-digit multiple of the actual amount of the Royalty Purchase Price received by us, unless earlier terminated pursuant to the mutual written agreement of us and Blackstone. If no Products are commercialized, we would not have an obligation to make Product Payments to Blackstone, which is the sole mechanism for repaying the liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, as partial consideration for the Amendment, we issued two warrants to the Blackstone Purchaser to purchase an aggregate of 550,661 shares of our common stock at an exercise price equal to $13.62 per share, each of which became exercisable upon the receipt by Galera of the applicable specified milestone payment. The issued warrants expire six years after the initial exercise date of each respective warrant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">U.S. Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#x2019;s good laboratory practice, or GLP, regulations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of any FDA inspections or audits of the sponsor, clinical research organizations and clinical study sites to assure compliance with GCP requirements and the integrity of the clinical data;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing or sale of the drug in the United States; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, or to conduct a post-approval study. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov website.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketing Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#x2019;s continued safety, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision. The actual review time may be significantly longer, depending on the complexity of the review, FDA requests for additional information and the sponsor&#x2019;s submission of additional information.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical trials or preclinical studies in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA Expedited Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA offers a number of expedited development and review programs for qualifying product candidates. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product candidate is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need for such disease or condition. The sponsor of a fast track-designated product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development. In addition, the FDA may review sections of the NDA for a fast track-designated product candidate on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six and ten month review periods are measured from the &#x201c;filing&#x201d; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful advantages over existing treatments may be eligible for accelerated approval and may be approved upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may also designate a product candidate as a breakthrough therapy, which is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval and approval is not guaranteed. Such designation may, however, expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warning or other safety information about the product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Hatch-Waxman Act and Marketing Applications for Follow-On Drugs</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute and also enacted Section 505(b)(2) of the FDCA. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing conducted for a drug product previously approved under an NDA, known as the reference listed drug, or RLD. Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#x201c;bioequivalent&#x201d; to the innovator drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orange Book Listing</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent that has claims that cover the applicant&#x2019;s product or method of therapeutic use. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. If an applicable patent issues between filing and approval, the applicant is required to amend the application to include that patent. Companies also may list applicable patents in the Orange Book after receiving product approval so long as the patent is submitted to FDA within 30 days of patent issuance. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA. The ANDA requests permission to market a drug product that has the same active ingredients in the same strengths and dosage form as the RLD and has been shown through bioequivalence testing to be therapeutically equivalent to the RLD. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, nonclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#x201c;generic equivalents&#x201d; to the innovator drug and can often be substituted by pharmacists under prescriptions written for the original listed drug referenced by the ANDA applicant if the FDA&#x2019;s listing for the generic drug in the Orange Book indicates that it is &#x201c;therapeutically equivalent&#x201d; to the RLD.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In contrast, Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. A Section 505(b)(2) applicant may eliminate the need to conduct certain preclinical or clinical studies if it can establish that reliance on studies conducted for a previously approved product is scientifically appropriate. Unlike the ANDA pathway used by developers of bioequivalent versions of innovator drugs, which does not allow applicants to submit new clinical data other than bioavailability or bioequivalence data, the 505(b)(2) regulatory pathway does not preclude the possibility that a follow-on applicant would need to conduct additional clinical trials or nonclinical studies; for example, it may be seeking approval to market a previously approved drug for new indications or for a new patient population that would require new clinical data to demonstrate safety or effectiveness.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When an ANDA applicant submits its application to the FDA, it is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#x2019;s Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement, certifying that its proposed ANDA label does not contain or carves out any language regarding the patented method-of-use, rather than certify to a listed method-of-use patent. Moreover, to the extent that the Section 505(b)(2) NDA applicant is relying on studies conducted for an already approved product, the applicant also is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the applicant does not challenge the innovator&#x2019;s listed patents, FDA will not approve the ANDA or 505(b)(2) application until all the listed patents claiming the referenced product have expired. A certification that the new product will not infringe the already approved product&#x2019;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Patent Exclusivity</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon NDA approval of a new chemical entity or NCE, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which time the FDA cannot receive any ANDA seeking approval of a generic version of that drug. Certain changes to a drug, such as the addition of a new indication to the package insert or a different formulation, are associated with a three-year period of exclusivity. During the exclusivity period, the FDA cannot accept for review any ANDA or 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed on an NCE patent and any time after approval if the application is filed based on a new indication or a new formulation.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Hatch-Waxman Act also provides three years of data exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving follow-on applications for drugs containing the original active agent. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA or 505(b)(2) NDA may be filed before the expiration of the exclusivity period. Five-year and three-year exclusivity also will not delay the submission or approval of a traditional NDA filed under Section 505(b)(1) of the FDCA. However, an applicant submitting a traditional NDA would be required to either conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, and transparency laws and regulations with respect to drug pricing and payments and other transfers of value made to physicians and other healthcare professionals, as well as similar foreign laws in the jurisdictions outside the U.S. Violations of such laws, or any other governmental regulations that apply, may result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, additional reporting and oversight obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and individual imprisonment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. With respect to off-label uses, third-party payors may provide coverage and reimbursement under certain limited circumstances. By way of example, Medicare covers off-label uses of FDA-approved drugs if the use is supported as a medically accepted indication by certain compendia and is not otherwise listed as unsupported, not indicated, not recommended, or equivalent terms, in any such compendia. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. Moreover, for drugs and biologics administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#x2019; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect the pharmaceutical industry. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs and reimbursement adjustments. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#x201c;branded prescription drugs&#x201d; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded the eligibility criteria for Medicaid programs, created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the Affordable Care Act. In addition, other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year until 2031, which was temporarily suspended from May 1, 2020 through March 31, 2022, and further reduced payments to several types of Medicare providers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester.  Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several presidential executive orders.  Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Further, it is possible that additional government action is taken in response to the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from the comparable regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product candidates in those countries. The requirements and process governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Clinical Studies and Clinical Trials</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar to the United States, the various phases of non-clinical and clinical research in the European Union, or EU, are subject to significant regulatory controls.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Non-clinical studies are performed to demonstrate the health or environmental safety of new biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain countries outside of the United States have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials of medicinal products in the European Union, or EU, must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#x2018;no fault&#x2019; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#x2019;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketing Authorization</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, medicinal products can only be placed on the market after obtaining a marketing authorization, or MA. To obtain regulatory approval of an investigational medicinal product under European Union regulatory systems, we must submit an MA application, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Essentially, there are two types of MAs. The centralized MAs are issued by the European Commission, based on the opinion of the EMA&#x2019;s Committee for Medicinal Products for Human Use, or CHMP, and are valid across the entire territory of the European Union. The centralized procedure is compulsory for human medicines that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicines and (iv) advanced therapy medicinal products, or ATMPs, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, in the EU, a &#x201c;conditional&#x201d; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#x201c;normal&#x201d; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#x201c;under exceptional circumstances&#x201d; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#x201c;under exceptional circumstances&#x201d; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">National MAs are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the national competent authority of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the centralized procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#x2019;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. The benefits of a PRIME designation include the appointment of a CHMP rapporteur before submission of a MAA, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data and Marketing Exclusivity</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The European Union also provides opportunities for market exclusivity. Upon receiving MA, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the EU from referencing the innovator&#x2019;s data to assess a generic or biosimilar application. During the additional two&#x2011;year period of market exclusivity, a generic/biosimilar MA can be submitted, and the innovator&#x2019;s data may be referenced, but no generic/biosimilar product can be marketed until the expiration of the market exclusivity. The overall ten-year market exclusivity period may be extended to a maximum of eleven years if, during the first eight years, a new therapeutic indication with significant clinical benefit over existing therapies is approved. However, there is no guarantee that a product will be considered by the EU or member state regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For other countries outside of the European Union, such as countries in Latin America or Asia, the requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Data Privacy and Security Laws</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerous state, federal and foreign laws govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or CCPA, the California Privacy Rights Act, or CPRA and the EU General Data Protection Regulation, or GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">had 30 em</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ployees. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated in Delaware in November 2012. Our offices are located at 2 W. Liberty Blvd, Suite 100, Malvern, Pennsylvania 19355. Our common stock is listed on the Nasdaq Global Market under the symbol &#x201c;GRTX.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Available Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our internet website address is www.galeratx.com. In addition to the information about us and our subsidiaries contained in this Annual Report on Form 10-K, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">electronically filed with or furnished to the Securities and Exchange Commission, or SEC. Additionally the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC's website is www.sec.gov.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a clinical stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred losses in each year since our inception in 2012 and anticipate incurring losses for the foreseeable future. To date, we have invested substantially all of our efforts and financial resources in identifying, acquiring, in-licensing and developing our product candidates, including commencing and conducting clinical trials and providing general and administrative support for these operations. Our future success is dependent on our ability to develop, obtain regulatory approval for and successfully commercialize one or more of our product candidates. We have not yet demonstrated our ability to obtain regulatory approvals, manufacture a drug at commercial scale, or conduct sales and marketing activities. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a marketable product. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Typically, it takes many years to develop one new drug from the time it is discovered to when it is available for treating patients, and development may cease for a number of reasons.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant losses related to expenses for research and development and our ongoing operations. Our net losses for the years ended December 31, 2021 and 2020 were $80.5 million and $74.2 million, respectively. As of December 31, 2021, we had an accumulated deficit of $316.1 million. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue our clinical development of our product candidates;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance our programs into more expensive clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance our ongoing research and preclinical development activities for our existing product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increase our manufacturing needs or add additional manufacturers or suppliers; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to identify, assess, acquire or develop additional product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">make royalty or other payments under any royalty or purchase agreements, including our Amended and Restated Purchase and Sale Agreement, or the Royalty Agreement, as amended, by and among us, Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P., or, collectively, Blackstone or Blackstone Life Sciences (formerly Clarus); </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to maintain, protect and expand our intellectual property portfolio; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek to attract and retain skilled personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">create additional infrastructure to support our product development and our planned future commercialization efforts; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience any delays or encounter issues with any of the above, including but not limited to failed trials, complex results, safety issues, other regulatory challenges that require longer follow-up of existing trials, additional major trials or additional supportive trials in order to pursue marketing approval. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining regulatory approval, and manufacturing, marketing and selling any product candidates for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In cases where we are successful in obtaining regulatory approval to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period to period comparison of our results of operations may not be a good indication of our future performance. We expect to incur additional costs associated with operating as a public company. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may need substantial funding to meet our financial obligations and to pursue our business objective. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect our expenses to increase in connection with our ongoing development activities related to avasopasem for the reduction in the incidence of severe oral mucositis, or SOM, in patients with locally advanced HNC, seek marketing approval for avasopasem,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursue clinical trials and marketing approval of avasopasem in other indications, pursue clinical trials and marketing approval of rucosopasem and advance any of our other product candidates we may develop or otherwise acquire. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to manufacturing, product sales, marketing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications for our product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we expect to continue to incur significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed on attractive terms, if at all, we will be forced to delay, reduce or eliminate certain of our clinical development plans, research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development process for our product candidates is highly uncertain, and we cannot estimate with certainty the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of our product candidates. Based on our current operating plan and assumptions, we believe that our existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second half of 2023. Our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than expected, through public or private equity, debt financings or other sources. Our future capital requirements will depend on and could increase significantly as a result of many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results, time and cost necessary for completing our ongoing and planned clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number, size and type of any additional clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcomes of seeking and potentially obtaining approvals from the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory authorities, such as the European Commission, or the competent authorities of the member states of the European Union, or EU, including the potential for the FDA or comparable regulatory authorities to require that we conduct more studies and trials than those that we currently expect to conduct and the costs of post-marketing studies or risk evaluation and mitigation strategies, or REMS, or similar risk management measures that could be required by regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of transferring manufacturing technology to third-party manufacturers, producing product candidates to support clinical trials and preparing to manufacture our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully commercialize any of our product candidates, including the cost and timing of forming and expanding our sales organization and marketing capabilities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of sales revenues from our product candidates, if approved, including the sales price and the availability of coverage and adequate third-party reimbursement; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">competitive and potentially competitive products and technologies and patients&#x2019; receptivity to our product candidates and the technology underlying them in light of competitive products and technologies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cash requirements of any future acquisitions, developments or discovery of additional product candidates, including any licensing or collaboration agreements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the time and cost necessary to respond to technological and market developments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any product liability or other lawsuits related to our product candidates or any products; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with being a public company; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our need and ability to hire additional personnel; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receptivity of the capital markets to financings by biotechnology companies generally and companies with product candidates and technologies such as ours specifically. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Dislocations in the financial markets may make equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet our fundraising needs when they arise. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our preclinical studies, clinical trials or other research or development programs, the commercialization of any product candidate. We may also be unable to expand our operations or otherwise capitalize on our business opportunities or may be required to relinquish rights to our product candidates or products. Any of these occurrences could materially affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time as we can generate substantial product revenues, if ever, we expect to finance our cash needs through securities offerings or debt financings, or possibly, license and collaboration agreements or research grants. The terms of any financing may adversely affect the holdings or the rights of our stockholders and our issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common stock to decline. The sale of additional equity or convertible securities would dilute all of our stockholders, including your ownership interest. The incurrence of indebtedness would result in increased fixed or variable payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies, product candidates or future revenue streams, or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our stockholders, and may cause the market price of our shares to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Discovery and Development of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are heavily dependent on the success of our lead product candidate, avasopasem, and if avasopasem does not successfully complete clinical development or receive regulatory approval, our business may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have no products that are approved for commercial sale. We have not completed the development of any product candidates and we may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to the advancement of avasopasem, through clinical trials and the regulatory approval process, as well as the commercialization of avasopasem following regulatory approval, if received.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that avasopasem will receive regulatory approval, or be successfully commercialized even if we receive regulatory approval. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of products are, and will remain, subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing regulations. We are not permitted to market avasopasem in the United States until we receive approval of a New Drug Application, or NDA,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or in any foreign country until we receive the requisite approvals from the appropriate authorities in such countries for marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not yet demonstrated our ability to obtain regulatory approval for any of our product candidates, and there can be no assurance that the results from our Phase 3 ROMAN trial together with the randomized Phase 2b trial of avasopasem will be sufficient for us to submit an NDA for the reduction of SOM in patients with HNC. For example, as a result of the appearance of trace amounts of visible fine particles identified through stability testing of our avasopasem drug product candidate, our two INDs for avasopasem were temporarily placed on clinical hold in May and July 2019, respectively, following our April 2019 decision to voluntarily suspend dosing of avasopasem in all active clinical trials. We have since identified the particles as manganese carbonate, determined that the particles do not present safety or efficacy concerns for patients who may already have been dosed and have designed the manufacturing process to reduce formation of the particles. The FDA lifted the clinical holds in August 2019. Subsequently, in our ongoing stability testing of avasopasem, we have observed the appearance of visible manganese carbonate particles in drug product batches stored at room temperature (25&#xb0;C) or refrigerated conditions. In our clinical trials, we added a filtration step to the preparation procedure for both avasopasem and placebo before administration to trial subjects to remove any particles that might form in the future, and we notified the FDA of the reasons for this change. There can be no assurance that we will be able to eliminate the formation of particles such as manganese carbonate, that a similar or different manufacturing issue will not occur, or that one or more of our programs will not be placed on clinical hold in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the clinical hold on our ROMAN trial, the data from the approximately 30 patients in the trial that did not complete dosing with avasopasem during the time the trial was on clinical hold will not be considered for purposes of our efficacy analysis in the trial. However, the data from these patients will be considered for purposes of evaluating the safety of avasopasem in our ROMAN trial. Following the lifting of the clinical hold, we increased the size of our ROMAN trial from 335 patients to approximately 365 patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we are currently continuing our ongoing clinical trials, the COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for certain of our clinical trials of avasopasem. We delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy due to concerns with clinical trial enrollment in Europe during the COVID-19 pandemic. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to this delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to ensure we were positioned to maintain the overall planned size of the safety database in a timely manner.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our Phase 3 ROMAN trial did demonstrate a statistically significant difference for the active 90 mg dose compared to placebo for the primary endpoint and a key secondary endpoint, we do not know whether the FDA will find these results together with the results from the randomized Phase 2b trial of avasopasem in patients with HNC sufficient to support the submission of an NDA.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not submitted an NDA for avasopasem or any other marketing authorization application for any other product candidates to the FDA or any comparable application to any other regulatory authority. Obtaining approval of an NDA or similar regulatory approval is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or other foreign regulatory authorities may delay, limit or deny approval of any of our current or future product candidates for many reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to demonstrate that avasopasem is effective as treatments for any of our targeted indications to the satisfaction of the FDA or other relevant regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the relevant regulatory authorities may require additional pre-approval studies or clinical trials, which would increase our costs and prolong our development timelines; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or other relevant regulatory authorities for marketing approval; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the contract research organizations, or CROs, that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or breaches of protocols, that materially adversely impact our clinical trials and ability to obtain market approvals; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may not find the data from preclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of avasopasem outweigh their safety risks; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may not be convinced that avasopasem has an acceptable safety profile; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may disagree with our interpretation of data or significance of results from the preclinical studies and clinical trials of avasopasem, or may require that we conduct additional studies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may not accept data generated from our clinical trial sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if our NDA or other foreign application is reviewed by an advisory committee, the FDA or other relevant regulatory authority, as the case may be, may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant regulatory authority, as the case may be, require, as a condition of approval, additional nonclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may require additional post-marketing studies, which would be costly; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of earlier studies and trials may not be predictive of future trial results. If development of our product candidates is unsuccessful or delayed, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the clinical trial process. Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. The results of preclinical studies and clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have agreements with our CROs governing their committed activities, and the ability to audit their performance, we have limited influence over their actual performance. We rely on third-party vendors, such as CROs, scientists and collaborators to provide us with significant data and other information related to our preclinical studies or clinical trials and our business. If such third parties provide inaccurate, misleading or incomplete data, our business, prospects and results of operations could be materially adversely affected. For example, in October 2021, we announced topline data from the Phase 3 ROMAN trial of avasopasem in SOM and reported that the trial did not achieve statistical significance on the primary endpoint. Upon further analysis of the ROMAN data, an error by the CRO was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints, including the achievement of statistical significance on the primary endpoint. We announced the corrected topline results in December 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience delays in initiating our clinical trials and we cannot be certain that the trials or any other future clinical trials for our product candidates will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure related to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities, such as the competent authorities of the member states of the EU, disagreeing as to the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the study population for further analysis of the study&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining regulatory approval to commence a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining institutional review board, or IRB, or Ethics Committee approval at each site; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruiting suitable patients to participate in a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">having patients complete a trial or return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing patient safety concerns that arise during the course of a trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing any conflicts with new or existing laws or regulations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adding a sufficient number of clinical trial sites; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing sufficient quantities of product candidate for use in clinical trials. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities, such as the competent authorities of the member states of the EU. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, such as the competent authorities of the member states of the EU, resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, conducting clinical trials in foreign countries, as we plan to do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the FDA&#x2019;s and other regulatory authorities&#x2019; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#x2019;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is currently unclear to what extent the United Kingdom, or UK, will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a MA in the EU for our product candidates on the basis of clinical trials conducted in the UK.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we encounter difficulties or delays enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patient eligibility criteria defined in the protocol; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity of patients to study sites; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the design of the trial; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain patient consents; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical studies and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and early clinical trials does not ensure that later, large-scale efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical studies and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We plan to conduct clinical trials for our product candidates outside the United States and the FDA may not accept data from such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have conducted certain of our clinical trials outside the United States, and we plan to conduct additional clinical trials outside the United States. For example, we conducted a Phase 1 dose and schedule escalation study of rucosopasem in healthy volunteers in Australia. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, for clinical trials not otherwise subject to an IND, such clinical trials must be conducted in accordance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with good clinical practices, or GCP, requirements and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, such clinical trials would be subject to the applicable local laws of the foreign jurisdictions where the clinical trials are conducted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. There can also be no assurance that the comparable foreign regulatory authority in any jurisdiction in which we seek marketing approval for our product candidates will accept data from clinical trials conducted outside such jurisdiction. If the FDA or any such foreign regulatory authority does not accept any such data, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our development plan. In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign regulatory requirements that could burden or limit our ability to conduct our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">administrative burdens of conducting clinical trials under multiple foreign regulatory schemes; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign exchange fluctuations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing, customs, shipment and storage requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cultural differences in medical practice and clinical research; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diminished protection of intellectual property in some countries. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities, such as the EMA or the competent authorities of the member states of the EU. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. To date, patients treated with our product candidates have experienced drug-related side effects including lymphopenia, nausea, fatigue, oropharyngeal pain, constipation, radiation skin injury and vomiting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical trials include cancer patients who are very sick and whose health may deteriorate, and we expect that additional clinical trials of our other product candidates will include similar patients with potentially deteriorating health. It is possible that some may die during our clinical trials for various reasons, including because the patient&#x2019;s underlying disease continues to advance despite treatment, or because the patient experiences medical problems that may not be related to our product candidate. For example, during the treatment phase of our Phase 2b trial of avasopasem, there was one non-treatment-related death in each of the placebo, 30 mg treatment and 90 mg treatment arms. Even if the deaths are not related to our product candidate, the deaths could affect perceptions regarding the safety of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may suspend, withdraw or limit their approval of the product, or seek an injunction against its manufacture or distribution; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to recall a product or change the way such product is administered to patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to implement a REMS or similar risk management measures, or create a Medication Guide outlining the risks of such side effects for distribution to patients, or implement other changes to how a product is distributed or administered; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the product may become less competitive; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reputation may suffer. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a full analyses of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline, or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, top-line, or preliminary data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development, research, testing, manufacturing, labeling, approval, selling, import, export, marketing, promotion and distribution of drug products are subject to extensive and evolving regulation by federal, state and local governmental authorities in the United States, principally the FDA, and by foreign authorities, such as the EU institutions or the competent authorities of the member states of the EU, which regulations differ from country to country. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States or foreign jurisdictions until we receive regulatory approval of an NDA from the FDA or similar approval from foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining regulatory approval of an NDA or a similar foreign application can be a lengthy, expensive and uncertain process. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. The number of preclinical studies and clinical trials that will be required for FDA or foreign regulatory authorities approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a drug candidate for any or all indications. The FDA or foreign regulatory authorities may also require us to conduct additional studies or trials for our product candidates either prior to or post-approval, such as additional drug-drug interaction studies or safety or efficacy studies or trials, or it may object to elements of our clinical development program such as the number of subjects in our current clinical trials from the United States or abroad. We may experience difficulty in identifying and enrolling patients in such a trial, if one were to be required, which could interrupt, delay or halt the process of obtaining regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical studies or clinical testing or abandon a program for many reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or the applicable foreign regulatory agency&#x2019;s disagreement with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement with the interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s requirement for additional preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement regarding the formulation, labeling and/or the specifications of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete clinical testing and receive approval of an NDA or foreign marketing application for our product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or in the case of the FDA, the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or a narrower patient population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA or foreign</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities notification or FDA or foreign regulatory authorities approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, in an effort to optimize scale-up efficiencies for avasopasem, we implemented certain changes to the manufacturing process related to the order of addition of ingredients. However, subsequent to this manufacturing change trace amounts of visible fine particles were observed in the drug product. Following notification to the FDA in April 2019 that we had voluntarily suspended dosing of avasopasem in all active clinical trials until we were able to resolve the issue, our INDs for avasopasem were temporarily placed on clinical hold. While we have now modified the manufacturing process and the FDA lifted the clinical holds in August 2019, and subsequently we added a filtration step to the preparation procedure for both avasopasem and placebo before administration to trial subjects to remove any particles that might form in the future, there can be no assurance that a similar or different manufacturing issue will not occur and one or more of our programs will not be placed on clinical hold in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited financial and management resources, we focus on development programs and product candidates that we identify for specific indications. As such, we are currently primarily focused on the development of avasopasem and rucosopasem. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for avasopasem or rucosopasem that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">While we have received Breakthrough Therapy Designation for avasopasem, we may not receive such designation for our other product candidates, and such designation for avasopasem or any other product candidate may not lead to a faster development or regulatory review or approval process and will not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received Breakthrough Therapy Designation from the FDA for avasopasem for the reduction of SOM induced by radiotherapy, with or without systemic therapy. We may also seek Breakthrough Therapy Designation for any other product candidates that we may develop. A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification. Similarly, our products may not qualify for similar programs in other jurisdictions, such as the PRIME scheme in the EU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have received Fast Track Designation for avasopasem, and we may seek such designation for some or all of our other product candidates. We may not receive such designation, and even for those product candidates for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">which we do, it may not lead to a faster development or regulatory review or approval process and will not increase the likelihood that product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received Fast Track Designation from the FDA for avasopasem for the reduction of the severity and incidence of radiation and chemotherapy-induced OM, and we may seek Fast Track Designation for some or all of our other product candidates. If a drug is intended for the treatment of a serious or life-threatening condition or disease, and preclinical or clinical data demonstrate the potential to address an unmet medical need, the product may qualify for Fast Track Designation, for which sponsors must apply. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a NDA is submitted, the product candidate may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. The FDA has broad discretion whether or not to grant this designation. Thus, even if we believe a particular product candidate is eligible for this designation, the FDA may decide not to grant it. Moreover, even if we do receive Fast Track Designation, we or our collaborators may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Many drugs that have received Fast Track Designation have failed to obtain approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions, such as the European Commission, or the competent authorities of the member states of the EU, must also approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market size will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union on January 31, 2020 and ratified a trade and cooperation agreement governing its future relationship, commonly known as Brexit. The agreement, which was applied provisionally from January 1, 2021 and entered into force on May 1, 2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and will require complex additional bilateral negotiations between the United Kingdom and the EU as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. Since January 1, 2021, however, the United Kingdom has operated under a separate regulatory regime to the EU. EU laws regarding medicinal products only apply in respect of the United Kingdom to Northern Ireland (as set out in the Protocol on Ireland/Northern Ireland). The EU laws that have been transposed into United Kingdom law through secondary legislation remain applicable. While the United Kingdom has indicated a general</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">intention that new laws regarding the development, manufacture and commercialization of medicinal products in the United Kingdom will align closely with EU law, there are limited detailed proposals for future regulation of medicinal products. The trade and cooperation agreement includes specific provisions concerning medicinal products, which include the mutual recognition of Good Manufacturing Practice, or GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued (such mutual recognition can be rejected by either party in certain circumstances), but does not foresee wholesale mutual recognition of United Kingdom and EU pharmaceutical regulations. For example, it is not clear to what extent the United Kingdom will adopt legislation aligned with, or similar to, the EU CTR which became applicable on January 31, 2022 and which significantly reforms the assessment and supervision processes for clinical trials throughout the EU. Therefore, there remains political and economic uncertainty regarding to what extent the regulation of medicinal products will differ between the United Kingdom and the EU in the future. Any divergences will increase the cost and complexity of running our business, including with respect to the conduct of clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Brexit also materially impacted the regulatory regime with respect to the approval of our product candidates. Great Britain is no longer covered by the EU&#x2019;s procedures for the grant of marketing authorizations (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). As of January 1, 2021, all existing centralized marketing authorizations were automatically converted into United Kingdom marketing authorizations effective in Great Britain and issued with a United Kingdom marketing authorization number on January 1, 2021 (unless marketing authorization holders opted out of this scheme). A separate marketing authorization is now required to market drugs in Great Britain. It is currently unclear whether the regulator in the United Kingdom, the Medicines and Healthcare products Regulatory Agency is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Further, the United Kingdom&#x2019;s withdrawal from the European Union has resulted in the relocation of the EMA from the United Kingdom to the Netherlands. This relocation has caused, and may continue to cause, disruption in the administrative and medical scientific links between the EMA and the U.K. Medicines and Healthcare products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Similar requirements may be requested by foreign regulatory authorities. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practice-grade, or cGMP, or similar foreign requirements and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning or untitled letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#x2019;s and foreign regulatory authorities&#x2019; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s and foreign regulatory authorities&#x2019; ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and other regulatory agencies, including the Component Authorities of the EU member states, strictly regulate the promotional claims that may be made about prescription products, as our product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. Physicians may nevertheless prescribe such drugs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to their patients in a manner that is inconsistent with the approved label. For example, if we obtain approval for avasopasem for the reduction in the incidence of SOM in patients with locally advanced HNC receiving radiotherapy, we may pursue a strategy for avasopasem for the reduction of radiotherapy-induced esophagitis by presenting clinical data to entities like the National Comprehensive Cancer Network, or NCCN, to support use of avasopasem under these circumstances as a medically accepted indication in published drug compendia, notwithstanding the fact that we may not seek approval for avasopasem for radiotherapy-induced esophagitis by the FDA. Even if we are successful in obtaining Category 1 or Category 2A status from NCCN for avasopasem for the reduction of esophagitis, we will nevertheless be restricted from marketing and promoting the product for the reduction of esophagitis unless and until it is approved by the FDA for such indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are found to have promoted off-label uses, or if the government takes the position that our presenting clinical data related to off-label uses of avasopasem to NCCN or other drug compendia publishers to establish compendia-listed indications constitutes off-label promotion, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. The same applies in foreign jurisdictions, including the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely, and will continue to rely, on third parties to conduct our clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have relied, and expect to continue to rely, on CROs for the conduct of preclinical studies and clinical trials of avasopasem, rucosopasem and/or any other product candidates that we may progress to clinical development. We expect to continue to rely on third parties, such as clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. We have no control over the ability of our CROs to maintain adequate quality control, quality assurance and qualified personnel. For example, in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 2021, we announced topline data from the Phase 3 ROMAN trial of avasopasem in SOM and reported that the trial did not achieve statistical significance on the primary endpoint. Upon further analysis of the ROMAN data, an error by the CRO was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints, including the achievement of statistical significance on the primary endpoint. We announced the corrected topline results in December 2021. If our CROs and other third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, their standard operating procedures and policies, or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on these parties for execution of our preclinical studies and clinical trials, and generally do not control their activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and foreign regulatory authorities require us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fails to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP or similar foreign conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or foreign regulatory authorities. The FDA or foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or foreign regulatory authorities and may ultimately lead to the denial of marketing approval of avasopasem, rucosopasem and any other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We contract with third parties for the manufacture and supply of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have any manufacturing facilities or personnel. We do not have any long-term contractual arrangements with manufacturers and instead rely on third parties to manufacture our product candidates on a purchase-order or work-order basis. We currently have limited manufacturing arrangements, and we cannot be certain that we will be able to establish redundancy in manufacturers for our product candidates, which could lead to reliance on a limited number of manufacturers for one or more of our product candidates. This reliance increases the risk that we will not have sufficient quantities of our drug candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also expect to rely on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of avasopasem, if approved, and any other product candidates for which we obtain marketing approval. The facilities used by our contract manufacturing organizations, or CMOs, to manufacture our product candidates must be approved by the FDA or other regulatory authorities for the manufacture of our product candidates pursuant to inspections that will be conducted after we submit our NDA or comparable marketing application to the FDA or other regulatory authority. We do not have control over a supplier&#x2019;s or manufacturer&#x2019;s compliance with laws, regulations and applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. If our current or future suppliers are unable to supply us with sufficient raw materials for our preclinical studies and clinical trials, we may experience delays in our development efforts as we locate and qualify new raw material manufacturers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to establish any agreements with future third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, qualifying and validating such manufacturers may take a significant period of time and reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reliance on the third party for regulatory compliance and quality assurance; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible increase in costs for the raw materials or drug substance in avasopasem or any of our other product candidates; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible termination or nonrenewal of any agreement by any third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party manufacturers may not be able to comply with cGMP regulations or other regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates and any drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. There are no assurances we would be able to enter into similar commercial arrangements with other manufacturers that operate under cGMP regulations or other regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements outside the United States and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek collaborations with third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek third-party collaborators for the development and commercialization of our product candidates, including for the commercialization of any of our product candidates that are approved for marketing outside the United States. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaborations involving our product candidates would pose the following risks to us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not perform their obligations as expected, including compliance with all applicable regulatory requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we seek, but are not able to establish, collaborations, we may have to alter our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">candidates do not achieve an adequate level of acceptance, we may not generate significant revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy, safety and potential advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer our products for sale at competitive prices; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the perception by members of the healthcare community, including physicians or patients, that the process of administering our product candidates, including our intravenous infusion procedure, is not unduly cumbersome; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the clinical indications for which our product candidates are approved; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the limited number of infusion sites where our product candidates can be administered; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully develop, or make arrangements with third-party manufacturers for, commercial manufacturing processes for any of our product candidates that receive regulatory approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to hire and retain a sales force in the United States; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the recognition of uses for our products as medically accepted indications in recognized drug compendia; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of third-party coverage and adequate reimbursement for avasopasem and any other potential product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any restrictions on the use of our products together with other medications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to establish our own sales, marketing and distribution capabilities, or enter into agreements with third parties to sell and market avasopasem or any other product candidates, we may not be successful in commercializing our product candidates if and when they are approved, and we may not be able to generate any revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently have a sales, marketing or distribution infrastructure. We have never sold, marketed or distributed any therapeutic products. To achieve commercial success for any approved product candidate, we will need to establish a sales and marketing organization. Under the amended Royalty Agreement with Blackstone, we are required to establish a trained sales force sufficiently in advance of any anticipated commercial launch in a country where we seek to commercialize avasopasem or related product candidates. We expect to build a specialized</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sales and marketing organization of approximately 40 sales representatives to market our product candidates to the approximately 5,000 radiation oncologists in the United States. There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any drug launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to equip medical and sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to develop or obtain sufficient operational functions to support our commercial activities; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to establish our own sales, marketing and distribution capabilities and are forced to enter into arrangements with, and rely on, third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we had developed such capabilities ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown and cannot be precisely determined. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our business. Further, even if we obtain significant market share for our product candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The successful commercialization of avasopasem or any other product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products, could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to set their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#x201c;transfers of value&#x201d; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an Executive Order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester.  On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug's average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In addition, the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries, and Congress has proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. We expect that additional U.S. healthcare reform measures will be adopted in the future, any of which could limit the amounts paid for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our customers&#x2019; ability to obtain reimbursement for our product candidates in foreign markets; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to directly control commercial activities because we are relying on third parties; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">import or export licensing requirements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">longer accounts receivable collection times; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">longer lead times for shipping; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">language barriers for technical training and the need for language translations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced protection of intellectual property rights in some foreign countries; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the existence of additional potentially relevant third-party intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign currency exchange rate fluctuations; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any product candidates that we may develop. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for any product candidates that we may develop; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory investigations that could require costly recalls or product modifications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant costs to defend the related litigation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of potential revenue; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the diversion of management&#x2019;s attention away from managing our business; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize any product candidates that we may develop. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur and is subject to deductibles and coverage limitations. We anticipate that we will need to increase our insurance coverage when and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If we are unable to obtain insurance at acceptable cost or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may materially and adversely affect our business and financial position. These liabilities could prevent or interfere with our commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Competition, Retaining Key Employees and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and commercialization of new drugs and biologics is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or biologics are pursuing the development of therapies in the fields in which we are interested. Some of these competitive products and therapies are based on entirely different scientific approaches to our approach. Potential competitors also include academic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources, a more established presence in the market, and more expertise in research and development, manufacturing, preclinical studies and clinical trials, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining highly qualified scientific, sales, marketing and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we or our collaborators may develop. Because our product candidates are designed to reduce normal tissue toxicity from radiotherapy, or to increase the anti-cancer efficacy, our commercial opportunities could also be reduced or eliminated if radiotherapy methods are improved in a way that reduces normal tissue toxicity or increases anti-cancer efficacy, or if new therapies are developed which effectively treat cancer with less or without normal tissue toxicity. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related products, market acceptance by physicians and patients, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a limited operating history and are highly dependent on the research and development, clinical, commercial and business development expertise of the principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The failure to recruit, or the loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. If we are not able to continue to attract and retain, on acceptable terms, the qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to increase our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, certain employees may need to perform activities that are beyond their regular scope of work, and we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in executing our growth strategy to identify, discover, develop, in-license or acquire additional product candidates or our growth strategy may not deliver the anticipated results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to source new product candidates that are complementary to our existing product candidates through our internal discovery program, or in-licensing or acquiring them from other companies or academic institutions. If we are unable to identify, discover, develop, in-license or acquire and integrate product candidates in accordance with this strategy, our ability to pursue this part of our growth strategy would be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research programs and business development efforts to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. In-licensing and acquisitions of technology often require significant payments, expenses and will consume additional resources. We will need to devote a substantial amount of time and personnel to research, develop and commercialize any acquired technology, in addition to our existing portfolio of programs. Our research programs, business development efforts or licensing attempts may fail to yield additional complementary or successful product candidates for clinical development and commercialization for a number of reasons, including, but not limited to, the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates with a high probability of success for development progression; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able or willing to assemble sufficient resources or expertise to in-license, acquire or discover additional product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for product candidates we seek to in-license or acquire, we may not be able to agree to acceptable terms with the licensor or owner of those product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our product candidates may not succeed in preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not succeed in formulation or process development; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive regulatory approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates that we develop may be covered by third parties&#x2019; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates that we develop may not allow us to leverage our expertise and our development and commercial infrastructure as currently expected; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of these events occurs, we may not be successful in executing our growth strategy or our growth strategy may not deliver the anticipated results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to adequately protect our proprietary technology and product candidates, if the scope of the patent protection obtained is not sufficiently broad, or if the terms of our patents are insufficient to protect our product candidates for an adequate amount of time, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our product candidates may be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely primarily upon a combination of patents, trademarks, trade secret protection, and other intellectual property rights as well as nondisclosure, confidentiality and other contractual agreements to protect the intellectual property related to our brands, product candidates, including avasopasem and rucosopasem, and other proprietary technologies. Our success depends on our ability to develop, manufacture, market and sell our product candidates, if approved, and use our proprietary technologies without alleged or actual infringement, misappropriation or other violation of the patents and other intellectual property rights of third parties. There have been many lawsuits and other proceedings asserting patents and other intellectual property rights in the pharmaceutical and biotechnology industries. We cannot assure you that our product candidates, including avasopasem and rucosopasem, will not infringe existing or future third-party patents. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing our product candidates, including avasopasem and rucosopasem. There may also be issued patents or pending patent applications that we are aware of, but that we think are irrelevant to our product candidates, including avasopasem and rucosopasem, which may ultimately be found to be infringed by the manufacture, sale, or use of our product candidates, including avasopasem and rucosopasem. Moreover, we may face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. In addition, many of our product candidates, including avasopasem and rucosopasem, have a complex structure that makes it difficult to conduct a thorough search and review of all potentially relevant third-party patents. Because we have not yet conducted a formal freedom to operate analysis for patents related to our product candidates, we may not be aware of issued patents that a third party might assert are infringed by one of our current or future product candidates, which could materially impair our ability to commercialize our product candidates. Even if we diligently search third-party patents for potential infringement by our products or product candidates, including avasopasem or rucosopasem, we may not successfully find patents that our products or product candidates, including avasopasem or rucosopasem, may infringe. If we are unable to secure and maintain freedom to operate, others could preclude us from commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process of obtaining patent protection is expensive and time-consuming, and we may not be able to prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations or products and may choose not to pursue patent protection in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, in some jurisdictions some of our products currently or in the future may not be, protected by patents. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which we have patent protection that may not be sufficient to terminate infringing activities. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, we cannot guarantee that any patents will be issued from any pending or future owned or licensed patent applications, or that any current or future patents will provide us with any meaningful protection or competitive advantage. Even if issued, existing or future patents may be challenged, including with respect to ownership, narrowed, invalidated, held unenforceable or circumvented, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our product candidates, including avasopasem and rucosopasem, and technologies. Moreover, should we be unable to obtain meaningful patent coverage for clinically relevant infusion rates for avasopasem and rucosopasem in jurisdictions with commercially significant markets, our ability to extend and reinforce patent protection for these product candidates in those jurisdictions may be adversely impacted, which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for those product candidates. Other companies may also design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our products or practicing our own patented technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights may be uncertain. The standards that the United States Patent and Trademark Office, or the USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly. Changes in either the patent laws, implementing regulations or the interpretation of patent laws may diminish the value of our rights. The legal systems of certain countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. For example, patent laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of treatment of the human body more than United States law does. In addition, many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#x201c;work&#x201d; the invention in that country, or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because patent applications in the United States, Europe and many other jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to conceive or reduce to practice the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or pending patent applications. We can give no assurance that all of the potentially relevant art relating to our patents and patent applications has been found; overlooked prior art could be used by a third party to challenge the validity, enforceability and scope of our patents or prevent a patent from issuing from a pending patent application. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the validity, enforceability and scope of our patents in the United States, Europe and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in other countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against our competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third parties may challenge any existing patent or future patent we own or license through adversarial proceedings in the issuing offices or in court proceedings, including as a response to any assertion of our patents against them. In any of these proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable, or even if valid and enforceable, insufficient to provide protection against competing products and services sufficient to achieve our business objectives. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or reexamination by the USPTO if a third party asserts a substantial question of patentability against any claim of a U.S. patent we own or license. The adoption of the Leahy-Smith America Invents Act, or the Leahy-Smith Act, in September 2011 established additional opportunities for third parties to invalidate U.S. patent claims, including inter partes review and post-grant review proceedings. Outside of the United States, patents we own or license may become subject to patent opposition or similar proceedings, which may result in loss of scope of some claims or the entire patent. In addition, such proceedings are very complex and expensive, and may divert our management&#x2019;s attention from our core business. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our products, and if we do not own or have exclusive rights to other enforceable patents protecting our products or other technologies, competitors and other third parties could market products and use processes that are substantially similar to, or superior to, ours and our business would suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to develop products that are similar to, or better than, ours in a way that is not covered by the claims of our patents; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we might not have been the first to conceive or reduce to practice the inventions covered by our patents or pending patent applications; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we might not have been the first to file patent applications for our inventions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own. We currently in-license certain intellectual property from third parties to be able to use such intellectual property in our products and product candidates and to aid in our research activities. In the future, we may in-license intellectual property from additional licensors. We may rely on certain of these licensors to file and prosecute patent applications and maintain, or assist us in the maintenance of, patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted diligently or in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate, or support our efforts to initiate, an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights, trade secrets or other intellectual property, or those of our licensors. To counter infringement, misappropriation, unauthorized use or other violations, we may be required to file legal claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to prevent, alone or with our licensees or any future licensors, infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third party or a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates, including avasopasem and rucosopasem. Such a loss of patent protection could harm our business. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from exploiting the claimed subject matter at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from exploiting its technology on the grounds that our patents do not cover such technology. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making, using, importing and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In any infringement, misappropriation or other intellectual property litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. We may not be able to detect or prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries are subject to rapid technological change and substantial litigation regarding patent and other intellectual property rights. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for or obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates, including avasopasem and rucosopasem, and services. Numerous third-party patents exist in the fields relating to our products and services, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our product candidates, including avasopasem and rucosopasem, services and technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that cover our product candidates, including avasopasem and rucosopasem, services and technologies. Therefore, it is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies for our product candidates, including avasopasem and rucosopasem, or processes, or to obtain licenses or cease certain activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are determined to be held invalid or unenforceable. Our failure to obtain or maintain a license to any technology that we require to develop or commercialize our current and future product candidates, including avasopasem and rucosopasem, may materially harm our business, financial condition and results of operations. Furthermore, we would be exposed to a threat of litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who allege that our product candidates, including avasopasem and rucosopasem, components of our product candidates, including avasopasem and rucosopasem, services, and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or proceedings include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our product candidates, including avasopasem and rucosopasem, or processes do not infringe those third parties&#x2019; patents; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our collaborators may participate at substantial cost in International Trade Commission proceedings to abate importation of third-party products that would compete unfairly with our products; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, derivation or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if third parties initiate litigation claiming that our processes or product candidates, including avasopasem and rucosopasem, infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if third parties initiate litigation or other proceedings, including inter partes reviews, oppositions or other similar agency proceedings, seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their products, services, or technologies do not infringe our patents or patents licensed to us, we will need to defend against such proceedings; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our product candidates, including avasopasem and rucosopasem; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or product candidates, including avasopasem and rucosopasem, infringe or misappropriate its patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect our business. Any such claim could also force use to do one or more of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the product candidate, service, or technology at issue infringes or violates the third party&#x2019;s rights, and if the court finds that the infringement was willful, we could be ordered to pay up to treble damages and the third party&#x2019;s attorneys&#x2019; fees; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pay substantial damages to our customers or end users to discontinue use or replace infringing technology with non-infringing technology; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the product or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product, service, or technology; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">redesign our product candidates, including avasopasem and rucosopasem, services, and technology so they do not infringe or violate the third party&#x2019;s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enter into cross-licenses with our competitors, which could weaken our overall intellectual property position; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">find alternative suppliers for non-infringing products and technologies, which could be costly and create significant delay; or </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">relinquish rights associated with one or more of our patent claims, if our claims are held invalid or otherwise unenforceable. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our product candidates, including avasopasem and rucosopasem. Third parties may assert infringement claims against our customers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors, or may be required to obtain licenses for the product candidates, including avasopasem and rucosopasem, or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our common stock. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to patent and trademark protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Because we expect to rely on third parties to manufacture our product candidates, including avasopasem and rucosopasem, and we expect to continue to collaborate with third parties on the development of our product candidates, including avasopasem and rucosopasem, we must, at times, share trade secrets with them. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them prior to disclosing our proprietary information, such as our consultants and vendors, or our former or current employees. These agreements typically limit the rights of third parties to use or disclose our confidential information, including our trade secrets. We also enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, however, any of these parties may breach the agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to enforce trade secret protection. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, operating results and financial condition. Additionally, we cannot be certain that competitors will not gain access to our trade secrets and other proprietary confidential information or independently develop substantially equivalent information and techniques.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future product candidates, including avasopasem and rucosopasem, and processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involves both technological and legal complexity, and is therefore costly, time consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith Act was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, and switched the United States patent system from a &#x201c;first-to-invent&#x201d; system to a &#x201c;first-to-file&#x201d; system. Under a &#x201c;first-to-file&#x201d; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had conceived or reduced to practice the invention earlier. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular, the first-to-file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">applications. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#x201c;nonexclusive, nontransferable, irrevocable, paid-up license&#x201d; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#x201c;march-in rights.&#x201d; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#x201c;nonexclusive, partially exclusive, or exclusive license&#x201d; to a &#x201c;responsible applicant or applicants.&#x201d; If the patent owner refuses to do so, the government may grant the license itself. We partner with a number of universities, including the University of Iowa, Northwestern University, and the University of Texas Southwestern Medical Center, with respect to certain of our research, development and manufacturing. While it is our policy to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we do not obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, including avasopasem and rucosopasem, thereby potentially extending the term of marketing exclusivity for such product candidates, including avasopasem and rucosopasem, our business may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, including avasopasem and rucosopasem, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to a maximum of five years beyond the normal expiration of the patent if the patent is eligible for such an extension under the Hatch-Waxman Act as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request and the patent term may still expire before or shortly after we receive FDA marketing approval. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, including avasopasem and rucosopasem, or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our own, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During trademark registration proceedings, our trademark application(s) may be rejected. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties can oppose pending trademark applications and seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product candidate(s), including avasopasem and rucosopasem, in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. In addition, third parties have used trademarks similar and identical to our trademarks in foreign jurisdictions and have filed or may in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In any case, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to adequately protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our key patent families have been filed in the United States, as well as in numerous jurisdictions outside the United States. However, our intellectual property rights in certain jurisdictions outside the United States may be less robust. The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. For example, the requirements for patentability may differ in certain countries, particularly developing countries, and we may be unable to obtain issued patents that contain claims that adequately cover or protect our current or future product candidates, including avasopasem and rucosopasem. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market current or future product candidates, including avasopasem and rucosopasem. Consequently, we may not be able to prevent third parties from practicing our technology in all countries outside the United States, or from selling or importing products made using our technology in and into those other jurisdictions where we do not have intellectual property rights. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our product candidates, including avasopasem and rucosopasem, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates, including avasopasem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">and rucosopasem.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot guarantee that any of our or our licensors&#x2019; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates, including avasopasem and rucosopasem, in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates, including avasopasem and rucosopasem could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates, including avasopasem and rucosopasem, or the use of our products. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates, including avasopasem and rucosopasem. We may incorrectly determine that our product candidates, including avasopasem and rucosopasem, are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates, including avasopasem and rucosopasem, and services. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates, including avasopasem and rucosopasem, and services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates, including avasopasem and rucosopasem, that are held to be infringing. We might, if possible, also be forced to redesign products, product candidates, including avasopasem and rucosopasem, or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our product candidates, including avasopasem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">and rucosopasem, for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan, and the protection patents afford is limited. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Even if patents covering our product candidates, including avasopasem and rucosopasem, are obtained, once the patent life has expired for patents covering a product or product candidate, we may be open to competition from competitive products and services. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we seek broad coverage under our existing patent applications, there is always a risk that an alteration to products or processes may provide sufficient basis for a competitor to avoid infringing our patent claims. In addition, patents, if granted, expire and we cannot provide any assurance that any potentially issued patents will adequately protect our product candidates, including avasopasem and rucosopasem. Once granted, patents may remain open to invalidity challenges including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology, but that are not covered by the claims of the patents that we own or control, assuming such patents have issued or do issue; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third parties performing manufacturing or testing for us using our product candidates, including avasopasem and rucosopasem, or technologies could use the intellectual property of others without obtaining a proper license; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop or in-license additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do and may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our licensors, competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, and we are not currently subject to any claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or product candidates, including avasopasem and rucosopasem. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and could result in customers seeking other sources for the technology, or in ceasing from doing business with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, while we typically require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. To the extent that we fail to obtain such assignments, such assignments do not contain a self-executing assignment of intellectual property rights or such assignment agreements are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property and this may interfere with our ability to capture the commercial value of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. We may be subject to claims that former collaborators or other third parties have an ownership interest in our patents or other intellectual property. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we are unsuccessful, we could lose valuable rights in intellectual property that we regard as our own.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in obtaining necessary intellectual property rights to future products through acquisitions and in-licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we intend to develop products and technology through our own internal research, we may also seek to acquire or in-license technologies to grow our product offerings and technology portfolio. However, we may be unable to acquire or in-license intellectual property rights relating to, or necessary for, any such products or technology from third parties on commercially reasonable terms or at all. In that event, we may be unable to develop or commercialize such products or technology. We may also be unable to identify products or technology that we believe are an appropriate strategic fit for our Company and protect intellectual property relating to, or necessary for, such products and technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The in-licensing and acquisition of third-party intellectual property rights for product candidates, including avasopasem and rucosopasem, is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights for products that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to additional technologies or products, our business, financial condition, results of operations and prospects for growth could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for products and technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for products or technology on terms that would allow us to make an appropriate return on our investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Risks Related to Our Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The COVID-19 pandemic has adversely impacted and could continue to adversely impact, our business, including our preclinical studies and clinical trials, results of operations and financial condition.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended. In response to the spread of COVID-19, we have intermittently closed our executive offices with our administrative employees continuing their work outside of our offices and restricted on-site staff to only those required on-site to execute their job responsibilities. While we are currently continuing our ongoing clinical trials, the COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for certain of our clinical trials. In April 2020, we delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem manganese in patients with HNC undergoing standard-of-care radiotherapy. The first patient was dosed in the trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to ensure we are positioned to maintain the planned size of the safety database in a timely manner. We have since completed the enrollment in the Phase 2a trial in Europe and the ROMAN trial. We are continuing to monitor the impact of the COVID-19 pandemic on our operations and ongoing clinical development activity, generally. As a result of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COVID-19 pandemic, we may experience further disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in enrolling patients in our clinical trials;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in the operations of the FDA or foreign regulatory authorities, which may impact approval timelines;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing or supply shortages, production slowdowns, global shipping delays or stoppages and disruptions in delivery systems; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations on employee resources, including at our third-party vendors, that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA or foreign regulatory authorities to accept data from clinical trials in affected geographies;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties with equity offerings due to disruptions and uncertainties in the securities market.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the trading prices for our and other biopharmaceutical companies&#x2019; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms. The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak further impacts our business, including our preclinical studies and clinical trials, results of operations and financial condition will depend on future developments which are highly uncertain and cannot be predicted with confidence. Such factors include but are not limited to the duration of the outbreak, travel restrictions, quarantines, shelter-in-place orders and social distancing in the United States and other countries, business closures or business disruptions, the effectiveness of vaccines and vaccine distribution efforts, the availability and effectiveness of COVID-19 testing, the ultimate impact of COVID-19 on financial markets and the global economy, and the effectiveness of other actions taken in the United States and other countries to contain and treat the disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes which prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician providers (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified-nurse midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Doing business internationally involves a number of risks, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws and export and import restrictions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employment laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional potentially relevant third-party patent rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">complexities and difficulties in obtaining protection and enforcing our intellectual property; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties in staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limits in our ability to penetrate international markets; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">natural disasters, political and economic instability, including wars, such as the developing conflict between Russia and Ukraine, terrorism, political unrest, outbreak of disease, such as the novel coronavirus, and boycotts; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">curtailment of trade, and other business restrictions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">certain expenses including, among others, expenses for travel, translation and insurance; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our internal computer systems, or those of our third-party CMOs, CROs, contractors and consultants, may fail or suffer security breaches, which could result in a material disruption of our product candidates&#x2019; development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite the implementation of security measures, our internal computer systems and those of our third-party CMOs, CROs, contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, theft, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we do not believe that we have experienced any such system failure or accident, from time to time, we have been the target of cybersecurity breach attempts and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and becoming more prevalent. While we do not believe that these cybersecurity breaches have had a material impact on our operations, future breaches may do so. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or collectively, HIPAA. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. We are not currently regulated as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#x2019;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#x2019;s requirements for disclosure of individually identifiable health information. As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Such state laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the CCPA went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the CPRA recently passed in California. The CPRA will significantly amend the CCPA and will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations abroad, including our clinical trial programs outside the United States may also be subject to increased scrutiny or attention from data protection authorities. Our activities outside the United States impose additional compliance requirements and generate additional risks of enforcement for noncompliance. In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, ; in July 2020, the Court of Justice of the EU, or CJEU, limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SCCs). The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU, and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the United Kingdom; the United Kingdom&#x2019;s Information Commissioner&#x2019;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we conduct our business, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. Failure by our CROs and other third-party contractors to comply with strict rules on the transfer of personal data outside of the EU/EEA into the United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, from January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term. The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us, our third-party CMOs, CROs, contractors, or consultants to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#x2019; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Claims that we have violated individuals&#x2019; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We could incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of changes to applicable laws and regulations and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There has been increasing public focus by investors, environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation may suffer. In addition, we may experience increased costs in order to execute upon our sustainability goals and measure achievement of those goals, which could have an adverse impact on our business and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Insurance policies are expensive and protect us only from some business risks, which leaves us exposed to uninsured liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of the insurance policies we currently maintain include general liability, employment practices liability, property, workers&#x2019; compensation, umbrella, and directors&#x2019; and officers&#x2019; insurance. These policies may not adequately cover all categories of risk that our business may encounter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for avasopasem, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property or result in public exposure of personal information of our employees, clinical trial patients, customers and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image and goodwill. Any of these events could have a material adverse effect on our business, prospects, operating results and financial condition and could adversely affect the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees and independent contractors, including consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Misconduct by our employees and independent contractors, including consultants, vendors, and any third parties we may engage in connection with development and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA and other comparable regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, public health emergency, such as the novel coronavirus, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, under Section 382 of the Code, a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre change net operating losses, or NOLs, to offset future taxable income. Our existing NOLs may be subject to limitations arising from ownership changes, and if we undergo an ownership change, our ability to utilize NOLs could be further limited by Section 382 of the Code. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs even if we attain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a multinational company that faces complex taxation regimes in various jurisdictions. Audits, investigations, and tax proceedings could have a material adverse effect on our business, results of operations, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to income and non-income taxes in multiple jurisdictions. Income tax accounting often involves complex issues, and judgment is required in determining our worldwide provision for income taxes and other tax liabilities. In particular, the jurisdictions in which we operate have detailed transfer pricing rules, which require that all transactions with non-resident related parties be priced using arm&#x2019;s length pricing principles within the meaning of such rules. We could be subject to tax audits involving transfer pricing issues. We believe that our tax positions are reasonable and our tax reserves are adequate to cover any potential liability. However, tax authorities in certain jurisdictions may disagree with our position, including the propriety of our related party arm&#x2019;s length transfer pricing policies and the tax treatment of corresponding expenses and income. If any of these tax authorities were successful in challenging our positions, we may be liable for additional income tax and penalties and interest related thereto in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our directors, officers and principal stockholders own a significant percentage of our stock and, if they choose to act together, are able to exercise influence over matters submitted to stockholders for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our officers, directors and principal stockholders each holding more than 5% of our common stock, collectively, control approximately 35% of our outstanding common stock as of December 31, 2021. Accordingly, these stockholders, if they act together, will be able to exert a significant degree of influence over our management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control of us, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of us or our assets, and might affect the prevailing market price of our common stock due to investors&#x2019; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an &#x201c;emerging growth company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering, or IPO (December 31, 2024), (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years, or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">last business day of our most recently completed second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#x2019;s report on the financial statements; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may choose to take advantage of some, but not all, of the available exemptions. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our shares price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a &#x201c;smaller reporting company&#x201d; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are considered a &#x201c;smaller reporting company.&#x201d; We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred and expect to continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we have incurred, and particularly after we are no longer an &#x201c;emerging growth company,&#x201d; expect to continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have engaged in a process to document and evaluate our internal control over financial reporting, which has been both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm, as applicable, will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could cause us to need to restate our previously issued financial statements and could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, other employees or our stockholders to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our amended and restated certificate of incorporation or our amended and restated bylaws, or (4) any action asserting a claim governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, or the rules and regulations thereunder. In addition, our bylaws provide that the federal district courts of the United States are the exclusive forum for any complaint raising a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation and bylaws described above.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive forum provisions may have the effect of discouraging lawsuits against us and our directors, officers and other employees. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation or bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. Additionally, the proposal to pay future dividends to stockholders will effectively be at the sole discretion of our board of directors after taking into account various factors our board of directors deems relevant, including our business prospects, capital requirements, financial performance and new product development. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may acquire businesses, or products or product candidates, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have acquired and in-licensed, and may acquire or in-license additional businesses or products, from other companies or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition or license, we will achieve the expected synergies to justify the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The impact of the Tax Act on our financial results is not entirely clear and could differ materially from the financial statements provided herein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 22, 2017, the United States enacted the Tax Act, which significantly reformed the U.S. Internal Revenue Code of 1986, as amended, or the Code. Among a number of significant changes to the current U.S. federal income tax rules, the Tax Act reduced the marginal U.S. corporate income tax rate from 35% to 21%, limited the deduction for net interest expense, shifted the United States toward a more territorial tax system, and imposed new taxes to combat erosion of the U.S. federal income tax base. The financial statements contained herein reflect the effects of the Tax Act based on current guidance. However, there remain uncertainties and ambiguities in the application of certain provisions of the Tax Act, and, as a result, we made certain judgments and assumptions in the interpretation thereof. The U.S. Treasury Department and the Internal Revenue Service may issue further guidance on how the provisions of the Tax Act will be applied or otherwise administered that differs from our current interpretation. In addition, the Tax Act could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation on us. Moreover, the U.S. government may enact significant changes to the taxation of business entities including, among others, the imposition of minimum taxes or surtaxes on certain types of income. As we further analyze the impact of the Tax Act and any new tax legislation and collect relevant information to complete our computations of the related accounting impact, we may make adjustments to the provisional amounts that could materially affect our provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may not be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An active public trading market for our common stock may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The price of our common stock is likely to be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our share price is likely to be volatile. The shares market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at a price that you consider reasonable. The market price for our common stock may be influenced by many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of clinical trials for our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in the commencement, enrollment and the ultimate completion of clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results and potential impact of competitive products or technologies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to manufacture and successfully produce our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">financing or other corporate transactions, or inability to obtain additional funding; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to meet or exceed expectations of the investment community; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our efforts to discover, develop, acquire or in-license additional product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic, industry and market conditions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in voting control of our executive officers and certain other members of our senior management or affiliates who hold our shares; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the other factors described in this &#x201c;Risk Factors&#x201d; section. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our shares price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. We do not have any control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrades our shares or issues other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the price of our common stock or its trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in dilution of the percentage ownership of our stockholders and could cause our common stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing additional common stock or other equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our principal office is located at 2 W. Liberty Blvd, Suite 100, Malvern, Pennsylvania 19355, where we lease approximately 12,200 square feet of office space under a lease that terminates on February 28, 2023. We intend to add new facilities or space as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not subject to any material legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ty Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INFORMATION ABOUT OUR EXECUTIVE OFFICERS AND DIRECTORS</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth information regarding our executive officers and directors as of the date of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:41.998%;"></td>
    <td style="width:8.077%;"></td>
    <td style="width:49.925%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Age</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Position</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Executive Officers</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">J. Mel Sorensen, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Christopher Degnan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mark Bachleda</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Commercial Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robert A. Beardsley, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Operating Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jon T. Holmlund, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Medical Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jennifer Evans Stacey</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Legal &amp; Compliance Officer and Secretary</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Directors</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Michael Powell, Ph.D.(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chairman of the Board</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lawrence Alleva(1)(2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emmett Cunningham, M.D., Ph.D., MPH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Kevin Lokay(1)(2)(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Linda West (1)(2)(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05555555555555555in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;border-bottom:0.750pt solid;margin-right:88.0%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	Member of the Audit Committee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)	Member of the Compensation Committee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(3)	Member of the Nominating and Corporate Governance Committee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Executive Officers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">J. Mel Sorensen, M.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served as Director, Chief Executive Officer and President of Galera since 2012. Dr. Sorensen serves on the boards of directors of several private companies including Esanik Therapeutics, Medsyn Biopharma and PlanetVerify Ltd. He is an advisor to the Biomarkers Consortium of the National Institutes of Health and to the Irish Cancer Society. Dr. Sorensen holds an M.B., B.Ch. and B.A.O. from University College, Dublin. Dr. Sorensen&#x2019;s postgraduate education and work has been in the United States, including an internal medicine residency in St. Louis and medical oncology fellowship at the Mayo Clinic, seven years at the National Cancer Institute as Senior Investigator in the Cancer Therapy Evaluation Program and four years each with Bayer and GlaxoSmithKline. Dr. Sorensen served as Director, Chief Executive Officer and President of Ascenta Therapeutics from 2004 until he joined Galera. We believe Dr. Sorensen&#x2019;s experience in the industry, his role as our Chief Executive Officer and President and his knowledge of the Company enable him to make valuable contributions to our board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Christopher Degnan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served as our Chief Financial Officer since October 2019 and served as our Secretary from October 2019 to October 2021. Mr. Degnan was most recently the Chief Financial Officer at Verrica Pharmaceuticals Inc., a public, late-stage biotechnology company focused on medical dermatology, from March</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 to October 2019. Prior to Verrica, Mr. Degnan held roles of increasing responsibility at Endo International plc, a generics and specialty branded pharmaceutical company, beginning in November 2014, where he most recently served as the Vice President of Finance, Corporate FP&amp;A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. Prior to that, he served as the Vice President of Finance, Chief Financial Officer for Endo&#x2019;s U.S. Branded Pharmaceuticals segment from March 2016 to December 2016, and as the Senior Finance Director, U.S. Branded Pharmaceuticals from November 2014 to March 2016. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004, most recently as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014. He is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status). Mr. Degnan holds a B.B.A. degree in Accountancy from the University of Notre Dame.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mark J. Bachleda, Pharm.D., MBA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as our Chief Commercial Officer since October 2021. Prior to Galera, Dr. Bachleda served as Vice President &amp; US Business Unit Head of the CAR T Cell Therapy Franchise at Bristol Myers Squibb (BMS), launching Breyanzi&#174; (liso-cel), a CD19 CAR T in large B cell lymphoma, and Abecma&#174; (ide-cel), the first BCMA CAR T in relapsed/refractory multiple myeloma. He held the same role at Celgene Corporation before its acquisition by BMS for $74 billion in 2019. He served as Vice President, Sales &amp; Account Management at Juno Therapeutics before its $9 billion sale to Celgene in 2018. Previously, Dr. Bachleda worked at Amgen for 15 years in commercial operations roles of increasing responsibility up to Country President &amp; General Manager of Amgen Czech Republic where he led an enterprise of 11 commercialized therapies including launches of Kyprolis&#174;, Blincyto&#174;, and Repatha&#174;. Dr. Bachleda is a registered pharmacist and received his Doctor of Pharmacy degree (Pharm.D.) from the University of Illinois at Chicago. He completed a post-doctoral fellowship in Health Policy &amp; Economics at Thomas Jefferson University and holds Master of Business Administration (MBA) degrees from both Columbia University and University of California at Berkeley.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Robert A. Beardsley, Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a co-founder of the Company, has served as our Chief Operating Officer since 2015, and previously served as our Executive Chair from 2012 to 2017. Prior to this, Dr. Beardsley was the Chief Executive Officer at Galera Therapeutics, LLC from 2010 to 2012, at Metabolic Solutions Development Corporation from 2009 until 2010, and at Kereos from 2003 until 2009, and the acting Chief Executive Officer at Metaphore Pharmaceuticals, Inc. in 2002. He has also served in various management roles at Confluence Life Sciences, bioStrategies Group, Vector Securities International, Enzyme Organics and Mobil Oil. Dr. Beardsley has served on a number of boards of directors of public and private companies including Euclises, Epigenetx, KemPharm, Kereos, CollaGenex Pharmaceuticals, Bioseek, and Metaphore Pharmaceuticals. Dr. Beardsley received a B.S. in Chemical Engineering, a Ph.D. in Biochemical Engineering from the University of Iowa and an M.B.A. in Finance from the University of Chicago.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Jon T. Holmlund, M.D. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served as our Chief Medical Officer since October 2012. Dr. Holmlund previously served as the Chief Medical Officer of Ascenta Therapeutics from April 2004 until November 2007 and at Isis (now lonis) Pharmaceuticals from August 1997 until March 2004, including as Vice President of Development from March 2003 until March 2004. Dr. Holmlund has also been an independent consultant on oncology drug development to the biopharmaceutical industry. He previously served as Medical Director of Aspire IRB, LLC, and as a senior investigator in the National Cancer Institute&#x2019;s Cancer Therapy Evaluation Program and Biological Response Modifiers Programs. Dr. Holmlund received his M.D. from SUNY Buffalo and completed postgraduate training in internal medicine and medical oncology at George Washington University Medical Center.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Jennifer Evans Stacey, Esq.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as our Chief Legal &amp; Compliance Officer and Secretary since October 2021. Prior to Galera, Ms. Stacey served as Vice President, General Counsel, Secretary and Government Relations at The Wistar Institute, an international biomedical research institute focused on cancer, vaccines and infectious disease from April 2016 to October 2021. Previously, she served as Senior Vice President, General Counsel, Human Resources and Secretary at Antares Pharma, Inc. from May 2014 to July 2015. Prior to that, Ms. Stacey served as Executive Vice President, General Counsel, Human Resources, and Secretary at Auxilium Pharmaceuticals, Inc., and as Senior Vice President, Corporate Communications, General Counsel and Secretary at Aventis Behring, LLC (now CSL Behring). She began her career in life sciences at Rh&#xf4;ne-Poulenc Rorer (now Sanofi) including two years in their Paris office. Ms. Stacey currently serves on the board of directors of Context Therapeutics. Ms. Stacey graduated with an A.B. from Princeton University and earned her J.D. from the University of Pennsylvania Law School.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Directors</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Michael Powell, Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served as a member of our board of directors since November 2016 and as its Chair since July 2017, and also serves as Chair of our Nominating and Corporate Governance Committee. In August 2021, Dr. Powell joined Omega Funds as an Executive Partner. Previously, he was a General Partner at Sofinnova Investments, a biopharmaceutical investment firm, from 1997 until June 2021. Dr. Powell was Group Leader of Drug Delivery at Genentech from 1990 until 1997, and Director of Product Development at Cytel from 1987 until 1990. Dr. Powell currently serves as the Chair of the boards of directors of Checkmate Pharma and Dauntless Pharmaceuticals and sits on the board of directors of several private companies, including Pionyr Immunotherapeutics and Aeovian Pharmaceuticals. He also serves on the Washington University board of trustees in St. Louis and is an Adjunct Professor of Pharmaceutical Chemistry at the University of Kansas. Dr. Powell holds a Ph.D. in Physical Chemistry from the University of Toronto and he completed post-doctoral studies in Bioorganic Chemistry at the University of California as a National Science and Engineering Research Council Scholar. We believe Dr. Powell is qualified to serve on our board of directors due to his extensive experience in investing in pharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lawrence Alleva</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since June 2019 and also serves as Chair of our Audit Committee. He is a former partner with PricewaterhouseCoopers LLP (PwC), where he worked for 39 years from 1971 until his retirement in June 2010, including 28 years&#x2019; service as a partner. Mr. Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm&#x2019;s Assurance Practice from 2006 until 2010. Mr. Alleva currently serves on the boards of directors of Bright Horizons Family Solutions, Inc., Mersana Therapeutics, Inc. and Adaptimmune Therapeutics PLC and chairs the audit committee for those companies. He previously served on the boards of directors and as chair of the audit committees of TESARO, Inc. from March 2012 to the time of its sale to GSK in January 2019, Mirna Therapeutics, Inc. from June 2015 until its merger with another company in September 2017 and of GlobalLogic, Inc. from June 2011 through the sale of the company in June 2014. Mr. Alleva is a Certified Public Accountant (inactive). He received a B.S. degree in Accounting from Ithaca College and attended Columbia University&#x2019;s Executive M.B.A. non-degree program. We believe Mr. Alleva is qualified to serve on our board of directors due to his finance background and industry experience, including his service on the boards of directors of other public biotechnology companies.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emmett Cunningham, M.D., Ph.D.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since September 2018. Dr. Cunningham is an Operating Partner at Blackstone Life Sciences, a life sciences investment firm, having joined Blackstone as part of its acquisition of Clarus in December 2018. He joined Clarus in 2006 as a Principal. From February 2004 to December 2005, he was Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., a pharmaceutical company. From April 2002 to February 2004, Dr. Cunningham was Vice President of Clinical Research Development and Licensing. Dr. Cunningham is also Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine and the co-founder and Chair of the Ophthalmology Innovation Summit. Dr. Cunningham has served on the boards of directors of SFJ Pharmaceuticals Group since June 2014, Annexon Biosciences since December 2014, Silktech Biopharmaceuticals since November 2017 and Lumos Pharma Inc. since January 2019. He previously served on the board of directors of Graybug Vision from May 2016 to September 2020 and the Chair of the board of directors of Restoration Robotics from October 2017 to June 2018. Dr. Cunningham received a B.S. from Drexel University, a B.A., M.D. and M.P.H. from Johns Hopkins University and a Ph.D. in neuroscience from the University of California at San Diego. We believe Dr. Cunningham is qualified to serve on our board of directors due to his experience in research and investing in medical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Kevin Lokay </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served as a member of our board of directors since March 2019. Mr. Lokay is Head of the U.S. Immuno-oncology Franchise at AstraZeneca plc, a pharmaceutical company, a position he has held since November 2019. Prior to that, Mr. Lokay was the Head of the U.S. Lung Cancer Franchise at AstraZeneca plc from August 2018 until November 2019. Mr. Lokay served as an advisor to AbbVie Inc., a pharmaceutical company, from August 2017 until December 2017. Mr. Lokay was previously Vice President and Business Unit Head, Oncology at Boehringer Ingelheim, a pharmaceutical company, a position he held from December 2009 until December 2016. Prior to joining Boehringer Ingelheim, he was President and Chief Executive Officer of Cytogen Corporation from 2007 until 2008 and served in various positions at GlaxoSmithKline from 1997 until 2007 and at Merck &amp; Co. from 1981 until 1997. Mr. Lokay received a B.A. in Economics from Lafayette College and a M.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">from Purdue University. We believe that Mr. Lokay is qualified to serve on our board of directors due to his extensive experience in the biopharmaceutical industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Linda West</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since March 2020 and also serves as Chair of our Compensation Committee. Ms. West served in multiple leadership roles of increasing responsibility for E. I. du Pont de Nemours and Company from August 1981 until her retirement in December 2019. Ms. West most recently served as Vice President, Corporate Planning and Analyses, where she led the execution of transformational transactions from October 2009 until her retirement, including major divestitures, spin-offs, acquisitions, and the merger with The Dow Company followed by simultaneous spin-offs into three independent companies. Throughout her career with DuPont, Ms. West led early and late stage businesses including DuPont Imaging Technologies, DuPont Personal Protection, DuPont Microcircuit Materials, and DuPont Industrial Imaging. Prior to serving as Vice President, Corporate Planning and Analyses, Ms. West was the Chief Financial Officer of multiple DuPont businesses and was the Vice President, General Auditor and Chief Ethics and Compliance Officer for five years during the initial implementation of the Sarbanes-Oxley Act of 2002. Ms. West currently serves on the board of directors of Context Therapeutics. Ms. West holds a B.S. in Accounting with a minor in Business Administration from the University of Delaware. We believe that Ms. West is qualified to serve on our board of directors due to her finance background and extensive experience in business management and corporate transactions.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information and Holders</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has been publicly traded on the Nasdaq Global Market under the symbol &#x201c;GRTX&#x201d; since November 7, 2019. Prior to that time, there was no public market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 4, 2022, there w</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ere 13 hold</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ers of record of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividends</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We did not repurchase any of our equity securities during the quarter ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We did not make any sales of unregistered securities during the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. [</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span id="item_7_managements_discussion_analysis_f"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the sections titled &#x201c;Summary Risk Factors&#x201d; and Part I, Item 1A. &#x201c;Risk Factors&#x201d; in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below. Our results of operations for the year ended December 31, 2019, including a discussion of the year ended December 31, 2020 compared to the year ended December 31, 2019, has been reported previously in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021, under the heading &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Avasopasem manganese (GC4419, also referred to as avasopasem) is a highly selective small molecule dismutase mimetic in development for the reduction of severe oral mucositis, or SOM, in patients with head and neck cancer, or HNC, and for the reduction of esophagitis in patients with lung cancer. SOM is a common, debilitating complication of radiotherapy in patients with HNC. In February 2018, the U.S. Food and Drug Administration, or FDA, granted Breakthrough Therapy Designation to avasopasem for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Our second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy, or SBRT, in patients with non-small cell lung cancer, or NSCLC, and locally advanced pancreatic cancer, or LAPC.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we announced corrected topline efficacy results from a Phase 3 trial of avasopasem for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC, which we refer to as the ROMAN trial. We had previously announced topline results from the ROMAN trial in October 2021. Upon further analysis following the October topline data announcement, an error by the contract research organization was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints. The corrected results demonstrated efficacy across multiple SOM endpoints with a statistically significant 16% relative reduction on the primary endpoint of reduction in the incidence of SOM (p=0.045) and a statistically significant reduction on the secondary endpoint of number of days of SOM (p=0.002), with a median of 18 days in the placebo arm versus 8 days in the avasopasem arm (56% relative reduction). Exploratory analyses, such as time to SOM onset and SOM incidence at various landmarks of radiotherapy delivered, also demonstrated clinical efficacy of avasopasem in reducing the burden of SOM. Avasopasem appeared to be generally well tolerated compared to placebo. The ROMAN trial is our second randomized trial conducted in patients with HNC to achieve statistical significance and demonstrate improved clinical benefit in reducing SOM. We plan to meet with the FDA in 2022 to discuss the results from the ROMAN trial together with the previously completed randomized Phase 2b trial with respect to the potential submission of a New Drug Application, or NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we also announced topline results from a Phase 2a multi-center trial in Europe assessing the safety and efficacy of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, which we refer to as the EUSOM trial. This trial was conducted in twelve centers across six countries in Europe and enrolled 38 patients, of which 33 completed full treatment. Avasopasem appeared to be generally well tolerated. The incidence of SOM was 54.5% and median number of days of SOM was 9 days in the EUSOM trial, in line with the ROMAN trial in which the incidence of SOM in the avasopasem arm was 54% and the median duration was 8 days.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Avasopasem is also being studied in a Phase 2a trial for its ability to reduce the incidence of radiotherapy-induced esophagitis in patients with lung cancer, which we refer to as the AESOP trial. We expect to report topline data from the AESOP trial in the first half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to developing avasopasem for the reduction of normal tissue toxicity from radiotherapy, we are developing our dismutase mimetics to increase the anti-cancer efficacy of higher daily doses of radiotherapy, or SBRT. Our second dismutase mimetic product candidate, rucosopasem, is being developed to increase the anti-cancer efficacy of SBRT and we have successfully completed Phase 1 trials of intravenous rucosopasem in healthy volunteers. In September 2021, in support of rucosopasem, we also announced final results from our pilot Phase 1/2 safety and anti-cancer efficacy trial of avasopasem in combination with SBRT in patients with unresectable or borderline resectable LAPC. The results included a minimum follow up of one year on all 42 patients enrolled in the trial and were consistent with the positive interim results reported with a minimum follow up of six months. In this proof-of-concept trial, relative improvements were observed in overall survival, progression-free survival, local tumor control and time to distant metastases. 46% of patients in the active arm were alive at last follow-up (11 out of 24) compared to 33% in the placebo arm (6 out of 18). As previously reported, 29% of patients in the active arm achieved a 30% or greater decrease in primary tumor size (partial response) compared to 11% of patients in the placebo arm. Avasopasem was well tolerated, with similar rates of early and late adverse events in the active and placebo arms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We used our observations from the pilot LAPC trial of avasopasem to inform the design of our rucosopasem clinical trials in combination with SBRT. We initiated a Phase 1/2 trial in patients with non-small cell lung cancer, or NSCLC, in October 2020, which we refer to as the GRECO-1 trial. The GRECO-1 trial is supported in part by a Small Business Innovation Research grant from the National Cancer Institute of the National Institutes of Health for the investigation of our dismutase mimetics in combination with SBRT for the treatment of lung cancer. We intend for this trial to assess the anti-cancer efficacy and safety of rucosopasem in combination with SBRT. We expect to report initial data from this trial in the first half of 2022. We initiated a Phase 2b trial of rucosopasem in combination with SBRT in patients with LAPC in May 2021, which we refer to as the GRECO-2 trial. In the future, we intend to assess the anti-cancer efficacy and safety of rucosopasem in combination with SBRT and a checkpoint inhibitor.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, we initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The randomized, double-blind, placebo-controlled Phase 2 trial is designed to assess the safety and efficacy of avasopasem in improving 28-day mortality, compared to placebo. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. In June 2021, we ceased enrolling subjects in this trial. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations in the United States at the time, we determined that it was not feasible to complete the trial.</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, acquiring and developing product and technology rights, and conducting research and development. We have incurred recurring losses and negative cash flows from operations and have funded our operations primarily through the sale and issuance of equity and proceeds received under the Amended and Restated Purchase and Sale Agreement, which we refer to as the Royalty Agreement, with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P., or collectively, Blackstone or Blackstone Life Sciences (formerly known as Clarus Ventures).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss was $80.5 million and $74.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had $71.2 million in cash, cash equivalents and short-term investments and an accumulated deficit of $316.1 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we operate as a public company, advance our product candidates through all stages of development and clinical trials, build our commercial infrastructure and, ultimately, seek regulatory approval of our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result, we will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There is no assurance that we will be successful</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all. If we are unable to secure adequate additional funding as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Business Update Regarding COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current COVID-19 pandemic continues to present a substantial public health and economic challenge around the world and is affecting our employees, communities, clinical trial sites and business operations, as well as the U.S. economy and international financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, including the effectiveness of vaccines and vaccine distribution efforts, the impact of new variants of COVID-19 and the economic impact on local, regional, national and international markets. See &#x201c;Risk Factors&#x2014;Other Risks Related to Our Business&#x2014;The COVID-19 pandemic has adversely impacted, and could continue to adversely impact, our business, including our preclinical studies and clinical trials, results of operations and financial condition&#x201d; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we are currently continuing our ongoing clinical trials, the COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for our clinical trials. We delayed the initiation of the EUSOM trial due to concerns with clinical trial enrollment in Europe during the COVID-19 pandemic. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients to ensure we were positioned to maintain the planned size of the safety database in a timely manner. We reported topline data from the ROMAN trial and the EUSOM trial in the fourth quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mitigation activities to minimize COVID-19-related operation disruptions are ongoing given the severity and evolving nature of the situation, and we are continuing to monitor the impact of the COVID-19 pandemic on our operations and ongoing clinical development activity.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third-party contract manufacturing partners continue to operate at or near normal levels. While we currently do not anticipate any material interruptions in our clinical trial supply or manufacturing scale-up activities, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our third-party suppliers and contract manufacturing partners' ability to manufacture our clinical trials supply or progress manufacturing scale-up activities.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also implemented measures designed to protect the health and safety of our workforce. Essential activities at our facilities are continuing and we are taking precautionary measures to protect our employees working in our facilities in such capacities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those described below. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalty Purchase Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to our amended Royalty Agreement with Blackstone Life Sciences, we have received cash payments totaling $117.5 million from Blackstone based upon the achievement of specified clinical milestones, which have been recorded as long-term debt obligations. Interest expense on such obligation is imputed by estimating risk adjusted future royalty payments over the term of the amended Royalty Agreement which takes into consideration the probability of obtaining FDA approval. Other significant assumptions include adjustments to estimated gross revenues to arrive at net product sales from which a royalty payment can be estimated. The non-cash interest expense recorded increases the balance of our royalty obligation. The royalty obligation will be reduced when royalty payments are made, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual royalty payments, however, are highly uncertain and may change depending on a number of factors, including our ability to obtain FDA approval, successfully commercialize our product candidates and the timing of future royalty payments. We impute interest expense on our royalty purchase obligations based on such factors at each reporting period. As these factors change, we will adjust our estimate of the imputed interest expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We accrue an expense for manufacturing, preclinical studies and clinical trial activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with CMOs, CROs and clinical trial sites. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal research and development personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of these activities are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">JOBS Act Transition Period</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to opt out of such extended transition period and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. However, we may take advantage of the other exemptions discussed below.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to certain conditions, as an emerging growth company we may rely on certain exemptions and reduced reporting requirements, including, without limitation, (1) not being required to provide an auditor&#x2019;s attestation report on our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (2) not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier to occur of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO (December 31, 2024), (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years, or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">last business day of our most recently completed second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel expenses, including salaries, benefits and share-based compensation expense for employees engaged in research and development functions; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs of funding research performed by third parties, including pursuant to agreements with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fees paid to consultants who assist with research and development activities; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses related to regulatory activities, including filing fees paid to regulatory agencies; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocated expenses for facility costs, including rent, utilities, depreciation and maintenance. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We track our external research and development expenses on a program-by-program basis, such as fees paid to CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to personnel-related and share-based compensation expense, early-stage research expenses and other costs that are deployed across multiple projects under development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses by program for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:73.365%;"></td>
    <td style="width:1.103%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:10.106%;"></td>
    <td style="width:0.707%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:10.127%;"></td>
    <td style="width:0.707%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Avasopasem manganese (GC4419)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,120</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,172</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rucosopasem manganese (GC4711)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,332</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,583</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other research and development expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,905</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,403</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel related and share-based compensation<br />&#160;&#160;&#160;expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,060</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,687</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,417</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,845</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development activities are central to our business model. Product candidates in later stages of clinical development, such as avasopasem, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Our research and development expenses may increase over the next several years as we increase personnel costs, including stock-based compensation, conduct our later-stage clinical trials for avasopasem and rucosopasem, if applicable, conduct other clinical trials for current and future product candidates and prepare regulatory filings for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of our product candidates, including the significant costs associated with our ongoing and planned clinical trials, which likely will vary significantly as a result of many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in regulators or institutional review boards authorizing us or our investigators to commence our clinical trials, or in our ability to negotiate agreements with clinical trial sites or CROs; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to secure adequate supply of our product candidates for our trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of clinical sites included in the trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability and the length of time required to enroll suitable patients; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients that ultimately participate in the trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of doses patients receive; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any side effects associated with our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration of patient follow-up; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant and changing government regulations; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of unforeseen events, such as the COVID-19 pandemic, on the initiation and completion of our preclinical studies, clinical trials and manufacturing scale-up. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of our product candidates. A change in the outcome of any of these variables with respect to the development of a product candidate could result in a significant change in the costs of and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense consists primarily of personnel expenses, including salaries, benefits and share-based compensation expense for employees in executive, finance, accounting, legal, information technology, commercial, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, not otherwise included in research and development expense, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our general and administrative expense will increase in the future to support our continued research and development activities, potential commercialization efforts, and to expand our operations and organizational capabilities. These increases will likely include increased costs related to the hiring of additional personnel, fees to outside consultants, lawyers and accountants and expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. Should we commercialize our product candidates, we expect to incur significantly increased expenses associated with building our commercial infrastructure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income consists of amounts earned on our cash and cash equivalents held with large institutional banks, U.S. Treasury obligations and a money market mutual fund invested in U.S. Treasury obligations, and our short-term investments in U.S. Treasury and government agency obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense consists of non-cash interest on proceeds received under the Royalty Agreement with Blackstone and non-cash interest expense associated with the amortization of the debt discount recorded for the Blackstone warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Gains (Losses)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency gains (losses) consist primarily of exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Tax Benefit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the year ended December 31, 2020, we recognized an income tax benefit for the revaluation of our deferred tax liability as a result of changes to the anticipated effective tax rate in certain state and local jurisdictions in which we have operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Operating Loss and Research and Development Tax Credit Carryforwards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had federal and state tax net operating loss carryforwards of $145.3 million and $167.3 million, respectively, which each begin to expire in 2032 unless previously utilized. We also had foreign net operating loss carryforwards of $1.5 million which do not expire. As of December 31, 2021, we also had federal, state and foreign research and development tax credit carryforwards of $6.1 million. The federal research and development tax credit carryforwards will begin to expire in 2032 unless previously utilized. The foreign research and development tax credit carryforwards do not have an expiration date.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the federal and state net operating losses and credits may be subject to a substantial annual limitation. The annual limitation may result in the expiration of our net operating losses and credits before we can use them. We have recorded a valuation allowance on substantially all of our deferred tax assets, including our deferred tax assets related to our net operating loss and research and development tax credit carryforwards, given the current uncertainty over our ability to utilize such amounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations for the Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth our results of operations for the years ended December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.532%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:8.178%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:8.2%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:8.167%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,417</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,845</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,428</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,951</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,708</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,243</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(73,368</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(70,553</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,815</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,174</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,142</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7,194</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4,880</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,314</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency gain (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax benefit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(80,534</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(74,234</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,300</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax benefit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(80,534</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(74,218</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,316</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense decreased by $2.4 million from $54.8 million for the year ended December 31, 2020 to $52.4 million for the year ended December 31, 2021. The decrease was primarily attributable to a decrease of $7.1 million for avasopasem development costs, as expenses decreased for the ROMAN, EUSOM, AESOP and pilot LAPC trials, all of which have completed patient enrollment, and the completion of avasopasem toxicology studies in 2020. Partially offsetting these decreases, rucosopasem development costs increased $0.7 million due to increased expenses for the GRECO-1 and GRECO-2 trials, personnel related and share-based compensation expense increased $0.4 million, and other research and development expenses increased $3.5 million due to increased costs for independent contractors and consultants primarily associated with the avasopasem SOM program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense increased by $5.2 million from $15.7 million for the year ended December 31, 2020 to $21.0 million for the year ended December 31, 2021. The increase was primarily attributable to a $2.0 million increase in personnel related and share-based compensation expense, primarily due to increased employee headcount and stock options granted to new and existing employees and board members, and a $1.8 million increase in expenses related to preparation for potential commercialization of avasopasem, and increased insurance, legal and recruiting expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income decreased by $1.1 million from $1.2 million for the year ended December 31, 2020 to $32,000 for the year ended December 31, 2021. Lower average invested cash balances during the year ended December 31, 2021 were compounded by lower average interest rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognized $7.2 million and $4.9 million in non-cash interest expense during the years ended December 31, 2021 and 2020, respectively, in connection with the Royalty Agreement with Blackstone Life Sciences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently have any approved products and have never generated any revenue from product sales. Through December 31, 2021, we have funded our operations primarily through the sale and issuance of equity and $117.5 million of proceeds received under the Royalty Agreement with Blackstone Life Sciences, receiving aggregate gross proceeds of $338.9 million. In November 2019, we completed our IPO, which resulted in the issuance and sale of 5,000,000 shares of common stock at a public offering price of $12.00 per share, generating net proceeds of $53.0 million after deducting underwriting discounts and other offering costs. On December 9, 2019, in connection with the partial exercise of the over-allotment option granted to the underwriters of our IPO, 445,690 additional shares of common stock were sold at the IPO price of $12.00 per share, generating net proceeds of approximately $5.0 million after deducting underwriting discounts and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into an Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, as sales agent, pursuant to which we may, from time to time, issue and sell common stock with an aggregate value of up to $50.0 million in &#x201c;at-the-market,&#x201d; or ATM, offerings under our Registration Statement on Form S-3 (File No. 333-251061) filed with the SEC on December 1, 2020. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for our common stock. During the year ended December 31, 2021, we sold an aggregate of 891,368 shares of our common stock under the Sales Agreement, at a weighted average price per share of $9.27, generating aggregate net proceeds of $7.9 million, after deducting fees, commissions and other expenses. As of December 31, 2021, there was $41.7 million of common stock remaining available for sale under the Sales Agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $71.2 million in cash, cash equivalents and short-term investments and an accumulated deficit of $316.1 million. We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table shows a summary of our cash flows for the periods indicated (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:73.298%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:10.032%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.017%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:10.032%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(67,958</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(59,537</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,238</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,547</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,707</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,506</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,987</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,484</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, we used $68.0 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $80.5 million and a $2.6 million net decrease in cash from changes in our operating assets and liabilities, partially offset by non-cash charges of $15.2 million related to share-based compensation, interest expense on our Royalty Agreement with Blackstone Life Sciences and depreciation expense. The primary use of cash was to fund our operations related to the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, we used $59.5 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $74.2 million, partially offset by a $3.9 million net increase in cash from changes in our operating assets and liabilities and non-cash charges of $10.8 million related to share-based compensation, interest expense on our Royalty Agreement with Blackstone and depreciation expense. The primary use of cash was to fund our operations related to the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, investing activities provided $5.2 million of net cash, primarily attributable to the $5.5 million in net proceeds from the purchases and sales of our short-term investments, partially offset by $0.3 million for the purchase of property and equipment.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, investing activities provided $36.5 million of net cash, primarily attributable to $37.0 million in net proceeds from the purchases and sales of our short-term investments, partially offset by $0.5 million for the purchase of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, financing activities provided $66.7 million in net cash proceeds, primarily attributable to $57.5 million in proceeds received in connection with the Royalty Agreement with Blackstone Life Sciences, $7.9 million in net proceeds from the sale of our common stock under the ATM Sales Agreement, and $1.3 million in proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, financing activities provided $20.5 million in net cash proceeds, primarily attributable to $20.0 million in proceeds received in connection with the Royalty Agreement with Blackstone Life Sciences and $0.5 million in proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operating expenses increased substantially in 2020 and 2021, and our expenses may continue to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur significant costs associated with operating as a public company. Accordingly, we would need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the direct and indirect impact of COVID-19 on our business and operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, prioritization and number of our research and development programs;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any;</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of securing manufacturing arrangements for commercial production; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of scaling-up or contracting for sales and marketing capabilities as we prepare for the potential commercialization of our product candidates.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for the next couple of years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical companies&#x2019; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms. See &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders&#x2019; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalty Agreement with Blackstone Life Sciences (Formerly Known as Clarus Ventures)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, we entered into the Royalty Agreement with Blackstone Life Sciences. Pursuant to the Royalty Agreement, Blackstone agreed to pay us, in the aggregate, up to $80.0 million, or the Royalty Purchase Price, in four tranches of $20.0 million each upon the achievement of specified clinical milestones in our ROMAN trial. We agreed to apply the proceeds from such payments primarily to support clinical development and regulatory activities for avasopasem, rucosopasem and any pharmaceutical product comprising or containing avasopasem or rucosopasem, or, collectively, the Products, as well as to satisfy working capital obligations and for general</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">corporate expenses. We received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively, under the Royalty Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, we entered into Amendment No. 1 to the Royalty Agreement, or the Amendment, with Clarus IV Galera Royalty AIV, L.P., or the Blackstone Purchaser. The Blackstone Purchaser is affiliated with Blackstone Life Sciences, successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $37.5 million to $117.5 million by increasing the fourth tranche from $20.0 million to $37.5 million and adding a new $20.0 million tranche upon the achievement of an additional clinical enrollment milestone. We received the new $20.0 million tranche of the Amendment in June 2021, in connection with the enrollment of the first patient in the GRECO-2 trial. Also in June 2021, we completed enrollment in the ROMAN trial, thereby achieving the milestone associated with the fourth tranche, and received the associated $37.5 million in July 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the amended Royalty Agreement, in connection with the payment of each tranche of the Royalty Purchase Price, we have agreed to sell, convey, transfer and assign to Blackstone all of our right, title and interest in a high single-digit percentage of (i) worldwide net sales of the Products and (ii) all amounts received by us or our affiliates, licensees and sublicensees with respect to Product-related damages (collectively, the Product Payments) during the Royalty Period. The Royalty Period means, on a Product-by-Product and country-by-country basis, the period of time commencing on the commercial launch of such Product in such country and ending on the latest to occur of (i) the 12th anniversary of such commercial launch, (ii) the expiration of all valid claims of our patents covering such Product in such country, and (iii) the expiration of regulatory data protection or market exclusivity or similar regulatory protection afforded by the health authorities in such country, to the extent such protection or exclusivity effectively prevents generic versions of such Product from entering the market in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amended Royalty Agreement will remain in effect until the date on which the aggregate amount of the Product Payments paid to Blackstone exceeds a fixed single-digit multiple of the actual amount of the Royalty Purchase Price received by us, unless earlier terminated pursuant to the mutual written agreement of us and Blackstone. If no Products are commercialized, we would not have an obligation to make Product Payments to Blackstone, which is the sole mechanism for repaying the liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, as partial consideration for the Amendment, we issued two warrants to the Blackstone Purchaser to purchase an aggregate of 550,661 shares of our common stock at an exercise price equal to $13.62 per share, each of which became exercisable upon the receipt by Galera of the applicable specified milestone payment. The issued warrants expire six years after the initial exercise date of each respective warrant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patheon Manufacturing Agreements</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2021, we entered into a Master Manufacturing Services Agreement with Patheon, or the Master Agreement. The Master Agreement governs the general terms under which Patheon, or one of its affiliates, will provide non-exclusive manufacturing services to Galera for the drug products specified by us from time to time. Pursuant to the Master Agreement, we have agreed to order from Patheon at least a certain percentage of our commercial requirements for a product under a related product agreement. Each product agreement that we may enter into from time to time will be governed by the terms of the Master Agreement, unless expressly modified in such product agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In August 2021, we and Patheon entered into a product agreement for avasopasem, or the Product Agreement, under the Master Agreement to govern the terms and conditions of Patheon&#x2019;s manufacture and commercial supply to us of avasopasem manganese from Patheon&#x2019;s Greenville, North Carolina manufacturing site.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Master Agreement, and any related product agreement, has an initial term that expires on December 31, 2027 and includes renewal terms, as applicable. In addition, each party has the ability to terminate the Product Agreement upon the occurrence of certain customary conditions. The Master Agreement contains representations, warranties and indemnity obligations customary for agreements of this type, and the Product Agreement establishes certain pricing for avasopasem that may be adjusted as set forth in the Master Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our obligation to purchase avasopasem under the Product Agreement is subject to certain binding forecast periods at certain established prices, which will be reviewed each year on January 1 by us and Patheon. We currently do not have any contractual commitment to purchase avasopasem under the Product Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial Statements and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.778%;"></td>
    <td style="width:7.222%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_comprehensive_lo"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Comprehensive Loss for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_changes_in_redee"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Changes in Stockholders&#x2019; Equity (Deficit) for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and Board of Directors<br />Galera Therapeutics, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Galera Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#x2019; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66bde388-2857-466a-b8c2-ab4414e1c23a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KPMG LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2014.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3441d54-eecf-4eb6-8f6c-434ca68b40e7" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Philadelphia, Pennsylvania</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />March 10, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED BA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">LANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(IN THOUSANDS EXCEPT SHARE AND PER-SHARE AMOUNTS)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.87%;"></td>
    <td style="width:1.488%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.77%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.499%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.77%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03ae8b3a-915d-42f0-9b83-70f5d83f2607" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8ba7eff-402b-47c6-a1b2-7c975cb7c636" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9751c37-fbce-4a74-a26a-298faf032f1f" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,358</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2248decf-7c37-42d0-8874-7544b409b44c" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea3ff55c-daae-48e4-99ce-0e781b6efc15" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c412ca29-fd05-41a5-aeb0-970ead320bca" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b99b6e16-a114-41f8-8256-58510003dda4" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f82797c-9b2c-4917-8f2f-7da04036b1ca" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,929</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05aca8b6-f07e-4855-a26c-c2ab26556fcd" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2a39386-de14-464b-9a1f-0ad56ee178c8" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired intangible asset</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7ced12e-9f38-4113-90e0-580ffb4b9671" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c34c419c-5045-47e9-8bd9-b98a5d9218e8" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f39d9aa0-c455-49c5-8775-e066eee5c503" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">881</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8bf7cd1-f82c-4bce-b746-158882aae03e" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">881</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use lease assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bd3644e-652c-48ec-b289-b16ef83c682c" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5940dd3-e322-4d7b-8ed0-10543cbdf82d" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_225a2847-95fd-442e-a6c5-dab42e898fcd" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e3c7cd1-dc96-4036-bd97-2e17d23f9359" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfb9afdc-3a6a-4542-99e6-4e23acacceea" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb7133f1-b9d5-404a-8a4d-379257e7d71a" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities and stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b255a598-ecf0-4f78-98d7-1c87bd8cb8c9" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,044</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51da1514-2c45-4713-9666-81c0bfc011d0" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe8ed4cf-ed62-48b0-8c45-2093285920dd" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f63c7a79-5902-43be-8b8d-10260be12ca3" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_397aef74-9dda-4c45-88f5-67db1af30c8b" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f973378d-030b-49fb-b743-39b15f886667" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc2f3fb6-c810-4303-a37c-778bf52cbe01" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e99ea15-731d-4e93-b8f0-2633510f6ea3" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalty purchase liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e22dbe74-2f08-4046-9731-a4c9b9a48294" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49409c0c-58e0-4ca4-89e9-c93947e08460" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41ecd391-106f-431e-9dde-37ae1321446a" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3a5b897-2429-494e-906a-f8272f2052cd" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4b95860-1eea-4dfb-bd45-7e19dfa18801" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxLiabilitiesDerivatives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41d7f2b3-9ff9-4fc6-b596-602ed3c6eb0b" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxLiabilitiesDerivatives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4707192b-16ec-4338-bff6-695e330f4438" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d7a7b50-1c4d-4c7d-b490-84aa3509953f" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7e88d7e-b198-42f1-a229-84f2b5828095" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b233e431-aff8-46dc-be30-ea3f59515d79" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments (Note 8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; equity (deficit):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58e0dd8b-251f-4cfc-8423-617997e49f3a" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_ca11f347-ed0f-4cb6-a3d8-a4a3ba936647" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value: </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26f1c4e5-8a49-4cf8-9dcf-b64eff3592c3" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e516d2c8-4d33-4fbb-9dfd-008819337dc3" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f191429-e08d-486f-8078-47991344b088" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5c7932d2-3da3-4727-b52e-f25ad72aea0f" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a975f507-d58d-463a-a230-a784cd8eb493" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_95f09a32-fd81-46af-9034-159645aac14f" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_045ad157-ef8a-4924-8723-a3b44032c818" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe8cdd05-65cb-4dbf-b7c5-56bc5ba237e5" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70b619b8-90f3-44ca-b4bd-eed36502c159" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_16b9a5ff-fbc3-4ded-9877-070afbb27888" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value: </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75c1f7f0-1ac6-4978-84d7-8e9c6b984cb7" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d1dc4974-c770-4c94-98fe-94ead0694c6b" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized; <br />&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da9d2293-a976-40b0-8c80-e505c8428f6d" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6681d9ec-8865-4104-b0f8-d233623eca62" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,458,767</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7153d062-5bf5-4ce3-b04d-758891ec0e79" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4bf574a7-0dfc-4849-a094-a596ab713030" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,976,142</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding at <br />&#160;&#160;&#160;December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af81d054-ddd2-49a5-91fb-75b8839f3b45" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2215632-1446-45b5-a5b7-7dacbec46e11" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0c0e5e1-54bb-4444-990b-376284e759fa" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">258,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac492c4f-63a4-44e0-87a1-693cd22ae093" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">241,649</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e330697-f6c7-4451-8ebf-c2387e90ac18" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f722f766-62ba-427a-bbdc-3365dddc397e" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5645756-7b7a-4e40-836b-affdcbec9ab7" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">316,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_825c6cf3-42df-41f6-bc1a-9c59a5e3cf11" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">235,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9084f80-7dfd-4045-8f3b-b1636400da98" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51fc4262-e363-4dc1-9fd7-1bca59520bdc" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities and stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b88c2e7b-f52a-4e8b-a60e-20928f284249" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e8f03e4-037f-4b1d-8739-8820585aac8f" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ENTS OF OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.078%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.074%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.074%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_566fcf4d-cc56-44a5-bc65-7deb1a48a156" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,417</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb80925d-f6eb-4380-8d72-90ed03dcc962" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,845</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2ec54f4-4c62-48f4-a40a-bc188ed3d5b2" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3214b2fe-09ad-4f0c-8656-28eef1e887c8" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d6b797b-2fc0-43d2-9210-2501f361b401" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e495de38-1e8c-4193-9294-65147d91a5c7" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">70,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expenses):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04e15582-0611-40e6-8761-41a18a435a1c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6ef01b3-9e6c-4a46-8c40-ccac3ccc21bd" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e02ebc59-8958-4e56-9d9b-fc5a05483765" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29502f09-d8c6-4739-981d-b1274f11ff07" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign currency gain (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39ab62e4-5d7b-4386-bf00-013fd969b119" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da72af63-6d79-447f-b8ef-baeda5256bdc" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax benefit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2cac130-2458-4b64-a175-e5df9bb9bb34" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cd0ecf0-662e-4817-b5f6-7b3c9e872cbc" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,234</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax benefit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47c89ab6-b6cc-4859-8a37-e6d1285f43ec" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dae0cda2-64a3-4013-b2cd-ba794d3f980c" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e859500-7b81-4ad2-bb73-ce44c96921c1" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09f96192-56b1-48c2-8416-75fe76430c6c" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share of common stock, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7623f939-936e-4cb3-a64c-09b6a1059663" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">3.12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57c4d773-1619-4863-b4d4-04b107c2062e" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.98</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding, basic and<br />&#160;&#160;&#160;diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3db43a0d-a18a-4a0b-af98-c33f74235724" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,789,458</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_283ef596-8d8b-48a0-9d17-71b420b80d24" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">24,869,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_comprehensive_lo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEMENTS </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OF COMPREHENSIVE LOSS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(IN THOUSANDS)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.667%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.802%;"></td>
    <td style="width:0.942%;"></td>
    <td style="width:1.552%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.802%;"></td>
    <td style="width:0.942%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_214a8cc4-6dde-421e-bdc7-e75366c6aa55" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_138436f8-ebff-49ec-b715-8a08ce8cecce" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized loss on short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bffb2923-9959-4650-946c-a4aba53128b9" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4721e29-17f9-4be0-bd29-99dfeafd60eb" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf1f11f8-458c-45c3-ac0a-3f72d1ff675a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_824f720a-3f1b-4079-9b56-bddb577b95d8" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_changes_in_redee"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEMENTS OF CHANGES IN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> STOCKHOLDERS&#x2019; EQUITY (DEFICIT)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(IN THOUSANDS EXCEPT SHARE AMOUNTS)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.731%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:8.974%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:8.524%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:8.535%;"></td>
    <td style="width:0.557%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:8.417%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:8.407%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:1.157%;"></td>
    <td style="width:1.124%;"></td>
    <td style="width:8.407%;"></td>
    <td style="width:0.739%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Additional<br />paid-in</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Accumulated<br />other<br />comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;<br />Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">income (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Balance at January 1, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2288b57b-32ec-469e-ab52-30df7f84f8ac" contextRef="C_2a9a3126-74c3-4629-800e-3c042fa2b51f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,811,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aaf19177-e299-42bc-8fe9-86ba20ef72a9" contextRef="C_2a9a3126-74c3-4629-800e-3c042fa2b51f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88ca5d12-977f-42ac-8aeb-86e9c21e2021" contextRef="C_0d65dbd3-c5d4-4b15-adcd-9b943970247a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">230,895</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9353109b-af63-46a7-b14a-69f3c3ea2c7f" contextRef="C_5872ee23-7a9b-4c65-8dcc-db0a2b7bf7b8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89201c68-8431-4fe8-ac50-d59ec94a7847" contextRef="C_eb27f37f-1cab-4e5e-87cb-015e4b21b863" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01eb18c4-03b4-48a2-b832-fb7bd4b12751" contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,608</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Issuance of common stock warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1c0218b-8a81-4899-880b-fe75bdf9ac58" contextRef="C_f9a832f5-9650-4043-bd50-c48a5692f4e5" name="grtx:IssuanceOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de9b08aa-400f-44d8-871a-37c88ec81cb5" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:IssuanceOfCommonStockWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05509f01-6625-4abb-b6f1-e0083af4c0c7" contextRef="C_f9a832f5-9650-4043-bd50-c48a5692f4e5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fc1d842-78a3-4bbf-833c-a6af5568a649" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95bc5944-b1cd-4fda-a386-c9aa6fd3521a" contextRef="C_283a587d-af22-4372-b32e-6522c523cb6e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">164,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_581a58fb-8329-4778-867d-e20f6dc9bc4b" contextRef="C_f9a832f5-9650-4043-bd50-c48a5692f4e5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57cb1a0a-26b2-46dd-9097-35bd6f4afd26" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Unrealized gain on short-term<br />&#160;&#160;&#160;investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1167400-a51b-4335-8b8f-629fc21cbc76" contextRef="C_959739eb-48eb-46c2-beb8-069b0136e9fc" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75fe50f2-f457-4dc5-a0ba-977a3031000f" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcadf226-7e17-4b18-8a57-65c4ab64f799" contextRef="C_373e0480-111d-42c8-8898-a0604bcd9d8d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c958ad5a-7a08-4ed7-b9d9-139d5971a7b2" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29e0a52d-98dc-4124-bd88-96ce811a0337" contextRef="C_90454ea7-bd37-4277-92c9-e6be357b98f4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,976,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0154fafa-2c2c-4738-931d-4441ee3d185a" contextRef="C_90454ea7-bd37-4277-92c9-e6be357b98f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_906be6f7-2541-4c2c-82fb-f41a988f9c8a" contextRef="C_8372daa2-ef3f-464f-9b15-3e1083aa76c0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">241,649</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b7d4c0a-e904-47eb-993c-e5f21ec07265" contextRef="C_161a7224-4479-4a28-b4d5-77a29763ab5d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4dcdd75d-61e0-4ab1-980e-98b70ae8e1f3" contextRef="C_0f6342f9-c1df-4acb-9bdb-a02055460487" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">235,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8b61973-4dda-441e-9e47-b79afa96d6c7" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,118</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ede47b9f-20ab-4a74-abbc-e68c82c6b877" contextRef="C_747599dd-834b-4762-88a4-e8ce71446162" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_956c885f-20b2-4217-986c-bd1854bcedd7" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6aef0bfd-f94c-4e41-8908-22c2fe1cb739" contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">591,257</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e96e5134-17aa-4646-8efe-457be2e87812" contextRef="C_747599dd-834b-4762-88a4-e8ce71446162" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1859675d-5c1b-4f07-8a69-928a4f52fc84" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Sale of shares under Open Market Sale <br />&#160;Agreement, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81bd0b7a-999e-4ccf-8232-0397b2f5a7bb" contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf" name="grtx:SaleOfSharesUnderOpenMarketSaleAgrrementShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">891,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3252fa9d-3e8c-4187-a346-b9cde56da863" contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf" name="grtx:SaleOfSharesUnderOpenMarketSaleAgrrement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_daed8111-9cf3-414d-b01d-1aea5fae8c47" contextRef="C_747599dd-834b-4762-88a4-e8ce71446162" name="grtx:SaleOfSharesUnderOpenMarketSaleAgrrement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_361c1898-cf3a-4e53-9a1d-49578348fa76" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:SaleOfSharesUnderOpenMarketSaleAgrrement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Unrealized loss on short-term<br />&#160;&#160;&#160;investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b8d26e2-7a15-46e5-b7ec-de051faea375" contextRef="C_3097c236-8fd6-46ae-9c61-fb91d2b9fe52" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9f8b751-d566-4425-8b30-1a69c0d2a14d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a8a8623-8f22-419a-a204-074559f19530" contextRef="C_61bbf69e-e94a-42b1-8fab-75d4e9b55dcc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4ee66ab-1b32-49d4-be4b-6eadb41cb386" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de951d96-b361-4b24-9fbb-718f31900278" contextRef="C_ba6ef8ac-9f4f-4b23-bbad-8188c1047172" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,458,767</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_288a45a4-4d39-485c-ae34-f3a110df76bb" contextRef="C_ba6ef8ac-9f4f-4b23-bbad-8188c1047172" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd0a6792-3aa2-4a30-a72a-f89205cd4b57" contextRef="C_50484754-2125-4a69-bac3-8fcfeb669f39" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">258,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e118a4b0-5e57-4eca-b285-c6887a4d9cdd" contextRef="C_99780757-769e-45eb-9aeb-da23f499cad1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28f77251-0b8c-4cbf-9df3-e2da3311914f" contextRef="C_2d1b5e52-e6b7-4acf-ae56-9c937aa16f4c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">316,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd510bb2-bc82-4fbf-a6da-a9f7edae3fa6" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ENTS OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(IN THOUSANDS)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.781%;"></td>
    <td style="width:1.402%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.9%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.402%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.911%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_403430fc-9e80-4937-8712-55771a315dae" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c385b7f9-0600-4a9e-957f-3b0700dce98d" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0e2e674-196e-4bdb-af67-bafb2562af4d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">778</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d69e3312-757f-4c49-9c5d-6a308328ec1d" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncash interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0503e3cd-c1e1-4fe0-b069-2df6db44be4f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5dfc2318-4414-4171-8516-384e4f6a34ce" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e20ff16-5f01-4094-ba30-15bcb8baea43" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77b6a0d9-5383-477e-aae2-fdc0e0fbbc6c" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_599b82ed-0a14-4189-a252-7a81f93d9e26" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:IncreaseDecreaseInDeferredTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62359589-94de-4900-8ea1-58b5b2b1182b" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:IncreaseDecreaseInDeferredTaxLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e56a7440-ba96-4a47-97a8-a83a42007472" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e9c445f-a925-4507-ad84-9aff7aa236c1" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b133be6f-5ec4-48db-9b4e-d918dabb5e9d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b30566a-efe5-4c3b-ac59-23d99919bade" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95daebca-b12a-4c9a-bff9-1f2d1bddc908" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea43fa1c-2ca0-4096-9117-b824e790aee9" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec082dfd-f6c3-48a0-be75-0243d3851884" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4c6b1cc-fa29-497a-8710-158b4f3f5b1e" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfef8033-f717-4fc6-afa2-771f6f1c9a0c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">307</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3301037f-b844-4e18-8bae-2d6d03df5e88" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7be4c73-cc71-488a-a29f-324d7f00a4e6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">67,958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1710b3a4-aa6e-4338-bde6-651e191da3a2" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,537</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dde04f28-511e-4643-b274-abf4de741a3e" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ffb8f34-01c1-40e7-b897-07b2f3eca644" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,746</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from sales of short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acefd0d4-02a9-4d18-ac9e-407f025d399d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_111a4bfe-d23c-4a0e-b4f0-552dd6e81048" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_072110a1-a9fe-4972-818f-dc72ce5c1d1f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2804282b-28d5-4f59-8db0-25a041ee03d0" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">457</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f23042b-1c93-4bd2-858e-54bad810f577" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae1e0e12-deb3-403d-9be9-4978df71324f" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,547</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from royalty purchase agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1341f251-8861-458c-8d61-8ec613fc9443" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:ProceedsFromRoyaltyPurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03c83baa-789a-480e-8bf3-c041559685d8" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:ProceedsFromRoyaltyPurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from the sale of common stock, <br />&#160;&#160;&#160;net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4cbd5ca1-7c62-4567-be02-4c80ccc48726" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee5fd7ea-37a9-4850-8598-390ba7337bc0" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3665c9da-6819-41a9-ab2c-2d1cd9c1bd6d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc09f193-d636-419c-92d7-7f7eb01f1d20" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69bd231c-d3a0-4bcd-966d-d06e6f85d37f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,707</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74a646d4-43b2-4a62-9a21-8cde430b1135" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17eedde7-7547-4b1f-b60b-733348e11f3a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,987</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90331b74-576f-4a58-89e6-7ec2bcd19c21" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at beginning of year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48050fe6-ff90-46dd-b383-1c543612d0db" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41b888e5-944c-488e-9f44-5f8990d38c57" contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents at end of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78af1ab1-2aeb-40ba-8554-ffe47e889df3" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bf604e8-e16e-47a0-9bf6-5109959fbd44" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental schedule of non-cash financing activities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of warrants in conjunction with amendment to the Royalty <br />&#160;&#160;&#160;&#160;Purchase Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b458f3f-a02d-470f-87a6-2ef8c7d6e45a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcdf9784-63fa-4538-9acd-ea28d0d1a743" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred offering costs included in accounts payable and accrued<br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68f8dfb3-fed4-47bd-8a17-73371ee6232f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c0db40f-b76c-4ebf-a123-97515c1b2f2a" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment included in accounts payable and<br />&#160;&#160;&#160;accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81d27e0d-9147-47e2-ba6d-7041bcfdd4c9" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30050375-565b-43ad-985e-bab2af704fc1" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f663148d-c3db-429a-86dc-d3d67016c76b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.	Organization and description of business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc. was incorporated as a Delaware corporation on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81b21c8e-b733-4ac0-9087-cc10bb00bcd7" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 19, 2012</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (inception) and together with its subsidiaries (the Company, or Galera) is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem manganese (GC4419, also referred to as avasopasem) is in development for radiotherapy-induced toxicities, including severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) and esophagitis in patients with lung cancer. In February 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to avasopasem for the reduction of SOM induced by radiotherapy with or without systemic therapy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Galera&#x2019;s second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company announced corrected topline efficacy results from a Phase 3 trial (referred to as the ROMAN trial) evaluating avasopasem for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. The Company had previously announced topline results from the ROMAN trial in October 2021. Upon further analysis following the October topline data announcement, an error by the contract research organization was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints. The corrected results demonstrated efficacy across multiple SOM endpoints with a statistically significant reduction on the primary endpoint of reduction in the incidence of SOM and a statistically significant reduction on the secondary endpoint of number of days of SOM. The ROMAN trial is the Company&#x2019;s second randomized trial conducted in patients with HNC to achieve statistical significance and demonstrate improved clinical benefit in reducing SOM. The Company plans to meet with the FDA in 2022 to discuss the results from the ROMAN trial together with the previously completed randomized Phase 2b trial with respect to the potential submission of a New Drug Application, or NDA. Avasopasem is also being studied in a Phase 2a trial for its ability to reduce the incidence of radiotherapy-induced esophagitis in patients with lung cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to developing avasopasem for the reduction of normal tissue toxicity from radiotherapy, the Company is developing its dismutase mimetics to increase the anti-cancer efficacy of higher daily doses of radiotherapy, or SBRT. The Company&#x2019;s second dismutase mimetic product candidate, rucosopasem, is being developed to increase the anti-cancer efficacy of SBRT and has successfully completed Phase 1 trials of intravenous rucosopasem in healthy volunteers. In September 2021, in support of rucosopasem, the Company announced final results from its Phase 1/2 pilot trial of avasopasem in combination with SBRT in patients with unresectable or borderline resectable LAPC. In this proof-of-concept trial, survival and tumor outcome benefits were observed. The Company used its observations from this pilot trial to inform the design of rucosopasem clinical trials in combination with SBRT. The Company is currently evaluating rucosopasem in combination with SBRT in a Phase 1/2 safety and anti-cancer efficacy trial in NSCLC and a Phase 2b trial of rucosopasem in combination with SBRT in patients with LAPC.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13fc43ca-bfd4-40ca-8026-f8caa507da70" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_829d33a7-4e53-4110-bdbf-1dde39fab1c1" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">316.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company expects its existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2023. In the future, if the Company is not able to continue to raise sufficient capital to fund its operations, the Company may decide </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to delay or discontinue certain activities, including planned research and development activities, hiring plans, manufacturing activities and commercial preparation efforts. In December 2020, the Company filed a registration statement with the Securities and Exchange Commission (SEC) which covers the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d2cf89c-1c73-457b-8154-1283139a0a70" contextRef="C_9df347f3-5a56-4f15-95db-ac9ca27ed0ae" name="grtx:MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in Company securities, which includes an Open Market Sale</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with Jefferies LLC (the Sales Agreement) covering the offering, issuance and sale of up to a maximum aggregate offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9754e16-797b-43ce-9400-ede947071b7c" contextRef="C_45be0985-0b88-45c8-908b-dfddf0179f67" name="us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#x2019;s common stock, which could be utilized to raise funding for future operating expenses and capital expenditure requirements. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we sold approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_782f4c49-b955-45e4-ab52-6dd4d8f6fae1" contextRef="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of common stock and received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dbfb8f9-7fef-44c3-83ea-b8f29cd8ca2e" contextRef="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million pursuant to the Sales Agreement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there remained $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb5f4f84-7a98-4cb3-9650-2721748e25aa" contextRef="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476" name="grtx:ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available under the Sales Agreement.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb386c7d-9899-41ea-81ba-8fe125bce6b7" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.	Basis of presentation and significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91a89347-0eea-447e-88cb-fe164b2179e0" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of presentation and consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of Galera Therapeutics, Inc. and its wholly owned subsidiaries, Galera Therapeutics Australia Pty Ltd (Galera Australia) and Galera Labs, LLC. All intercompany accounts and transactions have been eliminated in consolidation.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined the functional currency of Galera Australia to be the U.S. dollar. The Company records remeasurement gains and losses on monetary assets and liabilities, such as accounts payable, which are not denominated in U.S. dollars in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d45fcf72-d4f3-4652-b9db-0d07be4ba14e" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management&#x2019;s estimates include the share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_977f8627-c380-42f4-a565-6ad368be3cda" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. The royalty purchase liability is accounted for as debt and interest is accreted over the expected repayment period which approximates fair value.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab05c102-57b7-4809-a60a-8de385b14583" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_396f8481-12cf-4b61-acc9-2e4d69ea3600" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> consisted of bank deposits, U.S. Treasury obligations and a money market mutual fund invested in U.S. Treasury obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f863e00f-b339-4ce7-8e7a-5c0f6c608cfc" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Short-term investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments consist of debt securities with a maturity of greater than three months when acquired. The Company classifies its short-term investments at the time of purchase as available-for-sale securities, which are net of unrealized losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_307bf3d2-b989-49b5-a542-e3e3b7d22126" contextRef="C_ad6a9a6d-8f04-4896-b2eb-e94cb204175f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_16142bfb-e456-4785-a3ff-f7bd6ddad76f" contextRef="C_7bd9d8bb-1771-4a1a-9624-32a8d3f04ef8" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">26,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Available-for-sale securities are carried at fair value. Unrealized gains and losses on available-for-sale securities are reported in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e46e4b06-39ac-4f7a-a37f-92bcbf4f79d4" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost and depreciated using the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c059b04d-7a6b-4582-825e-61e49689ed5b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">straight-line method</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> over their estimated useful lives ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6609fc12-0319-49c0-95cd-2a3e1d272227;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c7a0722-bd80-4096-a2fb-8d87608c2c63" contextRef="C_593a8fd2-e876-4c36-8f67-ec70818d7144" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. The costs of maintenance and repairs are expensed as incurred. Improvements and betterments that add new functionality or extend the useful life of the asset are capitalized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c7d53ee-7bba-49e4-944e-91185948ea9f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company believes that no revision of the remaining useful lives or write-down of long-lived assets is required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab0f07cd-649d-43bf-975d-2cf7b998b863" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and acquired intangible asset</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2012, the Company completed a Series A redeemable convertible preferred stock (Series A) financing with venture capital investors and simultaneously acquired Galera Therapeutics, LLC (LLC), a limited liability company incorporated in Missouri in 2009. LLC was renamed Galera Labs, LLC in January 2013 and operates as a wholly-owned subsidiary of the Company. The Company applied the purchase method of accounting under which the consideration given to the LLC members and noteholders was allocated to the fair value of the net assets assumed from the LLC at the date of the acquisition. The sole intangible asset acquired represented the fair value of in-process research and development (IPR&amp;D) which has been recorded on the accompanying consolidated balance sheets as an indefinite life intangible asset. A deferred tax liability was recorded for the difference between the fair value of the acquired IPR&amp;D and its tax basis of zero which was recognized as goodwill in applying the purchase method of accounting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets related to IPR&amp;D are considered indefinite-lived intangible assets and, along with goodwill, are not amortized, but are assessed for impairment annually or more frequently if impairment indicators exist. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. If the associated research and development effort related to IPR&amp;D is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its consolidated statements of operations. For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company determined that there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23bddc62-c90a-4862-ac7c-66fa354ea68d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_588a79df-8fba-4bb7-af1a-c742513865b6" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment to goodwill or IPR&amp;D.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16b2bb65-3816-4001-9a00-164694544fbf" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:RoyaltyPurchaseLiabilityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalty purchase liability</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, the Company entered into an Amended and Restated Purchase and Sale Agreement (the Royalty Agreement), with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. (collectively, Blackstone or Blackstone Life Sciences). Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bb3d66b-0504-431e-8628-c58beb1e9202" contextRef="C_36e5cf66-783f-49af-adeb-a81f9fe9b685" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the Royalty Purchase Price) in four tranches of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b5e5aef-fce5-4c65-8f8e-64495b2c0abc" contextRef="C_5cdbba6c-4c21-4368-9002-fbaec59111a5" name="grtx:ProceedsFromRoyaltyPurchaseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively. The proceeds received have been recorded as long-term debt obligations. Interest expense on such obligation is imputed by estimating risk adjusted future royalty payments over the term of the Royalty Agreement which takes into consideration the probability of obtaining FDA approval. Other significant assumptions include adjustments to estimated gross revenues to arrive at net product sales from which a royalty payment can be estimated. The non-cash interest expense recorded increases the balance of the royalty obligation. The royalty obligation will be reduced when royalty payments are made, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec4e69b3-d6c9-4628-88a2-534254b61837" contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39b2c275-f4e5-434c-8f7b-330359750b37" contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">117.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, by increasing the fourth tranche from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5fa47d3-69d6-4e2c-980c-352cb80a3b74" contextRef="C_f6dfbed4-0d76-449c-8163-dee538b8360e" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c6ab2f0-e6d1-45e9-a9a1-d4c4b3e15e2d" contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was received in July 2021, and adding a new $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_696a6152-e8bb-4b45-a46c-4a59d28ae393" contextRef="C_fd22c5c9-25d5-4067-8c16-626d9550cb64" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million tranche upon the achievement of an additional clinical enrollment milestone, which was received in June 2021. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual royalty payments are highly uncertain and may change depending on a number of factors, including the Company&#x2019;s ability to obtain FDA approval, successfully commercialize the Company&#x2019;s product candidates and the timing of future royalty payments. The Company imputes interest expense on the royalty purchase obligations based on such factors at each reporting period. As these factors change, the Company will adjust its estimate of the imputed interest expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a4fe437-43e4-4079-bf06-e1bbed38a2b9" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (short-term leases). For short-term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. The Company had no short-term leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement, and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e63045d-0b42-49ce-9fb8-6000dd2309db" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. The Company accrues and expenses preclinical studies and clinical trial activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with clinical research organizations and clinical trial sites. The Company determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including the Company&#x2019;s clinical development plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management makes estimates of the Company&#x2019;s accrued expenses as of each balance sheet date in the Company&#x2019;s consolidated financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company was awarded a Small Business Innovation Research grant from the National Cancer Institute of the National Institutes of Health, which will partially fund its Phase 1/2 safety and anti-cancer efficacy trial in NSCLC (the Grant). Costs entitled to reimbursement under the Grant are accounted for as a reduction to research and development expenses. During the years ended December 31, 2021 and 2020, the Company recorded a reduction to research and development expense of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5da7f329-6ea5-4719-b723-d89a2edd223c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1639e3c-bddb-4d15-96e1-b9564de2189b" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, for expenses for which it has been reimbursed, or is entitled to reimbursement, under the Grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdf8c92c-0a64-48cc-9dcf-f9379052d619" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected life of the stock options is estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38dcb292-b43f-4f61-92d9-77e1af49b259" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:EmployeeBenefitPlanPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Benefit Plan</span></p><p style="text-indent:8.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company sponsors a 401(k) defined contribution plan for its employees. Employee contributions are voluntary. The Company matches employee contributions in an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_674828ae-9332-4f5a-8312-661e2cf1e42c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the first </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a583c5e-773d-4ca1-a5ba-b85ac40286ae" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of eligible compensation, and such employer contributions are immediately vested. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, the Company provided matching contributions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52d9af49-2ec2-48ec-8b30-27996a781894" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_561a7579-eadc-4de1-bcd3-99e76fed3293" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8c8d178-c2ef-44e7-ac4b-4414e10ae135" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99f55068-dc2d-4721-b996-fbc0e7a2ac09" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and common stock warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1935664a-c573-4ab5-b51d-c50e297896d6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:76.814%;"></td>
          <td style="width:1.145%;"></td>
          <td style="width:0.706%;"></td>
          <td style="width:9.034%;"></td>
          <td style="width:0.706%;"></td>
          <td style="width:1.145%;"></td>
          <td style="width:0.706%;"></td>
          <td style="width:9.034%;"></td>
          <td style="width:0.706%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1a00b68-9524-4788-8aff-f1bff3d04a77" contextRef="C_d5282f06-c797-4fe4-b19a-c3d0534f9f5f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,970,975</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3204d222-5932-4377-9448-6843fa63f5f5" contextRef="C_d7306d50-8a8a-4d6c-a10f-596f186d7d3e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,463,078</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_826e7e66-8b93-41f6-8c41-33a4f06f1ec9" contextRef="C_b49a26cc-28b3-4484-a6c0-28d5227aaace" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">550,661</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55783571-1a18-494f-b275-7ff1212eb540" contextRef="C_cb9a312e-caf8-4908-aa1d-2b259e84c87a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">550,661</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_180f9b96-5931-4bc0-9597-3a10d4dbd09d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,521,636</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d869192-13fc-44aa-8227-3a82d8b7fa2e" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,013,739</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ffa27de-ed45-4690-8012-ace1daa4d248" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:Covid19Update" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Update</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company&#x2019;s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial and the EUSOM trial in the fourth quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations at the time, the Company determined that it was not feasible to complete the trial.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_9ecfeae1-9387-4604-ac28-adc3cf6cd2b6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill and allocating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">income taxes to separate financial statements of entities not subject to income tax. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods therein. Upon adoption, the Company must apply certain aspects of this standard retrospectively for all periods presented while other aspects are applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted this ASU on January 1, 2021. There is no impact to the Company&#x2019;s consolidated financial statements.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6998aa1-5f52-4ddf-ac92-e08d6dc43cc2" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.	Fair value measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1adab41-23d6-4dd7-9782-c0462a663565" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.689%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.329%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.329%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.372%;"></td>
        <td style="width:0.707%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds and U.S. Treasury obligations <br />&#160;&#160;&#160;(included in cash equivalents)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81a1df4f-1e0f-481a-b958-314955bd59f9" contextRef="C_a8e23883-6f88-4b3e-8a59-993c4b0a8e68" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4b016ec7-c9de-4004-9397-7645b2c3a792;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f1fec276-850c-48f5-82e0-7c1f144c9d23;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_82ec9d38-55d6-49a7-9b4c-1f328cfde640;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05fadd08-ccfd-4c62-906a-ebda2729e543" contextRef="C_f3513012-929a-445a-a467-3e5db3bbe70d" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,413</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_90fe34be-68f6-4f3e-996c-414d28713b22;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65823d1a-1ce7-40a1-b29f-6fd3f4b056a1" contextRef="C_305118ea-acc7-41f9-8491-7c1c62482e6c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b5ca7b31-6e3b-4277-a915-633d3b089c9c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_39ac49a9-a08d-470b-9d8e-441479f7cc65;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:12.25pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1d6d1eb-72c5-4e26-a9c1-1bfd96f02759" contextRef="C_25712525-0b37-43f7-91fa-c953260ec5ca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02104109-c543-463d-bfc4-de03ff7d0015" contextRef="C_0d6f0a55-359d-403b-a434-44702e4affb5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,413</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_71db6aad-ca49-4c24-a01f-b7baac31ab94;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.453%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.425%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.425%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.415%;"></td>
        <td style="width:0.707%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds and U.S. Treasury obligations<br />&#160;&#160;&#160;(included in cash equivalents)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5eebf839-f7f5-4119-b80e-cf9ed88f8cce" contextRef="C_93f1c71c-423d-48c2-972d-165e521b4a2e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,943</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fee3e958-b0d8-4163-ada6-e3c148fc641f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7504513d-1b52-40d2-8f6d-82f97b393bcc" contextRef="C_3bda9d35-0891-4ab3-af62-f84219914e3e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c89274bf-8d90-49f0-888d-378fdc6d56bc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0f95648-57b8-4712-8af4-66e6093c2018" contextRef="C_9fffc937-6507-4e45-b94f-02243159331f" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,842</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91e4179f-31fb-40c8-a060-5969474d7348" contextRef="C_7c7d9157-dcfd-4f05-9f1d-325119845497" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,842</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3b9fffe-3286-4f57-b829-efe5067eaefe" contextRef="C_3f5fa676-9ecf-47ef-9aa5-1a0b787f12a9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ac483134-1335-48d8-8e13-9abac8dd12bf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92a2f3fb-37a2-45ff-bbdd-9866762c82a7" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a5930de5-f8d3-4e46-8114-e6d51a63ae17" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> changes in valuation techniques during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s short-term investment instruments classified using Level 1 inputs within the fair value hierarchy are classified as such because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The fair value of Level 2 securities is estimated based</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term on the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23d2a69d-c44b-4d99-afe2-bb63f10559f5" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.	Property and equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_794261c7-d6d0-4ba7-85f5-cb9c65e1de2f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consist of (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.296%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.544%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.544%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c19b707-32a3-4f96-888e-75d85909ab36" contextRef="C_4d891bfc-c9b7-4664-aa86-cb70d7dca47d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd1f135e-4e6b-4b5c-a2c3-26d730bab799" contextRef="C_fe1042c2-2d5c-47e5-8b71-e66bdb49c74b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer hardware and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee2342fe-a7da-4cbb-a450-1a5c7f031f6b" contextRef="C_6d323ff0-f330-4ed0-8d21-499632ec29a4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_459c2879-3923-47c6-8121-bb8380369efe" contextRef="C_52a132bc-811e-41a6-8227-721ecf66a245" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ca26eda-a63c-41c0-80c3-445179617a47" contextRef="C_dbe44deb-cd48-49e6-b9b3-3243f04236e4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b29281d7-b99c-43b8-9a41-f0ef7e8373af" contextRef="C_7c9a6f1f-9227-4c02-9d86-d4296da459d1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9fd28dd-59f0-4994-bdf2-84723e34e0b3" contextRef="C_f9d64566-02c3-4d28-9715-ba795d3bd45a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54b2014e-ffac-45aa-8694-44f9e22910e5" contextRef="C_a54c4234-e2dc-4d64-9b15-6d41a7216e47" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">173</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c20a9681-b9cc-4f96-9606-d5b3a45dc1e2" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac2e5deb-0383-44ea-9ba5-b99a7dd350fb" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12ac44b1-092c-4725-b6d8-678cb949c90b" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7df19ad-9e2c-4fef-a072-8487727845a3" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e83fc4f-7a70-4877-a54d-cab4b99c6b6e" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_420956c1-ac48-40a4-af85-daff94f63a16" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,023</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3749a9b0-267d-4c1e-b24a-805b295c6408" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5c1d55d-24ee-4036-908c-1566e5cfb3c8" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdf7bf3b-673d-40f4-b612-d8e2c191028a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26ce2da3-fd70-4688-8f60-ba46cccff4ce" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.512%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.65%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.65%;"></td>
        <td style="width:0.707%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_286baa19-4fcc-4f3c-b480-9ba0d87f775f" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,038</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a001c534-6ca9-40da-be6b-c716ba03f211" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,632</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f610e64-5a8e-4a89-906f-9eeddb4141a5" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="grtx:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,360</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90c9f04b-fe90-45a0-84fe-e644180dc74a" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="grtx:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees and other expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1061da38-03e3-4994-bfda-2b981872d774" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="grtx:AccruedProfessionalFeesAndOtherExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ea89914-6fc8-4dc1-97ae-f739c5362418" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="grtx:AccruedProfessionalFeesAndOtherExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd2ec665-479c-4679-aba3-08b33fedc677" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d349261-441f-4a41-9980-3767a17e57d8" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90258f59-0dc1-4b80-8782-39ef024e5c8c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock" escape="true" continuedAt="F_90258f59-0dc1-4b80-8782-39ef024e5c8c_1"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	Royalty purchase liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36903286-b028-48c3-bd66-d410fb987356" contextRef="C_36e5cf66-783f-49af-adeb-a81f9fe9b685" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the Royalty Purchase Price) in four tranches of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc77f36f-109d-44d5-ba14-79907cb68fc3" contextRef="C_5cdbba6c-4c21-4368-9002-fbaec59111a5" name="grtx:ProceedsFromRoyaltyPurchaseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_764086d9-d606-4ab4-8bc1-fab2ad944fde" contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f59612a8-4bb5-46cb-8a6f-a7a2d2109d18" contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">117.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million by increasing the fourth tranche from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b44e607-c2a2-493b-9110-37e3256c5439" contextRef="C_f6dfbed4-0d76-449c-8163-dee538b8360e" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c398af85-e69d-4525-8e83-bd33ce394609" contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and adding a new $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_712b2ef3-dc19-496d-9675-8679461ce2c2" contextRef="C_fd22c5c9-25d5-4067-8c16-626d9550cb64" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million tranche upon the achievement of an additional clinical enrollment milestone. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method. In June 2021, the Company received the new tranche ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44d284e5-08d8-41dd-a3a5-435343f5de57" contextRef="C_b5e004bf-3018-4d7e-9906-d7992b1097fd" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) under the Amendment in connection with the enrollment of the first patient in a Phase 2b trial of rucosopasem in combination with SBRT in patients with locally advanced pancreatic cancer, which the Company refers to as the GRECO-2 trial. Also in June 2021, the Company completed enrollment in the ROMAN trial, thereby achieving the milestone associated with the fourth tranche ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_432f16e7-5343-4328-9985-596df5ed1c16" contextRef="C_434d1ba1-6f87-483a-9518-2b7eea1ec42f" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) under the Amendment, which was received in July 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for the Royalty Agreement as a debt instrument. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4021f37-be54-4770-b2f9-3543fc1e8439" contextRef="C_1c572ee6-0f00-49f1-a14c-f6c0a3c80911" name="grtx:ProceedsFromRoyaltyPurchaseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">117.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in proceeds received as of December 31, 2021 have been recorded as a liability on the accompanying consolidated balance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sheets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense is imputed based on the estimated royalty repayment period described below, which takes into consideration the probability and timing of obtaining FDA approval and the potential future revenue from commercializing its product candidates, and which results in a corresponding increase in the liability balance. As the Company continues to evaluate the next steps for its programs focused on the reduction of radiotherapy-induced toxicity, planned or possible next steps may have a material impact on the royalty purchase liability. The Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b65b65bc-7924-4a22-a808-ffafd48c13d8" contextRef="C_1c572ee6-0f00-49f1-a14c-f6c0a3c80911" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cc51431-a615-4004-9d08-a397d97c116d" contextRef="C_10927f54-f772-42ac-8e0e-6713aa190f61" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in noncash interest expense during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the effective interest rate was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0c6d044-7a27-4a57-a209-f86522b13d33" contextRef="C_a84419a9-fda0-4f1c-b1a3-4f9270aa2e0b" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Royalty Agreement and the Amendment, in connection with the payment of each tranche of the Royalty Purchase Price, the Company has agreed to sell, convey, transfer and assign to Blackstone all of its right, title and interest in a high single-digit percentage of (i) worldwide net sales of avasopasem and rucosopasem (collectively, the Products) and (ii) all amounts received by the Company or its affiliates, licensees and sublicensees with respect to Product-related damages (collectively, the Product Payments) during the Royalty Period. The Royalty Period means, on a Product-by-Product and country-by-country basis, the period of time commencing on the commercial launch of such Product in such country and ending on the latest to occur of (i) the 12th anniversary of such commercial launch, (ii) the expiration of all valid claims of the Company&#x2019;s patents covering such Product in such country, and (iii) the expiration of regulatory data protection or market exclusivity or similar regulatory protection afforded by the health authorities in such country, to the extent such protection or exclusivity effectively prevents generic versions of such Product from entering the market in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Royalty Agreement and the Amendment will remain in effect until the date on which the aggregate amount of the Product Payments paid to Blackstone exceeds a fixed single-digit multiple of the actual amount of the Royalty Purchase Price received by the Company, unless earlier terminated pursuant to the mutual written agreement of the Company and Blackstone. If no Products are commercialized, the Company would not have an obligation to make Product Payments to Blackstone, which is the sole mechanism for repaying the liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_919a3233-6809-49a1-9056-b816b178697a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the Amendment, the Company issued common stock warrants to the Blackstone Purchaser, each of which became exercisable upon the receipt by the Company of the applicable specified milestone payment. The issued warrants expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b50704e8-6798-4adf-8757-49aaf313c37b" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the initial exercise dates, as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.19%;"></td>
        <td style="width:2.484%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:12.765%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:2.484%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:11.791%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:2.484%;"></td>
        <td style="width:13.429%;"></td>
        <td style="width:2.484%;"></td>
        <td style="width:13.429%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise Price</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Initial Exercise Date</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New Milestone Warrant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_080d5e28-41e4-412a-a120-6eb7dbca158a" contextRef="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">293,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c247e17d-22e8-42d4-8e79-ceccc904727a" contextRef="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75c9fe19-843f-4bbc-aca6-33adf23d6b3f" contextRef="C_7bf5e8de-1ddb-476f-8d38-35c1b5ab97dd" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/7/2021</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be87b585-6a92-4de2-b680-b4a3889abfc5" contextRef="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/6/2027</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fourth Milestone Warrant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37dd7473-d569-4cfd-a54d-4c7af44e671c" contextRef="C_3cc167f7-0366-47b7-bbfd-33156a4567b4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">256,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3dc37078-92a7-4826-91cb-489df0331609" contextRef="C_3cc167f7-0366-47b7-bbfd-33156a4567b4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_075d0187-f2f9-4c75-a8b2-c6c88dff98fe" contextRef="C_f1539b5e-d51f-4a4e-95e6-8cccb7631150" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7/19/2021</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce5227a8-5efa-4c52-8814-2ff1b615dbf9" contextRef="C_3cc167f7-0366-47b7-bbfd-33156a4567b4" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7/18/2027</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_90258f59-0dc1-4b80-8782-39ef024e5c8c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrants are equity-classified and were valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae96f315-bedc-46f3-8350-3afc43a9a98f" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million using the Black-Scholes option pricing model. The warrants were recorded as a discount to the royalty purchase liability. The Company amortizes the debt discount to interest expense over the estimated term of the royalty purchase liability utilizing the effective-interest method.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32844b07-77bb-4b93-889b-d010f9dbf71c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.	Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has non-cancelable operating leases for office and laboratory space in Malvern, Pennsylvania and Creve Coeur, Missouri which, as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, have remaining lease terms of approximately 1.2 and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_827c5b10-94d6-4a53-af51-39e79d973fec" contextRef="C_5ef0432b-dbc1-49fa-b25a-eee0df54a3d8" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, respectively. The discount rate used to account for the Company&#x2019;s operating leases is the Company&#x2019;s estimated incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_287b8332-5311-4288-8f42-eca85c2707c9" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_866f01ea-7c38-4ea2-86a1-6f15d91ba172" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental balance sheet information related to leases was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.015%;"></td>
        <td style="width:1.713%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:9.176%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:1.274%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:9.176%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use lease assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00a70726-fba5-427b-af5f-3c726c1c9a6d" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9db8dff3-49d8-42d9-adfc-aebe638e2145" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59a90f60-fd7a-4fda-b22e-588df2e69efb" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">258</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a03a907-5690-4b9a-9bbf-48a8a9e5cebf" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, net of current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92f63644-5111-4a82-8ad5-b7e715036c73" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5b7699b-001b-426f-8f01-bc6638e6775a" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba2fe609-5a2e-4b90-9959-0f0ededcbbcc" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2dbb1da1-2bc1-42b8-b41a-c54783f314ec" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23a1bbe0-67dc-46d1-bf5d-7ca5cc66e22f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease expense were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.04%;"></td>
        <td style="width:1.67%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.34%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:2.419%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.885%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease rental expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5872b93-aebf-4aea-bd4e-2eea9805d328" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1563df2-581d-4ebe-a588-18a69886c9f7" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">262</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest on lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30a072ad-73fc-462a-8362-2923b35af187" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:OperatingLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5a7f53f-2e03-44b5-82f9-22f147b5384f" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:OperatingLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4ed4a28-b9d1-4380-8b06-024d6f92bb71" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">325</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_786e6e00-74c7-4e3b-8db8-4ccc35b1e30a" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">297</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f618a50d-002a-47ee-8535-f2001ce3c093" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information related to leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.328%;"></td>
        <td style="width:1.734%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:9.678%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:1.895%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:7.719%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows for operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb8bea98-3b44-4c20-ae14-7004ebfca650" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">325</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a4672bf-70f5-454f-8adc-9fb2748dd1ed" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets obtained in exchange for lease obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48971dc2-12db-45d1-816b-ceb1de89e34d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5094ff90-67c8-4ea1-8a37-9ab1420d5f1b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 will mature, as follows (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:87.596%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:9.103%;"></td>
        <td style="width:0.919%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a193bed-b966-411e-9b0e-d41ba972aabb" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0a064cd-da11-4988-921a-789805c4e87e" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f299d413-528b-402f-ad7d-097d257faf57" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">310</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55beaefc-de27-4229-9ece-bad4146081e4" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69449328-0702-4c89-8ad5-241ddcdc5931" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a60671c-7d47-488b-8c15-07a6aea161d1" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.	Commitments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Executive employment agreements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into employment agreements with certain key executives, providing for compensation and severance in certain circumstances, as described in the respective agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal matters</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ea76815-c635-4218-9b66-f851d9b5dc17" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:LossContingencyPendingClaimsNumber" unitRef="U_Claim" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> claims or legal actions that would reasonably be expected to have a material adverse effect on the Company&#x2019;s results of operations, financial condition or cash flows.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0e6bf95-e6c9-4ce7-bf84-92533ee971bd" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.	Stockholders' Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> (Deficit)</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity offerings</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into the Sales Agreement with Jefferies LLC (Jefferies) as sales agent, pursuant to which it may, from time to time, issue and sell common stock with an aggregate value of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33cc0e18-582e-4bdd-bbdd-76dacdbd1e33" contextRef="C_6796aa74-9221-4cd7-bee7-288036afa9bd" name="grtx:AggregateValueOfCommonStockSaleUnderOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in &#x201c;at-the-market&#x201d; (ATM) offerings under the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-251061) filed with the SEC on December 1, 2020. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company&#x2019;s common stock. The Company is required to pay Jefferies a commission equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70e31909-1f97-4b5d-9dfc-08cce4974efd" contextRef="C_976e5af6-a09b-4243-b493-8a6bf08de5c8" name="grtx:CommissionToAgentAsPercentageOfATMOfferingProceeds" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent of the gross sales proceeds and has provided Jefferies with customary indemnification rights. During the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5eb5133f-1bb3-4cc7-835e-baab3d9ca055" contextRef="C_ff4d9ca7-3a8c-4c0e-91f3-4d20825252ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">891,368</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were sold under the Sales Agreement at a weighted average price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb49ffb9-d13e-4478-aa54-2b35671e5c92" contextRef="C_89c8d8d2-8951-4199-b591-7a7a075b63cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.27</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b9ab7f7-6a7d-4b36-9fca-46b91b0d9991" contextRef="C_ff4d9ca7-3a8c-4c0e-91f3-4d20825252ba" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. As of December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e18e872f-a968-44c1-8316-d0591ec7aa6f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:AggregateValueOfCommonStockSaleUnderOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of available capacity under the Sales Agreement.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Company&#x2019;s Initial Public Offering, or IPO, in November 2019, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the Galera Therapeutics, Inc. 2019 Incentive Award Plan (the 2019 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the IPO. Upon effectiveness of the 2019 Plan, the Company ceased granting new awards under the Prior Plan (as defined herein).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially available for issuance under the 2019 Plan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e292be2e-7361-449b-907a-404e2830791f" contextRef="C_4c71197f-876f-45b6-af5b-bb409d6b1c8e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,948,970</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock plus the number of shares subject to awards outstanding under the Prior Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6123648f-ba85-4a00-828d-4999178d5687" contextRef="C_7d2525df-46a5-40bb-8481-d3306638d529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#x2019;s outstanding shares of common stock on the final day of the immediately preceding calendar year, and (ii) such smaller number of shares of common stock as determined by the Company&#x2019;s board of directors. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43a4d8e9-ecaa-459b-bcd1-4569ddb479af" contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,251,930</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance under the 2019 Plan, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b60a9986-2a90-4814-940b-0bbafd1e7a68" contextRef="C_7f6a782f-8c22-436d-9355-d84bb1aec291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">999,045</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares added pursuant to this provision effective January 1, 2021. Pursuant to this provision, the Company added an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48437aef-9633-49e0-ab74-77fd76d0344a" contextRef="C_7d2525df-46a5-40bb-8481-d3306638d529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,058,350</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares to the total shares available for issuance under the 2019 Plan effective January 1, 2022. The maximum number of shares of common stock that may be issued under the 2019 Plan upon the exercise of incentive stock options is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_849147c6-77dc-4b2b-97ac-a4efd1a81965" contextRef="C_e3841438-e11c-4976-96af-f274931b7060" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,130,029</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2019, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the ESPP). The ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The number of shares of common stock initially available for issuance under the ESPP was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e42b732e-2030-4cf8-afbb-4747aeac3efc" contextRef="C_362fa296-c948-48d8-8633-02f4c1279301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">243,621</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. In addition, the number of shares of common stock available for issuance under the ESPP is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_225ecc42-2851-4e9d-8fc6-13856a198dae" contextRef="C_f2b24743-77df-4859-afed-60ec1f89419a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#x2019;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#x2019;s board of directors, provided that not more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81112ed3-3306-4a55-95e0-d638e0283ca1" contextRef="C_0749fd21-5c0d-4d48-bf75-581475061ab8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,288,886</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock may be issued under the ESPP. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e11080f1-24ce-4b9e-a461-4fa453004c1b" contextRef="C_11baed89-bceb-4f0a-b7cf-02d6f3284e9c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">741,497</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for issuance under the ESPP, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f671c7e0-fec6-438e-985c-8fd4a7ea3a3f" contextRef="C_f2b24743-77df-4859-afed-60ec1f89419a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">249,761</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares added pursuant to this provision effective January 1, 2021.  Pursuant to this provision, the Company added an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ab4cbb8-b461-4f1c-9d1b-5ddc4e868fcd" contextRef="C_c71d8cd3-e5bd-471e-b060-cec87aa74c28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">264,587</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares to the total shares available for issuance under the ESPP effective January 1, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2012, the Company adopted the Equity Incentive Plan (the Prior Plan). The total number of shares subject to outstanding awards under the Prior Plan as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df545849-01e5-43ed-a9a6-7beb0c1ac305" contextRef="C_722e6ba2-bc11-4290-88a5-e542358ad8a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,167,546</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f94725a-1752-432d-b073-92c5294b9a0e" contextRef="C_32d0e2d4-86a8-4678-8bc2-8f2c07f319d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">remain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">available for issuance under the Prior Plan and no further grants will be made under the Prior Plan; however, the Prior Plan continues to govern awards that are outstanding under it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's stock option awards vest based on the terms in the governing agreements and generally vest over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28c59129-6b72-4898-ac11-43a9201b3597" contextRef="C_d4d49bf1-a218-4aaa-a336-133680ab18c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and have a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74fa1eec-c2b3-4fec-9db6-deada4875451" contextRef="C_d4d49bf1-a218-4aaa-a336-133680ab18c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79d4c341-bc53-4aff-91eb-7a16162b8f1e" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expense was as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.368%;"></td>
        <td style="width:1.103%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.105%;"></td>
        <td style="width:0.706%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.126%;"></td>
        <td style="width:0.706%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34888c81-b957-4d06-986c-7ce1560bc22a" contextRef="C_3286eeb2-2aa4-477b-b07d-a1e64579ceed" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7bc27bdb-ce26-4542-bc90-db1f238465b9" contextRef="C_36d53670-b4ec-458a-b3e8-080466455ca0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06920204-41f7-455c-a03d-2117f24c1d39" contextRef="C_b3ba5c9b-58df-4b65-82e0-7c06fcb7e9e7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30922920-45fa-4fe3-b9ba-d0c89ed9640d" contextRef="C_57afcb19-5891-4994-9bdc-91438deda211" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,086</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ac4d3ff-7861-41d7-824a-3c7ba6e9c6d8" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_060e3a72-5b2a-4621-ae7b-952dc92eebc9" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6f23507-dd23-4183-af16-bf405134aaad" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to stock option grants for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.982%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:0.985%;"></td>
        <td style="width:9.442%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:8.543%;"></td>
        <td style="width:0.717%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:0.717%;"></td>
        <td style="width:8.554%;"></td>
        <td style="width:0.717%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />average<br />exercise<br />price per<br />share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />average<br />remaining<br />contractual<br />life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at January 1, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2736d3f-698d-4640-8a3b-0d8fc9d402ce" contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,537,946</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47e35dda-f814-4f51-94f6-6da38987859e" contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f9f9d6e-dcca-4b23-a740-91c5fd5d795b" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,238,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f9bfcee-9477-4942-932a-8d032dfa1f7f" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f35c0f59-8421-422f-b6d9-904125a241a6" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">164,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f95cc31-86b2-4fd9-9c0f-8e33545f3f65" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca849cfa-6f32-40c3-a705-88c8d805dc26" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">148,866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed8cb919-64ed-4974-a6e3-706ab8b31fac" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd32548c-15ad-4f57-9f7b-84a4432acf07" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,463,078</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_333559ec-543c-4636-b487-6fadd88024f8" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b690a89-53a3-48c6-95f4-1e9623ff87c1" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,653,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0e6f2a5-39ca-4b22-8057-968708fa141b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4ddd1f6-d90c-4c22-81cf-96bf028dbd62" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">591,257</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9ccb9f0-bd15-4c64-aac4-193d18caaea1" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69bbb6a9-7519-4870-9b21-52ce93faec72" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">554,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c97cb29-0143-4336-8a76-93ae13198198" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6684c9c-4fab-4137-b549-17084a82db8d" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,970,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecf4bf4d-1c20-4be3-ade7-edff2c8fdb7d" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76d9067e-2402-43b4-a12e-3ac720af93a4" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba88cd92-5735-4a0e-ac12-42b6c1dbf913" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,810,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d02e231c-a4d5-472a-96ce-f0aad72d53b0" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">6.78</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f42bf1f9-ff82-4f25-8649-c72ade39c8f1" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_932db667-0f8c-47ae-82c7-948a76b2e92e" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,970,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69d2638b-bc8d-44a9-99fd-cb27851ab9c4" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b5eef25-5a9f-473c-bf4b-ba33f8be61d8" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the unrecognized compensation cost was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ba39555-e49d-46ff-b5a6-7c4b7c86de0e" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and will be recognized over an estimated weighted-average remaining amortization period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca3d4555-793f-491b-beec-8f15142d6e6c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The aggregate intrinsic value of options outstanding and options exercisable as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98a71226-f929-4f40-b70d-4afad203dda4" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4a961b5-9649-463c-b94d-66ace2f9cf99" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Options granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> had weighted-average grant-date fair values of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecc91ac5-ca95-4fef-bcfb-8cb5590ef5f6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.73</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edeffdd0-e2e9-432e-827d-734d0b31981e" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.19</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at the grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options during the years ended December 31, 2021 and 2020 was determined using the methods and assumptions discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, as prescribed in SEC&#x2019;s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term. </span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#x2019;s industry which were commensurate with the expected term assumption as described in SAB No. 107. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend yield is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9291cd8-b3cb-4f9a-80e0-3e88d73b876d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s board of directors has determined the per share value of the Company&#x2019;s common stock based on the closing price as reported by the NASDAQ Global Market on the date of the grant.  </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22c0693f-a0c2-473c-b039-445182aca7e2" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.827%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:8.051%;"></td>
        <td style="width:2.323%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:8.051%;"></td>
        <td style="width:2.323%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea5facc3-f2f7-447d-a43f-51f5f2c078b5" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad46539a-0aff-49e5-9795-acebcece9754" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_baa2ea0f-5eda-49d1-9d03-61e612ea2fdb" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">89.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7b50d1b-8c43-4a00-a5f2-da7b0177969b" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">89.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_437e91f7-c7eb-4e95-bc14-dcee9548d61c" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b619cc46-4263-40e3-915f-5e77c8d0ce0a" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ee6b375-a179-437c-a85c-3680e7d5b80d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41ae7a09-f4a1-4071-b4f9-9ee81d6f7cf3" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f4028a8-232d-483c-90f4-98c387892ea8" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_9f4028a8-232d-483c-90f4-98c387892ea8_1"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.	Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_2fa32b0a-a49b-4d2f-9e09-2cf491c68ef6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s loss before income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is as follows (in thousands):</span></p><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.597%;"></td>
        <td style="width:3.083%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:14.795%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:3.083%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:14.795%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f4797b3-e36a-4c1f-85f4-28167caf43d9" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b63cb5db-098e-49d5-8b03-80d151c84189" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf4a007c-9ec3-4a3f-bdc3-913bae80104d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b0faa56-3741-4763-a49d-89b9d19a6552" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,227</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ed46be6-bb6c-4f68-8b26-a9318aa5b6e4" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,534</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c524aa1-0f71-4e71-932d-c3ec04d00753" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">74,234</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_928d90e9-fb43-407e-970d-3b324ad76fd0" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s tax benefit for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is summarized as follows (in thousands):</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.097%;"></td>
        <td style="width:3.362%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:16.251%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:3.362%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:16.283%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54312554-b569-4e71-9df8-bfe9c175836a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af80ed96-2470-4cb5-b075-b61bab47ef32" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32e36ba0-eea9-497b-9ab5-c00a115b29e0" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a73f5e18-42ed-454b-a1ef-2bf10cac4707" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4ab8250-4f04-4520-89dc-af84f7dea8d6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8b08afd-0121-4312-9923-b281d0944418" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_263cf84e-a435-40fb-85dd-0617924df5ea" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef5d7737-d7bd-4ab3-aaca-9043995bc5e4" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2898b585-def6-4c7b-9d7b-0cf217cbe745" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5181a80c-d876-4bd8-aa9b-32721dd791b3" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10d58cae-986b-4307-b4b9-148e27c91c4f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7406d037-7c29-43fb-85a5-4fcdb981d800" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f759691-e434-4e91-a4b9-c23106ea2877" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4eee7cdf-f7be-43ed-acdc-cdbad203fcce" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total income tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e137451-4263-4f6d-91d1-27d1d0503fab" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a20799b-3922-4a26-88fd-6fbe9be63105" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_f8f3acfa-8b9e-4d77-a2bb-78550c8fc812" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.147%;"></td>
        <td style="width:3.011%;"></td>
        <td style="width:0.714%;"></td>
        <td style="width:15.669%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:4.963%;"></td>
        <td style="width:0.714%;"></td>
        <td style="width:15.669%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:2.13%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rate reconciliation:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal tax benefit at statutory rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c97bcd31-eb28-4f46-aba6-e08aa8eee7bd" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8949359-3b25-479c-af36-f5d8e7a7dd95" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af83040a-5e38-4641-a718-1a07bcaafd6b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b4b46ae-a4c8-408e-aac5-880136d602e5" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c99cafdb-b9b9-48c4-8e0d-7aa9eb0a1f3b" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbc22bdd-a00c-4d13-bac9-63c38e972d14" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sale of royalty interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cbbf227-4763-47fc-83b9-a169adec6004" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d452f050-1134-4a8b-aa19-fe4afa77e451" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Difference in foreign rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6804fae0-1097-4cb6-8659-d173d1fdee0e" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad27b1a0-cafb-4b16-8b64-a56c2b307b50" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="grtx:EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_250b7a78-e961-40a3-8e41-42d2f2dd054d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1f8244b-4871-4082-a8b3-609b1343922b" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b841722e-26db-4bb8-9654-27bdf1ac48bd" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f982c7bb-4ada-4007-96e3-844e095ca2ba" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfc675d3-468a-4d6f-a16c-1e6316c3b59f" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d3b2b6f-7f06-4080-9e9f-b68d80e61bfd" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc8f0657-95a3-4e42-89e4-d3c533b0fd67" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eac1e2c9-4577-457e-971f-15f5bff31211" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da6a7f89-5295-4755-ae0d-bea02dc53ce1" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a97bef3-9079-4aa4-bc3c-c692aaae605b" contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_611c13ab-8dae-46c1-b05a-eeca5b30f9ed" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.61%;"></td>
        <td style="width:2.602%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.259%;"></td>
        <td style="width:0.942%;"></td>
        <td style="width:2.602%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.281%;"></td>
        <td style="width:0.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8088242b-8bf6-4307-b6bd-0167ef8e82ae" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4b2c911-3378-4a6e-bbc2-34884453c598" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43f154ce-620e-44d0-a0e9-a73243fe8259" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aff0e861-a71a-47b2-aada-d07ad06e5dbe" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,593</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d2b79b4-a5ca-4ec7-92fe-f47c6d34e644" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_246b1989-581d-496a-9a3f-f120f04712b5" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cabdc487-fdef-4baf-b61a-4672743c151c" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="grtx:DeferredTaxAssetsAccruedLiabilitiesAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b22a500-f168-408c-9d7e-c6770229346c" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="grtx:DeferredTaxAssetsAccruedLiabilitiesAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f64bc02b-4f71-4253-a50c-c9184595fcee" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,889</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8695b4d-55fa-460b-bd2f-fa43b0c8395b" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_108b44ca-ac59-4d8a-843c-1cdc020ab1e1" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61e1e050-170f-4b26-ae13-485c6d278cbb" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,309</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a69ff1f-ce00-4bda-bf2a-b2f41b12def3" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e06e74af-513a-4075-a17a-2d9643e9884b" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93fcdc99-ad48-41f7-8254-03c22e59a9c5" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="grtx:DeferredTaxLiabilitiesAccruedExpensesAndOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfcea0b2-42c3-424a-bf14-7e423bc31669" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="grtx:DeferredTaxLiabilitiesAccruedExpensesAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired in-process research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d907cfc-a7ea-46b2-ba00-48595b8170e4" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">653</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a74641f5-834f-419c-a520-eed979a16c25" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">653</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8e59fb3-8d9f-449f-bea0-d8cb5ced8b52" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90fdd2b7-3e8e-4f3c-8a80-0c7126e1e947" contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In assessing the need for a valuation allowance, the Company may utilize indefinite-lived deferred tax liabilities from an intangible asset as a future source of income. The Company&#x2019;s acquired IPR&amp;D intangible asset can be utilized as a source of income arising from the future reversal of temporary differences that can be offset against post 2017 indefinite-lived net operating losses, or NOLs. Therefore, the Company is permitted to offset the indefinite-lived deferred tax liability up to the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_612aa89d-a707-4256-a5c6-8d293c055b4d" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent limitation for NOLs generated subsequent to January 1, 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40f78c96-f331-4673-8388-dae8021c2ccf" contextRef="C_3a54c939-736d-4e51-b6f0-2b61907375c8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a535ee09-8968-4666-8dc8-755a4e7e153b" contextRef="C_1065604f-6672-47c1-8be6-5334d0edc400" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_5c5ecbb0-8056-41ef-868e-47954b17ba16" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes carryforwards of federal, state and foreign NOLs as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively (in thousands):</span></p><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.893%;"></td>
        <td style="width:3.436%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:16.251%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:3.436%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:16.829%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Combined NOL Carryforwards:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_098f8835-babe-4da8-b049-8537018b4c02" contextRef="C_ef60c426-c561-4135-a8f9-593afe49a453" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58c3634b-727d-4378-badc-5f1212178c5d" contextRef="C_f40e1447-029f-430d-b180-94abe2cbf70c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0da7a37-8829-434d-9adc-1f6902232222" contextRef="C_efe17399-273f-425a-8f72-453a258c293e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167,252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78d685d2-39d3-42d8-86e5-261403bb892d" contextRef="C_6f568e62-0715-4e4c-a97a-e44b2148e476" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f45b256-e653-48a3-96f3-6248db5bd2d5" contextRef="C_230365fe-9c24-4694-9fc3-5ece4ab88972" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,516</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5ab786e-da7e-432a-bb57-04e1b3eb6515" contextRef="C_a550fef5-0f03-494a-a55a-4b38cad970c8" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NOL carryforwards begin expiring in 2032 for both federal and state income tax purposes. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2641fc7b-5499-4b26-81ad-db9d5234335b" contextRef="C_a70b00b9-2347-4b6b-81cc-9944932bfaf9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">illion that will begin to expire</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2032, unle</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ss previously utilized.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. In general, under Section 382 of the Code, a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32010120-dce3-44bb-8eaf-c07e9a7b6f88" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="grtx:PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre change tax credits as well as its NOLs to offset future taxable income. During the year ended December 31, 2021, the Company conducted a Section 382 study and determined that approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fbbe429-fad1-40b9-8534-e9f2838f6dbb" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">63.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in NOLs and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3eab5da-4d05-4280-b7a6-ad2684b1657b" contextRef="C_b8b04265-e6c4-456e-b08c-93fe2b0c7f68" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in research and development tax credits are limited by Section 382 as of December 31, 2021. As a result of the Section 382 analysis, approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91545752-ab34-4513-8d3d-1ae2fc952766" contextRef="C_e00e7a20-1841-49e0-bf38-357903c57486" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of research and development tax credits are scheduled to expire unused due to the annual Section 382 limitation and therefore were written off during 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_9f4028a8-232d-483c-90f4-98c387892ea8_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will recognize interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2e36a83-27ae-422f-a75d-4af55d992351" contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest and penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations. Due to NOL and tax credit carryforwards that remain unutilized, income tax returns from </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 through 2020 re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">main subject to examination by the taxing jurisdictions. The NOLs remain subject to review until utilized.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_529a418e-ac29-46de-92f2-a6213918687a" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11.	Related Party Transactions</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IntellectMap provides IT-advisory services to the Company. The chief executive officer of IntellectMap is the brother of the Company&#x2019;s chief executive officer. Fees incurred by the Company with respect to IntellectMap during the years ended December 31, 2021 and 2020 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cd19e8d-b1de-4722-99df-600896335a9e" contextRef="C_e58e8310-2bcc-41d3-91b9-08c841d3541d" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e17f804a-394a-4160-9f6e-a4ff25e292b9" contextRef="C_8002ece0-6266-462e-8ed6-a5bfe859d9a4" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GALERA THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="limitations_on_effectiveness_controls_pr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Limitations on Effectiveness</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> of Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="evaluation_disclosure_controls_procedure"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evaluation of Disclosure </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#x201c;Internal Control - Integrated Framework (2013)&#x201d; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Attestation Report of the Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for &#34;emerging growth companies.&#34;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no changes in our internal control over financial reporting identified in management&#x2019;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended December 31, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_foreign_juridiction"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Code of Ethics</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors has adopted a written Code of Business Conduct and Ethics applicable to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of our Code of Business Conduct and Ethics on our website at www.galeratx.com in the &#x201c;Investors&#x201d; section under &#x201c;Corporate Governance.&#x201d; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq&#x2019;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above. The information contained on our website is not incorporated by reference into this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Executive Officers and Directors</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information concerning our executive offers and directors required by this Item 10 is contained under the caption &#x201c;Information about our Executive Officers and Directors&#x201d; at the end of Part I of this Annual Report on Form 10-K. The remainder of the information required to be disclosed by this Item 10 will be included in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders under the headings &#x201c;Corporate Governance,&#x201d; &#x201c;Delinquent Section 16(a) Reports&#x201d; (if applicable) and &#x201c;Committees of the Board&#x201d; and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item 11 will be included in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders under the headings &#x201c;Executive and Director Compensation&#x201d; and &#x201c;Compensation Committee Interlocks and Insider Participation&#x201d; (if applicable) and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.887%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:2.269%;"></td>
    <td style="width:10.009%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:2.869%;"></td>
    <td style="width:11.015%;"></td>
    <td style="width:0.706%;"></td>
    <td style="width:1.242%;"></td>
    <td style="width:0.706%;"></td>
    <td style="width:11.571%;"></td>
    <td style="width:0.706%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Plan Category</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Securities to be<br />Issued Upon<br />Exercise of<br />Outstanding<br />Options, Warrants and Rights</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-Average<br />Exercise Price of<br />Outstanding<br />Options, Warrants and Rights</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Securities<br />Remaining<br />Available<br />for Issuance<br />Under Equity<br />Compensation<br />Plans (4)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensation plans approved by<br />&#160;&#160;&#160;security holders (1)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$8.45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,993,427</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensation plans not approved by<br />&#160;&#160;&#160;security holders</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,993,427</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consists of the Galera Therapeutics, Inc. Equity Incentive Plan, as amended (the &#x201c;Prior Plan&#x201d;), the 2019 Incentive Award Plan (the &#x201c;2019 Plan&#x201d;) and the 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;).</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consists of 2,167,546 outstanding options to purchase stock under the Prior Plan and 2,803,429 outstanding options to purchase stock under the 2019 Plan.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the weighted-average exercise price of outstanding options under the Prior Plan was $4.38 and the weighted-average exercise price of outstanding options under the 2019 Plan was $11.60.</span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Includes 1,251,930 shares available for future issuance under the 2019 Plan and 741,497 shares available for issuance under the 2019 ESPP. As of November 6, 2019, in connection with our initial public offering, no further grants are made under the Prior Plan. The 2019 Plan provides for an annual increase to the number of shares available for issuance thereunder on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029, by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by our board of directors (but no more than 14,130,029 shares may be issued upon the exercise of incentive stock options). The 2019 ESPP provides for an annual increase to the number of shares available for issuance thereunder on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029, by an amount equal to the lesser of (i) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as is determined by our board of directors, provided that no more than 3,288,886 shares of our common stock may be issued under the 2019 ESPP. As of the date of this Annual Report on Form 10-K, we have not commenced offering periods under the ESPP.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other</span></p>
  <p style="text-indent:9.173%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining information required by this Item 12 will be included in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders under the headings &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item 13 will be included in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders under the headings &#x201c;Corporate Governance&#x201d; and &#x201c;Certain Relationships and Related Person Transactions&#x201d; and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tant Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our independent registered public accounting firm is KPMG LLP, Philadelphia, PA, Auditor Firm ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_105b19ba-e568-461a-ae34-32346ba67dc6" contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this Item 14 will be included in our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders under the heading &#x201c;Independent Registered Public Accounting Firm Fees and Other Matters&#x201d; and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits and Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="n1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)(1) Financia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">l Statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements required by this item are listed in Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)(2) Financial Statement Schedules.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(a)(3) Exhibits.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.859%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:40.846%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.86%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.852%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:5.853%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.852%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.852%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Form</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">File No.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filed/</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Furnished</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Herewith</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Restated Certificate of Incorporation of Galera Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519290084/0001193125-19-290084-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">8-K</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519290084/d828492dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">3.1</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">11/12/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Amended and Restated Bylaws of Galera Therapeutics, Inc.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312520254547/0001193125-20-254547-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">8-K</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312520254547/d81670dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">3.</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">09/25/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Form of Certificate of Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">4.1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Description of Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459021012244/0001564590-21-012244-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10-K</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459021012244/grtx-ex42_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">4.2</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">03/11/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">  </span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Second Amended and Restated Investors&#x2019; Rights Agreement, dated as of August 30, 2018, by and among Galera Therapeutics, Inc. and the investors party thereto, as amended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">4.2</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;4.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Form of Warrant to Purchase Stock, dated May 11, 2020, issued by Galera Therapeutics, Inc. to Clarus IV Galera Royalty AIV, L.P., together with a schedule of warrantholders</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459020038606/0001564590-20-038606-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10-Q</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459020038606/grtx-ex41_65.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">4.1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">08/10/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.1#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Employment Agreement, dated October 25, 2019, by and between Galera Therapeutics, Inc. and J. Mel Sorensen, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.2</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.2#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Employment Agreement, dated October 25, 2019, by and between Galera Therapeutics, Inc. and Robert A. Beardsley, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.3</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.3#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Employment Agreement, dated October 25, 2019 by and between Galera Therapeutics, Inc. and Christopher Degnan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.4</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.4#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Employment Agreement, dated October 25, 2019, by and between Galera Therapeutics, Inc. and Jon T. Holmlund, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.5</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.5#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Employment Agreement, dated October 7, 2021, by and between Galera Therapeutics, Inc. and Jennifer Evans Stacey</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001563577/000095017021003917/0000950170-21-003917-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10-Q</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000095017021003917/grtx-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.2</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">11/10/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.6#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="grtx-ex10_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">Employment Agreement, dated October 7, 2021, by and between Galera Therapeutics, Inc. and Mark Bachleda and amendment to Employment Agreement, dated January 31, 2022, by and between Galera Therapeutics, Inc. and Mark Bachleda</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.7#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Form of Indemnification Agreement between Galera Therapeutics, Inc. and its directors and officers</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.8</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.8.1#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Galera Therapeutics, Inc. 2019 Incentive Award Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.8</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.8.2#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Form of Stock Option Award Agreement under the Galera Therapeutics, Inc. 2019 Incentive Award Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.10</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.8.3#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Form of Restricted Stock Award Agreement under the Galera Therapeutics, Inc. 2019 Incentive Award Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.11</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.8.4#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Form of Restricted Stock Unit Award Agreement under the Galera Therapeutics, Inc. 2019 Incentive Award Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.12</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;10.9#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/0001193125-19-275478-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1/A</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519275478/d692555dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.14</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/28/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.859%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:40.846%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.86%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.852%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:5.853%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.852%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.852%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;&#160;10.10#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Galera Therapeutics, Inc. Equity Incentive Plan, as amended</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001563577/000119312519266859/0001193125-19-266859-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519266859/d692555dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.8</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/11/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.11#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Galera Therapeutics, Inc. Non-Employee Director Compensation Policy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459021012244/0001564590-21-012244-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10-K</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459021012244/grtx-ex1010_8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.10</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">03/11/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.12.1&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Amended and Restated Purchase and Sale Agreement, dated as of November 14, 2018, by and among Galera Therapeutics, Inc. and Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P., and Clarus IV-D, L.P.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001563577/000119312519266859/0001193125-19-266859-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519266859/d692555dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/11/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.12.2&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Amendment No. 1 Amended and Restated Purchase and Sale Agreement, dated May 11, 2020, by and between Galera Therapeutics, Inc. and Clarus IV Galera Royalty AIV, L.P.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459020038606/0001564590-20-038606-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10-Q</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459020038606/grtx-ex101_63.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">08/10/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.13&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Warrant Purchase Agreement, dated May 11, 2020, by and between Galera Therapeutics, Inc. and Clarus IV Galera Royalty AIV, L.P.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459020038606/0001564590-20-038606-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10-Q</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459020038606/grtx-ex102_64.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.2</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">08/10/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;10.14&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Master Manufacturing Services Agreement between Patheon Manufacturing Services LLC and Galera Therapeutics, Inc., dated August 13, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001563577/000156459021045026/0001564590-21-045026-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">8-K</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">001-39114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000156459021045026/grtx-ex100_16.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">10.0</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">08/18/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Subsidiaries of Galera Therapeutics, Inc.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519266859/0001193125-19-266859-index.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">S-1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">333-234184</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1563577/000119312519266859/d692555dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">21.1</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">10/11/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;23.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="grtx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">Consent of KPMG LLP</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;31.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="grtx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;31.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="grtx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;32.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="grtx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">**</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">&#160;&#160;32.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="grtx-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.5pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">**</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">*	  Filed herewith.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">**	  Furnished herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">#     	  Indicates management contract or compensatory plan.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.0%;"></td>
    <td style="width:95.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">URES</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.801%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:4.154%;"></td>
    <td style="width:45.889%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">J. Mel Sorensen, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">J. Mel Sorensen, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Chief Executive Officer and President</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Christopher Degnan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Christopher Degnan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Chief Financial Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.002%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:43.301%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:21.624%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ J. Mel Sorensen, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer, President and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">J. Mel Sorensen, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(principal executive officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Christopher Degnan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Christopher Degnan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(principal financial and accounting officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mike Powell, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Michael Powell, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Lawrence Alleva</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lawrence Alleva</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Emmett Cunningham, M.D., Ph.D., MPH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emmett Cunningham, M.D., Ph.D., MPH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Linda West</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Linda West</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Kevin Lokay</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Kevin Lokay</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>grtx-ex10_6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<html>
 <head>
  <title>EX-10.6</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Employment, Confidentiality, Noncompete and Invention Rights Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Employment, Confidentiality, Noncompete and Invention Rights Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and Mark Bachleda (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Recitals</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Effective as of the date Employee commences employment with the Company, which is expected to be October 8, 2021 or another date mutually agreed on by Employee and the Company (in any case, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), Company desires to benefit from the services of Employee, and Employee desires to render such services, on the terms and conditions set forth in this Agreement. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Company is engaged in, among other things, the business of developing superoxide dismutase mimetics for the treatment and prevention of various diseases, including cancer and the serious side effects associated with current cancer therapies as well as other agents to treat cancer and the serious side effects associated with current cancer therapies.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Company shall expend a great deal of time, money and effort to develop and maintain its proprietary Confidential Information (as defined below).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The success of Company depends to a substantial extent upon the protection of its Confidential Information and goodwill by all of its employees. Employee recognizes and acknowledges that Employee&#x2019;s position with Company will provide Employee with access to Confidential Information.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Company compensates its employees to, among other things, develop and preserve goodwill with its customers, landlords, suppliers and partners on Company&#x2019;s behalf and business information for Company&#x2019;s ownership and use.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Employee were to leave Company, Company, in all fairness, would need certain protections in order to prevent competitors of Company from gaining an unfair competitive advantage over Company or diverting goodwill from Company, or to prevent Employee from misusing or misappropriating the Confidential Information.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Agreements</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the Employee&#x2019;s employment and compensation by the Company and the recitals, mutual covenants and agreements hereinafter set forth, Employee and Company agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Employment Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Effective as of the Effective Date, Employee shall be employed by Company upon the terms and conditions hereinafter set forth. Employee shall report directly to the Chief </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Executive Officer of the Company and shall provide services to Company as Chief Commercial Officer. Employee&#x2019;s duties will include those duties and responsibilities customarily associated with such position and such other duties and responsibilities as are reasonably requested by the Chief Executive Officer to fulfill the duties of this position.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee agrees that throughout Employee&#x2019;s employment with Company, Employee will (a) faithfully render such services as may be assigned to Employee by Company, (b) devote Employee&#x2019;s full working time to the Company using Employee&#x2019;s good faith efforts, ability, skill and attention to Company&#x2019;s business, and (c) follow and act in accordance with all of the rules, policies and procedures of Company, including those outlined in any Employee Handbook that the Company may adopt and revise from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Employee Handbook</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Term of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Employee&#x2019;s employment with the Company pursuant to this Agreement will begin on the Effective Date and shall continue indefinitely until terminated by the Company or by the Employee at any time, with or without cause, subject to the provisions of Section 4 below. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the term of this Agreement, Employee shall be entitled to the following:</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A base salary of $475,000 per year, subject to review and adjustment as determined by the Board of Directors of the Company or an authorized committee thereof (in either case, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), to be paid according to the Company&#x2019;s regular payroll practices (such base salary as it may be adjusted from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">An opportunity to earn an annual performance-based bonus targeted at 40% of Base Salary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Target Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) based upon achievement of objectives for the applicable year as determined by the Board (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The payment of any Bonus is subject to Employee&#x2019;s continued employment by the Company on the last day of the calendar year to which the Bonus relates and will be made in accordance with the Company&#x2019;s annual performance-based bonus program, but not later than March 15 of the calendar year following the calendar year in which such Bonus is earned;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee shall receive a relocation payment in the amount of $350,000 (such payment, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Relocation Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), less applicable withholdings, on January 31, 2022, subject to Employee&#x2019;s continued employment with the Company through such date. Notwithstanding the foregoing, (x) if Employee fails to relocate Employee&#x2019;s primary residence to within 35 miles of the Company&#x2019;s corporate offices in Malvern, Pennsylvania by August 15, 2022 (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Failure to Relocate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), or Employee is terminated for &#x201c;good cause&#x201d; (as defined below) or resigns other than for &#x201c;good reason&#x201d; (as defined below), in either case, within twelve (12) months following the Effective Date, Employee will repay the 100% of the gross amount of the Relocation Payment to the Company, or (y) if Employee is terminated for &#x201c;good cause&#x201d; or resigns other than for &#x201c;good reason&#x201d;, in either case, between twelve </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(12) and twenty-four (24) months following the Effective Date, Employee will repay 50% of the gross amount of the Relocation Payment to the Company. Any such repayment shall be made within 30 days of such termination.  The Company will be entitled (but not required) to deduct the amount of any such repayment obligation from any after-tax amounts otherwise payable to Employee by the Company or any of its affiliates;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to the approval of the Board, as soon as practicable after the Effective Date, an option (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to purchase 200,000 shares of the Company&#x2019;s common stock with an exercise price per share equal to the fair market value per share of the Company&#x2019;s common stock as of the date of grant, as determined under the Company&#x2019;s 2019 Incentive Award Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The Option will be subject to the terms and conditions of the Plan and a separate stock option award agreement and will vest over a four year period with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 substantially equal monthly instalments thereafter, so long as Employee continues to be employed by the Company.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee will be eligible to participate in all benefit plans of the Company generally available to employees of the Company as in effect from time to time, in accordance with and subject to the terms thereof.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee shall be entitled to paid vacation and paid sick leave in accordance with the Company&#x2019;s policies as set forth in the Employee Handbook or otherwise in effect from time to time.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All compensation payable by Company to Employee under this Agreement shall be subject to customary withholding taxes and other employment taxes as required with respect thereto.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upon Employee&#x2019;s submission of proper substantiation, the Company shall reimburse Employee for all reasonable business expenses and travel expenses actually and necessarily paid or incurred by Employee in the course of and pursuant to the business of the Company, in accordance with the Company&#x2019;s policies. No expenses incurred after the Employee&#x2019;s termination of employment with the Company shall be subject to reimbursement under this Section 3.5.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company shall use commercially reasonable efforts to acquire and ensure that Employee shall be covered (for both liability and representation) at all times as an &#x201c;Officer&#x201d; or &#x201c;Executive Officer&#x201d; or the equivalent thereof under, one or more reasonable and customary directors and officers insurance policies, which shall be applicable to the Company and any subsequent renewals, extensions or replacements thereof, in each case as approved by the Board and to the same extent as other similarly situated officers of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Agreement and Employee&#x2019;s employment may be terminated under the following circumstances:</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Automatically upon the death of Employee.</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By the Company in the event Employee, by reason of physical or mental disability, shall with reasonable accommodation be unable to perform a material portion of the services required of Employee hereunder for a continuous ninety (90) day period. In the event of a disagreement concerning the existence of any such disability, the matter shall be resolved by a disinterested licensed physician chosen by Company or its insurers with approval by Employee.</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By the Company for &#x201c;good cause,&#x201d; which for the purposes of this Agreement shall mean: (i) the Employee&#x2019;s refusal to substantially satisfy the material responsibilities and objectives reasonably assigned to Employee by the Company (other than due to a physical or mental disability); (ii) a material breach by Employee of this Agreement or any other agreement between Employee and the Company; (iii) Employee&#x2019;s commission of a felony or a crime involving moral turpitude, or the commission of any other act or omission involving dishonesty or fraud with respect to the Company or any of its affiliates or any of their respective customers or suppliers; (iv) behavior by Employee constituting sexual harassment, unlawful discrimination or similar behavior; (v) Employee&#x2019;s material breach of any confidentiality or non-compete obligations; (vi) conduct by Employee that tends to bring the Company, or any of its affiliates, into public disgrace or disrepute; (vii) Employee&#x2019;s gross negligence or willful misconduct with respect to the Company or any of its affiliates; or (viii) a Failure to Relocate. In order for Employee&#x2019;s termination to be considered to be for good cause pursuant to clauses (i) or (ii) above, the Company must notify the Employee of the existence of good cause within ninety (90) days of the initial existence of the condition alleged to give rise to good cause and provide the Employee with a period of thirty (30) days in which to remedy the condition. In the event the Employee remedies the condition within such thirty (30) day period, &#x201c;good cause&#x201d; shall not be deemed to exist with respect to such condition.</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By the Employee for &#x201c;good reason,&#x201d; which for the purposes of this Agreement shall mean: (i) a failure by Company to comply with the material terms of this Agreement; (ii) any requirement by Company that Employee perform any act which is illegal; (iii) any material reduction in Employee&#x2019;s Base Salary which is not consented to by Employee, except in connection with across-the-board salary reductions based on the Company&#x2019;s financial condition or performance similarly affecting all or substantially all senior management employees of the Company; or (iv) any material reduction in Employee&#x2019;s responsibilities, positions, duties or authority which is not consented to by Employee and which occurs within twelve (12) months after a Change in Control (as defined below). In order for Employee&#x2019;s termination to be considered to be for good reason, the Employee must (x) notify </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Company of the existence of good reason within ninety (90) days of the initial existence of the condition alleged to give rise to good reason, (y) provide the Company with a period of thirty (30) days in which to remedy the condition and (z) after the Company fails to timely remedy the condition, terminate the Employee&#x2019;s employment within sixty (60) days following expiration of such thirty (30) day period. In the event the Company remedies the condition within such thirty (30) day period, &#x201c;good reason&#x201d; shall not be deemed to exist.</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By the Company without &#x201c;good cause&#x201d; or by the Employee for any other reason other than &#x201c;good reason&#x201d; or for no reason.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any termination of Employee&#x2019;s employment by the Company or by Employee under this Section 4 (other than termination pursuant to Section 4.1(a)) shall be communicated by a written notice to the other party hereto (i) indicating the specific termination provision in this Agreement relied upon, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Employee&#x2019;s employment under the provision so indicated, if applicable, and (iii) specifying a Date of Termination (as defined below) which, if submitted by Employee, shall be at least thirty (30) days following the date of such notice (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); provided, however, that in the event that Employee delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of Company&#x2019;s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination, but the termination will still be considered a resignation by Employee. A Notice of Termination submitted by the Company may provide for a Date of Termination on the date Employee receives the Notice of Termination, or any date thereafter elected by the Company. The failure by either party to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of &#x201c;good cause&#x201d; or &#x201c;good reason&#x201d; shall not waive any right of the party hereunder or preclude the party from asserting such fact or circumstance in enforcing the party&#x2019;s rights hereunder. For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Date of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means (A) if Employee&#x2019;s employment is terminated by Employee&#x2019;s death, the date of Employee&#x2019;s death; or (B) if Employee&#x2019;s employment is terminated pursuant to Sections 4.1(b) &#x2013; (e), either the date indicated in the Notice of Termination or the date specified by the Company pursuant this Section, whichever is earlier.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">4.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upon the Date of Termination, all rights and obligations of the parties hereunder shall cease except that termination of employment pursuant to this Section 4 or otherwise shall not terminate or otherwise affect the rights and obligations of the parties pursuant to Section 4 through Section 14, Section 17, Section 19, Section 20 or Section 22.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">4.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, on the Date of Termination, Employee is a member of the Board or any governing body of the Company or any of its subsidiaries, or holds any other offices or positions with the Company or its subsidiaries, Employee shall be deemed to have resigned from all such directorships, offices and positions as of the Date of Termination.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">4.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee&#x2019;s right to payment and benefits from the Company under this Agreement for periods after the Date of Termination shall be limited to the following provisions of this Section 4.5:</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following termination of Employee&#x2019;s employment for any reason, Company shall pay to Employee:</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in accordance with Company&#x2019;s usual payroll practices, the Base Salary earned up to and including the Date of Termination, but not yet paid;</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">any Bonus awarded for the calendar year prior to the calendar year in which the Date of Termination occurs, determined in accordance with Section 3.1(b), but unpaid as of the Date of Termination, which Bonus shall be paid when such amounts would have otherwise been paid pursuant to Section 3.1(b);</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in accordance with Company&#x2019;s usual payroll practices, payment for unused vacation days accrued up to and including the Date of Termination in accordance with Company policy;</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in accordance with Company&#x2019;s policy and regular business practice, payment for all reasonable, customary and documented business expenses incurred up to and including the Date of Termination; and</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">any other payments or benefits to be provided to Employee by Company pursuant to any employee benefit plans or arrangements adopted by Company, to the extent such amounts are due from Company, which amounts shall be payable in accordance with the terms and conditions of such plans or arrangements.</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to Sections 4.5(c) and (d) below and Employee&#x2019;s continued compliance with Sections 5, 6, 8 and 9, if the Company terminates Employee&#x2019;s employment for reasons other than death (Section 4.1(a)), physical or mental disability (Section 4.1(b)), or &#x201c;good cause&#x201d; (Section 4.1(c)) or if the Employee terminates Employee&#x2019;s employment as a result of circumstances constituting &#x201c;good reason&#x201d; (Section 4.1(d)), then, in addition to the amounts payable in accordance with Section 4.5(a), Employee shall receive the following: </font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a cash severance payment equal to 9 months (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Severance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of Employee&#x2019;s Base Salary as in effect on the Date of Termination. Such severance shall be paid in equal installments over the Severance Period according to the Company&#x2019;s regular payroll practices, with the first installment payment (which will include any installment payments that would have otherwise been earlier made) occurring on the first regular payroll date immediately following the date the Release (as defined below) becomes effective and irrevocable; however, if the period for submitting the Release, which shall not extend beyond sixty (60) days following Employee&#x2019;s Date of Termination, spans two calendar years, payment of the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">cash severance under this paragraph (b)(i) shall not commence before the first regular payroll period of the second calendar year; and</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">if Employee timely elects to receive continued health coverage under any Company group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then, during the period commencing on the Date of Termination and ending upon the earliest of (X) the last day of the Severance Period, (Y) the date that Employee is no longer eligible for COBRA or (Z) the date Employee becomes eligible to receive health coverage from a subsequent employer (and Employee agrees to promptly notify the Company of such eligibility), the Company shall pay, or reimburse Employee for, a percentage of the applicable monthly premium for such continuation coverage equal to the same percentage contributed by the Company towards the Employee&#x2019;s health plan coverage in effect immediately prior to the Date of Termination. Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act) or incurring an excise tax, the Company may alter the manner in which health coverage is provided to Employee after the Date of Termination so long as such alteration does not increase the after-tax cost or materially diminish the level of such benefits to Employee.</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to Section 4.5(d) below and Employee&#x2019;s continued compliance with Sections 5, 6, 8 and 9, in lieu of the payments and benefits set forth in Section 4.5(b), if the Company terminates Employee&#x2019;s employment for reasons other than death (Section 4.1(a)), physical or mental disability (Section 4.1(b)), or &#x201c;good cause&#x201d; (Section 4.1(c)) or if the Employee terminates Employee&#x2019;s employment as a result of circumstances constituting &#x201c;good reason&#x201d; (Section 4.1(d)), in any case, on or within 12 months following the date of a Change in Control, then, in addition to the amounts payable in accordance with Section 4.5(a), Employee shall receive the following: </font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a cash severance payment equal to the sum of (A) 12 months (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">CIC Severance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of Employee&#x2019;s Base Salary as in effect on the Date of Termination, plus (B) 1 times the Target Bonus. Such severance shall be paid in equal installments over the CIC Severance Period according to the Company&#x2019;s regular payroll practices, with the first installment payment (which will include any installment payments that would have otherwise been earlier made)  occurring on the first regular payroll date immediately following the date the Release becomes effective and irrevocable; however, if the period for submitting the Release, which shall not extend beyond sixty (60) days following Employee&#x2019;s Date of Termination, spans two calendar years, payment of the cash severance under this paragraph (c)(i) shall not commence before the first regular payroll period of the second calendar year;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the benefits set forth in Section 4.5(b)(ii), provided that the Severance Period will mean the CIC Severance Period; and</font></div></div>
  <div style="margin-left:13.13%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.556%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.546909174628755%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">all unvested equity or equity-based awards held by Employee under any Company equity compensation plans that vest solely based on the passage of time shall immediately become 100% vested (for the avoidance of doubt, with any such awards that vest in whole or in part based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement).</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In no event shall Employee be entitled to receive any amounts, rights, or benefits under Section 4.5(b) or Section 4.5(c) unless Employee executes, timely delivers to the Company and does not revoke a release of claims against Company in substantially the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall have the meaning set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Both during the period of Employee&#x2019;s employment with the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Employment Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and following termination of employment, Employee agrees to keep secret and confidential, and not to use or disclose to any third parties, except as directly required for Employee to perform Employee&#x2019;s employment responsibilities for Company, any of Company&#x2019;s proprietary Confidential Information.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">5.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee acknowledges and confirms that certain data and other information (whether in human or machine readable form) that comes into Employee&#x2019;s possession or knowledge (whether before or after the date of this Agreement) and that was obtained from Company, or obtained by Employee for or on behalf of Company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is the secret, confidential property of Company or its affiliates. This Confidential Information includes, but is not limited to: (a) lists or other identification of customers or prospective customers of Company or its affiliates (and key individuals employed by or engaged by such parties); (b) lists or other identification of sources or prospective sources of Company&#x2019;s or its affiliates&#x2019; products or components thereof, its landlords and prospective landlords and its current and prospective alliance, marketing and media partners (and key individuals employed or engaged by such parties); (c) all compilations of information, correspondence, designs, drawings, files, compounds, formulae, lists, machines, maps, methods, models, notes or other writings, plans, records, regulatory compliance procedures, protocols, reports, schematics, specialized or technical data, source code, object code, documentation, and software used in connection with the discovery, development, manufacture, fabrication, assembly, use, marketing and sale of Company&#x2019;s or its affiliates&#x2019; products; (d) financial, sales and marketing data relating to Company, its affiliates or to the industry or other areas pertaining to Company&#x2019;s activities and contemplated activities (including, without limitation, licensing, leasing, manufacturing, transportation, distribution and sales costs and non-public pricing information); (e) chemical compositions, equipment, materials, designs, procedures, processes, and techniques used in, or related to, the development, manufacture, assembly, fabrication or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">other production and quality control of Company&#x2019;s or its affiliates&#x2019; products; (f) Company&#x2019;s or its affiliates&#x2019; relations with its past, current and prospective licensees, licensors, customers, suppliers, landlords, alliance, marketing and media partners and the nature and type of products or services rendered to, received from or developed with such parties or prospective parties; (g) Company&#x2019;s or its affiliates&#x2019; relations with its employees (including, without limitation, salaries, job classifications and skill levels); and (h) any other information designated by Company or its affiliates to be confidential, secret and/or proprietary (including without limitation, non-public information provided by licensees, licensors, customers, suppliers and alliance partners of Company or its affiliates). Notwithstanding the foregoing, the term Confidential Information shall not include: (i) any data or other information which has been made publicly available or otherwise placed in the public domain other than by Employee in violation of this Agreement; (ii) information that Employee already knew prior to commencement of Employee&#x2019;s employment (or other service relationship, if any, that commenced prior to employment) with the Company, other than by disclosure to Employee by the Company; (iii) information that Employee lawfully receives from someone outside the Company or its affiliates who is not obligated to keep the information confidential; or (iv) information that is explicitly approved in writing for release by the Chief Executive Officer.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">5.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the Employment Period, Employee will not copy, reproduce or otherwise duplicate, record, abstract, summarize or otherwise use, any papers, records, reports, studies, computer printouts, equipment, tools or other property owned by Company except (i) as expressly permitted by Company in writing or (ii) as required for the proper performance of Employee&#x2019;s duties on behalf of Company. Employee will promptly notify Company if Employee is legally compelled to disclose any Confidential Information by the order of any court or governmental investigative or judicial agency pursuant to proceedings over which such court or agency has jurisdiction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Restrictions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Employee recognizes that (i) Company will spend substantial money, time and effort in developing and solidifying its relationships with its customers, suppliers, landlords and alliance partners and in developing its Confidential Information; (ii) long-term customer, landlord, supplier and partner relationships often can be difficult to develop and require a significant investment of time, effort and expense; (iii) Company has paid its employees to, among other things, develop and preserve business information, customer, landlord, vendor and partner goodwill, customer, landlord, vendor and partner loyalty and customer, landlord, vendor and partner contacts for and on behalf of Company; and (iv) Company is hereby agreeing to employ Employee based upon Employee&#x2019;s assurances and promises not to divert good will of customers, landlords, suppliers or partners of Company, either individually or on a combined basis, or to put Employee in a position following Employee&#x2019;s employment with Company in which the confidentiality of Company&#x2019;s Confidential Information might somehow be compromised. Accordingly, Employee agrees that, regardless of how Employee&#x2019;s termination occurs and regardless of whether it is with or without cause, Employee will not, directly or indirectly (whether as owner, partner, consultant, employee, or otherwise) anywhere in the United States:</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">during the Employment Period and for twelve (12) months immediately following the Date of Termination, provide any labor, services, expertise, advice or assistance to, or have an interest in, any person or entity engaged in, or planning to engage in, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">discovery, development, manufacture, marketing or sales of (i) any products or potential products for the treatment or prevention of mucositis, (ii) any products or potential products primarily for the treatment or prevention of any fibrosis indication for which the Company has products or potential products under development during the Employment Period, (iii) superoxide dismutase or superoxide dismutase mimetics for the treatment and prevention of various diseases, including cancer and the serious side effects associated with current cancer therapies, or (iv) other agents which have the same mechanism of action or molecular target as those under development by the Company during the Employment Period or during the Employment Period, provide any labor, services, expertise, advice or assistance to, or have an interest in, any person or entity engaged in, or planning to engage in, any other business in which the Company may engage during the Employment Period (together, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Restricted Activity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), including, without limitation, Employee providing labor, service, expertise, advice or assistance to any investment fund or other investment entity for the purpose of evaluating and/or making an investment in any company engaged or planning to engage in the Restricted Activity; and</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">during the Employment Period and for twelve (12) months immediately following the Date of Termination, induce or solicit or attempt to induce or solicit any (i) employee, consultant, partner or advisor of Company to accept employment or an affiliation or (ii) distributor, supplier, representative or agent of the Company to terminate or modify its relationship with the Company;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">that, nothing in this Section 6 shall prohibit Employee from: (x) investing in stocks, bonds, or other securities in any business if such stocks, bonds, or other securities are listed on any United States securities exchange or are publicly traded in an over the counter market, and such investment does not exceed, in the case of any capital stock of any one issuer, two percent (2%) of the issued and outstanding capital stock, or in the case of bonds or other securities, two percent (2%) of the aggregate principal amount thereof issued and outstanding, (y) indirectly investing in securities in any corporation or other business entity by virtue of Employee&#x2019;s passive investment (with no ability to manage or direct investments) in a venture capital limited liability partnership or private equity fund or any other similar venture, private equity or seed capital firm, or (z) participating in activities as specifically consented to in writing by the Board that would otherwise be Restricted Activities.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Acknowledgment Regarding Restrictions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee recognizes and agrees that the restraints contained in Section 6 (both separately and in total), are reasonable and enforceable in view of Company&#x2019;s legitimate interests in protecting its Confidential Information and customer goodwill and the limited scope of the restrictions in Section 6.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee acknowledges that nothing contained herein shall prohibit Employee from (a) filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or cooperating with any governmental agency or entity or making other disclosures that are protected under the whistleblower provisions of </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">applicable law or regulation and/or (b) communicating directly with, cooperating with, or providing information (including trade secrets) in confidence to, any federal, state or local government regulator (including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice) for the purpose of reporting or investigating a suspected violation of law, or from providing such information to Employee&#x2019;s attorney or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding.  Employee hereby acknowledges that Company has provided Employee with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) Employee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of Confidential Information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Employee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of Confidential Information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose the Confidential Information to Employee&#x2019;s attorney and use the Confidential Information in the court proceeding, if Employee files any document containing the Confidential Information under seal, and does not disclose the Confidential Information, except pursuant to court order.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Inventions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any and all ideas, inventions, discoveries, patents, patent applications, continuation-in-part patent applications, divisional patent applications, technology, copyrights, derivative works, trademarks, service marks, improvements, trade secrets, compounds, formulas, recipes, mixtures, processes and the like (including any modifications thereto) (each an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Invention</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Inventions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which are developed, conceived, created, discovered, learned, produced and/or otherwise generated by Employee, whether individually or otherwise, during the Employment Period, whether or not during working hours, that (i) result from work performed for the Company, (ii) use the Company&#x2019;s Confidential Information or other proprietary materials or (iii) directly relate to discovery, development, manufacture, use or commercialization of (w) any products or product candidates for the treatment or prevention of mucositis, esophagitis, fibrosis or other radiation-related toxicities, (x) any products or potential product for any radiation-related indication for which the Company has or had products or potential products under development during the Employment Period, (y) superoxide dismutase or superoxide dismutase mimetics, including for the treatment and prevention of various diseases, including cancer and the serious side effects associated with current cancer therapies, or (z) other agents which have similar chemistry, mechanism of action or molecular target as those under development by the Company during the Employment Period shall be the sole and exclusive property of Company, and Employee hereby assigns, and to the extent not assignable at present, agrees to assign to Company, and Company shall own, any and all right, title and interest to such Inventions, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">that any ideas, inventions, discoveries, patents, patent applications, continuation-in-part patent applications, divisional patent applications, technology, copyrights, derivative works, trademarks, service marks, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">improvements, trade secrets, compounds, formulas, recipes, mixtures, processes and the like (including any modifications thereto) that would be Inventions except (a) that no equipment, supplies, facility, or confidential or proprietary information of the Company was used and (b) which do not directly relate to discovery, development, manufacture, use or commercialization of superoxide dismutase or superoxide dismutase mimetics, or of other agents which have similar chemistry, mechanism of action or molecular target as those under development by the Company during the Employment Period, shall not be considered Inventions.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee shall promptly make a complete written disclosure to Company of any Invention, when and as it arises, is conceived or is reduced to practice, specifically pointing out the features or concepts that Employee believes to be new or different. Employee shall give Company and its attorneys all reasonable assistance in connection with the preparation and prosecution of any patent applications filed in connection with any such Invention. Company shall have the right to name Employee as inventor in any patent application where applicable. Whenever requested to do so by Company, at Company&#x2019;s expense, Employee agrees to execute any and all applications, assignments or other instruments which Company deems necessary and/or desirable to protect such interests. Furthermore, Employee hereby agrees to execute, acknowledge and deliver, from time to time as may be requested by Company, any and all documents and take such other action as Company believes, in its sole discretion, to be necessary to: (a) protect, register, and/or otherwise vest Company&#x2019;s right, title and interest in and to the Inventions; (b) make a record with any and all government agencies, authorities, courts, tribunals, or third parties of the fact that Company owns all right, title and interest in and to the Inventions; and (c) make such a record that Employee has no right, title or interest, of any kind or nature, in or to the Inventions. Employee further agrees that Employee&#x2019;s obligation to execute or cause to be executed any such instrument or papers shall continue after the termination of this Agreement.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Company is unable for any reason to secure Employee&#x2019;s signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering Inventions or original works of authorship assigned to Company as above, then Employee hereby irrevocably designates and appoints Company and its duly authorized officers and agents as Employee&#x2019;s agent and attorney-in-fact, to act for and in its name, place and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force and effect as if executed by Employee. Notwithstanding the occurrence of a breach by Company of any legal duty or obligation imposed by any contract (including this Agreement), by the law of torts (including simple or gross negligence, strict liability or willful misconduct), or by federal or state laws, rules, regulations, orders, standards or ordinances, during the term of this Agreement, Employee shall have no right to revoke or restrict in any manner or to any degree whatsoever, through injunctive relief or otherwise, the rights granted to Company under this Agreement, it being understood and agreed that each such breach shall be compensable, if at all, by a remedy at law.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employee acknowledges that as part of Employee&#x2019;s work for Company Employee may be asked to create, or contribute to the creation of, computer programs, documentation or other copyrightable works. Employee hereby agrees that any and all computer programs, documentation and other copyrightable materials that Employee has prepared or worked on for Company, or is asked to prepare or work on by Company, shall be treated as and shall be a &#x201c;work made for hire,&#x201d; for the exclusive ownership and benefit of Company according to the copyright laws of the United States, including, but not limited to, Sections 101 and 201 of Title 17 of the U.S. Code (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">U.S.C.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) as well as according to similar foreign laws. Company shall have the exclusive right to register the copyrights in all such works in its name as the owner and author of such works and shall have the exclusive rights conveyed under 17 U.S.C. &#167;&#167;106 and 106A, including, but not limited to, the right to make all uses of the works in which attribution or integrity rights may be implicated. Without in any way limiting the foregoing, to the extent the works are not treated as works made for hire under any applicable law, Employee hereby irrevocably assigns, transfers and conveys to Company and its successors and assigns any and all right, title and interest that Employee may now or in the future have in or to the copyrightable works, including, but not limited to, all ownership, U.S. and foreign copyrights, all treaty, convention, statutory and common law rights under the law of any U.S. or foreign jurisdiction, the right to sue for past, present and future infringement and moral, attribution and integrity rights. Employee hereby expressly and forever irrevocably waives any and all rights Employee has arising under 17 U.S.C. &#167;106A, rights that may arise under any federal, state or foreign law that conveys rights that are similar in nature to those conveyed under 17 U.S.C. &#167;106, and any other type of moral right or droit moral.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Employee acknowledges that any and all notes, records, sketches, computer diskettes, training materials and other documents relating to Company obtained by or provided to Employee, or otherwise made, produced or compiled during the Employment Period, regardless of the type of medium in which they are preserved, are the sole and exclusive property of Company and shall be surrendered to Company upon Employee&#x2019;s termination of employment and on demand at any time by Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Non-Waiver of Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Company&#x2019;s or Employee&#x2019;s failure to enforce at any time any of the provisions of this Agreement or to require at any time performance by the other party of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement, or any part hereof, or the right of Company or Employee thereafter to enforce each and every provision in accordance with the terms of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Right to Injunctive Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. In the event of a breach or threatened breach of any rights, duties or obligations under the terms and provisions of Section 5 &#x201c;Confidential Information&#x201d;, Section 6 &#x201c;Restrictions&#x201d;, Section 8 &#x201c;Inventions&#x201d;, or Section 9 &#x201c;Company Property&#x201d;, either Company or Employee shall be entitled, in addition to any other legal or equitable remedies the party may have in connection therewith (including any right to damages that the party may suffer), to temporary, preliminary and permanent injunctive relief restraining such breach or threatened breach. The parties hereby expressly acknowledge that the harm which might result to the Employee or to the Company&#x2019;s business as a result of any noncompliance with any of the provisions of Section 5, Section 6, Section 8 or Section 9 might be largely irreparable. The parties </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">specifically agree that if there is a question as to the enforceability of any of the provisions of Section 5, Section 6, Section 8 or Section 9 the parties will not engage in any conduct inconsistent with or contrary to such sections until after the question has been resolved by a final judgment of a court of competent jurisdiction. Employee and Company agree that the running of the periods set forth in Section 6 shall be tolled during any period of time in which Employee violates that section.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Judicial Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. If any provision of this Agreement is adjudicated to be invalid or unenforceable under applicable law in any jurisdiction, the validity or enforceability of the remaining provisions thereof shall be unaffected as to such jurisdiction and such adjudication shall not affect the validity or enforceability of such provisions in any other jurisdiction. To the extent that any provision of this Agreement is adjudicated to be invalid or unenforceable because it is overbroad, that provision shall not be void but rather shall be limited only to the extent required by applicable law and enforced as so limited. The parties expressly acknowledge and agree that this Section 12 is reasonable in view of the parties&#x2019; respective interests.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Employee Representations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Employee represents that the execution and delivery of the Agreement and Employee&#x2019;s employment with Company do not violate any previous or existing employment agreement or other contractual obligation of Employee. Employee agrees that Employee will not, during Employee&#x2019;s employment with the Company, bring onto Company premises or improperly use or disclose any confidential or proprietary information or trade secrets of any former or other employer or third party for whom Employee has been engaged to provide services without the explicit written consent of such employer or third party. If, at any time during Employee&#x2019;s employment with the Company, Employee is (a) requested by the Company to perform work which Employee believes may cause Employee to violate a duty Employee has to a third party or (b) requested by a third party to perform work which Employee believes may cause Employee to violate a duty Employee has to the Company, Employee will immediately inform the Company (subject to any confidentiality obligations Employee may have to such third party and the Company) so that an assessment of the situation may be made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Right to Recover Costs and Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. In any action to enforce, or arising out of, this Agreement, the prevailing party shall be entitled to be awarded allowable costs and reasonable attorney&#x2019;s fees incurred.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Amendments; Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. No modification, amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing specifically referring hereto, and signed by the parties hereto. This Agreement is intended as the complete, final and exclusive agreement between the parties regarding Employee&#x2019;s terms of employment, Confidential Information, ownership of and assignment of Inventions, and dispute resolution, and supersedes all prior understandings, writings, proposals, representations or communications, oral or written, relating to the subject matter hereof, including without limitation, the letter regarding Employee&#x2019;s offer of  employment dated as of September 29, 2021.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Assignments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. This Agreement shall be freely assignable by Company to and shall inure to the benefit of, and be binding upon, Company, its successors and assigns and/or any other entity which shall succeed to the business conducted by Company. Being a contract for </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">personal services, Employee cannot assign or transfer any of Employee&#x2019;s obligations under this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Choice of Forum and Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. In light of Company&#x2019;s substantial contacts with the State of Delaware, the parties&#x2019; interests in ensuring that disputes regarding the interpretation, validity and enforceability of this Agreement are resolved on a uniform basis, the parties agree that: (a) subject to Section 22, any litigation involving any noncompliance with or breach of the Agreement, or regarding the interpretation, validity and/or enforceability of the Agreement, shall be filed and conducted in the state courts of New Castle County, Delaware or district court for the District of Delaware; and (b) the Agreement shall be interpreted in accordance with and governed by the laws of the State of Delaware, without regard for any conflict of law principles.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when: (i) delivered personally to the recipient; (ii) sent to the recipient by reputable express courier service (charges prepaid); (iii) mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid; or (iv) telecopied to the recipient (with hard copy sent to the recipient by reputable overnight courier service (charges prepaid) that same day) if telecopied before 5:00 p.m. Eastern Time on a business day, and otherwise on the next business day. Such notices, demands and other communications shall be sent to the parties at the addresses indicated below:</font></div></div>
  <p style="margin-left:13.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">If to Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></p>
  <p style="margin-left:19.68%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</font></p>
  <p style="margin-left:19.68%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2 W Liberty Blvd #100</font></p>
  <p style="margin-left:19.733%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Malvern, Pennsylvania 19355</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:19.68%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: Chief Executive Officer</font></p>
  <p style="margin-left:13.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">If to Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">: to the last address Company has in its personnel records for Employee</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party. The parties agree that service of process may be effected by certified or registered mail, return receipt requested, directed to the other party at the address set forth above, and service so made shall be completed when received.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Application of Specific Tax Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that Company determines in good faith that any payment or benefit received or to be received by Employee pursuant to this Agreement or otherwise (all such payments and benefits, including, without limitation, salary and bonus payments, being hereinafter called the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Total Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) would be subject to the excise tax (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), by reason of being considered &#x201c;contingent on a change in ownership or control&#x201d; of Company within the meaning of Section 280G of the Code, then such Total Payments shall be reduced to the minimum extent necessary so that the Total Payments will </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">be less than three times Employee&#x2019;s &#x201c;base amount&#x201d; (as defined in Section 280G(b)(3) of the Code), but only if the amount of such reduction would be less than 100% of the Excise Taxes on such Total Payments. The reduction, if any, of the Total Payments shall apply as follows, unless otherwise agreed and such agreement is in compliance with Section 409A of the Code, (i) first, any cash severance payments due under the Agreement shall be reduced, with the last such payment due first forfeited and reduced, and sequentially thereafter working from the next last payment, and (ii) second, any acceleration of vesting of any equity shall be disregarded beginning with the most recent equity award and each prior award thereafter in chronological order based on each award grant date.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All determinations regarding the application of this Section 19 shall be made by an accounting firm or consulting group selected by the Company with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Independent Advisors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company. In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 19, the excess amount shall be returned promptly by Employee to the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Compliance with Code Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">20.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Agreement and the payments and benefits hereunder are intended to comply with, or qualify for exemption from, the requirements of Section 409A of the Code (including the Treasury Regulations and other administrative guidance promulgated thereunder) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and this Agreement shall be interpreted in a manner consistent with such intent. </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">20.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding anything herein to the contrary, if at the time of Employee&#x2019;s termination of employment Employee is a &#x201c;specified employee&#x201d; as defined in Section 409A, and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A, then Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Employee) to the extent necessary to comply with the requirements of Section 409A until the Company&#x2019;s first regular payroll date that is more than six months following Employee&#x2019;s termination of employment with Company (or the earliest date as is permitted under Section 409A). Upon the first business day following the expiration of the applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Employee (or Employee&#x2019;s estate or beneficiaries), and any remaining payments due to Employee under this Agreement shall be paid as otherwise provided herein.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">20.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If any other payments or benefits due to Employee hereunder could cause the application of an accelerated or additional tax under Section 409A, such payments or benefits shall be deferred if deferral will make such payments or provision of benefits compliant under Section 409A or such payments or benefits shall be restructured, to the extent possible, in a manner, determined by the Company and Employee, that does not cause such an accelerated or additional tax. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">20.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding anything to the contrary herein, to the extent required by Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a &#x201c;separation from service&#x201d; within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a &#x201c;resignation,&#x201d; &#x201c;termination,&#x201d; &#x201c;termination of employment&#x201d; or like terms shall mean a &#x201c;separation from service&#x201d; within the meaning of Section 409A. </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">20.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For purposes of Section 409A, each payment made under this Agreement shall be designated as a &#x201c;separate payment&#x201d; within the meaning of Section 409A. Notwithstanding anything to the contrary in this Agreement, all taxable reimbursements provided under this Agreement that are subject to Section 409A shall be made in accordance with the requirements of Section 409A. The amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year. Reimbursement of an eligible expense shall be made in accordance with the Company&#x2019;s policies and practices and as otherwise provided herein, provided, that, in no event shall reimbursement be made after the last day of the year following the year in which the expense was incurred. The right to reimbursement is not subject to liquidation or exchange for another benefit. Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or interest pursuant to Section 409A.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Section headings are provided in this Agreement for convenience only and shall not be deemed to substantively alter the content of such sections.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">Section 22.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Mutual Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Except as specifically excluded in Section 22.1, arbitration shall be the sole and exclusive remedy for any dispute, claim, or controversy of any kind or nature (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) arising out of, relating to, or connected with Employee&#x2019;s employment relationship with the Company, or the termination of Employee&#x2019;s employment relationship with the Company. This Agreement applies to any Claim Employee may have against the Company, any parent, subsidiary, or affiliated entity of the Company, or their respective directors, officers, general or limited partners, employees or agents. It also applies to any Claim the Company, or any parent, subsidiary or affiliated entity of the Company may have against Employee. Excepting only claims excluded in Section 22.1, this Agreement specifically includes (without limitation) all claims under or relating to any federal, state or local law, whether based on tort, contract, statute, regulation, equitable law or otherwise, including claims for discrimination, harassment or retaliation based on race, color, religion, national origin, sex, sexual orientation, age, disability or any other condition or characteristic protected by law; demotion, discipline, termination or other adverse action in violation of any contract, law or public policy; entitlement to wages or other economic compensation; and any claim for personal, emotional, physical, economic or other injury. To the maximum extent permitted by law, Employee hereby waives any right to bring on behalf of persons other than Employee, or to otherwise participate with other persons in, any class or collective action, subject to Section 22.1, below.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">22.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Agreement does not apply to any claims by Employee: (a) for workers&#x2019; compensation benefits; (b) for unemployment insurance benefits; (c) under a benefit plan where the plan specifies a separate arbitration procedure; (d) under a collective bargaining agreement </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">containing a separate grievance and arbitration procedure; or (e) filed with an administrative agency which are not legally subject to arbitration under this Agreement.  Further, this Section 22 does not preclude the bringing of an action for injunctive relief or specific performance or before a court as contemplated by Section 11.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">22.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any arbitration will be under the Federal Arbitration Act and administered by Judicial Arbitration &amp; Mediation Services, Inc., pursuant to its Employment Arbitration Rules &amp; Procedures, which are available at </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">http://www.jamsadr.com/rules-employment-arbitration/.</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> The arbitrator shall have the power to decide any motions brought by any party to the arbitration, including but not limited to motions for summary judgment and/or adjudication, and motions to</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">dismiss and demurrers, applying the standards set forth under applicable law. The arbitrator shall issue a written decision on the merits. The arbitrator shall have the power to award any remedies available under applicable law, and the arbitrator shall award attorneys, fees and costs to the prevailing party, where provided by applicable law. The decree or award rendered by the arbitrator may be entered as a final and binding judgment in any court having jurisdiction thereof. The Company shall bear all fees and costs unique to the arbitration forum (e.g., filing fees, transcript costs and arbitrator&#x2019;s fees). The parties shall be responsible for their own attorneys&#x2019; fees and costs, except that the arbitrator shall have the authority to award attorneys&#x2019; fees and costs to the prevailing party in accordance with the applicable law governing the dispute.  Any arbitration hereunder shall be confidential and neither any party nor the arbitrator shall disclose the existence, contents or results of such process without the prior written consent of all parties to this Agreement, except where necessary or compelled in a court to enforce this arbitration provision or an award from such arbitration or otherwise in a legal proceeding.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">PLEASE NOTE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">: BY SIGNING THIS AGREEMENT, EMPLOYEE IS HEREBY CERTIFYING THAT EMPLOYEE (A) HAS RECEIVED A COPY OF THIS AGREEMENT FOR REVIEW AND STUDY BEFORE EXECUTING IT; (B) HAS READ THIS AGREEMENT CAREFULLY BEFORE SIGNING IT; (C) HAS HAD SUFFICIENT OPPORTUNITY BEFORE SIGNING THE AGREEMENT TO ASK ANY QUESTIONS EMPLOYEE HAS ABOUT THE AGREEMENT AND HAS RECEIVED SATISFACTORY ANSWERS TO ALL SUCH QUESTIONS; AND (D) UNDERSTANDS EMPLOYEE&#x2019;S RIGHTS AND OBLIGATIONS UNDER THE AGREEMENT.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Signature Page Follows]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties hereto have caused this Employment, Confidentiality, Noncompete and Invention Rights Agreement to be executed as of the day and year first above written.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">						</font>&#160;</p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Mark Bachleda	</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mark Bachleda</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ J. Mel Sorensen	</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name:	 J. Mel Sorensen, M.D.</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:	 President and Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GENERAL RELEASE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I, ________________, in consideration of the obligations of Galera Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), under that certain Employment, Confidentiality, Noncompete and Invention Rights Agreement, dated as of _____ 20__ (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), do hereby release and forever discharge, as of the date hereof, the Company and its affiliates and all present and former directors, officers, agents, representatives, employees, successors and assigns of the Company and its affiliates and the Company&#x2019;s direct and indirect owners (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Released Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to the extent provided below.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I understand that any payments or benefits paid or granted to me under Section 4.5(b) or Section 4.5(c) of the Agreement represent, in part, consideration for signing this General Release and are not salary, wages or benefits to which I was already entitled. I understand and agree that I will not receive the payments and benefits specified in Section 4.5(b) or Section 4.5(c) of the Agreement unless I execute this General Release and do not revoke this General Release within the time period permitted hereafter or breach this General Release. I also acknowledge and represent that I have received all payments and benefits that I am entitled to receive (as of the date hereof) by virtue of my employment with the Company.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as provided in Section 4 and Section 5 below and except for the provisions of the Agreement that expressly survive the termination of my employment with the Company, I knowingly and voluntarily (for myself, my heirs, executors, administrators and assigns) release and forever discharge the Company and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and attorneys&#x2019; fees, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date I execute this General Release) and whether known or unknown, suspected, or claimed against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or are connected with my employment with, or my separation or termination from, the Company (including, but not limited to, any allegation, claim or violation, arising under: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act of 1993; the Worker Adjustment Retraining and Notification Act; the Employee Retirement Income Security Act of 1974; any applicable Employee Order Programs; the Fair Labor Standards Act; or their state or local counterparts; or under any other federal, state or local civil or human rights law, or under any other local, state, or federal law, regulation or ordinance; or under any public policy, contract or tort, or under common law; or arising under any policies, practices or procedures of the Company; or any claim for wrongful discharge, breach of contract, infliction of emotional distress, defamation; or any claim for costs, fees, or other expenses, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">20</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">including attorneys&#x2019; fees incurred in these matters) (all of the foregoing are collectively referred to herein as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I represent that I have made no assignment or transfer of any right, claim, demand, cause of action or other matter covered by Section 2 above.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This General Release does not release claims that cannot be released as a matter of law, including, but not limited to, my right to report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation, my right to file a charge with or participate in a charge, investigation or proceeding by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company (with the understanding that my release of claims herein bars me from recovering monetary or other individual relief from the Company or any Released Parties in connection with any charge, investigation or proceeding, or any related complaint or lawsuit, filed by me or by anyone else on my behalf before the federal Equal Employment Opportunity Commission or a comparable state or local agency), claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#x2019;s group benefit plans pursuant to the terms and conditions of COBRA, claims to any benefit entitlements vested as the date of separation of my employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates, my rights or remedies in connection with my ownership of vested equity securities of the Company, my right to indemnification by the Company or any of its affiliates pursuant to contract or applicable law, and my rights under applicable law. </font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I further agree that this General Release does not waive or release any rights or claims that I may have under the Age Discrimination in Employment Act of 1967 which arise after the date I execute this General Release. I acknowledge and agree that my separation from employment with the Company in compliance with the terms of the Agreement shall not serve as the basis for any claim or action (including, without limitation, any claim under the Age Discrimination in Employment Act of 1967).</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In signing this General Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that this General Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver is an essential and material term of this General Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further agree that in the event I should bring a Claim seeking damages against the Company, or in the event I should seek to recover against the Company in any Claim brought by a governmental agency on </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">21</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">my behalf, this General Release shall serve as a complete defense to such Claims. I further agree that I am not aware of any pending charge or complaint of the type described in Section 2 above as of the execution of this General Release.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I agree that neither this General Release, nor the furnishing of the consideration for this General Release, shall be deemed or construed at any time to be an admission by the Company, any Released Party or myself of any improper or unlawful conduct.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I agree that I will forfeit all amounts payable by the Company pursuant to Section 4.5(b) or Section 4.5(c) of the Agreement if I challenge the validity of this General Release; provided that this forfeiture shall not apply with respect to challenges regarding the validity of any waiver or release under the Age Discrimination in Employment Act of 1967. I also agree that if I violate this General Release by suing the Company or the other Released Parties, I will pay all costs and expenses of defending against the suit incurred by the Released Parties, including reasonable attorneys&#x2019; fees, and return all payments received by me pursuant to Section 4.5(b) or Section 4.5(c) of the Agreement.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I agree not to criticize, denigrate or otherwise disparage the Company, its past and present investors, officers, directors or employees or its affiliates, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that nothing in this Section 9 shall limit my response to questions on any and all such subjects from the Company&#x2019;s Chief Executive Officer, members of its board of directors, its legal counsel or my own legal counsel, or as otherwise required by law. I further agree to keep all confidential and proprietary information about the past or present business affairs of the Company and its affiliates confidential unless a prior written release from the Company is obtained. I further agree that as of the date hereof, I have returned to the Company any and all property, tangible or intangible, relating to its business, which I possessed or had control over at any time (including, but not limited to, company-provided credit cards, building or office access cards, keys, computer equipment, manuals, files, documents, records, software, customer data base and other data) and that I shall not retain any copies, compilations, extracts, excerpts, summaries or other notes of any such manuals, files, documents, records, software, customer data base or other data.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding anything in this General Release to the contrary, this General Release shall not relinquish, diminish, or in any way affect any rights or claims arising out of any action or inaction by the Company or by any Released Party after the date hereof.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I recognize and agree that the restraints contained in Sections 5 &#x2013; 9 of the Agreement (both separately and in total) are reasonable and enforceable and I agree to abide by the terms of those sections.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.565%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Whenever possible, each provision of this General Release shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this General Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or its validity and enforceability in any other jurisdiction, but this General Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">22</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT:</font></p>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I HAVE READ IT CAREFULLY;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY ACT OF 1963, THE AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I VOLUNTARILY CONSENT TO EVERYTHING IN IT;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR, AFTER CAREFUL READING AND CONSIDERATION, I HAVE CHOSEN NOT TO DO SO OF MY OWN VOLITION;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS GENERAL RELEASE TO CONSIDER IT, AND ANY CHANGES MADE SINCE SUCH DATE WILL NOT RESTART THE REQUIRED 21-DAY PERIOD;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS GENERAL RELEASE TO REVOKE IT AND THAT THIS GENERAL RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED;</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT; AND</font></div></div>
  <div style="margin-left:6.565%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:6.565%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.026274950500348%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">DATE: __________________________________      __________________________________</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">           </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">		                                                                       Mark Bachleda</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">23</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For purposes of the Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means and includes each of the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A transaction or series of transactions (other than an offering of the Company&#x2019;s common stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any &#x201c;person&#x201d; or related &#x201c;group&#x201d; of &#x201c;persons&#x201d; (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a &#x201c;person&#x201d; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#x2019;s securities outstanding immediately after such acquisition; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Board member(s) (other than a Board member designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the Board members then still in office who either were Board members at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company&#x2019;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction:</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">which results in the Company&#x2019;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#x2019;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Successor Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#x2019;s outstanding voting securities immediately after the transaction, and</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">24</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any amount that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such amount shall only constitute a Change in Control for purposes of the payment timing of such amount if such transaction also constitutes a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Board shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#x201c;change in control event&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">* * * * *</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">25</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">AMENDMENT NO. 1 TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Employment, Confidentiality, Noncompete and Invention Rights Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Amendment No. 1 (the &#x201c;Amendment&#x201d;) by and between Galera Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), and Mark Bachleda (&#x201c;Employee&#x201d;) to the Employment, Confidentiality, Noncompete and Invention Rights Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), made and entered into as of October 7, 2021, is made and entered into as of January 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Recitals</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:11.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company and Employee mutually desire to amend the terms of the Agreement as set forth below. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Agreements</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, Employee and Company agree as follows:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 3.1(c) of the Agreement shall be deleted and replaced with the following:</font></div></div>
  <p style="margin-left:7.4%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;(c) Employee shall receive a relocation payment in the amount of $350,000 (such payment, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Relocation Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), less applicable withholdings, within thirty (30) days following Employee&#x2019;s relocation of his primary residence to within 35 miles of the Company&#x2019;s corporate offices in Malvern, Pennsylvania, subject to Employee&#x2019;s continued employment with the Company through such date. Notwithstanding the foregoing, (x) if Employee fails to relocate Employee&#x2019;s primary residence to within 35 miles of the Company&#x2019;s corporate offices in Malvern, Pennsylvania by August 15, 2022 (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Failure to Relocate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), or Employee is terminated for &#x201c;good cause&#x201d; (as defined below) or resigns other than for &#x201c;good reason&#x201d; (as defined below), in either case, within twelve (12) months following the Effective Date, Employee will repay the 100% of the gross amount of the Relocation Payment to the Company, or (y) if Employee is terminated for &#x201c;good cause&#x201d; or resigns other than for &#x201c;good reason&#x201d;, in either case, between twelve (12) and twenty-four (24) months following the Effective Date, Employee will repay 50% of the gross amount of the Relocation Payment to the Company. Any such repayment shall be made within 30 days of such termination.  The Company will be entitled (but not required) to deduct the amount of any such repayment obligation from any after-tax amounts otherwise payable to Employee by the Company or any of its affiliates;&#x201d;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:11.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All other terms and conditions of the Agreement remain unchanged and in full force and effect.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">26</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">PLEASE NOTE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">: BY SIGNING THIS AMENDMENT, EMPLOYEE IS HEREBY CERTIFYING THAT EMPLOYEE (A) HAS RECEIVED A COPY OF THIS AMENDMENT FOR REVIEW AND STUDY BEFORE EXECUTING IT; (B) HAS READ THIS AMENDMENT CAREFULLY BEFORE SIGNING IT; (C) HAS HAD SUFFICIENT OPPORTUNITY BEFORE SIGNING THE AMENDMENT TO ASK ANY QUESTIONS EMPLOYEE HAS ABOUT THE AMENDMENT AND HAS RECEIVED SATISFACTORY ANSWERS TO ALL SUCH QUESTIONS; AND (D) UNDERSTANDS EMPLOYEE&#x2019;S RIGHTS AND OBLIGATIONS UNDER THE AMENDMENT.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Signature Page Follows]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">27</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.6</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the day and year first above written.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:11.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">						</font>&#160;</p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Mark Bachleda	</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mark Bachleda</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc.</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ J. Mel Sorensen	</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name:	 J. Mel Sorensen, M.D.</font></p>
  <p style="margin-left:45.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:	 President and Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">28</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>grtx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:20.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the registration statements (No. 333-251061) on Form S-3 and (No. 333-234607) on Form S-8 of our report dated March 10, 2022, with respect to the consolidated financial statements of Galera Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ KPMG LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Philadelphia, Pennsylvania<br>March 10, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>grtx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, J. Mel Sorensen, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. I have reviewed this Annual Report on Form 10-K of Galera Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ J. Mel Sorensen, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">J. Mel Sorensen, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer, President and Director</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>grtx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Christopher Degnan, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. I have reviewed this Annual Report on Form 10-K of Galera Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Christopher Degnan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Christopher Degnan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(principal financial officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>grtx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Galera Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ J. Mel Sorensen, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">J. Mel Sorensen, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer, President and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>grtx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Galera Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Christopher Degnan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Christopher Degnan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(principal financial officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img187335194_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) G # 2(  A$! Q$!_\0
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MF?\ "0:;_P ]I?\ P'D_^)H_X2#3?^>TO_@/)_\ $T :=%9G_"0:;_SVE_\
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M]6!I=]H>CZ9!I]F\RP0+M7=#(Q/.222O))))^M7/^$@TW_GM+_X#R?\ Q-#
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M9\N567<V,=,ACGN#BI_[1TB.W$BRH62X-[L5/F,C*0$&1C"MCVZUZ3PM!?\
M+O\ ,\U8K$/_ )>?@C>_X7)<?] 6+_P(/_Q-+_PN.X_Z L7_ ($'_P")K"AU
M'1O/M]TL:Q2W1NR63YH7V+D' Z%@PP/4'M7/:9);P:DMS=%0D"^8JH,[W ^4
M#MUP3GT-5'"8=IWI_F3+&8A-6J;^AWW_  N.X_Z L7_@0?\ XFC_ (7'<?\
M0%B_\"#_ /$US#/H%U,UU(Z!Y65BC@C!?&XD#@;2K=/[X]*;*F@[Y!F%8RL;
M%D8LV=HW*HXP<[N1D?A2^JX;K3?X_P"8_K6)Z5%^!U/_  N.X_Z L7_@0?\
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MN<_CSTJ/JV&M?V;_ !+^LXF_\1?@=+_PN.X_Z L7_@0?_B:/^%QW'_0%B_\
M @__ !-<EMT7RSYGV82[/W^PMM!VMCRO?=MS_AFN>K2."PTOL?G_ )F4\=B8
MV]_\O\CT[_A<=Q_T!8O_  (/_P 31_PN.X_Z L7_ ($'_P")KS&BK_L_#?R_
MBS/^T<3_ #?@CT[_ (7'<?\ 0%B_\"#_ /$T?\+CN/\ H"Q?^!!_^)KS&BC^
MS\-_+^+#^T<3_-^"/2Y?C!<2Q,AT6(;AC_CX/_Q-/_X7'<?] 6+_ ,"#_P#$
MUYC11_9^&_E_%A_:.)_F_!'IW_"X[C_H"Q?^!!_^)H_X7'<?] 6+_P "#_\
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M @Y![T %%%0RW4$-Q!!)*JRSDB)3U8@9./PH FHIC31)*D32*)'!*(3RP'7
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M^/&W_P"N:_RKPFYU.UL?$&KI<QO)G5O-PK%<!6DR>#R1D<'K7NUG_P >-O\
M]<U_E6&/!OAV\+W-QI-O)-*[.[D'+$L<GK79A,1"BY<Z>O8XL9AYUN7D:5NY
MXW-K4;7$"0SF,-$L,UVJMN4;RQ*IG [$=ZLR:S8/9-;/*)(8VPD;1%F=-A ^
M=AD-N.2>/;IBO7?^$$\+_P#0%MOR/^-'_"">%_\ H"VWY'_&NWZ_0[/\#C6
MQ%_B7XGB.DZK#I,D]R5,]P[*@"G8/+SE^W? &,=":OPZAH,,D>V/(!.YG@'*
MJ0%'0]5)S[C\:]?_ .$$\+_] 6V_(_XT?\()X7_Z MM^1_QIRS&@W>S_  )C
MEU>*M=?B>-F_TC:0HC4JSB$B#(7._:S C)(RO )^G%69KW1/*MV(A\IQDQI;
MC>'$G+D]@0#\OH>E>M_\()X7_P"@+;?D?\:3_A!/"_\ T!;;\C_C2>84>S_
MK^SZW>/XGD$FHZ*9)"8T,16,L$APSL% 89(Q@D$Y^4\Y]J<VKZ2LF5MX#E_F
M;[.#E-LF!R!C!*=!VZG%>O?\()X7_P"@+;?D?\:/^$$\+_\ 0%MOR/\ C1]?
MH=G^ O[/K]X_B>*1:AIHN[B66W5U,,<D8\H8,ZH 01V4DL3]!5;5Y[2Y:.2V
M90P4AT2/:HY.,< ]/7/U->Z?\()X7_Z MM^1_P :9+X&\,+"[#1K;(4D<'_&
MK6944[V?X$O+*S5KK\3QV'7H8+JTV*1&+>**>3YBWRCD 9QU YJ2>_T<Q*+8
MQQS",HLK6VX+\RD9&,$[=PZ<>O>O7H_ OAAHU)T6VR0#T/\ C3_^$$\+_P#0
M%MOR/^-3_:%"][/\"O[/KVLVOQ/(H]7TJ.)T@\NW+V_EJY@WE#A<AAC!!()_
MBJCJ%[I<UG,MK"(]Q_=Q^5AE;>27W>A7 V_X9KVO_A!/"_\ T!;;\C_C1_P@
MGA?_ * MM^1_QH684$[V?X \NKM6NOQ/GFBOH;_A!/"__0%MOR/^-'_"">%_
M^@+;?D?\:U_M:E_*_P ##^QZO\R/GFBOH;_A!/"__0%MOR/^-'_"">%_^@+;
M?D?\:/[6I?RO\ _L>K_,CYYHKZ&_X03PO_T!;;\C_C1_P@GA?_H"VWY'_&C^
MUJ7\K_ /['J_S(\Z^'?AC4))CKK2RVMFBD(%X-QZC_<_R*]FJO<1I%8-'&BH
MBIM55&  .PJQ7D8G$2KU.=GLX;#QP]/D04445SG0%%%% !1110 4444 %17'
M^K7_ *Z)_P"A"I:BN/\ 5K_UT3_T(4 2T444 <OJ%GK-EJ^H7&FZ;::A'J4<
M:,;B;RQ"RJ5PXP=R8.<#G[W'-8EWX8UZ34KYX8U6:1)MM^EXRAXVA*I (NB
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M21#AI6'8?[/J?PKEQF$PZI.5N6QUX+%XB551OS7/;****^=/HPHHHH AN_\
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MH1K-#&9'R"$ "[C\^-I(4AB,YQSBF1^+="DTR?43J"16T#A)6G1HF5B,@%6
M;)!&..>U8O\ 86N073"WM; V\-Q+?V^Z=@6E:)D6%AMX4,Q^8'H!Q1;Z!JM[
MX:U:WU2SMAJUV"?M#7'FAWV[01\@\L < #/'<DDE =I10. ** "BBB@ K,\1
M_P#(L:M_UY3?^@&M.LSQ'_R+&K?]>4W_ * : !/^1HF_Z\H__0WK3K,3_D:)
MO^O*/_T-ZTZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *1_N-]*6D?[C?2@"&S_X\;?\ ZYK_ "K)3POH-T&GGTBSDED=
MF=VA!+$L<DUK6?\ QXV__7-?Y5Y%>^-/%D>KZE;6,\ M[:[>%=\<8Q\S!1EL
M9/!KIPU&I5;]F[6\['+B:U.DE[17OY7/2O\ A#_#G_0$L?\ ORM'_"'^'/\
MH"6/_?E:\GN/B)XQM&"W$T<3$9 :V4<5(_CSQM'&9'9541K(<VJ_=8D*<>AP
M:[?J.*_G7WLX_KV%VY']R/5/^$/\.?\ 0$L?^_*T?\(?X<_Z EC_ -^5KRQ/
M'?C9[4W*RQ&$*7W>0G('4@=3COBJQ^)?BQ>MU$/K;+_A0L#BGM/\6#Q^%6\/
MP1ZY_P (?X<_Z EC_P!^5H_X0_PY_P! 2Q_[\K7E$WQ"\96\,$TLT:1SIOB8
MVZX9<XS^=1?\+*\6Y ^TQY;@?Z,O/TXH6!Q3^W^+$\?A%O#\$>N?\(?X<_Z
MEC_WY6C_ (0_PY_T!+'_ +\K7D?_  LOQ9_S\Q]<?\>R]?3I0?B7XL&[-U$-
MIP?]&7@^_%/ZAB_Y_P 6']H83^3\$>N?\(?X<_Z EC_WY6F2^$?#JPN1HECD
M*3_J17DQ^)7BT$@W,8(&3FV7C]*1_B3XLV$/<QA2,'-LHZ_A2^H8K^?\6']H
M83^3\$>M1^$/#AB0G1+') _Y8BG_ /"'^'/^@)8_]^5KR$?$WQ2  +R' _Z=
MUJ]I'Q4UF#48VU1H[FS/$B)$%8#U!'<>E#P&+2OS?BPCF&#;MR_@CU#_ (0_
MPY_T!+'_ +\K1_PA_AS_ * EC_WY6M*QOK;4K**\LYEE@E7<CJ>#5BO.=6JG
M9R?WGI*E2:NHK[C$_P"$/\.?] 2Q_P"_*UL0PQV\*0PQK'$@"JBC 4#L!3Z*
MB4Y2^)W+C",?A5@HHHJ2@HHHH AN_P#CTE_W:FJ&[_X])?\ =J:@ HHHH **
M** "BBB@ HHHH *BN/\ 5K_UT3_T(5+45Q_JU_ZZ)_Z$* ):*** "BL?5/$^
MEZ1<_9[J2<R*@DE\FW>40H<_/(5!"+P>3Z&M59HFQMD0Y7=PW;U^E #Z*8)8
MSTD7OW].M0R:A;17-M;M*/,N&98P!D$J"2,]N!0!9HJLU_:+<P6YN(_.N S1
M+NY<+C=CZ9%/DNH(K9KAY5\I03N!R./3UH FHK&F\4:3;G3Q).__ !,$1X"L
M+D;6*A68@?("649;') IVK>([+1[J*VN([R662-I0MK:23E4! +'8#@9(ZT
M:]%4VU6R72CJ?GJUF(?/\Q><IMW9 Z].:;<:O9VQ@#R,S3[O+6-"Y;:,GI[4
M 7J*JW6HVMFJ--* 'E6$8YP[' !QTJQYB94;URXRHS][Z4 .HJJ-1M3J0T\2
MYN?*,VP#.%! //3J1Q5J@ K,\1_\BQJW_7E-_P"@&M.LSQ'_ ,BQJW_7E-_Z
M : !/^1HF_Z\H_\ T-ZTZS$_Y&B;_KRC_P#0WK3H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&^XWTI:0C((]: (;/\
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MY3DY2W9[,(1A%1CL@HHHJ2PHHHH **** (;O_CTE_P!VIJAN_P#CTE_W:FH
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MXUH_ FH>3)M73++>3BWM-_E#Y N_D?>;&3QV')/->A44 >=VOP]NTU*^,_V
MZ?<W<<[P$F0RA92YW$J#T)&TE^O4#BHU^'6HQZUIMU'>0+;VNP*JO@P*DK.%
MCS&3@JP! 9.G<5Z110!QOA?PE=Z)KC7DT6FH@M&MS+;;O-N6+AO,ER,;CSGD
M\]\=.RHHH *S/$?_ "+&K?\ 7E-_Z :TZS/$?_(L:M_UY3?^@&@ 3_D:)O\
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M/5%7[?:\#'^M7_&E_M33_P#G^MO^_P O^-']I8CO^ O[,PW;\3RG_A3^J_\
M03L_^^6H_P"%/ZK_ -!.S_[Y:O5O[4T__G^MO^_R_P"-']J:?_S_ %M_W^7_
M !H_M+$=_P  _LS#=OQ/*?\ A3^J_P#03L_^^6KT#PGX3L_"VG^7%B6[D \^
MX(Y8^@]%'I6M_:FG_P#/];?]_E_QH_M33_\ G^MO^_R_XUE6QM:M'EF]#6C@
MJ-&7-!:ENBJG]J:?_P _UM_W^7_&C^U-/_Y_K;_O\O\ C7*=9;HJI_:FG_\
M/];?]_E_QH_M33_^?ZV_[_+_ (T 2W?_ !Z2_P"[4U49M0T^6%D^WVHW#&?-
M7_&G_P!J:?\ \_UM_P!_E_QH MT54_M33_\ G^MO^_R_XT?VII__ #_6W_?Y
M?\: +=%5/[4T_P#Y_K;_ +_+_C1_:FG_ //];?\ ?Y?\: +=%5/[4T__ )_K
M;_O\O^-']J:?_P _UM_W^7_&@"W153^U-/\ ^?ZV_P"_R_XT?VII_P#S_6W_
M '^7_&@"W45Q_JU_ZZ)_Z$*A_M33_P#G^MO^_P O^--DU'3Y% ^WVHPP/^M7
ML<^M %VBJG]J:?\ \_UM_P!_E_QH_M33_P#G^MO^_P O^- $TEK;S2>9+#&[
M[&CW,H)VMC*_0X&1[5BS>#/#\L=K -+M$M+=WD^RK @B=F7!++CDUJ?VII__
M #_6W_?Y?\:/[4T__G^MO^_R_P"- "'2=.,F\V-OOR#GRQGC;C\MB?\ ?(]*
MCFT+2;F:&:?3+226%VDC=X5)1B<D@XX)//UJ7^U-/_Y_K;_O\O\ C1_:FG_\
M_P!;?]_E_P : (+GP]HUYJ2:E<Z59S7J8VSR0JSC'3DCM37\-Z')<7-P^D6+
M372LL\A@7=(#U#''.<#-6?[4T_\ Y_K;_O\ +_C1_:FG_P#/];?]_E_QH BL
M]#TG3[R2\L]-M+>YER))HH55FS@G) R>@JQ-8VEPTC36T4AD01N70'<H.0#Z
MC))IG]J:?_S_ %M_W^7_ !H_M33_ /G^MO\ O\O^- $CV=M(T[/;QLTZ".4E
M1EU&<*?4?,?S-9L/A+P[;VD]I#H>GI;W&WS8EMU"OM^[D8YQVJ]_:FG_ //]
M;?\ ?Y?\:/[4T_\ Y_K;_O\ +_C0!4E\+Z!/=Q7<FC6+7$(18Y# NY GW0#C
M@#MZ4_3?#NBZ-.\VF:7:6<KKM9X(50D9S@X]ZL?VII__ #_6W_?Y?\:/[4T_
M_G^MO^_R_P"- %NBJG]J:?\ \_UM_P!_E_QH_M33_P#G^MO^_P O^- %NLSQ
M'_R+&K?]>4W_ * :L?VII_\ S_6W_?Y?\:S?$.I6#>&M55;VV)-G, !*O/R'
MWH M:A>6:7:V\MC+=S!-^(X/,VJ20.3TR0?RJK]IL?\ H 7/_@&M6D_Y&B;_
M *\H_P#T-ZP;WQ/JL>JZC;6J:4L-FP7-U.8V;Y0W%3*2CN95JT:23EU-3[38
M_P#0 N?_  #6C[38_P#0 N?_  #6F0>+;#^QK&^O-\#W49<0JC.P ^\< ?=]
MZM77B32K1+=GNMWVB/S(O+1GRG]XX' ]S1S+N)8FDU?F71_?L0?:;'_H 7/_
M (!K1]IL?^@!<_\ @&M0:1XCFU"'1WE^SQ-?"8L@#$G9G&T]![Y_"KUKXETF
M\O1:076Z1B0A*,$D(ZA6(PV/8T*28H8FE-)I[_JD_P!2#[38_P#0 N?_  #6
MC[38_P#0 N?_  #6K%GXBTV_NQ;V\SLQW;6,3!'QUPQ&#^=%IXCTN^G>&WN=
MSJK,,HP#A>I4D8;'M3YEW*5>D[6DM?,K_:;'_H 7/_@&M'VFQ_Z %S_X!K3[
M3Q7HU[*D<-V<R1M(I>-E4@#+8)&,@=13[?Q'87T<_P!DD??'$90987564?Q
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M  #6C[38_P#0 N?_  #6MBY9DMI&4X('!J6@#"^TV/\ T +G_P  UH^TV/\
MT +G_P  UK=HH POM-C_ - "Y_\  -:/M-C_ - "Y_\  -:W:* ,+[38_P#0
M N?_  #6C[38_P#0 N?_  #6MVB@#"^TV/\ T +G_P  UH^TV/\ T +G_P
MUK=HH POM-C_ - "Y_\  -:/M-C_ - "Y_\  -:W:CF8J@*G!WJ/S84 8WVF
MQ_Z %S_X!K1]IL?^@!<_^ :UNT4 87VFQ_Z %S_X!K1]IL?^@!<_^ :UNT4
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M]P^OX7_GXOO.NB_U*?[HI]<>GQ'T!8U4M=< #_4__7IW_"R?#_\ >NO^_/\
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MHHH **** "BBB@ K,\1_\BQJW_7E-_Z :TZS/$?_ "+&K?\ 7E-_Z : !/\
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MO&G9>J_S/.:[GX<:CJJ:D;&",S6#?-,&.!#_ +0/J?3O5[_A5)_Z# _\!_\
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MWFWY>=O0XY /3J*\J.J^+C:0:DK7;W?V.XCAC%N2DF)8_G8>4N'"%R/E&=G
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M_P#0#0 )_P C1-_UY1_^AO6G68G_ "-$W_7E'_Z&]:= !1110 4444 %%%%
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M %T3_P!"% $M%%% !1110!%<6\-W \%Q$DL+C#(XR"/<5+110 4444 %%%%
M!1110 4444 %%%% !69XC_Y%C5O^O*;_ - -:=9GB/\ Y%C5O^O*;_T T "?
M\C1-_P!>4?\ Z&]:=9B?\C1-_P!>4?\ Z&]:= !1110 5QNF>(XX?!SF.^AG
MU."*63RI)-[_ "LQY&<]*[%CM4GT&:SDNK"*U@NF@6,SQ[P%CR0N,G.!T&>3
M4R3>QC5ISE)2B[:-??;_ ",67Q-<RWDD-E+:NGVJU@23&X8D4ENAYZ5$WB>_
M%O&&DLX9%%UOFD0[)&B;:%49X)Z]3TK?-_IT,+2A (D/WUA.TXSR#CG&#5"Z
M;3=4F>WN/.@$);:8I"HDR<'@>OY\U+C+HS"5"O:ZGK_P;_EH1ZKJ%Q)X8TZZ
M>9[>.Y:$W<T/!CC898@]AG SVS53^UK;3M/*Z1JC78DN?+5[E_,2,[-Q =B!
MCCN3Z5OO>6UC<VNF+$!$4"=1MC'101[X(_"HDU;3F>2W,>V*.,2J6B(5@2>5
M&/I]<TW%MW3*>'J-I\VMK?\ #:]3GCXKU.2Q%U$+10FG+>.I0G<V\J0#G@<5
MI'Q!<_VE<)OM56*5HELV#>=(!'O#*1ZGVQCOFM(ZGIBJPQT.QE$))QC=R,=,
M9-.;4]/0^><YY19!$?F SG!QR!@T<K[BCAZRM>=]CFK;Q5JEQ8M(!:"1I+<*
MP&X)YC8*D!CT]R#Z@5VD8=8E$C!W &Y@, GUQVJA#?6<UVEM!$&60-)Y@3"$
MJ1D@]SS^E76FC$;N&#;020IR:<4UN:T*4X?'*_\ 3)**HV^IQR67VB5?+.0/
M+&2P)Q@8P#GFHX=<M)(U9R\1;>0&4_PDY_' )Q5&YI455BU&VGN3!$[.Z]2%
M.!U[_@:JSZR(&N@8.(%9B#( QVCKM/8^HS0!J45C-KZ#CRX<[F4LTX"<*#P2
M/]KTJW;7\MQ<B/[-L0Q++N9_F ;. 1CKQZT 7J*** "BBB@ HHHH *\/U**X
MFUO4G-XT,7VV2-<LQRVXG&!V ZFO<*\;O;'6TUC4&@TBYG@:\DFC;R7QG<>0
M5QU'YUC66B/%SF+E&&CW>QG1Z9?2",+?-O=4;!9\ ,P4<]#R>E126EU&TF^]
MF2.-=SNXD7'.!@'DY-:0C\4[PSZ1=N!L(1K=]H96W!@.QY/X$U!_9>MAI,>'
M[D1RC$B&&0AN<@]<@@^E<]O(\*5-6]V+_$J):74C(JZCDRN4@Q(V)2/0]NH'
M/>J\*W<]M<3K=L!  65I3N.2!P/QK6%EXA#*W]@SAHV+0XM7'E$@#@#Z \YY
MYJN-(\0XE#:1>-YJ"-LVS#@$'L/:BS(E3?2+_$J6L=U<^>3>2(L"AF.YFSE@
MO&.O)J26QU6.Z>!7FD92>5D.",XSU]:L6VE>(K/SC;Z5?1&4 ;EA<%<,&&#]
M0*NB/Q("Q&@3!FR"1;/T)R1]"2?SHL.-*\;24K^C,=;35G^YY[\X&V7.>G3!
MY'(YZ4BVNJOG89GP<?+-G/3I@\]1TZ5J)9>((HPD>@W"A057$$F54D$J#GU&
M<]>O-31Q>(A<1ROH5R=C?*1;ON4$ -@]R0.IS341^Q_Q?=_P#':SU99&0^?N
M4$D"7/3.<<\G@\#T-(+356;9F;. 2/.Z9Q@'G@G(X//-;03Q%%(_DZ!<)%EM
MJ?9Y/E!+9Y[YW'KQT]*C2+Q)#$$&C78C50#^ZDR<8(^;.0!CIG'6DD-T%_>^
M[_@&6UCJZ0^:PG"!=W^MYQC/3.>G/TID5OJDR;XS.4V"0MYF %R1G)/L?RK4
M^S>)6RW]CW)W#K]G?G]WL_D?SIL%CXC@MH;<:/>&.)V<?N'!R1C&1@X'/YFB
MVI/LM=I&3 +R>^CM/M,BR/((\F0D DX[5;?3[_[/Y\5X\B$X +,AZG/#8P..
MM3#2M?745OET2Z659/,P+=@N[.>E2VMCXDM6E;^R+V4R !C)"Y(QGH>HZFA+
MN*%-ZJ49?B9WV35MQ4^>&WE-IDP<CKQGMZ]*>]CJJ6HG\R4@DC:LN3@ '(YY
M&&'(S6H\/B1[I;DZ'<><KLRL+>3Y=W4?0\^_)I#!XEVKC1+H2)GRY##(S)D
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MQ L:@S1Y  /SBG?:8/\ GO'_ -]BO(Z* /7/M,'_ #WC_P"^Q1]I@_Y[Q_\
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(KS:CM0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img187335194_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_1.jpg
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M ?_$ !\  0 !! ,! 0$            )!@<("@0%"P$" __$ $(0  $$ P$
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M%\3!M[[<";:2?WJK&+ ?(5V5@?(S:].ZXU7%*KF"O4*1Y\P*KP/W;:UXD_\
MXE;D_P!83<9\%_*AY%^0Z"VKBMU<A>E1P&CK/Q.^I#@>F0++>DI*.%C$&%@6
MR 8<6C2[#4I"8CQ$OB-3.XB0)2 F/M4T//TEOUFOE23LF35N]+?(%M@:W/\
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MUUHHV"JHV _'U)/<G<DDDF0'??;DW6Y%[M;=<[666-YLS'<GY#Y    ;
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M@Y(W^Z>T_J))7H_:/4-;]&/>3NV<#Y(/1JQQ6*Z#V'GSU#D>KW&&-N=K=E7
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M"(>/HSJH=]^Y=F))),:;5D48&+5F6M=E+4IR+';FQN?=[!R]51F*)ML BJ%
M  F3.64OIBYZ9\<<"]:0"(CKU.:,EP1G!Z_>H-QN(O5:TYM2_I%3R&'MO!Z=
M6MY4-,#2L"\^K]0_%N/I;=1M?2_6O4/2&0;M&S62FQ@V3I]X-V!E;;#[;'+#
MBY "^/0U.0J_"MP4D'7M?Z7T;J2D5:GBAK44K3ETD59E&^YVKN .Z;DGPK5L
MI+?$:R=B->+OWP<>@*02;*<'LU>[-6]*<=%A)(D.D7X=KZ[6D=;,L4FIROX6
M_P#9J-9L,6^8XG[FH0?\FFD]'].^WCIW/5*>H,7(T/)[!KZU?/T]CY%@U*',
MIY'OP;&M5!YWMMN82UGV1ZUB,]FCY%&JT=RM-C+B9@'<[$6M[M9L-AS%]9<^
M52^4B\O?E7TMS(A]B]\&ZQ6TCJ4E9QM%L3D.Y]G\*4+.B $0QC>O_P!T0]]K
M_C]_TR5M/ZLZ8U15;3^H-'RBVQ%=>H8WCC?R#X[6+?6?W7K4_21]F=.Z]@$C
M,T?4J /VWP[_  CMY\;E0U,/JKD2S6J[8-D?I-04QLKZ_;^FU&&[(^[Z_3Z?
MA_!^3Z_7^/I]OU^O\9FO>,?CS\>GAY\O%3C_ ,[EM_.8KP;M^/A6<O+CP;?^
M&V\O;0O)GISIY#+%$X'UBP(?4E*)!FCSXD(C:M_1.R;!)!!P8B5?\%ER#*-Z
MUO?W?36]ZP6H=7]+:4K-J'4.D8Q7N:VS\=[SMY\<:MWR'_!*V/\ &9;#Z;U_
M4& P]&U*\']M<.]:AOY<KG1:E_%G DI7G_X,^Y7$D&6] VZ!Y#7=J;=+KD 2
M'=;Z0WK>E."[> >53H;;J-_:W()FK$L=S[MNPSNDZ2J*.HO;SH.$ME/3N'D:
MSD[$)DY"O@Z>I\@^UBC-OV/<UFC&##RO&^XD/1?9%J^4RV:UDTZ91N"U%+)E
MYC#U&Z$XM6X\G\6\@^=7SV'?-_DCA'E*M+KW'*6+$%&LLM3]NDEZE;K:%L_1
M25SMB?;00ZQIW6WV8D!L""#>6XX!%";<<^[G'J?K'J#J[*&3K6<UR5L3CX=0
M\'!Q >VV/C*2H;;X3=8;<AU %ES["3;H736C].8YHTO%6MG %V38?$R\@CUN
MO(!(W[BM E*G<I6NYF2F:O,]&(GD6^S.IE]O];^F.N&$J*5T/NO4K0&M2]K2
MS$2=SF'8,%E6][W^EC87]!'!IWO>T"BLH^N_M^NY\TZ@8V!AXX '@XM%9V]6
M6M0Y_%FW8_4F<ZZID'*U'.R2=_&R[W'T4VMP'X*G$#Z"8TY>2QC$29KX7_BR
M<^2ON-EU>I>8J_GGC D),=4F(%30]@LDE8'SD5?GM:.*8)'CS9U$1,2$Q-;%
M,W"PD6ZAMAN2EXAY.N]1ZY^AL9/"57R\DLM"ON414V\2UP""0O)0J[CDS#S5
M6$V;IC0/TYE6>,S5X>,%:]DV#NSD^'2A((!<*S,VQXJOER93*?\ 67L7DW+O
M3]]YOY1\G>1H+S9QV\S'/:]7>A>?N>]DLO6(VE2K\%)VF\]9Z9$V7KS2KB8
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MLX!4?$-B2.(Y2GJA:<W6K<K$S,*^G+\!4=<JD"MJL:NIO&Y,OAC>LD,?A((
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M6MR4-4!;8K,B^+200H))Y"PHNP![,P)]-^T\EU+#>BS)6UC34RH[>!>"&8@
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M1Y\/N:L!IU]."9E :6+3=9RJ^H+,YKJ<?314G*K$LOLLLMQT?X;+U1>-?CV
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MCS'2YWGCCZ]CZERYFON)81:MR<7M72^N_HO(.-DMM@Y+#F3OMCW=E%^W?X"
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MI76I=V/R55!)_(3=2^(O^G79YG+5?TE[]B(>=NL:Z'.T'S;^8*=KE7D&5()
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M>8N'F6.^BY=@%R'=O<K6.PRZ1YA1_P"\UJ/M*_C56L10VY,&8'(AB2$>4.<
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MD<2&#;@BQGK2N\(X=ZIN7+ZAQ\HR@\LL9U<E8^9Z)9WIFZ[V!&+6:]-#Z93
MK")V8N+:  ?;TDA.I34GII"$Y[H_)U_7ND\+5<W6434-6QJ\FJRC3<5:,'[2
MT!%H;D<@.G 6FRQ22I\(U;DS$=24:/I'465I^-IC-A:=>]%B6YV0;<OX*]W:
MT;>"4;D:PB$=_M/$  DAWR-^)_)OD7@E.Z!SWG5LF+1T2RBU:.=LG1IMZ.K;
M9U5F9U4ML$-@=4J:*X".T**\0P$I2UNE)?;1^E=CGV:=<]7]8]0YNG:EJ6'3
MB:9C-E6KBZ;0MN4:\NG'%/B.S>#6X=B[JK6; *A4GFN[]==*=-],Z/BYF%@Y
M%N1FY"XZ&_.N*4!\>VXV<%"^(ZE%"J2$W)+!@.)@)SH.0S)6_)/@&JV_@%Y]
ME>FYJQ5K@E)B)V6K]6J:Q ;?TQVONN!.I&EI$<H2&AY"PMHJL:I SA\Q++*2
MV5""B,2!T2=8>T/+P^HL#HKI:C&RNH<Z['IR<O,#V86EC)"V#G34R/?=7C$Y
M=OQBNBD(2E[NU=<C=-=&8V5HN9U3K]M]&CXE=UM&/C%4R=0-!*MQL=66JI[Q
M[LFRE[+>>S4JH=[8>?3_ "+WGM%<XYT+@3/'ZQTN='I].Z!S;IG2)"XU*PS;
M^@JLNSIZ)8;A3K*(=*.@Q4D0#5*HV*HQ4FAA ["A,RO45?6/3^B9.M:=U"VM
M96EX[9N;IVJ:7IE>%F8U"^)EC%_1N/A9N*]=2V75+9F9A?AX18LP>8_17Z:U
MG5J-+S=&&F8^?<N+BYF!GYSY6-=<W#&.1[]=E8MZO84KL9,?'"\O$ "J5EN/
M;/CB[>+NL_V#8SV[)6)X%R=Y_=QA%!#V6"21L9]LH/;I"8V>AR/M&FHM)1*6
M/S!&L/.@R0;KF2Z&ZTP>M]'_ $CC5G%RL>P8^HX#.+&Q<CCR4H^R^+CW+N]%
MO!>6SHRBRJQ18]6=+Y?2NI>Y7N+\>Y#=A9:KP7(IY<2&3=O#NJ;9;:^3;;JX
M)1U)PZS=)J\S[^,7KQ''/:_%9/\ 5*'A[O/ZY58FOOVVR7'="^R"CD$J^NM:
M'!M+M=F5;5O[$KBVU+^B=;WJ/?:GHRZUT-KE7 -=@X_Z6QCMNR6Z;OD6%!_6
MLQ%R:.W<BX@=S-RZ U-M+ZKTJSEM5EW?HZ\>09,[:FOD?14R#1:?0>'W[3>%
MSA&=;1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B=?+'HBHJ3E'$_>W&QYIZT_Z?<@,9PA2?K_ ,/K
MIO>O_KGI36;KJJ1V-ME=8/U=@H_[Y18XKKLL/E6C.?P52W^:><W(GE2L@=*'
M.J?-DC"3S'E?[SQ1CRR"'5?7Z[^YQYQ:]_SO^=Y^E-=:55I56 J5HM:*/)41
M0J@?0  3AQW:QWL<[O8S.Q/JS$LQ_,DF</*Y3)N?@:__ #8=-_\ Z\63_P#Z
M3RS(+_P@/]Z&E_\ ZDQ?_P"LU>2Q['O]\N?_ /D>1_\ S]-EN/=4YXW&]>=]
M8OG,_2$O<&K\>FP254[+S:!KIDA^E#_(]$0\MQ&PR,>'M'V:0.9-23R5:5O9
M*M*UI.3Z!Q^M&Z-Z>; U3IFG#.G5G'JR]$U/(R4KYOLMU].O8U5C^>[)14O[
MOJ;+J^[I=>IM9&9I^N6Y0S'\:S&U7!IH=^*[FJJS2;W1=MOA:US^])(/G,VS
MOROY_P!CI<0/OJ49MA#RTN/(9WSFQ_B2ZXA#2''$H^W2UH:;2I6MJ2A&MZ3J
M-/8-R_W6=1\B"WZ+MY%00"WZ2Q]R 22 3Y DD#U,WKVN[?[GM&VW _2*; G<
M[>XW[;D  G;S.P_ 35MSJR<]3:V]/*CT?![4_P"S_LU#JXGYA2=L3Z?PM5JY
ME^__ *C\?^A*K%^I3*?3_4M16G/XVO.2.E?$_P#3OF>^[^-^G.JO#Y_+W35?
M=^._[(Q>)IW\D";=]IT9U!P'LDQO==O"_173_/A\_><#QM]OVO'Y>)^]R!]9
MK"\L4<CIW.5Q?WZDT7RH*CMM_7\GZY-@C]B?C^W_ #??^HTW]OV_S]WT^G\Y
MU1JHK.EZD+=C4<#,%H/D:_=[.>^_;;COOO.?].YC4,$U[\QF8O#;SY^.G';Z
M[[;39 ^?G]A_PQ\[_J/T_P#<_P#?ES_:?N^W]5^P_P!OQ?\ </XO_;_3_N']
ML?J/I_E_)^F^[^?MSF;_  >O>/TIU)QY>Z_H_!\;;?A[Q[Q=[MR].7A^]\?7
M;GMZR=/;-X/Z/T3EQ\?WS+\/^MX/@U^/MZ\>?N_+Z\?I-8/.J)S_ "HZ?/$5
M6VU:SB+4T57+'"3PSB=_:ILB'DQ9!E:5:_G2D.#I5K>O]-Z^N6V9CKEXF5BN
M-TR<:_'<>>ZW5-6P_,,9[XMS8^3CY"G9J+ZKE/R:JQ7!_BL]%W/S8G<,8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(G72\>F6B92+6K[$24<;'J7_K]J3!G1U*_C^?\NG-[_C_ -V>
MM-AINJN W-5M=@'S*.&V_E*+4%E=E9["Q'0GZ,I7_//.;D 2HL\V,.:4P;'%
MD@F,*_A3)0CRQR&E:_\ B;=;6C?_ (ZS]**W6VM+4/)+$5T8>3*X#*1^((,X
M<=&K=D<;,C,C ^C*2"/R((G$RN4R5;XN_2GG[R)T&Y=:ZU;;;N6L-%DN? 4Z
ML49V82R*=9*Q85SIL^[- L)5K=;;$8C6 7E*T4Z^\4SME#3T3>U7ICJ+K'3<
M+1]'Q,,4XVH5:C9FY>>*=WKQLO&&/7CK18Q_QHNUK6+MP"JC<BRR)[/M>T7I
MK.RM3U+)R?$NP[,),7'Q#;LKWXUYN:XVH!_BX45A"3R)+#8 V1]7VGS[W3U+
M;>IU;JUECJ'U*PGV.>)E^8G:G:4YH",;T$U$#V%3%E_7$H,2$\S(Q:64,HT<
MEG[].*SO2.)U%H/2F'I.7I.+9J&DXU>-CK3JB''SAXEIYM<V,&Q>"%"ZFJ[<
MD^'RVVF)ZCR=%U?J')U''U'(3#U"][[FMT]_&Q#PK' 5+>1?S8,%865[ #F%
MWD@WR)^XO)?KW@]2YY1KGT*OV;GEC'M,1JP\W6N-L>P:M,0.H8@P.P;<AWRW
M#QWFI'8IP[.VG&GA](=T^Q'7LWZ#ZOZ-U_-U+/P]-R<74L9L6[W;4]K<;Q,N
MG(\94?&VN5!6RFOFC'<$,2.+;KUQU=TWU/H^-A8F5G4Y&%>,BOQL'[._ACVT
M^$S+>346+J0_%E&Q!78[C&_C_0N'77Q[ZB@.B^?^04^L\XHD&#QGJ4?!;1V&
M9[=.K+9KD1+7HPAV6MLK-/ $V>> AFHJ&@ZY'3#"H4:N*"'"V;6M.U[!ZSZ4
MR-,ZAUK-R=3U"]];TFS(WT6C0L<(<FZK 113AU4"U<7'LO-U]^5;2PO;*\1K
M,%IF;I&7TQU#3G:-I>+1@X=*Z5J%=/\ ZSMU:TL**K,QV-N39:4-]R5"NJJA
M+1X2T%%7^7E+WW5*QYYO7C#TW#62P\(ND1-1=:MU1;$/M_,GYPA4E]S,/)$A
MB3D+&653=KC4(+:/B9-!:$BS898X$?\ >KO9[EY74FG];]+7XN-U!@W46Y6'
MF%Z\/55H45;-=4ECX]]N*#AVDH:[JBAY4.C66?.G.LL;'T3,Z5U^J^_1\NNV
MNC)Q@KY.GFUC9N*G9%NJKR-LE &#UV!OAN5@B6IX%%^2>']DK/7^B]_&ZU5N
M;3XEQJW/^:\SZ2%<KA.P)*9"LBV170ZY3J;6@F)5@&0E6 [7:FRFQ78M#JF2
M5&HRW4-O5^O:+E:-IO3K:/EZICOA9>HZIJFF/@X6/D+X>4^+^C<G-SLJQJ6L
MKI9\/#*%UN(Y+X9QVC5]-:1JF/J>=K2ZECX-RY6/A8&!GIE9-U+<\=;_ 'ZC
M%Q:*UL"66!,G)Y!34.S<Q07MKV1=?:/6O[^L0"*U5X %R"Y_21RU&L5J"61L
ME]TLS;0Z9&?F"/L)FI-(HR7OPA L,MA1P;:,AT-T5@]$:/\ H_&L.5E9%@R-
M1SF05ME9 7BH2ODWA8]*[I15S;CN[LQLL<FSZLZHR^JM2]]O08^/2AIPL16+
MK13RY,6?90]UK?%;8%7?9$ "(HF'.;I-7E0U&"(M%KK%9$0IPJQ6&%@AFTZ^
MJG")>2&CV4)UK^=J4X0E.M:_UWOZ9;Y>0N)B964Y 3&Q[LAR?(+36UC$_0!2
M3/?&I;(R<?'4;M??52H^;6V*@'YEIZ+^?FO.X8Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FB?\
MA?(B.*^Q^[5)0JAHN3NLA>JW]$;2.NNW]7]W1[0:OI]'!XQ4L_!J5KZ_:3%D
M,JWM;2MYWS[.=977.B] S.8:ZK!KP,KONPR=._4["_R:WP5OV]5M5AV(G(/6
MNF-I/5&L8W'C79EOEX_;X? S?UFL+\Q7XAI)_K5L/,3"_-WFJQB(Q$8B23N>
MN?(XG(H7GT/XB)<ME/J-@C:5?K-W^R3C$7?9V-<:=Z9,406HP].L$ZJ73'29
MC),:SHL*%A:^DD>(AHE@&,AT?UB^LWZC=UVHP\S-QK<[3L7IW%H-NGX]H(TN
MG/?-OS<;'\$VU(R6MPLOOR2K77W-9O9ZEZ:73:L*KI)CD8V-=7BYE^MY%RUY
MEU9!S[<)<:K%NN-H2QPR#DE55/):JJ@D;&2;-$C$1B(Q$SV^,GD1'8_:_$HK
M]*HB(I=B1U*PN[1M;(L;SS[;  HI/TWI0Y]F'@(525:VA;DHVAS7XU*R/O:C
MK*Z+T-KMW,+=FXQTG&&^S/;J7ZM9P/\ 6KQ6R+_F!22.X$W+H#3&U3JO2:^.
M]>)?^D;SMN%KPOMDY?NOD"FK\;!-XK.$)UM&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$@6^<#R
MN7>N>5?TY4(U94]RL?\ M?H;0K7Y"2N>29RR(F:6E&MN+;J-A-)23I"5;1'6
M8R0(4V)$.+3T#[">K$P-1R^ELVT)CZLWO>FESLJZE4@2Z@;]@<S&12I)[VXB
M5J"]PD.>UKIULS"Q]?QJ^5VG+[OG!1NS85C\JK>W<C&O9@VP[)D,[$+49JT9
MU?.>HQ$8B,1&(C$1B(Q$8B;7WPF^5B^7\@GO0UOC5"6OM;0H=/9*9V@N.Y?%
M$*(&-3I>D.LZNLTG]U_&I*FB8:&K,D.YM!BM9R-[<^K4U76<?IO#MYXFA,[Y
MK*=TMU6U0K5]MPWN-'V.XV*7WY53#>N='>RCIU]/TR[6\JLIDZL%7%5ALR:?
M6>2OZ$>]V_:;'<-55CV*=GDX601):C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B=;,0\588B4@)
MV/#EX2;CC8B8BI!ALH"3BY(9T.0CS1GDJ:($,$>=')8=2IMUEQ;:T[2K>L]:
M;K<:ZK(Q['IOHMKNINK8I95;4X>NRMUV*NCJK*P(*L 1W$\[:J[ZK*;JUMIN
MK>JVMU#)978I5T=3N&5E)5@>Q!(,TN/D:\#67QYT=^;K84A+\$NTF0[0[)M+
MI6ZX4_\ E*70;,5O[]LRT8VEW]F-)7]MCAF-&LN+D0YL2/[=]FOM"Q>M-,6C
M)>NGJ'!J4:AB[JGO*+L@U#%3MRIM.WCH@_5;F\-@*WH>SE;KCHW(Z8SFNH1[
M=&R[&.'D=V\!FW8X>0W[-M8!\)F[7U#FI+K<E<;&2=-$C$1B(Q$8B,1&(DH_
MQJ?'Y/>M^@"W:\1IL=Y\H\JR[:)1Q+PG]]RPBFR&Z'7R-?8XZE_ZM*M,D(O7
M[/$N;';('EI&.4F*?:?[1,?H[3FP<&U+.H\^EAB5#B_Z/I?=3J&2IW X_$,2
MIQ]M<.15J:K09"Z#Z+NZES5R\NMDT7$L!R+#NOOEB[,,.ENQ._8Y%BG[.L\0
M18Z;;EX (46"'&1H@T?'1PHX,> $PT*&$$(R@<4009E*&1QAF&VV6&&D(:::
M0AMM*4IUK7%%ECVV/;:[66V.UEECL7>QW)9W=F)9F9B69B22223N9U(B)6BU
MUJJ5HJHB( JHB@*JJHV"JH       $Y642J,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$HZ_\
M_I?4Z?/4#H=;B[;3K,"N.FX"8'T0$:.O:5H5KZ;0\,6,\ALH \1U@Z.-98-!
M)'+89>1>Z=J.=I.;CZCIN5;AYN+8+:,BEN+UL-P?/=61E)2RMPU=M;-78K(S
M*;7,PL74<6["S:*\G%R$*74VKR1U/\"K*=F1U*NC@.C*R@C5I]J?#=U'DIDO
M?/-8\KUKF6UO&NTQI.B^G4]C>U+4,P"RA&[S%L?P@4F&:W8TH4EHN#*2,_,$
M=7]#^VK2=82G3^IVIT?5-EK&:3PTK-;L [6,3[A:W<NEY]UW!9,A"ZT+SUU5
M[+M1TU[,S05LU+ )+G%&S9^*/ZH0;>^5C]EJAX^W9JFXFUH3S RX\LD \4D$
MX)]T4P(QAT8L0EA:FGQR1WDH>8?9<2IMUEU"7&UI4A:=*UO63DCI8BV5LKUN
MH='1@R.K#=65E)#*P((()!!W!D4.C5LR.K(Z$JR."K*P.Q5E(!!![$$ @^<X
MV52F,1&(G,CHZ0ESPXN) ,E).0(:# CHX5\T\XM]>FV!0PQD.D$D/.*2VTPR
MVMUQ:M)0G:MZUE%EE=-;VW6)556I>RRQE2M$4;LSNQ"JJCN68@ =R94B/8ZU
MUHUECL%1$4N[L3L%55!9F)[  $D^4G'\4?#-T3I)L1T#U(/)<RYXA;)PW.$N
M;$Z/;6D[2X@::0GZJHD0_P#P@M!?_G:XVA\5N-@UNC3#<#]<>VS3=+2[3^DV
MJU74CRK;4B.>F89\BU)/;4+E\TX?J8)5S;> ]!ESI3V69V>U6;U"+-/PMPZX
M(/'.R1V/&W^QUMY,&_62-P*Z25MFT-3*74^=U:#I%&K\75:E6H]F+@H"%%;#
MCHT)GZ[2TPPWK7U4XM2WR'W-N$%DNO%%.O$O.NKY4SL[+U++R,_/R+<O,RK&
MMR,B]R]MMC>99CZ  *JC940*B!54 =!8N)C8./3B8=%>/C4(*Z::E"HB#T '
MJ3N68[LS$LQ+$DU/EK+B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(F,O<O''F?T>EQ
M[K_(:K99E;6F4VL9A^O7-I"$:2PG5MKK\7/OL#?32F0C#R0-;UO2Q%H4M"MI
MT'K7JCID@:-K.7BT [G#=ER<$DG=C[GDK;CJS>36)6MGR<$ C :OTOH.N[G4
M],Q[[2-ADJ&IR@!Y?K-!KN(7T5G9/FI&XD ON7XR//?GX'4YS^=ZFG]:.HM,
M7-6.N24:'O;CB=,"JU3AI13*=(U]/UDF6_\ 7>_N>5_'TZ'Z!]J/474EIQ]1
MQ])^S(3Q<?&R:K7[#XGWS7JY'?\ 8J1?DLAGJ[H'1-%06X5VH_&I;P[;Z+$7
MOY+^JK9M_E6,?K(.6H45=B_:-N$?IOU'XOOTIO\ /]OWZ3]?NVUMO[OIO_7\
M7T^O_#)W-S#'\;9>7$MML>.^Q]-]_3YR)!4IO\+=N.X&_;?T^FWK\I.YX?\
MB]\Z=YBE6/H$WU0C8+31*H>*LM>C(DW[EH2IDM3=/7+I9WI6_P#U*6#>U_'T
M>UD ]>^U7J3IZ\8NG4:2HL9E\:[%R;;DVY;,F^:*>7;]NEU_=DO](^S_ $/6
M:S?FVZBW!5?PJ[Z*ZWW(!#;8QMV_R+%/UD^'#_(OF[SBTG_!SD=4J4E^'8[M
ME_3/3=P):6G[76B+?/ORED6.]]5*<#3)H!^Y6_QC(3]$ZY\U[K+J;J8_^NM8
MR\RKER&+R6C"4@]BN'C+5C<E\@YJ-G;NY/>3)I/3.A:&!^B],QL:S;B<CB;<
9I@?,'*N-EY4^J^($^2B9'9K,SL8B,1/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img187335194_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_2.jpg
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M87@W.4)B8W21M[C6_\0 & $! 0$! 0                $" P3_Q  N$0$
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M=,X!46[K7/J:/;EFM>B'/VU2);;[Z:[%IX<YW?X(Q^&]O[<^Y4Y$>ID,<_?
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M@./E34OG$O,JX<R*<3F1NL?/267R-YCYHL8>[>=O2@Q9(LA+$>/:$6;P#@'
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MU)Y;)S3G9](YG-)&0W6*RB8R<FHL3D$A*N%WQ%ZMMMOOHCHBBD29JLC@' .
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MJ>A'-LNRX;4,,*SV>%5!4>$[,6VV6H\B:+E2QA^V#@(Y&X\%:OSLGE4E-OF
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MT52?J#UXGDA,22R8 K:[@X_<$70.X)E/;<@C-=SO[BB,?K6R93*:\BH[7?\
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:ND4_'.O_ '9Y-[>&!P#@' . < X!P#@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img187335194_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %&!#,# 2(  A$! Q$!_\0
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M_P ]U_[]K_A6-11[*'8.>7<V?^$HU;_GNO\ W[7_  H_X2C5O^>Z_P#?M?\
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MLTC6D+3#$I12XQC#8YI1=U?T_$&K.WK^!+1113 **** "BBB@ HHHH ****
M"BBB@ HHHH *VT_U:_05B5MI_JU^@J)E1'4445F6%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\D<' R#C(.!D$5R+4Z#4G@ANH)(+B))89%*O'(H96!Z@@\$4]55$"(H55&
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M_LR*7-Y"CMM5B=YW,,@LNP8!//'*33T_KR_,;NM3T**&.WA2&&-(XHU"HB*
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M]:JG1/\ B:Z3??:/^0?;2P;-G^LWA.<YXQLZ<]:UZ*//^OZU"X4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6VG^K7Z"L2MM/\ 5K]!43*B8/C+
M_D!VW_85TW_TMAKH*Y_QE_R [;_L*Z;_ .EL-=!6984444 %%%% '/\ CO\
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MY/%>H44^M_ZW;_472W];6.1\46.M7&A7,4\UM>HUS;&*&ULG1U47"$[B9'W
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MZM?H*B943!\9?\@.V_["NF_^EL-=!7/^,O\ D!VW_85TW_TMAKH*S+"BBB@
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M;W-;.IM/<Z7=06KJL\D3(C.< $C&3P:Z(0M15XZI;/O_ ,.92G^\=GN<_P"
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MZ^8A!3^&3@,-ISS0\/:'KFE0^"_M&DR%M-M+BQNUCFB/E[B@609890[">/F
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ML%OOU'[!##Y.]1\ZA<C<3CL>]=C11W\_TO\ YB[>7ZV_R.0C\,R7VL^+$U&
MK8:FELD,BN-Q*1D%A@Y4JV""<<C(K%T?PEXB?0KXZDMM'K46N?VE:R%_W4Y4
M*H)VY*JX##ID;NAZ5Z35'6M5@T+1+W5;I)'@LX6FD6( L549. 2!G\:6SO\
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MP_\ ?@?XUZO]I4.YP?4ZO8P_.H\[WK<_X0+4O^?P_P#?@?XT?\(%J7_/X?\
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MRSXHT_4M5\,:A8Z1?FPU":$K!<@D;&^HY&>F1R,Y%1^$=-U;2/"MA8:YJ/\
M:.I0H1-<Y+;CDD#)Y; P,GDXS6W17GK2YV,*Y+X:_P#(BV?_ %VN?_1\E=;6
M'_PA?A47'VC_ (1G1O.W[_,^P1;MV<YSMSG/>CJ!P6HVUC<>%_&&N:BL:^(K
M*ZN$@NL_O[4J?]&6,YR@(*$*,!MYZ[CG4LM-TOQ!XA\2'Q9;6]Q-:1P"-;L
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M*,#@$\D=S4=MX:T&SNS=VNB:;!<F3S3-%:HKE\$;MP&<X9N?<^M/39_UJ_\
M,3ZV_K1?Y'F<.J2WML?[0DN<>#M,N5O'@P)3=8>)&4D$;O+1G![>8IJWH5L=
M)^).D6Z66D:6;O2IWDM=.F,KS %"LDS[4WL3OP=N>&.YL\>FI86<37+1VD"-
M='=<%8P#*<;<M_>X '/:J=GX:T+3_*^Q:)IMMY4AEC\FU1-CD;2PP."1QGTH
M=WJ]_P#.]_S^Y6\P:5K+^MK?E^)YIX?TBSTWP[X!U6QMUCU*YN5BFN1_K)D:
M&4[&;J5RJX4\#:,=*VO!VFZ')X7TCQ!=1VW_  D$KL6O97\N>6[.Y6B9L@MS
ME?+)QP!C@8[M--L(X;:%+*V6*U8-;HL2A82 0"@Q\IP2./4U#'H.CQ:JVJQZ
M38IJ+9W7:VZ"8Y&#E\9Z<=:'K?S_  &W=W_KJ>5:#87\^@Z+KGV?P_9:I)=Q
MM/K$^J.+F60R8EAD7R1DGYD\HN0. /NBDU_3](O_ (;^+-6UE83KL-S=1M<R
MMB:!A(1#$K'E4*;,(.&#GCYC7JB^'M%35CJRZ/IZZD22;P6R";)&"=^-W3CK
MTI+SPYH>HWAO+[1=.NKHIY9FGM4=RN"-NXC.,$C'O0_Z_#_+^NHG9_UY_P"9
M<LO^/&W_ .N2_P JY?Q=HQU?6=*VKI&H-"DK-HVJOB.=3M'FKA6PR' R488<
MC@G-=!::5%::I?7R; UVL2E40+@("!GU/)Y],#M3M2T?3-9A2'5-.M+Z)&WJ
MEU LJJV,9 8'!Y-$M7<F*LK'G&F?V9K&H^'M,NM+6VT7%]&=-FG\^W-Y'(J[
M!N^5T \PHN,#&0HV\4;"+3=/U]H=.=18P^,(HDP^Y8S]C*[!Z ,=H'0< =*]
M4FT;2[C2UTN?3;.73U"JMH\"M$ O0!",<8&.*S-/\'Z99)J]M):V<^G:A.DH
ML6M5\J-5C1 NWD$90'H,?A36C_K75/\ 3[A]'_71K]3B[Z[MKOQ+KEC' FH&
M\UVWMQ;/<"*WE9+0%DF;8^5&P_* <LH'3-8KQC_A&/%FE;K2*&#7K*,6^FL4
MAMBSP[TC[C#;@2 N6!.%Z#UL^&M!:Q>Q.B::;.0J7MS:IY;%0 N5Q@X  'IB
MGIX?T6-"B:18*I6-2%MD (C.8QTZ*>GIVI15OP_"W^7XC;O_ %Z_Y_UTX5?"
M/A\_$#5]..D6?]GKI$,XL_*'D>:7D4R>7]W?A0-V,]>>35'PC%#XEE\/VOB6
M**_MET"*:TAO )$EEW%9'VMPS*NP9(R WN:]3^R6PNGNOL\7VB1!&\NP;V0$
MD*3U(!)X]S5.Y\/:)>V$%A=:/I\]E!S#;RVR-''QCY5(P.">E)?U_P"3?Y_@
M#UO_ %V_R_$\]\*W1?7O#&^X>6V#:O;V,LC%B\*RIY8#$G<-JG!SR%J#3=-C
M\0%9[9M&U2-=5U.0:5J4G[JY0S?ZY,*_S)P,[&&'(XSFO3;[1M+U.RCLK_3;
M.[M8R"D$\"R(I P"%(P, D5%<>&]"O+1;2YT73I[99#*(9;5&0.<Y;:1C<<G
MGKS3ZW\K?B%]+>?^?^9G^"+BTG\-(+.P:P2&>:%[7SS,D3HY5E1NZ @XQ@ <
M #I6&NEZ-KWBWQ6/$MO;W/V/R5MQ=8Q;6YB#%XR3\F7WY<8.5Z_*,=U;VT%G
M;1VUK#'!!$H2.*)0JHHZ  < 54U#0='U>:*;4M)L;V6'_5/<VZ2,G?Y2P./P
MHZW$MCSB>Q?7O$OB,3Z9HVJ0VR0K9SZCJ;QM;6QA5A+$1%)C+;CYH8$E?]FJ
M&J&Z:,&]O;>^N?[)TCS+JVDWQS'[<?G5L#(/7->JZEX?T769(Y-5TBPOGB!$
M;75LDI0'K@L#BIY],T^YD:2>QMI7945FDB5B51MR@DCH&Y'H>:%HT^W_  ?\
MP[_UU3_0M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!S_C+_D!VW_85TW_ -+8:Z"N?\9?\@.V_P"PKIO_ *6PUT%
M!63J7A?0-9F\[4]$TZ]EQCS+BU1VQ]2,UK5Y]\3+YK:Z\.VM[JEWI6@W=TZ:
MA>6LAB8$)F-&D ^56;()XZ?B$QHZ_3/#^BZ)N_LK2;&Q+##&VMTC+?4J!FM*
MO$OAWKLMQJ_A73=*U>:[6)=1_M*W\TRHL/FL8G8_WB=N#UP?0\^VU71,GJT<
M_P"._P#DGGB7_L%77_HIJZ"N?\=_\D\\2_\ 8*NO_135T%(84444 (_W&^E8
MGA/_ ) :_P#71JVW^XWTK$\)_P#(#7_KHU:+X'\OU(?QHW****S+"DVJ>PI:
M* $V+_=%&Q?[HI:* $V+_=%&Q?[HI:* $V+_ '11L7^Z*6B@!-B_W11L7^Z*
M6B@!-B_W11L7^Z*6B@!-B_W11L7^Z*6B@!-B_P!T4;%_NBEHH 38O]T4;%_N
MBEHH 38O]T4;%_NBEHH 38O]T4;%_NBEHH 38O\ =%&Q?[HI:* $V+_=%&Q?
M[HI:* $V+_=%&Q?[HI:* $V+_=%&Q?[HI:* $V+_ '11L7^Z*6B@!-B_W11L
M7^Z*6B@!-B_W11L7^Z*6B@!-B_W11L7^Z*6B@!-B_P!T4FQ?[HIU% "!0.@%
M+110 4444 %%%% 'G&N_\AR[_P"NE9U:.N_\AR[_ .NE9U>M#X4>?+XF%%%%
M42%%%% !1110 4444 %%%% !1110 4444 %%%% !7<>#_P#D#O\ ]=F_D*X>
MNX\'_P#('?\ Z[-_(5SXGX#:A\99\4:X?#?AC4-9%G)>&SA,OD1G!?'O@X'<
MG!P 34?A'Q#_ ,)7X5L-;^Q2V7VM"WD2G)7!(X.!D'&0<#((K;HKSUU.QA7D
M/@[2]*N/#<4MQ\-_[5E:>XW7OV>Q;S?WS]Y)0_'3D#I7KU<AHWAOQ+H.FKIU
MCKVDFV221T\_29&<;W+X)%P >6]!2ZAT,+Q!<QZ3XEO)(M.M3&FEZ9&MI<1!
MHXP;QE VJ<97.1@X! ]*W+K7/$%_?:V-#&FI;Z.PB9;N-W:ZE""1E#*ZB, ,
MHR0W)/''+]5\&SZQ<RW5UJ<:SS6UI#(8K8A=T,_G%@"Y(#9QC)QUR:R-;%YI
M^M:W%I<FJVO]HA6EC31I+I9I-@3?!,C;(F( 4^;P"H. .2G?EMUU_/3]2E:_
MW?DC+OO$4^O^#]7FN;.RCGN?"*7DDT,1#EG\W*;B2=@QD#L2>>:Z33M6UW2I
M= M=86PEM=43R(Q:Q.CVL@B+JK,S$2 A6&0$Y XYXJZ=\/YQX8^Q7-Z(;BX\
M/1:1*JQ[Q$RA\N#D;N7(QQTZ\UK:?X5ODO--EU?6([^+2T(LT2T\D[BNSS)#
MO;>P4D#:%')..F+FE[R7]:R_1K^KD7NE_72/ZIG%^'?&8T_0- T.+5]$TEH]
M*CN9;K5CE6W%E5$3S(\GY22=W''!SQW?AOQ!)XH\*_VA:O;17698"Z9FA$J,
M5++@KO0D9'(R".16=IO@F\T*'3WT?5X(KRWLELKB2XLC+'<(I)4[!(I5@6;!
MW'@G(/&.FTVVNK73HX;Z_:^N0#YEPT2Q[B?15& !V')QU)/-*>J?S_/_ "*>
M^G]:?YGFW@BXOM-\,^'].TY=*75M;C>[DNWLV $: ;FE ?,TA+ 9W+U]L'8G
M\7:XDB:4D-@NJIK"Z;-,T;F%D>%I5E5-P(XQE"QZ$;N01H6_@N:PTC0H;#4T
MBU+1XC%%=R6V])$8 .KQ[@<' /# @@<]05@\%E9[>\GU'S;\:H-3NI1#M65A
M$T015W?(H4C&2QXY)SFGO+R_X*_2_P#5A/K;S_)_K_6YMZA=WVF>';F[6W&H
M7]O;-)Y-NA3SY%7.%7+$9/098_6N$O?$NJZMX.UR:P\2>';T)I4LSM91213V
MK;"<&,RL<D;ADE"I ^5N0/1KJ*2>TEBAN'MI70JDT:J6C/8@,"#CW!%<K=>#
M+W6)KB?6]6MIIWTZ?3XGLK$P;5E #,^Z1RQ& 0,J!SP<\1)-I^GZ,J+2:]?\
MBC>>(M3T73--M9=6T2TF-BLJRW$#.UT_18HK=9A(2!C)!;)( 'I);^+M:UJ/
MPJ-+AL;9]:LI;F9[I'E$!01GY55EW?>(P2.H.>,&U'X2U>"Z6ZAUVV2XEL8[
M&[D&GDED0MM:+,O[ML.<YWJ2 <=JDT+P8^C#0 ^I"X&CVT]LG[C:9$D*;<_,
M<%0@!]<YXK1M.3?G_G_P"(JR7I^B_P""9^G^+]:U::TT>WBL(-7:2[6YN)$9
MX42WD$998PX8[F9<#?QSR<<Y>BZOJ>D'Q7/>S:5:W;:VD,]W<2!+:%?(C_>E
M6<$Y &$#9RP&>":Z&/P5/9SK?:=JJP:DEW=3I+);&2-HYWWM$Z!P6 (7!#*<
MJ#TR*J0> ;^&22].O1S:HVJ#4DFEL<Q!_)\HH8PX)7&<?,"..3@DS';7MK]Z
M_3^MBI=;=]/N=OZ_X)4A\?ZC+X9UJ[@%C>7>GW\%K%.D,D,%RDK1X8*S%@,2
M<'<P. PR#6Q_:?B.XUF30K2ZTH7EG:I<7=Y)9R&-C(S".-(A+D<(26+GMQSQ
M7'@2[DBUA;K6Q,^J75M>2-]DV^7)$R$A1O\ N$1J #DCN6K6U+0+U]:.KZ-J
M45C>2P"WN!<6QN(Y44DH=H="&4LV#G&&.0>,'3^NW^8?U^/^1F?#!IW\'NUS
M&L=PVHWAE1&W!6^T/D ]QGO4-WXJUMM/UG7K".P;2=*EEC:UDC<SW A)$K"0
M,%CZ-M!1L[>2,\7=#\!Z7IVEP6NJP6FLW,$\TZ7=W9QEP9)#(<9S@Y/;'(S@
M5'>>"[F>+4M.MM76WT34Y&DN;7[+NE4N<R".7< H;G.48C<V".,#O?Y?CI_P
M1*W7O^&O_ *'A2TDO?B!XEU>Y:PG*/#'!)]C(FC1H4955RYVKACE0.6)/'2M
MK4=5U:Y\3G0M&:SMV@M%NKBZNX'F7#,RHBHKIS\K$DMQ@<'/$D/A'3OM&K_;
M8+:^L]0FBE%K<6ZND?EQ+&!ALAON9S@8S45QX5>TU2'4?#EQ9Z5*EL+1X'LO
M-@:(,64!%=-I!+8(.,$Y!XP::+I_P/\ ,.GG_P -^AGZYXEU;24MK>[OM!TR
M\-KYC&;?<_:9LX\N"%720]CG!/S  $Y-16WBW6-:C\*C3([&T?6K*6YF>YB>
M80E!&<!0R;L[B.HZ@]L&\_A35EU%K^#Q OVFYLTM+R::Q5W<*S$-%M95C/SM
MU#CA<@X.30O!CZ,- #ZD+@:/;3VR?N-ID20IMS\QP5" 'USGBA;Z_P!;_P#
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M2].^W6U[:6\D<$IPXVX+MO 9/O*^.HX(-:D.N^([2[TF/5O[+VZPCI;K;Q2
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ML3PG_P @-?\ KHU:+X'\OU(?QHW****S+"BBB@ HHHH **** "BBB@ HHHH
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M,"BWX?U_7WATL>>W^)!>^%2WRZ<]U?NOK#LWQ#V >4 ?]<J[3PG_ ,B?HO\
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M8,?FZ%><5-]V]D.VWF?0&ZC=7BFH>+=5U+Q)\.KI;NYM(]117NK>&9ECD.X
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MLG[I@LL4J[7C)Z9&2/Q!(IOBKQE8^$(+2XU&VO'MKB7RC- BLL1[;\L"!UZ
M]#0]-P6NQU&ZC=7*6OCG2[[Q?)X;LX[FXN8H1-+<1*IA12 1EMV<\CH#U^M+
MXZ@UB^\&ZA;: \RZHX3R##-Y3C#J3ALC'&>])NRN-*[L=5NHW5\['3_%VB^,
M/"NE7?B[6)[S4&CFNK1KF3$"AOF4D2,'X#^W'O7O&HZBNFZ;=7SQ2RI;Q-*T
M<0!=@HR0 2 3QZTW91YO7\!:WM_6IH[J-U<5+\2-$A\$1>+&6Z^PRML6((OF
MEMQ7&-V,\$]>@JYJOC;3-)N]%M76>XEUAPMJ(%4\''S-DC"_,/6BVMOD'F=3
MOHW5P?BCXJ^'O"FI_P!G7?VNYNU4-)':1AO+!&?F)8#IS6M!XVT*?PH?$JWH
M&F*NYG8'<ISC:5Z[L\8I7TN.VMCIMU&ZO/O#GQ;\-^)=832[<7EM<2Y\DW42
MJLI'92&//!ZX_.L?P_XBN8/BOXQ74=4N/[+LK?S1'-,QBA V9(4G []!3ZV?
M9O[A/:_I^)ZSNHW5QEI\1='N?"D_B6:*\L],B?8DES$ TQS@%%4DD$\=N_H:
MSM ^+_ASQ#J\.F0PZC;7$_$(N+<8D/MM9OS.!1UL'2YZ)NHW57\RCS* +&ZC
M=5?S*/,H L;J-U5_,H\R@"QNHW57\RCS* +&ZC=5?S*/,H L;J-U5_,H\R@"
MQNHW57\RCS* +(?!R*E)6X0*Q*NO*L.JFJ/F4HDP<B@#3MKHNY@FPLRC/LP]
M15JL5Y$F0!WV.IRCYY4U:T_4X[J1[9W3[3&,LJG(8?WA[4AHT****0SSC7?^
M0Y=_]=*SJT==_P"0Y=_]=*SJ]:'PH\^7Q,****HD**** "BBB@ HHHH ****
M "BBB@ HHHH **** "NX\'_\@=_^NS?R%</7<>#_ /D#O_UV;^0KGQ/P&U#X
MR[X@UVT\-:!>:S?B0VUI'O<1+N8\X  R.22!R13/#7B&Q\5^'[36M.\T6MRI
M*B5=KJ02I!'/(((X)%:5Q;PW=O);W,,<T$JE)(Y%#*ZGJ"#P126MK;V5K';6
MD$4%O$NV.*) B(/0 < 5YZZG8R6O+S<PI#./%&LZ[H6O-<.J7TDT\=BC EHB
MA!%LR;0!M?EL$-R:]/(R".>?2N0ATWQ?9Z9/HP?2M1MB&BAU"]N9?.$3?\](
MMC"1ER1GS%W8'W>:3OT_K_(:_K^NI<NM?U"/4X=%TNSM]3U%+1;FZEEN#;0H
MI)53D+(=S$,0N.@.3TS63QL;V#3(=+TWSM4OGF0VEQ/Y2VYA.V7S'56Z-@#"
MG.1VY&5/\.8;.XTZ:VTO1]<6WTZ+3Y(=8&.(\[9$?RY-I.2"NWGCD8YO1>%M
M3T]=&U#3;;1(-0L5F26QMD:VM'27:652%8A@54[MOS8/RKGBG:_]?(E;?UV_
MS+UQXDU. 6-BVB1C7+R214M&O1Y(CC/S2F4*3LP5Q\F[+ %1R12G\=7$44=N
MNBE]6_M,:9-:"Y 1)&C,BN)-OS(0 <[0<$\9&#/=Z1X@N+K3=<QI9U>S:9/L
MOF2+ T$F,IYNTMN&U3OV8/(VCK56+PAJ3W]OJEU/:_;9-974;J.-F*1QK T*
MQH2,L0"O)"YYX' I+?7^M5^E_P"K#Z??^3_6W]7)5\;W"F:PFT@#7$OUL$M(
M[G=$[M'YH?S2@(0)DD[,C! !XSGV'B'6X_&7B,7^FW!EM;&T$5A:W#3QN[O(
M Z$JN <KN8J,;3G(&:N7OA#47UZ]UNTFM1>+J$5[9)*6V,!;B%TD(&5R-V",
MXX.#TK/O_!WB36;O7+V_;2HVOH;2.*TBFD>-EAE9VBD<H"5<'!(7^(C:<<BZ
M?UT_X?\ RV&]OZ[_ .1IKXYEA/B*VOK"U74-%LOMDD5I?>?&Z[6(4L44HWR\
M@KT(/.:MV/BF[:_L8-6TR&QBO[:2YMY4NC+@(%;8X*+M;:Q. 6'RGDU@KX(U
M<R:V8K71-/MM1T9]/AL[-F"6SY<J<B-0P8R,2=JD=,-U-KQQI@O=#T71HKZ.
M#5C/&D 1AO9"IBG*CK@1NY)[<4:_/_@M?Y,';Y:_DO\ @HZO0M3.M:'9ZF8#
M +J,2I&6R0AY4G@<D8/MGO6A3(HHX($AC4+'&H15'0 # %89\"^$"23X5T,D
M]_[/B_\ B:;WT$MM2K\1[N:Q\ ZG<074MK(@C_?12F-D!D4$A@01P3SFN?DO
M]%CUS0T\)>(Y]2O)+U5N;:/69;]#;8/F,ZM(X0#@AN#G SSBNI\4>'FU7P?/
MHFF+;6V5C2%"-D:*CJ< *#@87  %,UW0+N?6]-UW17@AU*V817 F8JES;$_-
M&Q )R#\RG'!SZFDOB^?]?+OY7$]G_7]/MYE*Y\:W4<&H:G;:.L^A:=,\-Q=_
M:MLI\LXE>.+80RJ<]7!.TX!XR_4?%-_.VJQZ%I*WT&G(!<SM=>4Q8H'VP@(V
M]@K*>2@R0,]<8[_#TVMW?);>'?"E_%=73W"7VIP;YH1(VYE9/+/FX).W]XG&
M!QC)U9= UW3+K5AH/]EM;:J1(_VIWC-K+L6,LJJK!U(53M)7!!YYXEIN'R_'
M^O\ ARU92^?X$/@'Q%/?:5I.G70DFG&B6U])=RREFD9RRD'(SGY,YSSFGZ=X
MWO-<BTZ/2-'AEO;FQ6^GCN;PQ101LQ51O$;%F)!P-HX!R1QFIH_A/Q#X?72Y
M+%]-GFCT>+3+H32NJQM&Q*R)A"7'S-\IV9P.1V70_">O>&(M,N+$Z=>74>FQ
MV%Y!-</#&Q1F99$<1L?XF!!7G(Y&.=).\F_-_P#MUOT_JY$=(_=^E_U_JQ6O
M?$FO1:WJ[7^F+!86WA_[7)9C42LJ-^\SAHT^\2FW(;@ ,#DE1T,WB*[-Y9Z9
MHVG17=Z]HMW,+F\,4<$1X7+A'9F)! ^7L22.,Y>J>&?$.HSZA-))I;R:EH;:
M=.RO)&(I?WA4JNUMR_O "20>,X[5?ET/5M.U>VU?2$L;BX-BEC=074[Q*P0D
MJZ.J/@@E@05Y!'(QS*VU_K67_ *EW7]:1_X)63QU<7TFDVVEZ*9KN_\ M*21
MW-R(EMI(&575V"MD9)P5![<<Y#8/'=Q>OI]E::5 NK74ES$T%W>^5$K6[;9%
M60(Q<Y(( 3E<DXQ3]&\'WFF:II-[+=PSO +Z6\8 KNEN'1_D'/R@J1R<]*B/
MA?4X;">TDTW0-8MI]1NKM[34"P4"20LC!O+<!@"01L[\-QR>O].X:6T_I:_\
M ZO3+F\NK%9+^P-C<Y*O#YJRC@XRK#JIZC(!]0#Q7-ZCXL71QXDN8].GN9-/
MN[6 QBZ)\XRK$!L#?*F/,Z#@D9)&2:U/"6BS>'_#\6GSR(2LDCK'$S-' K,6
M$2%N2J@[02!P.@Z5DZGX2O[W_A(/+FMA_:-_9W,.YF^58?)W!N."?+;&,]1T
MHZ_UW7_!$O,T]'UZ]N];O-'U338K*]@@CN5\BY,\;QN64?,40A@5((QCIR:B
MU'Q'?)XC?0M)T^TNKR*T%W(+R]-L&1F*CR\1N7Y4Y. !E>>:MQ:3<)XTN=9+
MQ_9Y=/BM54$[]ZR2,21C&,.._K5#Q3HEYK4@B;0_#^L6?ED(FI,T<D#G@LK"
M.3.1CH$(QU.>$[V7S_7_ ( ]+OY?I_P1TWB;4I=0ATO3M$5]3^R+=W4-Y>")
M+96)"J719-S$AL #&%)R.,LT7QK#JVIPVCV3VHEM99=\D@)66&3RYHB ,94E
M3D$Y!S6))\/)()M/NY+'1_$5Q%I\=C<+K (R4)*R(Y20@_,001R,<\<SZQX'
MO[_PC8V-@=)TK4H)68_V? 88$CE5DE50,DG8YP<#+*#A>S?E_7;Y=>HE_7W:
M_CI_5RQIOCF^UU;:/1]%BEN9K<WC+<WABCC@+LL3%A&QW.%+!=O SD],R)XW
MN+Z32;?2](66[OQ<K)'<W7E+;20,JR*[*CYY) (!S@=CD0:SX$MWUN#4K/0]
M#U.-;-+)K/5%VK&J$E&C;RY,<,01MYXY&.;6E^%KJRU+0KLP:1:)9072SV^G
M0F&)6E,9 1>^-ARQQGK@9P&K7^_];!_7X?YF3?>(M6<Z7_8]LB))XBGLYUN-
M0D/F;/-XR48JA*DX'W<!0""<;UKXO%Q'91FRV7UQJ4NGO;^;GRC&6+/G;R-B
M[AP,[ATZUG/X3U:&TMVMFLI+FWU^;5%CEE=$>-S)\I8(2&Q)Z$9'XT:+IL-U
M\2-8U:UNXY[&)%7;$0RI=LJI+R/X@D48(ZC<?6E#9)_UI'\-T$]W;^M7_P !
MG3ZYK$&A:1/J-PCR+'@+&F-TCL0JJ,X&2Q Y]:Y+Q#XLUNQT;5+.YTRWL-6.
MESWEH\-\98]J#Y_F\L$2+N!"[2IX^;KCI_$NB_V_H4]@)1#*626&0KN"2(P=
M"1D9&Y1D9Z5SNI^&=>\1K=W&J?V=:W TJYL+6"VGDEC,DR@-([LBD#Y5 4*<
M<G)Z5,KM-?UM_F5&R:O_ %K_ )&]X4MI[7PU9+=!_/:,.^^^ENR2>_F2 -R,
M'&,#.!7$FYA2&<>*-9UW0M>:X=4OI)IX[%&!+1%""+9DV@#:_+8(;DUZ19P-
M!I\%NY!:.)48J>X&.*Y>'3?%]GID^C!]*U&V(:*'4+VYE\X1-_STBV,)&7)&
M?,7=@?=YJY_$VOZ_R(I_"K_U_F/O'NM9\2V_A^2_GBM8-/2\NY;-S URS.55
M0RG<B_(S':03P,XSG,U>XNO#-SJ&D07][+:7>CW5U:F>=I9;:6(#=ME8ER"'
M!&XD@C@@<#2B\)W>AII%QH,T$MWI]BFGRQWA*)=PKC&74,48$$@A6')&.<A)
M_#>JZN=2O]4:RBOYM/EL+.W@=GBMU<?,S2%0S%B%R0H  Q@]3,UHTO/];?H5
M#=7\OTO^IC>'M>U&V^&D\4]W-<ZO!Y=M!/.Q9Y7G5&A8D\G'FJ"?]DUN_#::
MYF\"6#7EW<7<ZO,C3W$ADD?;*Z@ECR> *J6O@V_@UW0;HW-L+.TLX4O81DF6
M>%&6-ER,8'F,2>#\J_AM>$=&N- \-P:==/$\T<DK%HB2N&D9AU /1AVJY-7;
M7]6_ILSC>R3_ *N9FK^-+G1KB*:ZTJ.+3)+Y;%)9[KR[B1RVW?'"4PR9YSO!
M*@MC'5FJ>-=0LKO7Q;:$EQ::&%>ZG:\V,Z&-9#Y:[#E@">"5' YYP,._\ :Q
M-'?QVUMH7VJ:_P#M@U69G-S<()A*L+XC^11M5=P9AA!\O/'177AF^N+7QE&)
M+=7UN/;;_.V$/V=8OG^7CY@>F>/RK/7EOU_X;_@FJ2Y[/;_@_P"0R]\67]TN
MIC0M(^VP6$0^TRO<^2^YHP^V)=K;V"LI.2@R0,]<7? ES/=^ -!N;J:2>>2Q
MB>265RS.Q49))Y)K,3P[X@T?^T8M%;3)(=21'E-W(Z&VF$:QLRA4/F*0JG:2
MAR#SSQN^%M)GT/PEI6DW+QO/:6D<$C1$E2RK@X) ./PJY:*5O+];D:NU_/\
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M?[!9_P#/I!_W['^%'V"S_P"?2#_OV/\ "K%%',Q61ES:#I\MU]I>!254 1@
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M_P"ON.H3Q#JEC>6<6OZ/!9P7D@ABN+2\-PJ2G[J29C0KGH"-PSP2,C+/#GC
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M@[&1%;S8PC$;"022P Q]TT/1V_K^F"UNSO5OK-YXX$NH&FEB,T<8D!9X^/G
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M>HK^[?R?Y'M-%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,=-=A_PC=G_ ':/^$;L_P"[1<+''?VW;_\ /7]#1_;=O_SU_0UV/_"-V?\
M=H_X1NS_ +M%PL<=_;=O_P ]?T-']MV__/7]#78_\(W9_P!VC_A&[/\ NT7"
MQQW]N6__ #U_\=-']N6W_/7_ ,=-=C_PC=G_ ':/^$;L_P"[1<+''?VY;?\
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M=:6;:X*,V)D5'2-))$4;E^4 Y (..=[PIJ0O+R^@&OWFH^2$+6^HZ?\ 9;F
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M RN[ALY/4C HE[KL_/\ !-C2;O;^M4CT6JMKJ5A>LJVE[;7!:(3*(I5?,9)
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M4 %%%% '/^,O^0';?]A73?\ TMAKH*Y_QE_R [;_ +"NF_\ I;#704 %%%%
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MS\^YG8!0  2S$  #@=A3]/\ %D=Z%EGTC5+"S>!KB.\NHD$31J <DJ[&/@Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /.-=_Y#EW_ -=*SJT=
M=_Y#EW_UTK.KUH?"CSY?$PHHHJB0HHHH **** "BBB@ HHHH **** "BBB@
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M'<H&#D #FDMO#VBV6GSZ?:Z/I\%E<9\ZWBMD6.3(P=R@8/''-+^OZ_JWD/\
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MWI>DWCWDKQ6WB#3+EA/=L49P\RXRX902?G==P!P.,0Z5=0'PA\-H!,GFM?*
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MW36QW0&>!7,1XY7(^7H.GH*5M+?UL_\ ,;=_Z]/\CRGP9H&E>)#86VJ6D5W
M?#%L$650P4M+,-Z@\!@.C=1D^M174]QK^A7ME>$N_A71;R*[+#[]T4DA1O\
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MGEW#ECV#^PM+_P"?*+\J/["TO_GRB_*BBCGEW#ECV#^PM+_Y\HORH_L+2_\
MGRB_*BBCGEW#ECV#^PM+_P"?*+\J/["TO_GRB_*BBCGEW#ECV#^PM+_Y\HOR
MH_L+2_\ GRB_*BBCGEW#ECV#^PM+_P"?*+\J/["TO_GRB_*BBCGEW#ECV#^P
MM+_Y\HORH_L+2_\ GRB_*BBCGEW#ECV#^PM+_P"?*+\J/["TO_GRB_*BBCGE
MW#ECV#^PM+_Y\HORJU;6L%G$8[>)8T)SA?6BBAR;W8U%+9$U%%%2,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img187335194_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@#E?
M'VMW^A:);3Z=+'%-+=K"SO'OPI5ST_X"*X#_ (3WQ1_T%(/_  #7_&NK^+;;
M?#-B?^H@G_HN2O)?/]Z]C+\+3JTG*2OK_D>/F&+G1JJ,7;0Z_P#X3WQ1_P!!
M2#_P#7_&C_A/?%'_ $%(/_ -?\:Y#S_>CS_>N_ZA1_E.#^TJO\QU_P#PGOBC
M_H*0?^ :_P"-'_">^*/^@I!_X"+_ (UR!G.#@\UZK9V%FNCV$FD^'K+5[*2(
M&YE\Q?/#'[V >_MD5A7P]"BDW#<Z*&*K5FTI;?UT.9_X3WQ1_P!!2#_P$7_&
MC_A/?%'_ $%(/_ 1?\:ET33M*^U:[JUW9SG3],YCLYN'W'HK?3I5K3KG2?&M
MM?60T:WTZ^A@::WEM^AQV/ ]JB5&@KODT5KOM?YEQKUG9<^KO;SM\BA_PGOB
MC_H*0?\ @(O^-'_">^*/^@I!_P" B_XUK7NEV=Q\-+.6"UA74/LZW'F(@#N
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M^-'_  GOBC_H*0?^ :_XUR'G^]'G^]'U"C_*']I5?YCK_P#A/?%'_04@_P#
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MZ7%!)X UVZ>&-IXIH@DA4%E!(S@]JN)X'!GLK>37;6*>]A$MO$T3;F)&2.O
M]^_I6CH86+:E&UO7LF9QQ&)DDXN]U?IWL1_\)[XH_P"@I!_X!K_C1_PGOBC_
M *"D'_@(O^-4+#PY+/%?7&H7T.GV=E,8))I%+YD!QA0.M:&D:(T'BE[&&[TV
M]4VC3+*\?FH5QW7(PWXTY4,*KZ;>HHXC$NVN^G3T$_X3WQ1_T%(/_ -?\:/^
M$]\4?]!2#_P$7_&J5AX<%QHL>J7^JVVG0SN8[<3*6,A'TZ#/>MSQ'X<^V>*H
MK&R%M:0Q6"SW$H7"(!G+''6IE1PJERV[]^@XU\4X\U^W;J4/^$]\4?\ 04@_
M\ U_QH_X3WQ1_P!!2#_P#7_&J=SX::.;37M=1AN['4)A!'=1H1M?.""IYJY<
M^"VA74HX=9M;B\L$,LMLJ,"$'.<],X[53HX1=/S]/D)8C%O;]/Z8?\)[XH_Z
M"D'_ (!K_C1_PGOBC_H*0?\ @&O^-16_A(-;6AOM:L[&ZO(_-@MY@<E<9!9N
MBYJOI_AS[18-?7^JVUA:F<V\4C R>:XZXQV]Z/887M^?]/Y"^LXK37\OQ[?,
MN_\ ">^*/^@I!_X!K_C7:?#[Q%J>NC4UU*>.8V[QB-DB"<,I)!P?:O*M7L+G
M1-3FL+O;YL>/F4Y# \@CVKO?A"V\:X?^FD/_ *":PQN&I0H>T@NQO@L55G7]
MG-[7/3:***\8]D\_^+YQX5LO^P@G_HN2O'-U>Z?$+19O$.F:9ID$\<$DM^")
M)%+*,12'H/I7%_\ "G=7_P"@S8?^ [__ !5>QE^,I4:3C-ZW/%S'!5J]52@M
M+'G^ZC=7H'_"G=7_ .@S8?\ @.__ ,51_P *=U?_ *#-A_X#O_\ %5W_ -IX
M;^;\&>?_ &5B?Y?Q1Y_NKO[/4_!LLEKJ0NK[1KN)5\ZVLU(21AZ$ \'ZBE_X
M4[J__09L/_ =_P#XJC_A3NK_ /09L/\ P'?_ .*K*KC<-46LVO2_^1M1P&*I
M7M!/UM_F1P^.-.N/$.LF_M9/[(U15C=5^^NT8#8]?_K41:SX6\+V%Z^@W%W?
M:A=1&%9)DVK$I_ ?Y%2?\*=U?_H,V'_@._\ \51_PIW5_P#H,V'_ (#O_P#%
M5C[?![*3MIIKK;OH;>PQN[BF]==-+]M2;2?&&D6@\-Q37!,-M:RPWBF)B%+8
M([<\CM65K7B6SU/PQ?6XF)NYM6>Y5"I_U9& <]/3BK__  IW5_\ H,V'_@._
M_P 51_PIW5_^@S8?^ [_ /Q5-5\&I<W,[^GG?L#P^-<.3E5O7RMW,+POJ]EI
MMCKL5W*4>[LC#" I.YN>..GXU8O=<L)M$\*VT<Q,M@Y-R-A^0;@?QX':M7_A
M3NK_ /09L/\ P'?_ .*H_P"%.ZO_ -!FP_\  =__ (JK>+PCGS\SOZ/M;L9Q
MP>,C#D45;;?S3[^03>*M%N]<\16\\\JZ;JR1A;I(R3&RJ!DJ><9_E6=87?AG
M1/$ND7%C>W4\<#%KJYDB*J>#C:F-U:/_  IW5_\ H,V'_@.__P 51_PIW5_^
M@S8?^ [_ /Q51'$82*LINUK?A;MV+EAL9)W<%>]_QOW[E6'6]$U/2]4T?4KR
M:TADOWO+:Z2(N#DG@KUZ?SK0;QEHNG:EX=EL'GGMK&"2WF#1X<*V!NYX)XS@
M5#_PIW5_^@S8?^ [_P#Q5'_"G=7_ .@S8?\ @.__ ,52=?!O>3MV]5;L4J&-
M6T5?O\[]^Y#XE\417>E-:P>([C4!+*I:$V"1*J @\G .1CMUJP?%6C_\+-CU
MG[4WV!;?RS)Y;9W;,=,9ZTW_ (4[J_\ T&;#_P !W_\ BJ/^%.ZO_P!!FP_\
M!W_^*H5?!J/+S/JMN]NR\A.AC7+FY5TZ]O5E1=5\/:YH6GV.KWT]C)I\CA2D
M)<31L<X&.AQCK5GP_P"*M*TN'4]+M+VZTZUEF$MK=R0+,R\ $,N.^.*=_P *
M=U?_ *#-A_X#O_\ %4?\*=U?_H,V'_@._P#\53>(PC3BY.SZ6\[]OS!8?&*2
MDHJZZW\K=SG_ !;K0U;48C'J<VH10Q[5EEMUBY/7 4#CZUS^ZO0/^%.ZO_T&
M;#_P'?\ ^*H_X4[J_P#T&;#_ ,!W_P#BJWIX_"PBHJ6WE_P#GJ9=BJDG.2W\
M_P#@GG^ZC=7H'_"G=7_Z#-A_X#O_ /%4?\*=U?\ Z#-A_P" [_\ Q57_ &GA
MOYOP9G_96)_E_%' (W[V+_KJG_H0KTGXQG&H:'_URN/YQ5FW_P +-3TNR>_E
MU6SDCMRLK(L+@L 0< [JZSQ]X7N?%6N:5:VMU#;M#;3R%I4+ C=$,#!%<%;&
M4I8F%1/1'H4,%6AA:E)K5_\  /&]U&ZO0/\ A3NK_P#09L/_  '?_P"*H_X4
M[J__ $&;#_P'?_XJN_\ M/#?S?@SS_[*Q/\ +^*//]U&ZO0/^%.ZO_T&;#_P
M'?\ ^*H_X4[J_P#T&;#_ ,!W_P#BJ/[3PW\WX,/[*Q/\OXHYCPW?:3::BZZU
M9BYLIHS&S 9:(]F6NDN]=\/Z3X9U#3-)U*_U)[U1&JW (2$>H! Y^GM3_P#A
M3NK_ /09L/\ P'?_ .*H_P"%.ZO_ -!FP_\  =__ (JL*F+PLY<SD_36VGR.
MFE@\73CRJ*]=+Z_,BDUGPOXGT^R.OW%W8ZA:1"%I84W"51^!J>/QEHZ>*-%2
MW$EOHNEQNB.ZDLQ*XR0.?3]:;_PIW5_^@S8?^ [_ /Q5'_"G=7_Z#-A_X#O_
M /%5G[?![<SMKIKI?MH7]7QO\JOIKI=V[Z^0-XRT\^&(K(2G[2-0#/\ NSGR
M!*9 <X_2N8\6:C;:IXHO[VSD,EO*X*,5(S\H'0_2NG_X4[J__09L/_ =_P#X
MJC_A3NK_ /09L/\ P'?_ .*JZ6*P=.7-&3Z]'UMY>1-7"XRK'EE%=.O:_GYA
M<WG@_6]*T=-2UBZ@GL[586CBA8@GC/.TU&WC73E\8Z1<V\,J:3IL1MX\CYRI
M&"V/R_*I/^%.ZO\ ]!FP_P# =_\ XJC_ (4[J_\ T&;#_P !W_\ BJA5\'UF
MVM?QWZ%/#XSI!)Z?.VW4AN=4\-V/AK7[#3]2GNKB_=9$+P%%^]G:/H,\G%9_
MB+6]+U&7P\49KB&TM8XKI I4\$;E&?;-:W_"G=7_ .@S8?\ @.__ ,51_P *
M=U?_ *#-A_X#O_\ %54,3A(OFYVW_P "W84\+BYKEY$E_P &_?N7Y?%/AN&W
MU6WM-2=;>\M&C@MDLO+C@.W&"0,L23UK!EUK2+SPIH4,EY)%?:9)S!Y)(<%Q
MD[AP, 9J_P#\*=U?_H,V'_@._P#\51_PIW5_^@S8?^ [_P#Q53&O@XZJ;[[>
M5NW8J=#&2T<%LUOWU[^07'BO1KK7_$$$\LW]EZK'&HN(XSNC95 !VGG&?Y5#
M!X@T/1K?2]*L+N:ZMX]02[NKQX2@X[*O7_\ 54W_  IW5_\ H,V'_@.__P 5
M1_PIW5_^@S8?^ [_ /Q5"KX-*W,[:?@K7V$\/C&VW%7U_'?J5;7Q'ID>N>*[
MEK@B+4()$MF\MOG)Z=N/QKB=U>@?\*=U?_H,V'_@._\ \51_PIW5_P#H,V'_
M (#O_P#%5M3QN%I[2?3H^GR,:N!Q=7XHKJ]UU^9Y_NHW5Z!_PIW5_P#H,V'_
M (#O_P#%4?\ "G=7_P"@S8?^ [__ !5:_P!IX;^;\&8_V5B?Y?Q1Y_NH#<BO
M0/\ A3NK_P#09L/_  '?_P"*I?\ A3NKY_Y#-A_X#O\ _%4?VGAOYOP8?V5B
M?Y?Q1J1?\F_O_P!>+_\ H9KSK1=7DT36[;48EWM ^2A.-PZ$?E7J*Z<Z?!F3
M2S*AD$+VWF8.W/FE<XZX[USY^#NKDY_MFP_\!W_^*KSL%B:--351Z,]/'86M
M5<'36L?^ 6+77?"%GJ,NL6>J:K:/.PEFL8DP';.<$XQC)/>LM?%=A=P>+)9M
MT$NIHHMXB"V<9')' [5;_P"%.ZO_ -!FP_\  =__ (JC_A3NK_\ 09L/_ =_
M_BJV5?!K5R;V_!W[>1BZ&-=K12Z_A;OYE/PWK.@V.@*LMR]CJ<<_F231VHE>
M9!T16(^3]*T+KQ9HEWXCUI)IY?[,U:UCC,Z1G=$RKCE2,FH_^%.ZO_T&;#_P
M'?\ ^*H_X4[J_P#T&;#_ ,!W_P#BJ<J^#E)R<GK_ ,#R\A1P^,C%145I_7?S
M(Y-?T+2/#5E8Z5>2WEQ::BET3)"8Q(!R2/0=!SS5[6O&UK=6=Y-9^(KH&="(
M['[ GR9&"K.1R/QS]:J_\*=U?_H,V'_@._\ \51_PIW5_P#H,V'_ (#O_P#%
M5/ML&W=R;?I_P!JCC4K**2M;1_\ !\SF]$\3MHNGW=D=-M+R&Z*F03@\@=!P
M>E:7CKQ'IVN360T^&+$4"AYE1E8'GY.?X16E_P *=U?_ *#-A_X#O_\ %4?\
M*=U?_H,V'_@._P#\56KQ>#=15+Z_,R6#QJINE96^7J9^AZ[HMUX;/A[Q"9XH
M8Y3+;W,(W&,GL1^)['K4FI:]H6G: NA: UQ-%-.LMU=3+@L 0< 8'H.W\ZN?
M\*=U?_H,V'_@._\ \51_PIW5_P#H,V'_ (#O_P#%5+Q.$<N;F>][:VOWV*6%
MQBAR\JVM?2]NVYI2>/=(35-=GBN&=)K>,V;&)N90C*>W'7J:X_Q+K%GJ6F:#
M#;2EY+2S$4X*D;6XXYZUO?\ "G=7_P"@S8?^ [__ !5'_"G=7_Z#-A_X#O\
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M =5P< ]L5W-M-Y.APS8!V6RM@L%!PN>IX'UI8]4L7GCMC=VZW3C(@\Y2_3.
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M.S=W^EO^ 9ND:'<VNHP7D]O;19^T.T<1R(2[(553CGH<GCDFKUC_ ,C3J_\
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M^_+5G?\ "M[+_G_N/^^5H_X5O9?\_P#<?]\K1R9?_,_Z^0>TSC^2/]?,T?\
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M_P#HR*N ]8U7=8XV=ONJ"3]*YS_A/-!_Y[R_]^6KHI8Q+"\9. ZE<CWKC/\
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M'W&:6B@!F)/[Z_\ ?/\ ]>C$G]]?^^?_ *]/HH 9B3^^O_?/_P!>C$G]]?\
MOG_Z]/HH 9B3^^O_ 'S_ /7HQ)_?7_OG_P"O3Z* &8D_OK_WS_\ 7HQ)_?7_
M +Y_^O3Z* &8D_OK_P!\_P#UZ,2?WU_[Y_\ KT^B@!F)/[Z_]\__ %Z,2?WU
M_P"^?_KT^B@!F)/[Z_\ ?/\ ]>C$G]]?^^?_ *]/HH 9B3^^O_?/_P!>C$G]
M]?\ OG_Z]/HH 9B3^^O_ 'S_ /7HQ)_?7_OG_P"O3Z* &J'!^9E(]EQ_6G44
M4 8_BK_D5M1_ZXFEE_Y&^T_Z\)__ $9%2>*O^16U'_KB:67_ )&^T_Z\)_\
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MF]O^>3?F/\:-[?\ /)OS'^-/)P,GI47VFW_Y[Q_]]B@!V]O^>3?F/\:-[?\
M/)OS'^--^TP?\]X_^^Q1]I@_Y[Q_]]B@!V]O^>3?F/\ &C>W_/)OS'^--^TP
M?\]X_P#OL4JSPNP5948GH P- "[V_P">3?F/\:-[?\\F_,?XT^B@!F]O^>3?
MF/\ &C>W_/)OS'^-/HH 9O;_ )Y-^8_QHWM_SR;\Q_C3Z* &;V_YY-^8_P :
M-[?\\F_,?XT^B@!F]O\ GDWYC_&C>W_/)OS'^-/HH 9O;_GDWYC_ !H#MG_5
ML/Q'^-/HH *Q['_D:=7_ .N-O_)ZV*Q['_D:=7_ZXV_\GH V**** ,K5_P#C
M_P!$_P"OX_\ HB6M+SH@"?,3 ;:?F'!]/K6;J_\ Q_Z)_P!?Q_\ 1$M9/]AW
MR6[IY*2_,05D=<NQ5AOSCH,@@'G@T =2'1C@.IYQP>_I3JYJUT2^TZ_@>VDW
MQ!P'WE3P0-S=._3U]3UKI&!(P"1[B@!:*9L;_GJWY#_"C8W_ #U;\A_A0!SU
MS>7*W4RK/( '( !Z<U5GU:2V53->2(&.!R3G\J?=?\?<W.?G//XUF:EIYOQ$
M595>,M@L"<9'48_B&.*!EV;7/L[.LNH%63;N&XDC=TS]<&IH]2GE!*73L 2I
M(;N.M89T-3+=N]PTPG48$BCY6!/S9&">N,59TVP?3UEC,YDC9LQJ<_*/Q[_3
MB@#>L+NXDOHE>9V4GD$]>*Z"N8T\$W\(!QSU_ UTFQO^>K?D/\*!#Z*9L;_G
MJWY#_"C8W_/5OR'^% #Z*9L;_GJWY#_"N"\:WEW#KA@M[S4HY/[.WV\=F6(>
M?S,+N [=N:UHTG5ERHRK5%3AS,] JO:W]G>^9]DNX)_+.U_*D#;3Z''2N9DT
MSQ%)?W<\EPS6DENX6$7/\1CP!LV\?-_M5C>$9H;&_2Y^Q7%O#'IUM9SG[*RY
MN-Y!XQS[M6JPZ<6T[M6V,GB&I)6LM=SOXK^SGN9+:&[@DGB_UD22 LGU Y%(
MVH620S3->0+%"VR5S( (V]&/8\]Z\VT>&\MM1@%EIDQU.RBOC/NBV!W=LQ@N
M>&S]:?96]^WAK6=&U#3[Z&*!(9F9(DDD>1FW2-P</SSUX K1X2*?Q=OSM?\
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MS+_=3\S_ (4^B@!F9?[J?F?\*,R_W4_,_P"%/HH 9F7^ZGYG_"C,O]U/S/\
MA3Z* &9E_NI^9_PHS+_=3\S_ (4^B@!J[\_,%Q[&G444 <<?^2>2_P#7=_\
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M %W?_P!*372ZHK/ILRI:FZ8@8A#!=_/0DD<>OK7-'_DGDO\ UW?_ -*378T
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M&&",B@!:*C\F/^[1Y,?]V@#F;O\ X_)_^NC?SJ&I;H 7<P'3>?YU%0,****
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M@KO9_P#CWD_W3_*N"'04 +1110 5>T;_ )"]O]3_ "-4:O:-_P A>W^I_D:
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MUZ#^+_ZU.W2_\\U_[Z_^M2I_JU^@IU AFZ7_ )YK_P!]?_6HW2_\\U_[Z_\
MK4^B@!FZ3_GFO_?7_P!:OFO7?^1BU//_ #]R_P#H9KZ7KYHU[_D8M4_Z^Y?_
M $,U[&4?'(\;.?@CZF?1117N'@!2-]T_2EI&^Z?I3 ^EM%:3^PM.PBX^S1_Q
M?[(]JO[I?^>:_P#?7_UJJ:)_R =._P"O6/\ ]!%7J^,G\3/MH?"AJER?F4 >
MQS3J**DHXX_\D\E_Z[O_ .E)KK9I##"\@C>0J,[$&2?85R1_Y)Y+_P!=W_\
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M]8__ $$5>KXR?Q,^VA\*&JS$\H5]R13J**DHXX_\D\E_Z[O_ .E)KL:XX_\
M)/)?^N[_ /I2:[&@ HK*O=2N[;4/*2V)A\OY7*GYW(.%!SQT'8]:9I6M&^G-
MO/&(I@OW=K#+#KUZ<8X//7TH V**:TBIC<<9IOG1_P!Z@ G_ ./>3_</\JX(
M=!7=331F"3YOX3_*N%'04 +1110 5>T;_D+V_P!3_(U1J]HY"ZK 2<#)_D:
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MC_&GT4 ,WM_SR;\Q_C7S7KO_ ",6I_\ 7W+_ .AFOI>OFC7O^1BU3_K[E_\
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M[ROF>CT445\T?3A6/8_\C3J__7&W_D];%8]C_P C3J__ %QM_P"3T ;%%%%
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MJ_M:OV7X_P"9R?V10[O\/\CP3_A6OBO_ *!J?^!$?^-(?AKXK(/_ !+4_P#
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M+JH '3[QYZG.!VJE8VVJ+'Y5_;ZI)I:7\C-'$DJ,T;1+Y>T;C)L#[^,Y!P2
M*[+[-KW_ $%-/_\  !__ ([1]FU[_H*:?_X /_\ ':!W.*N]/UV>[OP?MP+K
M((%,4C[[<PD+&S;]@.>O!;=SSG-265CJ$=E"L%KJT6E*MJMY;RL_G,P#>84&
M=V,F/.W@X.,\UV/V;7O^@II__@ __P =H^S:]_T%-/\ _ !__CM AOAJ.\CT
M6-;P3*WF2&)9VS(L6\^6&/J%V]>?7FM>LK[-KW_04T__ , '_P#CM'V;7O\
MH*:?_P" #_\ QV@#5HK*^S:]_P!!33__   ?_P".T?9M>_Z"FG_^ #__ !V@
M#E+O2M;FU*3Q((%W+> +;"-OM!M1F(J#NQR"TF,=<57EL_$+6[)=Q7SI%(+!
M2&=M\<:L1.51@6+L5&<C!7)XKL_LVO?]!33_ /P ?_X[1]FU[_H*:?\ ^ #_
M /QVE;2P[]3D+2#7#+H\\L>H2WIMH$D2X61!"X4AWWJVP\\LK Y['D50NUO[
M6/3_ +0FL1V\DMM%?KYCAY[@N=^SG)4C.=O!& *[[[-KW_04T_\ \ '_ /CM
M->RUN3;OU'36VD,N[3V.#ZC][UI];B.(U&'Q&+*%;>VU(>66EM,>8\BIY^51
MOF #",#._=D' &<U;U"TUP76J+IR7LDDHD8SR"2-D7S%.P?-L?*;@I7:1@=Z
MZ[[-KW_04T__ , '_P#CM'V;7O\ H*:?_P" #_\ QV@#BGTG6+B&4*^IM EK
M>/;H@E@V2[8_+ #.6/S!RN[U.!C%=1X9M+VRN]0BG%S]G(@>(SN7RYC'F8))
M_BZ^]7?LVO?]!33_ /P ?_X[1]FU[_H*:?\ ^ #_ /QV@#5HK*^S:]_T%-/_
M / !_P#X[1]FU[_H*:?_ . #_P#QV@!GBK_D5M1_ZXFEE_Y&^T_Z\)__ $9%
M4-]I.L:C92V=QJMF(91M?R[%@V/8F4X_*K5_IUW-J4%]97D,$D4+PE98#*&#
M%3GAEP?E_6@#3HK*^S:]_P!!33__   ?_P".T?9M>_Z"FG_^ #__ !V@#5HK
M*^S:]_T%-/\ _ !__CM'V;7O^@II_P#X /\ _': -6N"M/#6HS^%0E[-*?LY
MN9K>R$(5A(3($RV<GAL]LY%=1]FU[_H*:?\ ^ #_ /QVC[-KW_04T_\ \ '_
M /CM)JXT['#P6_B5=03[-;WL$GV:>#D-L#>4/*)8G9C<.-J_+_$<];-[:7;V
MUD+&VU:*Q!;[6EPL[N9=B[2 KA\#YLD';NP>>M=?]FU[_H*:?_X /_\ ':/L
MVO?]!33_ /P ?_X[5-W$<98:;J\.JRL(]2_M-[JW?[9(I2&2(0H)"RABN3A@
M1R<XQTK9\*P:C%J"F:.^C0686]-TS$276[EDR3QC=RO&"OIQM?9M>_Z"FG_^
M #__ !VC[-KW_04T_P#\ '_^.T@-6BLK[-KW_04T_P#\ '_^.T?9M>_Z"FG_
M /@ _P#\=H U:BNIFM[2:98GF:-"PC099R!T'N:S_LVO?]!33_\ P ?_ ..T
M?9M>_P"@II__ ( /_P#': .-B\.>(K'9-O0SZC#(+E[561X[C<9HW<[CD!MT
M? '##M5;4(_$TUI'>?9-1CO)\7@C0NYA8R#]T K!5(C49W9SD@#.<]W]FU[_
M *"FG_\ @ __ ,=H^S:]_P!!33__   ?_P".T+0#E+JUUE;W4Q9QW\QD$C-,
MWF1.J^8IV+EMCY3<%*@$8&><U0NEN%UA;9X=:^P2173V%M')() 0L(#,,[@-
MY;;NZ9["NZ^S:]_T%-/_ / !_P#X[339:V9!(=1TXNH(#?V>V0#U&?-]A0!R
M2Q>(_P"W[)KB.^612(;F2 ,RLIM\;@2=@'F= %)!Y)Q5=;/6Q:1PI%>&R2=/
MM$KI<!YQY;#)BW[QAMI)0X.1QP:[?[-KW_04T_\ \ '_ /CM'V;7O^@II_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img187335194_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $I G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_:MIW^806QDXW$=\8S[UI5PR5FT=L7S13.>E_Y*':_]@R3_ -&+70USTO\
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MB/-3/*\@8SDCMFL33O ^JI;6#W>J?\>UP\@TV262>V1#)N4!B5=F4<!FR/\
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M*/*C_P">:?\ ?(H ?D>M&1ZTSRH_^>:?]\BCRH_^>:?]\B@#!U0C_A,_#_\
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MX?SKJ_-7T?\ [X- A]%,\U?1_P#O@T>:OH__ 'P: 'T4SS5]'_[X-'FKZ/\
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MYGQ!+):RW,T2>:8U#$,3T YZ FL675[A"Y6R$BJ%8[)-VU3_ 'L#@XY^G7%
M'H274$KA$F1F/0!LU+7)>'KJ._N8Y(W'\0(5LE>#@'WQ74^5_P!-'_[ZH DH
MJ/RO^FC_ /?5'E?]-'_[ZH DHJ/RO^FC_P#?5'E?]-'_ .^J )**C\K_ *:/
M_P!]4>5_TT?_ +ZH DKG]:_X_E_W!_,UN>5_TT?_ +ZK"UA=MZHR3\@ZGW-
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MB@9Q_P 8L&_T<,2%V2Y(&>,K7-'PA$L$DLE^\.V-9-DL/SH""V& /7: <#)
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M\B6?^OF/^M>'5[A\56!\&'!!_P!)C[_6O#Z^CRO^!\SYK-OX_P @KZ.\(?\
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MTSR"D;[I^E+2-]T_2OJ3Y,^G[!$_LZV^1?\ 5)V]A5CRT_N+^50V'_(.M?\
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MUS_CVB_W_P"AK"H&!Z&I_'2J/A]J)VC/DIV_VEJ ]*L>.O\ DGNH_P#7%/\
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MM_SS?]/\:Y?X;_\ (AZ=]9/_ $8U=77R6)_C3]7^9]AA?X$/1?D,WM_SS?\
M3_&GT45@;A1110 4444 %%%% !115>_ADN-.NH(CB22)D4YQ@D$"@!RWEJRH
MRW,)5VV*0XPS>@]3[5*K*XRK C.,@US*Z/)=++.UM) V^,0QY48(502>HQD
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M5&ERS>MSQ,?@JU:KS06ECR"OH[PA_P B=H__ %Z1_P#H(KD/^%.Z=_T%;O\
M[X6N[TS3SI>EVMA%+OCMXEC5F7D@#&3BL\PQ=*O!*#ZFF782K0FW-;HS)?\
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MIG(]*=JVI:A#+>1VLH#1RVXC78#D,3N'XXQ[5MMI]D[NS6D!9QM<F,?,/?\
M2I#;P,Y<PQEB022HR2.A_"@#EGUR\N=1;R)I?L<DL?DB!$+E-DF2-P[LGY"K
M4-U>76GZ;<"^F3[1<&,[53)3YB-PVG#X SCH<UO)9VL90I;0J4QMVH!MQG&/
M3J?S-*+:!?NPQCYS)PH^\>K?7D\T 2 8 &2<=SWI:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *MU?PVCJL@?+#(VC-9NI:W-9WTL$8MSY<"RA)&.^
M4DL-J@=_E_6M6>T@N65IHPQ48')I5MHTNY+D ^9(BHW/&%)(X_X$: ,!O%#P
MS2&:&/RUDEC"#<&RN<<D;23C& >_L:U;6\N?MQL[R.)93%YJ-$Q*D9P0<]P<
M?7-,.A6;N_FF66)I'D\EWR@9LY('XG\ZL6NGQ6DC2AY9964)OE?<0HZ >U %
M%?$, CB>6&4+*"ZE%R%CWA0S?7(.!FKAORT,[0VEP\D:Y".GE[SZ MQ4$6AV
MZV_DR%G55:-<'&$+[@/PP!GVJ[%9VL&\PV\41<88H@4GZXHZ 8X\1.WV<^2B
M@PPRSEBV%\SL& P,8[]>.E+;>('EB\^2%%B/E.!\P8)(=H.".<''(XZ^E7?[
M%L]L2X?9&B(4W<2!/N[O7%,;0X-@1'?9N3(<[L1H=P0>@SB@#4KGE\9Z4WB?
M_A'P+C[;O*?ZOY,[=W7/I70UD#PQHRZW_;(LE_M#=N\[>V<XQTSCI[5I3=/7
MGOMI;N9U/::<EM];]B&3Q YU.[LK>*&1XXV\G,O,DJ@%D([<$<^QI+KQ'LA\
MRVBB?=#&4\R38#)(?E4GMP"3^%7UT>S180L9#0R^:LF?G+<Y)/4YR<_6FP:'
M86[ADB) E>4*S97<PP>#Z#@>E9F@@U=)M-L[N!0YNV1$7/ )ZY/L ?RI(-<M
M[@R!(;G* L!Y62X#%25 ]Q3VTF%8%CMR8]EQ]H3N%;.2 .P.3^=.CT>RC/,7
MF+M*;9/F!!;=T/N: *]UJMQ!+;.ENGD3.L860E96).#A<<!1R<]L]*KGQ#*]
MMJD]O9>:MH 8OW@'FKMSN]AU]21]:O?V/;+>I<Q-)$501B./ 3;G)&,<9[XZ
MT)HNGQ+=K%;I$+M DHC&WC&.,=.* )8+WS+Z2U90&$22J1W4Y'YY!_2K=58;
M(1WTMT6R6C6)!C[JC)_F3^E6J "BBB@ HHHH Y[5?^1S\/\ _7.Y_P#05KH:
MY[5?^1S\/_\ 7.Y_]!6NAK6I\,?3]61'>7K^B"BBBLBPHHHH **** .>E_Y*
M':_]@R3_ -&+70USTO\ R4.U_P"P9)_Z,6NAK6IM'T(AU]0HHHK(L**** "B
MBB@ HHHH **** "BBB@ HHHH *R$FNY[S9]J>-"9N%1>-C #J/0UKUD?VPR3
ME)85_P!;(BA>K*.!CWSP: )X+F6'1!>3.9G$/FG.%SQG' XJH=?*AR;=#L5C
M\LN0V 3E>.5^7D]LU-+JUM)&T3VT[QLI#\# X)(Z]@#3?[5M9H6C>!V0J1G:
M &Z?*.?0B@"*377:)T1$68'"E7W!A@_,..1\N/QIIUZ22X=$C01INRP?);IC
M&1]<U<MM4AFM)[L1D0Q %0!\Q&T'^9I?[6M0,-&ZON*E-HR&!QCTR: *_P#;
MCDD+;*0#EL2=!D<=/O<]/UK9K)BUN"6XV+$P3D'@9W<'L<8Q3O[=MBLC+',P
MC )(4=_QXQ[T :E%,,J+ 9B?D"[B?;&:STURV=$?RY@'W;<J.PR>_IS_ /7X
MH TZ*SGUF&)XTEAF1W4MM(!('8G![T6^J_:9IHUMI%\J(2'>1G)Y X/I@T :
M-%9-KK0EA@\V"3S9< !0,$G&0.>V14]WJT5G,T;Q3-MVC<H&,G.!U]C0!?HK
M+.M1J#F"9B,[BH7 QNXZ^BF@Z[;^<\2PS,R<G:%.1@G/7V/O0!J453EU."*S
M-T0[1[]BX ^8YQQ[9J :W"QPD$Y+<)P!O/' R>/O#KB@#3HK)AUQ'CBW6\ID
M< *% PS8!(&3VW#KBD?7XEB=TADEP"1@!1T. <GO@T :]%-1B\:L5*D@'![4
MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Y[5?^1S\/_\ 7.Y_]!6NAKE_$=TNG^)-
M$O98KAX(EN YAA:0@E5 X4&IO^$TTS_GAJ7_ ( 2_P#Q-=$J<Y1BXJ^GZLR4
MXQ;N_P"K(Z*BN=_X333/^>&I?^ $O_Q-'_"::9_SPU+_ , )?_B:CV%3^5E>
MTAW.BHKG?^$TTS_GAJ7_ ( 2_P#Q-'_"::9_SPU+_P  )?\ XFCV%3^5A[2'
M<Z*BN=_X333/^>&I?^ $O_Q-'_"::9_SPU+_ , )?_B:/85/Y6'M(=Q9?^2A
MVO\ V#)/_1BUT-<E8:C'J_CB*ZMH;I88]/>-FFMWC&XNIQ\P%=;3K)KE3["I
MN]VNX4445B:!1110 4444 %%%% !1110 4444 %%-HH =4+6ENX^:"-OO=5'
M\77\ZDHH C%I;*H401A0,8VCIC'\J0V5J4V&WBV^FT?Y[5+10!"UC;M:R6RQ
M*D4@VL$ '&,4];:!8DB$*"-#E5V\ ^M/HH KC3;(1F,6L.P]1L'/^<"G-8VK
M!@;>,AL9&T<XZ5-10 B1)&K*JX#')%1BRM5  MXL#I\H]<_SJ6B@"#^S[3RP
MBP(H (&T8(SUQ2P6-M;(JQ0HNU=F0.<5-10!$MG;(^]8(PW'(4=NE-:PMGNG
MN'B5Y&4+EAG 'I4]% #/LMOS^YCYSGY1WS_B?SIBV-LFXQ0I$YS\Z* 1GT_,
MU-10!$EI EHEKY8,*J%"GG@4-9VSJ5:",@]1M'M_@/RJ6B@"JNEV2^;_ *.A
M\PC=E1T&, >W J8VEL008(L'K\HY_P Y-244 *JJBA5 "@8 '84M-HH =13:
M* '44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '
M44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44V
FB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img187335194_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $0 1(# 2(  A$! Q$!_\0
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M.^$MJD66GG>I9 L@)<#.=O//0]/2CZUA[WL_P!8/$VMS1_$\H\17,-WKUU-
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M?\:/[4I_RL/['J_S+\3PRBO<_P#A#_#O_0(M_P!?\:/^$/\ #O\ T"+?]?\
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MUAKIU%KQ)$\IX@@0@X8H1WQQL].<\UOT[^S)_P#H(2?]^D_PH_LR?_H(2?\
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M5.*:VD>)_*N5>>>1Y'(8K-A6&YB&7]X#P-HQ\@QV;'/3_;K[_GVM_P#O\?\
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M-.N8\3:/?:CJ-K+:Q*ZI&4W;@-K>8C?/GJN%_A^;(K4^W7W_ #[6_P#W^/\
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MPW>[//6P8+*)B/EP[ $98?Q?>/6ERR[%\\>YC7'CMY80+&S3?)!YD;S.=JL
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M!"7_ +]I_A1_I?\ T$)?^_:?X5)11<.5$?\ I?\ T$)?^_:?X4?Z7_T$)O\
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M,^2\@9LOGJJ%7^Y]?J=G0K;4K2WG@U!HF1)"+<IC)3U./7KSSG.:+ARHT?\
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MZ;_&C^S[3_GB/^^F_P :.6/?^OO#FEV_K[ATOA32I[7[/(MPR;2A/VF0,4(
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M-W[MNH7)VG!^YP?^^:-.XM>PVBI/[+;_ )_[K_QS_P")H_LMO^?^Z_\ '/\
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MJJY3S(\A6.%.-O?(_,4O=[CN^P^&/R8(HM[/Y:!-[G+-@8R?>GU)_9;?\_\
M=?\ CG_Q-']EM_S_ -U_XY_\33NNXM>Q'14G]EM_S_W7_CG_ ,31_9;?\_\
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M&EPP7=I)>:BXMXQ)'(CKN"E0!C[QY&=N,@ \G-=CNNO^@?<?]])_\51NNO\
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MNO\ H'W'_?2?_%4;KK_H'W'_ 'TG_P 50D',245'NNO^@?<?]])_\51NNO\
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?8.>/<QH?]3'_ +H_E11!S!&0K8*C^$^E%=+.5;'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img187335194_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %P!$$# 2(  A$! Q$!_\0
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M(+DWVJ?_ )Z-1]JG_P">C5#119!<F^U3_P#/1J/M4_\ ST:H:*+(+DWVJ?\
MYZ-1]JG_ .>C5#119!<F^U3_ //1J/M4_P#ST:H:*+(+DWVJ?_GHU'VJ?_GH
MU0T4607)OM4__/1J/M4__/1JAHHL@N3?:I_^>C4?:I_^>C5#119!<F^U3_\
M/1J/M4__ #T:H:*+(+DWVJ?_ )Z-1]JG_P">C5#119!<F^U3_P#/1J/M4_\
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M?,NE OLFW."0X"%R<XX&T9R<"JVG>*-(U2Y2WM+F0R2(9(O,MY(EF4=6C9U
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M3K^#3X[TV=TRV/B*XO)+=(R9)(2\@#*O\6-X8 9R!QDXH3;M_76/^;$U:_\
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M4 -HIVQ_[C?E1L?^XWY4 -HIVQ_[C?E1L?\ N-^5 #:*=L?^XWY4;'_N-^5
M#:*=L?\ N-^5&Q_[C?E0 VBG;'_N-^5&Q_[C?E0 VBG;'_N-^5&Q_P"XWY4
M-HIVQ_[C?E1L?^XWY4 -K8MO^/:/Z5D['_N-^5:UL"+:,'TJ)[%1W,3QE_R
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M]FC[5<?\]Y?^^S4-%%D%V3?:KC_GO+_WV:/M5Q_SWE_[[-0T46079-]JN/\
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MJU_M*AW_ #(^I5>QA>9[T>9[UN_\(+J?_/V/_ ?_ .RH_P"$%U/_ )^Q_P"
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M?]I4._YA]2J]C"\SWH\SWK=_X034_P#G\_\ )?\ ^RH_X034_P#G\_\ )?\
M^RH_M*AW_,/J57L87F>]'F>];O\ P@FI_P#/Y_Y+_P#V5'_"":G_ ,_G_DO_
M /94?VE0[_F'U*KV,+S/>CS/>MW_ (034_\ G\_\E_\ [*D_X034_P#G\_\
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M?\9?\@.V_P"PKIO_ *6PUT%<_P",O^0';?\ 85TW_P!+8:Z"@ HHHH ****
M"N?\/?\ (<\6?]A6/_TBM:Z"N?\ #W_(<\6?]A6/_P!(K6@#H**** "L+Q;_
M ,@3_MJO]:W:PO%O_($_[:K_ %K2E\:(J? S=HHHK,L**** &E%/511L7^Z*
M=10 W8O]T4;%_NBG44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10 W8O]T4;%_N
MBG44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10 W8O]T4;%_NBG44 -V+_=%&Q?
M[HIU% #=B_W11L7^Z*=10 W8O]T4;%_NBG44 -V+_=%&Q?[HIU% #=B_W11L
M7^Z*=10 W8O]T4;%_NBG44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10 W8O]T4
M;%_NBG44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10 W8O]T4;%_NBG44 -V+_=
M%*% Z "EHH **** "BBB@ HHHH \XUW_ )#EW_UTJ_X=(%AJA:X:W&Q,RJ"2
MG)YXYJAKO_(<N_\ KI4%M?2VMK<VZ*A2X4*Y8'(QZ5Z?+S4TEY'#>T[FS/<6
M]Y:6VEI?27LLEP#Y\B$; >,#/-!L=,N9[S3[>VDBFMD8K.TA.\KUR.@KGD=H
MW5T8JRG((Z@UIS^(+N>&1/+MXWE7;)+''AW'H32=.2^$:FG\1H?9M)@73(I;
M)Y)+N--SB5AM)XSCN<]JK7FEV]KI=ZX4M+#=^4KDG[N!VZ5+/KX@MK!+58)F
MB@ /FQ$F-_4'CFL^UUJYMEG5DAG6=M[K.FX;O6I49[_UN.\=OZV-J&T@M&D\
MA-GF:49'Y)RQZGFDT[1;*>VACGM2DDL6[S9)]KD_[*#J/K65+K]W-*\K)#N:
MW-N<*1\I[]>M/B\27D0AQ#;,\2[!(T?S%?0G/3Z4G"I;3<:E#^OD:4#6S:1I
M,1MSEKC8KK*05(89;CU_2J\UI96POKZZA>Y NVA2+S2/?);K6?;:U<6ULD A
M@=$D\Q"Z$E#G/!S1%K=S%)<,8X)8[AS(\4J;DW>H&:?))-V%SQM_7F:L.CV#
MWRR&-S:S69G6,L=R'COWZ]ZHWMO8RZ)'?VENUNPF\IE,A;=QG/-0?VY=_;)+
MDB,L\1A"[3M53V !JO\ ;I?[-^P;4\KS?-S@[LXQ^54H3O=L3E'^O0JT445L
M9!1110 4444 %>D:%_R [3_KG7F]>D:%_P @.T_ZYURXKX4;X?XF9'CT>*SX
M6E_X0TQC5_,3&_9G9GYMOF?+GIU[9[XK<TO[=_9-G_:?E?;_ "4^T^5]SS,#
M=M]LYJW17"M+G6];&;XA_P"1:U7_ *\YO_0#53PBQ7P+H; 9(TZ @>O[L5LW
M%O%=6TMO,NZ*5"CKDC*D8(X]JQM.\(:5I3V[6<FJ(MN (HFU:Z>-0!@#8TA4
MC'8C%)+?SM^%_P#,'T\K_I_D<9%=7T7@W2O&(U._.J7=W;M-#)<NT#)+,L;0
MB'.Q0%; (4-E<DY)SL:#92^)7U'5;O5M3ANH=4FAA2UNWCCACADVJAB_U;9"
MY8LK$[CTXQN1>$-#AU(7R6;>8)C<+&9Y#"DIZR+"6\M7Y)W!0<DG.2:+KPAH
M=Y?RWDUI(7F=9)HEN95AF=<8:2(,$<\#EE/0>E-:?UMM_D_O]0>O]>O^:."U
MS5]0#/K.GR:N_E:RD'V^2\\FT\OSUB,*6X=O,QDJ69%R0S!N *EU*,3>.;F(
MLZA_$=LNY&*L,Z>W((Z'WKL+KP'X<O6G^T6,CI/*9FB^US"-92<F1$#[4?/.
MY0#R>>35]O#>E->F]-INN?M"7>\ROS*D?EJW7^YQZ=\9I):*_P#6W^0[ZNW5
M/];?F<MX2U74=6U2PT^XNY'DT6UEBU$[SF:<2&%"W/.5C=^?[P/I6UXQO#!:
M6%JLE^7O+M8A;Z>0L]P K,460NGE\+DMN!PI Y-6?#VCR:<^I7MU#;Q7VI7/
MVB=+=RZ+A510&*J6X7.<#DFKFK:-8ZW!%#?1.PBD$L3Q3/%)&X!&Y70AE."1
MP>A(IO6U_G^;_P A+1NWR_0\VMM;UJST;Q!8F>ZLVCUBTLXFGNOM4MG%/Y6[
M,CYRP#GJ6"DX!( -'B/PY=6OC6&WT75=26Z?1;J6V$][+,R2I)"PP[L6VO@*
M5SC /')KO+7P?H%G%?Q1:>ICU! EXDDCR"? (W.&)RQR<M]X]R:33?!^B:5J
MBZI;6\[7ZQ& 7%Q>33OY9P=N9';CY1@=N<8R<G]?A;\]0_K\;_\  .,N/%,F
MNF\UJSU"]MM-AL[6TB2U^9Y+FX9'9%4L%\P*T:!B?E+D]C4 U#5+!O&EDO\
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M-6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_I%:UT%<_P"'O^0YXL_["L?_ *16M(9T%%%% !6%XM_Y G_;5?ZUNUA>+?\
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MHHH **** "BBB@ HHHH **** "BBB@#G_&7_ " [;_L*Z;_Z6PUT%<_XR_Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ><:[_R'+O\ ZZ5G5LZSJ%W%K%TB7$BJKX !Z51_M2^_Y^I?^^J]
M2%^5'!*W,RI15O\ M2^_Y^I?^^J/[4OO^?J7_OJKU)T*E%6_[4OO^?J7_OJC
M^U+[_GZE_P"^J-0T*E%6_P"U+[_GZE_[ZH_M2^_Y^I?^^J-0T*E%6_[4OO\
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MVBS_ +[_ /?9_P :?UZ/8/82[/[C6HK)^T6?]]_^^S_C1]IL_P"^_P#WV?\
M&E]?CV#V$NS^XUJ*ROM-G_??_OL_XT?:;/\ OO\ ]]G_ !H^O1[!["79_<:M
M%97VFS_OO_WV?\:/M-G_ 'W_ .^S_C3^O1[![&79_<:M%97VFS_OO_WV?\:/
MM-G_ 'W_ .^S_C2^OQ[!["79_<:M%97VFS_OO_WV?\:/M-G_ 'W_ .^S_C1]
M?CV#V$NS^XU:*ROM-G_??_OL_P"-'VFS_OO_ -]G_&CZ_'L'L)=G]QJT5E?:
M;/\ OO\ ]]G_ !H^TV?]]_\ OL_XT_KT>P>PEV?W&K165]IL_P"^_P#WV?\
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MK6N@KG_#W_(<\6?]A6/_ -(K6D4=!1110 5A>+?^0)_VU7^M;M87BW_D"?\
M;5?ZUI2^-$5/@9NT445F6%(WW#]*6D;[A^E '"1G_3;O_KNU6LU34XOKO_KN
MU6-U?-UW^]EZL]ZFOW<?1$F:,U'NHW5E<NQ)FC-1[J-U%PL/S1FF;J-U%PL2
M9HS4>ZC=1<+$F:,U'NHW47"Q)FC-1[J-U%PL29HS4>ZC=1<+$F:,U'NHW47"
MQ)FC-1[J-U%PL29HS4>ZC=1<+$F:,U'NHW47"Q)FC-1[J-U%PL29HS4>ZC=1
M<+$F:,U'NHW47"Q)FC-1[J-U%PL29HS4>ZC=1<+$F:,U'NHW47"Q)FC-1[J-
MU%PL29HS4>ZC=1<+$F:57*FHMU&ZBX<I=M[F2UF\^#DG_61YX<?XUT=M<Q7<
M EA;*GJ.X/H?>N15RIJQ;W4EK-Y\')/WX\\./\?>N["8OV;Y9;?D<>(PW/K'
M<ZRBH;6ZBO(!-"V5/!!ZJ?0^]35[2::NCRVFG9A1113$><:[_P AR[_ZZ5G5
MHZ[_ ,AR[_ZZ5G5ZT/A1Y\OB844451(4444 %%%% !1110 4444 %%%% !11
M10 4444 %=I8?\@RT_ZY"N+KM+#_ )!EI_UR%85]D;4=V8GC?2-:UOPW)9Z!
MJATZ^,B,)O,:/*@\KN7YE_#TQWK8TV"YMM+M(+RX^TW4<*)-/C'F.  6Q[GF
MK5%<JTOYF[UL9^N_\B]J?_7I+_Z :Y;2-$UG6? ^G6%WJ]FFFW-C$DB6]@RS
M&(H,J)&E8 D<$[.YP!V[>2-)8VCD171P596&00>H(I(H8[>%(88TCBC4*B(H
M"J!P  .@I):OSM^%_P#,+[?/]#SG4=*L6_X6!=O:Q//;6Y2W=U#&$?8U!V$_
M=R.#CJ ,]*E31M.UCQA<)J5I%=Q1Z#;%8IEW("6D^;:>-P['J,G'6N\:QLW6
MY#6L#"Z&+@&,'SAC;\_][CCGMQ2I9VL<QF2VA65HQ$7$8#%!G"Y]!D\>])QO
M_7DU^I7-II_6J_R/,-%M;;3]&\"ZO%'B_N9@ES=_>FF0PR$JS'EA\JX!Z;1C
MI45D1'J_@_5(K:QLSJ-R<3^?YM[>HT;DF9PJCKLROS#)&", 'U%=-L4BMHDL
MK=8[4[K=!$H$)P1E!CY>"1QZU6C\.:'"\CQZ-IR-)(LKLMJ@+.IR&/')!)(/
M7FJ^U?SO^6A+VMY6_,X>'1()O#GB#5K:UC;5[;5+JX@G* R9BG+B,-U"G;C'
M3YCZUT_A"8:I%?Z\I+1ZE<%H"1C]R@V)^!PS?\"K7N;%UL)X-,:VLI96+%S;
M[UW,<LQ4%<L>><]>3FI-/LH=-TZVL;=<0V\2Q(#Z 8%**LK>2_X+_!#D[N_F
M_P#@%">Y\2+/(+?2=)DA#$(\FIR(S+V)46Y /MD_6M"T>[>T5KZ&&&X.=T<$
MQE0<\88JI/'L*L446TL(\FM'\0VOPM@GAN[0Z2WF+=+%9,;F&W,C"1T8R%68
M#)^Z.,]<<Z-W9"_\4VNFP:;I>JZ5!I$36$&H712)@20TB@1N'8 (,X& 1_>K
MT*&SMK>U%K#;PQ6X! B1 J8/48''.352?P_HMU90V5QI%A+:0?ZF"2V1HX_]
MU2,#\*5OZ^3_ ,QW_K[CAM-M?M5]H&DZY<65_IA2\\F..X-S!)(KKY<3,P'F
M,B%P 1U4GJ,UGZ9'86.LO%8NGV*+Q8D:;6W*G^BE=H/8!CM [8 KTZ?2=-NM
M.33[C3[26R0*%MI(5:-0O0!2,#':HQH.CK8RV(TFQ%I+M,EN+=/+?  &5Q@X
M"KCZ#TIK1W_IZI_I8+Z6_K9K]3S_ %&:&[\2:E;R2AM-N-?MK>]P?D8"V'[M
MSZ&0*I'?H>N*OZ_X?\,0:IHEM:Z?IV?[703VRJI6/=#)@>7T0-M4X &XJ#R>
M:[./1=*BLY;./3+)+690LL*P*$<   ,N,$  #GL*C7P]HBZ?]@71]/%EO\S[
M.+9/+W_WMN,9]Z$K6^7X6_R!N_W6_/\ S.&)#:.MM.0--N?$]S#>Y;:IC,LF
M%8_W6?8I'?..]5_$5I;6D^OZ1IJBWTP#36D@MOD2"9KD [ OW&*!2<8['OFO
M2CIUDUK-:FSMS;SEC+"8EV2%N6+#&#GOGK4<&C:7;6/V&#3;.*TWA_L\<"K'
MN!!!V@8SD Y]12C&UO*WY)?I<&];_P!;W_X!S^C:?::/X\U&RTVWCM+1].@G
M:"%0B>9YDBEMHXR0 ">^*L:K_P C[H'_ %YWO_M&NA%O +EKD0QBX9!&9=HW
M%020N>N,DG'N:1[:"2XCN'AC::,,J2%064-C(!Z@' S]!0U=6]?QO_F%];_U
ML>8^']*L]/T7P-J5K"L5]<7*Q3W _P!9*C12$HS=2HVK@'@8&.E=7XQVR3:%
M:W9QI=Q?B.\!.$<>6Y1']59PH(/!X'>M]=/LDAMX4L[=8K9@T"")0(B 0"HQ
M\IP2./4U)<VT%Y;26UU!'/!(-KQ2H&5AZ$'@BJ_SO^0-W=_+_/\ S/)M7M-+
MTK6?%,.FK##;0II;RQ0X"0-]IRP"CA1C#$#U)[UH^-7ANM>UB!902MGIL<@1
ML%";PGMT."#^-=[;:#H]G!+!:Z38P0RQ^5)'%;HJNG/RD <CYFX]SZTD'A_1
M;6(Q6^D6$49"C9';(HP&W#@#LWS#WYI):KR'S;^=OT_R..U[3=.;4[C2K71]
M*-K8:<)66_(2UM%=G)DCA5/F?Y22=R= ,C)-4?#UO::E<> [V\A@NKIM*G/G
MS('<LGE[3N/.5RV/3)KT.[TC3-0N8+F]TZTN9X#F&6:!7:,YS\I(R.1GBF_V
M)I(6!1I=EMMY#+"/LZ8B<G)9>."3SD<TN73^O/\ S$W_ %]W^1P&CPPWVD^!
MM.U*..72I[21GAE_U<TZA3&K \-QO(4]USVJ&6SMKG45TE07T:'Q*D4$(/[M
M1]F8R1+_ + <L"O3DC&.*](ETC39].&G3:?:26*@ 6SPJ8@!R/E(QQ3H]-L(
M8+>"*RMDAMFW01K$H6(X(RHQ\IP3T]33MK?S_5/]+ W_ %\G_F8'A.VAT_6?
M$NGVD:PV<%Y&88(QM2+="C,%4< $DG ]:AU&SM-7\?"PUFW@N;./3Q-:6]PH
M:-Y-Y$C;3PS ;!G' ;WKJX[>"*666.&-))B&E=5 +D# +'OP .>PJ#4-*T[5
MH5AU*PM;V)&W*ES"L@4],@,#S1;;R_RL%]SS?P]96=_X@\/3W%O#=I$=16TN
M)T$C-%%,GDD,<D[03M.?I79>,'TL:7;QZLT\,$ETB)>0N$-I+SLD+D_+@\9Y
M&2 1@FML6=L)(9!;PAX$*1-L&8U.,A3V!P.!Z"GS0Q7$$D$\:2Q2*4>-U#*R
MG@@@]11;1+^O^'"^IR_VO5M%\1Z=IDVJ+JMOJ+R!5FB1+F +'NWYCVJR9&/N
M @N.3TI?!-W;V7@V.WNIXX9M,#Q7WF/CRG4DL6)Z _>R>H.:V].T32=(,ATS
M2[*R,F YMK=(]V.F=H&>II+O0M(O[R.\O-*L;FZCQLFFMT=UP<C#$9&#S0(\
MT32I=3@T&U8M$+]]5FM=P(,:/EHC@].JL*FNM0'B2XTS7< +%J-A9HG]R3(>
M8?\ ?3*I_P!RO4'MH)9XIY((WFASY4C("R9&#@]1D=<5"NEZ>L2Q+8VPC6;S
MP@A7 DSG?C'WL\YZYH2LT^UOP?\ D#=TUWO^/_!+=%%%, HHHH **** "BBB
M@ HHHH **** "BBB@ K8MO\ CVC^E8];%M_Q[1_2HGL5'<Q/&7_(#MO^PKIO
M_I;#705S_C+_ ) =M_V%=-_]+8:Z"LRPKD/%M_I.IZ/KFE:G8ZM+;6?D-/\
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M1NJ#=1NKFYCIY2?=2K)M-5]U,DG$:Y)HY@Y+FI;7DEI/]H@(.?\ 61D\./\
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M<5\*-\/\3-"BBBN$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_8%G_<%']@6?]P4?V/1[L/[5J]D>;?;W_Y]KC_OV:/M[_\ /M<?]^S7I/\
M8%G_ '!1_8%G_<%']CT>[#^U:O9'FWV]_P#GVN/^_9J/R+W5[I+:WBEB5OOR
M.N-H]O>O3?[ L_[@JQ;:7;6K;D09JX931C)-NY,\SJRBTE8H:!H%OI-HB)&
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MW!MK#MD$@_A5::_UU?Z6%_7X+];E%O&5E8V(G:/4[TS:M-IT48BC+^:I?Y0
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M(H+9  .3S@<&K\GCG3RNE"SLM0OIM368V\,$2APT1 D1][*$8$G.X@94C.<
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M/!D$J^'([RX!%QJ,CWT@88(\P[E4_1=J_A26JOY+\4G_ )_<$M&UYO\ -_\
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M HHHH **** "BBB@ HHHH **** "BBB@#G_&7_(#MO\ L*Z;_P"EL-=!7/\
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M HHHH **** "BBB@ HHHH **** "O0]&N(8M&M%9QGRP>AKSRNTL/^09:?\
M7(5SXE7BC:B[-F[]LM_^>GZ&C[9;_P#/3]#6317'R(Z>9FM]LM_^>GZ&C[9;
M_P#/3]#6%>7<=C:O<2K,R)C(AA>5^N.%0%C^ K%C\::/-)+'$FJN\+;)%71[
MLE&P#@CRN#@@\^M'*@YF=O\ ;+?_ )Z?H:/MEO\ \]/T-9"L'0,,X(R,@@_D
M:6GR(.9FM]LM_P#GI^AH^V6__/3]#634%W>6]C;M<74JQ1*0"S>I( 'U)('X
MTN1!S,W?MEO_ ,]/T-'VRW_YZ?H:R:*.1!S,UOMEO_ST_0T?;+?_ )Z?H:R:
M*.1!S,UOMEO_ ,]/T-'VRW_YZ?H:R:*.1!S,UOMEO_ST_0T?;+?_ )Z?H:PH
MKRWGN)[>*57EMRHE4?P$C(!]\$'\14]'(@YF:WVRW_YZ?H:/MEO_ ,]/T-<Y
MJFKV6CV\<U[(ZK)((HUCB>5W<YPJJ@+$\'H.U3RW=O!9M=SRK!;HGF/),=@1
M<9RV[&/QHY5N',S<^V6__/3]#1]LM_\ GI^AKD+/Q3I-[>0VB27,4TX)A%U9
MS6XEQR0AD10QQS@$G'/2I+_Q'IFFW?V6:2>2X";VBM;66X=%[%A&K%0>Q.,X
M..E#BD',SJ_MEO\ \]/T-'VRW_YZ?H:Y&]\4Z)I^D6^JW&HQ"PN'6.*= 75F
M;.!\H/H?ICFK&L:WIV@:>;[4[D6]MO5-^UFRS' &%!)HY$',SIOMEO\ \]/T
M-'VRW_YZ?H:R1R,T4<B#F9K?;+?_ )Z?H:/MEO\ \]/T-9-%'(@YF:WVRW_Y
MZ?H:/MEO_P ]/T-9-%'(@YF:WVRW_P">GZ&C[9;_ //3]#6311R(.9FM]LM_
M^>GZ&C[9;_\ /3]#6311R(.9FM]LM_\ GI^AH^V6_P#ST_0UDT4<B#F9K?;+
M?_GI^AH^V6__ #T_0UDT4<B#F9K?;+?_ )Z?H:/MEO\ \]/T-9-%'(@YF:WV
MRW_YZ?H:/MEO_P ]/T-9-%'(@YF:WVRW_P">GZ&C[9;_ //3]#6311R(.9FM
M]LM_^>GZ&C[9;_\ /3]#6311R(.9FM]LM_\ GI^AH^V6_P#ST_0UDT4<B#F9
MK?;+?_GI^AH^V6__ #T_0UDT4<B#F9K?;+?_ )Z?H:/MEO\ \]/T-9-%'(@Y
MF:WVRW_YZ?H:/MEO_P ]/T-9-%'(@YF:WVRW_P">GZ&IE8.H93D'I6'6Q;?\
M>T?TI2BD-.YB>,O^0';?]A73?_2V&N@KG_&7_(#MO^PKIO\ Z6PUT%04%%%%
M !1110 5S_A[_D.>+/\ L*Q_^D5K705S_A[_ )#GBS_L*Q_^D5K0!T%%%% !
M6#XL_P"0=;?]?*_R:MZL'Q9_R#K;_KY7^35I2^-$5/A9O4445F6%%%!Z&@"I
M;W@N99D4A3&Y7!'7%6<2?WE_+_Z]<_9L5N[D@X(G:M7[3)_>_2G85RWB3^\O
MY?\ UZ,2?WE_+_Z]5/M,G][]*/M,G][]*+!<MXD_O+^7_P!>C$G]Y?R_^O53
M[3)_>_2C[1)_>_2BP7+>)/[R_E_]>C$G]Y?R_P#KU4^T2?WOTH^T2?WOTHL%
MRWB3^\OY?_7HQ)_>7\O_ *]5/M$G][]*/M$G][]*+!<MXD_O+^7_ ->DQ)ZK
M^7_UZJ_:)/[WZ4?:)/[WZ46"Y:Q)ZK^7_P!>C$GJOY?_ %ZJ_:9/[WZ4?:9/
M[WZ46"Y:Q)ZK^7_UZ,2>J_E_]>JOVF3^]^E'VF3^]^E%@N6L2>J_E_\ 7HQ)
MZK^7_P!>JOVF3^]^E'VF3^]^E%@N6L2>J_E_]>C$GJOY?_7JK]ID_O?I1]ID
M_O?I18+EO$G]Y?R_^O1A_P"\O_?/_P!>JGVF3^]^E'VF3^]^E%@N6\/_ 'E_
M[Y_^O1A_[R_]\_\ UZJ?:9/[WZ4?:9/[WZ46"Y;P_P#>7_OG_P"O1A_[R_\
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M_4TE&RM_6R2_5_<-N[O_ %NV_P!#67[H^E+0.!BBJ)6P4444#"BBB@ HHHH
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MK,/]G_9/[-N?(SYWF>9RPS]T8^[TYZUU>^CS GW4;J@WTN^@";=1NJ#?2[Z
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M>$-06:XO(IK7[7'=V]W:!RVPF.!8F5\#(!^;!&<9!P>E)7N[^7YO]"M+??\
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M3/'D%MI&N:7INF:<)EEDGBD4G XZ"1R>">,#GO5WR4M?V@M.@CSLBTL(N>N
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MNE_\_6N?^#V]_P#CU=!10!S_ /PANE_\_6N?^#V]_P#CU'_"&Z7_ ,_6N?\
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M23^)KL** .._X0B#_)-'_"$0?Y)KL:* .._X0>#_ "QH_P"$(@]_^^C78T4
M<=_PA$'O_P!]&C_A"(/?_OHUV-% ''?\(1!ZG_OHT?\ "$0^I_[Z-=C10!QW
M_"$0^I_[Z-'_  A$/J?^^C78T4 <=_PA$/J?^^C1_P (1">Y_P"^C_C78T4
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M$ND:DQCNM9O[L1^9)-<)%,P0Y4(RJJ(5Y9<!06ZGDFNY_LY/^>C?E1_9R?\
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M^SD_YZ-^56XT$<:H#G Q4R:944T.HHHJ"@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img187335194_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ G # 2(  A$! Q$!_\0
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M57['"7M;\^U_R)^L8NU_\N]MO4F_X3SQ1_T%(?\ P$7_ !H_X3SQ1_T%(?\
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M5UH4'VL'^UD5PWE_ZK<1[\]?:JC0P[;4H6:_RO\ D1+$UTE*$KKO\[?F7_\
MA//%'_04A_\  1?\:/\ A//%'_04A_\  1?\:BM/"7VFZUJ*75(K>/2G"R2O
M&<,.<G@\=.G-0V6@6%VTCOXAMH;8SB"W=HB7G;UV9RH[9-/V&%[?@^H?6,5W
M_%=-RW_PGOBC_H*0?^ B_P"-'_">^*/^@I!_X"+_ (U?T'PQ9V]_K]GJUQ"T
M]E;G:=C,$4KGS??&>G6LB?3Y7\)V36IMKA9M0:"%D@VRR'D EB>A],<5*HX5
MRLH]N_74IU\3&-V^_;H6/^$\\4?]!2'_ ,!%_P :/^$\\4?]!2'_ ,!%_P :
M1_!G[V:QM]:M9]7@C+R62HPZ#) ;H3[4RT\)Q3:=IE[=ZW!:+J'RQH\3,V_.
M O!_4XQ3]CA+7M^8O;XN]O\ +^NI)_PGGBC_ *"D/_@(O^-'_">>*/\ H*0_
M^ B_XUSNKV<VC:M<Z?.RM) VTLO0\9!_(U2\_P!ZVC@:$DFHZ,PEF%:+<9/5
M'7_\)YXH_P"@I#_X"+_C1_PGGBC_ *"D/_@(O^-<AY_O1Y_O5?4*/\I/]I5?
MYCK_ /A//%'_ $%(?_ 1?\:Z_P"'_B35=<N]3AU*XCG$"1/&4B"$;BX.<=?N
MBO(?/]Z]$^$3[]1UL_\ 3*W_ )RUQX["4Z=%RBK,[,#C*E6LH292U'QUXDCU
M:_BAU"".**ZFB1/LJMA5=E')// JM_PGOB?_ *"D'_@(O^-<YJ\VW7]6'I?W
M'_HUJ[:=K'PH-.TNWT.'5=5NHEEE:8;LD_PJ,'T-4L-1C3@^2[:_34EXJK*I
M-<UE%_K9&;_PGOBC_H*0_P#@(O\ C1_PGGBC_H*0_P#@(O\ C4FK:-#J7B;3
M;6TTZZT<7RD.L\7RJX&3L&>1^549?#EK'JW]GKK]H6A#M=RLA18-O8$GYR?0
M54:.%:5X]+]?T%+$8E-V?E_5RU_PGGBC_H*0_P#@(O\ C1_PGOBC_H*0?^ B
M_P"-5;WPK-')I7]G7T5_!J;%()0ACY'7(/0?X5T&B^'=.LGUM#J5GJ4MO9R+
M)%Y1S#(.XSD'H1D5,Z6%C'F4;_?Z?+YCA6Q4I<M[?=_3^1D_\)YXH_Z"D/\
MX"+_ (T?\)YXH_Z"D/\ X"+_ (U!I_A(W-E8O=:K!9W5^NZTMW1F,@[$D?=S
M6#]DO#JO]F"$F\\WR?+']_.*UCA<-)M);&4L9B8I-O<Z7_A/?%'_ $%(/_ 1
M?\:/^$\\4?\ 04A_\!%_QJYXIT[3=,\%62V0CEFBNS#-<A1EW ;<,^F>/PK,
M\'V5C<IJ6JZG$9[33H?,,(/WV.< _E6<:.'=-U.31&DL1B(U%3YM7_7X$W_"
M>^)_^@I!_P" B_XT?\)[XG_Z"D'_ ("+_C6CI=[I7C5;S36T6VL+M(&EMIK;
MC!'8\#/:IKC3;2X^&-J\5K"-0^S^>)%0!VVN W/4\-4.E0BU&5.SNE]_7\"X
MUJTUS0G=6;^ZVGXF1_PGOB?_ *"D'_@(O^-+_P )[XH_Z"D'_@(O^-;/C#3[
M#3O!,*6]K"ES;3Q02S*@#,VS+9/7O7/>!8X+S5[Q+B&.95L97 D4, 1CGGO5
M0HX>5)U5#1$RQ%>-6-)RU98_X3SQ1_T%(?\ P$7_ !H_X3SQ1_T%(?\ P$7_
M !JKIWAJ&YT&TU>\UF"RMYY3%B2(L0P.!C'7./;%./@^\7Q%=:5)=0QQ6L7G
MS7; [%CQG./7V]JOV&$3:MMZ]"%B,4TFNOIU+'_">^*/^@I!_P" B_XT?\)[
MXH_Z"D'_ ("+_C5>/1H+?6='-CJ]CJ$5W.%7,9^4Y_CC)SBI7\.-=ZGK5S>7
MUK86-E<&.2=82$+9Z(@/Z9[TO885?9_/O;8:Q&)>S_+M?<?_ ,)[XH_Z"D'_
M ("+_C1_PGGBC_H*0_\ @(O^-7M9\/K+I/ABPTTVL]Q=&0?:8EP)1P=Q.,\"
ML75/#BV>FSWUCJD.H16L@BNA'&4,3'COU&>]*%'"RM[N_KWL.=?$QZWTOT[7
M^?R+G_">>*/^@I#_ . B_P"-'_">>*/^@I#_ . B_P"-3GP(O]H)I_\ ;UL+
MV:'S8(#$V7&,G/.!6=8>&5DT^.]U35H--BGE,, D0N9&!P3QT&>]-4<(U=+\
MP=?%IV?Z?TBU_P )YXH_Z"D/_@(O^-'_  GGBC_H*0_^ B_XU3M/#)EFU%[G
M5+6"PL&"27B9D5F/0*!UJAKNE3:'=11M,EQ!/&)H)X^!(A[X['VJXX;"RERI
M:_,B6+Q,8\S>GR]#T+P'XIUC6M=NK/4;J*>)+42KMA"$-NQV//%>A5X_\*'W
M^*[X_P#3B/\ T97L%>-C*:IUY1BM%_D>Q@ZCJ4(SEN_\PHHHKF.D\&^))QX_
MO_\ KC#_ .@URNZO4_$7@2Z\5^,M5N[?4H;58A#$5D@+DG8#G(8>M4/^%-ZC
M_P!!VT_\ V_^+KWL+CZ%.C&$GJO(^>Q>75ZM>4XK1^:/.]U&ZO1/^%-ZC_T'
M;3_P#;_XNC_A3>H_]!VT_P# -O\ XNNC^T\/W_!G/_96)[?BCD/#NH:?8:LL
MFJV2WEDZE)$*Y*Y_B7W%=2VO>&=$T34K71KS4;V2]B,*PW&?+B![X('K[U-_
MPIO4?^@[:?\ @&W_ ,71_P *;U'_ *#MI_X!M_\ %UA4Q>%J.[D_QL=%+!XN
MDK1BO72Y3CUSPWX@T6QM?$3W=K>6,?E)<0+N$B=@>#_*I_\ A,=(BUW0K>R2
M6#1=+9CO=<NY((W8'/\ ^LU+_P *;U'_ *#MI_X!M_\ %T?\*;U'_H.VG_@&
MW_Q=1]8P;^T[:Z:V5_D6L/C$OA5]-=+NWS(I_&=@_AFYLED8W+Z@74F,_P"H
M,OF=?Z5SGC#5+75_%-Y?63E[>7;L8J5)PH!X/N*ZC_A3>H_]!VT_\ V_^+H_
MX4WJ/_0=M/\ P#;_ .+JJ>*P=.7-%OKT[V\O(FKA<95CRRBNG7M?S\RI#XGT
MM-1\)3&9]FFP%+D^6?E..WK^%4K77M/BLO%L3RL&U$G[-\A^;YF//IP1UK8_
MX4WJ/_0=M/\ P#;_ .+H_P"%-ZC_ -!VT_\  -O_ (NCZSA/YG_3OV[C^JXS
M^5??Y6[]BG=ZOX7\0QZ?>:Q<WD%Q:VP@EMH8L^;MZ%6Z#D]ZI0>(+"T\(?8K
M=I/M4>J+=11.,_NQTRPXS6S_ ,*;U'_H.VG_ (!M_P#%T?\ "F]1_P"@[:?^
M ;?_ !="Q6$2MS.W;^D)X7%O7E5[6O\ *W<FM/$7A*/Q;_PDC7EZD\ZG?;&
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M%-,YCM()HKQ3$2!N''UY':E_X4WJ/_0=M/\ P#;_ .+H_P"%-ZC_ -!VT_\
M -O_ (NH=?!R7O2;\_DUV\S18?&1?NQ27;YI]_(R]:\3V>I^'-1MA(WVJ?56
MN44H<>5C Y_+BJ/@W6+/1]3NY[V1DCDLY(E*J6RQQ@<5T7_"F]1_Z#MI_P"
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M6,)I:3T_2_EYB^K8S6\5KO\ AY^17T'Q7I.DC5-.L[F]T^SGD$EK=&-970@
M$,N.0<5A^+=:75[^$QZE<W\4,>T2SPK&<GK@*!Q]:Z3_ (4WJ/\ T';3_P
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M^%'_  KW1?[]W_W\'^%%\O\ ,+9QWB1_\+%TC_GWO/\ OA?_ (JC_A8ND?\
M/O>?]\+_ /%5)_PKW1?[]W_W\'^%'_"O=%_OW?\ W\'^%%\O\PMG'>)'_P +
M%TC_ )][S_OA?_BJ/^%BZ1_S[WG_ 'PO_P 54G_"O=%_OW?_ '\'^%'_  KW
M1?[]W_W\'^%%\O\ ,+9QWB1_\+%TC_GWO/\ OA?_ (JC_A8ND?\ /O>?]\+_
M /%5)_PKW1?[]W_W\'^%'_"O=%_OW?\ W\'^%%\O\PMG'>)'_P +%TC_ )][
MS_OA?_BJ/^%BZ1_S[WG_ 'PO_P 54G_"O=%_OW?_ '\'^%'_  KW1?[]W_W\
M'^%%\O\ ,+9QWB1_\+%TC_GWO/\ OA?_ (JC_A8ND?\ /O>?]\+_ /%5)_PK
MW1?[]W_W\'^%'_"O=%_OW?\ W\'^%%\O\PMG'>)'_P +%TC_ )][S_OA?_BJ
M/^%BZ1_S[WG_ 'PO_P 54G_"O=%_OW?_ '\'^%'_  KW1?[]W_W\'^%%\O\
M,+9QWB1_\+%TC_GWO/\ OA?_ (JC_A8ND?\ /O>?]\+_ /%5)_PKW1?[]W_W
M\'^%'_"O=%_OW?\ W\'^%%\O\PMG'>)'_P +%TC_ )][S_OA?_BJM:=XVTW4
M]0ALH8;I9)3A2ZJ!TSZ^U0_\*]T7^_=_]_!_A5G3_!>EZ;?Q7D#7!EB.5W2
MCICT]ZF;P/*^6]S2FLUYUSN-KZ^@Y?\ D+^(O^O>'_T!ZELK^+2_!EC>SJ[1
MQ6<)8(,G[JC^M1+_ ,A?Q%_U[P_^@/4UC8PZGX.L;.<L(I;.$-M.#]U3_2O/
MAR\RYMCUZG/R/DWMIZF5_P +%TC_ )][S_OA?_BJ/^%BZ1_S[WG_ 'PO_P 5
M4G_"O=%_OW?_ '\'^%'_  KW1?[]W_W\'^%>E?+_ #/$MG'>)'_PL72/^?>\
M_P"^%_\ BJ/^%BZ1_P ^]Y_WPO\ \54G_"O=%_OW?_?P?X4?\*]T7^_=_P#?
MP?X47R_S"V<=XD?_  L72/\ GWO/^^%_^*H_X6+I'_/O>?\ ?"__ !52?\*]
MT7^_=_\ ?P?X4?\ "O=%_OW?_?P?X47R_P PMG'>)'_PL72/^?>\_P"^%_\
MBJ/^%BZ1_P ^]Y_WPO\ \54G_"O=%_OW?_?P?X4?\*]T7^_=_P#?P?X47R_S
M"V<=XD?_  L72/\ GWO/^^%_^*H_X6+I'_/O>?\ ?"__ !52?\*]T7^_=_\
M?P?X4?\ "O=%_OW?_?P?X47R_P PMG'>)'_PL72/^?>\_P"^%_\ BJ/^%BZ1
M_P ^]Y_WPO\ \54G_"O=%_OW?_?P?X4?\*]T7^_=_P#?P?X47R_S"V<=XD?_
M  L72/\ GWO/^^%_^*H_X6+I'_/O>?\ ?"__ !52?\*]T7^_=_\ ?P?X4?\
M"O=%_OW?_?P?X47R_P PMG'>)'_PL72/^?>\_P"^%_\ BJ/^%BZ1_P ^]Y_W
MPO\ \54G_"O=%_OW?_?P?X4?\*]T7^_=_P#?P?X47R_S"V<=XD?_  L72/\
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MY][S_OA?_BJ/^%BZ1_S[WG_?"_\ Q52?\*]T7^_=_P#?P?X4?\*]T7^_=_\
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M //)OS%&]_\ GDWYBGT4 ,WO_P \F_,4;W_YY-^8I]% #-[_ //)OS%&]_\
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M_)C_ +@H\F/^X*DHH C\F/\ N"CR8_[@J2B@"/R8_P"X*D  &!THHH Y]?\
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MQ)_X_K#_ *YO_,5Q%?5Y?_NT?ZZGY_G'^^U/E^2"N_\ ANX6+4LY^]'T!/\
M>K@*] ^&O^JU+_>C_DU3F7^[2^7YHO)/]^A\_P F=SYJ^C?]\&CS5]&_[X-/
MK(\1:I<Z596\EI%#)--=1VZB9B%&\XR2*^8C%R:BC[N4E&+D^AJ>:OHW_?!H
M\U?1O^^#7&'QIJ*VENW]G0O,9I8)]AD90R/MRI5&X/OBJ[ZIJ0\4>?\ VC,(
MAK T_P"R\>7Y9CW9QC.[/?-;K"SZZ&#Q4%MJ=WYJ^C?]\&CS5]&_[X-<)XBU
M348M=OY;?4988]/-GY<"8V2>:^&W#&3Q5:WU76Y=666#4)));NXOK9+9]OE)
MY2GR\#'!R!DTUA9./-=?TK_D*6+BI<MG_3M^9Z)YJ^C?]\&G@Y&:X_P+>:G=
M'44OI+MXX'2/_2]N]9=O[P KQMSC%=A6-6FZ<N5NYM2J>TAS)6.?7_D+^(O^
MO>'_ - >KFC(TGA?3D61HRUG$ ZXROR#D9XJFO\ R%_$7_7O#_Z ]:&@?\BY
MIG_7I%_Z *S-#F+Z:[C\%10Q?:V39(TEPC;G^5SA2<YY[GT!]:[5&W1JV"N0
M#@]12X&,8&/2EH 868' C)'KD4R9W\F3]T?NGN/2IJ9-_J)/]T_RH Y(=!10
M.@HH&%;FC,PLVPA;YSR"/05AUO:)_P >3?\ 70_R% %_>_\ SR;\Q1O?_GDW
MYBGT4"&;W_YY-^8HWO\ \\F_,4^B@!F]_P#GDWYBC>__ #R;\Q3Z* &;W_YY
M-^8HWO\ \\F_,4^B@!F]_P#GDWYBC>__ #R;\Q3Z* &;W_YY-^8HWO\ \\F_
M,4^B@!F]_P#GDWYBC>__ #R;\Q3Z* &!WS_JC^8K,A_Y&^\_Z\(/_1DM:U9,
M/_(WWG_7A!_Z,EH @T>X:VT(NEO+.YO+A0D0&<F>3KG@#W-2#Q';&/>()_D!
M,XP/W #%3NYYY!Z9Z9JK80WL_AQHK"5(I6O+@,[$@A?/DS@@'!]\<4Z309S"
M881;6\<UN+:9%+-M4,3E21R3N.<]^: +L.N6\]S) D4N]7"+T^?YBI(YX *M
MUQP,UJ5B:GHCW32/;&*)SM( RF\_Q;F7GD8&?;WK6MHWAM88I)#+(B!6D/5B
M!R?QH EIK_ZMOH:0Q@G.YOP8TUXAY;?,_0_Q&@#E!THH'2B@85NZ'_QZR?[_
M /05A5MZ*@:UDY8?/V..PH U:*9Y0_O/_P!]&CRA_>?_ +Z- B#4KT:=IMQ>
M,AD$*%RH.,XKC_\ A94'_0,D_P"_H_PKH?$T8'AG43N?_4-U8UXG*T@N45)"
M26'[L*,!>Y)KUL!AJ-6FY5%?6Q\_FV-Q%"M&%&5KJ^W_  &>E_\ "RH/^@9)
M_P!_1_A1_P +*@_Z!DG_ ']'^%>8[KEOM"@@LKKM"#D*1SC/?ZTZVN?,;9(W
M[P@< <<#GG]?I7<L%A6[<OXO_,\IYIF"BY*:=O)=K]CW?1=376-*BOEB,0DW
M?(3G&"1U_"K]<YX*C#>%+0[F'+]&/]\UT'E#^\__ 'T:\"O%0JRC'9-GUN$J
M2J8>$Y;M)_@/HIGE#^\__?1H\H?WG_[Z-9'0/HIGE#^\_P#WT:/*']Y_^^C0
M ^BF>4/[S_\ ?1H\H?WG_P"^C0!E/_R.4'_8/D_]&)6Q6,PQXO@3G'V&1LGK
M_K$[^GM6S0 4444 8^E_\C!KO_76'_T4M;%8^E_\C!KO_76'_P!%+5'5VOF\
M1:>WV><11RLD)1EV,3$V6;G/!P!D=CZT =-D>M%<9:6<=[!Y44BQQK9QO=ED
MW*9E;)#C(R>N>_3VJ_HEY)%J/V"2%R[1*?,=OG"A1MR,=,'&<_>S0!TE%(<@
M' R?2F;I/^>8_P"^J ,76_\ C\3_ *Y_U-9M:.LEC=IN7!V>N>YK.H&%;FA_
M\>\O^_\ TK#K:T4L+>7:F?G]<=J -:BH]TG_ #S'_?5&Z3_GF/\ OJ@1Y]\2
M?^/ZP_ZYO_,5Q%=M\1RQO;#<N/W;]\]Q7$U]7E_^[1_KJ?G^<?[[4^7Y(*]
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M<T4;@!HU8#U&:>  ,#@4 ,+,#@1DCUR*9,[^3)^Z/W3W'I4U,F_U$G^Z?Y4
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MH]N^1%W=,L!F@!]%-WH2P#+\IP>>E.H *:_^K;Z&G4U_]6WT- '(CI10.E%
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M9/+;Y%Z'^+_ZU2TU_P#5M]#0!R(Z44#I10,*V]%+BUDVJ#\_<X["L2MW0_\
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M^1@UW_KK#_Z*6MBL?2_^1@UW_KK#_P"BEI][?W=MK%M$$B^R/'(S')+LRKG
M'0"@#5HKF!JNJO HC(DEGMX[I?+BR8E)P5 S\V,C&?>M'2M6^V2F&XEB6XV
MB%?8?,<_7MZ8/>@#6HI"0HR3@4WSH_\ GHOYT 8FM_\ 'XG_ %S_ *FLVM'6
M65KM"I!&SM]36=0,*W-#_P"/>7_?_I6'6UHKHEO*&8#Y^Y]J -:BF>='_P ]
M%_.CSH_^>B_G0(\]^)/_ !_6'_7-_P"8KB*[;XCLK7MAM(/[M^GU%<37U>7_
M .[1_KJ?G^<?[[4^7Y(*] ^&O^JU+_>C_DU>?UWWPW=4BU+<P'S1]3_O5.9?
M[M+Y?FB\D_WZ'S_)G?44SSH_^>B_G1YT?_/1?SKY8^]/,?C)_J-&_P!^;^2U
MY37JOQB=7@T?:P/SR]#[+7E5?3Y=_NT?G^9\MF?^\R^7Y!7I7P=_Y"FJ?]<4
M_P#0C7FM>D_!]E74]4W$#]RG7_>-5C_]VE_74G+O]YC_ %T/7J*9YT?_ #T7
M\Z>"",CD5\L?5G/K_P A?Q%_U[P_^@/6AH'_ "+FF?\ 7I%_Z *SU_Y"_B+_
M *]X?_0'K0T#_D7-,_Z](O\ T 4 9WBZ^N;72I$MC<1$H7:XBC9M@7'&0.">
MF?3-;Z-O16&<$ \C!_*AT21"CJK*>"K#(-.H 86<' C)'KD5',[^3)^Z/W3W
M'I4],F_U$G^Z?Y4 <D.@HH'044#"MS1F86;80M\YYR/05AUO:)_QY-_UT/\
M(4 7M[_\\C^8HWO_ ,\C^8J2B@1FZT[G0M0S&1_HTG<?W37BO:O;=;_Y .H?
M]>TG_H)KQ+M7OY/\$O4^1XD_BP]&%%%%>P?-'J7@-F'AA,(3^^?G(]:Z;>__
M #R/YBN<\ _\BNG_ %V?^==/7R.,_P!XGZL_1LN_W2GZ(CWO_P \C^8HWO\
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M2VR+ 8HII#)*B;3&P8JP.'48Y!Q5AM?T]41]\A5@68B,_N@#M)?^[R".?0T
M:&9?[B?]]?\ UJ,R_P!Q/^^O_K4^B@"AJEG+J6EW-F"D9F0IO))QGVQ7%?\
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MQJW_ ,(_:_\ /UJ?_@QG_P#BZ/\ A'[7_GZU/_P8S_\ Q= &?+X<N9_MLCO
M);J"9&')"LY7 SCD849_E46HZ==6=_<W<40N#<H\:Q^6S*H*(O. <'*_0CN*
MU?\ A'[7_GZU/_P8S_\ Q='_  C]K_S]:G_X,9__ (NE8/,MZ9 ]KI5G;R !
MXH$1@.Q"@&K597_"/VO_ #]:G_X,9_\ XNC_ (1^U_Y^M3_\&,__ ,738+0U
M:1E#(5(!!&,'H:R_^$?M?^?K4_\ P8S_ /Q='_"/VO\ S]:G_P"#&?\ ^+H
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MJI9:]>7MTD(M8XPT^PESRJ@,2" ?O?+WQUZ5NM!$\Z3,@,D8(5O0'&?Y"GX
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MH&H749A2YMP=I4%D'&?7G_/ Z4R77;B)I7<0! 72-@6VG#(N3VYW<<CZUT0
M P *,#&,#% &/X?U&;4TGGE^4'853LN5YQ^-;-'%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img187335194_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (D!*$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHKA_&GCV_\,^(=)T33/#K:Q>:E'(\:+=B$C9R1RI!XR>HZ47UL'F=Q17
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M^D:MIKJMQ:2R>9@-G!#8&>GIW&,YKH[W6]*TV=8+[4[*UF:-I5CGN%1BB]6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV))*;2"3QW/I7N@SCGK4KX4RG\304444 %%%% !1110 4444 %%%% !1110
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M3*Y_Z%+7/^_EG_\ )%'UJA_.OO0>SGV9U5%<K_PF5S_T*6N?]_+/_P"2*/\
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M .$^;_H5=<_[[M/_ (_1_P )\W_0JZY_WW:?_'Z/:0[H.:/<["BN/_X3YO\
MH5=<_P"^[3_X_1_PGS?]"KKG_?=I_P#'Z/:0[H.:/<["BN/_ .$^;_H5=<_[
M[M/_ (_1_P )\W_0JZY_WW:?_'Z/:0[H.:/<["BN/_X3YO\ H5=<_P"^[3_X
M_1_PGS?]"KKG_?=I_P#'Z/:0[H.:/<["BN/_ .$^;_H5=<_[[M/_ (_1_P )
M\W_0JZY_WW:?_'Z/:0[H.:/<["BN/_X3YO\ H5=<_P"^[3_X_1_PGS?]"KKG
M_?=I_P#'Z/:0[H.:/<["BN/_ .$^;_H5=<_[[M/_ (_1_P )\W_0JZY_WW:?
M_'Z/:0[H.:/<["BN/_X3YO\ H5=<_P"^[3_X_1_PGS?]"KKG_?=I_P#'Z/:0
M[H.:/<["BN/_ .$^;_H5=<_[[M/_ (_1_P )\W_0JZY_WW:?_'Z/:0[H.:/<
M["BN/_X3YO\ H5=<_P"^[3_X_1_PGS?]"KKG_?=I_P#'Z/:0[H.:/<["BN/_
M .$^;_H5=<_[[M/_ (_1_P )\W_0JZY_WW:?_'Z/:0[H.:/<["BN/_X3YO\
MH5=<_P"^[3_X_1_PGS?]"KKG_?=I_P#'Z/:0[H.:/<["BN/_ .$^;_H5=<_[
M[M/_ (_1_P )\W_0JZY_WW:?_'Z/:0[H.:/<["BN/_X3YO\ H5=<_P"^[3_X
M_1_PGS?]"KKG_?=I_P#'Z/:0[H.:/<["BN/_ .$^;_H5=<_[[M/_ (_1_P )
M\W_0JZY_WW:?_'Z/:0[H.:/<["BN/_X3YO\ H5=<_P"^[3_X_1_PGS?]"KKG
M_?=I_P#'Z/:0[H.:/<["BN/_ .$^;_H5=<_[[M/_ (_1_P )\W_0JZY_WW:?
M_'Z/:0[H.:/<["BN-D^(D-O&T]YX>UFUM8P7FN)#;,L2#EG(28L0!DX4$\<
MGBNRJE)/9C33V"BBN4'C@RRW"VOAO6;F*&XEM_.C:U57:.1HV(#3!L;E/4"I
MG4A!7F[>I2BWLCJZ*Y7_ (3*Y_Z%+7/^_EG_ /)%'_"97/\ T*6N?]_+/_Y(
MK/ZU0_G7WHKV<^S.JHKE?^$RN?\ H4M<_P"_EG_\D4?\)E<_]"EKG_?RS_\
MDBCZU0_G7WH/9S[,ZJBN5_X3*Y_Z%+7/^_EG_P#)%'_"97/_ $*6N?\ ?RS_
M /DBCZU0_G7WH/9S[,ZJBN5_X3*Y_P"A2US_ +^6?_R11_PF5S_T*6N?]_+/
M_P"2*/K5#^=?>@]G/LSJJ*Y7_A,KG_H4M<_[^6?_ ,D4?\)E<_\ 0I:Y_P!_
M+/\ ^2*/K5#^=?>@]G/LSJJ*Y7_A,KG_ *%+7/\ OY9__)%'_"97/_0I:Y_W
M\L__ )(H^M4/YU]Z#V<^S.JHKE?^$RN?^A2US_OY9_\ R11_PF5S_P!"EKG_
M '\L_P#Y(H^M4/YU]Z#V<^S.JHKE?^$RN?\ H4M<_P"_EG_\D4?\)E<_]"EK
MG_?RS_\ DBCZU0_G7WH/9S[,ZJBN5_X3*Y_Z%+7/^_EG_P#)%'_"97/_ $*6
MN?\ ?RS_ /DBCZU0_G7WH/9S[,ZJBN5_X3*Y_P"A2US_ +^6?_R11_PF5S_T
M*6N?]_+/_P"2*/K5#^=?>@]G/LSJJ*Y7_A,KG_H4M<_[^6?_ ,D4?\)E<_\
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MUS_ONT_^/T>TAW0<T>YV%%<?_P )\W_0JZY_WW:?_'Z/^$^;_H5=<_[[M/\
MX_1[2'=!S1[G845Q_P#PGS?]"KKG_?=I_P#'Z/\ A/F_Z%77/^^[3_X_1[2'
M=!S1[G845Q__  GS?]"KKG_?=I_\?H_X3YO^A5US_ONT_P#C]'M(=T'-'N=A
M17'_ /"?-_T*NN?]]VG_ ,?H_P"$^;_H5=<_[[M/_C]'M(=T'-'N=A17'_\
M"?-_T*NN?]]VG_Q^C_A/F_Z%77/^^[3_ ./T>TAW0<T>YV%%<?\ \)\W_0JZ
MY_WW:?\ Q^C_ (3YO^A5US_ONT_^/T>TAW0<T>YV%%<?_P )\W_0JZY_WW:?
M_'Z/^$^;_H5=<_[[M/\ X_1[2'=!S1[G845Q_P#PGS?]"KKG_?=I_P#'Z/\
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M90_E7W!S2[G!>+/".F:9X-UR_LY]8CNK73[B:%_[9NSM=8V*G!EP<$#K3O\
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MZ#6L?^#*?_XNC^T=4_Z#6L?^#*?_ .+K-\N^_P"?FW_[\-_\71Y=]_S\V_\
MWX;_ .+H_P"WOS#ZGAO^@9?=#_,TO[1U3_H-:Q_X,I__ (NC^T=4_P"@UK'_
M (,I_P#XNLWR[[_GYM_^_#?_ !='EWW_ #\V_P#WX;_XNC_M[\P^IX;_ *!E
M]T/\S2_M'5/^@UK'_@RG_P#BZ/[1U3_H-:Q_X,I__BZS?+OO^?FW_P"_#?\
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M+HYY?S_F'U#!_P#0*O\ P&'^9?\ M=__ -!;5?\ P83?_%T?:[__ *"VJ_\
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MOU/-_P#G\_\ P*1\I_J[CO\ GS^,?\ST;_A"M'_OZK_X.+O_ ..T?\(5H_\
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M-6?M=_\ ]!;5?_!A-_\ %UD(EY_:,_[^#=Y,>3Y!QC+XXW_6K'EWW_/S;_\
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M 'X;_P"+KMH8J->'/3J77S_R/1PU'+L3#VE'#)K_  P_4O\ VN__ .@MJO\
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M "*OVJ;_ )\+C_OJ/_XJC[5-_P ^%Q_WU'_\55JBCF7;\_\ ,/8S_P"?C_\
M)?\ (J_:IO\ GPN/^^H__BJ/M4W_ #X7'_?4?_Q56J*.9=OS_P P]C/_ )^/
M_P E_P BK]JF_P"?"X_[ZC_^*H^U3?\ /A<?]]1__%5:HHYEV_/_ ##V,_\
MGX__ "7_ "*OVJ;_ )\+C_OJ/_XJC[5-_P ^%Q_WU'_\55JBCF7;\_\ ,/8S
M_P"?C_\ )?\ (J_:IO\ GPN/^^H__BJKW]S*VG70-E.H,+@L63 X//#5I55U
M+_D%W?\ UQ?_ -!-5"2YEI^9AB:4_8S]][/^7MZ'U[1117T1^.!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ/M4W_/A<?\ ?4?_ ,55JBCF7;\_\P]C/_GX_P#R7_(J_:IO^?"X_P"^H_\
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MO(?^$V\6_P#0Q7'_ (#6W_QJC_A-O%O_ $,5Q_X#6W_QJC^Q\?\ \_E]\O\
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MM_\ OTO^%>X?\*1T/_H.:Y_WW;__ !FC_A2.A_\ 0<US_ONW_P#C-=/U*O\
MS?BSP_\ 67*O^?+_ / 8_P"9X?\ V;8_\^5O_P!^E_PH_LVQ_P"?*W_[]+_A
M7N'_  I'0_\ H.:Y_P!]V_\ \9H_X4CH?_0<US_ONW_^,T?4J_\ -^+#_67*
MO^?+_P# 8_YGA_\ 9MC_ ,^5O_WZ7_"C^S;'_GRM_P#OTO\ A7N'_"D=#_Z#
MFN?]]V__ ,9H_P"%(Z'_ -!S7/\ ONW_ /C-'U*O_-^+#_67*O\ GR__  &/
M^9X?_9MC_P ^5O\ ]^E_PK1T'2=-F\1:9%+I]H\;W<2LC0J0P+C((QR*]?\
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MU?8T:+OZ1_S.5_LVQ_Y\K?\ []+_ (4?V;8_\^5O_P!^E_PH^RS?\_\ <?\
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M .@YKG_?=O\ _&:]ZA3GB:4:U.7NM>9SPXBRRFG&5)WN_LQZMON>'_V;8_\
M/E;_ /?I?\*/[-L?^?*W_P"_2_X5[A_PI'0_^@YKG_?=O_\ &:/^%(Z'_P!!
MS7/^^[?_ .,UK]2K_P WXLO_ %ERK_GR_P#P&/\ F>'_ -FV/_/E;_\ ?I?\
M*/[-L?\ GRM_^_2_X5W'Q$\!VGA+^S?L&JZE)]J\W?YYA.-NS&,1C^\:X?[+
M-_S_ -Q_WS'_ /$USU(SIR<92U^9[6$K8?%T57I4/=?E'H[=P_LVQ_Y\K?\
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M"6W_ ,:H_P"%A^-?^AFN/_ 2V_\ C5'UZB'^JN8]E]Y[A_P@G@__ *%30_\
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MC_A)K/\ Y\=<_P#!'>?_ !JN^IF>>U%RRHNW^!FV%Q#PE3VM"5I?)_F>8_\
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M]HW_ (&2_P#QFLO1=-U>TUW3KF?0-<2&&YCD=O[*N#A0P). GI7L7_"36?\
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M44 %<QXN_P"0CX6_["K_ /I'<UT]4]2TG3=9MUM]4T^TOH%<.L=U"LJAL$9
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M&Q#Z>YJHJ-GK_5_4PJRK<\/=6_=_RO\ NFE157^S;'_GRM_^_2_X4?V;8_\
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M\'53BOAEU?9_W3Z<HKAO^$+\*_\ 0LZ-_P" $7_Q-'_"%^%?^A9T;_P B_\
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M0;N>;F605,!",I33N>E45PW_  A?A7_H6=&_\ (O_B:/^$+\*_\ 0LZ-_P"
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M /!O-_\ (U?&XO)\VJUYS5---O7W-NF^I\MB:N']M/V3]V[MOM?0J?V#J/\
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MA<)CY7>914MN7FY7ZVW\CZ3AVC@JSJ1JQYGI;1OO?;Y'4_\ ";>+?^ABN/\
MP&MO_C5>C>%[;6-;\.6FHW/BK54FFW[ECAM HP[*,9@/85XGYE]_S[6__?\
M;_XBNY\/_$>^T+0[?3?["MY_)W?O/M[+G+%NGE'U]:QS+ 2E22PU./-?M#:S
M[GJ9MEE&5%+!TGS7[-:6??Y'I?\ 8.H_]#;K/_?JS_\ C%21Z3JT2[4\7ZR!
MG/\ J;/_ .1ZX/\ X6]??]"W;_\ @R;_ .,UT>@>*O$'B.P>\L]"TQ(TE,1$
MVJR Y ![6YXY%>+[#,L'^]24/-."_(^8KY=B*,.>M!I>9N?V=K/_ $..L_\
M?BR_^1Z9)I.K2KM?Q?K)&<_ZFS_^1ZC^U>*O^@-HW_@VE_\ D:C[5XJ_Z VC
M?^#:7_Y&J*F89C4BX3JW3Z.4;?F<*A!;(/[!U'_H;=9_[]6?_P 8H_L'4?\
MH;=9_P"_5G_\8H^U>*O^@-HW_@VE_P#D:C[5XJ_Z VC?^#:7_P"1JX_WW]S_
M ,D*T_JX?V#J/_0VZS_WZL__ (Q1_8.H_P#0VZS_ -^K/_XQ1]J\5?\ 0&T;
M_P &TO\ \C4?:O%7_0&T;_P;2_\ R-1^^_N?^2!I_5P_L'4?^AMUG_OU9_\
MQBC^P=1_Z&W6?^_5G_\ &*/M7BK_ * VC?\ @VE_^1J/M7BK_H#:-_X-I?\
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M****ZB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\[TK54TJ.^M+O3]9$HU.^?]WI%U(I5[J5U(98RI!5@<
M@]Z]$HKS\RRVEF%)4JK:2=]+=FNJ?<N$W!W1Q/\ PDUG_P ^.N?^".\_^-5>
ML_%NG10E7M-<!W9_Y 5[_P#&JZBBN++^'L+@:WMZ4I-[:M6_!(J=64E9G/\
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M_P""R?\ ^(H_LO5O^@'K/_@LG_\ B*^C:*V_UBE_S[_'_@&_^L^-_EC]S_\
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M_P"C;NN@JY\)8*;NY2Z+==%;^4/;R.)_X2:S_P"?'7/_  1WG_QJC_A)K/\
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M?LZA;_X0;1O^>NL_^#R]_P#CM'_"#:-_SUUG_P 'E[_\=JIYWC#_ *"^A_\
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M$]O*DT3-?W#A75@RG!D(." >178T4<D>PGB:S5G-_>PHHHJC$**** "BBB@
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M[Z12TL^OW$O_  ANE_\ /UKG_@]O?_CU4;WX9^%M1F$U];:A=2JNT//JUV[
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MA.UG_O\ V7_R16E_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
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MQ_Y_;?\ [^K_ (U]#D,)KVEZ5MOYO/NSZKAJ45[6]3E^'MY]T'VJ;_GPN/\
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M_H:]#_\ !C#_ /%4 =!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%4 =!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4
M =!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4 =!17/\
M_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4 =!17/\ _"=^#_\
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MP?\ ]#7H?_@QA_\ BJYL7A*>+HRH5?A?Z.XXR<7=&;_:.L_]"=K/_?\ LO\
MY(IA\47NE7-LMWX3UI&NY#!"!)9G<^QI,<3\?+&QY]/I6K_PG?@__H:]#_\
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M_P"A9N/_  +MO_CM>X?\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\
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M_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_ /A._!__ $->A_\
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M_P#BJ/L$/]^X_P# F3_XJN"T>_X?\$^LYJ_\J^]__(EJO0_@W_R-]W_UX/\
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M_CE'_"I/!7_0+N/_  97/_QRO*_LZ7\Q]Y_KC0_Y]/[T>!45[[_PJ3P5_P!
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MRR=VV%%%%= @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVC?\]=9_\'E[_P#':S_U-K_\_5]S']878FHK.O?!NE0[-D^LC.<_\3N\]O\
MIK53_A$]._Y^=9_\'5Y_\=KY_'8&&#KRP]2;;5MEIJK]UW-8R<E=&Y16'_PB
M>G?\_.L_^#J\_P#CM'_")Z=_S\ZS_P"#J\_^.UR<M#^9_P#@*_\ DBM3<HK#
M_P"$3T[_ )^=9_\ !U>?_':/^$3T[_GYUG_P=7G_ ,=HY:'\S_\  5_\D&IN
M45A_\(GIW_/SK/\ X.KS_P".T?\ ")Z=_P _.L_^#J\_^.T<M#^9_P#@*_\
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M^2J/L?C#_H.Z'_X)IO\ Y*H_X2'5/^A,US_O]9?_ "11_P )#JG_ $)FN?\
M?ZR_^2* #['XP_Z#NA_^":;_ .2J/L?C#_H.Z'_X)IO_ )*H_P"$AU3_ *$S
M7/\ O]9?_)%'_"0ZI_T)FN?]_K+_ .2* #['XP_Z#NA_^":;_P"2J/L?C#_H
M.Z'_ .":;_Y*H_X2'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\ DB@#A_&7
MCCQAX2U>*P^T:'=^9 )M_P#9TT>,LPQC[0?[OZUSW_"X/&'_ #ST/_P#F_\
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MC?\ @IE_^2:\X\+^'O$VB>([34;GPU>O##OW+'<6Q8Y1E&,RCN:]'_M[4?\
MH4M9_P"_MG_\?KYK.*KJ5TZ4H-6[P?5]SYK/JU"MB8RHRYERKJWU?</LOBK_
M *#.C?\ @IE_^2:;H5MXJUOP]IFK?VSHT/VZTBN?*_LF5MF] VW/VD9QG&<"
MG?V]J/\ T*6L_P#?VS_^/TWPUKFI:-X5TC2[CPEK+3V5E#;R-'+9E2R(%)&9
MP<9'H*ZLBIX.?M/K_)TM=Q7>^S]#Y^JY*W)<T/[#\5?]!_1O_!/+_P#)-<%)
M\,M3\3>)O$-U<>(;.&>&]CA?R],;:Y%K P(!FR.& QD\@G/.!Z#_ ,)=>?\
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MCDPOE]X?6,_[5/\ P%_Y&3_PH^^_Z&FW_P#!6W_Q^C_A1]]_T--O_P""MO\
MX_6M_P +NT/_ * >N?\ ?%O_ /'J/^%W:'_T ]<_[XM__CU')A?+[P^L9_VJ
M?^ O_(R?^%'WW_0TV_\ X*V_^/UJ^&/A-<^'_%&GZS-K\5TMFSL(4L#&7+1O
M']XRMC&_/3M2_P#"[M#_ .@'KG_?%O\ _'JU?#OQ2T7Q'K<.DQ66I6EQ.&\D
MW4<>UV52Q4%';!VACR /E/.< U".'4ERVN8XFOG,J4E74^3K=.WY'<4445U'
MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^A.UG_O_ &7_ ,D5Q8:.?86')0@XK?2,=_N*?LI:LD\[QA_T%]#_ /!1-_\
M)-'G>,/^@OH?_@HF_P#DFH_[1UG_ *$[6?\ O_9?_)%']HZS_P!"=K/_ '_L
MO_DBNCZQQ+V?_@,?\A6HDGG>,/\ H+Z'_P""B;_Y)H\[QA_T%]#_ /!1-_\
M)-1_VCK/_0G:S_W_ ++_ .2*/[1UG_H3M9_[_P!E_P#)%'UCB7L__ 8_Y!:B
M2>=XP_Z"^A_^"B;_ .2:@FC\63N&;6=%! QQI,O_ ,DT_P#M'6?^A.UG_O\
MV7_R11_:.L_]"=K/_?\ LO\ Y(K#$?V_B(>SK1;7;EC_ )#7LD[H@^R^*O\
MH,Z-_P""F7_Y)H^R^*O^@SHW_@IE_P#DFI_[1UG_ *$[6?\ O_9?_)%']HZS
M_P!"=K/_ '_LO_DBN'^R\T_Y\_\ DL?\BN>'<@^R^*O^@SHW_@IE_P#DFE2W
M\5HZL-9T7(.?^03+_P#)-3?VCK/_ $)VL_\ ?^R_^2*/[1UG_H3M9_[_ -E_
M\D4XY;FL6I*CJO[L?\@YX=R3SO&'_07T/_P43?\ R31YWC#_ *"^A_\ @HF_
M^2:C_M'6?^A.UG_O_9?_ "11_:.L_P#0G:S_ -_[+_Y(KU/K'$O9_P#@,?\
M(BU$D\[QA_T%]#_\%$W_ ,DT>=XP_P"@OH?_ (*)O_DFLZV\47=Y&\D'A767
M5)9(6/F6@P\;E'',_9E8?AQ4W]O:C_T*6L_]_;/_ ./UQRSK.(2<954FO\!7
MLZ?;\RA:R^*O^$WU0KJFC"?^SK/>QTN4J5\RYV@+]HR"#NR<G.1P,<[7G>,/
M^@OH?_@HF_\ DFN;MM:OQXTU.0>&-6+MI]FIB$MKN4"2YPQ_?8P<D#!)^4Y
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MGU;T_P#X^&_W?ZBNO \5?6L1"A[&W,[7YK_^VBE0Y5>Y1_X3OP?_ -#7H?\
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M]G*,FAEO/R2<N:V_E?\ S,ZE1S"BBBO9,PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \_L+ :X+V^OK[5?._M"\A @U.X@0)
M'<21H D;JHPJ*.!SC)R235K_ (1FS_Y_M<_\'EY_\=I\6C^)-*>ZM["STJ[M
M9+N>Y26>_D@?][*TI4H(7 VERN=QSC/&<"7R?&'_ $"-#_\ !O-_\C5\#C,!
MGLL34E2<N5R=O?2TOIIS::'5&5*RO^17_P"$9L_^?[7/_!Y>?_':/^$9L_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/
MQ#XPT/PJUJNLWCP-=!S"$MY92P3;N^XIQC<O7UK%_P"%M^"O^@I<?^"VY_\
MC=<E\</^0IX;_P"N-Y_Z%;UY?7!B,7*E/E2/K,HX=I8_#*O*;3NU]Q] V_Q3
M\(W<ZP6U]>S3-G;''I=TS' R< 1^E7_^$YT;_GEK/_@CO?\ XU7BGP__ .1W
MT[_MK_Z+:O<:^>S+B6KA*JIQIIW5]WW9PYMD\,#65*,F[J_XM?H0_P#"<Z-_
MSRUG_P $=[_\:I__  F6E_\ /KKG_@BO?_C-/K=KT,BSF>9>TYXJ/+;;SO\
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M***[3YH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *P;OQCH]EJ%S8R'4)+BV8),+;3+F=48JK@;HXRN=K*<9[
MUO5QNG?\C'XJ_P"PG'_Z1VU>7G&82P&&=>*N[I?>73AS2L7_ /A.=&_YY:S_
M .".]_\ C5.7QKI+C*V^ML/4:%>G_P!I5)6EI_\ Q[M_O?T%>/D_$57'XE4)
M025F_N-*E%1C>YE?\)EI?_/KKG_@BO?_ (S6!XD\26EY>:!+!9:VR6NH--,3
MHEXNU#;3IGF+GYG48'//H#7?U4U#_CW7_>_H:]O-Y\F JMJ_NM??H9TU>2.1
M_P"$LT[_ )]M9_\ !+>?_&J!XKTXD 6NM$GM_8MY_P#&JW*D@_X^(_\ >'\Z
M_*:*H5*D8.+U:6Z_^1.YW2,+_A)K/_GQUS_P1WG_ ,:H_P"$FL_^?'7/_!'>
M?_&J[:BOO/\ 4_ _SS^]?_(G+]8D<3_PDUG_ ,^.N?\ @CO/_C5'_"36?_/C
MKG_@CO/_ (U7;44?ZGX'^>?WK_Y$/K$CRZ#Q)91^-=3E>UU<*^G6:@?V/=[L
MB2Y)ROEY ^88)&#SC.#C8_X2S3O^?;6?_!+>?_&JMS?\E#U3_L%6/_HV[K1K
MY+.*&'PN,E02;Y>5;K^5?W3>FW*-S#_X2S3O^?;6?_!+>?\ QJC_ (2S3O\
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M[6?^AQUG_OQ9?_(]']G:S_T..L_]^++_ .1Z/]:LN[O[@]A,[*BN-_L[6?\
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MM+&U(2P]1Q26M[K\DS:E!Q6J#_A"_"O_ $+.C?\ @!%_\37SW_9MC_SY6_\
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MG-0BY/9 M3HJ*XW^SM9_Z''6?^_%E_\ (]']G:S_ -#CK/\ WXLO_D>OG?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPN(IPFYX=K3JI]UYAS)O<V/M7BK_ * VC?\ @VE_^1J/M7BK_H#:-_X-I?\
MY&H_X2S3O^?;6?\ P2WG_P :H_X2S3O^?;6?_!+>?_&JY/9U/^?'X2_S'==P
M^U>*O^@-HW_@VE_^1J/M7BK_ * VC?\ @VE_^1J/^$LT[_GVUG_P2WG_ ,:H
M_P"$LT[_ )]M9_\ !+>?_&J/9U/^?'X2_P PNNX?:O%7_0&T;_P;2_\ R-1]
MJ\5?] ;1O_!M+_\ (U'_  EFG?\ /MK/_@EO/_C5'_"6:=_S[:S_ ."6\_\
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M . /_(R]G2[_ (EO^W/%7_0 T;_P<2__ "-37UKQ4\;+_8.C#<",_P!L2_\
MR-5;_A)K/_GQUS_P1WG_ ,:H/B:R )-EK@ [_P!AWG_QJIGFN>RBXRI.S_N,
M%"EW&?:O%7_0&T;_ ,&TO_R-1]J\5?\ 0&T;_P &TO\ \C4?\)9IW_/MK/\
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MX'J*[JL/QI!-=>!?$-O;Q233RZ9<I''&I9G8Q,  !R23QBO'_P!6\K_Y]?\
MDTO\S3VT^YA?:O%7_0&T;_P;2_\ R-1]J\5?] ;1O_!M+_\ (U/_ .$FL_\
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M;_Y&H\GQA_T"-#_\&\W_ ,C5>_X3+2_^?77/_!%>_P#QFC_A,M+_ .?77/\
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M[-H.CS\UW>]K=$N[[&52?.[G045S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
M^A4T/_P70_\ Q->J9G05QNG?\C'XJ_["<?\ Z1VU:7_"">#_ /H5-#_\%T/_
M ,36'H7@OPK-K'B=)?#6C.D.IHD2M81$(OV2W;"_+P-S,<#N2>]>;FN7_P!H
M8=T.;EU3O:^WS1<)\CN;]%,_X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FOF/\ 4O\ Z?\ _DO_ -L;?6/(?13/^$$\'_\ 0J:'_P""Z'_XFL^^
M\$>$TG4+X7T51MZ#3XAW/^S7!F7#<<!0]O*K=72^'O\ ]O%PK<SM8TZ*P_\
MA"_"O_0LZ-_X 1?_ !-'_"%^%?\ H6=&_P# "+_XFOG.6A_,_P#P%?\ R1MJ
M;E%8?_"%^%?^A9T;_P  (O\ XFC_ (0OPK_T+.C?^ $7_P 31RT/YG_X"O\
MY(-3<HK#_P"$+\*_]"SHW_@!%_\ $T?\(7X5_P"A9T;_ , (O_B:.6A_,_\
MP%?_ "0:FY4]G_Q]I^/\JYS_ (0OPK_T+.C?^ $7_P 363XA\(>&8+"T:+P[
MI,;-J=@A*648)5KJ)6'W>A!(([@D5W9;&C]=HVD_BCT7=?WB)WY6>GT5S_\
MP@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $U^NG =!4<__ ![R
M?[I_E6'_ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-9U8>T
MA*'=-#3L[CZ*9_P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-?%?
MZE_]/_\ R7_[8Z/K'D/HIG_"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\
M\%T/_P 31_J7_P!/_P#R7_[8/K'D'@3_ ))YX:_[!5K_ .BEKH*C@@AM;>*W
MMXHX8(D"1QQJ%5% P  .  .,5)7W)S!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17EOA'PCX
M:N?!>A3S^'M)EFET^W>222RC9G8QJ222N22>];/_  A?A7_H6=&_\ (O_B:^
M0J<74*<W!TWH[;HZ%AVUN3Z=_P C'XJ_["<?_I';5JUA_P#"%^%?^A9T;_P
MB_\ B:/^$+\*_P#0LZ-_X 1?_$U\=CL10Q6(G7NUS.]K)_J=$4XJQN45RD7@
M_P ,'QUIMN?#FD&!],O':/[#%M9EEM@I(VX) 9@#VW'UKJ/^$$\'_P#0J:'_
M ."Z'_XFO;R_AB.-PT<1&M92OIR]FU_-Y&4ZW*[6,GQ-_P @ZS_["NG?^ED-
M=M6'!X+\*VMQ%<6_AK1H9XG#QR1V$2LC Y!!"Y!!YS6Y7V&3Y9_9M!T>?FN[
MWM;HEW?8PJ3YW<****]4S"BBB@ HHHH **** "BBB@ HHHH **** .?L_P#D
MH>L_]@JP_P#1MW705S]G_P E#UG_ +!5A_Z-NZZ"@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.US1X]=TIK
M"6XGMP98IEF@V[T>.19%(W*R_>0=0:R?^$1O/^AOUS_OW9__ "/73T5SUL)A
MZ[3K4U*W=)_F-2:V9POB/1=3T3POJVK6OBW66N+&RFN8A)%9E2R(6&0(!QD>
MM6/[.UG_ *''6?\ OQ9?_(];WB739M9\*ZOI=NT:SWME-;QM(2%#.A4$X!.,
MGT-8/]HZS_T)VL_]_P"R_P#DBOG<ZPV+H*FLKARWOS<J2[6O^)M3<7?G#^SM
M9_Z''6?^_%E_\CT?V=K/_0XZS_WXLO\ Y'H_M'6?^A.UG_O_ &7_ ,D52MO%
M%W>1O)!X5UEU262%CYEH,/&Y1QS/V96'X<5\[6KYY0CS592BO-I?F;)4GL7?
M[.UG_H<=9_[\67_R/1_9VL_]#CK/_?BR_P#D>H/[>U'_ *%+6?\ O[9__'Z/
M[>U'_H4M9_[^V?\ \?KF_M3-/^?W_DT?\Q\D.Q/_ &=K/_0XZS_WXLO_ )'H
M_L[6?^AQUG_OQ9?_ "/4']O:C_T*6L_]_;/_ ./TZ/6=4E;:GA'62<9_UUG_
M /)%53S#-JDE"%6[?12C?\P<*:W1+_9VL_\ 0XZS_P!^++_Y'H_L[6?^AQUG
M_OQ9?_(]']HZS_T)VL_]_P"R_P#DBD;4]852Q\'ZR !D_OK+_P"2*ZV^(4KO
MF_ G]T+_ &=K/_0XZS_WXLO_ )'H_L[6?^AQUG_OQ9?_ "/4']O:C_T*6L_]
M_;/_ ./T?V]J/_0I:S_W]L__ (_7%_:F:?\ /[_R:/\ F5R0[$_]G:S_ -#C
MK/\ WXLO_D>C^SM9_P"AQUG_ +\67_R/2+J>L,H8>#]9((R/WUE_\D4O]HZS
M_P!"=K/_ '_LO_DBNU/B%JZYOP)_=!_9VL_]#CK/_?BR_P#D>C^SM9_Z''6?
M^_%E_P#(]']HZS_T)VL_]_[+_P"2*/[1UG_H3M9_[_V7_P D4_\ C(O[_P"
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M_9VL_P#0XZS_ -^++_Y'H_L[6?\ H<=9_P"_%E_\CU!_;VH_]"EK/_?VS_\
MC]']O:C_ -"EK/\ W]L__C]9?VIFG_/[_P FC_F/DAV)_P"SM9_Z''6?^_%E
M_P#(]4K+3M7U'Q/J&GS^+=8\JVL[:=&6&S#%I'G5@?W&,?NEQQW/X3?V]J/_
M $*6L_\ ?VS_ /C]5M.U;5+/Q+J.I2>$]8,-S9VT"*LUGN#1O.S$_O\ &,2K
MCGL?Q]'*L=5K8A0S"I&5.STDXM7Z$3BDO<6IM_\ "(WG_0WZY_W[L_\ Y'H_
MX1&\_P"AOUS_ +]V?_R/1_PEUY_T*&N?]_+/_P"2*/\ A+KS_H4-<_[^6?\
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M5E8'N"".#7H]%>9FN60S&BJ,Y6L[Z>C7ZEPGR.YPW_":>%?^AFT;_P #XO\
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M;1?%WAJ+5?$3R>(=)1)=01XV:]C =?LMNN1\W(RK#/J".U=K6'H/_(8\3_\
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MYET<94D9P1Q[UVM%>AEO#M+ 5_;QFV[-?>3.LY*U@JGJ6K:;HUNMQJFH6EC
MSA%DNIEB4M@G +$#. 3CV-7*YCQ=_P A'PM_V%7_ /2.YKV\56]A0G6M?E3=
MO17,HJ[2)_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ?17QO
M^NG_ $X_\F_^U.CZOYC/^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
MXJGT4?ZZ?]./_)O_ +4/J_F:MC?V>IV<=Y87<%W:R9V302"1&P2#AAP<$$?A
M5BN<\#?\BY+_ -A/4?\ TLFKHZ^UI3]I",^Z3.=JS.?L_P#DH>L_]@JP_P#1
MMW705S]G_P E#UG_ +!5A_Z-NZZ"M!!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!YWI6E)JL=]=W>H:R93J=\G[O5[J-0J74J* JR!0 J@8
M[5>_X1FS_P"?[7/_  >7G_QVLK1;?Q \-^UCJ>F0VQU74-D<^G22N/\ 2YLY
M83J#SG^$?UK2^R^*O^@SHW_@IE_^2:_+LPQF*CBZL8XEI*4M+STU>FBL=L(Q
MY5H-/@_2C</<&;5S.Z*C2?VS=[F522H)\W) +,0.VX^M._X1/3O^?G6?_!U>
M?_':/LOBK_H,Z-_X*9?_ ))H^R^*O^@SHW_@IE_^2:\Z5>M-\TL1=^L_\B[+
ML'_")Z=_S\ZS_P"#J\_^.T?\(GIW_/SK/_@ZO/\ X[1]E\5?]!G1O_!3+_\
M)-'V7Q5_T&=&_P#!3+_\DU/M*G_/_P#&7^0678/^$3T[_GYUG_P=7G_QVC_A
M$]._Y^=9_P#!U>?_ !VC[+XJ_P"@SHW_ (*9?_DFC[+XJ_Z#.C?^"F7_ .2:
M/:5/^?\ ^,O\@LNP?\(GIW_/SK/_ (.KS_X[1_PB>G?\_.L_^#J\_P#CM'V7
MQ5_T&=&_\%,O_P DT?9?%7_09T;_ ,%,O_R31[2I_P __P 9?Y!9=@_X1/3O
M^?G6?_!U>?\ QVL;1?#%A)JOB)&N-6 BU!$7;J]TI(^RVYY(DRQR3R<G&!T
M V?LOBK_ *#.C?\ @IE_^2:QM%MO$IU7Q$(]6TE7&H()"VF2$,WV6WY ^T#
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MQX $J^%,3NCS#4+\2/&A16;[9-DA220,]LG'J:Z>OU[#?P8>B_(X'N<_9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML-@,2J\G)JS6RZ_]O&=2,I1L=W17$_\ ",V?_/\ :Y_X/+S_ ..T?\(S9_\
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M2:0?8_&'_0=T/_P33?\ R51]C\8?]!W0_P#P33?_ "51_P )#JG_ $)FN?\
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M ,B3J?\ V&)__08ZG^*&F7,OB'POJ\NA76NZ+8R3"\L+:$3L2Z@(WEG[V#^
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M^BQ0EMN]+D$LS+U.1CKSQ6KXB\2^-G\3>-X-(UV&SL=!MHKJ.-[..1C^[W%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y&;_ )*'JG_8*L?_
M $;=UUU9^IZ%H^M^5_:VE6-_Y.?+^UVZ2[,XSC<#C.!T]!7#F6"^O866'YN7
MFMK:^S3VT[%0ERRN4J*9_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
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M9PS&BZT(VL[:^B?ZD3AR.QT%%<__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\
MZ%30_P#P70__ !->F0=!7/\ A[_D.>+/^PK'_P"D5K1_P@G@_P#Z%30__!=#
M_P#$UR=AX0\,OK_B6-O#ND-'#J")$ILHR$7[);MA1MX&68X'<D]Z\_,LPC@*
M'MY*ZNE]Y<(<SL>F45PW_"%^%?\ H6=&_P# "+_XFC_A"_"O_0LZ-_X 1?\
MQ-?._P"N5#_GT_O1K]7?<[FBN&_X0OPK_P!"SHW_ ( 1?_$U)X3TO3])\::[
M!IMC;6<+:?8NT=M"L:EO,NAG"@#. .?:O0RWB*ECZ_L(P:=F_N)G1<5>YVM%
M%%?1&(4444 %%%% !1110 4444 %%%% !1110 4444 >5_ /_D2=3_[#$_\
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MO^Y2(Y_Z:&O9Z>G3^OZW^9.M[/I^?]:?(****!A1110 4444 %%%% !1110
M5Y7\ _\ D2M4_P"PQ/\ ^@1UZI7E?P#_ .1*U3_L,3_^@1T >J4444 %%%%
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M.L@.<]J[,OH9]'$P>(;Y+ZZQV^3)FZ7*[;G8T445]H<P4444 %%%% !1110
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M*+Y%S<Q@>:B$,6P@&T%E (CX)Q0M5?R_K^NX/1_U_7_ .UHKDOB1_P BD/\
MK_LO_2B.J$_BW77TG5?$=I#8#1]-GFC-I)&YGN(X6*R.)-X5#PV%*-TY(SPK
M_P!?=_F.W]?UZ'>45YQK/Q"U'3=.U9HK:U>\M;U!;HZ.!):M#Y^\@-]X(L@S
MG&5Z=JFU?XA26-Q=I'+IT-N^H1Z?9W5VVR)&\H22R2-N 95!P ,9(QGG(?\
M7Y?YB_K\_P#(]!HKS:3XCSPZ/XB-O=Z/JU[I4$5Q#<V#$V\Z.VW:RAV*,"""
M-QZ@^U=WI2:HMJ3JUQ9S3L<C[+;M$J#'W3N=BQSGGC/H* +U%<]XNO\ [!!I
M+?9+6X\[5;:'%Q'O";FQO7T8=CVKG;KQCXABTW7=82/3!8Z/J+VK6[12&2XC
M5U!(??A&PW]U@2.U"U_KT_S0/3^O7_(]#HKC[K7O$-_J^L6V@6]BT>D"-7CN
MD8O>2L@D,:,'41?*0-S!AD],#F+7O%$>@^()KFYTZ K;Z%)>L^P?: 5D4>4'
M!(VDGIR,\TK[?UT;_0/Z_%+]3M:*\YO9->C\6^$;W79-.,.;F0K:1/&86^SL
M2AW,V\8'WOEZ?=YXK67Q1$\>G:E)JOA][6^N4B_LJ&8&]@CD;:KL?,.YAE2R
M!!@$\G'+MK85]+GI]%>>77C'Q#%INNZPD>F"QT?47M6MVBD,EQ&KJ"0^_"-A
MO[K D=JT[K7O$-_J^L6V@6]BT>D"-7CND8O>2L@D,:,'41?*0-S!AD],#D6J
M3^8^K1V%%</KWC?['XB714U31M%ECM%NIY]8<,,N2%C11(F3P26W$#C@YK<\
M(^(5\4>'8=2"Q"3>\,HADWQET8J2C?Q*<9!]"*%J!N45S%_K&KW?BF30=%-E
M;M;6B75Q=7D+3#YV94145T/\#$MNXZ8.:X_7+^^\8IX4BF33XHY-6FM+RSN;
M4W,33PI*"3\ZATRI(!&<X.>,$6MK?UK8'I>_]:7/5Z*YCQWJ,^@^!KR;3F%O
M,!%;PN@ $.]UCW#L-H;(^@K"\0:%X0\,:=%*T5UIM[!BX&MVVGS3S*0?F:69
M$.[=R&#M@YZ4 >B45R4.M:YJ7C+4=,L7T^'3["*WF:26W>2282 DJ,2*%^Z?
MF.<9'!K!3XC72ZC8B2[TNX6XO(K>?3[*%YGLQ*Y1/,ND=HMX(!*D+GD#IDBU
M=@Z7/2Z*\L\6:OK?B/P'KVH6GV"/1TEDMT@DB?SY$CDVM)YF[:/F4X78>!]X
M$\:&J^/VBUG5;&TUCP]IW]EA4,>JR@27<A0.53]XNQ0"!N(;DGCCE7"VMCT.
MBL[0=7AU_0+#5H$9(KR!)E1NJY&<?ATKGO'MY<WFF7>@:9.\-Q)9R3W=Q&>;
M>W /3T9R"H]MQ_AHF^2]^@XKFL=E16)X-_Y$C0?^P?!_Z+6L""QM/%GCSQ!#
MK=O%>V>D>1!:V=PH>)6>/>TI0\%CNP&(X XQDU4E:3CV)B[Q4CNJ*\7\7Q+8
MZ%XU\+Q%CI4']GSVT)8D6ZRRJ&B7^ZN4R%Z#)Q@5M:U<FZ^'"^&W:0W&^73[
MC)^;R[=69F/^\B)S_P!-14MVBY?UY_=<I*[M_7?\CTZBLGPO_P BEHO_ %X0
M?^BUK6JY+EDT1%\T4PHHHJ2@KROX!_\ (E:I_P!AB?\ ] CKU2O*_@'_ ,B5
MJG_88G_] CH ]4HHHH **** "BBB@ HHHH **** .?L_^2AZS_V"K#_T;=UT
M%<_9_P#)0]9_[!5A_P"C;NN@H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=3\5:5I.
MHFPN6O7NA$LS);6$]QM1BP4DQHP&2C=?0UM5R,W_ "4/5/\ L%6/_HV[KS\U
MQDL%A)XB*NXVT]6E^I<(\TK%O_A.=&_YY:S_ .".]_\ C5<_XE\6Z9>:CX;$
M$&KL8M29V!T>[4D?9;@?*#%ECEAP,G&3T!(Z:LK4?^1C\*_]A.3_ -([FOEL
M/Q%4S&HL'4@E&I>+:>MFNALZ*@N9/8C_ .$FL_\ GQUS_P $=Y_\:I\7B>R6
M9&-EK@ 8$_\ $CO?_C5=G17HT^$L%":FI2TUW7_R)+KR9S__  F6E_\ /KKG
M_@BO?_C-'_"9:7_SZZY_X(KW_P",UT%%?4&!S_\ PF6E_P#/KKG_ ((KW_XS
M1_PF6E_\^NN?^"*]_P#C-=!10!R5YXJL)9@R6>N$;<?\@*]_^-56_P"$FL_^
M?'7/_!'>?_&J[:BOG,7PQA,56E7G*5Y:Z-6_(VC6E%61Q&DW?]I^.K*X@L]2
MC@@TR[222ZT^>W4,\ML5 ,B*"2$8X'H:[>BBO8P.#A@Z$</3;:5]]]7?R[F<
MI.3NPHHHKK)"BBB@ KG_  ]_R'/%G_85C_\ 2*UKH*Y_P]_R'/%G_85C_P#2
M*UH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R
MOX!_\B5JG_88G_\ 0(Z]4KROX!_\B5JG_88G_P#0(Z]4H *ANK6WOK62UNX(
MKBWE7;)%*@=''H0>"*FJ&\N[>PLI[R[E6*W@C:261NBJ!DG\J3M;4:\CG+3P
M#H>G^+8-=L=-TZT\FU:!8(+)$PY8'S PQ@XRO3H3S6CI&A?V9JVM:@UP)I-3
MN$F/[O:8U6-45,Y.[&TG/'7I5;3/%UKJ-Y:VTNGZA8&]C,MD]Y&BK<J!DE=K
M,5.,':X5L'IP<5;;Q_IUS/;,MCJ*Z;=77V2WU1HD^SRR9P ,-O +#:&*A2>]
M4K[?UO\ Y_Y$Z;_UM_E_F;EYIOVW4+*>67]Q:LTH@V_?EQA6)ST4%N,=2#_"
M*P].\%FQUN&Y;4!+86ES<7=I:F##Q2S9W[I-QW*-SX&T8W<DXJW;^+["YUPZ
M:L%TJ&X>TCO&">3).B[GC7#;L@!N2H'RD FM2PU&+41<- D@CAG: 2,!MD*\
M,5P>@;*\XY4]L$I=U_7]:#?9_P!;_P#!_$J>)-$_X2#2!8?:/L_^D0S;]F__
M %<BOC&1UVX]LUA77@6YEM-1TBWUGR=!U&=YKBU-MNF7>VZ1(Y=X"JQSU1B-
MQP>F.TK.UW6;?P_H\^IW:2O!#MW+$ 6.Y@HQD@=2.]']?E_D%S%O/ UK>>*T
MUAK@K;BP-F]EY>48X95DSGJ$=UZ=#UJM8_#_ .P>%=+TR/5I#J6FW)NX=0:+
M.Z4EL[TW<J58J1N''0BNTHH_K\;A_7X6_(Y.^\(ZAJ^C:Q:ZIKIFN-11(PT4
M#);VZH<C9"7;DG)+%LGCH !75@8 'I5'6=7M="TN34+S?Y,;(I"+DDLP50/Q
M85?H R=?T3^W(K!/M'D_9+Z&\SLW;_+.=O48SZ_I63<>"O/\.:_I']H;?[6O
M)+KS?)SY6]E.W&[YL;>N1UKK**%I_7I_D@>O]>O^;.6O?"E]_:>HW6D:U_9Z
M:HB+>J;<R.&5=GF0MO7RWVX&2&&0#CCE^H^#+35-0>6[N))+6327TQX6RSLK
M,#O\PG.[CN.O.:DN?%JK=WL&G:+JFJBQ;9<RV:Q!8Y,9*#S)$+L!@_*#U Z\
M5)/XPTB/0K+5H)9+N&_(2RBMXRTMPY!(15.,'@YW8 P<D8I=/ZZZ?KI^ ;?U
MV_X;4S[?PEJSZGI%SJNOQ7D&EAUCB2Q\HRAHRA,C;SEL$<J%'7CG@T[PAJ6G
M6]EI<7B%UT2RE5XH(X"ERR*<K$\P?!0' (" D  GKG2T_P 30WFJ'2[NPO=,
MU#RC-';W@CS+&" 61HW=#@D9&[(R,C!!IGA+Q=I_C/2'U+3HKF*))6A9+E K
M@@ YP"1@@@CFJOK?^OZN*VEBE<>"O/\ #FOZ1_:&W^UKR2Z\WR<^5O93MQN^
M;&WKD=:?>^%+[^T]1NM(UK^STU1$6]4VYD<,J[/,A;>OEOMP,D,,@'''-_PS
MXGLO%>G37UA'<)#%</!^_4*6*X^88)^4@@@^E;5*VWI^ ^K^?WWU.;NO#-W%
MK$>K:+JBVMW]E6SG%Y UTDT:DE20'1MX)/S;N<G(/6M71M/DTO2XK6>^N+Z9
M<M)<W#9:1B22<?PC)X4< 8':K]% '/:EX>O'UXZWHVI165[);BVG6XMC/%*B
MDLIVAT(8%C@[L8)R*J6G@>&QAT*.&^D8Z9>RWTLDB M<R2+(')P0%R9"> >F
M/>NLK)LM?BU%KQ;2SNI39WQLIA\@PP )?EAE0&'O[4+31?UK_FP?G_6G^19U
M;2K36]*N=,OX_,MKE"CJ#@_4'L0>0>Q%<Y?^$]:U?2GT74O$J2Z3(#'*8[ )
M=RQ\X5I2Y3/3)$8SCC&:["B@#$LO#J6FMZMJ'GEH]0A@A\G9CRQ&K+][/.=W
MH,8[USL7P^U)-)TG1V\0Q?V9I-U#<6T<=ALD<1R!E65O,PW'&55><,<XP>]H
MH6CO_6@K:6.'U#P'?S:;J6CV&O1V>CW\SSF V7F2Q,[;F59-X&PMDX*DX) (
MXQH7/A?4H-2U*[T/6H[ :F%-TDUIY^V0*$$D1#KM;:!]X,,@<=<Z^E:S;ZO)
MJ"6Z2J;&Z:TE\P 9=0"2,$\?,.N*T:.B_K0?4@L;46-A;VBS3S"&-8_-GD+R
M/@8RS'DD]S65KGA'0O$$=PU]I&G37DL)B6ZGM$DD3@@$$C/&<CFMRJ&I:O:Z
M4]BESOW7MTMK"$7.78$\^@PI-$ES:/J"TVZ$?A[1;?P[X?L=)MEB"6T*QEHX
MA&'8#YGVCH2<D^YJE?>'KD:W)K.B7\5C?3QK%=+/;F>&=5SM)0.A#C. P;IP
M0>,;4$SRF4/;2P['**9"I\P?WAM)X^N#QTJ:FW=W8DK*R.-O? *W^@:K9SZF
M[ZEJLT,]U?-".3&RE45 1M0!< 9)&222>MF;P9'+XAU?51>L!J%FUNL)CR(7
M951Y <\[ECC&./N]>:ZFBI:NK?UM;\AIVV*FEV7]FZ196'F>9]F@2'?MQNVJ
M!G';I5NBBJ;;=V)))604444AA7E?P#_Y$K5/^PQ/_P"@1UZI7E?P#_Y$K5/^
MPQ/_ .@1T >J4444 %%%% !1110 4444 %%%% '/V?\ R4/6?^P58?\ HV[K
MH*Y^S_Y*'K/_ &"K#_T;=UT% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%<A#XHU^]:Y>QT/37MH
MKJ>V1Y]4DC=O*E:,DJ(& R4)QD\&I/[<\5?] #1O_!Q+_P#(U>94SG 4YN$Z
MJ36C]2U3D];'5T5RG]N>*O\ H :-_P"#B7_Y&H_MSQ5_T -&_P#!Q+_\C5/]
MN9=_S^0_93['5T5RG]N>*O\ H :-_P"#B7_Y&H_MSQ5_T -&_P#!Q+_\C4?V
MYEW_ #^0>RGV.KHKE/[<\5?] #1O_!Q+_P#(U']N>*O^@!HW_@XE_P#D:C^W
M,N_Y_(/93['5T5RG]N>*O^@!HW_@XE_^1JCF\4:_9-;/?:'IJ6TMU!;.\&J2
M2.OFRK&"%,"@X+@XR.!54\YP%2:A"JFWHO43IR6MCKZ***],@**** "BBB@
MHHHH **** "BBB@ HHHH **** "LO4O#6@ZS<+<:IHFFWTZH$62ZM4E8+DG
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ME]"IA\-"E5=Y):O_ (<PFTY-H****["0HHHH **** "N?\/?\ASQ9_V%8_\
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MTZTN;)-NVWF@5XUV],*1@8[4V'1-)M[=+>'2[**%)%E2-+=%574 *P & 0
M#U&!33M*_P#3U3_2PI*ZM_6S7ZGC?B=S<^'O$/B2"VTRV-K>SHFIW[>?J!G2
M151(MH00*"/E&YN,97DFNCO-&T[5]=\>RZC:17;0VD#0^<NX1-]G8[T!^ZW
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MSEVFNF4MSV^554#CH *H1^&84UB/4)=0U"Y$,KS06\\P>.%W!!*\;NC, "Q
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M4_[#$_\ Z!'7=>(?%V@^%$M6US48[,74GEP[E9MQ[_=!P!D9)X&1S7"_ /\
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M10 4444 <_9_\E#UG_L%6'_HV[KH*Y^S_P"2AZS_ -@JP_\ 1MW704 %%%%
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M&4N,)*[4G9:_Y_UTW-#_ (37P]_T2OPU_P!]Q_\ R/5W1O&?A]_$&EQ)\-=
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M0_\ P70__$TE@)*_O[^7_!-)<5TI)*6&3MM>5[?^2GS95W1/^1GT+_L*V?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!3CTV&+6;G5%:3S[BWAMW4D;0L;2,I'&<YE;//8=.
M]RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img187335194_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &P \ # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN9\5V
MUT[6%Q]N9+6.]ML6R(!O8RJ,NW4CT QSR<\8.J0=&SIJ*YVXM;?5_%D]I?P)
M<6MM9QO'#*NY-[LP+8/&<* #VY]:R--9M5FTG3+\&YM8_M9=)AN67RI B;L_
M>P#W[C-"U!Z'<T5Q2V<UQ#=V$5L;NQT_5!_H>5P\)C#!!N(4A6;(!(& !Z4Z
MPN8M-BLH=5D98[#=MC5&F(E(+;<*"2(XR!GH-WM0!V=%,BECFB26)U>-U#*R
MG(8'H0:>2 "2< 4 %%1?:8/^>T?_ 'T*/M,'_/:/_OH4 2T5%]I@_P">T?\
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M^>T?_?0H^TP?\]H_^^A0!+147VF#_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\
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M%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147VF#_GM'_WT*/M,'_/:/\ [Z%
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M 2T5%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147VF#_GM'_WT*/M,'_/:/\
M[Z% $M%1?:8/^>T?_?0H^TP?\]H_^^A0!+147VF#_GM'_P!]"C[3!_SVC_[Z
M% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH4 2T5%]I@_Y[1_]]"C[3!_SVC_
M .^A0!+12*RLH92"#T(-+0 51U33_P"TK>*+S?+\NXBFSMSG8X;'7OC%7J*
M,N]TNXDU%=0T^[CMKDQ>3(98/-5USD<!E((.<'/<\57'AT6UO8?V?<B&ZL]^
MV:6/S!('Y?<H*YR>>",$?A6Y10!0TW33IUM,/.$MS/(TTTQ3 :0]]N> ,  9
MZ#KWK/N/#DC0V;6UZL5Y;B4-/)#O$AD'SDKN').".>.G-;]% +0KV%G'I^GV
MUE$6,<$2Q*6ZD 8&:L444-WU!*V@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<@VD;6P#CGV(I.+6Z&I)[,GHHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M?_GXD_)?\*/*?_GXD_)?\*EHH B\I_\ GXD_)?\ "CRG_P"?B3\E_P *EHH
MB\I_^?B3\E_PH\I_^?B3\E_PJ6B@"+RG_P"?B3\E_P */*?_ )^)/R7_  J6
MB@"+RG_Y^)/R7_"CRG_Y^)/R7_"I:* (O*?_ )^)/R7_  H\I_\ GXD_)?\
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M=J6J)%S2$\44'I0!D-_R']._ZZ/_ .BVK;U?_D#WG_7%_P"1K$;_ )#^F_\
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M+=/_ ,\X_P#OX?\ "C=/_P \X_\ OX?\*EHH BW3_P#/./\ [^'_  HW3_\
M/./_ +^'_"I:* (MT_\ SSC_ ._A_P *-T__ #SC_P"_A_PJ0LJXR0,\#-)O
M7^\* &;I_P#GG'_W\/\ A1NG_P"><?\ W\/^%/WJ/XA1YB?WU_.@!FZ?_GG'
M_P!_#_A1NG_YYQ_]_#_A3_,3^\/SH#H6"AAN(SC/- #-T_\ SSC_ ._A_P *
M-T__ #SC_P"_A_PJ6B@"+=/_ ,\X_P#OX?\ "C=/_P \X_\ OX?\*EHH BW3
M_P#/./\ [^'_  HW3_\ /./_ +^'_"I:* (MT_\ SSC_ ._A_P *-T__ #SC
M_P"_A_PJ1F5%+,P55&22< "H?MEK_P _$7_?8II-[";2';I_^><?_?P_X4;I
M_P#GG'_W\/\ A2?;+;_GXB_[[%)]MM?^?F'_ +[%/EEV#F7<=NG_ .><?_?P
M_P"%&Z?_ )YQ_P#?P_X4W[;:_P#/S#_WV*47EJ2 +B+)( &\<D]!2Y7V#F7<
M7=/_ ,\X_P#OX?\ "C=/_P \X_\ OX?\*EHI#(MT_P#SSC_[^'_"C=/_ ,\X
M_P#OX?\ "I:* (MT_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "I:* (MT_P#SSC_[
M^'_"C=/_ ,\X_P#OX?\ "I:* (MT_P#SSC_[^'_"@M/C_5Q_]_#_ (5+0>E
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M]<F_E6U6)XC_ .05=_\ 7)OY4 =/;?\ 'JG^[7'S_P#(8OO^N@_]!%=A;?\
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M_P#C\LO^ON'_ -&+7J"?<7Z5YF/^->AVX;X6.HHHKA.@**** "BBB@ HHHH
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M"I:*@HB^TP?\]H_^^A1]I@_Y[1_]]"I:* (OM,'_ #VC_P"^A1]I@_Y[1_\
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M+0>E ',V[!]0O&5@1YHP0?\ 9%:59T/_ "$KW_KJ/_016A3$+1244Q%/4?\
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M(_\ D%7?_7)OY4 =5;?\>J?[M<;<?\AF_P#^NH_] 6NRMO\ CU3_ ':XV?\
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M**!THKP3TPHHHH **** "BBB@ H/2B@]* .9B/\ Q,KW_KJ/_016AFLZ(_\
M$SO?^NH_]!%:&:8AV:,TW-&:8BGJ)_<M_NFKOAK_ )%VP_ZX)_Z"*HZB?W+?
M[IJ]X:_Y%RP_ZX)_Z"*3&C#U?_D8I?\ KBG\VIHZ4NL?\C%+_P!<4_FU,'2O
MG<7_ !I'NX?^#$=1245SFI'/]PUK^"_^0"/^NTO_ *,:L>?[E:_@K_D #_KM
M+_Z,:O1RW^(_0X\?_#7J9WC#_D+6/_7.3^:UF+]T5I>,3_Q-K'_KG)_-:RU/
MRBOL\'_!1\UB/XC'T4F:,UTF(V;_ %9K8\!?ZG4_^OL_^BTK%F/[LUL^ ?\
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M]3T,O_BOT)**3-+FO#/5"JU[_J&^AJSFJMZ?W#_0TT-'4^%?^17TW_KVC_\
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MBOA96!X%+FHP>*,U[QYA)FH;@_)3LU%<'Y*3 Z_P!_R*\7_76;_T8U=37)>
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M_/./_OX?\* ):*BW3_\ /./_ +^'_"C=/_SSC_[^'_"@"6@]*BW3_P#/./\
M[^'_  H+3X_U<?\ W\/^% ',+_R%K[_KJ/\ T$5>S6>A/]JWVX 'S1P#G^$5
M?JA"YHS244"*FHG_ $=_]TUI^&/^1:T__KW3_P!!%96H_P"H?_=-:/AEIO\
MA&]/Q'&1]G3&7/\ ='M28T8FM_\ (R2?]<$_]":HQTIVLESXCDW@ ^0G0Y_B
M;VJ,=*^;QG\>1]!AOX,1U%)17*;$<_W#6WX'_P"1>7_KM-_Z,:L.?[E;'@DR
M_P#"/KM1"/.EY+D?\M&]J]/+/XC]#AS#^''U,SQP?^)MI_\ N2_^RUC*?E%:
MOC<O_:NG[U5?DEQM;/\ =]A6.I^45]O@?X*/EL1_$9)FC-,S1FNPQ$F/[LUT
M/PZ_X]=3_P"OP_\ HM*YN8_NS70?#PR?9=3V*A'VP]6Q_P LT]JX,P_A?,Z<
M+\9W5%1;I_\ GG'_ -_#_A1NG_YYQ_\ ?P_X5XIWDM%1;I_^><?_ '\/^%&Z
M?_GG'_W\/^% $M%1;I_^><?_ '\/^%&Z?_GG'_W\/^% $M%1;I_^><?_ '\/
M^%&Z?_GG'_W\/^% $M9?B#_D$2?[Z?\ H0J_NG_YYQ_]_#_A69KYE_LE]R(!
MO3D.3_$/:@"K"?EJ6H83\M29JB1U(>E)F@GB@#-7_D9-+_ZZO_Z+:NCUK_D"
M7W_7!_\ T$US(+#Q'I>T GS7P"<?\LVKH=9:;^Q;W,<8'D/G#G^Z?:HG\++A
M\2.2M_\ 5+]!4U06_P#JU^@J:OE#Z5[BT4E%(12N/^/_ $__ *_(?_0Q7H5S
M_P >K_[M>=W)/VZPQ@G[9#C)_P!L5W]RT_V5_P!W']W_ )Z'_"O<RW^&_4\K
M,?XB]#RK3C_HD7^Z*NYK/TX_Z+%_NBKN:^XCL?+O<?FC-,S1FJ J3'_B8V'_
M %^0?^C%KU]/N+]*\=F)_M&PQU^V08S_ -=%KUU&GV+^[CZ?\]#_ (5XN8?Q
M%Z'?A?A9/146Z?\ YYQ_]_#_ (4;I_\ GG'_ -_#_A7 =)+146Z?_GG'_P!_
M#_A1NG_YYQ_]_#_A0!+12+N*C< #W .:6@ HHHH K7FG6.HJJWUE;W2H<J)X
ME<*?;(IUQ96EW;?9KFUAF@X_=21AEXZ<'BIZ* (X[>&*W6WCAC2!5V"-5 4+
MZ8Z8J*XTZQN[9+:YLK>:"/&R*2)65<# P",# JS10 =!@4444 %%%% !1110
M U_N-]*Y*P^]-_UWD_\ 0C76O]QOI7(6!^>?_KO)_P"A&FA,TJ*;FC-,0ZL7
MQ'_R";O_ *Y-_*MC-8OB,_\ $IN_^N3?RH [6V_X]4_W:X>[_P"0[J'_ %T7
M_P! 6NXMO^/5/]VN&N_^0[J'_71?_0%KS<R_@KU/1R[^*_0DHIM&:\(]<=56
M]/[A_P#=-6,U6O?]0_\ NFA#1UOA7_D5]-_Z]H__ $$5R'BPX\5-_P!>R?\
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M %^P_P#H8JQFJH/_ !.--_Z_8?\ T,5E6_AOT+I_$CUP=**!THKYP]4****
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M^_ZX/_Z":B?PLN'Q(XRW_P!4OT%2YJ"W_P!4OT%35\D?3O<7-&:2B@12N?\
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MV/%/_( F_P!Y/_0Q7-1]*Z'Q//$^@S*LJ,2R<!@?XQ7.Q]*\/,_XB]#V<O\
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M=FC--HKE-[#)S\E;_@;_ )%Q/^NTW_HQJY^?[AK<\#SQ+X=0-*BD33<%@/\
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M]I@_Y[1_]]"O/.HEHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*165E#*00>A!I:
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MU\#_ -!:J<9^2FA,ES1FFYHS3$*Q^4U2T?\ Y&Y?^O.3_P!#2K;'Y35/1O\
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MZ'I83X&.HHHKSCJ"BBB@ HHHH **** "BL?67N(6,\FK1Z9IT4>6F&S>TA/
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MV_Y$ZW_ZZS?^C7KKJ^7J_P 27JSVH?"@HHHK,H**** "BBB@ HHHH P_$O\
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M2#_Q--,_W)?_ &2N64_**^^P'\!?/\SX_%?Q62YHS4>:,UVG.$I^0UV7PO\
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M+XT>W"!,?>D_[^-_C1Y"?WI/^_C?XU*.E%?,'LD7D)_>D_[^-_C1Y"?WI/\
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M7S@X_P"6;UU&MP(-#OB#)Q _61O[I]ZYFS_Y&;3?^NC_ /HMJZO7/^0%?_\
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MSP[<JRQJC$9!!Y#*<@]ZHQ33:=);C3?*59DF6WGNU+KY48W,QP5^:1R6SG&
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M 'F9]1@_]W@%%%%<9TD<WW*Z7P(9AX;0+&A'G3=7(/\ K6]JYF;[AKK/ O\
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MQ%Z'JX'X&,W3_P#/./\ [^'_  HW3_\ /./_ +^'_"I:*\P[2+=/_P \X_\
MOX?\*-T__/./_OX?\*EHH 1=Q4;@ >X!S2T44 %%%% !13)98X(GEFD6.- 6
M9W. H'<D]*9<W=M96YN+JXB@A&,R2N%49Z<GB@":BJSZA9160O9+RW2T(!$[
M2 (0>AW9QS4@NK<QQ2">(I,0(FWC#Y&1M/?CGB@"6BBB@ HHHH **** &O\
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M2U_Z^!_Z"U947W:U?%?_ !Z6O_7P/_06K)B^[30F244E%,0-]TTSP]_R-/\
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M17R9[X4444 %%%% !1110 4'I10>E '"W'_(<O\ _KHO_H(JQ5:X_P"0Y?\
M_71?_015BJ$+1244"*E__J6^E=1X8_Y%O3_^O=/_ $$5RU__ *IOI74^&/\
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MG]V3_OVW^%'GI_=D_P"_;?X5+12&1>>G]V3_ +]M_A1YZ?W9/^_;?X5+10!
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MZ?W9/^_;?X5+10!SGBF57M;4 /\ \? ZH1_"WJ*S(ONUK>*_^/2T_P"O@?\
MH+5D1'Y::$R2BC-&:H0C?=-1Z X3Q1DAC_HK]%)_B3TI['Y32>'?^1I/_7J_
M_H24F,UO%DRMX=N  ^=R=4(_C'M7')TKM?%W_(MW/^\G_H:UQ4?2OF<Z_C1]
M/U9]!E7\&7K_ )#Z***\<],*71V"^*]-)SC>_09_Y9MZ4E.T7_D;=,_WY/\
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M,/\ >9GU6"_W> M%)17$=)'-]PUU7@>54\.1@A\^;+T0G_EHWH*Y6;[AKK?
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MJ6H8/]6OTJ6OA6?8L6BDHI"*X.-4T\G/%W#T&?XQ7IES.GV5^)/N_P#/-O\
M"O,U_P"0KIW_ %^0_P#H8KU&Y_X]7_W:^ER;^#+U/"S;^+'T/G2S/[A/I5JJ
MEF?W*?2K.:_2H['PSW'44W-&:8KBV9QKVF'GB]@Z?]=%KZ!2=-B\2=/^>;?X
M5\^V/_(?TO\ Z_H/_1BU]#I]Q?I7@9K_ !%Z'K8#X&,\]/[LG_?MO\*//3^[
M)_W[;_"I:*\L[R+ST_NR?]^V_P *//3^[)_W[;_"I:* $5@R@C.#ZC%+110
M4444 %%%% !1110 4444 %%%% !1110 U_N-]*X&W_X^+G_KO)_Z$:[Y_N-]
M*X&#_CYN?^N\G_H1IH3+E%)15"%K)US_ (\+C_</\JU:R=</^@7'^X?Y4@/1
M;;_CU3_=KSK5/^1CU#_KHO\ Z M>BVW_ !ZI_NUYUJG_ ",6H?\ 71?_ $!:
M\?.?]W7JOU/5RG^._3_(CHHHKY<^@"J]W_J6^E6*KW?^I;Z4UN"._P#"O_(K
MZ;_U[1_^@BO,OB3_ ,CDO_7HG_H;UZ;X5_Y%?3?^O:/_ -!%>8_$K_D<D_Z]
M$_\ 0WK])RK^+'T/@\P_AR]3FATI::.E+7U!X(M13?<J2HION4GL-'K_ ,,?
M^1(M/]^;_P!&M78UQOPP_P"1(M/]^;_T:U=E7R-;^++U9]%2^"/H%%%%9&@4
M444 %%%% !1110!S_BS_ (\[3_KX'_H+5D1?=K7\6?\ 'G:_]? _]!:L>(_+
M30F2449HS5"$;[IIOAW_ )&K_MU?_P!#2E8_*:3P[_R-7_;H_P#Z&E)C-OQ?
M_P BW<_[R?\ H:UQ,?2NV\7_ /(MW/\ O)_Z&M<3'TKYC.OXT?3]6?0Y3_!E
MZ_HA]%%%>,>F%.T7_D;M,_WY/_1;4WM3M%_Y&[3/]^3_ -%M77@?]XAZHY\5
M_ GZ'<>)O^16U7_KTE_] ->"P'Y!]*]Z\3?\BMJW_7I+_P"@&O X#\@^E?IV
M4?#(^ S'>)/FC-)17LGF7%S4FDG_ (J?2/\ K^A_]#%15)I/_(SZ1_U_0?\
MH8K'$?PI>C-:/\1>I]#CI10.E%?(GT04444 %%%% !1110 4'I10>E '"7/_
M "'+_P#ZZ+_Z"*GJ"Y_Y#E__ -=%_P#014U4A"T4E%,14O\ _4M_NUU7AC_D
M6]/_ .O=/_017*7_ /J6^E=5X8_Y%O3_ /KW3_T$5+&CE/$__(S-_P!>Z?\
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M%PDUPJ*0TT1*J@# @!B"<=3C -;NEWMYJ$\;2CR4A@07$84<SLH8KSR-H_\
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MTG_?QO\ &CR$_O2?]_&_QH EHJ+R$_O2?]_&_P :/(3^])_W\;_&@#$\6?\
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M!PCPT'%N]SS\9B5B)J25K'S?:?ZA#[58W5[L/"GA\# T:R _ZXBC_A$_#_\
MT!K+_OR*^H_M9+[)\_\ V<^YX3NHW5[M_P (GX?_ .@-9?\ ?D4?\(GX?_Z
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MQ#"Z^0?-)*58<<@ %2,8&3B@#>/B'&J_8?LO_+Z+3?YGK%YF[&/PQ^-7=4U
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M98II(9;26+S$5P64;U 8X!X[UG:A:W&I3:G?6MG<?97-INBDA:-[CRW+/A&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img187335194_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ([!24# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *PO$OB>T\.6@+JT][*K?9[6,9:0@=?91W-;M9VLPQ'2KZ
M8QH91:2J'VC<!M/&?2JC:^HI7MH4;#Q%N\#P^(=05%/V3[1*L0(&<9P,D_2L
M9O$_B/3].M-=U6RT]=(G9#+%"7\^W1R K,3\K8R,@ =:K-#)<? X1Q*6?^S
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M\: )**CQ-_?3_O@_XT8F_OI_WP?\: )**CQ-_?3_ +X/^-&)O[Z?]\'_ !H
MDHJ/$W]]/^^#_C1B;^^G_?!_QH DHJ/$W]]/^^#_ (TG[T?\M(_^^#_C0!+1
M47[W_GI'_P!\'_&C][_STC_[X/\ C0!+147[W_GI'_WP?\:/WO\ STC_ .^#
M_C0!+147[W_GI'_WP?\ &C][_P ](_\ O@_XT 2T5%^]_P">D?\ WP?\:/WO
M_/2/_O@_XT 2T5'B;_GHG_?!_P :,3?WT_[X/^- $E%1XF_OI_WP?\:,3?WT
M_P"^#_C0!)14>)O[Z?\ ?!_QHQ-_?3_O@_XT 245'B;^^G_?!_QHQ-_?3_O@
M_P"- $E%1XF_OI_WP?\ &C$W]]/^^#_C0!)14>)O[Z?]\'_&C$W]]/\ O@_X
MT 245'B;^^G_ 'P?\:,3?WT_[X/^- $E%1XF_OI_WP?\:,3?WT_[X/\ C0!)
M14>)O[Z?]\'_ !HQ-_?3_O@_XT 245'B;^^G_?!_QHQ-_?3_ +X/^- $E%1X
MF_OI_P!\'_&C$W]]/^^#_C0!)14>)O[Z?]\'_&C$W]]/^^#_ (T 245'B;^^
MG_?!_P :,3?WT_[X/^- $E%1XF_OI_WP?\:,3?WT_P"^#_C0!)14>)O[Z?\
M?!_QHQ-_?3_O@_XT 245'B;^^G_?!_QHQ-_?3_O@_P"- $E%1XF_OI_WP?\
M&C$W]]/^^#_C0!)14>)O[Z?]\'_&C$W]]/\ O@_XT 245'B;^^G_ 'P?\:,3
M?WT_[X/^- $E%1XF_OI_WP?\:,3?WT_[X/\ C0!)14>)O[Z?]\'_ !HQ-_?3
M_O@_XT 245'B;^^G_?!_QHQ-_?3_ +X/^- $E%1XF_OI_P!\'_&C$W]]/^^#
M_C0!)14>)O[Z?]\'_&C$W]]/^^#_ (T 245'B;^^G_?!_P :,3?WT_[X/^-
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MG_?!_P :,3?WT_[X/^- $E%1XF_OI_WP?\:,3?WT_P"^#_C0!)14>)O[Z?\
M?!_QHQ-_?3_O@_XT 245'B;^^G_?!_QHQ-_?3_O@_P"- $E%1XF_OI_WP?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*DKE]1N7D\2:/DX43OA?^V3UTXZ4 <YXK^Y8_P#7R/\ T%JI+TJ[XK^Y8_\
M7R/_ $%JI+T%>+C_ .+\CUL'_"^8M%%%<1TA1110 4444 17'^K;Z5H^"/\
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M_&C01AR_\C#)_P!<%_\ 0FK0K.=0OB"0#/\ J5ZDG^)O6M&@ HHHIB"BBB@
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M];!_POF.HI**XCJ%HI** %HI** (Y_\ 5M]*T?!'_(NQ_P#7:?\ ]&O6;/\
MZH_2K_@J-6\/1DE_]=/T<C_EJ]>AEWQOT./'? O4Z*X_U+?2O/;;_7W7_7Q)
M_P"A&N^N(5\EN7Z?\]&_QK@;48FNAZ7$G_H1KZ7 _$_0\/$_"BU1117H'&%%
M%% !1110 'I5?1?^1RB_Z])/_0XZG/2J^CJ&\8Q Y_X]9.A(_CCK+$?PI&M'
MXT>BCH*6HA"N!R__ '\;_&E\E?5_^_C?XUX^AWDE%1^2OJ__ '\;_&CR5]7_
M ._C?XT: 245'Y*^K_\ ?QO\:/)7U?\ [^-_C1H!)14?DKZO_P!_&_QH\E?5
M_P#OXW^-&@$E%1^2OJ__ '\;_&CR5]7_ ._C?XT: 245'Y*^K_\ ?QO\:/)7
MU?\ [^-_C1H!)14?DKZO_P!_&_QH\E?5_P#OXW^-&@$E%1^2OJ__ '\;_&CR
M5]7_ ._C?XT: 245'Y*^K_\ ?QO\:/)7U?\ [^-_C1H!)14?DKZO_P!_&_QH
M\E?5_P#OXW^-&@$E%1^2OJ__ '\;_&CR5]7_ ._C?XT: 245'Y*^K_\ ?QO\
M:/)7U?\ [^-_C1H!)14?DKZO_P!_&_QH\E?5_P#OXW^-&@$E%1^2OJ__ '\;
M_&CR5]7_ ._C?XT: 245'Y*^K_\ ?QO\:/)7U?\ [^-_C1H!)14?DKZO_P!_
M&_QH\E?5_P#OXW^-&@$E%1^2OJ__ '\;_&CR5]7_ ._C?XT: 245'Y*^K_\
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MC1H!)14?DKZO_P!_&_QIRH$Z%OQ8G^=(8ZBBB@ HHHH **** "BBB@ HHHH
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M ".47_7I)_Z''6.)_@R-:/QH]%'04M(.@I:\8] **** "BBB@ HHHH ****
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M;_"I**-!$?G+Z/\ ]^V_PH\Y?1_^_;?X5)11H!'YR^C_ /?MO\*;),NP\/\
M]^V_PJ:FR?</THT YW2CG[0?^F\G_H1K3K-TOK<_]=Y/_0C6E3$%%%% !111
M0 4'I10>E &#?$+XAT@G/^O?H,_\LGKJEF7 X?\ []M_A7+7G_(Q:1_UW?\
M]%/76K]T4AHYKQ3('6R #?\ 'P.JD?PMZU37H*O>*_N6/_7R/_06J@O05XF8
M?QOD>O@_X7S'44E%<)U"T4E% "T4E% $=Q_JV^E7_!4BKX>C!#_ZZ?HA/_+5
MZSY_]6?I6GX(_P"1=C_Z[3_^C7KT<N^-^AQ8[X%ZFW<3+Y+</T_YYM_A7G]J
M<SW1_P"GB3_T(UZ)<?ZEOI7G=M_Q\7?_ %\2?^A&OI<#\3]#P\3\*+5%)FC-
M>D<8M%)FC- "T4F:,T !Z5!HS!?&,1.?^/63H"?XXZG)XJ'1/^1RB_Z])/\
MT..L<3_!D:T?C1Z")EP.'_[]M_A2^<OH_P#W[;_"GCH*6O&T.\C\Y?1_^_;?
MX4><OH__ '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A
M1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;_"I**- (_.7T?_OVW^%'
MG+Z/_P!^V_PJ2BC0"/SE]'_[]M_A1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><
MOH__ '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A1YR^
MC_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;_"I**- (_.7T?_OVW^%'G+Z/
M_P!^V_PJ2BC0"/SE]'_[]M_A1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__
M '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A1YR^C_\
M?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^
MV_PJ2BC0"/SE]'_[]M_A1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;
M_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A1YR^C_\ ?MO\
M*DHHT C\Y?1_^_;?X4><OH__ '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ
M2BC0"/SE]'_[]M_A1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;_"I*
M*- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A1YR^C_\ ?MO\*DHH
MT C\Y?1_^_;?X4><OH__ '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0
M"/SE]'_[]M_A1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;_"I**- (
M_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A1YR^C_\ ?MO\*DHHT C\
MY?1_^_;?X4><OH__ '[;_"I**- (_.7T?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE
M]'_[]M_A1YR^C_\ ?MO\*DHHT C\Y?1_^_;?X4><OH__ '[;_"I**- (_.7T
M?_OVW^%'G+Z/_P!^V_PJ2BC0"/SE]'_[]M_A3E</T#?BI'\Z=12&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4=J*.U '/3?\ (Q2?]<%_]":K
M]4)_^1BD_P"N"_\ H35?IH04444Q!1110 4444 8/BK_ ) 5Y_UQ;^5=7;_Z
ME?I7*>*O^0%>?]<6_E75V_\ J5^E)C1F^)/^0+=_]<6_E7/VW^H3Z"N@\2?\
M@6[_ .N+?RKG[;_4)]!7D9EO$]/ _#(EHHHKS#N"BBB@ HHHH 9)]TU+X,_U
MNI_]?9_]%I44GW#4O@S_ %NI_P#7V?\ T6E=^7_Q?D<N-_A?,Z\]#7!:U_R,
MS_\ 7NG_ *$U=Z>AK@=;_P"1F;_K@G_H35])@_XJ/#Q'P#:*2BO7//%HI**
M%HI** %K.O?^/W3_ /K]M_\ T8M:%9UY_P ?VG_]?L'_ *,6HJ? _0N'Q(]1
MC^X*=38_N"G5X)Z84444 %%%% !39/N'Z4ZFR?</TH Y[2^MS_UWD_\ 0C6E
M69I?6Y_Z[R?^A&M*J)%HI** %HI** %I#THH/2@#"O/^1BTC_KN__HIZZY?N
MBN1O/^1CTC_KN_\ Z*>NN7[HI,:.<\6?<L?^OD?^@M5!>@J_XL^Y8_\ 7R/_
M $%JH+T%>'F'\7Y'KX/^%\Q:***X3J"BBB@ HHHH BG_ -6?I6GX(_Y%V/\
MZ[3_ /HUZS)_]6?I6GX(_P"1=C_Z[3_^C7KT<M^-^AQX[X%ZF_<?ZEOI7G5M
M_P ?%W_U\2?^A&O1;C_4M]*\ZMO^/F[_ .OB3_T(U]-@/B?H>%B?A1:HI**]
M(XQ:*2B@!:*2B@ /2H=#_P"1RB_Z])/_ $..I3TJ+0_^1RC_ .O23_T..L<3
M_!D:4?C1Z,.@I:0=!2UXIZ(4444 %%%% !1110 4444 %%%% !1110 4444
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M^0%>?]<6_E75V_\ J5^E<GXJ/_$BO?\ KBW\JZRW_P!2OTI,:,WQ)_R!;O\
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MHH **** (I_]6WTK4\$?\B['_P!=I_\ T:]9<_\ JV^E:G@C_D78_P#KM/\
M^C7KT<M^-^AQX[^&O4W[C_4M]*\YM_\ CYN_^OB3_P!"->C7'^I;Z5YS;_\
M'S=_]?$G_H1KZ; ?$_0\+%?"BU1245Z9Q"T4E% "T4E%  3Q4.A?\CG'_P!>
MDG_H<=2GI46A?\CE'_UZ2?\ H<=88G^#(UH_Q$>CCH*6D'04M>*>B%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMG+*N,]SU)QDXHYXM68N1IW1T%%%%8FHPF7)PB$>['_"DS-_<3_OL_X5)13
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M3_OL_P"%244 1YF_N)_WV?\ "C,W]Q/^^S_A4E% $>9O[B?]]G_"C,W]Q/\
MOL_X5)10!'F;^XG_ 'V?\*,S?W$_[[/^%244 1YF_N)_WV?\*,S?W$_[[/\
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M)10!'F;^XG_?9_PHS-_<3_OL_P"%244 1YF_N)_WV?\ "C,W]Q/^^S_A4E%
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MHH **** "BBB@ HHHH **** "CM11VH YVX_Y&)_^N"?^A-5ZJ-Q_P C$_\
MUP3_ -":KU-""BBBF(**** "BBB@#!\5?\@*\_ZXM_*NMM_]2OTKDO%7_("O
M/^N+?RKK;?\ U*_2DQHS?$G_ "!;O_KB_P#*N=MO]0GT%=%XD_Y EW_UQ?\
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M4>@?\CG'_P!>DG_H<=88K^#(UH?Q$>DCH*6D'04M>&>D%%%% !1110 4444
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M@K_6:G_U]G_T6E>AEW\7Y')C?X7S.P/0UY[KW_(SM_U[I_Z$U>A'H:\]U_\
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M7PHM44F:,UZIPBT4F:,T +129HS0 -TIGA__ )'./_KTD_\ 0XZ<QXIGA_\
MY'./_KTD_P#0XZY\5_!9M0_B(]*'04M(.@I:\,](**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-24=J+L5CFIU">(7 S_ *E>I)_B:K]4;G_D8G_ZX+_Z$U7J8!1110(****
M"BBB@#!\4_\ ("O/^N+?RKJ[>%?)7E^G_/1O\:Y3Q3_R KS_ *XM_*NOM_\
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M2UX=V>E8C\E?5_\ OXW^-'DKZO\ ]_&_QJ2BB["Q'Y*^K_\ ?QO\:/)7U?\
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MW^-'DKZO_P!_&_QJ2BB["Q'Y*^K_ /?QO\:/)7U?_OXW^-244786(_)7U?\
M[^-_C3E0)T+?BQ/\Z=12N.P4444 %%%% !1110 4444 %%%% !1110 4444
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M J1ZYZ5R-M90:Q\2=9>_BCN$TZUMXK>.50RKY@+,0#QGC&:R$T^<P>//#6E
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M9-(_Z[/_ .BGKLE^Z*XRZ95\1Z06( \Y^3_UR>NO6>' _>I_WT*5AG/>+O\
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M3_T)J*-7_P"1E;_KW3_T)J*\#%_QI'LX?^%$****YS8**** "BBB@#'\2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT 8?BC_D"7G_ %R;^5=M;_ZE?I7$^*/^0)>?]<F_E7;6_P#J5^E)C1F>)?\
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M,U] >2.S1FFYHS0 [-&:;FC- #LU48_\3;3/^OZW_P#1BU9S54G_ (FVE_\
M7];_ /HQ:RK_ ,.7H72^-'M,?W!3J;']P4ZOF#VPHHHH **** "FR?</TIU-
MD^X?I0!R6G_ZVZ_Z^)/_ $(U?K/T_P#UMU_U\2_^A&K]42+1244 +1244 +1
MVI*.U &1+_R,VD?]=G_]%/7;K]T5P\G_ ",VD?\ 79__ $4]=POW128T<QXQ
M_P!19?\ 7R/_ $!JR%Z"M?QE_J+'_KY'_H#5CJ>!7SN9_P ?Y'N8#^#\QU%)
MFC-><=HM%)FC- "T4F:,T 1S_P"K/TK=\"_\BU%_UVG_ /1KU@S_ .K/TK>\
M"?\ (M1?]=I__1KUZN5?Q)>AY^8_PX^IT-Q_J6^E>0Y_XF-__P!?4O\ Z&:]
M>N/]2WTKR _\A&__ .OJ7_T,U]?EO\1^A\WC?A1-FC--S1FO:/-'9HS3<T9H
M =FC--S1F@!2>*L>$O\ D=5_Z\Y/_0XZK$\58\(_\CJO_7G)_P"AQUR8W^#(
MWPW\1'JXZ"EI!T%+7SQZX4444 %%%% !5:^_X]F^E6:K7W_'LWTH Q=%_P"0
M9!_N"M&LW1?^09!_N"M&J)%HI** %HI** %IK_<-+37^X: ,?1_^1HO_ /KC
M#_-ZZWM7):/_ ,C1?_\ 7&'^;UUO:I*.-UC_ )&5O^O=/_0FIM+K/_(RM_U[
MK_Z$U-KY[%_QI'MX?^%$6BDS1FN8V%HI,T9H 6BDS1F@#)\1_P#(%N_^N3?R
MKT:W_P!2OTKSCQ'_ ,@6[_ZY-_*O1[?_ %*_2O7RWX9'G9AO$H>(_P#D7[__
M *]Y/_037%VI_<)]*[/Q'_R+^H?]>\G_ *":XNU/[A/I7TV ^&1X>*W18S1F
MFYHS7<<H[-&:;FC- #LT9IN:,T #GY:G\%_\A_5O^N4'\Y*K.?EJSX)_Y#^K
M?]<H/YR5S8S^"S;#_&=Y1117CGH!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5=26^?3;A=->&.]9"(7F!V*WJ<5P5R
MT^A:SI%GI_B*^U+6I+F-+VREN/-0QD9=BN/W8 Y'3CUKNM6O+C3])N;NULVO
M)H4+K;JVTR8[ X/\J\]\2ZKHOBFPMH- @W^(I;B.2)HX"DMLP(+-(V!@  @\
M^GI6]%/Y?UN95&OF;UV+SQ%XTO=*&H7EEI^FV\;.+.4Q/)+)DC+#G  /'K6>
M-9U;3-!\6Z<;J2YO=& ,%S)AI#'(NY2WJ0,\^U6KC4H/"OCW4KS5&,&GZI;P
MF.Y*$HLD8*["1T.#FK'@]&U'5/$.OF%EM=3FC2W\Q"IDCB38&P>QR:>RNUII
M]_\ 5Q;NW74H:=K$6AZO=K_;%QJ.E1:2MY+)-.9BLN[ "D\C</X:Z?PY!?QZ
M7]HU.20WMVYN)(F<E8-W2-0>@48'UR:QI-.L;_Q-'I-A96UOI^GNMW?"&)4$
MLW6)#@<XY<_\!KF]%$/]IZ-Y/G?\)-_:,W]J9W;_ "<OG?GC;_J]OZ<T.*DO
MZ_K^D";BSU2BBBN<V"BF&)2227_!R/ZTGDKZO_W\;_&GH!)1VJ/R5]7_ ._C
M?XT>2N.K_P#?QO\ &C01S-__ ,C(W_7!/_0FJQ56^4)XC< G_4)U)/\ $U6:
M8"T4E% A:*2B@!:*2B@#$\3_ /($O/\ KDW\J[FW_P!2OTKAO$__ "!+S_KD
MW\J[6WA7R5Y?I_ST;_&D-%#Q-_R KS_KB_\ *N2M_P#4I]!74^)8E&AWAR_^
MI?JY]/K7*V_^H3Z"O#S?XHGL9;\,B?-&:;17CGI#LT9IM% #LT9IM% "2?=-
M7O W74_^OL_^BTJ@_P!TU<\#H';4B2W_ !]GHQ'_ "S3TKT\K_C?(X<P_@_,
M[8]#7EWBW_D;/^W9/_0FKTTPK@\O_P!_&_QKR_Q:H3Q7@9_X]DZDG^)J^MP'
M\='S>*_A,HT4W-&:^@/)'44W-&: '44W-&: '55S_P 3?2_^OZW_ /1BU8S5
M7KJVF#UOK?\ ]&+65?\ AR]#2E\:/;8_N"G5#'"NP<O_ -_&_P :=Y*^K_\
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M ._C?XT>2OJ__?QO\:- )**C\E?5_P#OXW^-'DKZO_W\;_&C0"2BH_)7U?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 44$@#)X%4+?6])N[HVMMJEE-<#K%'<(S_D#FG9L+E^BJ
MU[J-CIL2R7][;VL;' :>54!/IDFI8KB">W6XBFCDA8;A(C J1ZYZ46>X7)**
MK6>HV.HH[V-[;W2H<,8)5<*?0X/%217,%P\J0SQR-$VR0(X)1L9P<=#@CBBS
M"Y+1112 **** "CM11VH Y/4?^1E;_K@G_H35-FH-2_Y&5O^O=/_ $)JFS3$
MQ<T9I,T9IB%S1FDS1F@!<T9I,T9H Q?$W_(%O/\ KDW\J[RW_P!2OTK@O$Q_
MXDMY_P!<F_E7>V_^I7Z4F-&7XF_Y 5[_ -<'_P#037(6_P#J4^@KK_$__("O
M?^N#_P#H)KC[?_4I]*\'-_BB>SEGPR)J*2BO'/3%HI** %HI** &R?=-:/@3
M_F)_]?9_]%I6<_W36CX$_P"8G_U^'_T6E>GE7\9^APYC_!^9VAZ&O*?&1_XJ
MT?\ 7JG_ *$]>K'H:\H\9_\ (VC_ *]4_P#0GKZ_+_XZ/F<7_"9F9HS3,TN:
M^B/''9HS3<T9H =FC--S1F@!V:KJ?^)SI7_7_;_^C%J7-0(?^)UI7_7_ &__
M *,6L:_\.7H:4OC1[G']P4ZFQ_<%.KY8]T**** "BBB@ ILGW#]*=39/N'Z4
M <=8G]_=_P#7Q+_Z&:O9JA8G]_=_]?$O_H9J]FJ)%S1FDS1F@!<T9I,T9H 7
M-(3Q1FD)XH RV_Y&?2/^NS_^BGKNE^Z*X1O^1GTC_KL__HIZ[M?NBDQHY;QI
M_P >]C_U]#_T!ZQ1TK:\:?\ 'O8_]?0_] >L0=!7S>:?Q_D>]E_\#YCJ*2BO
M-.X6BDHH 6BDHH CF_U9^E=#X#_Y%B'_ *[3_P#HUZYV;_5FNB\!_P#(L0_]
M=I__ $:]>ME'\27H>=F?\./J=%<?ZEOI7B\G_(4U#_KZE_\ 0S7M%Q_J6^E>
M+2G_ (FNH?\ 7W+_ .AFOLLL_B/T/F,=\"),T9IN:,U[9Y8[-&:;FC- #LT9
MIN:,T *QXJ]X,_Y'8?\ 7G)_Z''6>3Q5_P %?\CL/^O.3_T..N3'?P)'1A?X
MJ/71T%+2#H*6OG#V0HHHH **** "JU]_Q[-]*LU6OO\ CV;Z4 <_HW_(-A_W
M!6AFL[1C_P 2V'_<%:&:HD7-&:3-&: %S1FDS1F@!<TUS\II<TUS\IH R]$_
MY&>__P"N,/\ .2NP[5Q^A_\ (SZA_P!<8?YR5V':I*1Q6M_\C,?^O9/_ $)J
MCI^N?\C,?^O9/_0FJ+-?-XW^/(][#?P8CJ*2BN4W%HI** %HI** ,GQ%_P @
M:[_ZY-_*O2[?_4K]*\R\1?\ (&N_^N3?RKTVW_U*_2O9ROX9'F9CO$SO$O\
MR+FH_P#7M)_Z":X"U/[A/I7?^)?^1<U'_KVD_P#037GMJ?W"_2OJ\MVD?/XS
M=%K-&:9FC->E8XQ^:,TS-&:+ /S1FF9HS18!7/RU?\!G.NZO_P!<H/YR5FN?
MEK1\!'.NZQ_US@_G)7'COX+.C#?Q#T*BBBO#/2"BBB@ HHHH **** "BBB@
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M3-&:+@9/B'_D#7?_ %R;^5>E6\\/DK^]3I_>%>:>(3_Q)KO_ *Y-_*O3[?\
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M&5OH<TZBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[44=J
M.1U3_D9F_P"O=/\ T)JDS46J?\C,W_7NG_H35)FF)BYHS29HS3$+FC-)FC-
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M2E\:/>H_N"G4V/[@IU?*'OA1110 4444 %-D^X?I3J;)]P_2@#BK+_CXN_\
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M]T_]":GTQ,6BDHIB%HI** %HI** ,7Q-_P @6[_ZY-_*O0K?_4K]*\\\2_\
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MDS1F@!<T9I,T9H 7-!/%)F@GB@#,'_(TZ/\ ]=G_ /13UWZ_=%< /^1IT?\
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M_P"1EU#_ *Y0_P Y*[3M4E'"^(/^1G/_ %[)_P"A/5>I_$/_ ",Y_P"O9/\
MT)ZK9KY;'/\ VB1]%A/X$1U%-S1FN2YT#J*;FC-%P'44W-&:+@9?B _\2:Z_
MZY-_*O4[?_4K]*\K\0?\@>Z_ZY-_*O5+?_4K]*]S*/AE\CRLTWB9GBC_ )%G
M4_\ KUE_] ->6VS?N5^E>I>*?^18U/\ Z]9?_0#7E%LW[E?I7V&5[2/F<=NB
MWNHW5'FC->K8X;DFZC=4>:,T6"Y)NHW5'FC-%@N.=OEK<^'!SK6L_P#7.W_G
M)7/NWRUO_#4YUG6?^N=O_.2N',/X#.G"?Q$>ET445X!ZP4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)HDN()(95W1R
M*489Z@C!KD+2QM=.^)MO:65O'!;QZ$P6.-< ?OUKLJSSI%N?$*ZUOE^TBT-I
MMR-FPN'SC&<Y'K^%7&5KDR5[&%HQ1?B3XF5Q^\>"T://=0K X_'%4;'38-<\
M1^.[&1B+.Y-M"2@P0XBPQ'N#C\JZ#5_#%IJU_#?BYO+&^B0QBYLY0CE#SM.0
M01^%6M%T2TT*R-K:>8V]S+++*^Z25SU9CW)J^=6NM[+\/^&)Y7>SV.0U+1KZ
M/4X;*75WO=5U*W^QF9(1']GLU.Z1^"<L20,D\D^U6-(\1Z@D6CS?8[*+1+ZY
M:RM88MPEA"[@A8DX((C/  QQ750:3!!J]UJFZ22YN$2/+D$1HO\ "O' )))Z
MY-9MIX/T^SOX;E)KMXK>5YK>T>4&&%VSEE7&>YZDXR<4<\6K,7(T[HZ"BBBL
M3483+DX1"/=C_A29F_N)_P!]G_"I**8$>9O[B?\ ?9_PHS-C[B?]]G_"I*.U
M CC=4+'Q*VX '[.G0Y_B:I*CU?\ Y&<_]>Z?^A-3Z8"T4E% A:*2B@!:*2B@
M#%\2_P#(%N_^N3?RKT"W,WDK\B=/[Y_PKS[Q+_R!KO\ ZY-_*O1;?_4K]*3&
MC'\3&7^P;W*(!Y#]'/\ =/M7&P?ZE?H*[;Q1_P @"]_ZX/\ ^@FN(M_]2GT%
M?/YU\4#V\J^"1-FC-)17AGK"YHS244 +FC-)10 U_NFM3P&7QJ6U5(^V'JV/
M^6:>U93_ '36OX!^[J?_ %^'_P!%I7K91_'?H>?F?\#YG9$S8/R)_P!]G_"O
M(?'1;_A+UW  _94Z'/\ &]>Q'H:\=\?'_BL%_P"O1/\ T-Z^SR[^.CY3&?PF
M8F:,TW-&:^D/%'9HS3<T9H =FC--S1F@!V:CMR?[=TG'7[?;_P#HQ:=FF6I_
MXG^D_P#7_;_^C%K'$?PI>AI1^-'OL9FV#Y$_[[/^%.S-_<3_ +[/^%.C^X*=
M7RA]"1YF_N)_WV?\*,S?W$_[[/\ A4E% B/,W]Q/^^S_ (49F_N)_P!]G_"I
M** (\S?W$_[[/^%-D,VP_(G_ 'V?\*FILGW#]* .&L\_:+S/7[1+_P"AFKM4
M;3_CYO/^OF7_ -#-7:8A:*2B@!:*2B@!:#TI*#TH S,G_A*-(V@$^<_!./\
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M'FCWHN@)B>*V_AV?^*X;_KRD_P#0XZYXR@^M=!\.O^1Y;_KRD_\ 0XZX\?\
M[O(Z<)_&1[:.@I:0=!2U\P>Z%%%% !1110 56OO^/9OI5FJU]_Q[-]* .)T@
M_P#$OA_W15_-9>F2K'IT.3_"*M_:DJB2SFC-5OM24?:DH LYHS5;[4E'VI*
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M787M(=RY15/^T!_S[3_]\C_&C^T!_P ^T_\ WR/\:/9R[![2'<N453_M ?\
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M+DUT+5%%%8F@PHQ)(E<>P _PI/+;_GL_Y+_A4E%.X6(_+;_GL_Y+_A1Y;?\
M/9_R7_"I**+BL9=WH%C?7'GW E:7:%W"0KP"3VQZFH?^$5TO^[/_ -_V_P :
MVJ*+A8Q?^$5TO^[/_P!_V_QH_P"$5TO^[/\ ]_V_QK:HHN%C%_X172_[L_\
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M_/*;_O\ O_C6]11]7H_R+[D'MZO\S^]F#_PAVC_\\IO^_P"_^-'_  AVC_\
M/*;_ +_O_C6]11]7H_R+[D'MZO\ ,_O9@_\ "':/_P \IO\ O^_^-:&GZ3;Z
M5:+:V1DBA4L0N=W)))Y.3U)J]150IP@[QBE\B95)S5I-OYD30EA@S.1]!_A7
M.3?#[PY//+/):2F25VD<BX<98G). ?6NHHK:-24?A=C*4(RW5SE?^%<^&O\
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M+A8P_P#A$]*_NW'_ ($/_C1_PB>E?W;C_P "'_QK<HHN%C#_ .$3TK^[<?\
M@0_^-'_")Z5_=N/_  (?_&MRBBX6,/\ X1/2O[MQ_P"!#_XT?\(GI7]VX_\
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M>*K.?4/"FJVELI:>6U=44?Q''3\>E9_AVY_MKP'8II5^+2X2VCA,BQK(T#J
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M&0W$DTX4PJJ$J2">-S8 )]Z\\N;2=_AS<W-MHNEV^EM"TJ7-[+YMW)D\-E5
MWD],GCI722V\%UK'P_>XACE::VE\PN@;?BV!&<]>>:?LHK?S_(7M&_P.UOM7
MTW3"HO\ 4+2T+?=\^98\_3)K(\6>(I-&\,_VKIIMK@F6-49OG1@S $C:1G\Z
MYW9)J?BS79=(T>SO)$E6"XNM6E!1"JXVQH%)"^OK7-HQ/PFU!,QE4UK:HB^X
M!YBG"_[/)Q3C25U?R_$)5'K\SU#4-7GTW7]/MYTC_L^^S"DH!W)/U52>F& (
M'?(K9KC_ (E$KX7BDC_UZ7UNT/KOWC&/UKL*Q:]U,T3U:"BBBH*"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "LK5?#6CZW*DNH6*2S1\+*K,C@>FY2#^M:M%--K5":3W,?2_"
MVB:-.;BQT^..X/69V:23_OIB3^M6],TJRT>V:WL(?)B:1I2N]FRS<D\DU=HH
M<F]V"26QS_\ P@_AO[6]S_9499W\QD+OY9;U\O.W]*FE\):'-I-KI<E@&M+4
MY@4R/NCYS\KYW#\ZVJ*?/+N+ECV,C2O#&CZ)<O<:=9"":1/+=P[,6&<\Y)R<
M]^M56\"^&FNS<G2H]Q?S"F]_++>OEYV_I70T4<\KWN'+':P  # X%<S<_#_P
MQ=WD]W-ISF>XD:65A=3+N8G). ^*Z:BDI..S&XI[HH:3HUAH=F;33H6B@+ER
MK2,_)QW8D]A4.K>&])UR2*34+,2RQ#"2J[1NH]-RD''MFM6BCF=[WU"RM8R4
M\,Z-'HDNC1V$:6$HQ)$A*[_<L#DGCKG-:<,,=O!'#$NV.-0BC.< # I]%#;>
MX))%#5]%T[7K(6>IVPN( XD"%BOS#H<@@]S1<Z)IUYJUIJEQ:K)>V@802EC\
M@/7C.#^(XJ_11S/N%D96K>&])UR2*34+,2RQ#"2J[1NH]-RD''MFD3PSHT>B
M2Z-'81I82C$D2$KO]RP.2>.N<UK44^:5K7#E6]BE=:187VE_V9=6J36>P)Y3
M\C Z<]<C'7K532_"VBZ-=&YL;()<%=GFO(\C!?0%R2!]*V**7,[6N'*KW,"^
M\%>'M1O9;NYTU6FE.92LCHLA]652 WXBMR&&.WA2&&-8XHU"HBC 4#H *?10
MY-Z-@DEL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %8-]X,\/Z
MA=R74^G 3R??>&5XB_UV,,_C6]134FMF)I/<R(?"VB6VEW&FP:=#%:7*E9D3
M*F0>[ [C^=73IUFVF#37MT>S$0A\E_F&P# !SUXJU10Y-]0LCFE\ >&%@>'^
MRPR, OSS2,4 (/RDME>0/NXJYJ?A31-9NEN;ZQ$DX79YBR.C,OHQ4C</8YK9
MHI\\M[BY(]C,M/#ND6.FW&G6]C$ME<.SRP'+*Q;KP<X' X' JKIW@[0-*O$N
M[/3U6>,$1L\CR>6/]D,2%_#%;M%'/+N/E78*YYO OAIKLW)TJ/<7\PIO?RRW
MKY>=OZ5T-%)2:V8-)[@  ,#@5A7_ (,\/ZG>R7=UIRM-)_K"LCH)/]X*0&_$
M&MVBA2:V8-)[F?/H6F7"V*R6B!+"02VJH2BQ,.A 4@?@>*T***&VPL9]SHFG
M7FK6FJSVJO>V@802EC\H(P>,X/4]1Q2VVB:=9ZM=ZI!:JE[=A1/*&/S # XS
M@=.P&>]7Z*.9]PLC"O\ P9X?U.]DN[K3E::3_6%9'02?[P4@-^(-79]"TRX6
MQ62T0)82"6U5"46)AT("D#\#Q6A13YI=PY5V,W5M TO74B74;19C$28W#,C(
M>^&4@C\Z73-!TO1[:6WL;-(HYCF7)+F0]/F+$D_B:T:*7,[6OH%E>YSUOX'\
M-VMVES#I:!XWWHID=D1O4(3M'X"NAHHH<F]V"26P4444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %07EE;:A:O:WEO'/!(,-'(H8&IZ* .;C
M\ ^&(Y$;^RPX0Y5)9I)$'_ &8K^E:QT?3SJ=MJ/V8"ZMHC#"ZL0$0]0%!Q^E
M7J*ISD]V2HI;(RM7\-Z1KLD,NHV8EEA!$<BR-&Z@]MRD''M3;'POHFF3R36>
MGQQ/)#Y$F"2'3.2&!."<D\GGWK7HHYI6M<?*KWL<TO@#PNI!&ECA@R@S2$(0
M<_*-WR\CMBM#5O#>D:Y)%)J%F)98AA)5=HW4>FY2#CVS6K11SRO>XN6.UBEI
M>DV&BV@M=.M4MX<[BJYY/J2>2?<U=HHI-WU925BG;Z79VFHWNH00[+J]V?:)
M-Q._8-J\$X&!Z8J:[M+>_M);6[A2:"5=KQN,AA4U%%WN*R,33/".A:1=BZLM
M/5+A5VI))(\A0>B[B=OX8J]9:59:?<WEQ:P^7+>2>;.V]CO;IGD\?A5VBFY-
M[L%%+9#98HYHGBE19(W4JZ,,A@>H([BL.Q\%^'M.O8[NVTU5FB.8MTCNL9]5
M5B0OX"MZBDI-;,&D]PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#+U;PYI&MO&^H6*321_<E!*.OT92#^M1:9X4T/1[DW-E
MI\:7!_Y;2,TCCZ,Y)'YULT57-*UKBY5>]BGINE66D1316,/E)-,T[C>S9=NI
MY)_+I68?!/AQKY[LZ7&9'?S'7>_ELWJ8\[3^5;]%"E):W#E78Q7\):%)H\&E
M/8*UG;L7A0R/NC)).5;.X<D]#3]+\+Z-HMVUWI]D(9VC\II/,=BRYW<Y)R<]
MSS[UKT4<\MKARKL<]+X&\-37;W+Z5&7=_,9!(XC9O4H#M/Y5T"J%4*H  & !
MVI:*3DWNP22V,;5/">AZS=?:KZQ#W&W89$D>-F7T8J1D?6M&RL;73;..TLH$
M@MXQA(T& *L44.3:LV%DG<P-;TNY.M:7K>GQ>;<VKF&:+<%,D#\-@D@94X8?
M0UHRZ/83:JNIRVX>\6$VXD+''EDY*[<X/Y5>HI\S#E1S:> ?#";P-*0HX8&-
MI'9!N!!VJ6PIY/( QVJY>^%]'U&QL[*ZM"\-F MO^^=6C &.&!W= .];%%'/
M+N+ECV,*]\&^']0OY+VYT\-<28\QEE=!)C^\%(#?B#3SX2T,Z;/IPL%6SGG^
MTO"LCJOF9!R,'Y1P.!@>U;5%'/+N'+'L8&L:7<ZQKVEQRQ8TNR?[7(Y8?O9A
MPBXZX&2QSQTK?HHI-W20TK!1112&%%%% !1110 4444 %%%% !1110 4444
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M> !>1_XTN5]A\R->BN:USPI<:SJ'VJ+Q'J^GKL"^3:3E$X[X]:XNSTK4I_B
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M;6A_Z>5_]!:H_P"U]D/E!_FQC=Z5?U32XM6MD@FEEC"N'#1$ YP1W!]:R?\
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M9NN-O7H.I[=*ET+P7J6G^*=0U/4K^+4(]0M#%.YRCER1P%Q@* ,#FARA9Z]
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M>&VTZRD@CF,R/NF8A<#/H"?TJQXRT6Y\1>$[W2K1XDGG\O:TQ(4;75CD@$]
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MD1P1CLN>?\GU-+FCK*_2WX6'9_#;J8GP^L;9_%7C"]>%&N%U.6)9&&2JEW)
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 53T_2[/2HYH[*'R8Y96F9 Q*[FZD
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img187335194_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #S 4X# 2(  A$! Q$!_\0
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M2]_[Y3_XJC_A-+#_ )]+W_OE/_BJXNBCZM3[![6?<[3_ (32P_Y]+W_OE/\
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M8*GB*BLY*[MM^I\YBZDZ-:5.+T1Z_P#\+-T'_GG>_P#?H?\ Q5'_  LW0?\
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MM.C!2CW-</6G.=I$?C3_ )!=K_U\C_T!Z\^U+5['2%@:^G$(GD$49*DY8]N
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M-7^;*DC ##)./6M/0K'7H=<26]^UJBBX%U)-=B2*<F0&(Q1ACLPO^ROISUH
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MKAH0@Y*HF_\ @V_X/H:QJ-NSC8RO%G_(5B_ZX#_T)JP:WO%G_(5B_P"N _\
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M'_\ %4?VP/\ GQNOSC_^*HY)!S(TJ*S?[8'_ #XW7YQ__%4?VP/^?&Z_./\
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M/O4_^V!_SXW7YQ__ !5')(.9&E5'2?\ CSD_Z^;C_P!'/4?]L#_GQNOSC_\
MBJ=HK^9IQ?:5W7$YP>H_>OZ4W%J+O_6XKIR7]=B'7.NG_P#7R?\ T5)6%K%[
M>0S6-EIY@2ZO)&437"%TC55+$[0REB<  ;AU)SQ@[NNG']GG:S?Z2>$4L?\
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M%G_>F_\  >3_ .)HY)=@YEW+]%4/[8L_[TW_ (#R?_$T?VQ9_P!Z;_P'D_\
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M7=L[KA9HK9BZ'U&Y"N?J"*P9=)L)=&N=/_MO64DN[C[1=7:VR>;.VT+@@PE
M,*@^51]T>IR<DNP<R[DVL>.K71-=N=/NH[<1PVIFR;H+*S<8_=D8$9SCS"P
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M54#:J_='?.3DEV#F7<;J7CVVTG5Y;.[CM D=G]H++>#S&8@$84J!Y9SCS2P
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M=N'UMI/M;#6$1)T,#%$"K@;%*8&>ISD$]:K66@:+I6G16]E-/YD$DL\1^P+
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MUDAN%M93 RL"1^^"^6"0. 6ST]17/ZMX;\/:S#(EU+=L[W9N_,>Q2;:YC5"
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ML4/V61(D:2^"G+'!,V5 A7^($EMPZ#)"F)_"?@F31[;3)-(@>.V"K'*VF@R
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MWVN <>^,5;K)T/28=!L6M;=;Z56D,I+VFSDXSA8XU51QGA1DDDY))K3\P_\
M/"Z_\!I/\*=F ^BF>8?^>%U_X#2?X4>8?^>%U_X#2?X46$/HIGF'_GA=?^ T
MG^%'F'_GA=?^ TG^%%@'T4SS#_SPNO\ P&D_PH\P_P#/"Z_\!I/\*+ 9%QK5
MW::R+6;30;1XY'BECGWROL4,28]N O. =V<XX&:Y^+XC12Z5>70CTMI+<0N3
M'J8:!5EW8#R^7\C?(PV[3R5Y^;C?31I(]=GU1=0UG,PVM;FU4QJ-N %)BW@
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M'/'N7J*H_P!K6W_/.]_\ IO_ (FC^UK;_GG>_P#@%-_\31R2[!SQ[EZBJ/\
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M%=.2L7J***@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img187335194_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J!((# 2(  A$! Q$!_\0
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MK<D9_B_2@#U2BL#PKI&HZ58O_:.OW>KO-M=7N(U4QC'0;:WZ "BBB@ HHHH
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M] !17GWBGP^GA_3$U:PU;7!<I?6B@2ZI/)&0]Q&C HS%2"K$8Q7H- !1110
M4444 %%%% !1110!YGXB\'^-]4DUC2(-;LIM U:0,SW8<SVB?Q)&!\I'&!FN
MUOO#ME?^$Y?#LV_[&]I]ESGY@H7:#]1@&M>B@#R&]\!>.;[P['X5N+GPY<:9
M#%]GAU*:!VNHXL8P%Q@-@ 9![=:S/B#H=K<ZYX2\*Z7J#/JZP+IMZJ(0S61"
MEF;L!\I.,]Z]QIGDQ><9O*3S2-N_:-V/3- "1Q+;VZQ0H L:!47H  , 5Y9;
M> ?%UOXGC\9_VA9OK\MVPN;4RM]G-F0 (E;;G<  <XZ_3GU>B@#%\5Z7J>L>
M'I[31]4DTS4"5>&X3H"#G!]CT-<_X9\+^(#XPG\5^*9]/^W_ &,6,%OI^[RT
M3=N+$MR237=44 <CJGA>[O\ XEZ/X@'V=M/M+*:WF1R=[,^<8&,$?C53P=X1
MU3P?XDU:WM9H'\+W;>?;0&1O,M93U55QC:>>_8>]=S10!R.@^&;[3?B#XHUV
M=X#::HMN(%1B7'EH0VX8P.>G)KKJ** "BBB@ HHHH **** "BBB@ HHHH **
M*K:A8QZE82VDLMQ$DH +V\S12#G/#*01T[&@"S17#V^F?\(]\0-'L[34=4FM
M[RQNWFBO+Z6X4LC0[2 ['!&]NGK7<4 %%%% !1110 4444 %%%% ')7OAF^O
MOBAIGB&5H#IMA8211(6/F"9SRV,8QMXSFNEOK*#4=/N;&Y7=!<1-%(OJK#!_
MG5BB@#R-_ ?C:V\/?\(G;W'AV^T=%>.WO;Z!S<01MG@+@KN . :QOB#H-OIF
MB^$/">FZF7\20 6<82,AY+>9621CV"\=SVKW6F&&(S"8QH95& Y4;@/3- $.
MG6,.F:9:V%NNV&VB6)!Z*HP/Y5YC?> ?%MWXGD\9)J%HFO0W:BSM?-;[.+,
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M_P!*XJZJ@ HHHH **** "BBB@ HHHH **** "BBDW+OV;ANQG&><4 +1110
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M/_R)-S_U]6G_ *4Q5U5<K\1_^1)N?^OJT_\ 2F*@#JNU%':B@ HHHH ****
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MJKE?B/\ \B3<_P#7U:?^E,5 '5=J*.U% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)_#/_
M ))YI'^X_P#Z,:NLKD_AG_R3S2/]Q_\ T8U '64444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<GXKT?PC$K:OKLB:=)PIO(KI[:1_8LA!?Z'-=97"?$;0=5U.!;O3+%-0
M9;"[LS;%U5E:9 %E0MQD%<'D<,<4 :GA_P .^%[:[DN]-5;N\@;8]Q<7+W,L
M1(!QEV)3((.!CK73UQW@W3=474M1UC4M.&F?:8+>WCM3(KN?*#9D<KQD[L8!
M/"BNQH *J:CJ=EI%D][J%S';VZ?>>0X&>P'J3V Y-6Z:\:2;=Z*VU@R[AG!'
M0_6@#%L?%ND:CX7F\16\TATV)9&=VB96 C)#?*1GL:CT;Q?8Z[<I!:V6JQ[T
M\Q9;FPEBC(Z_>88KF/ NGQ:M\*K[3II_(CN[B^@:7CY=TSC//UJQ#=:YX4\5
M>'M"N-8CU:SU%9(1&ULL4L C3(<%>J\8.1Z<T :U]\0="L+FYCD-X\%I)Y5U
M>0VKO! _H[@8&,\XSCOBKNK^+--TB>WMF%S=W=S&98K:R@::1HQU?"]%YZG\
M*X;0+BT@^"OB%+UT#0MJ,=TKGD2%WX/N<K^8J;P*DMGXVCMK_*73>&;$1J_!
M(7(<#Z$C- '?Z+K=AX@TU;_3IC) 69#N0HR.IPRLIY4@]C6A7$_#T+)=^+;F
M @V<VMS&%E^ZQ"H'(]1N!_*NVH Y7XB?\BE_W$+'_P!*XJZJO-_&GA2UT[1$
MOH]2UJ9UU&R(CN-3FEB.;J(<HS$'KQZ<5Z10 4444 %%%% !1110 5EW>OV5
MEXAT[1)?,-YJ"2R0A5RH6, L2>W6M2N3@U"SU+XG7EA)IL1NM(L4>&\9B6 F
M/S*!T'"CGKUH ZRLB[N=?CNG6STNQFMQ]R22]9&/'=1&<<^]:]%)J_4TIS4'
M=Q3];_HT<_+J/B2"%YI=)TQ(T4LS-J+  #J3^ZKR5_B7J9\8C60@^SJGD_9!
M(=A3ZXZYYSBO=IH(KF!X9XTEB<;71QD,/0BLO_A%/#O_ $ M-_\  5/\*YJU
M&I*W+(]G+LQP5!3]O0NVK:7VZ[ME:WU/Q'=6\=Q!I.F212*'1UU%L$'H?]56
MQ8R7DEJ&OK>*"?)RD4ID4#MR0/Y5+!;PVL"06\210QC:D:*%51Z "I*Z(Q:W
M9Y-:K"6D()???\6SSV_TS5=2^(VN+I.OSZ3.FEVF#'!%*KDM/C<'4G QVQUJ
M_P##AH_[)OX[AISKB7C#5_/<,YN  -PP -A4*5P ,8KH[C5--LM9L[":18[_
M %!7\A?+.91&-S#=C' .<$^N.]$&HZ;)K=WIL#H=0ABCFN%6,Y"MD(6;&,_*
M>,YQ5&!C?#?GX>Z/_P!<F_\ 0VK+\6Z3XFNO%FA3V&JPQVRW3F,'33+]F_<N
M"SMO&X'D?P\D5U^HZA8:!I$]_>.MM8VJ%Y&5"0B_[J@G\A5J>7R+>27RWDV*
M6V1C+-@9P!W- &)XHT_4+_P)J>GPRB;4);%XPZ+L\Q]O.!DXW<C&>,URFN>,
M-.G\)Q_V-K^EV4D=L8WTFZM//FD;;@0^5N5@<_+]T]:]"L+K[=IUM>?9Y[?S
MXDE\FX39)'N .UU[,,X([&JS7.E#Q#'8LL7]JO;M<+^Z^8Q*P4G?C'5E&,YY
MH Y#2=6MM!\57\_B*:'3FU.SM);>:X(BC^2/:\08\*5;)VD_Q4FK:M=^(])O
ME\):1)<VT]XL%W>V\L<#7,07]XT3L1N/2/=]2.E=[/;PW,?EW$,<J9SMD4,/
MR-.1%C1410JJ,!5& !0!Y)HLGB)O#'B#3M$\.2VA.KM"R1W<*M#$0!(J'=@,
MH  /3YLC.*U_A_:K<KXHTB[\.BRT\7H0V\DL<J#]S$/+(4G/ !ST.[US7HB1
MI'NV(J[CN; QD^IH6-$+%$52QRQ QD^IH \WCL[*3P3XMAGG-E;0ZQ.ZRQ0F
M00E'1E.P#E00,CTS4OA:]O=;^(#7\NIZ=J,=KI;022Z8A\A'>165=Y)W,0I)
M&>./6O0UCC0,%15#$EL#&2>I--AMX;:/RX(HXDSG:BA1GZ"@"2BBB@ HHHH
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M.?4X''- &^.0*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M**9F<KJO_)3?#?\ V#[_ /\ 0K>NJKE=5_Y*;X;_ .P??_\ H5O754 %%%%
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MOI=MYJE6N3OW/)@CA01M'KR:[6@ HHHH **** "BBB@ HHHH **** "BBB@
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MW/*"N5^(_P#R)-S_ -?5I_Z4Q5U5<K\1_P#D2;G_ *^K3_TIBH ZKM11VHH
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M$**** "BBB@ HHHH **** "BBJVH-?)82MIL5O+> #RTN)"D9.>[ $CC/8T
M<]JO_)3?#?\ V#[_ /\ 0K>NJK@(I=>E^)F@_P!N6>G6^-/OO)^Q7+S;OF@S
MNW(N.V,9[UW] !1110 5SNM:A<WFJ)X<LK">5;B)OMUV<I';PL"/E8J0TA[*
M,^IQ46HWY\3?;]$T+57M9K>1([V\BA+"-3]Z.-_NB7&/7;GIG%=!96<6GV-O
M9P;_ "8(UC3>Y9L 8&2>2?<T 0:-I-KH6C6FE60<6UK$(HP[;C@>I]:O444
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M%$I=V/8"EEN88()9I942*%2TCD\( ,DGTXK#$2^,-,S=07%MIYF#1(6VFZC
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MDD22$'*JRN".#T-=/10!E>'M M_#NFM:PRRSR2RO/<7$Q!>:5CEG;''/H.@
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MMJ7]GRA/M$K$P"VS(-F,_.1G:?6M>RN==N]1N!<V$%E8*&6)C+OF<YP&P/E
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ME5R.<,2Z$(N6JMJEIUON_P"KDEWJ&M^(5_MS1[:2);9]MM'<2*G&#O9ESSV
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MY\.M"WA3780+ZS/FRQP[3MN8SCB4G)Q@<=2,XKH/^$LN,Y_X0CQ'G_KC;_\
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M>EFO)"S>YP15'3_&L-_;BZL?!GB&6+>Z!UA@'S(Q5AS-V92/PJ__ ,)C>?\
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MAJUU%[*;4U62.4022>6YBCD/\#2 ;0WL371]: "BBB@ HHHH **** "BBB@
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MV%E\3=0E\+P_9](L; P:@(F/DR76[*J!G!95ZD=,X/-8B:-:ZA\'+KQA-O\
M^$B>&745U'>1*DBNQ4*<\* H7;TQ7=^&/"VK^'8[:S.N6DVEP*5^RQ::(BV1
MU+[R<YY)P<UG?\*ZN5TV708_$$J>&I96=K'[,OF"-FW-$)<\(3G^'.#C- '9
MZ9</=Z39W,@Q)- DC#T)4$U:IJ(L:*B *JC  ["G4 %0WEW;V%E/>74JQ6\"
M&221CPJ@9)J:H;NTM[ZTEM;N&.>WE4I)%(NY6![$=Z /*[9KB^^(?A;Q'?2M
M'+J4ET(+8R<06RPDQJ1TW-DL?<@=JT=)T#3_ !G?^+;O7(?M4T6HRV%LSL?]
M&BC5<>7S\IR221SFM:Z^&/AF;6M+U"#2K"W2R>1W@2U7$^Y<+D]MIY'6G77@
MS48]1U2?0_$+Z9;ZJ_F74)M5E(DV[6>-B1M) '4'GF@"?X;W]UJ?P]T:YO96
MFN#"4>1CDOM8J"?7( KJJI:/I5KH>CVFEV2E;:UB$48)R<#N?<]:NT %%%%
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MQ>WM;HP1@*B2L&5B . 6"@FN[K%T#PY#H37D[7=S?7]ZX>YO+DKOD(&%&%
M4#@ "MJ@ HHHH *\Q\7:#HUSK6CZ!X?TVUBUI;Z._FN;>(![6%6RSNXYRW0
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MH,(WWD*LI4J< XQUJWX?\.V^@0W)6XN+N[NY?.NKNY(,DSXP,X        %
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M\:K 7B!'( 'R@Y7J!VKW6L^#0],M[>^MX[1/)OY7FNHW)997<88D'/4#ITH
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MMK>6KWCV:W,+72()&A#@NJ$D!BO7!(//M0!/165/XGT"UM;>ZN-<TR*WN?\
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MR20X1KF=8PQ]!N(S0!>HK#U#Q;H^F:YI.D7-W&MSJF[[/^\0#C[N<D'YCPN
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M37$.HJTH2)RCOY10=-I.-U=?=>(=%L([9[W5K*U6Z :#[1.L1D!Z;0Q&>HH
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MIV5EYIQ']IG6/>?0;B,U2OO%FD:=XDTS0;BZ1;W48WDA'F(  " ,Y.<L20N
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M6U]<B02P&,2;IG=64_QKM91D<<8[5V5% !1110 4444 %%%% !1110 4444
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M#RM/FAOG2W*[<P)\LIQU+9^]WSWKTBB@#C?AI:OI_AB73Y]-GLKBVOKD2"6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img187335194_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $D 9L# 2(  A$! Q$!_\0
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MK9YH8A&R7 *0QN$=HP&!R2IQ0![-J5]-!HMU>6%HVIW"6[36]I&ZQM<,%)5
MSD*I8X&6( SS7EW[//CCQCXTD^(L7C:.PMM3T?Q*VGP66FMYD-I ;&TF6(2%
M5,C S-N<CEB< +M ZCPK\'/"?@_Q3>^)M.TL1^([]9!>:DTKE[@R,'D8INV
MLRAOE4 =L#BH_AMX!O?!>O\ Q"O[NX@GC\2>(/[7MEA+9CC^Q6MOM?('S;K=
MCQD8(YZT".#\:?M!Z=\-/VC)/#?BKQ%;Z/X8E\*0:A;Q3Q9W7;7DT;,'52W^
MK11@G''K6;X#_:>T[7/&/CN<ZF^N^%$\2Z-X?T.2P@0".2[MH VXG:Q43NY)
M.2!T!X%>D0_#N^C^/EWX[-S;G39O#,.B"WRWG"5+J68N>,;=L@'7.0>*\_\
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MX@NI'OSX7U/5(?$L6N1>+=2NKJXU&>!+];A+98FCV6FV,"+=$[ JFW8-Q(]
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M'A8)IQL(;;PK%)-+,[.K/*\\L<;(N$4")01SDL<"O=*!!1110 4444 %%%%
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MLKL  P/RA1NR6 %>P^.]4\,Z+X4U"^\83Z;;>'84W7<FK[/LP7( W;_E.20
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M::$R8!P"Y!)50  %ZG<S=K\8/^2?:C_UUMO_ $HCIWPK_P"1?U/_ +#NK_\
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M_P!C5J'_ *$M>C4 %%%% !1110 4444 <O\ %/\ Y)CXO_[ ]Y_Z(>MO1/\
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M7=_#WX(:+\-=:FU/3M9\4ZC/+;M;&+6_$5YJ$(4LK;A'-(RALH/F R 2.YH
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MB[_R3K6?]R/_ -&+785Q_P 7?^2=:S_N1_\ HQ:4XJ-.279F6&K3K8VE*?\
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MN9'6,G#,>IY/4Y-:M%%-))61<8Q@N6*L@HHHIE!1110 4444 %%%% !1110
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MA^X\3WW]AV]W;7EW9V<D:SQ^9++)M=1,IC5LJQ+#Y<&@9]J44V.02QJZYVL
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M@Z\UR^@U;Q;)%=W$+B6UTB EK.R8=&Y \Z4?\]&  _A5>27_ !A_Y)-XS_[
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MG5SG><YP,=%124FKV$FUL%<A\8?^23>,_P#L#7G_ *)>NOKEOBAI>I:]\/\
M7M*TJVCNK[4+.6S199A$J^8A7<3@],YQWJZ?QKU*I_&CJ:*KV,T\]G#)=6XM
M;AD!DA$@<(W<;@.?K5BLR HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3
M:-Q; W'C/>HKSS_LLWV4QBYV-Y1F!*;\?+NQSC.,XJ:B@#PGX:Z%\7='3Q.'
M7PK:_:M>N[H?:H+K]X'9<.F'^X<<9YKL?+^+7_/QX+_\![O_ .+J;Q_\</"W
MPWU3^S=5?4;F]CM#J-S#I6F7%Z;.T#%?M$_E(WEQY5L$]=C8!VG';Z?J%MJV
MGVU]93QW5G=1+-!/"P9)(V 964CJ"""#[T <%Y?Q:_Y^/!?_ (#W?_Q='E_%
MK_GX\%_^ ]W_ /%UZ+10!YUY?Q:_Y^/!?_@/=_\ Q='E_%K_ )^/!?\ X#W?
M_P 77HM% 'G7E_%K_GX\%_\ @/=__%T>7\6O^?CP7_X#W?\ \77HM<WX\^(&
MB_#?18]3UN>9(I[B.SMK>UMY+BXNKAR=D,448+NYP> .@). ": .+N-0^,</
MB2QTU;;PC+9W%I<7$FHK#=>7"\;PJD3#?G<XE=A[0M6GY?Q:_P"?CP7_ . ]
MW_\ %U';_M">"Y?"^K:W-=WU@NE7<>GWFFWFG3Q:A%=2[?)A%L4\QGDWIL"J
M=V[@GFN@\ _$G1?B-:W\FE-=PW.GW'V6^T_4;22TNK27:KA9(I%##*LK XPP
M(()H P_+^+7_ #\>"_\ P'N__BZ/+^+7_/QX+_\  >[_ /BZ]%HH \Z\OXM?
M\_'@O_P'N_\ XNCR_BU_S\>"_P#P'N__ (NO1:* /.O+^+7_ #\>"_\ P'N_
M_BZ/+^+7_/QX+_\  >[_ /BZ]%HH \G\2:A\8]$T6XO;.V\(ZO<1E MG;PW8
M>3+A3@E^P)/T%:?E_%K_ )^/!?\ X#W?_P 76W'\3O#DWQ,?P!%J"R^*H],.
ML2V2*3Y5MYBQAF;H"6<84\XYQBL+PK^T!X-\9>)+71=-NKXR7S3IIM]<:=/#
M9:DT.?-%M<,@CF*A6/RDY"L5R 30 [R_BU_S\>"__ >[_P#BZ/+^+7_/QX+_
M / >[_\ BZ]%HH \Z\OXM?\ /QX+_P# >[_^+H\OXM?\_'@O_P ![O\ ^+KT
M6B@#SKR_BU_S\>"__ >[_P#BZ/+^+7_/QX+_ / >[_\ BZ]%HH \Z\OXM?\
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M\>"__ >[_P#BZ]%HH \Z\OXM?\_'@O\ \![O_P"+JGJ6H_%G18[2Y>U\+ZO
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MHW@3;RV7!VC'?GBOGSXM? .W\)^";K4K8>(/'EQ>ZYI%WXH?493?7VHZ7;7
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MHV!B#D8S0,^SZ***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<OX.^'&B^!]
M0UR_TY;N;4-:N1<WMYJ%Y+=32$9"('D9BL: D+&,*H)P.3110!U%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img187335194_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_15.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $' = # 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ JEK&M:?X=TRXU+5;^UTS3K==TUW>3+#%&,XRSL0
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M9VC8J>$9"-Y.[ 4#:U_XA^+?A5KWB6RUKX@R7MK/X+_M^*_U/2895TV^-RL
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M4;4O#^B"TOC;_8TN)KF:Y:"WR&\F(RNWE1Y .Q-J\#C@5W-% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF+&,%@@:@#U?X>Z?XJL]/D;Q3+H\$C!$MM)T&%Q;6$:@C8)7PTI/'S;(P H
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M(OVE+WQ)?Z5X;U?P[#:^";W1[)?$5M]CDNM1N)[><1!6.=B?9%5I/NDR_*6
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MW%8=N>G4X%>FL&_JWUB_]7L8>U_><A];T445YAN%%%% !1110 4444 %%%%
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ME"NK@$J0<;E&1G!&0<@D5+X9\)Z)X+TB'2O#^D6.B:9#_J[/3[=((E^BJ *
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MA^U1_9NA>([J[\)R:9J&E^*H/"L5IJFIPPQM+-##,DT\ZATA3;-SC?@@#DG
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M7E;_ #,L'CLCI4*L*N&DY25E>2EY[^Y;7>RV/28_C3XXN[>9X/A)JR-&N?\
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M^B5?%K_PB;O_  KWFB@#P;_AKJQ_Z)5\6O\ PB;O_"C_ (:ZL?\ HE7Q:_\
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M^$Y-+FU"2UE@CDNKB[BF$*^8JEF1+<E@!\OF*#@G% SW:BBB@04444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img187335194_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img187335194_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %( G # 2(  A$! Q$!_\0
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M/XBJ ?)P.3[4XQA)75F$ISB[/0C_ +.T_P#Y\+3_ +\+_A1_9VG_ //A:?\
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MG&#ZGI4K%4WWVN4\-45]M[')[J-U=G>>%-+@N=$>YE?3H+V22.X1[A91&5Z
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MBU);][1+>8QJLNQRP=AWYZ?2E1C55:3DM'Y_\$*TZ,J$5%ZKR^_H=[9:=/\
MV3H!L/"^G7\5Q INIYHEW*<]<Y],GH:Q[WPOHLU_KMVFIFSTZPF1/W<?F#YA
MR!SV;BN;U77WU"PTNUC22#[#;^2Q$G$G.<X'2DL];6U\-:CI!MRQO)(W$N[
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MN[!!! YR*MK$W?\ P/+_ ()">%LO7S\_^!_5R6UT>&U_X2:#S(+E;.TW)+)
M=W7L#@HWYU)!X-M";*RN]:6WU>]B$D-MY)91D94,W8FJMWXS:]NM9GEL\'4+
M5;90K_ZL#H2<?,?RJ>#QO; 6=W=:+'<:O9Q"*&[\XJN ,*67N12:Q%KK].W^
M>Y2EA;V]>_?[]MAEGX6LO['.H:MJK6(2\:T=!#YAW#TQ_G JGJOA74K'6[K3
MK2">_P#(VDR01%OE89&0.G_UJ@N?$+7?A]=.EB)F^W->/-NX8L.1C%2ZUXKO
M-0UN?4;&6YL!,B*R13D9VC')&,UK%5^:[\_3I;S[F,Y8;DLEV]>M_+L8C91B
MK A@<$'J#6AX?;/BK1?^PA!_Z&*S&<LQ9B2Q.23W-:'AT_\ %5Z+_P!?\'_H
M8K3$_P "?H_R,L*_W\/5?F=3\6#CQE;?]@]/_1DE<1NKMOBU_P CC;?]@]/_
M $9)7#9K'+O]VC\_S9OF?^]2^7Y(Z?P-;6][XB:*Z@CFC^S2MLD7(R!P:P[&
MUFU"_@L[< S3R"- >F2:N^&=;30-8%]);&X3RGC,8?;G<,=<&K4NN:+;M#<:
M/HDME?0RK)',]VT@&#G!4]<UI+GC4;2NFE;MU\S*/)*BDY6:;OO>VGD7;SPE
M9+!J"Z=K(O+[3D+W,!A*# ^]M/?%-N/"NGV5F$O==CM]4:V%R+=XCLP>0N_^
M]27WC&TDM[\Z=HJ65[J*%+JX\XN"#][:O;-)-XOL;NT5[W08;G4UMOLPN9)"
M4P!@,4Q][WK%?6;*]_PO_E:_S.AO"W=K?^36W^^]OD2:5X1@U;3C+!?3M<BW
M:<E;8^0A'_+,R'^+Z#%5M9MK>+P;X<N(X(TFF$WFR*N&?#8&3WK1MOB!%$EL
M9-.F9XK3[(52ZVQ8QC<J8P&Z5SU_K2WN@:5I@@*&P\S,A;._<<],<8JH*NYI
MR6E_+L_^ 3*6'C3:@];>?>/_  3L? ND6UWHDD\VFVLLS7&/,O$+"2$#YA$!
MSN'-<3J\*P:G/Y5K/;6SN7MTF4JWED_*>:VM+\86MII^GP7VDFZFTUF:TF2X
M:(KDYPP'7FL[Q+XB/B6]BO);2.WG6/9(48D/@\<'I12C55>4I+1^?]?\ 56=
M%X>,8OWEY??T_P"'.BEO[/0O"6@7 T33;N2Z20S/<0Y8[6['\:MW&@6,&N7S
M6L$*VT^BM>QQ2Q^9Y1/9>1@^A[5AP^)]'DT33=/U/0I+QK%6".+HH#N;)X ^
ME-_X36675M0OI[0;;FQ:RBBC? A4].W./ZUDZ56[Y4^O7?73J;*M1M'F:M[O
M3:RUZ%K_ (0I4T.&^EO)PTUK]H61+?? OHC,#D'WQBGWVBZ&O@W1;F*[,5U=
MR$--)$<.<@-N] O.,=:K:5XTBTBUC^S:?+'<)"8RJ7)%O(<8WM&0?F^A%,T_
MQA#9Z5IEM+I8GN--G,L$IE(7#-D@KCKU^G%4XXAN[OH_+;7_ (!"EADK*VJ\
MWKI_P274?",5MID6H6MW=- UVMLWVFV\HL#T=.>5^N*LWO@BRA?5+6VUOS[^
MPA,[PF J-@YQNSU^GJ*JZCXTAO=/EM$LKD;[Q+OS)[KS&R#RO(X'88Z5#_PE
MZ?VYK>H_8FQJ=NT C\S_ %>0!G..>E"6*:U\^WE_P1MX1/[N_G?]"QXGTO1;
M#P[HL]A,YN)XMYS$1YP/5B>V. !2^!KVVFU:UT>YTG3[F.>1BTTT.Z0?+G /
M3'%96HZ_;ZEX=T[3Y+ K=V*^6ER)3@IW&WUZ<^U5?#^K#1-=M=2:$S" D^6&
MVYR".OXUI[*;HRC*]];?H8RJP5>,H6MI?\+FYJ\<6K:-?ZJEI:6/]GW(MQ#:
M0[1(&/WF.>HQ4\/@F"2\2!]3:)&TL:@TC19"YZC&>@]:S=*\36MI::E97^F?
M;;.]E$Q03&-E8'(Y':K]QXZBFO9;A=,\I9-,-@(UEX3_ &AQT]JS<:\?=@M/
MEV7ZW-N?#R]^;U^??_*Q9B\$:7/)IYC\0$Q:DI^QYMCN=AUR,\"LRS\,VR:?
M-?ZUJ?V&V2X:VC\N(R-(ZG!./3K3;7Q:EO\ \([_ *&S?V07S^\QYNX_3C]:
M=;>*[1[6YLM5TD7UE)=/=0H)C&\3,<D;AU%/EQ"ZM_=?=[?*VY/-A7;1)_.U
M[=?GV+<7@F--0U&"]U00VUI;+=+<I'N$D;=\9]JY6Z%O'=RI:RO+;AB(Y'7:
M6'J1VKH)O&DES)J[36:@7UJMK$D;86!%Z=N?TKELUO056[=3R[&&(E1LE2\^
MX_=7K?PG_P"11U+_ *_I/_14=>0YKU[X3?\ (H:E_P!?TG_HJ.N/-_X"]?T9
MV9-_O#]/U1X]:M_H<'_7-?Y5-NJO:G_1(?\ KFO\JES7I0^%'ES;YF/W5K>'
M_$,WAV]DNK>VMYY7C\O]^I.T'KC!'6L;-&:)0C-.,EH$)RA)2B]4;\_B5)[Z
M"Y_L/28_*5U,20$))N'5AGDCM4NE^,]0TJPCM$@M)Q S-;23Q;FMR>NP]JYO
M-=+X4T73]5MM5N=02\D2RB218[0C>V201@@YZ5C5ITH4[R6G]?YF]*I6G42B
M]7_7Z& \[R3M-(Q>1FWLQZDYSFMUO&6I?\)#)K*+ LTL8BEBVDQN@ &""?:K
MFL^&+,:+8ZCI$6HQ/<W'V<6EZH$C'L5QVK-U#PAK.FQQO+#'*'E$)\B42%)#
MT5L=#252A4M?S6OXE.GB*;?+Y.Z);KQ?>W%W82I;VEO!8RB:&U@CV1;LYR1G
M)IUKXQO;>2_\RULKF"]F,\EO<1;XU<GJ!FJNH^%M2TVUDN)3;2)%((IA!.',
M+GH' Z5=N? &OVT<S-# S1)YAC2=2[+W(7J14_[+9;6_IE?[7S;._P#2_P T
M9^N^(+KQ#=17-W'"CQQ"(")2 0,\X_&KD?C&^CN[.Y$%OOM+,V: AL%",9//
M6H=+\(:QJ]BEY;11+#(Q6(S2A#*1V4'K3=/\)ZOJ2W9AAC0VD@BG$T@3RS[Y
M[53^KI<KM9?A<E?67+G2=W^-M?T(X/$%Y;:-%ID(1$BNA=I* =X<# ]L?A6A
M?>-[^^MS$;2P@,DJ2SO##M:9E((+'/MVJK)X0UB+57T^2*))$A^T-*TH$8C_
M +^[TIC>%M6_M.VL(XHYI+F/S89(I T;IW;=TP*']7;OIW#_ &J*MKV_K[_Q
M)5\6:@GB2;6T6%9YQMEBVDQNN "I!/3BI5\97L>IPWEO9V%ND,;1+;0P[8RK
M?>!P<\_6L[5]!O\ 1#";M8S',"8I89 Z/CK@CTK;T/0M(G\*OJ^H0:G<2"Z,
M CL<$XV@YP14S5!04[76WZ#@\2YN%[/?];E1_&%X8[&.&SL8(K%V:&-(B5PP
MP5(8G(]^OO3)?%M]LM8K*&WL(;:?[0D=NIP9/4[B?RZ5=UKP@(]2TV#1Q.?M
M\!F$-V0KP@==YZ ?X5%I_@F\N=9L+2>>W%K=J72YAF5U=5Z[3W;VI*6&Y>;U
M_7_@E2CBN9Q]/T_X!4UCQ/<:Q!Y+65C:J9/-D-M#M,C^K'K533=8GTN*^CA2
M-A>0&WDW@\*>XQWK3;P5J<FIWMO;&W,-M)L\Z2=0A)^ZN[NV,9%8-[9W&G7L
MMG=Q-%/$VUT/8UI3]C*/)"WH95/K$)>TG?M<UAXIO%O])O!#!YFF1"*$8.&
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M_P"%7>+?^?6R_P# O_[&NKZ_A_YOS.3^S\3_ "?D<A177_\ "KO%O_/K9?\
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M 5CZ5_R'-=_Z^(O_ $2E;%8^E?\ (<UW_KXB_P#1*4 ;%%%% !1110 4444
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M&I%3CLPHHHJ"PHHHH RO$7_(*3_K[M?_ $?'6K65XB_Y!2?]?=K_ .CXZU:
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M3/\ A4NA?\_6H?\ ?Q/_ (FC_A4NA?\ /UJ'_?Q/_B:]'_8/,\S_ (4?(?\
M\+8\/?\ /&__ ._*_P#Q5'_"V/#W_/&__P"_*_\ Q5,_X5+H7_/UJ'_?Q/\
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M_$_^)H_V#S#_ (4?(?\ \+8\/?\ /&__ ._*_P#Q5'_"V/#W_/&__P"_*_\
MQ5,_X5+H7_/UJ'_?Q/\ XFC_ (5+H7_/UJ'_ '\3_P")H_V#S#_A1\A__"V/
M#W_/&_\ ^_*__%4?\+8\/?\ /&__ ._*_P#Q5,_X5+H7_/UJ'_?Q/_B:/^%2
MZ%_S]:A_W\3_ .)H_P!@\P_X4?(?_P +8\/?\\;_ /[\K_\ %4?\+8\/?\\;
M_P#[\K_\53/^%2Z%_P _6H?]_$_^)H_X5+H7_/UJ'_?Q/_B:/]@\P_X4?(?_
M ,+8\/?\\;__ +\K_P#%4?\ "V/#W_/&_P#^_*__ !5,_P"%2Z%_S]:A_P!_
M$_\ B:/^%2Z%_P _6H?]_$_^)H_V#S#_ (4?(?\ \+8\/?\ /&__ ._*_P#Q
M5'_"V/#W_/&__P"_*_\ Q5,_X5+H7_/UJ'_?Q/\ XFC_ (5+H7_/UJ'_ '\3
M_P")H_V#S#_A1\A__"V/#W_/&_\ ^_*__%4?\+8\/?\ /&__ ._*_P#Q5,_X
M5+H7_/UJ'_?Q/_B:/^%2Z%_S]:A_W\3_ .)H_P!@\P_X4?(?_P +8\/?\\;_
M /[\K_\ %5J3ZQ;:]X=L-1M!((9-0M@HD7#<3J#QGVK(_P"%2Z%_S]:A_P!_
M$_\ B:UIM&M] \.6&G6KR/#'J%N09""W,ZD] /6L,1]6Y?W-[^9T8;ZWS_OK
M6\C1A_Y&V]_Z\+?_ -&35G7GQ \.6-[/:7%XZS0N8W A<X8'!YQ6C#_R-M[_
M ->%O_Z,FKE=3^%EMJ6JW=\VJS1M<2M*4$0(7)SCK6>'C1;?MFTO(TQ,JZ2]
M@DWYFG_PLOPO_P _TG_@._\ A1_PLOPO_P _TG_@._\ A6#_ ,*?M?\ H,3_
M /?E?\:/^%/VO_08G_[\K_C77[/ ?S/^OD<?M,Q_D7]?,WO^%E^%_P#G^D_\
M!W_PH_X67X7_ .?Z3_P'?_"L'_A3]K_T&)_^_*_XT?\ "G[7_H,3_P#?E?\
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M_P"OD'M,Q_D7]?,WO^%E^%_^?Z3_ ,!W_P */^%E^%_^?Z3_ ,!W_P *P?\
MA3]K_P!!B?\ [\K_ (T?\*?M?^@Q/_WY7_&CV> _F?\ 7R#VF8_R+^OF;W_"
MR_"__/\ 2?\ @._^%'_"R_"__/\ 2?\ @._^%8/_  I^U_Z#$_\ WY7_ !H_
MX4_:_P#08G_[\K_C1[/ ?S/^OD'M,Q_D7]?,WO\ A9?A?_G^D_\  =_\*/\
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M^&?^@S;?F?\ "C_A.?#/_09MOS/^%</_ ,*?NO\ H,P_]^#_ /%4?\*?NO\
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M#I5E<W%HT?BH(ES%&"ZXMN7 8$<G/4$<UZKH]A=Z=9M#>:K<ZG(7+":X2-6
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M)!,X>%(U\XIA<=5,8.<Y/(K.\/\ B;5K2/58H]3EUC4O[,FN8I(-02\MWD0
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MY9()7RQ@XZ<>V!4]% $7V6W^T_:?(B^T8V^;L&['IGK4M%% !1110!E>(O\
MD%)_U]VO_H^.M6LKQ%_R"D_Z^[7_ -'QUJT %8^E?\AS7?\ KXB_]$I6Q6/I
M7_(<UW_KXB_]$I0!L4444 86O:)=WMY9ZII-W':ZI9AT1IHR\4L;XW1N 0<9
M53D'((KGX/A]-?/J=SK,NG07%]:_9PFDVOE*AWAQ(2Q)=]P!Y]*[VB@#EK'2
M_%LVH6C:SK5E]CM&W[=/@>-[HX('FEF( YSM7J?I74T44 %17$1FMI8@0"Z%
M03VR*EHH:OH"=C@I/ 5^WPFMO!JZA LRHD4T^T[602;F '7D<5UEY;ZBK:?'
MI<UM!;Q2K]I26,L6A QM3'0].:T:*+W%8\[TOX<WECJ>FV\NHV\F@Z5?2W]G
M"L1$YD?<0KMG&U2Q((&3Q7HE%%'2P^MPKG?#/AV?0K_7[B:>.5=3U!KM @(V
M*548.>_%=%10!Q^A>&=:\.^%I-.L+^S%Z]_)<>;)$S)Y;REBN.N=I(^M8TO@
MKQ1)X^F\32W>BWI5MEE'=I*?L<6?X "!N(ZL>]>DT4+2P!1110 4444 %%%%
M !63XA_X\K7_ *_[7_T<E:U9/B'_ (\K7_K_ +7_ -')0 0_\C;>_P#7A;_^
MC)JUJR8?^1MO?^O"W_\ 1DU:U !6/XDT>76=/B6UG6"]M;A+JUD==R"1#P&
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MIR2XD$A;)7&,8/K6/8>&?$]SXOT_6M7_ +)MY=/CF22XL"P?4=XPHD4@;57
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M.X<=^*EU/P]9:NVEM=&8G3+E+J J^,NH(&[U')JNJ\K$]'YW-:BBBD,****
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MHHH *Q;'_7^(?^OO_P!MXJVJQ;'_ %_B'_K[_P#;>*@"QX=_Y%G2?^O.'_T
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M]K_\51_;T?\ SX7W_?M?_BJ/9R[![6'<UJ*R?[>C_P"?"^_[]K_\51_;T?\
MSX7W_?M?_BJ/9R[![6'<UJ*R?[>C_P"?"^_[]K_\51_;T?\ SX7W_?M?_BJ/
M9R[![6'<UJ*R?[>C_P"?"^_[]K_\51_;T?\ SX7W_?M?_BJ/9R[![6'<UJ*R
M?[>C_P"?"^_[]K_\51_;T?\ SX7W_?M?_BJ/9R[![6'<UJ*R?[>C_P"?"^_[
M]K_\51_;T?\ SX7W_?M?_BJ/9R[![6'<UJ*R?[>C_P"?"^_[]K_\51_;T?\
MSX7W_?M?_BJ/9R[![6'<UJ*R?[>C_P"?"^_[]K_\51_;T?\ SX7W_?M?_BJ/
M9R[![6'<UJ*R?[>C_P"?"^_[]K_\51_;T?\ SX7W_?M?_BJ/9R[![6'<UJR?
M$/\ QY6O_7_:_P#HY*/[>C_Y\+[_ +]K_P#%56U6\%[IMNX@FB U"U&)5 )_
M?)Z$TG"25V-5(R=DRS#_ ,C;>_\ 7A;_ /HR:M:L"6_ALO%MWYJRG?808\N,
MOTDFZXZ=:N?V]:?\\[K_ ,!W_P *%"35T@=2*=FS3HK,_MZT_P">=U_X#O\
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MP[FG6+8_Z_Q#_P!??_MO%4_]O6G_ #SNO_ =_P#"J^G-NE\0, 0#= X(P?\
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M8'((]17#:?KMAX8L]2T?5H;C[:UW<2K"EL\GV]9'+*4(!#9!"D$\8KL;#/\
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MH6IX_P"NR5H:/>RZCH]I>3P)!+/$KM&DJRJI([.O##T([56\0_\ 'E:_]?\
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MM9@7/09VG ZFCVC#V4286-R.F!]&H^P7'HO_ 'U6M11[1A[*)S^JP20:01(
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MEKD.@ZO:QC2H+B?5X-3M8HI)/* 3!,9)7(Z?>P<]>*]/\O5/^?FT_P"_+?\
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MLOS>C.K>EE^;T^76]Q<VEK,\IN?!/BRZ\36UW=6(G^S:\E\+D7RK&;?=T2$
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M-2_Y\(?_  )_^QHY'_30<Z_I,O451^T:E_SX0_\ @3_]C1]HU+_GPA_\"?\
M[&CD?]-!SK^DR]7%_%/1KW7_  1+I]A;27$SW,!*1$!MHD!8@^PS73?:-2_Y
M\(?_  )_^QH^T:E_SX0_^!/_ -C1R/\ IH?.OZ3/,H?A[<Z'XGU.SM[:YU#3
MM7TV6VM]1N)3+)I[LI!1LG[C<'(&>U3>&?#>K:CK&@KK&C365IHFC2:=<&9T
M*W,C (=FTG*;5)R<=<5Z/]HU+_GPA_\  G_[&C[1J7_/A#_X$_\ V-"BU_PZ
M\_\ ,3FOZ3\O\B33]-LM*MOLUA;1VT&XOY<8PH)Y.!VJU5'[1J7_ #X0_P#@
M3_\ 8T?:-2_Y\(?_  )_^QHY7_30<Z_I,O5S?C.RCO=,MO/T#^W+>&Y626U6
M3:X&"-RJ2 Y&?ND@$$UK?:-2_P"?"'_P)_\ L:/M&I?\^$/_ ($__8T<C_IH
M?.OZ3,'P)I<^FVFHM_9\FEV%Q=>;9:=(X9K=-J@Y )"[F!;:#@9KK*H_:-2_
MY\(?_ G_ .QH^T:E_P ^$/\ X$__ &-/E?\ 3%SK^DR]15'[1J7_ #X0_P#@
M3_\ 8T?:-2_Y\(?_  )_^QI<C_IH.=?TF7JY_P 1V-S=:CX>DMX&D2WU(2S%
M<?(GE2+N/XD#\:TOM&I?\^$/_@3_ /8T?:-2_P"?"'_P)_\ L:.1_P!-#YU_
M29>HJC]HU+_GPA_\"?\ [&C[1J7_ #X0_P#@3_\ 8T<C_IH7.OZ3(/$7_(*3
M_K[M?_1\=:M8>M27#Z2/M$"1$7EKC;)OS^_C]A6Y2:L4G<*Q]*_Y#FN_]?$7
M_HE*V*Q]*_Y#FN_]?$7_ *)2D,V**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K)\0_\>5K_ -?]K_Z.2M:LGQ#_ ,>5K_U_
MVO\ Z.2@ A_Y&V]_Z\+?_P!&35K5DP_\C;>_]>%O_P"C)JUJ "BBB@ HHHH
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MX#2?_'*BGT_6[TP1W=WI_D1SQ3-Y5NX8['#8!+D#.,=* )X?^1MO?^O"W_\
M1DU:U9%W8:D-7DOM/N+1/-@2%TN(6?[K.000P_O_ *4GE^(_^?K2O_ :3_XY
M0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/
M_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY
M0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/
M_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY
M0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/
M_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY
M0!L45C^7XC_Y^M*_\!I/_CE'E^(_^?K2O_ :3_XY0!L45C^7XC_Y^M*_\!I/
M_CE'E^(_^?K2O_ :3_XY0!L5BV/^O\0_]??_ +;Q4[R_$?\ S]:5_P" TG_Q
MRI=-TZYMX[]KR>&2:\F\QC#&55?W:I@ DG^#/7O0 OAW_D6=)_Z\X?\ T 5I
M5@6-AXAL+"VLX[S2V2")8E9K:3)"@ $_O/:I_+\1_P#/UI7_ (#2?_'* -BB
ML?R_$?\ S]:5_P" TG_QRCR_$?\ S]:5_P" TG_QR@#8HK'\OQ'_ ,_6E?\
M@-)_\<H\OQ'_ ,_6E?\ @-)_\<H V**Q_+\1_P#/UI7_ (#2?_'*/+\1_P#/
MUI7_ (#2?_'* -BBL?R_$?\ S]:5_P" TG_QRCR_$?\ S]:5_P" TG_QR@#8
MHK'\OQ'_ ,_6E?\ @-)_\<H\OQ'_ ,_6E?\ @-)_\<H V**Q_+\1_P#/UI7_
M (#2?_'*/+\1_P#/UI7_ (#2?_'* -BBL?R_$?\ S]:5_P" TG_QRCR_$?\
MS]:5_P" TG_QR@#8HK'\OQ'_ ,_6E?\ @-)_\<H\OQ'_ ,_6E?\ @-)_\<H
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M%FE2.R#LF6&)OE*!6;.=OHO;(YZU;L]7EO=62)(PEL8Y""6!9F5E'([=3]:
M-BBL0W]\+N[MVDA#BX1(B%X1-FXYSUX!_.EM-0N8M*O+Z=S<PQ O"^T(9%"\
MX[8SG!]/SH VJ*YZ?Q,T#"-K1?.$GENHEW!22 IR!T.>^._7%,7Q,\<$32VK
M232(C,D1RHR@8XP,]^_YB@#I**P#X@GDNH88[1%62?9N>3JF]D)P!P<KP*M6
MNM+/:7D\D!B-J"S1[LMC!([#T]QZ$T=+@:M%8)\1NLGEM9?,G^MVS A02@&#
MCG[X].AJWJ>KG3YUC%OYB^697;>%VJ& X'<_-TH TZ*YJ/Q288[=9X1*[PAF
M=&Q\^T-@C&!U]<]\8JY+KCQ74-J]H1,X^<QL76/)*CD#!Y'.<?C0!LT5S=OX
MFE%I'YUJ&G$(FD*RC:4V@DCC[W^S^M7=4U2:PN[<I%YD!B>21<[2 "@R/^^C
MQ0!KT5S[>)2US-:Q6JM*#B)O-PK#YN22,#[AZ9],U9CU:466G'REEGN8!*V7
M"* %!8Y]>>E &O17/P>(BLRP30M(=SEY1PJ#>X7/&,83DDC\:ETW7VU&[6W6
MTV,-Q=O,.% "D8R 3G>.PH VZ*Q;S7I;:YGC2R\Q(BPW><!G:@<\8]#^?YU%
M_P ),&O3;1VN\EE$;"3A@6()/';!Z9].#0!OT5SC>*""";1A^[$J*LJG>K E
M<\<'C_\ 75J/76:Y@ADM?+\R1HG;S,A6#%< XYSCOCVS0!LT5BZQKITR801P
M+([)D$N1M8@[<@#I\O<CVS4DVL/;6MA++ I^T*ID8/\ +'G'?'OWP/<4 :U%
M8A\1*6B5+4LSX)&\?*,OGMZ1G\Z@/BK:0K6+ESM8*C[\H5#9X'7!'!X]Z .B
MHK&CUTNP5K0KYKE(/G!\PA]A[<8Z]^*O:;</=62R2X\P,R,1T)5BN?QQ0!;H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B-O 0 8
M8SA]_P!T?>]?K[T44 +!!#;1"*"*.*,'(5%"C\A3G1)%*NJLIZAAD444 126
M5I,NV6VA<9SAHP>^?Y\U5OM&L[ZU%LR^5$#DK$J@'C'<'MW'(HHH MK:6R#"
MP1#H?NCMDC^9_.B*UMH(6AB@BCB;.45  <]>*** $:SM6"!K:$A&WKE!\K>H
M]Z=%;P0O(\4,:-(=SE5 +'U/K110 U;.U65I5MX1([!F8(,DCH2?6GM!"S%F
MBC))R25'/&/Y<444 1FQLRR,;6 LF=A\L?+GKCTI396A?>;:$OL\O=Y8SM_N
M_3VHHH :+"R41!;2 >2<QXC'R?3TJ*31]/E:(FUB"QN9 @0;68C&2,<FBB@"
M<V=J94E-M#YD9)1M@RN>3@]J26QM)RQFM8)"Q!;?&#DC@9HHH >;:W((,$7.
M<_(._7^0_*DCM+:)V>.WB1V;>65 "6Z9^O)HHH CFT^UN)FDFB63<@1D< JP
M!R,@]QD_G3Y+.UE55DMH756W ,@(!]?K110 RZT^VO98'N(UD\DEE5@"N2,<
M@TO]GV6]G^R6^YFW,?+&2<YR?QYHHH 7[%:;MWV6'=L"9\L?=]/I[426-G+N
M\RU@?<"&W1@Y!.3G\>:** '26EM- L$EO$\2XQ&R J,=.*<L,2-N6)%;GD*
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MT]*** $6RM8W9X[>%'8[BZH 2>><^O)_.JMGH=C:1NOEB;?()"944_,!@'
M&??&:** +#V$#W4$^,&#<8T4 *&;JW3KR?SJ6VMX[2W2"+.Q?4\D]23[YHHH
D EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>grtx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-09T14:02:55.6203+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="grtx-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="grtx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="grtx-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="grtx-20211231.xsd#DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="grtx-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1" xlink:href="grtx-20211231.xsd#DisclosurePropertyAndEquipment1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="grtx-20211231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiability" xlink:href="grtx-20211231.xsd#DisclosureRoyaltyPurchaseLiability" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="grtx-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="grtx-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:href="grtx-20211231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" xlink:href="grtx-20211231.xsd#Role_DisclosureLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="grtx-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="grtx-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlan" xlink:href="grtx-20211231.xsd#Role_Disclosure401KPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResults" xlink:href="grtx-20211231.xsd#Role_DisclosureUnauditedQuarterlyResults" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="grtx-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="grtx-20211231.xsd#DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="grtx-20211231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="grtx-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityTables" xlink:href="grtx-20211231.xsd#DisclosureRoyaltyPurchaseLiabilityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="grtx-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" xlink:href="grtx-20211231.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResultsTables" xlink:href="grtx-20211231.xsd#Role_DisclosureUnauditedQuarterlyResultsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="grtx-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:href="grtx-20211231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails" xlink:href="grtx-20211231.xsd#DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_Disclosure401KPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IssuanceOfCommonStockWarrants" xlink:label="grtx_IssuanceOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" xlink:label="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_18"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_IssuanceOfCommonStockWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommonStockIssuanceCosts" xlink:label="grtx_CommonStockIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="grtx_CommonStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RightOfUseAssetsAcquiredUnderOperatingLease" xlink:label="grtx_RightOfUseAssetsAcquiredUnderOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="grtx_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="grtx_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:label="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AtTheMarketOfferingsMember" xlink:label="grtx_AtTheMarketOfferingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" xlink:label="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInDeferredTaxLiability" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:label="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="grtx_RightOfUseAssetsAcquiredUnderOperatingLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_RegeneronPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_AtTheMarketOfferingsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="grtx_IncreaseDecreaseInDeferredTaxLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiability" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityAbstract" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock" xlink:label="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityAbstract" xlink:to="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResults" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LiquidityPolicyTextBlock" xlink:label="grtx_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityPolicyTextBlock" xlink:label="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EmployeeBenefitPlanPolicyTextBlock" xlink:label="grtx_EmployeeBenefitPlanPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_Covid19Update" xlink:label="grtx_Covid19Update"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock" xlink:label="grtx_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_LiquidityPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_EmployeeBenefitPlanPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_Covid19Update" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="grtx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityAbstract" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResultsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_JefferiesLLCMember" xlink:label="grtx_JefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" xlink:label="grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="grtx_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AtTheMarketOfferingsMember" xlink:label="grtx_AtTheMarketOfferingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OpenMarketSaleAgreementMember" xlink:label="grtx_OpenMarketSaleAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" xlink:label="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" xlink:label="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" xlink:label="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_JefferiesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_AtTheMarketOfferingsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_OpenMarketSaleAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grtx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AlbanyLeaseMember" xlink:label="grtx_AlbanyLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grtx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ThirdTrancheMember" xlink:label="grtx_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmendedRoyaltyAgreementsMember" xlink:label="grtx_AmendedRoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FifthTrancheMember" xlink:label="grtx_FifthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FirstTrancheMember" xlink:label="grtx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" xlink:label="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" xlink:label="grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grtx_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grtx_AlbanyLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_ThirdTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="grtx_AmendedRoyaltyAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FifthTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FirstTrancheMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="grtx_SummaryOfSignificantAccountingPoliciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractualObligation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommonStockWarrantsMember" xlink:label="grtx_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockOptionsMember" xlink:label="grtx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="grtx_CommonStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grtx_StockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="grtx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LaboratoryEquipmentMember" xlink:label="grtx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeFurnitureAndEquipmentMember" xlink:label="grtx_OfficeFurnitureAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_OfficeFurnitureAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_USTreasuryAndOherGovernmentSecuritiesMember" xlink:label="grtx_USTreasuryAndOherGovernmentSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FinancialInstitutionDebtSecuritiesMember" xlink:label="grtx_FinancialInstitutionDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_USTreasuryAndOherGovernmentSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_FinancialInstitutionDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" xlink:label="grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" xlink:label="grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" xlink:label="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_USTreasuryAndOherGovernmentSecuritiesMember" xlink:label="grtx_USTreasuryAndOherGovernmentSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FinancialInstitutionDebtSecuritiesMember" xlink:label="grtx_FinancialInstitutionDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_USTreasuryAndOherGovernmentSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_FinancialInstitutionDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="grtx_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" xlink:label="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="grtx_AccruedResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityAbstract" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityTable" xlink:label="grtx_RoyaltyPurchaseLiabilityTable"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FirstTrancheMember" xlink:label="grtx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityLineItems" xlink:label="grtx_RoyaltyPurchaseLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SecondTrancheMember" xlink:label="grtx_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmendedRoyaltyAgreementsMember" xlink:label="grtx_AmendedRoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ThirdTrancheMember" xlink:label="grtx_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FourthTrancheMember" xlink:label="grtx_FourthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FifthTrancheMember" xlink:label="grtx_FifthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityAbstract" xlink:to="grtx_RoyaltyPurchaseLiabilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FirstTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_SecondTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="grtx_AmendedRoyaltyAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityTable" xlink:to="grtx_RoyaltyPurchaseLiabilityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_ThirdTrancheMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_PaidInKindInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FourthTrancheMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FifthTrancheMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_ContractualObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityAbstract" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NewMilestoneWarrantMember" xlink:label="grtx_NewMilestoneWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FourthMilestoneWarrantMember" xlink:label="grtx_FourthMilestoneWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RoyaltyPurchaseLiabilityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="grtx_NewMilestoneWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="grtx_FourthMilestoneWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncomeTaxBenefitTable" xlink:label="grtx_IncomeTaxBenefitTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:label="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" xlink:label="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" xlink:label="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grtx_IncomeTaxBenefitTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="grtx_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandSixteenRegeneronAgreementMember" xlink:label="grtx_TwoThousandSixteenRegeneronAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" xlink:label="grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CRISPRProductMember" xlink:label="grtx_CRISPRProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OptionExercisedToIncreaseRegeneronTargetCapMember" xlink:label="grtx_OptionExercisedToIncreaseRegeneronTargetCapMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_HemophiliaCoCoAgreementsMember" xlink:label="grtx_HemophiliaCoCoAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ResearchAndDevelopmentServicesMember" xlink:label="grtx_ResearchAndDevelopmentServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="grtx_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockPurchaseAgreementMember" xlink:label="grtx_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ContractWithCustomerLiabilityAdditions" xlink:label="grtx_ContractWithCustomerLiabilityAdditions"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandAndTwentyRegeneronAmendmentMember" xlink:label="grtx_TwoThousandAndTwentyRegeneronAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:label="grtx_DevelopmentBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="grtx_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:label="grtx_RegulatoryBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CoDevelopmentAndCoPromotionAgreementsMember" xlink:label="grtx_CoDevelopmentAndCoPromotionAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronArrangementMember" xlink:label="grtx_RegeneronArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SalesBasedMilestonePaymentsUnderAgreement" xlink:label="grtx_SalesBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronAmendmentMember" xlink:label="grtx_RegeneronAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationAgreementFurtherOptionExtensionPeriod" xlink:label="grtx_CollaborationAgreementFurtherOptionExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NovartisArrangementMember" xlink:label="grtx_NovartisArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseInTargetCap" xlink:label="grtx_IncreaseInTargetCap"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AdditionalTargetInCap" xlink:label="grtx_AdditionalTargetInCap"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfUniqueExVivoProductsCommercialized" xlink:label="grtx_NumberOfUniqueExVivoProductsCommercialized"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:label="grtx_PaymentOfRoyaltyPercentageOnNetProductSales"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FeeToExtendCollaborationArrangement" xlink:label="grtx_FeeToExtendCollaborationArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationTermExtensionPeriod" xlink:label="grtx_CollaborationTermExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockPurchaseAgreementDate" xlink:label="grtx_StockPurchaseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" xlink:label="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OneTimePaymentToExtendCollaborationArrangement" xlink:label="grtx_OneTimePaymentToExtendCollaborationArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationAgreementExtensionPeriod" xlink:label="grtx_CollaborationAgreementExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPaymentObligationsExpirationPeriod" xlink:label="grtx_RoyaltyPaymentObligationsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TerminationOfAgreementNoticePeriod" xlink:label="grtx_TerminationOfAgreementNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfAgreementsEntered" xlink:label="grtx_NumberOfAgreementsEntered"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" xlink:label="grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfPerformanceObligations" xlink:label="grtx_NumberOfPerformanceObligations"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPrice" xlink:label="grtx_TransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPriceAllocatedToCommonStock" xlink:label="grtx_TransactionPriceAllocatedToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" xlink:label="grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:label="grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities" xlink:label="grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:label="grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CumulativeCatchUpAdjustment" xlink:label="grtx_CumulativeCatchUpAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement" xlink:label="grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PremiumOnSaleOfShares" xlink:label="grtx_PremiumOnSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPriceAllocatedToCombinedPerformanceObligation" xlink:label="grtx_TransactionPriceAllocatedToCombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" xlink:label="grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PaymentsDueFromAffiliates" xlink:label="grtx_PaymentsDueFromAffiliates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StrategicCollaborationAgreementAmendedDate" xlink:label="grtx_StrategicCollaborationAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_RegeneronPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandSixteenRegeneronAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grtx_CRISPRProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_OptionExercisedToIncreaseRegeneronTargetCapMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="grtx_HemophiliaCoCoAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grtx_ResearchAndDevelopmentServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_NovartisInstitutesForBioMedicalResearchIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_StockPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_ContractWithCustomerLiabilityAdditions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandAndTwentyRegeneronAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_DevelopmentBasedMilestonePaymentsUnderAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandTwentyStockPurchaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RegulatoryBasedMilestonePaymentsUnderAgreement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_CoDevelopmentAndCoPromotionAgreementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_RegeneronArrangementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_SalesBasedMilestonePaymentsUnderAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_RegeneronAmendmentMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborationAgreementFurtherOptionExtensionPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_NovartisArrangementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_IncreaseInTargetCap" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AdditionalTargetInCap" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_NumberOfUniqueExVivoProductsCommercialized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PaymentOfRoyaltyPercentageOnNetProductSales" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_FeeToExtendCollaborationArrangement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborationTermExtensionPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_StockPurchaseAgreementDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_OneTimePaymentToExtendCollaborationArrangement" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborationAgreementExtensionPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RoyaltyPaymentObligationsExpirationPeriod" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TerminationOfAgreementNoticePeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_NumberOfAgreementsEntered" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_NumberOfPerformanceObligations" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TransactionPrice" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TransactionPriceAllocatedToCommonStock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CumulativeCatchUpAdjustment" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PremiumOnSaleOfShares" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TransactionPriceAllocatedToCombinedPerformanceObligation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PaymentsDueFromAffiliates" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_StrategicCollaborationAgreementAmendedDate" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeSpaceMember" xlink:label="grtx_OfficeSpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CurrentOperatingLeaseLiability" xlink:label="grtx_CurrentOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeMember" xlink:label="grtx_OfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseExpirationMonthYear" xlink:label="grtx_LesseeOperatingLeaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LaboratorySpaceMember" xlink:label="grtx_LaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseExtendedExpirationDate" xlink:label="grtx_LesseeOperatingLeaseExtendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:label="grtx_IncreaseDecreaseInOperatingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingSubleaseExpirationMonthYear" xlink:label="grtx_LesseeOperatingSubleaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingSubleaseRenewalTerm" xlink:label="grtx_LesseeOperatingSubleaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseTerminateTerm" xlink:label="grtx_LesseeOperatingLeaseTerminateTerm"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AreaOfSpaceLeased" xlink:label="grtx_AreaOfSpaceLeased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" xlink:label="grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" xlink:label="grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" xlink:label="grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_OfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_CurrentOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_OfficeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseExpirationMonthYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_LaboratorySpaceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseExtendedExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_IncreaseDecreaseInOperatingRightOfUseAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingSubleaseExpirationMonthYear" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingSubleaseRenewalTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseTerminateTerm" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_AreaOfSpaceLeased" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLeaseInterestExpense" xlink:label="grtx_OperatingLeaseInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="grtx_OperatingLeaseInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="grtx_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ATMOfferingMember" xlink:label="grtx_ATMOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PerformanceBasedRestrictedStockUnitsMember" xlink:label="grtx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EquityIncentivePlanMember" xlink:label="grtx_EquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AggregateValueOfCommonStockSaleUnderOffering" xlink:label="grtx_AggregateValueOfCommonStockSaleUnderOffering"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PerformanceBasedStockOptionsMember" xlink:label="grtx_PerformanceBasedStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" xlink:label="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grtx_TwoThousandNineteenIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_ATMOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="grtx_PerformanceBasedRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grtx_EquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grtx_AggregateValueOfCommonStockSaleUnderOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="grtx_PerformanceBasedStockOptionsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="grtx_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_UnderwritingAgreementsMember" xlink:label="grtx_UnderwritingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="grtx_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandEighteenSalesAgreementMember" xlink:label="grtx_TwoThousandEighteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenSalesAgreementMember" xlink:label="grtx_TwoThousandNineteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="grtx_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" xlink:label="grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LegalAccountingAndOtherFees" xlink:label="grtx_LegalAccountingAndOtherFees"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" xlink:label="grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" xlink:label="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_UnderwritingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_RegeneronPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandEighteenSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandNineteenSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandTwentyStockPurchaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_LegalAccountingAndOtherFees" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_A401KPlanMember" xlink:label="grtx_A401KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="grtx_A401KPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IntellectMapMember" xlink:label="grtx_IntellectMapMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="grtx_IntellectMapMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>grtx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-09T14:02:55.0868+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:label="ntla_IncreaseDecreaseInOperatingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:label="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IntellectMapMember" xlink:label="grtx_IntellectMapMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OpenMarketSaleAgreementMember" xlink:label="grtx_OpenMarketSaleAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseExpirationMonthYear" xlink:label="ntla_LesseeOperatingLeaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfAgreementsEntered" xlink:label="ntla_NumberOfAgreementsEntered"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingSubleaseRenewalTerm" xlink:label="ntla_LesseeOperatingSubleaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CoDevelopmentAndCoPromotionAgreementsMember" xlink:label="ntla_CoDevelopmentAndCoPromotionAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="ntla_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingSubleaseExpirationMonthYear" xlink:label="ntla_LesseeOperatingSubleaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" xlink:label="ntla_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:label="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="ntla_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CumulativeCatchUpAdjustment" xlink:label="ntla_CumulativeCatchUpAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPrice" xlink:label="ntla_TransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FirstTrancheMember" xlink:label="grtx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityLineItems" xlink:label="grtx_RoyaltyPurchaseLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EmployeeBenefitPlanPolicyTextBlock" xlink:label="grtx_EmployeeBenefitPlanPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CurrentOperatingLeaseLiability" xlink:label="grtx_CurrentOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ResearchAndDevelopmentServicesMember" xlink:label="ntla_ResearchAndDevelopmentServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" xlink:label="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StrategicCollaborationAgreementAmendedDate" xlink:label="ntla_StrategicCollaborationAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPriceAllocatedToCombinedPerformanceObligation" xlink:label="ntla_TransactionPriceAllocatedToCombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PaymentsDueFromAffiliates" xlink:label="ntla_PaymentsDueFromAffiliates"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NewMilestoneWarrantMember" xlink:label="grtx_NewMilestoneWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" xlink:label="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ContractWithCustomerLiabilityAdditions" xlink:label="ntla_ContractWithCustomerLiabilityAdditions"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronAmendmentMember" xlink:label="ntla_RegeneronAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FourthMilestoneWarrantMember" xlink:label="grtx_FourthMilestoneWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PerformanceBasedStockOptionsMember" xlink:label="ntla_PerformanceBasedStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:label="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:label="ntla_PaymentOfRoyaltyPercentageOnNetProductSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" xlink:label="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AlbanyLeaseMember" xlink:label="ntla_AlbanyLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AdditionalTargetInCap" xlink:label="ntla_AdditionalTargetInCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" xlink:label="ntla_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseExtendedExpirationDate" xlink:label="ntla_LesseeOperatingLeaseExtendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LegalAccountingAndOtherFees" xlink:label="ntla_LegalAccountingAndOtherFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_JefferiesLLCMember" xlink:label="grtx_JefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandSixteenRegeneronAgreementMember" xlink:label="ntla_TwoThousandSixteenRegeneronAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ThirdTrancheMember" xlink:label="grtx_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityPolicyTextBlock" xlink:label="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="ntla_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FifthTrancheMember" xlink:label="grtx_FifthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" xlink:label="ntla_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLeaseInterestExpense" xlink:label="grtx_OperatingLeaseInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock" xlink:label="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" xlink:label="ntla_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TerminationOfAgreementNoticePeriod" xlink:label="ntla_TerminationOfAgreementNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" xlink:label="ntla_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" xlink:label="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" xlink:label="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OneTimePaymentToExtendCollaborationArrangement" xlink:label="ntla_OneTimePaymentToExtendCollaborationArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationAgreementExtensionPeriod" xlink:label="ntla_CollaborationAgreementExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockPurchaseAgreementDate" xlink:label="ntla_StockPurchaseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" xlink:label="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfUniqueExVivoProductsCommercialized" xlink:label="ntla_NumberOfUniqueExVivoProductsCommercialized"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandEighteenSalesAgreementMember" xlink:label="ntla_TwoThousandEighteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RightOfUseAssetsAcquiredUnderOperatingLease" xlink:label="ntla_RightOfUseAssetsAcquiredUnderOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" xlink:label="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LaboratorySpaceMember" xlink:label="grtx_LaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandAndTwentyRegeneronAmendmentMember" xlink:label="ntla_TwoThousandAndTwentyRegeneronAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_HemophiliaCoCoAgreementsMember" xlink:label="ntla_HemophiliaCoCoAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationTermExtensionPeriod" xlink:label="ntla_CollaborationTermExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPaymentObligationsExpirationPeriod" xlink:label="ntla_RoyaltyPaymentObligationsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseTerminateTerm" xlink:label="ntla_LesseeOperatingLeaseTerminateTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" xlink:label="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LaboratoryEquipmentMember" xlink:label="ntla_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LiquidityPolicyTextBlock" xlink:label="grtx_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfPerformanceObligations" xlink:label="ntla_NumberOfPerformanceObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" xlink:label="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncomeTaxBenefitTable" xlink:label="ntla_IncomeTaxBenefitTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FinancialInstitutionDebtSecuritiesMember" xlink:label="ntla_FinancialInstitutionDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AggregateValueOfCommonStockSaleUnderOffering" xlink:label="grtx_AggregateValueOfCommonStockSaleUnderOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityTable" xlink:label="grtx_RoyaltyPurchaseLiabilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PremiumOnSaleOfShares" xlink:label="ntla_PremiumOnSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" xlink:label="ntla_InitialPublicOfferingAndConcurrentPrivatePlacementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseInTargetCap" xlink:label="ntla_IncreaseInTargetCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeSpaceMember" xlink:label="grtx_OfficeSpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_A401KPlanMember" xlink:label="ntla_A401KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" xlink:label="ntla_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities" xlink:label="ntla_AmountAllocatedToTechnologyCollaborationAndResearchActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EquityIncentivePlanMember" xlink:label="grtx_EquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronArrangementMember" xlink:label="ntla_RegeneronArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" xlink:label="ntla_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IssuanceOfCommonStockWarrants" xlink:label="grtx_IssuanceOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_USTreasuryAndOherGovernmentSecuritiesMember" xlink:label="ntla_USTreasuryAndOherGovernmentSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" xlink:label="ntla_CollaborativeArrangementObligationToBeFundInDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeMember" xlink:label="grtx_OfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_UnderwritingAgreementsMember" xlink:label="ntla_UnderwritingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FourthTrancheMember" xlink:label="grtx_FourthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SecondTrancheMember" xlink:label="grtx_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="grtx_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NovartisArrangementMember" xlink:label="ntla_NovartisArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" xlink:label="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="ntla_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="ntla_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockOptionsMember" xlink:label="grtx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInDeferredTaxLiability" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PerformanceBasedRestrictedStockUnitsMember" xlink:label="ntla_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" xlink:label="ntla_AvailableForSalesSecuritiesNonCurrentMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ATMOfferingMember" xlink:label="grtx_ATMOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_Covid19Update" xlink:label="grtx_Covid19Update"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmendedRoyaltyAgreementsMember" xlink:label="grtx_AmendedRoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationAgreementFurtherOptionExtensionPeriod" xlink:label="ntla_CollaborationAgreementFurtherOptionExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommonStockWarrantsMember" xlink:label="grtx_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SalesBasedMilestonePaymentsUnderAgreement" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" xlink:label="ntla_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CRISPRProductMember" xlink:label="ntla_CRISPRProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommonStockIssuanceCosts" xlink:label="grtx_CommonStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" xlink:label="ntla_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenSalesAgreementMember" xlink:label="ntla_TwoThousandNineteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockPurchaseAgreementMember" xlink:label="ntla_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPriceAllocatedToCommonStock" xlink:label="ntla_TransactionPriceAllocatedToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AtTheMarketOfferingsMember" xlink:label="ntla_AtTheMarketOfferingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ntla_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeFurnitureAndEquipmentMember" xlink:label="ntla_OfficeFurnitureAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" xlink:label="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AreaOfSpaceLeased" xlink:label="ntla_AreaOfSpaceLeased"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OptionExercisedToIncreaseRegeneronTargetCapMember" xlink:label="ntla_OptionExercisedToIncreaseRegeneronTargetCapMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement" xlink:label="ntla_RemainingTransactionPriceTransferredAtInceptionOfArrangement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock" xlink:label="ntla_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityAbstract" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FeeToExtendCollaborationArrangement" xlink:label="ntla_FeeToExtendCollaborationArrangement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Acquired Intangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined NOL Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating right of use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Allowance, Operating Loss Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of Common stock initially available for issuance under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value: 200,000,000 shares authorized; 26,458,767 and 24,976,142 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IntellectMapMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IntellectMap.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IntellectMapMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellect Map [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IntellectMapMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IntellectMap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Loss Before Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Depreciation Methods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, depreciation methods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open Market Sale Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Market Sale Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open Market Sale Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of shares under open market sale agrrement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Shares Under Open Market Sale Agrrement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sale of shares under Open Market Sale Agreement , net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental balance sheet information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Balance Sheet Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease expiration month year (YYYY-MM).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfAgreementsEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of agreements entered.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfAgreementsEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Agreements Entered</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfAgreementsEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of agreements entered</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares of common stock outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in research and development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary contribution amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation and related benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingSubleaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease renewal term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingSubleaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingSubleaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease lease not yet commenced base rent per square foot for last year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Base Rent Per Square Foot For Last Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent per square foot for last year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CoDevelopmentAndCoPromotionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-Development and Co-Promotion Agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CoDevelopmentAndCoPromotionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Co Development And Co Promotion Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CoDevelopmentAndCoPromotionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-Development and Co-Promotion Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding amount of royalty agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant and Equipment Useful Life and Values [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life And Values [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingSubleaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating sublease expiration month year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingSubleaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Sublease Expiration Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingSubleaseExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue, Balance at End of Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue, Balance at Beginning of Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments (Note 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock in initial public offering, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and consolidation policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Consolidation Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable billed for long-term contracts or programs additions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Billed For Long Term Contracts Or Programs Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount receivable on cost of construction and tenant improvement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt and Lease Obligation, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial recognition of operating lease right-of-use asset and operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial recognition of operating lease right-of-use asset and operating lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Net Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation net operating loss carryforwards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment estimated useful lives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment at Cost and Recognizes Depreciation and Amortization Using the Straight-Line Method Over Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment unpaid at period end</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Quarterly Results</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CumulativeCatchUpAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative catch up adjustment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CumulativeCatchUpAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Catch Up Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CumulativeCatchUpAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative catch up adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cumulative increase in number of shares for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FirstTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FirstTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FirstTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty purchase liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Purchase Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Purchase Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use lease assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease lease not yet commenced annual base rent per square foot for first year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Annual Base Rent Per Square Foot For First Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent per square foot for first year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EmployeeBenefitPlanPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Benefit Plan [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EmployeeBenefitPlanPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefit Plan [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EmployeeBenefitPlanPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share of common stock, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and restricted cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CurrentOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CurrentOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount allocated to licenses to targets and associated research activities and evaluation plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Allocated To Licenses To Targets And Associated Research Activities And Evaluation Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount allocated to licenses to targets and associated research activities and evaluation plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ResearchAndDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ResearchAndDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ResearchAndDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from royalty purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Royalty Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from royalty purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money market funds and U.S treasury obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds And U S Treasury Obligations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds and U.S. Treasury Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StrategicCollaborationAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic collaboration agreement amended date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StrategicCollaborationAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Collaboration Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StrategicCollaborationAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic collaboration agreement amended date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis Institutes for BioMedical Research Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis Institutes For Bio Medical Research Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential dilutive securities excluded from computation of diluted net loss per common share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive Securities excluded from computation of earnings per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of use assets obtained in exchange for lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of shares under open market sale agrrement shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Shares Under Open Market Sale Agrrement Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sale of shares under Open Market sale agreement, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPriceAllocatedToCombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price allocated to combined performance obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPriceAllocatedToCombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Allocated To Combined Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPriceAllocatedToCombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to combined performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PaymentsDueFromAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due from affiliates.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PaymentsDueFromAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Due From Affiliates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PaymentsDueFromAffiliates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses to targets and associated research activities and evaluation plans performance period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licenses To Targets And Associated Research Activities And Evaluation Plans Performance Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses to targets and associated research activities and evaluation plans performance period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_NewMilestoneWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Milestone Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_NewMilestoneWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New milestone warrant member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_NewMilestoneWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Milestone Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued professional fees and other expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees And Other Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees and other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research &amp; development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Tax Provision (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid-in-Kind Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability additions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current - Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FourthMilestoneWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fourth Milestone Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FourthMilestoneWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth milestone warrant member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FourthMilestoneWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth Milestone Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of redeemable convertible preferred stock to redemption value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Redeemable Convertible Preferred Stock To Redemption Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PaymentOfRoyaltyPercentageOnNetProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of royalty percentage on net product sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PaymentOfRoyaltyPercentageOnNetProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Royalty Percentage On Net Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PaymentOfRoyaltyPercentageOnNetProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of royalty percentage on net product sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement, Maximum Potential Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining common stock available under Sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Remaining Common Stock Available Under Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of remaining common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AlbanyLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Albany Lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AlbanyLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Albany Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AlbanyLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Albany Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AdditionalTargetInCap_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional target in cap.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AdditionalTargetInCap_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Target In Cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AdditionalTargetInCap_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional regeneron target cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred - Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share of common stock, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sales securities, noncurrent, maturing beyond year five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sales Securities Noncurrent Maturing Beyond Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments that matured beyond five years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease extended expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LegalAccountingAndOtherFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal, accounting and other fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LegalAccountingAndOtherFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Accounting And Other Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LegalAccountingAndOtherFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal accounting and other fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current - State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Unrealized Gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandSixteenRegeneronAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen Regeneron Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandSixteenRegeneronAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Regeneron Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandSixteenRegeneronAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Regeneron Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration received on sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Purchase Liability [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Purchase Liability [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Purchase Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred - Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow On Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Follow-on public Offerings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FifthTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FifthTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fifth Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FifthTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fifth Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Operating Lease Liability Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-sale Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of stock options granted under the Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of premium over volume-weighted average trading price of common stock during 30-day period prior to closing of equity transaction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Premium Over Volume Weighted Average Trading Price Of Common Stock During30 Day Period Prior To Closing Of Equity Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of premium over volume-weighted average trading price of common stock during 30-day period prior to closing of equity transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease interest expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current - Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty purchase liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Purchase Liability Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Purchase Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of likelihood of realization needed in order for the company to record a tax benefit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Likelihood Of Realization Required To Record Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of likelihood of realization required to record tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Asset Backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TerminationOfAgreementNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notice period under which the collaboration may be terminated by the entity's partner.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TerminationOfAgreementNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Of Agreement Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TerminationOfAgreementNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination period of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of common stock , net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of gross proceeds from common stock as sales agent cash commission.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Gross Proceeds From Common Stock As Sales Agent Cash Commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds from common stock as sales agent cash commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commission to Agent as Percentage of ATM Offering Proceeds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commission To Agent As Percentage Of A T M Offering Proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission to agent as percentage of ATM offering proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Based Milestone Payments Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development based milestone payments under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected payments to be received from royalty purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Payments To Be Received From Royalty Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected payments to be received from royalty purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OneTimePaymentToExtendCollaborationArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of one time payment the entity could receive if the collaboration partner elected to extend the collaboration arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OneTimePaymentToExtendCollaborationArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Payment To Extend Collaboration Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OneTimePaymentToExtendCollaborationArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time collaboration payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs and Other Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Accrued Expenses and Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued expenses and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities accrued expenses and other.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationAgreementExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period by which the collaboration arrangement may be extended.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationAgreementExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Extension Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationAgreementExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration term extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StockPurchaseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StockPurchaseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StockPurchaseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchase agreement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating sublease option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfUniqueExVivoProductsCommercialized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of unique ex vivo products commercialized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfUniqueExVivoProductsCommercialized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Unique Ex Vivo Products Commercialized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfUniqueExVivoProductsCommercialized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of unique ex vivo products commercialized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RightOfUseAssetsAcquiredUnderOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets acquired under operating lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RightOfUseAssetsAcquiredUnderOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Acquired Under Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RightOfUseAssetsAcquiredUnderOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets acquired under operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Temporary Equity Redemption Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in temporary equity redemption value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Investments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Results of Operations on Quarterly Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandAndTwentyRegeneronAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty regeneron amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandAndTwentyRegeneronAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Regeneron Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandAndTwentyRegeneronAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Regeneron Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued (shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_HemophiliaCoCoAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hemophilia Co/Co agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_HemophiliaCoCoAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hemophilia Co Co Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_HemophiliaCoCoAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hemophilia Co Co Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding (shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Portions of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationTermExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration term extension period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationTermExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Term Extension Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationTermExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration term extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property, plant and equipment, estimated useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RoyaltyPaymentObligationsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period under which the Company may have royalty obligations to a collaboration partner following the termination of the collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RoyaltyPaymentObligationsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Obligations Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RoyaltyPaymentObligationsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment obligation expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Payment Award Terms Of Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Guarantees, Commitments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty purchase liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total agreed amount of royalty purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseTerminateTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease terminate term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseTerminateTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Terminate Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LesseeOperatingLeaseTerminateTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, terminate term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate transaction price remaining to be recognized, period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Employee Eligible For Compensation And Employer Contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Employee Eligible For Compensation And Employer Contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Recognized at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquired in-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisory services fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock in initial public offering, net of issuance costs of $7.3 million</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of performance obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Performance Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired intangible asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation techniques</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants in conjunction with amendment to the Royalty Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency gain (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash equivalents, included in prepaids and other current assets and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs to obtain or fulfill contract capitalized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current - Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Exercise Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Sale of Royalty Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of royalty interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation sale of royalty interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncomeTaxBenefitTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Benefit [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncomeTaxBenefitTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Benefit [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncomeTaxBenefitTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Benefit [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FinancialInstitutionDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial institution debt securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FinancialInstitutionDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Institution Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FinancialInstitutionDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Institution Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards cumulative change in ownership interest of significant shareholders period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Cumulative Change in Ownership Interest of Significant Shareholders Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AggregateValueOfCommonStockSaleUnderOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate value of common stock sale under offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AggregateValueOfCommonStockSaleUnderOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Value Of Common Stock Sale Under Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AggregateValueOfCommonStockSaleUnderOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate value of common stock sale under ATM offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty purchase liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Purchase Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Purchase Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PremiumOnSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium on sale of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PremiumOnSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium On Sale Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PremiumOnSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium on sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_InitialPublicOfferingAndConcurrentPrivatePlacementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering and concurrent private placements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_InitialPublicOfferingAndConcurrentPrivatePlacementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering And Concurrent Private Placements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_InitialPublicOfferingAndConcurrentPrivatePlacementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering and Concurrent Private Placements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseInTargetCap_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in target cap.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseInTargetCap_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Target Cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_IncreaseInTargetCap_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in regeneron target cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest percentage on the first anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_A401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">401(k) plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_A401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A401 K Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_A401KPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Accrued Liabilities and Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets accrued liabilities and other.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining transaction price allocated to combined performance obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Transaction Price Allocated To Combined Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining transaction price allocated to combined performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate transaction price remaining to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental schedule of non-cash financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToTechnologyCollaborationAndResearchActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount allocated to technology collaboration and research activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToTechnologyCollaborationAndResearchActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Allocated To Technology Collaboration And Research Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToTechnologyCollaborationAndResearchActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount allocated to technology collaboration and associated research activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution of employee contribution, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Defined Contribution Plan, Employer Matching Contribution, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Incentive Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred - State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Realized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary of Original Vesting Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount allocated to transfer license to develop factor VIII target for hemophilia A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Allocated To Transfer License To Develop Factor V I I I Target For Hemophilia A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount allocated to transfer license to develop factor VIII target for hemophilia A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized (shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IssuanceOfCommonStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_USTreasuryAndOherGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US treasury and other government securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_USTreasuryAndOherGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Oher Government Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_USTreasuryAndOherGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury and Other Government Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of equity classified warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrant, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and description of business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborativeArrangementObligationToBeFundInDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement obligation to be fund in development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborativeArrangementObligationToBeFundInDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Obligation To Be Fund In Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborativeArrangementObligationToBeFundInDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement obligation to be fund in development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_UnderwritingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_UnderwritingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_UnderwritingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment to goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, number of shares exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FourthTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth Tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FourthTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fourth Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_FourthTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease rental expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency, Pending Claims, Number, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency, Pending Claims, Number, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Pending Claims, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyPendingClaimsNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of pending claims or legal actions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Incentive Award Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NovartisArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NovartisArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NovartisArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Price Of Shares Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility of underlying stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum offering issuance and sale expense covered in company securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Offering Issuance And Sale Expense Covered In Company Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum Offering Issuance And Sale Expense Covered In Company Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock through private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Difference in foreign rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average period of unrecognized compensation costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron Pharmaceuticals Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegeneronPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred tax liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Tax Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AvailableForSalesSecuritiesNonCurrentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sales securities, non-current, maturity period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AvailableForSalesSecuritiesNonCurrentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sales Securities Non Current Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AvailableForSalesSecuritiesNonCurrentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sales Securities, non-current, maturity period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ATMOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ATMOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A T M Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ATMOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_Covid19Update_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_Covid19Update_lbl" xlink:role="http://www.xbrl.org/2003/role/label">COVID-19 Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_Covid19Update_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AmendedRoyaltyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended royalty agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AmendedRoyaltyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Royalty Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_AmendedRoyaltyAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Royalty Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Based Milestone Payments Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory based milestone payments under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred - Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationAgreementFurtherOptionExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement further option extension period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationAgreementFurtherOptionExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Further Option Extension Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CollaborationAgreementFurtherOptionExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement further option extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred to obtain collaboration agreements and costs to fulfill contracts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential sales-based milestone payments available to be earned under a collaboration arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone Payments Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales based milestone payments under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of remaining shares eligible for sale under agreement value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Remaining Shares Eligible For Sale Under Agreement Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from common stock offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CRISPRProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">crispr Product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CRISPRProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C R I S P R Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_CRISPRProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRISPR Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acceleration resulted in additional expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommonStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommonStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_CommonStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock in initial public offering, issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-exclusive license to regeneron under certain Crispr/Cas platform ip.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Exclusive License To Regeneron Under Certain C R I S P R Cas Platform I P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-exclusive License to Regeneron under Certain CRISPR/Cas Platform IP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandNineteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandNineteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TwoThousandNineteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax benefit at statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; Equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPriceAllocatedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price allocated to common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPriceAllocatedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Allocated To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_TransactionPriceAllocatedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AtTheMarketOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offerings.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AtTheMarketOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offerings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AtTheMarketOfferingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offerings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OfficeFurnitureAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office furniture and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OfficeFurnitureAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Furniture And Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OfficeFurnitureAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Maximum Offset Indefinite Lived Deferred Tax Liability For Net Operating Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Offset Indefinite Lived Deferred Tax Liability For Net Operating Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum offset indefinite lived deferred tax liability for net operating loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AreaOfSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of space leased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AreaOfSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Space Leased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_AreaOfSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of space leased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OptionExercisedToIncreaseRegeneronTargetCapMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercised to increase regeneron target cap.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OptionExercisedToIncreaseRegeneronTargetCapMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercised To Increase Regeneron Target Cap [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_OptionExercisedToIncreaseRegeneronTargetCapMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Exercised to Increase Regeneron Target Cap [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expire date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expenses):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RemainingTransactionPriceTransferredAtInceptionOfArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining transaction price transferred at inception of arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RemainingTransactionPriceTransferredAtInceptionOfArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Transaction Price Transferred At Inception Of Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_RemainingTransactionPriceTransferredAtInceptionOfArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining transaction price transferred at inception of arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements &#8211; Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on Recurring Basis [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New accounting pronouncements issued but not yet adopted policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Issued But Not Yet Adopted Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements &#8211; Issued but not yet adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty purchase liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grtx_RoyaltyPurchaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Purchase Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FeeToExtendCollaborationArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fee to extend collaboration arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FeeToExtendCollaborationArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fee To Extend Collaboration Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ntla_FeeToExtendCollaborationArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee to extend collaboration arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expense and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized equity-based compensation expense related to restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from common stock offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:to="ntla_IncreaseDecreaseInOperatingRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:to="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_IntellectMapMember" xlink:to="grtx_IntellectMapMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_OpenMarketSaleAgreementMember" xlink:to="grtx_OpenMarketSaleAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" xlink:to="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ntla_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingLeaseExpirationMonthYear" xlink:to="ntla_LesseeOperatingLeaseExpirationMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NumberOfAgreementsEntered" xlink:to="ntla_NumberOfAgreementsEntered_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingSubleaseRenewalTerm" xlink:to="ntla_LesseeOperatingSubleaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" xlink:to="ntla_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CoDevelopmentAndCoPromotionAgreementsMember" xlink:to="ntla_CoDevelopmentAndCoPromotionAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="ntla_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingSubleaseExpirationMonthYear" xlink:to="ntla_LesseeOperatingSubleaseExpirationMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:to="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" xlink:to="ntla_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:to="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" xlink:to="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="ntla_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CumulativeCatchUpAdjustment" xlink:to="ntla_CumulativeCatchUpAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TransactionPrice" xlink:to="ntla_TransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_FirstTrancheMember" xlink:to="grtx_FirstTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="grtx_RoyaltyPurchaseLiabilityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" xlink:to="ntla_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_EmployeeBenefitPlanPolicyTextBlock" xlink:to="grtx_EmployeeBenefitPlanPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_CurrentOperatingLeaseLiability" xlink:to="grtx_CurrentOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:to="ntla_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ResearchAndDevelopmentServicesMember" xlink:to="ntla_ResearchAndDevelopmentServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" xlink:to="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_StrategicCollaborationAgreementAmendedDate" xlink:to="ntla_StrategicCollaborationAgreementAmendedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="ntla_NovartisInstitutesForBioMedicalResearchIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" xlink:to="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TransactionPriceAllocatedToCombinedPerformanceObligation" xlink:to="ntla_TransactionPriceAllocatedToCombinedPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PaymentsDueFromAffiliates" xlink:to="ntla_PaymentsDueFromAffiliates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:to="ntla_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_NewMilestoneWarrantMember" xlink:to="grtx_NewMilestoneWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" xlink:to="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ContractWithCustomerLiabilityAdditions" xlink:to="ntla_ContractWithCustomerLiabilityAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegeneronAmendmentMember" xlink:to="ntla_RegeneronAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_FourthMilestoneWarrantMember" xlink:to="grtx_FourthMilestoneWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PerformanceBasedStockOptionsMember" xlink:to="ntla_PerformanceBasedStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:to="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:to="ntla_PaymentOfRoyaltyPercentageOnNetProductSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" xlink:to="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AlbanyLeaseMember" xlink:to="ntla_AlbanyLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AdditionalTargetInCap" xlink:to="ntla_AdditionalTargetInCap_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" xlink:to="ntla_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingLeaseExtendedExpirationDate" xlink:to="ntla_LesseeOperatingLeaseExtendedExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LegalAccountingAndOtherFees" xlink:to="ntla_LegalAccountingAndOtherFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_JefferiesLLCMember" xlink:to="grtx_JefferiesLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TwoThousandSixteenRegeneronAgreementMember" xlink:to="ntla_TwoThousandSixteenRegeneronAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ThirdTrancheMember" xlink:to="grtx_ThirdTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock" xlink:to="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_FollowOnPublicOfferingMember" xlink:to="ntla_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_FifthTrancheMember" xlink:to="grtx_FifthTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" xlink:to="ntla_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_OperatingLeaseInterestExpense" xlink:to="grtx_OperatingLeaseInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock" xlink:to="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" xlink:to="ntla_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TerminationOfAgreementNoticePeriod" xlink:to="ntla_TerminationOfAgreementNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" xlink:to="ntla_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" xlink:to="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:to="ntla_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" xlink:to="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_OneTimePaymentToExtendCollaborationArrangement" xlink:to="ntla_OneTimePaymentToExtendCollaborationArrangement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" xlink:to="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" xlink:to="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborationAgreementExtensionPeriod" xlink:to="ntla_CollaborationAgreementExtensionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_StockPurchaseAgreementDate" xlink:to="ntla_StockPurchaseAgreementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" xlink:to="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NumberOfUniqueExVivoProductsCommercialized" xlink:to="ntla_NumberOfUniqueExVivoProductsCommercialized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TwoThousandEighteenSalesAgreementMember" xlink:to="ntla_TwoThousandEighteenSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RightOfUseAssetsAcquiredUnderOperatingLease" xlink:to="ntla_RightOfUseAssetsAcquiredUnderOperatingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" xlink:to="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_LaboratorySpaceMember" xlink:to="grtx_LaboratorySpaceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TwoThousandAndTwentyRegeneronAmendmentMember" xlink:to="ntla_TwoThousandAndTwentyRegeneronAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_HemophiliaCoCoAgreementsMember" xlink:to="ntla_HemophiliaCoCoAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborationTermExtensionPeriod" xlink:to="ntla_CollaborationTermExtensionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RoyaltyPaymentObligationsExpirationPeriod" xlink:to="ntla_RoyaltyPaymentObligationsExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LesseeOperatingLeaseTerminateTerm" xlink:to="ntla_LesseeOperatingLeaseTerminateTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" xlink:to="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_LaboratoryEquipmentMember" xlink:to="ntla_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_LiquidityPolicyTextBlock" xlink:to="grtx_LiquidityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="ntla_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NumberOfPerformanceObligations" xlink:to="ntla_NumberOfPerformanceObligations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" xlink:to="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" xlink:to="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_IncomeTaxBenefitTable" xlink:to="ntla_IncomeTaxBenefitTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_FinancialInstitutionDebtSecuritiesMember" xlink:to="ntla_FinancialInstitutionDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" xlink:to="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_AggregateValueOfCommonStockSaleUnderOffering" xlink:to="grtx_AggregateValueOfCommonStockSaleUnderOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_RoyaltyPurchaseLiabilityTable" xlink:to="grtx_RoyaltyPurchaseLiabilityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PremiumOnSaleOfShares" xlink:to="ntla_PremiumOnSaleOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" xlink:to="ntla_InitialPublicOfferingAndConcurrentPrivatePlacementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_IncreaseInTargetCap" xlink:to="ntla_IncreaseInTargetCap_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_OfficeSpaceMember" xlink:to="grtx_OfficeSpaceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_A401KPlanMember" xlink:to="ntla_A401KPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:to="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" xlink:to="ntla_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AmountAllocatedToTechnologyCollaborationAndResearchActivities" xlink:to="ntla_AmountAllocatedToTechnologyCollaborationAndResearchActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_EquityIncentivePlanMember" xlink:to="grtx_EquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegeneronArrangementMember" xlink:to="ntla_RegeneronArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" xlink:to="ntla_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_IssuanceOfCommonStockWarrants" xlink:to="grtx_IssuanceOfCommonStockWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_USTreasuryAndOherGovernmentSecuritiesMember" xlink:to="ntla_USTreasuryAndOherGovernmentSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" xlink:to="ntla_CollaborativeArrangementObligationToBeFundInDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_OfficeMember" xlink:to="grtx_OfficeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_UnderwritingAgreementsMember" xlink:to="ntla_UnderwritingAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_FourthTrancheMember" xlink:to="grtx_FourthTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_SecondTrancheMember" xlink:to="grtx_SecondTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyPendingClaimsNumber" xlink:to="us-gaap_LossContingencyPendingClaimsNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="grtx_TwoThousandNineteenIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NovartisArrangementMember" xlink:to="ntla_NovartisArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" xlink:to="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TwoThousandTwentyStockPurchaseAgreementMember" xlink:to="ntla_TwoThousandTwentyStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegeneronPharmaceuticalsIncMember" xlink:to="ntla_RegeneronPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_StockOptionsMember" xlink:to="grtx_StockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="ntla_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_IncreaseDecreaseInDeferredTaxLiability" xlink:to="grtx_IncreaseDecreaseInDeferredTaxLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_PerformanceBasedRestrictedStockUnitsMember" xlink:to="ntla_PerformanceBasedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" xlink:to="ntla_AvailableForSalesSecuritiesNonCurrentMaturityPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ATMOfferingMember" xlink:to="grtx_ATMOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_Covid19Update" xlink:to="grtx_Covid19Update_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_AmendedRoyaltyAgreementsMember" xlink:to="grtx_AmendedRoyaltyAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:to="ntla_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CollaborationAgreementFurtherOptionExtensionPeriod" xlink:to="ntla_CollaborationAgreementFurtherOptionExtensionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_CommonStockWarrantsMember" xlink:to="grtx_CommonStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_SalesBasedMilestonePaymentsUnderAgreement" xlink:to="ntla_SalesBasedMilestonePaymentsUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" xlink:to="ntla_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_CRISPRProductMember" xlink:to="ntla_CRISPRProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_CommonStockIssuanceCosts" xlink:to="grtx_CommonStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" xlink:to="ntla_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TwoThousandNineteenSalesAgreementMember" xlink:to="ntla_TwoThousandNineteenSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_StockPurchaseAgreementMember" xlink:to="ntla_StockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_TransactionPriceAllocatedToCommonStock" xlink:to="ntla_TransactionPriceAllocatedToCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AtTheMarketOfferingsMember" xlink:to="ntla_AtTheMarketOfferingsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ntla_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="ntla_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_OfficeFurnitureAndEquipmentMember" xlink:to="ntla_OfficeFurnitureAndEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" xlink:to="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_AreaOfSpaceLeased" xlink:to="ntla_AreaOfSpaceLeased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_OptionExercisedToIncreaseRegeneronTargetCapMember" xlink:to="ntla_OptionExercisedToIncreaseRegeneronTargetCapMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_RemainingTransactionPriceTransferredAtInceptionOfArrangement" xlink:to="ntla_RemainingTransactionPriceTransferredAtInceptionOfArrangement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock" xlink:to="ntla_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grtx_RoyaltyPurchaseLiabilityAbstract" xlink:to="grtx_RoyaltyPurchaseLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ntla_FeeToExtendCollaborationArrangement" xlink:to="ntla_FeeToExtendCollaborationArrangement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>grtx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-09T14:02:52.2518+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.galeratx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:grtx="http://www.galeratx.com/20211231">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grtx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grtx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grtx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grtx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2" id="DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2">
        <link:definition>100020 - Disclosure - Leases - Summary of Operating Leases Liabilities Maturities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100090 - Disclosure - Organization and description of business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies1">
        <link:definition>100100 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100110 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1" id="DisclosurePropertyAndEquipment1">
        <link:definition>100130 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100140 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiability" id="DisclosureRoyaltyPurchaseLiability">
        <link:definition>100150 - Disclosure - Royalty Purchase Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100180 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation" id="DisclosureEquitybasedCompensation">
        <link:definition>100190 - Disclosure - Equity-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" id="Role_DisclosureLossPerShare">
        <link:definition>100200 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100210 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100220 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlan" id="Role_Disclosure401KPlan">
        <link:definition>100230 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResults" id="Role_DisclosureUnauditedQuarterlyResults">
        <link:definition>100240 - Disclosure - Unaudited Quarterly Results</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100270 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>100290 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100300 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityTables" id="DisclosureRoyaltyPurchaseLiabilityTables">
        <link:definition>100320 - Disclosure - Royalty purchase liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100330 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables" id="DisclosureEquitybasedCompensationTables">
        <link:definition>100340 - Disclosure - Equity-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" id="Role_DisclosureLossPerShareTables">
        <link:definition>100350 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResultsTables" id="Role_DisclosureUnauditedQuarterlyResultsTables">
        <link:definition>100360 - Disclosure - Unaudited Quarterly Results (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" id="DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Organization and description of business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo">
        <link:definition>100390 - Disclosure - Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment at Cost and Recognizes Depreciation and Amortization Using the Straight-Line Method Over Estimated Useful Lives (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" id="Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail">
        <link:definition>100410 - Disclosure - Marketable Securities - Summary of Available -for-sale Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails" id="DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Royalty Purchase Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails" id="DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails">
        <link:definition>100490 - Disclosure - Royalty purchase liability - Schedule of Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Summary of Company's Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Summary of Company's Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails" id="DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Schedule of Significant Portions of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails" id="DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail" id="Role_DisclosureCollaborationsAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails" id="DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails">
        <link:definition>100580 - Disclosure - Leases - Summary of Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails" id="DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails">
        <link:definition>100590 - Disclosure - Leases - Summary of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails" id="DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails">
        <link:definition>100600 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails" id="DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails">
        <link:definition>100610 - Disclosure - Leases - Summary of Operating Leases Liabilities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" id="DisclosureCommitmentsAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Commitments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails" id="DisclosureEquitybasedCompensationAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Equity-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails" id="DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails">
        <link:definition>100640 - Disclosure - Equity-based Compensation - Schedule of Equity-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100650 - Disclosure - Equity-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails" id="DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails">
        <link:definition>100660 - Disclosure - Equity-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100670 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" id="Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
        <link:definition>100680 - Disclosure - Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100690 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail" id="Role_Disclosure401KPlanAdditionalInformationDetail">
        <link:definition>100700 - Disclosure - 401(k) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="grtx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RoyaltyPurchaseLiabilityAbstract" name="RoyaltyPurchaseLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" name="AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" name="AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" name="AccruedProfessionalFeesAndOtherExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_AdditionalTargetInCap" name="AdditionalTargetInCap" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_AggregateValueOfCommonStockSaleUnderOffering" name="AggregateValueOfCommonStockSaleUnderOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" name="AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities" name="AmountAllocatedToTechnologyCollaborationAndResearchActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" name="AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_AreaOfSpaceLeased" name="AreaOfSpaceLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" name="AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" name="AvailableForSalesSecuritiesNonCurrentMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_CollaborationAgreementExtensionPeriod" name="CollaborationAgreementExtensionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_CollaborationAgreementFurtherOptionExtensionPeriod" name="CollaborationAgreementFurtherOptionExtensionPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_CollaborationTermExtensionPeriod" name="CollaborationTermExtensionPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" name="CollaborativeArrangementObligationToBeFundInDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" name="CommissionToAgentAsPercentageOfATMOfferingProceeds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_CommonStockIssuanceCosts" name="CommonStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_CumulativeCatchUpAdjustment" name="CumulativeCatchUpAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_CurrentOperatingLeaseLiability" name="CurrentOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsAccruedLiabilitiesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" name="DeferredTaxLiabilitiesAccruedExpensesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_DevelopmentBasedMilestonePaymentsUnderAgreement" name="DevelopmentBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" name="EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" name="ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_FeeToExtendCollaborationArrangement" name="FeeToExtendCollaborationArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_IncreaseDecreaseInDeferredTaxLiability" name="IncreaseDecreaseInDeferredTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_IncreaseDecreaseInOperatingRightOfUseAssets" name="IncreaseDecreaseInOperatingRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" name="IncreaseDecreaseInTemporaryEquityRedemptionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_IncreaseInTargetCap" name="IncreaseInTargetCap" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" name="InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_IssuanceOfCommonStockWarrants" name="IssuanceOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" name="IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_LegalAccountingAndOtherFees" name="LegalAccountingAndOtherFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_LesseeOperatingLeaseExpirationMonthYear" name="LesseeOperatingLeaseExpirationMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LesseeOperatingLeaseExtendedExpirationDate" name="LesseeOperatingLeaseExtendedExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" name="LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" name="LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LesseeOperatingLeaseTerminateTerm" name="LesseeOperatingLeaseTerminateTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LesseeOperatingSubleaseExpirationMonthYear" name="LesseeOperatingSubleaseExpirationMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LesseeOperatingSubleaseRenewalTerm" name="LesseeOperatingSubleaseRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" name="LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" name="MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_NumberOfAgreementsEntered" name="NumberOfAgreementsEntered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_NumberOfPerformanceObligations" name="NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" name="NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_NumberOfUniqueExVivoProductsCommercialized" name="NumberOfUniqueExVivoProductsCommercialized" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_OneTimePaymentToExtendCollaborationArrangement" name="OneTimePaymentToExtendCollaborationArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_OperatingLeaseInterestExpense" name="OperatingLeaseInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" name="OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" name="OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_PaymentOfRoyaltyPercentageOnNetProductSales" name="PaymentOfRoyaltyPercentageOnNetProductSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PaymentsDueFromAffiliates" name="PaymentsDueFromAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" name="PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" name="PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" name="PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" name="PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" name="PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" name="PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_PremiumOnSaleOfShares" name="PremiumOnSaleOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" name="ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_ProceedsFromRoyaltyPurchaseAgreement" name="ProceedsFromRoyaltyPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_RegulatoryBasedMilestonePaymentsUnderAgreement" name="RegulatoryBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" name="RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement" name="RemainingTransactionPriceTransferredAtInceptionOfArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_RightOfUseAssetsAcquiredUnderOperatingLease" name="RightOfUseAssetsAcquiredUnderOperatingLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_RoyaltyPaymentObligationsExpirationPeriod" name="RoyaltyPaymentObligationsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" name="SaleOfSharesUnderOpenMarketSaleAgrrement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" name="SaleOfSharesUnderOpenMarketSaleAgrrementShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_SalesBasedMilestonePaymentsUnderAgreement" name="SalesBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_StockPurchaseAgreementDate" name="StockPurchaseAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_StrategicCollaborationAgreementAmendedDate" name="StrategicCollaborationAgreementAmendedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_TerminationOfAgreementNoticePeriod" name="TerminationOfAgreementNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_TransactionPrice" name="TransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_TransactionPriceAllocatedToCombinedPerformanceObligation" name="TransactionPriceAllocatedToCombinedPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_TransactionPriceAllocatedToCommonStock" name="TransactionPriceAllocatedToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RoyaltyPurchaseLiabilityLineItems" name="RoyaltyPurchaseLiabilityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_A401KPlanMember" name="A401KPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_AlbanyLeaseMember" name="AlbanyLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_AmendedRoyaltyAgreementsMember" name="AmendedRoyaltyAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_ATMOfferingMember" name="ATMOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_AtTheMarketOfferingsMember" name="AtTheMarketOfferingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_CoDevelopmentAndCoPromotionAgreementsMember" name="CoDevelopmentAndCoPromotionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_CRISPRProductMember" name="CRISPRProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_FifthTrancheMember" name="FifthTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_FinancialInstitutionDebtSecuritiesMember" name="FinancialInstitutionDebtSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_FirstTrancheMember" name="FirstTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_FourthMilestoneWarrantMember" name="FourthMilestoneWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_FourthTrancheMember" name="FourthTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_HemophiliaCoCoAgreementsMember" name="HemophiliaCoCoAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" name="InitialPublicOfferingAndConcurrentPrivatePlacementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_IntellectMapMember" name="IntellectMapMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_JefferiesLLCMember" name="JefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_LaboratorySpaceMember" name="LaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" name="MoneyMarketFundsAndUSTreasuryObligationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_NewMilestoneWarrantMember" name="NewMilestoneWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" name="NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_NovartisArrangementMember" name="NovartisArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_NovartisInstitutesForBioMedicalResearchIncMember" name="NovartisInstitutesForBioMedicalResearchIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_OfficeMember" name="OfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_OptionExercisedToIncreaseRegeneronTargetCapMember" name="OptionExercisedToIncreaseRegeneronTargetCapMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_PerformanceBasedRestrictedStockUnitsMember" name="PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_PerformanceBasedStockOptionsMember" name="PerformanceBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RegeneronAmendmentMember" name="RegeneronAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RegeneronArrangementMember" name="RegeneronArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RegeneronPharmaceuticalsIncMember" name="RegeneronPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_ResearchAndDevelopmentServicesMember" name="ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_SecondTrancheMember" name="SecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_StockOptionsMember" name="StockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_ThirdTrancheMember" name="ThirdTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandAndTwentyRegeneronAmendmentMember" name="TwoThousandAndTwentyRegeneronAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandEighteenSalesAgreementMember" name="TwoThousandEighteenSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandNineteenSalesAgreementMember" name="TwoThousandNineteenSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandSixteenRegeneronAgreementMember" name="TwoThousandSixteenRegeneronAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_TwoThousandTwentyStockPurchaseAgreementMember" name="TwoThousandTwentyStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_UnderwritingAgreementsMember" name="UnderwritingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_USTreasuryAndOherGovernmentSecuritiesMember" name="USTreasuryAndOherGovernmentSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" name="BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock" name="NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_IncomeTaxBenefitTable" name="IncomeTaxBenefitTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_RoyaltyPurchaseLiabilityTable" name="RoyaltyPurchaseLiabilityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grtx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_Covid19Update" name="Covid19Update" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_EmployeeBenefitPlanPolicyTextBlock" name="EmployeeBenefitPlanPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock" name="RoyaltyPurchaseLiabilityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grtx_RoyaltyPurchaseLiabilityPolicyTextBlock" name="RoyaltyPurchaseLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>28
<FILENAME>grtx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-09T14:02:55.9725+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="grtx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:href="grtx-20211231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails" xlink:href="grtx-20211231.xsd#DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grtx_IncreaseDecreaseInDeferredTaxLiability" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="9" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInDeferredTaxLiability" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="grtx_AccruedResearchAndDevelopmentExpensesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccruedProfessionalFeesAndOtherExpensesCurrent" xlink:label="grtx_AccruedProfessionalFeesAndOtherExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="grtx_AccruedResearchAndDevelopmentExpensesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest" xlink:label="grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther" xlink:label="grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="grtx_OperatingLeaseInterestExpense" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLeaseInterestExpense" xlink:label="grtx_OperatingLeaseInterestExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>29
<FILENAME>grtx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-09T14:02:55.7957+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grtx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo" xlink:href="grtx-20211231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="grtx-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:href="grtx-20211231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails" xlink:href="grtx-20211231.xsd#DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails" xlink:href="grtx-20211231.xsd#DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails" xlink:href="grtx-20211231.xsd#DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail" xlink:href="grtx-20211231.xsd#Role_Disclosure401KPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="grtx-20211231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IssuanceOfCommonStockWarrants" xlink:label="grtx_IssuanceOfCommonStockWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" xlink:label="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" xlink:label="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_IssuanceOfCommonStockWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grtx_SaleOfSharesUnderOpenMarketSaleAgrrement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="grtx_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="grtx_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RightOfUseAssetsAcquiredUnderOperatingLease" xlink:label="grtx_RightOfUseAssetsAcquiredUnderOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:label="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AtTheMarketOfferingsMember" xlink:label="grtx_AtTheMarketOfferingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" xlink:label="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInDeferredTaxLiability" xlink:label="grtx_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" xlink:label="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_RegeneronPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="grtx_RightOfUseAssetsAcquiredUnderOperatingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_AtTheMarketOfferingsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="grtx_IncreaseDecreaseInDeferredTaxLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" xlink:label="grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_JefferiesLLCMember" xlink:label="grtx_JefferiesLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="grtx_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AtTheMarketOfferingsMember" xlink:label="grtx_AtTheMarketOfferingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OpenMarketSaleAgreementMember" xlink:label="grtx_OpenMarketSaleAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" xlink:label="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" xlink:label="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" xlink:label="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_JefferiesLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_AtTheMarketOfferingsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_OpenMarketSaleAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grtx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grtx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AlbanyLeaseMember" xlink:label="grtx_AlbanyLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ThirdTrancheMember" xlink:label="grtx_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmendedRoyaltyAgreementsMember" xlink:label="grtx_AmendedRoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FifthTrancheMember" xlink:label="grtx_FifthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FirstTrancheMember" xlink:label="grtx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" xlink:label="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" xlink:label="grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grtx_AlbanyLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_ThirdTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="grtx_AmendedRoyaltyAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FifthTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FirstTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_IncreaseDecreaseInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommonStockWarrantsMember" xlink:label="grtx_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockOptionsMember" xlink:label="grtx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="grtx_CommonStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grtx_StockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LaboratoryEquipmentMember" xlink:label="grtx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeFurnitureAndEquipmentMember" xlink:label="grtx_OfficeFurnitureAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_OfficeFurnitureAndEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_USTreasuryAndOherGovernmentSecuritiesMember" xlink:label="grtx_USTreasuryAndOherGovernmentSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FinancialInstitutionDebtSecuritiesMember" xlink:label="grtx_FinancialInstitutionDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_USTreasuryAndOherGovernmentSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_FinancialInstitutionDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" xlink:label="grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" xlink:label="grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" xlink:label="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_USTreasuryAndOherGovernmentSecuritiesMember" xlink:label="grtx_USTreasuryAndOherGovernmentSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FinancialInstitutionDebtSecuritiesMember" xlink:label="grtx_FinancialInstitutionDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_MoneyMarketFundsAndUSTreasuryObligationsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_USTreasuryAndOherGovernmentSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_FinancialInstitutionDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityLineItems" xlink:label="grtx_RoyaltyPurchaseLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPurchaseLiabilityTable" xlink:label="grtx_RoyaltyPurchaseLiabilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FirstTrancheMember" xlink:label="grtx_FirstTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SecondTrancheMember" xlink:label="grtx_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmendedRoyaltyAgreementsMember" xlink:label="grtx_AmendedRoyaltyAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ProceedsFromRoyaltyPurchaseAgreement" xlink:label="grtx_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ThirdTrancheMember" xlink:label="grtx_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FourthTrancheMember" xlink:label="grtx_FourthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FifthTrancheMember" xlink:label="grtx_FifthTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="grtx_RoyaltyPurchaseLiabilityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_RoyaltyPurchaseLiabilityTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FirstTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_SecondTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="grtx_AmendedRoyaltyAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_RoyaltyPurchaseLiabilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="grtx_ProceedsFromRoyaltyPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_ThirdTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_PaidInKindInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FourthTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="grtx_FifthTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grtx_RoyaltyPurchaseLiabilityLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NewMilestoneWarrantMember" xlink:label="grtx_NewMilestoneWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FourthMilestoneWarrantMember" xlink:label="grtx_FourthMilestoneWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="grtx_NewMilestoneWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="grtx_FourthMilestoneWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncomeTaxBenefitTable" xlink:label="grtx_IncomeTaxBenefitTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:label="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" xlink:label="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" xlink:label="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" xlink:label="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_IncomeTaxBenefitTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grtx_IncomeTaxBenefitTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="grtx_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandSixteenRegeneronAgreementMember" xlink:label="grtx_TwoThousandSixteenRegeneronAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" xlink:label="grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CRISPRProductMember" xlink:label="grtx_CRISPRProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OptionExercisedToIncreaseRegeneronTargetCapMember" xlink:label="grtx_OptionExercisedToIncreaseRegeneronTargetCapMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockPurchaseAgreementMember" xlink:label="grtx_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_HemophiliaCoCoAgreementsMember" xlink:label="grtx_HemophiliaCoCoAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ResearchAndDevelopmentServicesMember" xlink:label="grtx_ResearchAndDevelopmentServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NovartisInstitutesForBioMedicalResearchIncMember" xlink:label="grtx_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandAndTwentyRegeneronAmendmentMember" xlink:label="grtx_TwoThousandAndTwentyRegeneronAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ContractWithCustomerLiabilityAdditions" xlink:label="grtx_ContractWithCustomerLiabilityAdditions"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="grtx_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:label="grtx_DevelopmentBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CoDevelopmentAndCoPromotionAgreementsMember" xlink:label="grtx_CoDevelopmentAndCoPromotionAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:label="grtx_RegulatoryBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronArrangementMember" xlink:label="grtx_RegeneronArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_SalesBasedMilestonePaymentsUnderAgreement" xlink:label="grtx_SalesBasedMilestonePaymentsUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronAmendmentMember" xlink:label="grtx_RegeneronAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NovartisArrangementMember" xlink:label="grtx_NovartisArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationAgreementFurtherOptionExtensionPeriod" xlink:label="grtx_CollaborationAgreementFurtherOptionExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseInTargetCap" xlink:label="grtx_IncreaseInTargetCap"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AdditionalTargetInCap" xlink:label="grtx_AdditionalTargetInCap"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfUniqueExVivoProductsCommercialized" xlink:label="grtx_NumberOfUniqueExVivoProductsCommercialized"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:label="grtx_PaymentOfRoyaltyPercentageOnNetProductSales"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FeeToExtendCollaborationArrangement" xlink:label="grtx_FeeToExtendCollaborationArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationTermExtensionPeriod" xlink:label="grtx_CollaborationTermExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StockPurchaseAgreementDate" xlink:label="grtx_StockPurchaseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" xlink:label="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OneTimePaymentToExtendCollaborationArrangement" xlink:label="grtx_OneTimePaymentToExtendCollaborationArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborationAgreementExtensionPeriod" xlink:label="grtx_CollaborationAgreementExtensionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RoyaltyPaymentObligationsExpirationPeriod" xlink:label="grtx_RoyaltyPaymentObligationsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TerminationOfAgreementNoticePeriod" xlink:label="grtx_TerminationOfAgreementNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfAgreementsEntered" xlink:label="grtx_NumberOfAgreementsEntered"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" xlink:label="grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfPerformanceObligations" xlink:label="grtx_NumberOfPerformanceObligations"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPrice" xlink:label="grtx_TransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPriceAllocatedToCommonStock" xlink:label="grtx_TransactionPriceAllocatedToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" xlink:label="grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" xlink:label="grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities" xlink:label="grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" xlink:label="grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CumulativeCatchUpAdjustment" xlink:label="grtx_CumulativeCatchUpAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement" xlink:label="grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PremiumOnSaleOfShares" xlink:label="grtx_PremiumOnSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TransactionPriceAllocatedToCombinedPerformanceObligation" xlink:label="grtx_TransactionPriceAllocatedToCombinedPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" xlink:label="grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PaymentsDueFromAffiliates" xlink:label="grtx_PaymentsDueFromAffiliates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_StrategicCollaborationAgreementAmendedDate" xlink:label="grtx_StrategicCollaborationAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_RegeneronPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandSixteenRegeneronAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grtx_CRISPRProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="grtx_OptionExercisedToIncreaseRegeneronTargetCapMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_StockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="grtx_HemophiliaCoCoAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grtx_ResearchAndDevelopmentServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_NovartisInstitutesForBioMedicalResearchIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandAndTwentyRegeneronAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_ContractWithCustomerLiabilityAdditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandTwentyStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_DevelopmentBasedMilestonePaymentsUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_CoDevelopmentAndCoPromotionAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RegulatoryBasedMilestonePaymentsUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_RegeneronArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_SalesBasedMilestonePaymentsUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_RegeneronAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_NovartisArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborationAgreementFurtherOptionExtensionPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_IncreaseInTargetCap" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AdditionalTargetInCap" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_NumberOfUniqueExVivoProductsCommercialized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PaymentOfRoyaltyPercentageOnNetProductSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_FeeToExtendCollaborationArrangement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborationTermExtensionPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_StockPurchaseAgreementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_OneTimePaymentToExtendCollaborationArrangement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborationAgreementExtensionPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RoyaltyPaymentObligationsExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TerminationOfAgreementNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_NumberOfAgreementsEntered" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_NumberOfPerformanceObligations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TransactionPriceAllocatedToCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_CumulativeCatchUpAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PremiumOnSaleOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_TransactionPriceAllocatedToCombinedPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_PaymentsDueFromAffiliates" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grtx_StrategicCollaborationAgreementAmendedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeSpaceMember" xlink:label="grtx_OfficeSpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_OfficeMember" xlink:label="grtx_OfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CurrentOperatingLeaseLiability" xlink:label="grtx_CurrentOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseExpirationMonthYear" xlink:label="grtx_LesseeOperatingLeaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LaboratorySpaceMember" xlink:label="grtx_LaboratorySpaceMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseExtendedExpirationDate" xlink:label="grtx_LesseeOperatingLeaseExtendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:label="grtx_IncreaseDecreaseInOperatingRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingSubleaseExpirationMonthYear" xlink:label="grtx_LesseeOperatingSubleaseExpirationMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingSubleaseRenewalTerm" xlink:label="grtx_LesseeOperatingSubleaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseTerminateTerm" xlink:label="grtx_LesseeOperatingLeaseTerminateTerm"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AreaOfSpaceLeased" xlink:label="grtx_AreaOfSpaceLeased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" xlink:label="grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" xlink:label="grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" xlink:label="grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_OfficeSpaceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_OfficeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_CurrentOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseExpirationMonthYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grtx_LaboratorySpaceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseExtendedExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_IncreaseDecreaseInOperatingRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingSubleaseExpirationMonthYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingSubleaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseTerminateTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_AreaOfSpaceLeased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenIncentiveAwardPlanMember" xlink:label="grtx_TwoThousandNineteenIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ATMOfferingMember" xlink:label="grtx_ATMOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PerformanceBasedRestrictedStockUnitsMember" xlink:label="grtx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_EquityIncentivePlanMember" xlink:label="grtx_EquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PerformanceBasedStockOptionsMember" xlink:label="grtx_PerformanceBasedStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_AggregateValueOfCommonStockSaleUnderOffering" xlink:label="grtx_AggregateValueOfCommonStockSaleUnderOffering"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" xlink:label="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grtx_TwoThousandNineteenIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_ATMOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="grtx_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grtx_EquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="grtx_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grtx_AggregateValueOfCommonStockSaleUnderOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_FollowOnPublicOfferingMember" xlink:label="grtx_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_UnderwritingAgreementsMember" xlink:label="grtx_UnderwritingAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_RegeneronPharmaceuticalsIncMember" xlink:label="grtx_RegeneronPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandEighteenSalesAgreementMember" xlink:label="grtx_TwoThousandEighteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandNineteenSalesAgreementMember" xlink:label="grtx_TwoThousandNineteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="grtx_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" xlink:label="grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_LegalAccountingAndOtherFees" xlink:label="grtx_LegalAccountingAndOtherFees"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" xlink:label="grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" xlink:label="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grtx_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_UnderwritingAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grtx_RegeneronPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandEighteenSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandNineteenSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grtx_TwoThousandTwentyStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_LegalAccountingAndOtherFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_A401KPlanMember" xlink:label="grtx_A401KPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="grtx_A401KPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
    <link:loc xlink:type="locator" xlink:href="grtx-20211231.xsd#grtx_IntellectMapMember" xlink:label="grtx_IntellectMapMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="grtx_IntellectMapMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731680664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Galera Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001563577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,$0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,795,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1454898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 W. Liberty Blvd #100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">725-1500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Portions of the registrant&#8217;s definitive Proxy Statement, relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission are incorporated by reference into Part III of this Annual Report on Form 10-K.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733117640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,859<span></span>
</td>
<td class="nump">$ 15,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investments</a></td>
<td class="nump">51,358<span></span>
</td>
<td class="nump">56,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,175<span></span>
</td>
<td class="nump">5,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">77,392<span></span>
</td>
<td class="nump">77,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Acquired intangible asset</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">2,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">83,311<span></span>
</td>
<td class="nump">84,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,044<span></span>
</td>
<td class="nump">5,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,633<span></span>
</td>
<td class="nump">8,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Lease liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,935<span></span>
</td>
<td class="nump">13,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty purchase liability</a></td>
<td class="nump">128,063<span></span>
</td>
<td class="nump">63,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Deferred tax liability</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">141,315<span></span>
</td>
<td class="nump">77,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 8)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 200,000,000 shares authorized; 26,458,767 and 24,976,142 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">258,086<span></span>
</td>
<td class="nump">241,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(316,102)<span></span>
</td>
<td class="num">(235,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="num">(58,004)<span></span>
</td>
<td class="nump">6,118<span></span>
</td>
<td class="nump">$ 69,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 83,311<span></span>
</td>
<td class="nump">$ 84,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733048552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued for common stock</a></td>
<td class="nump">26,458,767<span></span>
</td>
<td class="nump">24,976,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">26,458,767<span></span>
</td>
<td class="nump">24,976,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733081992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 52,417<span></span>
</td>
<td class="nump">$ 54,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,951<span></span>
</td>
<td class="nump">15,708<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(73,368)<span></span>
</td>
<td class="num">(70,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,194)<span></span>
</td>
<td class="num">(4,880)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain (loss)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">(80,534)<span></span>
</td>
<td class="num">(74,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,534)<span></span>
</td>
<td class="num">$ (74,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock, basic and diluted</a></td>
<td class="num">$ (3.12)<span></span>
</td>
<td class="num">$ (2.98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding, basic and diluted</a></td>
<td class="nump">25,789,458<span></span>
</td>
<td class="nump">24,869,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731872744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,534)<span></span>
</td>
<td class="num">$ (74,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (80,560)<span></span>
</td>
<td class="num">$ (74,244)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731781928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 69,608<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 230,895<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="num">$ (161,350)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,811,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_IssuanceOfCommonStockWarrants', window );">Issuance of common stock warrants</a></td>
<td class="nump">4,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">5,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">164,575<span></span>
</td>
<td class="nump">164,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="num">$ (26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,218)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 6,118<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">241,649<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(235,568)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">24,976,142<span></span>
</td>
<td class="nump">24,976,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">591,257<span></span>
</td>
<td class="nump">591,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares', window );">Sale of shares under Open Market sale agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SaleOfSharesUnderOpenMarketSaleAgrrement', window );">Sale of shares under Open Market Sale Agreement , net</a></td>
<td class="nump">$ 7,941<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,534)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">$ (58,004)<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 258,086<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (316,102)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">26,458,767<span></span>
</td>
<td class="nump">26,458,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_IssuanceOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_IssuanceOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_SaleOfSharesUnderOpenMarketSaleAgrrement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of shares under open market sale agrrement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_SaleOfSharesUnderOpenMarketSaleAgrrement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of shares under open market sale agrrement shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731702840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (80,534)<span></span>
</td>
<td class="num">$ (74,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
<td class="nump">7,194<span></span>
</td>
<td class="nump">4,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_IncreaseDecreaseInDeferredTaxLiability', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(246)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense</a></td>
<td class="num">(951)<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other liabilities</a></td>
<td class="num">(307)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(67,958)<span></span>
</td>
<td class="num">(59,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(71,979)<span></span>
</td>
<td class="num">(67,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales of short-term investments</a></td>
<td class="nump">77,500<span></span>
</td>
<td class="nump">104,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing activities</a></td>
<td class="nump">5,238<span></span>
</td>
<td class="nump">36,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Proceeds from royalty purchase agreement</a></td>
<td class="nump">57,500<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from the sale of common stock , net of issuance costs</a></td>
<td class="nump">7,941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">66,707<span></span>
</td>
<td class="nump">20,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="num">(2,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">15,872<span></span>
</td>
<td class="nump">18,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">19,859<span></span>
</td>
<td class="nump">15,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement', window );">Issuance of warrants in conjunction with amendment to the Royalty Purchase Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_IncreaseDecreaseInDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_IncreaseDecreaseInDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_ProceedsFromRoyaltyPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_ProceedsFromRoyaltyPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729270376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and description of business</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.	Organization and description of business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Galera Therapeutics, Inc. was incorporated as a Delaware corporation on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 19, 2012</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (inception) and together with its subsidiaries (the Company, or Galera) is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem manganese (GC4419, also referred to as avasopasem) is in development for radiotherapy-induced toxicities, including severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) and esophagitis in patients with lung cancer. In February 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to avasopasem for the reduction of SOM induced by radiotherapy with or without systemic therapy. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Galera&#8217;s second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company announced corrected topline efficacy results from a Phase 3 trial (referred to as the ROMAN trial) evaluating avasopasem for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. The Company had previously announced topline results from the ROMAN trial in October 2021. Upon further analysis following the October topline data announcement, an error by the contract research organization was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints. The corrected results demonstrated efficacy across multiple SOM endpoints with a statistically significant reduction on the primary endpoint of reduction in the incidence of SOM and a statistically significant reduction on the secondary endpoint of number of days of SOM. The ROMAN trial is the Company&#8217;s second randomized trial conducted in patients with HNC to achieve statistical significance and demonstrate improved clinical benefit in reducing SOM. The Company plans to meet with the FDA in 2022 to discuss the results from the ROMAN trial together with the previously completed randomized Phase 2b trial with respect to the potential submission of a New Drug Application, or NDA. Avasopasem is also being studied in a Phase 2a trial for its ability to reduce the incidence of radiotherapy-induced esophagitis in patients with lung cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to developing avasopasem for the reduction of normal tissue toxicity from radiotherapy, the Company is developing its dismutase mimetics to increase the anti-cancer efficacy of higher daily doses of radiotherapy, or SBRT. The Company&#8217;s second dismutase mimetic product candidate, rucosopasem, is being developed to increase the anti-cancer efficacy of SBRT and has successfully completed Phase 1 trials of intravenous rucosopasem in healthy volunteers. In September 2021, in support of rucosopasem, the Company announced final results from its Phase 1/2 pilot trial of avasopasem in combination with SBRT in patients with unresectable or borderline resectable LAPC. In this proof-of-concept trial, survival and tumor outcome benefits were observed. The Company used its observations from this pilot trial to inform the design of rucosopasem clinical trials in combination with SBRT. The Company is currently evaluating rucosopasem in combination with SBRT in a Phase 1/2 safety and anti-cancer efficacy trial in NSCLC and a Phase 2b trial of rucosopasem in combination with SBRT in patients with LAPC.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">316.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company expects its existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2023. In the future, if the Company is not able to continue to raise sufficient capital to fund its operations, the Company may decide </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to delay or discontinue certain activities, including planned research and development activities, hiring plans, manufacturing activities and commercial preparation efforts. In December 2020, the Company filed a registration statement with the Securities and Exchange Commission (SEC) which covers the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in Company securities, which includes an Open Market Sale</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with Jefferies LLC (the Sales Agreement) covering the offering, issuance and sale of up to a maximum aggregate offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#8217;s common stock, which could be utilized to raise funding for future operating expenses and capital expenditure requirements. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we sold approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of common stock and received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million pursuant to the Sales Agreement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there remained $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available under the Sales Agreement.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729326152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.	Basis of presentation and significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of presentation and consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of Galera Therapeutics, Inc. and its wholly owned subsidiaries, Galera Therapeutics Australia Pty Ltd (Galera Australia) and Galera Labs, LLC. All intercompany accounts and transactions have been eliminated in consolidation.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined the functional currency of Galera Australia to be the U.S. dollar. The Company records remeasurement gains and losses on monetary assets and liabilities, such as accounts payable, which are not denominated in U.S. dollars in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management&#8217;s estimates include the share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. The royalty purchase liability is accounted for as debt and interest is accreted over the expected repayment period which approximates fair value.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> consisted of bank deposits, U.S. Treasury obligations and a money market mutual fund invested in U.S. Treasury obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Short-term investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments consist of debt securities with a maturity of greater than three months when acquired. The Company classifies its short-term investments at the time of purchase as available-for-sale securities, which are net of unrealized losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Available-for-sale securities are carried at fair value. Unrealized gains and losses on available-for-sale securities are reported in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost and depreciated using the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">straight-line method</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> over their estimated useful lives ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6609fc12-0319-49c0-95cd-2a3e1d272227;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. The costs of maintenance and repairs are expensed as incurred. Improvements and betterments that add new functionality or extend the useful life of the asset are capitalized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company believes that no revision of the remaining useful lives or write-down of long-lived assets is required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and acquired intangible asset</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2012, the Company completed a Series A redeemable convertible preferred stock (Series A) financing with venture capital investors and simultaneously acquired Galera Therapeutics, LLC (LLC), a limited liability company incorporated in Missouri in 2009. LLC was renamed Galera Labs, LLC in January 2013 and operates as a wholly-owned subsidiary of the Company. The Company applied the purchase method of accounting under which the consideration given to the LLC members and noteholders was allocated to the fair value of the net assets assumed from the LLC at the date of the acquisition. The sole intangible asset acquired represented the fair value of in-process research and development (IPR&amp;D) which has been recorded on the accompanying consolidated balance sheets as an indefinite life intangible asset. A deferred tax liability was recorded for the difference between the fair value of the acquired IPR&amp;D and its tax basis of zero which was recognized as goodwill in applying the purchase method of accounting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets related to IPR&amp;D are considered indefinite-lived intangible assets and, along with goodwill, are not amortized, but are assessed for impairment annually or more frequently if impairment indicators exist. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. If the associated research and development effort related to IPR&amp;D is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its consolidated statements of operations. For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company determined that there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment to goodwill or IPR&amp;D.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalty purchase liability</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, the Company entered into an Amended and Restated Purchase and Sale Agreement (the Royalty Agreement), with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. (collectively, Blackstone or Blackstone Life Sciences). Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the Royalty Purchase Price) in four tranches of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively. The proceeds received have been recorded as long-term debt obligations. Interest expense on such obligation is imputed by estimating risk adjusted future royalty payments over the term of the Royalty Agreement which takes into consideration the probability of obtaining FDA approval. Other significant assumptions include adjustments to estimated gross revenues to arrive at net product sales from which a royalty payment can be estimated. The non-cash interest expense recorded increases the balance of the royalty obligation. The royalty obligation will be reduced when royalty payments are made, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, by increasing the fourth tranche from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was received in July 2021, and adding a new $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million tranche upon the achievement of an additional clinical enrollment milestone, which was received in June 2021. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual royalty payments are highly uncertain and may change depending on a number of factors, including the Company&#8217;s ability to obtain FDA approval, successfully commercialize the Company&#8217;s product candidates and the timing of future royalty payments. The Company imputes interest expense on the royalty purchase obligations based on such factors at each reporting period. As these factors change, the Company will adjust its estimate of the imputed interest expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (short-term leases). For short-term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. The Company had no short-term leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement, and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. The Company accrues and expenses preclinical studies and clinical trial activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with clinical research organizations and clinical trial sites. The Company determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including the Company&#8217;s clinical development plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management makes estimates of the Company&#8217;s accrued expenses as of each balance sheet date in the Company&#8217;s consolidated financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company was awarded a Small Business Innovation Research grant from the National Cancer Institute of the National Institutes of Health, which will partially fund its Phase 1/2 safety and anti-cancer efficacy trial in NSCLC (the Grant). Costs entitled to reimbursement under the Grant are accounted for as a reduction to research and development expenses. During the years ended December 31, 2021 and 2020, the Company recorded a reduction to research and development expense of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, for expenses for which it has been reimbursed, or is entitled to reimbursement, under the Grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected life of the stock options is estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Benefit Plan</span></p><p style="text-indent:8.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company sponsors a 401(k) defined contribution plan for its employees. Employee contributions are voluntary. The Company matches employee contributions in an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the first </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of eligible compensation, and such employer contributions are immediately vested. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, the Company provided matching contributions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and common stock warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:76.814%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,463,078</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,521,636</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,013,739</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Update</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company&#8217;s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial and the EUSOM trial in the fourth quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations at the time, the Company determined that it was not feasible to complete the trial.</span></p></div><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill and allocating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">income taxes to separate financial statements of entities not subject to income tax. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods therein. Upon adoption, the Company must apply certain aspects of this standard retrospectively for all periods presented while other aspects are applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted this ASU on January 1, 2021. There is no impact to the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729174296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.	Fair value measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.689%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.329%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.329%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.372%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds and U.S. Treasury obligations <br/>&#160;&#160;&#160;(included in cash equivalents)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,346</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4b016ec7-c9de-4004-9397-7645b2c3a792;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f1fec276-850c-48f5-82e0-7c1f144c9d23;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_82ec9d38-55d6-49a7-9b4c-1f328cfde640;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,413</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_90fe34be-68f6-4f3e-996c-414d28713b22;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b5ca7b31-6e3b-4277-a915-633d3b089c9c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_39ac49a9-a08d-470b-9d8e-441479f7cc65;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:12.25pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,413</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_71db6aad-ca49-4c24-a01f-b7baac31ab94;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.453%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.425%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.425%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.415%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds and U.S. Treasury obligations<br/>&#160;&#160;&#160;(included in cash equivalents)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,943</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fee3e958-b0d8-4163-ada6-e3c148fc641f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c89274bf-8d90-49f0-888d-378fdc6d56bc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,842</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ac483134-1335-48d8-8e13-9abac8dd12bf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> changes in valuation techniques during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s short-term investment instruments classified using Level 1 inputs within the fair value hierarchy are classified as such because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The fair value of Level 2 securities is estimated based</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term on the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729310536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.	Property and equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consist of (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.296%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.544%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.544%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer hardware and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">179</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,587</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">809</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729280632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.512%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.65%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.65%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,360</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,525</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees and other expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,584</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729119000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityAbstract', window );"><strong>Royalty Purchase Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock', window );">Royalty Purchase Liability</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	Royalty purchase liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the Royalty Purchase Price) in four tranches of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million by increasing the fourth tranche from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and adding a new $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million tranche upon the achievement of an additional clinical enrollment milestone. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method. In June 2021, the Company received the new tranche ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) under the Amendment in connection with the enrollment of the first patient in a Phase 2b trial of rucosopasem in combination with SBRT in patients with locally advanced pancreatic cancer, which the Company refers to as the GRECO-2 trial. Also in June 2021, the Company completed enrollment in the ROMAN trial, thereby achieving the milestone associated with the fourth tranche ($</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million) under the Amendment, which was received in July 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for the Royalty Agreement as a debt instrument. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in proceeds received as of December 31, 2021 have been recorded as a liability on the accompanying consolidated balance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sheets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense is imputed based on the estimated royalty repayment period described below, which takes into consideration the probability and timing of obtaining FDA approval and the potential future revenue from commercializing its product candidates, and which results in a corresponding increase in the liability balance. As the Company continues to evaluate the next steps for its programs focused on the reduction of radiotherapy-induced toxicity, planned or possible next steps may have a material impact on the royalty purchase liability. The Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in noncash interest expense during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the effective interest rate was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Royalty Agreement and the Amendment, in connection with the payment of each tranche of the Royalty Purchase Price, the Company has agreed to sell, convey, transfer and assign to Blackstone all of its right, title and interest in a high single-digit percentage of (i) worldwide net sales of avasopasem and rucosopasem (collectively, the Products) and (ii) all amounts received by the Company or its affiliates, licensees and sublicensees with respect to Product-related damages (collectively, the Product Payments) during the Royalty Period. The Royalty Period means, on a Product-by-Product and country-by-country basis, the period of time commencing on the commercial launch of such Product in such country and ending on the latest to occur of (i) the 12th anniversary of such commercial launch, (ii) the expiration of all valid claims of the Company&#8217;s patents covering such Product in such country, and (iii) the expiration of regulatory data protection or market exclusivity or similar regulatory protection afforded by the health authorities in such country, to the extent such protection or exclusivity effectively prevents generic versions of such Product from entering the market in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Royalty Agreement and the Amendment will remain in effect until the date on which the aggregate amount of the Product Payments paid to Blackstone exceeds a fixed single-digit multiple of the actual amount of the Royalty Purchase Price received by the Company, unless earlier terminated pursuant to the mutual written agreement of the Company and Blackstone. If no Products are commercialized, the Company would not have an obligation to make Product Payments to Blackstone, which is the sole mechanism for repaying the liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the Amendment, the Company issued common stock warrants to the Blackstone Purchaser, each of which became exercisable upon the receipt by the Company of the applicable specified milestone payment. The issued warrants expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the initial exercise dates, as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.19%;"/>
        <td style="width:2.484%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.765%;"/>
        <td style="width:0.696%;"/>
        <td style="width:2.484%;"/>
        <td style="width:1.371%;"/>
        <td style="width:11.791%;"/>
        <td style="width:0.696%;"/>
        <td style="width:2.484%;"/>
        <td style="width:13.429%;"/>
        <td style="width:2.484%;"/>
        <td style="width:13.429%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise Price</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Initial Exercise Date</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New Milestone Warrant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">293,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/7/2021</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/6/2027</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fourth Milestone Warrant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,975</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7/19/2021</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7/18/2027</span></span></p></td>
       </tr>
      </table></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrants are equity-classified and were valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million using the Black-Scholes option pricing model. The warrants were recorded as a discount to the royalty purchase liability. The Company amortizes the debt discount to interest expense over the estimated term of the royalty purchase liability utilizing the effective-interest method.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_RoyaltyPurchaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_RoyaltyPurchaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730199928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.	Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s loss before income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is as follows (in thousands):</span></p><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.597%;"/>
        <td style="width:3.083%;"/>
        <td style="width:1.381%;"/>
        <td style="width:14.795%;"/>
        <td style="width:0.942%;"/>
        <td style="width:3.083%;"/>
        <td style="width:1.381%;"/>
        <td style="width:14.795%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,227</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s tax benefit for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is summarized as follows (in thousands):</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.097%;"/>
        <td style="width:3.362%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.251%;"/>
        <td style="width:0.942%;"/>
        <td style="width:3.362%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.283%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total income tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.147%;"/>
        <td style="width:3.011%;"/>
        <td style="width:0.714%;"/>
        <td style="width:15.669%;"/>
        <td style="width:0.993%;"/>
        <td style="width:4.963%;"/>
        <td style="width:0.714%;"/>
        <td style="width:15.669%;"/>
        <td style="width:0.993%;"/>
        <td style="width:2.13%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rate reconciliation:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal tax benefit at statutory rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sale of royalty interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Difference in foreign rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.61%;"/>
        <td style="width:2.602%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.259%;"/>
        <td style="width:0.942%;"/>
        <td style="width:2.602%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.281%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,111</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,324</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,593</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,827</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,477</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,889</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,492</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,787</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,309</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,102</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,183</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">803</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired in-process research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">653</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">653</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In assessing the need for a valuation allowance, the Company may utilize indefinite-lived deferred tax liabilities from an intangible asset as a future source of income. The Company&#8217;s acquired IPR&amp;D intangible asset can be utilized as a source of income arising from the future reversal of temporary differences that can be offset against post 2017 indefinite-lived net operating losses, or NOLs. Therefore, the Company is permitted to offset the indefinite-lived deferred tax liability up to the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent limitation for NOLs generated subsequent to January 1, 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes carryforwards of federal, state and foreign NOLs as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively (in thousands):</span></p><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.893%;"/>
        <td style="width:3.436%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.251%;"/>
        <td style="width:0.696%;"/>
        <td style="width:3.436%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.829%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Combined NOL Carryforwards:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,265</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135,580</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,516</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,565</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NOL carryforwards begin expiring in 2032 for both federal and state income tax purposes. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">illion that will begin to expire</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2032, unle</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ss previously utilized.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. In general, under Section 382 of the Code, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre change tax credits as well as its NOLs to offset future taxable income. During the year ended December 31, 2021, the Company conducted a Section 382 study and determined that approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in NOLs and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in research and development tax credits are limited by Section 382 as of December 31, 2021. As a result of the Section 382 analysis, approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of research and development tax credits are scheduled to expire unused due to the annual Section 382 limitation and therefore were written off during 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will recognize interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest and penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations. Due to NOL and tax credit carryforwards that remain unutilized, income tax returns from </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 through 2020 re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">main subject to examination by the taxing jurisdictions. The NOLs remain subject to review until utilized.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729245704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.	Commitments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Executive employment agreements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into employment agreements with certain key executives, providing for compensation and severance in certain circumstances, as described in the respective agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal matters</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> claims or legal actions that would reasonably be expected to have a material adverse effect on the Company&#8217;s results of operations, financial condition or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730200488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.	Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has non-cancelable operating leases for office and laboratory space in Malvern, Pennsylvania and Creve Coeur, Missouri which, as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, have remaining lease terms of approximately 1.2 and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, respectively. The discount rate used to account for the Company&#8217;s operating leases is the Company&#8217;s estimated incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental balance sheet information related to leases was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.015%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.176%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.274%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.176%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use lease assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">530</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">258</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">238</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, net of current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease expense were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.04%;"/>
        <td style="width:1.67%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.34%;"/>
        <td style="width:0.942%;"/>
        <td style="width:2.419%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.885%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease rental expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">262</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest on lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">325</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information related to leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.328%;"/>
        <td style="width:1.734%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.678%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.895%;"/>
        <td style="width:1.381%;"/>
        <td style="width:7.719%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows for operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">325</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">445</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets obtained in exchange for lease obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 will mature, as follows (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:87.596%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.378%;"/>
        <td style="width:9.103%;"/>
        <td style="width:0.919%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">310</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">302</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730234792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.	Stockholders' Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> (Deficit)</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity offerings</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into the Sales Agreement with Jefferies LLC (Jefferies) as sales agent, pursuant to which it may, from time to time, issue and sell common stock with an aggregate value of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in &#8220;at-the-market&#8221; (ATM) offerings under the Company&#8217;s Registration Statement on Form S-3 (File No. 333-251061) filed with the SEC on December 1, 2020. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company&#8217;s common stock. The Company is required to pay Jefferies a commission equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent of the gross sales proceeds and has provided Jefferies with customary indemnification rights. During the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">891,368</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were sold under the Sales Agreement at a weighted average price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. As of December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of available capacity under the Sales Agreement.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Company&#8217;s Initial Public Offering, or IPO, in November 2019, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the Galera Therapeutics, Inc. 2019 Incentive Award Plan (the 2019 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the IPO. Upon effectiveness of the 2019 Plan, the Company ceased granting new awards under the Prior Plan (as defined herein).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2019 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially available for issuance under the 2019 Plan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,948,970</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock plus the number of shares subject to awards outstanding under the Prior Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s outstanding shares of common stock on the final day of the immediately preceding calendar year, and (ii) such smaller number of shares of common stock as determined by the Company&#8217;s board of directors. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,251,930</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future issuance under the 2019 Plan, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">999,045</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares added pursuant to this provision effective January 1, 2021. Pursuant to this provision, the Company added an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,058,350</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares to the total shares available for issuance under the 2019 Plan effective January 1, 2022. The maximum number of shares of common stock that may be issued under the 2019 Plan upon the exercise of incentive stock options is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,130,029</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2019, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the ESPP). The ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The number of shares of common stock initially available for issuance under the ESPP was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">243,621</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. In addition, the number of shares of common stock available for issuance under the ESPP is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#8217;s board of directors, provided that not more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,288,886</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock may be issued under the ESPP. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">741,497</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for issuance under the ESPP, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">249,761</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares added pursuant to this provision effective January 1, 2021.  Pursuant to this provision, the Company added an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264,587</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares to the total shares available for issuance under the ESPP effective January 1, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2012, the Company adopted the Equity Incentive Plan (the Prior Plan). The total number of shares subject to outstanding awards under the Prior Plan as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,167,546</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">remain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">available for issuance under the Prior Plan and no further grants will be made under the Prior Plan; however, the Prior Plan continues to govern awards that are outstanding under it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's stock option awards vest based on the terms in the governing agreements and generally vest over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and have a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expense was as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.368%;"/>
        <td style="width:1.103%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.105%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.126%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,312</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,086</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,536</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to stock option grants for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.982%;"/>
        <td style="width:1.006%;"/>
        <td style="width:0.985%;"/>
        <td style="width:9.442%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.543%;"/>
        <td style="width:0.717%;"/>
        <td style="width:1.017%;"/>
        <td style="width:0.717%;"/>
        <td style="width:8.554%;"/>
        <td style="width:0.717%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at January 1, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,537,946</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,238,573</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164,575</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">148,866</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.59</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,463,078</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,653,852</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.40</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">591,257</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">554,698</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.50</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,810,494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.78</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the unrecognized compensation cost was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and will be recognized over an estimated weighted-average remaining amortization period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The aggregate intrinsic value of options outstanding and options exercisable as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Options granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> had weighted-average grant-date fair values of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at the grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options during the years ended December 31, 2021 and 2020 was determined using the methods and assumptions discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, as prescribed in SEC&#8217;s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry which were commensurate with the expected term assumption as described in SAB No. 107. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend yield is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock. </span></div></div><div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s board of directors has determined the per share value of the Company&#8217;s common stock based on the closing price as reported by the NASDAQ Global Market on the date of the grant.  </span></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.827%;"/>
        <td style="width:1.006%;"/>
        <td style="width:0.707%;"/>
        <td style="width:8.051%;"/>
        <td style="width:2.323%;"/>
        <td style="width:1.006%;"/>
        <td style="width:0.707%;"/>
        <td style="width:8.051%;"/>
        <td style="width:2.323%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729269256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11.	Related Party Transactions</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IntellectMap provides IT-advisory services to the Company. The chief executive officer of IntellectMap is the brother of the Company&#8217;s chief executive officer. Fees incurred by the Company with respect to IntellectMap during the years ended December 31, 2021 and 2020 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730129656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">316.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company expects its existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2023. In the future, if the Company is not able to continue to raise sufficient capital to fund its operations, the Company may decide </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to delay or discontinue certain activities, including planned research and development activities, hiring plans, manufacturing activities and commercial preparation efforts. In December 2020, the Company filed a registration statement with the Securities and Exchange Commission (SEC) which covers the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in Company securities, which includes an Open Market Sale</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with Jefferies LLC (the Sales Agreement) covering the offering, issuance and sale of up to a maximum aggregate offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#8217;s common stock, which could be utilized to raise funding for future operating expenses and capital expenditure requirements. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we sold approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million shares of common stock and received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million pursuant to the Sales Agreement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there remained $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available under the Sales Agreement.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of presentation and consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of Galera Therapeutics, Inc. and its wholly owned subsidiaries, Galera Therapeutics Australia Pty Ltd (Galera Australia) and Galera Labs, LLC. All intercompany accounts and transactions have been eliminated in consolidation.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined the functional currency of Galera Australia to be the U.S. dollar. The Company records remeasurement gains and losses on monetary assets and liabilities, such as accounts payable, which are not denominated in U.S. dollars in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management&#8217;s estimates include the share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. The royalty purchase liability is accounted for as debt and interest is accreted over the expected repayment period which approximates fair value.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> consisted of bank deposits, U.S. Treasury obligations and a money market mutual fund invested in U.S. Treasury obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Short-term investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments consist of debt securities with a maturity of greater than three months when acquired. The Company classifies its short-term investments at the time of purchase as available-for-sale securities, which are net of unrealized losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Available-for-sale securities are carried at fair value. Unrealized gains and losses on available-for-sale securities are reported in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost and depreciated using the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">straight-line method</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> over their estimated useful lives ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6609fc12-0319-49c0-95cd-2a3e1d272227;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. The costs of maintenance and repairs are expensed as incurred. Improvements and betterments that add new functionality or extend the useful life of the asset are capitalized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company believes that no revision of the remaining useful lives or write-down of long-lived assets is required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Goodwill and Acquired Intangible Asset</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill and acquired intangible asset</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2012, the Company completed a Series A redeemable convertible preferred stock (Series A) financing with venture capital investors and simultaneously acquired Galera Therapeutics, LLC (LLC), a limited liability company incorporated in Missouri in 2009. LLC was renamed Galera Labs, LLC in January 2013 and operates as a wholly-owned subsidiary of the Company. The Company applied the purchase method of accounting under which the consideration given to the LLC members and noteholders was allocated to the fair value of the net assets assumed from the LLC at the date of the acquisition. The sole intangible asset acquired represented the fair value of in-process research and development (IPR&amp;D) which has been recorded on the accompanying consolidated balance sheets as an indefinite life intangible asset. A deferred tax liability was recorded for the difference between the fair value of the acquired IPR&amp;D and its tax basis of zero which was recognized as goodwill in applying the purchase method of accounting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets related to IPR&amp;D are considered indefinite-lived intangible assets and, along with goodwill, are not amortized, but are assessed for impairment annually or more frequently if impairment indicators exist. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. If the associated research and development effort related to IPR&amp;D is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its consolidated statements of operations. For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company determined that there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment to goodwill or IPR&amp;D.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityPolicyTextBlock', window );">Royalty Purchase Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalty purchase liability</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, the Company entered into an Amended and Restated Purchase and Sale Agreement (the Royalty Agreement), with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. (collectively, Blackstone or Blackstone Life Sciences). Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the Royalty Purchase Price) in four tranches of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively. The proceeds received have been recorded as long-term debt obligations. Interest expense on such obligation is imputed by estimating risk adjusted future royalty payments over the term of the Royalty Agreement which takes into consideration the probability of obtaining FDA approval. Other significant assumptions include adjustments to estimated gross revenues to arrive at net product sales from which a royalty payment can be estimated. The non-cash interest expense recorded increases the balance of the royalty obligation. The royalty obligation will be reduced when royalty payments are made, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, by increasing the fourth tranche from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was received in July 2021, and adding a new $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million tranche upon the achievement of an additional clinical enrollment milestone, which was received in June 2021. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual royalty payments are highly uncertain and may change depending on a number of factors, including the Company&#8217;s ability to obtain FDA approval, successfully commercialize the Company&#8217;s product candidates and the timing of future royalty payments. The Company imputes interest expense on the royalty purchase obligations based on such factors at each reporting period. As these factors change, the Company will adjust its estimate of the imputed interest expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (short-term leases). For short-term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. The Company had no short-term leases as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement, and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. The Company accrues and expenses preclinical studies and clinical trial activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with clinical research organizations and clinical trial sites. The Company determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including the Company&#8217;s clinical development plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management makes estimates of the Company&#8217;s accrued expenses as of each balance sheet date in the Company&#8217;s consolidated financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company was awarded a Small Business Innovation Research grant from the National Cancer Institute of the National Institutes of Health, which will partially fund its Phase 1/2 safety and anti-cancer efficacy trial in NSCLC (the Grant). Costs entitled to reimbursement under the Grant are accounted for as a reduction to research and development expenses. During the years ended December 31, 2021 and 2020, the Company recorded a reduction to research and development expense of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, for expenses for which it has been reimbursed, or is entitled to reimbursement, under the Grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected life of the stock options is estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_EmployeeBenefitPlanPolicyTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Benefit Plan</span></p><p style="text-indent:8.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company sponsors a 401(k) defined contribution plan for its employees. Employee contributions are voluntary. The Company matches employee contributions in an amount equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the first </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of eligible compensation, and such employer contributions are immediately vested. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, the Company provided matching contributions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and common stock warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:76.814%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,463,078</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,521,636</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,013,739</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_Covid19Update', window );">COVID-19 Update</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Update</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company&#8217;s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial and the EUSOM trial in the fourth quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations at the time, the Company determined that it was not feasible to complete the trial.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements &#8211; Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and consolidation policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_Covid19Update">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Update</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_Covid19Update</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_EmployeeBenefitPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Benefit Plan [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_EmployeeBenefitPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_RoyaltyPurchaseLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_RoyaltyPurchaseLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729300968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock Outstanding</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:76.814%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,463,078</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,521,636</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,013,739</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729338872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.689%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.329%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.329%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.372%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds and U.S. Treasury obligations <br/>&#160;&#160;&#160;(included in cash equivalents)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,346</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4b016ec7-c9de-4004-9397-7645b2c3a792;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f1fec276-850c-48f5-82e0-7c1f144c9d23;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_82ec9d38-55d6-49a7-9b4c-1f328cfde640;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,413</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_90fe34be-68f6-4f3e-996c-414d28713b22;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b5ca7b31-6e3b-4277-a915-633d3b089c9c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_39ac49a9-a08d-470b-9d8e-441479f7cc65;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:12.25pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,413</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_71db6aad-ca49-4c24-a01f-b7baac31ab94;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.453%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.425%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.425%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.415%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds and U.S. Treasury obligations<br/>&#160;&#160;&#160;(included in cash equivalents)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,943</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fee3e958-b0d8-4163-ada6-e3c148fc641f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c89274bf-8d90-49f0-888d-378fdc6d56bc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury obligations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,842</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,842</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ac483134-1335-48d8-8e13-9abac8dd12bf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729288136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consist of (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.296%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.544%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.544%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer hardware and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">179</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,587</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">809</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730223304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consist of (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.512%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.65%;"/>
        <td style="width:0.707%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.65%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,360</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,525</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees and other expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,584</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730149512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Company's Loss Before Income Taxes</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s loss before income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is as follows (in thousands):</span></p><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.597%;"/>
        <td style="width:3.083%;"/>
        <td style="width:1.381%;"/>
        <td style="width:14.795%;"/>
        <td style="width:0.942%;"/>
        <td style="width:3.083%;"/>
        <td style="width:1.381%;"/>
        <td style="width:14.795%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,227</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Company's Tax Provision (Benefit)</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s tax benefit for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is summarized as follows (in thousands):</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.097%;"/>
        <td style="width:3.362%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.251%;"/>
        <td style="width:0.942%;"/>
        <td style="width:3.362%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.283%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total income tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.147%;"/>
        <td style="width:3.011%;"/>
        <td style="width:0.714%;"/>
        <td style="width:15.669%;"/>
        <td style="width:0.993%;"/>
        <td style="width:4.963%;"/>
        <td style="width:0.714%;"/>
        <td style="width:15.669%;"/>
        <td style="width:0.993%;"/>
        <td style="width:2.13%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Rate reconciliation:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal tax benefit at statutory rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sale of royalty interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Difference in foreign rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Portions of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.61%;"/>
        <td style="width:2.602%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.259%;"/>
        <td style="width:0.942%;"/>
        <td style="width:2.602%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.281%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,111</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,324</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,593</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,827</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,477</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,889</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,492</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,787</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,309</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,102</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,183</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">803</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired in-process research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">653</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">653</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">273</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes carryforwards of federal, state and foreign NOLs as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively (in thousands):</span></p><p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.893%;"/>
        <td style="width:3.436%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.251%;"/>
        <td style="width:0.696%;"/>
        <td style="width:3.436%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.829%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Combined NOL Carryforwards:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,265</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135,580</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,516</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,565</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729277256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty purchase liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityAbstract', window );"><strong>Royalty Purchase Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the Amendment, the Company issued common stock warrants to the Blackstone Purchaser, each of which became exercisable upon the receipt by the Company of the applicable specified milestone payment. The issued warrants expire </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the initial exercise dates, as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.19%;"/>
        <td style="width:2.484%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.765%;"/>
        <td style="width:0.696%;"/>
        <td style="width:2.484%;"/>
        <td style="width:1.371%;"/>
        <td style="width:11.791%;"/>
        <td style="width:0.696%;"/>
        <td style="width:2.484%;"/>
        <td style="width:13.429%;"/>
        <td style="width:2.484%;"/>
        <td style="width:13.429%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise Price</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Initial Exercise Date</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New Milestone Warrant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">293,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/7/2021</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6/6/2027</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fourth Milestone Warrant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,975</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.62</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7/19/2021</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7/18/2027</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_RoyaltyPurchaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_RoyaltyPurchaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731021016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental balance sheet information related to leases was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.015%;"/>
        <td style="width:1.713%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.176%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.274%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.176%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use lease assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">530</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">258</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">238</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, net of current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">296</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">302</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">534</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs and Other Information</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease expense were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.04%;"/>
        <td style="width:1.67%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.34%;"/>
        <td style="width:0.942%;"/>
        <td style="width:2.419%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.885%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease rental expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">262</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest on lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">325</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">297</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information related to leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.328%;"/>
        <td style="width:1.734%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.678%;"/>
        <td style="width:0.942%;"/>
        <td style="width:1.895%;"/>
        <td style="width:1.381%;"/>
        <td style="width:7.719%;"/>
        <td style="width:0.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows for operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">325</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">445</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets obtained in exchange for lease obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee Operating Lease Liability Maturity</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operating lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 will mature, as follows (amounts in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:87.596%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.378%;"/>
        <td style="width:9.103%;"/>
        <td style="width:0.919%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">310</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">302</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733144248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation expense was as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.368%;"/>
        <td style="width:1.103%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.105%;"/>
        <td style="width:0.706%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.126%;"/>
        <td style="width:0.706%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,312</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,086</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,536</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to stock option grants for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.982%;"/>
        <td style="width:1.006%;"/>
        <td style="width:0.985%;"/>
        <td style="width:9.442%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.381%;"/>
        <td style="width:8.543%;"/>
        <td style="width:0.717%;"/>
        <td style="width:1.017%;"/>
        <td style="width:0.717%;"/>
        <td style="width:8.554%;"/>
        <td style="width:0.717%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at January 1, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,537,946</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,238,573</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.68</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164,575</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">148,866</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.59</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,463,078</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,653,852</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.40</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">591,257</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">554,698</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.50</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,810,494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.78</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.827%;"/>
        <td style="width:1.006%;"/>
        <td style="width:0.707%;"/>
        <td style="width:8.051%;"/>
        <td style="width:2.323%;"/>
        <td style="width:1.006%;"/>
        <td style="width:0.707%;"/>
        <td style="width:8.051%;"/>
        <td style="width:2.323%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729349560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock Outstanding</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:76.814%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
          <td style="width:1.145%;"/>
          <td style="width:0.706%;"/>
          <td style="width:9.034%;"/>
          <td style="width:0.706%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,970,975</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,463,078</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550,661</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,521,636</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,013,739</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733104168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Nov. 19,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (316,102)<span></span>
</td>
<td class="num">$ (235,568)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grtx_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs, shares</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement', window );">Proceeds from issuance of remaining common stock</a></td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grtx_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member] | Jefferies L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities', window );">Maximum Offering Issuance And Sale Expense Covered In Company Securities</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Registration Payment Arrangement, Maximum Potential Consideration</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum offering issuance and sale expense covered in company securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining common stock available under Sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16207-108621<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grtx_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grtx_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grtx_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grtx_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725242904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, plant and equipment, depreciation methods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">straight-line method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total agreed amount of royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,063,000<span></span>
</td>
<td class="nump">63,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Reduction to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution', window );">Percentage Of Employee Eligible For Compensation And Employer Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total agreed amount of royalty purchase price</a></td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember', window );">Amended Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total agreed amount of royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Debt Securities, Available-for-sale, Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=grtx_FifthTrancheMember', window );">Fifth Tranche | Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=grtx_FifthTrancheMember', window );">Fifth Tranche | Amended Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=grtx_FirstTrancheMember', window );">First Tranche | Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Royalty purchase price</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Employee Eligible For Compensation And Employer Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_ProceedsFromRoyaltyPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_ProceedsFromRoyaltyPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grtx_FifthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grtx_FifthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grtx_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grtx_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729375864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities excluded from computation of earnings per share</a></td>
<td class="nump">5,521,636<span></span>
</td>
<td class="nump">5,013,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grtx_StockOptionsMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities excluded from computation of earnings per share</a></td>
<td class="nump">4,970,975<span></span>
</td>
<td class="nump">4,463,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=grtx_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities excluded from computation of earnings per share</a></td>
<td class="nump">550,661<span></span>
</td>
<td class="nump">550,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grtx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grtx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=grtx_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=grtx_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725153976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds and U.S. Treasury Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents and restricted cash equivalents</a></td>
<td class="nump">$ 12,346<span></span>
</td>
<td class="nump">$ 14,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | US Government Corporations and Agencies Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">45,945<span></span>
</td>
<td class="nump">51,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Money Market Funds and U.S. Treasury Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents and restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | US Government Corporations and Agencies Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">5,413<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Money Market Funds and U.S. Treasury Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents and restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | US Government Corporations and Agencies Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">45,945<span></span>
</td>
<td class="nump">51,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,413<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=grtx_MoneyMarketFundsAndUSTreasuryObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=grtx_MoneyMarketFundsAndUSTreasuryObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729320024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect', window );">Changes in valuation techniques</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318732546808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,114<span></span>
</td>
<td class="nump">$ 1,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,587)<span></span>
</td>
<td class="num">(809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729120968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 778<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730665832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">$ 2,038<span></span>
</td>
<td class="nump">$ 2,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">5,360<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_AccruedProfessionalFeesAndOtherExpensesCurrent', window );">Professional fees and other expenses</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 7,633<span></span>
</td>
<td class="nump">$ 8,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_AccruedProfessionalFeesAndOtherExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued professional fees and other expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_AccruedProfessionalFeesAndOtherExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725352152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Liability - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,063<span></span>
</td>
<td class="nump">$ 63,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,194<span></span>
</td>
<td class="nump">4,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total agreed amount of royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,063<span></span>
</td>
<td class="nump">63,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of equity classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty purchase liability</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total agreed amount of royalty purchase price</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_ProceedsFromRoyaltyPurchaseAgreement', window );">Royalty purchase price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Fourth Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Fifth Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember', window );">Amended Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Total agreed amount of royalty purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember', window );">Amended Royalty Agreements | Fifth Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RoyaltyPurchaseLiabilityLineItems', window );"><strong>Royalty Purchase Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding amount of royalty agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_ProceedsFromRoyaltyPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_ProceedsFromRoyaltyPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_RoyaltyPurchaseLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_RoyaltyPurchaseLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grtx_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grtx_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grtx_FourthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grtx_FourthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=grtx_FifthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=grtx_FifthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=grtx_AmendedRoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730182680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty purchase liability - Schedule of Common Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=grtx_NewMilestoneWarrantMember', window );">New Milestone Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, shares issued | shares</a></td>
<td class="nump">293,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 13.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Initial Exercise Date</a></td>
<td class="text">Jun.  07,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Jun.  06,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=grtx_FourthMilestoneWarrantMember', window );">Fourth Milestone Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, shares issued | shares</a></td>
<td class="nump">256,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 13.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Initial Exercise Date</a></td>
<td class="text">Jul. 19,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Jul. 18,  2027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=grtx_NewMilestoneWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=grtx_NewMilestoneWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=grtx_FourthMilestoneWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=grtx_FourthMilestoneWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730298104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Company's Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (80,587)<span></span>
</td>
<td class="num">$ (73,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(1,227)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">$ (80,534)<span></span>
</td>
<td class="num">$ (74,234)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731573048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Company's Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current - Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current - State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current - Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current - Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred - Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred - State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred - Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred - Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725213976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="nump">16.90%<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest', window );">Sale of royalty interest</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Difference in foreign rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation sale of royalty interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725220216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Portions of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,111<span></span>
</td>
<td class="nump">$ 40,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,874<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; development credits</a></td>
<td class="nump">7,827<span></span>
</td>
<td class="nump">7,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">53,889<span></span>
</td>
<td class="nump">49,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(52,787)<span></span>
</td>
<td class="num">(48,309)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">722<span></span>
</td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Acquired in-process research and development</a></td>
<td class="num">(653)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (273)<span></span>
</td>
<td class="num">$ (273)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets accrued liabilities and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities accrued expenses and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725544376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss', window );">Percentage of maximum offset indefinite lived deferred tax liability for net operating loss</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders', window );">Tax credit carryforward, amount</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember', window );">Valuation Allowance, Operating Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Maximum Offset Indefinite Lived Deferred Tax Liability For Net Operating Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725233320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Combined NOL Carryforwards</a></td>
<td class="nump">$ 145,265<span></span>
</td>
<td class="nump">$ 135,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Combined NOL Carryforwards</a></td>
<td class="nump">167,252<span></span>
</td>
<td class="nump">157,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Combined NOL Carryforwards</a></td>
<td class="nump">$ 1,516<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729125512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725562872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grtx_LaboratorySpaceMember', window );">Laboratory Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grtx_LaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grtx_LaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318821596072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Lease liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318725212472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease rental expense</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_OperatingLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease expense</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_OperatingLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_OperatingLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730879240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use assets obtained in exchange for lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730114104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Leases Liabilities Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729295528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Additional Information) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims or legal actions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318724962216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_AggregateValueOfCommonStockSaleUnderOffering', window );">Aggregate value of common stock sale under ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Acceleration resulted in additional expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,231<span></span>
</td>
<td class="nump">$ 5,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.73<span></span>
</td>
<td class="nump">$ 10.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">4,463,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,970,975<span></span>
</td>
<td class="nump">4,463,078<span></span>
</td>
<td class="nump">3,537,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,521,636<span></span>
</td>
<td class="nump">5,013,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Performance-based options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554,698<span></span>
</td>
<td class="nump">148,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grtx_ATMOfferingMember', window );">At-the-market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_AggregateValueOfCommonStockSaleUnderOffering', window );">Aggregate value of common stock sale under ATM offering</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds', window );">Commission to agent as percentage of ATM offering proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Weighted Average Price Of Shares Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grtx_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Incentive Award Plan | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of cumulative increase in number of shares for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058,350<span></span>
</td>
<td class="nump">999,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of cumulative increase in number of shares for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,761<span></span>
</td>
<td class="nump">741,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of Common stock initially available for issuance under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grtx_EquityIncentivePlanMember', window );">2012 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of Common stock initially available for issuance under the ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,167,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2019 Incentive Award Plan | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share Based Payment Award Terms Of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,130,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2019 Employee Stock Purchase Plan | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share Based Payment Award Terms Of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,288,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_AggregateValueOfCommonStockSaleUnderOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of common stock sale under offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_AggregateValueOfCommonStockSaleUnderOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission to Agent as Percentage of ATM Offering Proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grtx_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grtx_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grtx_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grtx_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grtx_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grtx_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731603912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Schedule of Equity-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 7,231<span></span>
</td>
<td class="nump">$ 5,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 4,312<span></span>
</td>
<td class="nump">$ 3,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318723721880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Summary of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning Balance</a></td>
<td class="nump">4,463,078<span></span>
</td>
<td class="nump">3,537,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">1,653,852<span></span>
</td>
<td class="nump">1,238,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(591,257)<span></span>
</td>
<td class="num">(164,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="num">(554,698)<span></span>
</td>
<td class="num">(148,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending Balance</a></td>
<td class="nump">4,970,975<span></span>
</td>
<td class="nump">4,463,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">2,810,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, expected to vest</a></td>
<td class="nump">4,970,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">10.40<span></span>
</td>
<td class="nump">13.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="nump">2.14<span></span>
</td>
<td class="nump">3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Forfeited</a></td>
<td class="nump">12.50<span></span>
</td>
<td class="nump">11.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</a></td>
<td class="nump">8.45<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercisable</a></td>
<td class="nump">6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, expected to vest</a></td>
<td class="nump">$ 8.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Expected to vest</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733082056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of underlying stock</a></td>
<td class="nump">89.50%<span></span>
</td>
<td class="nump">89.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.79%<span></span>
</td>
<td class="nump">1.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733119912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,534)<span></span>
</td>
<td class="num">$ (74,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted</a></td>
<td class="nump">25,789,458<span></span>
</td>
<td class="nump">24,869,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (3.12)<span></span>
</td>
<td class="num">$ (2.98)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318730239032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of diluted net loss per common share</a></td>
<td class="nump">5,521,636<span></span>
</td>
<td class="nump">5,013,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318729263608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318731859912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution of employee contribution, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140318733494392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=grtx_IntellectMapMember', window );">IntellectMap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Advisory services fees</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=grtx_IntellectMapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=grtx_IntellectMapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>grtx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:grtx="http://www.galeratx.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="grtx-20211231.xsd" xlink:type="simple"/>
    <context id="C_4c5d124b-43a8-4a57-b934-4599e22a52e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_91adba5e-65f4-4e18-bcd7-f7c48f289acd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_b00efb57-83ef-4313-8979-7bdb93bd618a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_15ffa14d-8ab6-4a7a-87e0-32c2877a3d2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0de6ffc2-2137-46dc-ae46-12e3c0e17006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_efe17399-273f-425a-8f72-453a258c293e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6225d527-e4ef-4f35-a66b-7bda00076a37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7bf5e8de-1ddb-476f-8d38-35c1b5ab97dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:NewMilestoneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4d891bfc-c9b7-4664-aa86-cb70d7dca47d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_593a8fd2-e876-4c36-8f67-ec70818d7144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_99780757-769e-45eb-9aeb-da23f499cad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5ef0432b-dbc1-49fa-b25a-eee0df54a3d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grtx:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_283a587d-af22-4372-b32e-6522c523cb6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a550fef5-0f03-494a-a55a-4b38cad970c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5cdbba6c-4c21-4368-9002-fbaec59111a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_c71d8cd3-e5bd-471e-b060-cec87aa74c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8002ece0-6266-462e-8ed6-a5bfe859d9a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">grtx:IntellectMapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b5e004bf-3018-4d7e-9906-d7992b1097fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FifthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_f2b24743-77df-4859-afed-60ec1f89419a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_3a54c939-736d-4e51-b6f0-2b61907375c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ba6ef8ac-9f4f-4b23-bbad-8188c1047172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_36d53670-b4ec-458a-b3e8-080466455ca0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b49a26cc-28b3-4484-a6c0-28d5227aaace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10927f54-f772-42ac-8e0e-6713aa190f61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_747599dd-834b-4762-88a4-e8ce71446162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb9a312e-caf8-4908-aa1d-2b259e84c87a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_161a7224-4479-4a28-b4d5-77a29763ab5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6796aa74-9221-4cd7-bee7-288036afa9bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fe1042c2-2d5c-47e5-8b71-e66bdb49c74b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0f6342f9-c1df-4acb-9bdb-a02055460487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d5282f06-c797-4fe4-b19a-c3d0534f9f5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grtx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e58e8310-2bcc-41d3-91b9-08c841d3541d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">grtx:IntellectMapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d4d49bf1-a218-4aaa-a336-133680ab18c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_230365fe-9c24-4694-9fc3-5ece4ab88972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_90454ea7-bd37-4277-92c9-e6be357b98f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7c9a6f1f-9227-4c02-9d86-d4296da459d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1065604f-6672-47c1-8be6-5334d0edc400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ff4d9ca7-3a8c-4c0e-91f3-4d20825252ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e00e7a20-1841-49e0-bf38-357903c57486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e9c572bf-158b-4aaa-b672-6edd20fde598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">grtx:AmendedRoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_373e0480-111d-42c8-8898-a0604bcd9d8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0d65dbd3-c5d4-4b15-adcd-9b943970247a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a526bee0-eb97-448d-b843-ed2b8330aa57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a8e23883-6f88-4b3e-8a59-993c4b0a8e68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_362fa296-c948-48d8-8633-02f4c1279301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_7bd9d8bb-1771-4a1a-9624-32a8d3f04ef8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4c71197f-876f-45b6-af5b-bb409d6b1c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_3286eeb2-2aa4-477b-b07d-a1e64579ceed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_722e6ba2-bc11-4290-88a5-e542358ad8a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9d9a581f-e062-40fd-b896-d6dce0738d15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02423d12-894b-44ac-a7a0-9a6e1fd4800c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_52a132bc-811e-41a6-8227-721ecf66a245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f3513012-929a-445a-a467-3e5db3bbe70d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6f568e62-0715-4e4c-a97a-e44b2148e476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b3ba5c9b-58df-4b65-82e0-7c06fcb7e9e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2650ce90-b6ea-4ce6-a377-81d00bcbaa95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d2525df-46a5-40bb-8481-d3306638d529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0d6f0a55-359d-403b-a434-44702e4affb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fd22c5c9-25d5-4067-8c16-626d9550cb64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FifthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">grtx:AmendedRoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0749fd21-5c0d-4d48-bf75-581475061ab8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_3df4a5dc-c1ad-4043-a5a8-530371ef0c5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1c572ee6-0f00-49f1-a14c-f6c0a3c80911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f40e1447-029f-430d-b180-94abe2cbf70c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_66dcf313-c339-4433-a31f-7b050bd059e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e3841438-e11c-4976-96af-f274931b7060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_45be0985-0b88-45c8-908b-dfddf0179f67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grtx:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a9a3126-74c3-4629-800e-3c042fa2b51f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_3bda9d35-0891-4ab3-af62-f84219914e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e9728d70-5cb0-41f9-97d9-56322b96a0a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:NewMilestoneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_acafa9c5-1a78-4420-88f9-7764339aa6cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dbe44deb-cd48-49e6-b9b3-3243f04236e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_87179a00-f82d-4ea2-a1dd-b16211dad274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f6dfbed4-0d76-449c-8163-dee538b8360e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_a54c4234-e2dc-4d64-9b15-6d41a7216e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f9d64566-02c3-4d28-9715-ba795d3bd45a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_57afcb19-5891-4994-9bdc-91438deda211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a84419a9-fda0-4f1c-b1a3-4f9270aa2e0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_305118ea-acc7-41f9-8491-7c1c62482e6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ad6a9a6d-8f04-4896-b2eb-e94cb204175f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_09c415d3-dc69-4465-956f-96ac5d96e0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6d323ff0-f330-4ed0-8d21-499632ec29a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7306d50-8a8a-4d6c-a10f-596f186d7d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grtx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ef60c426-c561-4135-a8f9-593afe49a453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_caca5273-7404-4350-bcc4-e533ba016ded">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="C_5872ee23-7a9b-4c65-8dcc-db0a2b7bf7b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_2d1b5e52-e6b7-4acf-ae56-9c937aa16f4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_32d0e2d4-86a8-4678-8bc2-8f2c07f319d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_02e529b0-9177-4d0a-8d45-26a8684d2f9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3f5fa676-9ecf-47ef-9aa5-1a0b787f12a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8372daa2-ef3f-464f-9b15-3e1083aa76c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_70b71d11-f6c2-4c62-8626-bd6d1fd6cb30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c7d9157-dcfd-4f05-9f1d-325119845497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_976e5af6-a09b-4243-b493-8a6bf08de5c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eb27f37f-1cab-4e5e-87cb-015e4b21b863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f1539b5e-d51f-4a4e-95e6-8cccb7631150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:FourthMilestoneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_61bbf69e-e94a-42b1-8fab-75d4e9b55dcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bf370159-17d8-430c-bf51-32824e192bad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c795c78f-8be7-43ca-9734-bcb7657f60da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_688f27b3-4933-4708-aa8f-2bbc99b732be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_25712525-0b37-43f7-91fa-c953260ec5ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f9a832f5-9650-4043-bd50-c48a5692f4e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_36e5cf66-783f-49af-adeb-a81f9fe9b685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="C_e0b87fd6-cc11-47a8-ac63-63b4dcfcc465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_959739eb-48eb-46c2-beb8-069b0136e9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_89c8d8d2-8951-4199-b591-7a7a075b63cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9fffc937-6507-4e45-b94f-02243159331f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_93f1c71c-423d-48c2-972d-165e521b4a2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">grtx:MoneyMarketFundsAndUSTreasuryObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_50484754-2125-4a69-bac3-8fcfeb669f39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7f6a782f-8c22-436d-9355-d84bb1aec291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b8b04265-e6c4-456e-b08c-93fe2b0c7f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3cc167f7-0366-47b7-bbfd-33156a4567b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">grtx:FourthMilestoneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3097c236-8fd6-46ae-9c61-fb91d2b9fe52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9df347f3-5a56-4f15-95db-ac9ca27ed0ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grtx:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_11baed89-bceb-4f0a-b7cf-02d6f3284e9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grtx:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_434d1ba1-6f87-483a-9518-2b7eea1ec42f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">grtx:FourthTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_a70b00b9-2347-4b6b-81cc-9944932bfaf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001563577</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_Claim">
        <measure>grtx:Claim</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c795c78f-8be7-43ca-9734-bcb7657f60da"
      id="F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_02e529b0-9177-4d0a-8d45-26a8684d2f9c"
      decimals="-3"
      id="F_fee3e958-b0d8-4163-ada6-e3c148fc641f"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_2650ce90-b6ea-4ce6-a377-81d00bcbaa95"
      decimals="-3"
      id="F_82ec9d38-55d6-49a7-9b4c-1f328cfde640"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <dei:EntityCentralIndexKey
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_93963c3e-bc42-4daa-b8ec-a0c05063cb3d">0001563577</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_02423d12-894b-44ac-a7a0-9a6e1fd4800c"
      id="F_6609fc12-0319-49c0-95cd-2a3e1d272227">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_66dcf313-c339-4433-a31f-7b050bd059e0"
      decimals="-3"
      id="F_39ac49a9-a08d-470b-9d8e-441479f7cc65"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_70b71d11-f6c2-4c62-8626-bd6d1fd6cb30"
      decimals="-3"
      id="F_4b016ec7-c9de-4004-9397-7645b2c3a792"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_688f27b3-4933-4708-aa8f-2bbc99b732be"
      id="F_ac483134-1335-48d8-8e13-9abac8dd12bf"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57"
      id="F_5722ee67-25cb-4023-b75d-50b07da9f90a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      id="F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      id="F_40b56f53-5ecf-4153-8f63-fdba1f4dd223"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_cccfab26-cd38-4711-a8ad-904460dbbf06">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_6225d527-e4ef-4f35-a66b-7bda00076a37"
      id="F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e9728d70-5cb0-41f9-97d9-56322b96a0a9"
      decimals="-3"
      id="F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_7b746d64-60bb-4bcd-b1e3-d69984c4454f">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_e0b87fd6-cc11-47a8-ac63-63b4dcfcc465"
      id="F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b00efb57-83ef-4313-8979-7bdb93bd618a"
      id="F_c89274bf-8d90-49f0-888d-378fdc6d56bc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bf370159-17d8-430c-bf51-32824e192bad"
      decimals="-3"
      id="F_f1fec276-850c-48f5-82e0-7c1f144c9d23"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0de6ffc2-2137-46dc-ae46-12e3c0e17006"
      decimals="-3"
      id="F_71db6aad-ca49-4c24-a01f-b7baac31ab94"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <dei:AmendmentFlag
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_fdfad8e8-00e1-4249-a04e-ba654390c002">false</dei:AmendmentFlag>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_15ffa14d-8ab6-4a7a-87e0-32c2877a3d2e"
      decimals="-3"
      id="F_90fe34be-68f6-4f3e-996c-414d28713b22"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3df4a5dc-c1ad-4043-a5a8-530371ef0c5c"
      decimals="-3"
      id="F_b5ca7b31-6e3b-4277-a915-633d3b089c9c"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <dei:DocumentType
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_95631a1d-c806-4121-86ab-99f45a85dbfc">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_55dc246a-5d30-46e7-a28b-bb7377e290c7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_7319fd9a-f8a1-4b97-a9b2-9ace26b3dcc6">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_8c2434c7-d096-4cfe-ad94-43ef5c86f78c">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_14ec26fe-f14b-4011-a8f5-31ef5dc11127">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_10264376-b01d-450f-b472-0727fcd6f7af">001-39114</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_b03d28ea-1dd7-4ec2-9e81-bcf35c8075f8">Galera Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_0b4c27bc-674f-4357-8c19-584ee89460c5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_74189663-54b1-4a77-abf4-8652dca72d11">46-1454898</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_b019b888-30b5-4f54-89d7-5d4e0f686d37">2 W. Liberty Blvd #100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_061a7b60-5410-40e8-a4ef-7b9e3a837df6">Malvern</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_de093d3f-25ef-432c-91e6-798774560542">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_1d3c8658-fb34-4cba-a058-85e7309c83d2">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_2878af02-05af-49c6-bb93-3a7a6601a31e">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_d74fd9af-3cad-447c-ba60-ab745f4f7d69">725-1500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_422fd3ba-4400-4998-b8af-9df21517537a">Common Stock,$0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_4fbda40a-e9a7-40f5-af08-a363f58bb998">GRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_8887dc8a-bdc1-467b-a4df-8530812105a7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_a455d377-777f-41a3-83f3-ed6618c515fd">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_a472e894-be57-4ed3-bff7-6d1db1d42a29">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_32d2c216-6be7-4f30-ac58-0a7d3f9f8fdf">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_108e9a01-816f-4942-b51e-7de221267831">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_35babd04-1857-449d-826a-372393754c56">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_bf0c09cd-91e8-4090-826b-ce487ba49379">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_763088d9-304e-44a5-bdb0-f689e90ea54d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_5fc9f76a-4484-409c-a81e-398f8d300a6f">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_e0a5c23b-0a5e-4ded-a12d-49b06c490c6b">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_a4ab76b4-ca90-4af6-b556-0237c6333808">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_91adba5e-65f4-4e18-bcd7-f7c48f289acd"
      decimals="-5"
      id="F_91d8d37a-a6d8-40e1-929f-8ecc600f9941"
      unitRef="U_USD">161600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_caca5273-7404-4350-bcc4-e533ba016ded"
      decimals="INF"
      id="F_ba2775cb-8611-46ab-9520-936cbab5bef0"
      unitRef="U_shares">26795172</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_6c956c03-0212-4c64-96bb-a2bf3e6c6b64">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement, relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_66bde388-2857-466a-b8c2-ab4414e1c23a">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_c3441d54-eecf-4eb6-8f6c-434ca68b40e7">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_03ae8b3a-915d-42f0-9b83-70f5d83f2607"
      unitRef="U_USD">19859000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_c8ba7eff-402b-47c6-a1b2-7c975cb7c636"
      unitRef="U_USD">15872000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_a9751c37-fbce-4a74-a26a-298faf032f1f"
      unitRef="U_USD">51358000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_2248decf-7c37-42d0-8874-7544b409b44c"
      unitRef="U_USD">56904000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_ea3ff55c-daae-48e4-99ce-0e781b6efc15"
      unitRef="U_USD">6175000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_c412ca29-fd05-41a5-aeb0-970ead320bca"
      unitRef="U_USD">5153000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_b99b6e16-a114-41f8-8256-58510003dda4"
      unitRef="U_USD">77392000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_9f82797c-9b2c-4917-8f2f-7da04036b1ca"
      unitRef="U_USD">77929000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_05aca8b6-f07e-4855-a26c-c2ab26556fcd"
      unitRef="U_USD">527000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_d2a39386-de14-464b-9a1f-0ad56ee178c8"
      unitRef="U_USD">1023000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_b7ced12e-9f38-4113-90e0-580ffb4b9671"
      unitRef="U_USD">2258000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_c34c419c-5045-47e9-8bd9-b98a5d9218e8"
      unitRef="U_USD">2258000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_f39d9aa0-c455-49c5-8775-e066eee5c503"
      unitRef="U_USD">881000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_b8bf7cd1-f82c-4bce-b746-158882aae03e"
      unitRef="U_USD">881000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_5bd3644e-652c-48ec-b289-b16ef83c682c"
      unitRef="U_USD">296000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_d5940dd3-e322-4d7b-8ed0-10543cbdf82d"
      unitRef="U_USD">530000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_225a2847-95fd-442e-a6c5-dab42e898fcd"
      unitRef="U_USD">1957000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_8e3c7cd1-dc96-4036-bd97-2e17d23f9359"
      unitRef="U_USD">1477000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_bfb9afdc-3a6a-4542-99e6-4e23acacceea"
      unitRef="U_USD">83311000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_eb7133f1-b9d5-404a-8a4d-379257e7d71a"
      unitRef="U_USD">84098000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_b255a598-ecf0-4f78-98d7-1c87bd8cb8c9"
      unitRef="U_USD">5044000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_51da1514-2c45-4713-9666-81c0bfc011d0"
      unitRef="U_USD">5146000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_fe8ed4cf-ed62-48b0-8c45-2093285920dd"
      unitRef="U_USD">7633000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_f63c7a79-5902-43be-8b8d-10260be12ca3"
      unitRef="U_USD">8584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_397aef74-9dda-4c45-88f5-67db1af30c8b"
      unitRef="U_USD">258000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_f973378d-030b-49fb-b743-39b15f886667"
      unitRef="U_USD">238000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_dc2f3fb6-c810-4303-a37c-778bf52cbe01"
      unitRef="U_USD">12935000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_6e99ea15-731d-4e93-b8f0-2633510f6ea3"
      unitRef="U_USD">13968000</us-gaap:LiabilitiesCurrent>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_e22dbe74-2f08-4046-9731-a4c9b9a48294"
      unitRef="U_USD">128063000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_49409c0c-58e0-4ca4-89e9-c93947e08460"
      unitRef="U_USD">63369000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_41ecd391-106f-431e-9dde-37ae1321446a"
      unitRef="U_USD">44000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_d3a5b897-2429-494e-906a-f8272f2052cd"
      unitRef="U_USD">296000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_e4b95860-1eea-4dfb-bd45-7e19dfa18801"
      unitRef="U_USD">273000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_41d7f2b3-9ff9-4fc6-b596-602ed3c6eb0b"
      unitRef="U_USD">273000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:OtherLiabilities
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_4707192b-16ec-4338-bff6-695e330f4438"
      unitRef="U_USD">0</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_5d7a7b50-1c4d-4c7d-b490-84aa3509953f"
      unitRef="U_USD">74000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_d7e88d7e-b198-42f1-a229-84f2b5828095"
      unitRef="U_USD">141315000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_b233e431-aff8-46dc-be30-ea3f59515d79"
      unitRef="U_USD">77980000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_58e0dd8b-251f-4cfc-8423-617997e49f3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_ca11f347-ed0f-4cb6-a3d8-a4a3ba936647"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_26f1c4e5-8a49-4cf8-9dcf-b64eff3592c3"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_e516d2c8-4d33-4fbb-9dfd-008819337dc3"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_4f191429-e08d-486f-8078-47991344b088"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_5c7932d2-3da3-4727-b52e-f25ad72aea0f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_a975f507-d58d-463a-a230-a784cd8eb493"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_95f09a32-fd81-46af-9034-159645aac14f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_045ad157-ef8a-4924-8723-a3b44032c818"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_fe8cdd05-65cb-4dbf-b7c5-56bc5ba237e5"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_70b619b8-90f3-44ca-b4bd-eed36502c159"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_16b9a5ff-fbc3-4ded-9877-070afbb27888"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_75c1f7f0-1ac6-4978-84d7-8e9c6b984cb7"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_d1dc4974-c770-4c94-98fe-94ead0694c6b"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_da9d2293-a976-40b0-8c80-e505c8428f6d"
      unitRef="U_shares">26458767</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_6681d9ec-8865-4104-b0f8-d233623eca62"
      unitRef="U_shares">26458767</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_7153d062-5bf5-4ce3-b04d-758891ec0e79"
      unitRef="U_shares">24976142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_4bf574a7-0dfc-4849-a094-a596ab713030"
      unitRef="U_shares">24976142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_af81d054-ddd2-49a5-91fb-75b8839f3b45"
      unitRef="U_USD">26000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_a2215632-1446-45b5-a5b7-7dacbec46e11"
      unitRef="U_USD">25000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_d0c0e5e1-54bb-4444-990b-376284e759fa"
      unitRef="U_USD">258086000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_ac492c4f-63a4-44e0-87a1-693cd22ae093"
      unitRef="U_USD">241649000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_2e330697-f6c7-4451-8ebf-c2387e90ac18"
      unitRef="U_USD">-14000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_f722f766-62ba-427a-bbdc-3365dddc397e"
      unitRef="U_USD">12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_e5645756-7b7a-4e40-836b-affdcbec9ab7"
      unitRef="U_USD">-316102000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_825c6cf3-42df-41f6-bc1a-9c59a5e3cf11"
      unitRef="U_USD">-235568000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_c9084f80-7dfd-4045-8f3b-b1636400da98"
      unitRef="U_USD">-58004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_51fc4262-e363-4dc1-9fd7-1bca59520bdc"
      unitRef="U_USD">6118000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_b88c2e7b-f52a-4e8b-a60e-20928f284249"
      unitRef="U_USD">83311000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_5e8f03e4-037f-4b1d-8739-8820585aac8f"
      unitRef="U_USD">84098000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_566fcf4d-cc56-44a5-bc65-7deb1a48a156"
      unitRef="U_USD">52417000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_bb80925d-f6eb-4380-8d72-90ed03dcc962"
      unitRef="U_USD">54845000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_b2ec54f4-4c62-48f4-a40a-bc188ed3d5b2"
      unitRef="U_USD">20951000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_3214b2fe-09ad-4f0c-8656-28eef1e887c8"
      unitRef="U_USD">15708000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_2d6b797b-2fc0-43d2-9210-2501f361b401"
      unitRef="U_USD">-73368000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_e495de38-1e8c-4193-9294-65147d91a5c7"
      unitRef="U_USD">-70553000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_04e15582-0611-40e6-8761-41a18a435a1c"
      unitRef="U_USD">32000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_b6ef01b3-9e6c-4a46-8c40-ccac3ccc21bd"
      unitRef="U_USD">1174000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_e02ebc59-8958-4e56-9d9b-fc5a05483765"
      unitRef="U_USD">7194000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_29502f09-d8c6-4739-981d-b1274f11ff07"
      unitRef="U_USD">4880000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_39ab62e4-5d7b-4386-bf00-013fd969b119"
      unitRef="U_USD">-4000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_da72af63-6d79-447f-b8ef-baeda5256bdc"
      unitRef="U_USD">25000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_f2cac130-2458-4b64-a175-e5df9bb9bb34"
      unitRef="U_USD">-80534000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_0cd0ecf0-662e-4817-b5f6-7b3c9e872cbc"
      unitRef="U_USD">-74234000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_47c89ab6-b6cc-4859-8a37-e6d1285f43ec"
      unitRef="U_USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_dae0cda2-64a3-4013-b2cd-ba794d3f980c"
      unitRef="U_USD">-16000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_7e859500-7b81-4ad2-bb73-ce44c96921c1"
      unitRef="U_USD">-80534000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_09f96192-56b1-48c2-8416-75fe76430c6c"
      unitRef="U_USD">-74218000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_7623f939-936e-4cb3-a64c-09b6a1059663"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_57c4d773-1619-4863-b4d4-04b107c2062e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.98</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="0"
      id="F_3db43a0d-a18a-4a0b-af98-c33f74235724"
      unitRef="U_shares">25789458</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="0"
      id="F_283ef596-8d8b-48a0-9d17-71b420b80d24"
      unitRef="U_shares">24869770</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_214a8cc4-6dde-421e-bdc7-e75366c6aa55"
      unitRef="U_USD">-80534000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_138436f8-ebff-49ec-b715-8a08ce8cecce"
      unitRef="U_USD">-74218000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_bffb2923-9959-4650-946c-a4aba53128b9"
      unitRef="U_USD">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_f4721e29-17f9-4be0-bd29-99dfeafd60eb"
      unitRef="U_USD">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_cf1f11f8-458c-45c3-ac0a-3f72d1ff675a"
      unitRef="U_USD">-80560000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_824f720a-3f1b-4079-9b56-bddb577b95d8"
      unitRef="U_USD">-74244000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2a9a3126-74c3-4629-800e-3c042fa2b51f"
      decimals="INF"
      id="F_2288b57b-32ec-469e-ab52-30df7f84f8ac"
      unitRef="U_shares">24811567</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2a9a3126-74c3-4629-800e-3c042fa2b51f"
      decimals="-3"
      id="F_aaf19177-e299-42bc-8fe9-86ba20ef72a9"
      unitRef="U_USD">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d65dbd3-c5d4-4b15-adcd-9b943970247a"
      decimals="-3"
      id="F_88ca5d12-977f-42ac-8aeb-86e9c21e2021"
      unitRef="U_USD">230895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5872ee23-7a9b-4c65-8dcc-db0a2b7bf7b8"
      decimals="-3"
      id="F_9353109b-af63-46a7-b14a-69f3c3ea2c7f"
      unitRef="U_USD">38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb27f37f-1cab-4e5e-87cb-015e4b21b863"
      decimals="-3"
      id="F_89201c68-8431-4fe8-ac50-d59ec94a7847"
      unitRef="U_USD">-161350000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57"
      decimals="-3"
      id="F_01eb18c4-03b4-48a2-b832-fb7bd4b12751"
      unitRef="U_USD">69608000</us-gaap:StockholdersEquity>
    <grtx:IssuanceOfCommonStockWarrants
      contextRef="C_f9a832f5-9650-4043-bd50-c48a5692f4e5"
      decimals="-3"
      id="F_f1c0218b-8a81-4899-880b-fe75bdf9ac58"
      unitRef="U_USD">4712000</grtx:IssuanceOfCommonStockWarrants>
    <grtx:IssuanceOfCommonStockWarrants
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_de9b08aa-400f-44d8-871a-37c88ec81cb5"
      unitRef="U_USD">4712000</grtx:IssuanceOfCommonStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f9a832f5-9650-4043-bd50-c48a5692f4e5"
      decimals="-3"
      id="F_05509f01-6625-4abb-b6f1-e0083af4c0c7"
      unitRef="U_USD">5536000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_0fc1d842-78a3-4bbf-833c-a6af5568a649"
      unitRef="U_USD">5536000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_283a587d-af22-4372-b32e-6522c523cb6e"
      decimals="INF"
      id="F_95bc5944-b1cd-4fda-a386-c9aa6fd3521a"
      unitRef="U_shares">164575</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f9a832f5-9650-4043-bd50-c48a5692f4e5"
      decimals="-3"
      id="F_581a58fb-8329-4778-867d-e20f6dc9bc4b"
      unitRef="U_USD">506000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_57cb1a0a-26b2-46dd-9097-35bd6f4afd26"
      unitRef="U_USD">506000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_959739eb-48eb-46c2-beb8-069b0136e9fc"
      decimals="-3"
      id="F_b1167400-a51b-4335-8b8f-629fc21cbc76"
      unitRef="U_USD">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_75fe50f2-f457-4dc5-a0ba-977a3031000f"
      unitRef="U_USD">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_373e0480-111d-42c8-8898-a0604bcd9d8d"
      decimals="-3"
      id="F_dcadf226-7e17-4b18-8a57-65c4ab64f799"
      unitRef="U_USD">-74218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_c958ad5a-7a08-4ed7-b9d9-139d5971a7b2"
      unitRef="U_USD">-74218000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_90454ea7-bd37-4277-92c9-e6be357b98f4"
      decimals="INF"
      id="F_29e0a52d-98dc-4124-bd88-96ce811a0337"
      unitRef="U_shares">24976142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_90454ea7-bd37-4277-92c9-e6be357b98f4"
      decimals="-3"
      id="F_0154fafa-2c2c-4738-931d-4441ee3d185a"
      unitRef="U_USD">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8372daa2-ef3f-464f-9b15-3e1083aa76c0"
      decimals="-3"
      id="F_906be6f7-2541-4c2c-82fb-f41a988f9c8a"
      unitRef="U_USD">241649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_161a7224-4479-4a28-b4d5-77a29763ab5d"
      decimals="-3"
      id="F_6b7d4c0a-e904-47eb-993c-e5f21ec07265"
      unitRef="U_USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0f6342f9-c1df-4acb-9bdb-a02055460487"
      decimals="-3"
      id="F_4dcdd75d-61e0-4ab1-980e-98b70ae8e1f3"
      unitRef="U_USD">-235568000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_d8b61973-4dda-441e-9e47-b79afa96d6c7"
      unitRef="U_USD">6118000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_747599dd-834b-4762-88a4-e8ce71446162"
      decimals="-3"
      id="F_ede47b9f-20ab-4a74-abbc-e68c82c6b877"
      unitRef="U_USD">7231000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_956c885f-20b2-4217-986c-bd1854bcedd7"
      unitRef="U_USD">7231000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf"
      decimals="INF"
      id="F_6aef0bfd-f94c-4e41-8908-22c2fe1cb739"
      unitRef="U_shares">591257</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_747599dd-834b-4762-88a4-e8ce71446162"
      decimals="-3"
      id="F_e96e5134-17aa-4646-8efe-457be2e87812"
      unitRef="U_USD">1266000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_1859675d-5c1b-4f07-8a69-928a4f52fc84"
      unitRef="U_USD">1266000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <grtx:SaleOfSharesUnderOpenMarketSaleAgrrementShares
      contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf"
      decimals="INF"
      id="F_81bd0b7a-999e-4ccf-8232-0397b2f5a7bb"
      unitRef="U_shares">-891368</grtx:SaleOfSharesUnderOpenMarketSaleAgrrementShares>
    <grtx:SaleOfSharesUnderOpenMarketSaleAgrrement
      contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf"
      decimals="-3"
      id="F_3252fa9d-3e8c-4187-a346-b9cde56da863"
      unitRef="U_USD">-1000</grtx:SaleOfSharesUnderOpenMarketSaleAgrrement>
    <grtx:SaleOfSharesUnderOpenMarketSaleAgrrement
      contextRef="C_747599dd-834b-4762-88a4-e8ce71446162"
      decimals="-3"
      id="F_daed8111-9cf3-414d-b01d-1aea5fae8c47"
      unitRef="U_USD">-7940000</grtx:SaleOfSharesUnderOpenMarketSaleAgrrement>
    <grtx:SaleOfSharesUnderOpenMarketSaleAgrrement
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_361c1898-cf3a-4e53-9a1d-49578348fa76"
      unitRef="U_USD">-7941000</grtx:SaleOfSharesUnderOpenMarketSaleAgrrement>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_3097c236-8fd6-46ae-9c61-fb91d2b9fe52"
      decimals="-3"
      id="F_8b8d26e2-7a15-46e5-b7ec-de051faea375"
      unitRef="U_USD">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_b9f8b751-d566-4425-8b30-1a69c0d2a14d"
      unitRef="U_USD">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_61bbf69e-e94a-42b1-8fab-75d4e9b55dcc"
      decimals="-3"
      id="F_7a8a8623-8f22-419a-a204-074559f19530"
      unitRef="U_USD">-80534000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_b4ee66ab-1b32-49d4-be4b-6eadb41cb386"
      unitRef="U_USD">-80534000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ba6ef8ac-9f4f-4b23-bbad-8188c1047172"
      decimals="INF"
      id="F_de951d96-b361-4b24-9fbb-718f31900278"
      unitRef="U_shares">26458767</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ba6ef8ac-9f4f-4b23-bbad-8188c1047172"
      decimals="-3"
      id="F_288a45a4-4d39-485c-ae34-f3a110df76bb"
      unitRef="U_USD">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50484754-2125-4a69-bac3-8fcfeb669f39"
      decimals="-3"
      id="F_cd0a6792-3aa2-4a30-a72a-f89205cd4b57"
      unitRef="U_USD">258086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_99780757-769e-45eb-9aeb-da23f499cad1"
      decimals="-3"
      id="F_e118a4b0-5e57-4eca-b285-c6887a4d9cdd"
      unitRef="U_USD">-14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2d1b5e52-e6b7-4acf-ae56-9c937aa16f4c"
      decimals="-3"
      id="F_28f77251-0b8c-4cbf-9df3-e2da3311914f"
      unitRef="U_USD">-316102000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_fd510bb2-bc82-4fbf-a6da-a9f7edae3fa6"
      unitRef="U_USD">-58004000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_403430fc-9e80-4937-8712-55771a315dae"
      unitRef="U_USD">-80534000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_c385b7f9-0600-4a9e-957f-3b0700dce98d"
      unitRef="U_USD">-74218000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_c0e2e674-196e-4bdb-af67-bafb2562af4d"
      unitRef="U_USD">778000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_d69e3312-757f-4c49-9c5d-6a308328ec1d"
      unitRef="U_USD">368000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_0503e3cd-c1e1-4fe0-b069-2df6db44be4f"
      unitRef="U_USD">7194000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_5dfc2318-4414-4171-8516-384e4f6a34ce"
      unitRef="U_USD">4880000</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_5e20ff16-5f01-4094-ba30-15bcb8baea43"
      unitRef="U_USD">7231000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_77b6a0d9-5383-477e-aae2-fdc0e0fbbc6c"
      unitRef="U_USD">5536000</us-gaap:ShareBasedCompensation>
    <grtx:IncreaseDecreaseInDeferredTaxLiability
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_599b82ed-0a14-4189-a252-7a81f93d9e26"
      unitRef="U_USD">0</grtx:IncreaseDecreaseInDeferredTaxLiability>
    <grtx:IncreaseDecreaseInDeferredTaxLiability
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_62359589-94de-4900-8ea1-58b5b2b1182b"
      unitRef="U_USD">-16000</grtx:IncreaseDecreaseInDeferredTaxLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_e56a7440-ba96-4a47-97a8-a83a42007472"
      unitRef="U_USD">1022000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_0e9c445f-a925-4507-ad84-9aff7aa236c1"
      unitRef="U_USD">-127000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_b133be6f-5ec4-48db-9b4e-d918dabb5e9d"
      unitRef="U_USD">246000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_1b30566a-efe5-4c3b-ac59-23d99919bade"
      unitRef="U_USD">274000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_95daebca-b12a-4c9a-bff9-1f2d1bddc908"
      unitRef="U_USD">-101000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_ea43fa1c-2ca0-4096-9117-b824e790aee9"
      unitRef="U_USD">1201000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_ec082dfd-f6c3-48a0-be75-0243d3851884"
      unitRef="U_USD">-951000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_d4c6b1cc-fa29-497a-8710-158b4f3f5b1e"
      unitRef="U_USD">2859000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_cfef8033-f717-4fc6-afa2-771f6f1c9a0c"
      unitRef="U_USD">307000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_3301037f-b844-4e18-8bae-2d6d03df5e88"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_f7be4c73-cc71-488a-a29f-324d7f00a4e6"
      unitRef="U_USD">-67958000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_1710b3a4-aa6e-4338-bde6-651e191da3a2"
      unitRef="U_USD">-59537000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_dde04f28-511e-4643-b274-abf4de741a3e"
      unitRef="U_USD">71979000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_0ffb8f34-01c1-40e7-b897-07b2f3eca644"
      unitRef="U_USD">67746000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_acefd0d4-02a9-4d18-ac9e-407f025d399d"
      unitRef="U_USD">77500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_111a4bfe-d23c-4a0e-b4f0-552dd6e81048"
      unitRef="U_USD">104750000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_072110a1-a9fe-4972-818f-dc72ce5c1d1f"
      unitRef="U_USD">283000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_2804282b-28d5-4f59-8db0-25a041ee03d0"
      unitRef="U_USD">457000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_2f23042b-1c93-4bd2-858e-54bad810f577"
      unitRef="U_USD">5238000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_ae1e0e12-deb3-403d-9be9-4978df71324f"
      unitRef="U_USD">36547000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <grtx:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_1341f251-8861-458c-8d61-8ec613fc9443"
      unitRef="U_USD">57500000</grtx:ProceedsFromRoyaltyPurchaseAgreement>
    <grtx:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_03c83baa-789a-480e-8bf3-c041559685d8"
      unitRef="U_USD">20000000</grtx:ProceedsFromRoyaltyPurchaseAgreement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_4cbd5ca1-7c62-4567-be02-4c80ccc48726"
      unitRef="U_USD">7941000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_ee5fd7ea-37a9-4850-8598-390ba7337bc0"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_3665c9da-6819-41a9-ab2c-2d1cd9c1bd6d"
      unitRef="U_USD">1266000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_dc09f193-d636-419c-92d7-7f7eb01f1d20"
      unitRef="U_USD">506000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_69bd231c-d3a0-4bcd-966d-d06e6f85d37f"
      unitRef="U_USD">66707000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_74a646d4-43b2-4a62-9a21-8cde430b1135"
      unitRef="U_USD">20506000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_17eedde7-7547-4b1f-b60b-733348e11f3a"
      unitRef="U_USD">3987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_90331b74-576f-4a58-89e6-7ec2bcd19c21"
      unitRef="U_USD">-2484000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_48050fe6-ff90-46dd-b383-1c543612d0db"
      unitRef="U_USD">15872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57"
      decimals="-3"
      id="F_41b888e5-944c-488e-9f44-5f8990d38c57"
      unitRef="U_USD">18356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_78af1ab1-2aeb-40ba-8554-ffe47e889df3"
      unitRef="U_USD">19859000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_8bf604e8-e16e-47a0-9bf6-5109959fbd44"
      unitRef="U_USD">15872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <grtx:IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_3b458f3f-a02d-470f-87a6-2ef8c7d6e45a"
      unitRef="U_USD">0</grtx:IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement>
    <grtx:IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_bcdf9784-63fa-4538-9acd-ea28d0d1a743"
      unitRef="U_USD">4712000</grtx:IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement>
    <grtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_68f8dfb3-fed4-47bd-8a17-73371ee6232f"
      unitRef="U_USD">0</grtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <grtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_6c0db40f-b76c-4ebf-a123-97515c1b2f2a"
      unitRef="U_USD">240000</grtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_81d27e0d-9147-47e2-ba6d-7041bcfdd4c9"
      unitRef="U_USD">9000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_30050375-565b-43ad-985e-bab2af704fc1"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f663148d-c3db-429a-86dc-d3d67016c76b">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1.	Organization and description of business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Galera Therapeutics, Inc. was incorporated as a Delaware corporation on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;November 19, 2012&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (inception) and together with its subsidiaries (the Company, or Galera) is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem manganese (GC4419, also referred to as avasopasem) is in development for radiotherapy-induced toxicities, including severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) and esophagitis in patients with lung cancer. In February 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to avasopasem for the reduction of SOM induced by radiotherapy with or without systemic therapy. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Galera&#x2019;s second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, the Company announced corrected topline efficacy results from a Phase 3 trial (referred to as the ROMAN trial) evaluating avasopasem for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. The Company had previously announced topline results from the ROMAN trial in October 2021. Upon further analysis following the October topline data announcement, an error by the contract research organization was identified in the statistical program. Correction of this error resulted in improved p-values for the primary and secondary endpoints. The corrected results demonstrated efficacy across multiple SOM endpoints with a statistically significant reduction on the primary endpoint of reduction in the incidence of SOM and a statistically significant reduction on the secondary endpoint of number of days of SOM. The ROMAN trial is the Company&#x2019;s second randomized trial conducted in patients with HNC to achieve statistical significance and demonstrate improved clinical benefit in reducing SOM. The Company plans to meet with the FDA in 2022 to discuss the results from the ROMAN trial together with the previously completed randomized Phase 2b trial with respect to the potential submission of a New Drug Application, or NDA. Avasopasem is also being studied in a Phase 2a trial for its ability to reduce the incidence of radiotherapy-induced esophagitis in patients with lung cancer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition to developing avasopasem for the reduction of normal tissue toxicity from radiotherapy, the Company is developing its dismutase mimetics to increase the anti-cancer efficacy of higher daily doses of radiotherapy, or SBRT. The Company&#x2019;s second dismutase mimetic product candidate, rucosopasem, is being developed to increase the anti-cancer efficacy of SBRT and has successfully completed Phase 1 trials of intravenous rucosopasem in healthy volunteers. In September 2021, in support of rucosopasem, the Company announced final results from its Phase 1/2 pilot trial of avasopasem in combination with SBRT in patients with unresectable or borderline resectable LAPC. In this proof-of-concept trial, survival and tumor outcome benefits were observed. The Company used its observations from this pilot trial to inform the design of rucosopasem clinical trials in combination with SBRT. The Company is currently evaluating rucosopasem in combination with SBRT in a Phase 1/2 safety and anti-cancer efficacy trial in NSCLC and a Phase 2b trial of rucosopasem in combination with SBRT in patients with LAPC.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;316.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as of December 31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company expects its existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2023. In the future, if the Company is not able to continue to raise sufficient capital to fund its operations, the Company may decide &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to delay or discontinue certain activities, including planned research and development activities, hiring plans, manufacturing activities and commercial preparation efforts. In December 2020, the Company filed a registration statement with the Securities and Exchange Commission (SEC) which covers the offering, issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in Company securities, which includes an Open Market Sale&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Agreement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;with Jefferies LLC (the Sales Agreement) covering the offering, issuance and sale of up to a maximum aggregate offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the Company&#x2019;s common stock, which could be utilized to raise funding for future operating expenses and capital expenditure requirements. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, we sold approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million shares of common stock and received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million pursuant to the Sales Agreement. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there remained $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million available under the Sales Agreement.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_81b21c8e-b733-4ac0-9087-cc10bb00bcd7">2012-11-19</dei:EntityIncorporationDateOfIncorporation>
    <grtx:LiquidityPolicyTextBlock
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      id="F_13fc43ca-bfd4-40ca-8026-f8caa507da70">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;316.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as of December 31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company expects its existing cash, cash equivalents and short-term investments as of December 31, 2021 will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2023. In the future, if the Company is not able to continue to raise sufficient capital to fund its operations, the Company may decide &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to delay or discontinue certain activities, including planned research and development activities, hiring plans, manufacturing activities and commercial preparation efforts. In December 2020, the Company filed a registration statement with the Securities and Exchange Commission (SEC) which covers the offering, issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in Company securities, which includes an Open Market Sale&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Agreement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;with Jefferies LLC (the Sales Agreement) covering the offering, issuance and sale of up to a maximum aggregate offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the Company&#x2019;s common stock, which could be utilized to raise funding for future operating expenses and capital expenditure requirements. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, we sold approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million shares of common stock and received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million pursuant to the Sales Agreement. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there remained $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million available under the Sales Agreement.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</grtx:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-5"
      id="F_829d33a7-4e53-4110-bdbf-1dde39fab1c1"
      unitRef="U_USD">-316100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <grtx:MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities
      contextRef="C_9df347f3-5a56-4f15-95db-ac9ca27ed0ae"
      decimals="-5"
      id="F_6d2cf89c-1c73-457b-8154-1283139a0a70"
      unitRef="U_USD">200000000.0</grtx:MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration
      contextRef="C_45be0985-0b88-45c8-908b-dfddf0179f67"
      decimals="-5"
      id="F_d9754e16-797b-43ce-9400-ede947071b7c"
      unitRef="U_USD">50000000.0</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476"
      decimals="INF"
      id="F_782f4c49-b955-45e4-ab52-6dd4d8f6fae1"
      unitRef="U_shares">0.9</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476"
      decimals="-5"
      id="F_8dbfb8f9-7fef-44c3-83ea-b8f29cd8ca2e"
      unitRef="U_USD">7900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grtx:ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement
      contextRef="C_e067ddaf-01db-4b82-9dd0-be1c6ad5d476"
      decimals="-5"
      id="F_eb5f4f84-7a98-4cb3-9650-2721748e25aa"
      unitRef="U_USD">41700000</grtx:ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_fb386c7d-9899-41ea-81ba-8fe125bce6b7">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2.	Basis of presentation and significant accounting policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements include the accounts of Galera Therapeutics, Inc. and its wholly owned subsidiaries, Galera Therapeutics Australia Pty Ltd (Galera Australia) and Galera Labs, LLC. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined the functional currency of Galera Australia to be the U.S. dollar. The Company records remeasurement gains and losses on monetary assets and liabilities, such as accounts payable, which are not denominated in U.S. dollars in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management&#x2019;s estimates include the share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. The royalty purchase liability is accounted for as debt and interest is accreted over the expected repayment period which approximates fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of credit risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents as of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; consisted of bank deposits, U.S. Treasury obligations and a money market mutual fund invested in U.S. Treasury obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term investments consist of debt securities with a maturity of greater than three months when acquired. The Company classifies its short-term investments at the time of purchase as available-for-sale securities, which are net of unrealized losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Available-for-sale securities are carried at fair value. Unrealized gains and losses on available-for-sale securities are reported in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost and depreciated using the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;straight-line method&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; over their estimated useful lives ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6609fc12-0319-49c0-95cd-2a3e1d272227;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. The costs of maintenance and repairs are expensed as incurred. Improvements and betterments that add new functionality or extend the useful life of the asset are capitalized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company believes that no revision of the remaining useful lives or write-down of long-lived assets is required.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill and acquired intangible asset&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2012, the Company completed a Series A redeemable convertible preferred stock (Series A) financing with venture capital investors and simultaneously acquired Galera Therapeutics, LLC (LLC), a limited liability company incorporated in Missouri in 2009. LLC was renamed Galera Labs, LLC in January 2013 and operates as a wholly-owned subsidiary of the Company. The Company applied the purchase method of accounting under which the consideration given to the LLC members and noteholders was allocated to the fair value of the net assets assumed from the LLC at the date of the acquisition. The sole intangible asset acquired represented the fair value of in-process research and development (IPR&amp;amp;D) which has been recorded on the accompanying consolidated balance sheets as an indefinite life intangible asset. A deferred tax liability was recorded for the difference between the fair value of the acquired IPR&amp;amp;D and its tax basis of zero which was recognized as goodwill in applying the purchase method of accounting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets related to IPR&amp;amp;D are considered indefinite-lived intangible assets and, along with goodwill, are not amortized, but are assessed for impairment annually or more frequently if impairment indicators exist. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives. If the associated research and development effort related to IPR&amp;amp;D is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its consolidated statements of operations. For the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company determined that there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment to goodwill or IPR&amp;amp;D.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Royalty purchase liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2018, the Company entered into an Amended and Restated Purchase and Sale Agreement (the Royalty Agreement), with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. (collectively, Blackstone or Blackstone Life Sciences). Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the Royalty Purchase Price) in four tranches of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively. The proceeds received have been recorded as long-term debt obligations. Interest expense on such obligation is imputed by estimating risk adjusted future royalty payments over the term of the Royalty Agreement which takes into consideration the probability of obtaining FDA approval. Other significant assumptions include adjustments to estimated gross revenues to arrive at net product sales from which a royalty payment can be estimated. The non-cash interest expense recorded increases the balance of the royalty obligation. The royalty obligation will be reduced when royalty payments are made, if any.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;117.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, by increasing the fourth tranche from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which was received in July 2021, and adding a new $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million tranche upon the achievement of an additional clinical enrollment milestone, which was received in June 2021. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Actual royalty payments are highly uncertain and may change depending on a number of factors, including the Company&#x2019;s ability to obtain FDA approval, successfully commercialize the Company&#x2019;s product candidates and the timing of future royalty payments. The Company imputes interest expense on the royalty purchase obligations based on such factors at each reporting period. As these factors change, the Company will adjust its estimate of the imputed interest expense accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (short-term leases). For short-term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. The Company had no short-term leases as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement, and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. The Company accrues and expenses preclinical studies and clinical trial activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with clinical research organizations and clinical trial sites. The Company determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including the Company&#x2019;s clinical development plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management makes estimates of the Company&#x2019;s accrued expenses as of each balance sheet date in the Company&#x2019;s consolidated financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company was awarded a Small Business Innovation Research grant from the National Cancer Institute of the National Institutes of Health, which will partially fund its Phase 1/2 safety and anti-cancer efficacy trial in NSCLC (the Grant). Costs entitled to reimbursement under the Grant are accounted for as a reduction to research and development expenses. During the years ended December 31, 2021 and 2020, the Company recorded a reduction to research and development expense of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, for expenses for which it has been reimbursed, or is entitled to reimbursement, under the Grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected life of the stock options is estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:8.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company sponsors a 401(k) defined contribution plan for its employees. Employee contributions are voluntary. The Company matches employee contributions in an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the first &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of eligible compensation, and such employer contributions are immediately vested. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and 2020, the Company provided matching contributions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and common stock warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:76.814%;"/&gt;
          &lt;td style="width:1.145%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:9.034%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:1.145%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:9.034%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,463,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,521,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,013,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;COVID-19 Update&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company&#x2019;s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial and the EUSOM trial in the fourth quarter of 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations at the time, the Company determined that it was not feasible to complete the trial.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill and allocating&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;consolidated &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;income taxes to separate financial statements of entities not subject to income tax. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods therein. Upon adoption, the Company must apply certain aspects of this standard retrospectively for all periods presented while other aspects are applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted this ASU on January 1, 2021. There is no impact to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <grtx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_91a89347-0eea-447e-88cb-fe164b2179e0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements include the accounts of Galera Therapeutics, Inc. and its wholly owned subsidiaries, Galera Therapeutics Australia Pty Ltd (Galera Australia) and Galera Labs, LLC. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined the functional currency of Galera Australia to be the U.S. dollar. The Company records remeasurement gains and losses on monetary assets and liabilities, such as accounts payable, which are not denominated in U.S. dollars in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</grtx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_d45fcf72-d4f3-4652-b9db-0d07be4ba14e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management&#x2019;s estimates include the share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_977f8627-c380-42f4-a565-6ad368be3cda">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. The royalty purchase liability is accounted for as debt and interest is accreted over the expected repayment period which approximates fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_ab05c102-57b7-4809-a60a-8de385b14583">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of credit risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_396f8481-12cf-4b61-acc9-2e4d69ea3600">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents as of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; consisted of bank deposits, U.S. Treasury obligations and a money market mutual fund invested in U.S. Treasury obligations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f863e00f-b339-4ce7-8e7a-5c0f6c608cfc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term investments consist of debt securities with a maturity of greater than three months when acquired. The Company classifies its short-term investments at the time of purchase as available-for-sale securities, which are net of unrealized losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Available-for-sale securities are carried at fair value. Unrealized gains and losses on available-for-sale securities are reported in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_ad6a9a6d-8f04-4896-b2eb-e94cb204175f"
      decimals="0"
      id="F_307bf3d2-b989-49b5-a542-e3e3b7d22126"
      unitRef="U_USD">26000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_7bd9d8bb-1771-4a1a-9624-32a8d3f04ef8"
      decimals="0"
      id="F_16142bfb-e456-4785-a3ff-f7bd6ddad76f"
      unitRef="U_USD">26000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_e46e4b06-39ac-4f7a-a37f-92bcbf4f79d4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost and depreciated using the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;straight-line method&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; over their estimated useful lives ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6609fc12-0319-49c0-95cd-2a3e1d272227;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. The costs of maintenance and repairs are expensed as incurred. Improvements and betterments that add new functionality or extend the useful life of the asset are capitalized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_c059b04d-7a6b-4582-825e-61e49689ed5b">straight-line method</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_593a8fd2-e876-4c36-8f67-ec70818d7144"
      id="F_9c7a0722-bd80-4096-a2fb-8d87608c2c63">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_5c7d53ee-7bba-49e4-944e-91185948ea9f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company believes that no revision of the remaining useful lives or write-down of long-lived assets is required.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_ab0f07cd-649d-43bf-975d-2cf7b998b863">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill and acquired intangible asset&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2012, the Company completed a Series A redeemable convertible preferred stock (Series A) financing with venture capital investors and simultaneously acquired Galera Therapeutics, LLC (LLC), a limited liability company incorporated in Missouri in 2009. LLC was renamed Galera Labs, LLC in January 2013 and operates as a wholly-owned subsidiary of the Company. The Company applied the purchase method of accounting under which the consideration given to the LLC members and noteholders was allocated to the fair value of the net assets assumed from the LLC at the date of the acquisition. The sole intangible asset acquired represented the fair value of in-process research and development (IPR&amp;amp;D) which has been recorded on the accompanying consolidated balance sheets as an indefinite life intangible asset. A deferred tax liability was recorded for the difference between the fair value of the acquired IPR&amp;amp;D and its tax basis of zero which was recognized as goodwill in applying the purchase method of accounting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets related to IPR&amp;amp;D are considered indefinite-lived intangible assets and, along with goodwill, are not amortized, but are assessed for impairment annually or more frequently if impairment indicators exist. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives. If the associated research and development effort related to IPR&amp;amp;D is abandoned, the related assets will be written-off and the Company will record a noncash impairment loss on its consolidated statements of operations. For the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company determined that there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairment to goodwill or IPR&amp;amp;D.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_23bddc62-c90a-4862-ac7c-66fa354ea68d"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_588a79df-8fba-4bb7-af1a-c742513865b6"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <grtx:RoyaltyPurchaseLiabilityPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_16b2bb65-3816-4001-9a00-164694544fbf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Royalty purchase liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2018, the Company entered into an Amended and Restated Purchase and Sale Agreement (the Royalty Agreement), with Clarus IV Galera Royalty AIV, L.P., Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P. and Clarus IV-D, L.P. (collectively, Blackstone or Blackstone Life Sciences). Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the Royalty Purchase Price) in four tranches of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively. The proceeds received have been recorded as long-term debt obligations. Interest expense on such obligation is imputed by estimating risk adjusted future royalty payments over the term of the Royalty Agreement which takes into consideration the probability of obtaining FDA approval. Other significant assumptions include adjustments to estimated gross revenues to arrive at net product sales from which a royalty payment can be estimated. The non-cash interest expense recorded increases the balance of the royalty obligation. The royalty obligation will be reduced when royalty payments are made, if any.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;117.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, by increasing the fourth tranche from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which was received in July 2021, and adding a new $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million tranche upon the achievement of an additional clinical enrollment milestone, which was received in June 2021. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Actual royalty payments are highly uncertain and may change depending on a number of factors, including the Company&#x2019;s ability to obtain FDA approval, successfully commercialize the Company&#x2019;s product candidates and the timing of future royalty payments. The Company imputes interest expense on the royalty purchase obligations based on such factors at each reporting period. As these factors change, the Company will adjust its estimate of the imputed interest expense accordingly.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</grtx:RoyaltyPurchaseLiabilityPolicyTextBlock>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_36e5cf66-783f-49af-adeb-a81f9fe9b685"
      decimals="-5"
      id="F_3bb3d66b-0504-431e-8628-c58beb1e9202"
      unitRef="U_USD">80000000.0</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <grtx:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="C_5cdbba6c-4c21-4368-9002-fbaec59111a5"
      decimals="-5"
      id="F_3b5e5aef-fce5-4c65-8f8e-64495b2c0abc"
      unitRef="U_USD">20000000.0</grtx:ProceedsFromRoyaltyPurchaseAgreement>
    <us-gaap:ContractualObligation
      contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598"
      decimals="-5"
      id="F_ec4e69b3-d6c9-4628-88a2-534254b61837"
      unitRef="U_USD">37500000</us-gaap:ContractualObligation>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598"
      decimals="-5"
      id="F_39b2c275-f4e5-434c-8f7b-330359750b37"
      unitRef="U_USD">117500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:ContractualObligation
      contextRef="C_f6dfbed4-0d76-449c-8163-dee538b8360e"
      decimals="-5"
      id="F_b5fa47d3-69d6-4e2c-980c-352cb80a3b74"
      unitRef="U_USD">20000000.0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598"
      decimals="-5"
      id="F_9c6ab2f0-e6d1-45e9-a9a1-d4c4b3e15e2d"
      unitRef="U_USD">37500000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_fd22c5c9-25d5-4067-8c16-626d9550cb64"
      decimals="-5"
      id="F_696a6152-e8bb-4b45-a46c-4a59d28ae393"
      unitRef="U_USD">20000000.0</us-gaap:ContractualObligation>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_1a4fe437-43e4-4079-bf06-e1bbed38a2b9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (short-term leases). For short-term leases, the Company records the rent expense on a straight-line basis and does not record the leases on the balance sheet. The Company had no short-term leases as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement, and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_0e63045d-0b42-49ce-9fb8-6000dd2309db">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. The Company accrues and expenses preclinical studies and clinical trial activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with clinical research organizations and clinical trial sites. The Company determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including the Company&#x2019;s clinical development plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management makes estimates of the Company&#x2019;s accrued expenses as of each balance sheet date in the Company&#x2019;s consolidated financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company was awarded a Small Business Innovation Research grant from the National Cancer Institute of the National Institutes of Health, which will partially fund its Phase 1/2 safety and anti-cancer efficacy trial in NSCLC (the Grant). Costs entitled to reimbursement under the Grant are accounted for as a reduction to research and development expenses. During the years ended December 31, 2021 and 2020, the Company recorded a reduction to research and development expense of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, for expenses for which it has been reimbursed, or is entitled to reimbursement, under the Grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <grtx:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-5"
      id="F_5da7f329-6ea5-4719-b723-d89a2edd223c"
      unitRef="U_USD">400000</grtx:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <grtx:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-5"
      id="F_f1639e3c-bddb-4d15-96e1-b9564de2189b"
      unitRef="U_USD">700000</grtx:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_fdf8c92c-0a64-48cc-9dcf-f9379052d619">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected life of the stock options is estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <grtx:EmployeeBenefitPlanPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_38dcb292-b43f-4f61-92d9-77e1af49b259">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:8.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company sponsors a 401(k) defined contribution plan for its employees. Employee contributions are voluntary. The Company matches employee contributions in an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the first &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of eligible compensation, and such employer contributions are immediately vested. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and 2020, the Company provided matching contributions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</grtx:EmployeeBenefitPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="INF"
      id="F_674828ae-9332-4f5a-8312-661e2cf1e42c"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <grtx:PercentageOfEmployeeEligibleForCompensationAndEmployerContribution
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_2a583c5e-773d-4ca1-a5ba-b85ac40286ae"
      unitRef="U_pure">0.04</grtx:PercentageOfEmployeeEligibleForCompensationAndEmployerContribution>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-5"
      id="F_52d9af49-2ec2-48ec-8b30-27996a781894"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-5"
      id="F_561a7579-eadc-4de1-bcd3-99e76fed3293"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_a8c8d178-c2ef-44e7-ac4b-4414e10ae135">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return if such a position is more likely than not to be sustained.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_99f55068-dc2d-4721-b996-fbc0e7a2ac09">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and common stock warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:76.814%;"/&gt;
          &lt;td style="width:1.145%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:9.034%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:1.145%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:9.034%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,463,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,521,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,013,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_1935664a-c573-4ab5-b51d-c50e297896d6">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:76.814%;"/&gt;
          &lt;td style="width:1.145%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:9.034%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:1.145%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
          &lt;td style="width:9.034%;"/&gt;
          &lt;td style="width:0.706%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,463,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,521,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,013,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d5282f06-c797-4fe4-b19a-c3d0534f9f5f"
      decimals="INF"
      id="F_f1a00b68-9524-4788-8aff-f1bff3d04a77"
      unitRef="U_shares">4970975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d7306d50-8a8a-4d6c-a10f-596f186d7d3e"
      decimals="INF"
      id="F_3204d222-5932-4377-9448-6843fa63f5f5"
      unitRef="U_shares">4463078</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b49a26cc-28b3-4484-a6c0-28d5227aaace"
      decimals="INF"
      id="F_826e7e66-8b93-41f6-8c41-33a4f06f1ec9"
      unitRef="U_shares">550661</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cb9a312e-caf8-4908-aa1d-2b259e84c87a"
      decimals="INF"
      id="F_55783571-1a18-494f-b275-7ff1212eb540"
      unitRef="U_shares">550661</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="INF"
      id="F_180f9b96-5931-4bc0-9597-3a10d4dbd09d"
      unitRef="U_shares">5521636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="INF"
      id="F_8d869192-13fc-44aa-8227-3a82d8b7fa2e"
      unitRef="U_shares">5013739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <grtx:Covid19Update
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_8ffa27de-ed45-4690-8012-ace1daa4d248">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;COVID-19 Update&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company&#x2019;s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients in order to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial and the EUSOM trial in the fourth quarter of 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations at the time, the Company determined that it was not feasible to complete the trial.&lt;/span&gt;&lt;/p&gt;</grtx:Covid19Update>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_9ecfeae1-9387-4604-ac28-adc3cf6cd2b6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f6998aa1-5f52-4ddf-ac92-e08d6dc43cc2">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3.	Fair value measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.689%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.329%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.329%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.372%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds and U.S. Treasury obligations &lt;br/&gt;&#160;&#160;&#160;(included in cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4b016ec7-c9de-4004-9397-7645b2c3a792;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f1fec276-850c-48f5-82e0-7c1f144c9d23;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_82ec9d38-55d6-49a7-9b4c-1f328cfde640;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_90fe34be-68f6-4f3e-996c-414d28713b22;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b5ca7b31-6e3b-4277-a915-633d3b089c9c;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_39ac49a9-a08d-470b-9d8e-441479f7cc65;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:12.25pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_71db6aad-ca49-4c24-a01f-b7baac31ab94;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.453%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.425%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.425%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.415%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds and U.S. Treasury obligations&lt;br/&gt;&#160;&#160;&#160;(included in cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fee3e958-b0d8-4163-ada6-e3c148fc641f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c89274bf-8d90-49f0-888d-378fdc6d56bc;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ac483134-1335-48d8-8e13-9abac8dd12bf;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; changes in valuation techniques during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s short-term investment instruments classified using Level 1 inputs within the fair value hierarchy are classified as such because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The fair value of Level 2 securities is estimated based&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;on &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term on the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_b1adab41-23d6-4dd7-9782-c0462a663565">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.689%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.329%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.329%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.372%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds and U.S. Treasury obligations &lt;br/&gt;&#160;&#160;&#160;(included in cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4b016ec7-c9de-4004-9397-7645b2c3a792;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f1fec276-850c-48f5-82e0-7c1f144c9d23;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_82ec9d38-55d6-49a7-9b4c-1f328cfde640;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_90fe34be-68f6-4f3e-996c-414d28713b22;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b5ca7b31-6e3b-4277-a915-633d3b089c9c;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_39ac49a9-a08d-470b-9d8e-441479f7cc65;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:12.25pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_71db6aad-ca49-4c24-a01f-b7baac31ab94;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.453%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.425%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.425%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.415%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds and U.S. Treasury obligations&lt;br/&gt;&#160;&#160;&#160;(included in cash equivalents)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fee3e958-b0d8-4163-ada6-e3c148fc641f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d10a024b-88f3-4b4f-9e27-c2a89177b2a3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_63d55f2d-a8d7-440a-aa9b-f34269b3a9be;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_c89274bf-8d90-49f0-888d-378fdc6d56bc;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5cae9da9-f0c0-40c2-90b8-5af4c37ca184;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a68b145d-3c36-44ac-97f0-1f4044dc7a0d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ac483134-1335-48d8-8e13-9abac8dd12bf;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a8e23883-6f88-4b3e-8a59-993c4b0a8e68"
      decimals="-3"
      id="F_81a1df4f-1e0f-481a-b958-314955bd59f9"
      unitRef="U_USD">12346000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f3513012-929a-445a-a467-3e5db3bbe70d"
      decimals="-3"
      id="F_05fadd08-ccfd-4c62-906a-ebda2729e543"
      unitRef="U_USD">5413000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_305118ea-acc7-41f9-8491-7c1c62482e6c"
      decimals="-3"
      id="F_65823d1a-1ce7-40a1-b29f-6fd3f4b056a1"
      unitRef="U_USD">45945000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_25712525-0b37-43f7-91fa-c953260ec5ca"
      decimals="-3"
      id="F_f1d6d1eb-72c5-4e26-a9c1-1bfd96f02759"
      unitRef="U_USD">45945000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0d6f0a55-359d-403b-a434-44702e4affb5"
      decimals="-3"
      id="F_02104109-c543-463d-bfc4-de03ff7d0015"
      unitRef="U_USD">5413000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_93f1c71c-423d-48c2-972d-165e521b4a2e"
      decimals="-3"
      id="F_5eebf839-f7f5-4119-b80e-cf9ed88f8cce"
      unitRef="U_USD">14943000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3bda9d35-0891-4ab3-af62-f84219914e3e"
      decimals="-3"
      id="F_7504513d-1b52-40d2-8f6d-82f97b393bcc"
      unitRef="U_USD">5062000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9fffc937-6507-4e45-b94f-02243159331f"
      decimals="-3"
      id="F_c0f95648-57b8-4712-8af4-66e6093c2018"
      unitRef="U_USD">51842000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7c7d9157-dcfd-4f05-9f1d-325119845497"
      decimals="-3"
      id="F_91e4179f-31fb-40c8-a060-5969474d7348"
      unitRef="U_USD">51842000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3f5fa676-9ecf-47ef-9aa5-1a0b787f12a9"
      decimals="-3"
      id="F_e3b9fffe-3286-4f57-b829-efe5067eaefe"
      unitRef="U_USD">5062000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_92a2f3fb-37a2-45ff-bbdd-9866762c82a7"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_a5930de5-f8d3-4e46-8114-e6d51a63ae17"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_23d2a69d-c44b-4d99-afe2-bb63f10559f5">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4.	Property and equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consist of (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.296%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.544%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.544%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer hardware and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_794261c7-d6d0-4ba7-85f5-cb9c65e1de2f">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consist of (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.296%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.544%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.544%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer hardware and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d891bfc-c9b7-4664-aa86-cb70d7dca47d"
      decimals="-3"
      id="F_0c19b707-32a3-4f96-888e-75d85909ab36"
      unitRef="U_USD">1379000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fe1042c2-2d5c-47e5-8b71-e66bdb49c74b"
      decimals="-3"
      id="F_dd1f135e-4e6b-4b5c-a2c3-26d730bab799"
      unitRef="U_USD">1135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6d323ff0-f330-4ed0-8d21-499632ec29a4"
      decimals="-3"
      id="F_ee2342fe-a7da-4cbb-a450-1a5c7f031f6b"
      unitRef="U_USD">292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_52a132bc-811e-41a6-8227-721ecf66a245"
      decimals="-3"
      id="F_459c2879-3923-47c6-8121-bb8380369efe"
      unitRef="U_USD">260000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dbe44deb-cd48-49e6-b9b3-3243f04236e4"
      decimals="-3"
      id="F_2ca26eda-a63c-41c0-80c3-445179617a47"
      unitRef="U_USD">264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7c9a6f1f-9227-4c02-9d86-d4296da459d1"
      decimals="-3"
      id="F_b29281d7-b99c-43b8-9a41-f0ef7e8373af"
      unitRef="U_USD">264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f9d64566-02c3-4d28-9715-ba795d3bd45a"
      decimals="-3"
      id="F_c9fd28dd-59f0-4994-bdf2-84723e34e0b3"
      unitRef="U_USD">179000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a54c4234-e2dc-4d64-9b15-6d41a7216e47"
      decimals="-3"
      id="F_54b2014e-ffac-45aa-8694-44f9e22910e5"
      unitRef="U_USD">173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_c20a9681-b9cc-4f96-9606-d5b3a45dc1e2"
      unitRef="U_USD">2114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_ac2e5deb-0383-44ea-9ba5-b99a7dd350fb"
      unitRef="U_USD">1832000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_12ac44b1-092c-4725-b6d8-678cb949c90b"
      unitRef="U_USD">1587000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_d7df19ad-9e2c-4fef-a072-8487727845a3"
      unitRef="U_USD">809000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_2e83fc4f-7a70-4877-a54d-cab4b99c6b6e"
      unitRef="U_USD">527000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_420956c1-ac48-40a4-af85-daff94f63a16"
      unitRef="U_USD">1023000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-5"
      id="F_3749a9b0-267d-4c1e-b24a-805b295c6408"
      unitRef="U_USD">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-5"
      id="F_c5c1d55d-24ee-4036-908c-1566e5cfb3c8"
      unitRef="U_USD">400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_cdf7bf3b-673d-40f4-b612-d8e2c191028a">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5.	Accrued expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses consist of (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.512%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.65%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.65%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees and other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_26ce2da3-fd70-4688-8f60-ba46cccff4ce">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses consist of (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.512%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.65%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.65%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees and other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_286baa19-4fcc-4f3c-b480-9ba0d87f775f"
      unitRef="U_USD">2038000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_a001c534-6ca9-40da-be6b-c716ba03f211"
      unitRef="U_USD">2632000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <grtx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_1f610e64-5a8e-4a89-906f-9eeddb4141a5"
      unitRef="U_USD">5360000</grtx:AccruedResearchAndDevelopmentExpensesCurrent>
    <grtx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_90c9f04b-fe90-45a0-84fe-e644180dc74a"
      unitRef="U_USD">5525000</grtx:AccruedResearchAndDevelopmentExpensesCurrent>
    <grtx:AccruedProfessionalFeesAndOtherExpensesCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_1061da38-03e3-4994-bfda-2b981872d774"
      unitRef="U_USD">235000</grtx:AccruedProfessionalFeesAndOtherExpensesCurrent>
    <grtx:AccruedProfessionalFeesAndOtherExpensesCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_6ea89914-6fc8-4dc1-97ae-f739c5362418"
      unitRef="U_USD">427000</grtx:AccruedProfessionalFeesAndOtherExpensesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_bd2ec665-479c-4679-aba3-08b33fedc677"
      unitRef="U_USD">7633000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_5d349261-441f-4a41-9980-3767a17e57d8"
      unitRef="U_USD">8584000</us-gaap:AccruedLiabilitiesCurrent>
    <grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_90258f59-0dc1-4b80-8782-39ef024e5c8c">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6.	Royalty purchase liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the Royalty Agreement, Blackstone agreed to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the Royalty Purchase Price) in four tranches of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million each upon the achievement of specific Phase 3 clinical trial patient enrollment milestones. The Company received the first tranche of the Royalty Purchase Price in November 2018, the second tranche of the Royalty Purchase Price in April 2019, and the third tranche of the Royalty Purchase Price in February 2020, in each case in connection with the achievement of the first three milestones, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2020, the Company entered into Amendment No. 1 to the Royalty Agreement (the Amendment) with Clarus IV Galera Royalty AIV, L.P. (the Blackstone Purchaser). The Blackstone Purchaser is affiliated with Blackstone Life Sciences, the successor in interest to Clarus Ventures. The Amendment increased the Royalty Purchase Price by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;117.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million by increasing the fourth tranche from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and adding a new $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million tranche upon the achievement of an additional clinical enrollment milestone. The Company accounted for the Amendment as a debt modification and is amortizing fees paid to the Blackstone Purchaser related to the Amendment over the estimated term of the royalty purchase liability utilizing the effective-interest method. In June 2021, the Company received the new tranche ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million) under the Amendment in connection with the enrollment of the first patient in a Phase 2b trial of rucosopasem in combination with SBRT in patients with locally advanced pancreatic cancer, which the Company refers to as the GRECO-2 trial. Also in June 2021, the Company completed enrollment in the ROMAN trial, thereby achieving the milestone associated with the fourth tranche ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million) under the Amendment, which was received in July 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for the Royalty Agreement as a debt instrument. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;117.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in proceeds received as of December 31, 2021 have been recorded as a liability on the accompanying consolidated balance&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;sheets. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest expense is imputed based on the estimated royalty repayment period described below, which takes into consideration the probability and timing of obtaining FDA approval and the potential future revenue from commercializing its product candidates, and which results in a corresponding increase in the liability balance. As the Company continues to evaluate the next steps for its programs focused on the reduction of radiotherapy-induced toxicity, planned or possible next steps may have a material impact on the royalty purchase liability. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in noncash interest expense during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the effective interest rate was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the Royalty Agreement and the Amendment, in connection with the payment of each tranche of the Royalty Purchase Price, the Company has agreed to sell, convey, transfer and assign to Blackstone all of its right, title and interest in a high single-digit percentage of (i) worldwide net sales of avasopasem and rucosopasem (collectively, the Products) and (ii) all amounts received by the Company or its affiliates, licensees and sublicensees with respect to Product-related damages (collectively, the Product Payments) during the Royalty Period. The Royalty Period means, on a Product-by-Product and country-by-country basis, the period of time commencing on the commercial launch of such Product in such country and ending on the latest to occur of (i) the 12th anniversary of such commercial launch, (ii) the expiration of all valid claims of the Company&#x2019;s patents covering such Product in such country, and (iii) the expiration of regulatory data protection or market exclusivity or similar regulatory protection afforded by the health authorities in such country, to the extent such protection or exclusivity effectively prevents generic versions of such Product from entering the market in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Royalty Agreement and the Amendment will remain in effect until the date on which the aggregate amount of the Product Payments paid to Blackstone exceeds a fixed single-digit multiple of the actual amount of the Royalty Purchase Price received by the Company, unless earlier terminated pursuant to the mutual written agreement of the Company and Blackstone. If no Products are commercialized, the Company would not have an obligation to make Product Payments to Blackstone, which is the sole mechanism for repaying the liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon execution of the Amendment, the Company issued common stock warrants to the Blackstone Purchaser, each of which became exercisable upon the receipt by the Company of the applicable specified milestone payment. The issued warrants expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; after the initial exercise dates, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.19%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.765%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:11.791%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:13.429%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:13.429%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Initial Exercise Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;New Milestone Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;293,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6/7/2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6/6/2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fourth Milestone Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7/19/2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7/18/2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The warrants are equity-classified and were valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million using the Black-Scholes option pricing model. The warrants were recorded as a discount to the royalty purchase liability. The Company amortizes the debt discount to interest expense over the estimated term of the royalty purchase liability utilizing the effective-interest method.&lt;/span&gt;</grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_36e5cf66-783f-49af-adeb-a81f9fe9b685"
      decimals="-5"
      id="F_36903286-b028-48c3-bd66-d410fb987356"
      unitRef="U_USD">80000000.0</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <grtx:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="C_5cdbba6c-4c21-4368-9002-fbaec59111a5"
      decimals="-5"
      id="F_fc77f36f-109d-44d5-ba14-79907cb68fc3"
      unitRef="U_USD">20000000.0</grtx:ProceedsFromRoyaltyPurchaseAgreement>
    <us-gaap:ContractualObligation
      contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598"
      decimals="-5"
      id="F_764086d9-d606-4ab4-8bc1-fab2ad944fde"
      unitRef="U_USD">37500000</us-gaap:ContractualObligation>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598"
      decimals="-5"
      id="F_f59612a8-4bb5-46cb-8a6f-a7a2d2109d18"
      unitRef="U_USD">117500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:ContractualObligation
      contextRef="C_f6dfbed4-0d76-449c-8163-dee538b8360e"
      decimals="-5"
      id="F_2b44e607-c2a2-493b-9110-37e3256c5439"
      unitRef="U_USD">20000000.0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_e9c572bf-158b-4aaa-b672-6edd20fde598"
      decimals="-5"
      id="F_c398af85-e69d-4525-8e83-bd33ce394609"
      unitRef="U_USD">37500000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_fd22c5c9-25d5-4067-8c16-626d9550cb64"
      decimals="-5"
      id="F_712b2ef3-dc19-496d-9675-8679461ce2c2"
      unitRef="U_USD">20000000.0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_b5e004bf-3018-4d7e-9906-d7992b1097fd"
      decimals="-5"
      id="F_44d284e5-08d8-41dd-a3a5-435343f5de57"
      unitRef="U_USD">20000000.0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_434d1ba1-6f87-483a-9518-2b7eea1ec42f"
      decimals="-5"
      id="F_432f16e7-5343-4328-9985-596df5ed1c16"
      unitRef="U_USD">37500000</us-gaap:ContractualObligation>
    <grtx:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="C_1c572ee6-0f00-49f1-a14c-f6c0a3c80911"
      decimals="-5"
      id="F_e4021f37-be54-4770-b2f9-3543fc1e8439"
      unitRef="U_USD">117500000</grtx:ProceedsFromRoyaltyPurchaseAgreement>
    <us-gaap:PaidInKindInterest
      contextRef="C_1c572ee6-0f00-49f1-a14c-f6c0a3c80911"
      decimals="-5"
      id="F_b65b65bc-7924-4a22-a808-ffafd48c13d8"
      unitRef="U_USD">7200000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_10927f54-f772-42ac-8e0e-6713aa190f61"
      decimals="-5"
      id="F_2cc51431-a615-4004-9d08-a397d97c116d"
      unitRef="U_USD">4900000</us-gaap:PaidInKindInterest>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_a84419a9-fda0-4f1c-b1a3-4f9270aa2e0b"
      decimals="3"
      id="F_c0c6d044-7a27-4a57-a209-f86522b13d33"
      unitRef="U_pure">0.072</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_919a3233-6809-49a1-9056-b816b178697a">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon execution of the Amendment, the Company issued common stock warrants to the Blackstone Purchaser, each of which became exercisable upon the receipt by the Company of the applicable specified milestone payment. The issued warrants expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; after the initial exercise dates, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.19%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.765%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:11.791%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:13.429%;"/&gt;
        &lt;td style="width:2.484%;"/&gt;
        &lt;td style="width:13.429%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Initial Exercise Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;New Milestone Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;293,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6/7/2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6/6/2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fourth Milestone Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7/19/2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7/18/2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      id="F_b50704e8-6798-4adf-8757-49aaf313c37b">P6Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088"
      decimals="INF"
      id="F_080d5e28-41e4-412a-a120-6eb7dbca158a"
      unitRef="U_shares">293686</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088"
      decimals="2"
      id="F_c247e17d-22e8-42d4-8e79-ceccc904727a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_7bf5e8de-1ddb-476f-8d38-35c1b5ab97dd"
      id="F_75c9fe19-843f-4bbc-aca6-33adf23d6b3f">2021-06-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_9d4c5149-766c-4bc5-83f6-bf6032eb2088"
      id="F_be87b585-6a92-4de2-b680-b4a3889abfc5">2027-06-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3cc167f7-0366-47b7-bbfd-33156a4567b4"
      decimals="INF"
      id="F_37dd7473-d569-4cfd-a54d-4c7af44e671c"
      unitRef="U_shares">256975</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3cc167f7-0366-47b7-bbfd-33156a4567b4"
      decimals="2"
      id="F_3dc37078-92a7-4826-91cb-489df0331609"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_f1539b5e-d51f-4a4e-95e6-8cccb7631150"
      id="F_075d0187-f2f9-4c75-a8b2-c6c88dff98fe">2021-07-19</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_3cc167f7-0366-47b7-bbfd-33156a4567b4"
      id="F_ce5227a8-5efa-4c52-8814-2ff1b615dbf9">2027-07-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-5"
      id="F_ae96f315-bedc-46f3-8350-3afc43a9a98f"
      unitRef="U_USD">4700000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_32844b07-77bb-4b93-889b-d010f9dbf71c">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7.	Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has non-cancelable operating leases for office and laboratory space in Malvern, Pennsylvania and Creve Coeur, Missouri which, as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, have remaining lease terms of approximately 1.2 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years, respectively. The discount rate used to account for the Company&#x2019;s operating leases is the Company&#x2019;s estimated incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.015%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.176%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.274%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.176%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.04%;"/&gt;
        &lt;td style="width:1.67%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.34%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:2.419%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.885%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease rental expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.328%;"/&gt;
        &lt;td style="width:1.734%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.678%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.895%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:7.719%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our operating lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 will mature, as follows (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:87.596%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:9.103%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_5ef0432b-dbc1-49fa-b25a-eee0df54a3d8"
      id="F_827c5b10-94d6-4a53-af51-39e79d973fec">P0Y1M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="3"
      id="F_287b8332-5311-4288-8f42-eca85c2707c9"
      unitRef="U_pure">0.053</us-gaap:LesseeOperatingLeaseDiscountRate>
    <grtx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_866f01ea-7c38-4ea2-86a1-6f15d91ba172">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.015%;"/&gt;
        &lt;td style="width:1.713%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.176%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.274%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.176%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use lease assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</grtx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_00a70726-fba5-427b-af5f-3c726c1c9a6d"
      unitRef="U_USD">296000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_9db8dff3-49d8-42d9-adfc-aebe638e2145"
      unitRef="U_USD">530000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_59a90f60-fd7a-4fda-b22e-588df2e69efb"
      unitRef="U_USD">258000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_5a03a907-5690-4b9a-9bbf-48a8a9e5cebf"
      unitRef="U_USD">238000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_92f63644-5111-4a82-8ad5-b7e715036c73"
      unitRef="U_USD">44000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_e5b7699b-001b-426f-8f01-bc6638e6775a"
      unitRef="U_USD">296000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_ba2fe609-5a2e-4b90-9959-0f0ededcbbcc"
      unitRef="U_USD">302000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_2dbb1da1-2bc1-42b8-b41a-c54783f314ec"
      unitRef="U_USD">534000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_23a1bbe0-67dc-46d1-bf5d-7ca5cc66e22f">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.04%;"/&gt;
        &lt;td style="width:1.67%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.34%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:2.419%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.885%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease rental expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_a5872b93-aebf-4aea-bd4e-2eea9805d328"
      unitRef="U_USD">303000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_c1563df2-581d-4ebe-a588-18a69886c9f7"
      unitRef="U_USD">262000</us-gaap:OperatingLeaseExpense>
    <grtx:OperatingLeaseInterestExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_30a072ad-73fc-462a-8362-2923b35af187"
      unitRef="U_USD">22000</grtx:OperatingLeaseInterestExpense>
    <grtx:OperatingLeaseInterestExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_c5a7f53f-2e03-44b5-82f9-22f147b5384f"
      unitRef="U_USD">35000</grtx:OperatingLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_e4ed4a28-b9d1-4380-8b06-024d6f92bb71"
      unitRef="U_USD">325000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_786e6e00-74c7-4e3b-8db8-4ccc35b1e30a"
      unitRef="U_USD">297000</us-gaap:OperatingLeaseCost>
    <grtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f618a50d-002a-47ee-8535-f2001ce3c093">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.328%;"/&gt;
        &lt;td style="width:1.734%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.678%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:1.895%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:7.719%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e2821b0d-4d2c-4fd2-a6e9-9b9114cc8f4b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</grtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_eb8bea98-3b44-4c20-ae14-7004ebfca650"
      unitRef="U_USD">325000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_6a4672bf-70f5-454f-8adc-9fb2748dd1ed"
      unitRef="U_USD">445000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_48971dc2-12db-45d1-816b-ceb1de89e34d"
      unitRef="U_USD">70000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_5094ff90-67c8-4ea1-8a37-9ab1420d5f1b">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our operating lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 will mature, as follows (amounts in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:87.596%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:9.103%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_3a193bed-b966-411e-9b0e-d41ba972aabb"
      unitRef="U_USD">266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_c0a064cd-da11-4988-921a-789805c4e87e"
      unitRef="U_USD">44000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_f299d413-528b-402f-ad7d-097d257faf57"
      unitRef="U_USD">310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_55beaefc-de27-4229-9ece-bad4146081e4"
      unitRef="U_USD">8000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_69449328-0702-4c89-8ad5-241ddcdc5931"
      unitRef="U_USD">302000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_9a60671c-7d47-488b-8c15-07a6aea161d1">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8.	Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Executive employment agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into employment agreements with certain key executives, providing for compensation and severance in certain circumstances, as described in the respective agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Legal matters&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; claims or legal actions that would reasonably be expected to have a material adverse effect on the Company&#x2019;s results of operations, financial condition or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_2ea76815-c635-4218-9b66-f851d9b5dc17"
      unitRef="U_Claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f0e6bf95-e6c9-4ce7-bf84-92533ee971bd">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.	Stockholders' Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; (Deficit)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company entered into the Sales Agreement with Jefferies LLC (Jefferies) as sales agent, pursuant to which it may, from time to time, issue and sell common stock with an aggregate value of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in &#x201c;at-the-market&#x201d; (ATM) offerings under the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-251061) filed with the SEC on December 1, 2020. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company&#x2019;s common stock. The Company is required to pay Jefferies a commission equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; percent of the gross sales proceeds and has provided Jefferies with customary indemnification rights. During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;891,368&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were sold under the Sales Agreement at a weighted average price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2021. As of December 31, 2021, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of available capacity under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Company&#x2019;s Initial Public Offering, or IPO, in November 2019, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the Galera Therapeutics, Inc. 2019 Incentive Award Plan (the 2019 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the IPO. Upon effectiveness of the 2019 Plan, the Company ceased granting new awards under the Prior Plan (as defined herein).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2019 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The number of shares of common stock initially available for issuance under the 2019 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,948,970&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock plus the number of shares subject to awards outstanding under the Prior Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s outstanding shares of common stock on the final day of the immediately preceding calendar year, and (ii) such smaller number of shares of common stock as determined by the Company&#x2019;s board of directors. As of December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,251,930&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for future issuance under the 2019 Plan, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;999,045&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares added pursuant to this provision effective January 1, 2021. Pursuant to this provision, the Company added an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,058,350&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares to the total shares available for issuance under the 2019 Plan effective January 1, 2022. The maximum number of shares of common stock that may be issued under the 2019 Plan upon the exercise of incentive stock options is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,130,029&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2019, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the Galera Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the ESPP). The ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The number of shares of common stock initially available for issuance under the ESPP was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;243,621&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. In addition, the number of shares of common stock available for issuance under the ESPP is subject to an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#x2019;s board of directors, provided that not more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,288,886&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock may be issued under the ESPP. As of December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;741,497&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for issuance under the ESPP, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;249,761&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares added pursuant to this provision effective January 1, 2021.  Pursuant to this provision, the Company added an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264,587&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares to the total shares available for issuance under the ESPP effective January 1, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2012, the Company adopted the Equity Incentive Plan (the Prior Plan). The total number of shares subject to outstanding awards under the Prior Plan as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,167,546&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;remain &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;available for issuance under the Prior Plan and no further grants will be made under the Prior Plan; however, the Prior Plan continues to govern awards that are outstanding under it.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's stock option awards vest based on the terms in the governing agreements and generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and have a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation expense was as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.368%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.105%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.126%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity related to stock option grants for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.982%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:9.442%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.543%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
        &lt;td style="width:8.554%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,537,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,238,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;164,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;148,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,463,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,653,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;591,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;554,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,810,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the unrecognized compensation cost was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and will be recognized over an estimated weighted-average remaining amortization period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years. The aggregate intrinsic value of options outstanding and options exercisable as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. Options granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; had weighted-average grant-date fair values of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.73&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.19&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at the grant date, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The fair value of stock options during the years ended December 31, 2021 and 2020 was determined using the methods and assumptions discussed below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, as prescribed in SEC&#x2019;s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data. The expected term of nonemployee options is equal to the contractual term. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#x2019;s industry which were commensurate with the expected term assumption as described in SAB No. 107. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected dividend yield is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:9.065%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s board of directors has determined the per share value of the Company&#x2019;s common stock based on the closing price as reported by the NASDAQ Global Market on the date of the grant.  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.827%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:8.051%;"/&gt;
        &lt;td style="width:2.323%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:8.051%;"/&gt;
        &lt;td style="width:2.323%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <grtx:AggregateValueOfCommonStockSaleUnderOffering
      contextRef="C_6796aa74-9221-4cd7-bee7-288036afa9bd"
      decimals="-5"
      id="F_33cc0e18-582e-4bdd-bbdd-76dacdbd1e33"
      unitRef="U_USD">50000000.0</grtx:AggregateValueOfCommonStockSaleUnderOffering>
    <grtx:CommissionToAgentAsPercentageOfATMOfferingProceeds
      contextRef="C_976e5af6-a09b-4243-b493-8a6bf08de5c8"
      decimals="2"
      id="F_70e31909-1f97-4b5d-9dfc-08cce4974efd"
      unitRef="U_pure">0.03</grtx:CommissionToAgentAsPercentageOfATMOfferingProceeds>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_ff4d9ca7-3a8c-4c0e-91f3-4d20825252ba"
      decimals="INF"
      id="F_5eb5133f-1bb3-4cc7-835e-baab3d9ca055"
      unitRef="U_shares">891368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_89c8d8d2-8951-4199-b591-7a7a075b63cd"
      decimals="2"
      id="F_fb49ffb9-d13e-4478-aa54-2b35671e5c92"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ff4d9ca7-3a8c-4c0e-91f3-4d20825252ba"
      decimals="-5"
      id="F_3b9ab7f7-6a7d-4b36-9fca-46b91b0d9991"
      unitRef="U_USD">7900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grtx:AggregateValueOfCommonStockSaleUnderOffering
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-5"
      id="F_e18e872f-a968-44c1-8316-d0591ec7aa6f"
      unitRef="U_USD">41700000</grtx:AggregateValueOfCommonStockSaleUnderOffering>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4c71197f-876f-45b6-af5b-bb409d6b1c8e"
      decimals="INF"
      id="F_e292be2e-7361-449b-907a-404e2830791f"
      unitRef="U_shares">1948970</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_7d2525df-46a5-40bb-8481-d3306638d529"
      decimals="INF"
      id="F_6123648f-ba85-4a00-828d-4999178d5687"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_acafa9c5-1a78-4420-88f9-7764339aa6cf"
      decimals="INF"
      id="F_43a4d8e9-ecaa-459b-bcd1-4569ddb479af"
      unitRef="U_shares">1251930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_7f6a782f-8c22-436d-9355-d84bb1aec291"
      decimals="INF"
      id="F_b60a9986-2a90-4814-940b-0bbafd1e7a68"
      unitRef="U_shares">999045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_7d2525df-46a5-40bb-8481-d3306638d529"
      decimals="INF"
      id="F_48437aef-9633-49e0-ab74-77fd76d0344a"
      unitRef="U_shares">1058350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_e3841438-e11c-4976-96af-f274931b7060"
      decimals="INF"
      id="F_849147c6-77dc-4b2b-97ac-a4efd1a81965"
      unitRef="U_shares">14130029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_362fa296-c948-48d8-8633-02f4c1279301"
      decimals="INF"
      id="F_e42b732e-2030-4cf8-afbb-4747aeac3efc"
      unitRef="U_shares">243621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_f2b24743-77df-4859-afed-60ec1f89419a"
      decimals="INF"
      id="F_225ecc42-2851-4e9d-8fc6-13856a198dae"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0749fd21-5c0d-4d48-bf75-581475061ab8"
      decimals="INF"
      id="F_81112ed3-3306-4a55-95e0-d638e0283ca1"
      unitRef="U_shares">3288886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_11baed89-bceb-4f0a-b7cf-02d6f3284e9c"
      decimals="INF"
      id="F_e11080f1-24ce-4b9e-a461-4fa453004c1b"
      unitRef="U_shares">741497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_f2b24743-77df-4859-afed-60ec1f89419a"
      decimals="INF"
      id="F_f671c7e0-fec6-438e-985c-8fd4a7ea3a3f"
      unitRef="U_shares">249761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_c71d8cd3-e5bd-471e-b060-cec87aa74c28"
      decimals="INF"
      id="F_4ab4cbb8-b461-4f1c-9d1b-5ddc4e868fcd"
      unitRef="U_shares">264587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_722e6ba2-bc11-4290-88a5-e542358ad8a9"
      decimals="INF"
      id="F_df545849-01e5-43ed-a9a6-7beb0c1ac305"
      unitRef="U_shares">2167546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_32d0e2d4-86a8-4678-8bc2-8f2c07f319d7"
      decimals="INF"
      id="F_0f94725a-1752-432d-b073-92c5294b9a0e"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_d4d49bf1-a218-4aaa-a336-133680ab18c2"
      id="F_28c59129-6b72-4898-ac11-43a9201b3597">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_d4d49bf1-a218-4aaa-a336-133680ab18c2"
      id="F_74fa1eec-c2b3-4fec-9db6-deada4875451">10 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_79d4c341-bc53-4aff-91eb-7a16162b8f1e">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation expense was as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.368%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.105%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.126%;"/&gt;
        &lt;td style="width:0.706%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3286eeb2-2aa4-477b-b07d-a1e64579ceed"
      decimals="-3"
      id="F_34888c81-b957-4d06-986c-7ce1560bc22a"
      unitRef="U_USD">2919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_36d53670-b4ec-458a-b3e8-080466455ca0"
      decimals="-3"
      id="F_7bc27bdb-ce26-4542-bc90-db1f238465b9"
      unitRef="U_USD">2450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b3ba5c9b-58df-4b65-82e0-7c06fcb7e9e7"
      decimals="-3"
      id="F_06920204-41f7-455c-a03d-2117f24c1d39"
      unitRef="U_USD">4312000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57afcb19-5891-4994-9bdc-91438deda211"
      decimals="-3"
      id="F_30922920-45fa-4fe3-b9ba-d0c89ed9640d"
      unitRef="U_USD">3086000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_0ac4d3ff-7861-41d7-824a-3c7ba6e9c6d8"
      unitRef="U_USD">7231000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_060e3a72-5b2a-4621-ae7b-952dc92eebc9"
      unitRef="U_USD">5536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f6f23507-dd23-4183-af16-bf405134aaad">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity related to stock option grants for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.982%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:9.442%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:8.543%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
        &lt;td style="width:8.554%;"/&gt;
        &lt;td style="width:0.717%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,537,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,238,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;164,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;148,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,463,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,653,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;591,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;554,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,810,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,970,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57"
      decimals="INF"
      id="F_f2736d3f-698d-4640-8a3b-0d8fc9d402ce"
      unitRef="U_shares">3537946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a526bee0-eb97-448d-b843-ed2b8330aa57"
      decimals="2"
      id="F_47e35dda-f814-4f51-94f6-6da38987859e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="INF"
      id="F_4f9f9d6e-dcca-4b23-a740-91c5fd5d795b"
      unitRef="U_shares">1238573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_2f9bfcee-9477-4942-932a-8d032dfa1f7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="INF"
      id="F_f35c0f59-8421-422f-b6d9-904125a241a6"
      unitRef="U_shares">164575</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_3f95cc31-86b2-4fd9-9c0f-8e33545f3f65"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="INF"
      id="F_ca849cfa-6f32-40c3-a705-88c8d805dc26"
      unitRef="U_shares">148866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_ed8cb919-64ed-4974-a6e3-706ab8b31fac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="INF"
      id="F_dd32548c-15ad-4f57-9f7b-84a4432acf07"
      unitRef="U_shares">4463078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="2"
      id="F_333559ec-543c-4636-b487-6fadd88024f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="INF"
      id="F_3b690a89-53a3-48c6-95f4-1e9623ff87c1"
      unitRef="U_shares">1653852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_f0e6f2a5-39ca-4b22-8057-968708fa141b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="INF"
      id="F_d4ddd1f6-d90c-4c22-81cf-96bf028dbd62"
      unitRef="U_shares">591257</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_f9ccb9f0-bd15-4c64-aac4-193d18caaea1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="INF"
      id="F_69bbb6a9-7519-4870-9b21-52ce93faec72"
      unitRef="U_shares">554698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_8c97cb29-0143-4336-8a76-93ae13198198"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_f6684c9c-4fab-4137-b549-17084a82db8d"
      unitRef="U_shares">4970975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="2"
      id="F_ecf4bf4d-1c20-4be3-ade7-edff2c8fdb7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_76d9067e-2402-43b4-a12e-3ac720af93a4">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_ba88cd92-5735-4a0e-ac12-42b6c1dbf913"
      unitRef="U_shares">2810494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="2"
      id="F_d02e231c-a4d5-472a-96ce-f0aad72d53b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f42bf1f9-ff82-4f25-8649-c72ade39c8f1">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="INF"
      id="F_932db667-0f8c-47ae-82c7-948a76b2e92e"
      unitRef="U_shares">4970975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="2"
      id="F_69d2638b-bc8d-44a9-99fd-cb27851ab9c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_4b5eef25-5a9f-473c-bf4b-ba33f8be61d8">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-5"
      id="F_9ba39555-e49d-46ff-b5a6-7c4b7c86de0e"
      unitRef="U_USD">16300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_ca3d4555-793f-491b-beec-8f15142d6e6c">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-5"
      id="F_98a71226-f929-4f40-b70d-4afad203dda4"
      unitRef="U_USD">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-5"
      id="F_f4a961b5-9649-463c-b94d-66ace2f9cf99"
      unitRef="U_USD">3000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_ecc91ac5-ca95-4fef-bcfb-8cb5590ef5f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_edeffdd0-e2e9-432e-827d-734d0b31981e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_b9291cd8-b3cb-4f9a-80e0-3e88d73b876d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_22c0693f-a0c2-473c-b039-445182aca7e2">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.827%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:8.051%;"/&gt;
        &lt;td style="width:2.323%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:8.051%;"/&gt;
        &lt;td style="width:2.323%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_ea5facc3-f2f7-447d-a43f-51f5f2c078b5">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      id="F_ad46539a-0aff-49e5-9795-acebcece9754">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_baa2ea0f-5eda-49d1-9d03-61e612ea2fdb"
      unitRef="U_pure">0.895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_a7b50d1b-8c43-4a00-a5f2-da7b0177969b"
      unitRef="U_pure">0.895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="4"
      id="F_437e91f7-c7eb-4e95-bc14-dcee9548d61c"
      unitRef="U_pure">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="4"
      id="F_b619cc46-4263-40e3-915f-5e77c8d0ce0a"
      unitRef="U_pure">0.0117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_0ee6b375-a179-437c-a85c-3680e7d5b80d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_41ae7a09-f4a1-4071-b4f9-9ee81d6f7cf3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_9f4028a8-232d-483c-90f4-98c387892ea8">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10.	Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s loss before income taxes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.597%;"/&gt;
        &lt;td style="width:3.083%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:14.795%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:3.083%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:14.795%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s tax benefit for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.097%;"/&gt;
        &lt;td style="width:3.362%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.251%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:3.362%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.283%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.147%;"/&gt;
        &lt;td style="width:3.011%;"/&gt;
        &lt;td style="width:0.714%;"/&gt;
        &lt;td style="width:15.669%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:4.963%;"/&gt;
        &lt;td style="width:0.714%;"/&gt;
        &lt;td style="width:15.669%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:2.13%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Rate reconciliation:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal tax benefit at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sale of royalty interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Difference in foreign rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.61%;"/&gt;
        &lt;td style="width:2.602%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.259%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:2.602%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.281%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In assessing the need for a valuation allowance, the Company may utilize indefinite-lived deferred tax liabilities from an intangible asset as a future source of income. The Company&#x2019;s acquired IPR&amp;amp;D intangible asset can be utilized as a source of income arising from the future reversal of temporary differences that can be offset against post 2017 indefinite-lived net operating losses, or NOLs. Therefore, the Company is permitted to offset the indefinite-lived deferred tax liability up to the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; percent limitation for NOLs generated subsequent to January 1, 2018.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes carryforwards of federal, state and foreign NOLs as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.893%;"/&gt;
        &lt;td style="width:3.436%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.251%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:3.436%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.829%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Combined NOL Carryforwards:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;157,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The NOL carryforwards begin expiring in 2032 for both federal and state income tax purposes. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; m&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;illion that will begin to expire&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in 2032, unle&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ss previously utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. In general, under Section 382 of the Code, a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre change tax credits as well as its NOLs to offset future taxable income. During the year ended December 31, 2021, the Company conducted a Section 382 study and determined that approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in NOLs and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in research and development tax credits are limited by Section 382 as of December 31, 2021. As a result of the Section 382 analysis, approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of research and development tax credits are scheduled to expire unused due to the annual Section 382 limitation and therefore were written off during 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company will recognize interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accrued interest and penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations. Due to NOL and tax credit carryforwards that remain unutilized, income tax returns from &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2018 through 2020 re&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;main subject to examination by the taxing jurisdictions. The NOLs remain subject to review until utilized.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_2fa32b0a-a49b-4d2f-9e09-2cf491c68ef6">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s loss before income taxes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.597%;"/&gt;
        &lt;td style="width:3.083%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:14.795%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:3.083%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:14.795%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_3f4797b3-e36a-4c1f-85f4-28167caf43d9"
      unitRef="U_USD">-80587000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_b63cb5db-098e-49d5-8b03-80d151c84189"
      unitRef="U_USD">-73007000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_bf4a007c-9ec3-4a3f-bdc3-913bae80104d"
      unitRef="U_USD">53000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_0b0faa56-3741-4763-a49d-89b9d19a6552"
      unitRef="U_USD">-1227000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_7ed46be6-bb6c-4f68-8b26-a9318aa5b6e4"
      unitRef="U_USD">-80534000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_3c524aa1-0f71-4e71-932d-c3ec04d00753"
      unitRef="U_USD">-74234000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_928d90e9-fb43-407e-970d-3b324ad76fd0">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s tax benefit for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.097%;"/&gt;
        &lt;td style="width:3.362%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.251%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:3.362%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.283%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_54312554-b569-4e71-9df8-bfe9c175836a"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_af80ed96-2470-4cb5-b075-b61bab47ef32"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_32e36ba0-eea9-497b-9ab5-c00a115b29e0"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_a73f5e18-42ed-454b-a1ef-2bf10cac4707"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_d4ab8250-4f04-4520-89dc-af84f7dea8d6"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_f8b08afd-0121-4312-9923-b281d0944418"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_263cf84e-a435-40fb-85dd-0617924df5ea"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_ef5d7737-d7bd-4ab3-aaca-9043995bc5e4"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_2898b585-def6-4c7b-9d7b-0cf217cbe745"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_5181a80c-d876-4bd8-aa9b-32721dd791b3"
      unitRef="U_USD">-16000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_10d58cae-986b-4307-b4b9-148e27c91c4f"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_7406d037-7c29-43fb-85a5-4fcdb981d800"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_8f759691-e434-4e91-a4b9-c23106ea2877"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_4eee7cdf-f7be-43ed-acdc-cdbad203fcce"
      unitRef="U_USD">-16000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="-3"
      id="F_2e137451-4263-4f6d-91d1-27d1d0503fab"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="-3"
      id="F_6a20799b-3922-4a26-88fd-6fbe9be63105"
      unitRef="U_USD">-16000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_f8f3acfa-8b9e-4d77-a2bb-78550c8fc812">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.147%;"/&gt;
        &lt;td style="width:3.011%;"/&gt;
        &lt;td style="width:0.714%;"/&gt;
        &lt;td style="width:15.669%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:4.963%;"/&gt;
        &lt;td style="width:0.714%;"/&gt;
        &lt;td style="width:15.669%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:2.13%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Rate reconciliation:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal tax benefit at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sale of royalty interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Difference in foreign rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_c97bcd31-eb28-4f46-aba6-e08aa8eee7bd"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_e8949359-3b25-479c-af36-f5d8e7a7dd95"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_af83040a-5e38-4641-a718-1a07bcaafd6b"
      unitRef="U_pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_4b4b46ae-a4c8-408e-aac5-880136d602e5"
      unitRef="U_pure">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <grtx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_c99cafdb-b9b9-48c4-8e0d-7aa9eb0a1f3b"
      unitRef="U_pure">0</grtx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards>
    <grtx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_bbc22bdd-a00c-4d13-bac9-63c38e972d14"
      unitRef="U_pure">0.001</grtx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_0cbbf227-4763-47fc-83b9-a169adec6004"
      unitRef="U_pure">0.169</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_d452f050-1134-4a8b-aa19-fe4afa77e451"
      unitRef="U_pure">-0.070</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <grtx:EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_6804fae0-1097-4cb6-8659-d173d1fdee0e"
      unitRef="U_pure">-0</grtx:EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest>
    <grtx:EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_ad27b1a0-cafb-4b16-8b64-a56c2b307b50"
      unitRef="U_pure">-0.002</grtx:EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_250b7a78-e961-40a3-8e41-42d2f2dd054d"
      unitRef="U_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_c1f8244b-4871-4082-a8b3-609b1343922b"
      unitRef="U_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_b841722e-26db-4bb8-9654-27bdf1ac48bd"
      unitRef="U_pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_f982c7bb-4ada-4007-96e3-844e095ca2ba"
      unitRef="U_pure">0.219</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_dfc675d3-468a-4d6f-a16c-1e6316c3b59f"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="3"
      id="F_5d3b2b6f-7f06-4080-9e9f-b68d80e61bfd"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="3"
      id="F_cc8f0657-95a3-4e42-89e4-d3c533b0fd67"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_eac1e2c9-4577-457e-971f-15f5bff31211"
      unitRef="U_pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_da6a7f89-5295-4755-ae0d-bea02dc53ce1"
      unitRef="U_pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_87179a00-f82d-4ea2-a1dd-b16211dad274"
      decimals="2"
      id="F_6a97bef3-9079-4aa4-bc3c-c692aaae605b"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_611c13ab-8dae-46c1-b05a-eeca5b30f9ed">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.61%;"/&gt;
        &lt;td style="width:2.602%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.259%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
        &lt;td style="width:2.602%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.281%;"/&gt;
        &lt;td style="width:0.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_8088242b-8bf6-4307-b6bd-0167ef8e82ae"
      unitRef="U_USD">43111000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_b4b2c911-3378-4a6e-bbc2-34884453c598"
      unitRef="U_USD">40324000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_43f154ce-620e-44d0-a0e9-a73243fe8259"
      unitRef="U_USD">2874000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_aff0e861-a71a-47b2-aada-d07ad06e5dbe"
      unitRef="U_USD">1593000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_2d2b79b4-a5ca-4ec7-92fe-f47c6d34e644"
      unitRef="U_USD">7827000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_246b1989-581d-496a-9a3f-f120f04712b5"
      unitRef="U_USD">7477000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <grtx:DeferredTaxAssetsAccruedLiabilitiesAndOther
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_cabdc487-fdef-4baf-b61a-4672743c151c"
      unitRef="U_USD">77000</grtx:DeferredTaxAssetsAccruedLiabilitiesAndOther>
    <grtx:DeferredTaxAssetsAccruedLiabilitiesAndOther
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_3b22a500-f168-408c-9d7e-c6770229346c"
      unitRef="U_USD">98000</grtx:DeferredTaxAssetsAccruedLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_f64bc02b-4f71-4253-a50c-c9184595fcee"
      unitRef="U_USD">53889000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_e8695b4d-55fa-460b-bd2f-fa43b0c8395b"
      unitRef="U_USD">49492000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_108b44ca-ac59-4d8a-843c-1cdc020ab1e1"
      unitRef="U_USD">52787000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_61e1e050-170f-4b26-ae13-485c6d278cbb"
      unitRef="U_USD">48309000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_9a69ff1f-ce00-4bda-bf2a-b2f41b12def3"
      unitRef="U_USD">1102000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_e06e74af-513a-4075-a17a-2d9643e9884b"
      unitRef="U_USD">1183000</us-gaap:DeferredTaxAssetsNet>
    <grtx:DeferredTaxLiabilitiesAccruedExpensesAndOther
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_93fcdc99-ad48-41f7-8254-03c22e59a9c5"
      unitRef="U_USD">-722000</grtx:DeferredTaxLiabilitiesAccruedExpensesAndOther>
    <grtx:DeferredTaxLiabilitiesAccruedExpensesAndOther
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_bfcea0b2-42c3-424a-bf14-7e423bc31669"
      unitRef="U_USD">803000</grtx:DeferredTaxLiabilitiesAccruedExpensesAndOther>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_4d907cfc-a7ea-46b2-ba00-48595b8170e4"
      unitRef="U_USD">653000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_a74641f5-834f-419c-a520-eed979a16c25"
      unitRef="U_USD">653000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_a8e59fb3-8d9f-449f-bea0-d8cb5ced8b52"
      unitRef="U_USD">273000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4c5d124b-43a8-4a57-b934-4599e22a52e8"
      decimals="-3"
      id="F_90fdd2b7-3e8e-4f3c-8a80-0c7126e1e947"
      unitRef="U_USD">273000</us-gaap:DeferredTaxLiabilities>
    <grtx:PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_612aa89d-a707-4256-a5c6-8d293c055b4d"
      unitRef="U_pure">0.80</grtx:PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_3a54c939-736d-4e51-b6f0-2b61907375c8"
      decimals="-5"
      id="F_40f78c96-f331-4673-8388-dae8021c2ccf"
      unitRef="U_USD">4500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_1065604f-6672-47c1-8be6-5334d0edc400"
      decimals="-5"
      id="F_a535ee09-8968-4666-8dc8-755a4e7e153b"
      unitRef="U_USD">16200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_5c5ecbb0-8056-41ef-868e-47954b17ba16">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes carryforwards of federal, state and foreign NOLs as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.893%;"/&gt;
        &lt;td style="width:3.436%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.251%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:3.436%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.829%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Combined NOL Carryforwards:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;157,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ef60c426-c561-4135-a8f9-593afe49a453"
      decimals="-3"
      id="F_098f8835-babe-4da8-b049-8537018b4c02"
      unitRef="U_USD">145265000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f40e1447-029f-430d-b180-94abe2cbf70c"
      decimals="-3"
      id="F_58c3634b-727d-4378-badc-5f1212178c5d"
      unitRef="U_USD">135580000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_efe17399-273f-425a-8f72-453a258c293e"
      decimals="-3"
      id="F_e0da7a37-8829-434d-9adc-1f6902232222"
      unitRef="U_USD">167252000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6f568e62-0715-4e4c-a97a-e44b2148e476"
      decimals="-3"
      id="F_78d685d2-39d3-42d8-86e5-261403bb892d"
      unitRef="U_USD">157506000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_230365fe-9c24-4694-9fc3-5ece4ab88972"
      decimals="-3"
      id="F_9f45b256-e653-48a3-96f3-6248db5bd2d5"
      unitRef="U_USD">1516000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_a550fef5-0f03-494a-a55a-4b38cad970c8"
      decimals="-3"
      id="F_a5ab786e-da7e-432a-bb57-04e1b3eb6515"
      unitRef="U_USD">1565000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_a70b00b9-2347-4b6b-81cc-9944932bfaf9"
      decimals="-5"
      id="F_2641fc7b-5499-4b26-81ad-db9d5234335b"
      unitRef="U_USD">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <grtx:PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      decimals="2"
      id="F_32010120-dce3-44bb-8eaf-c07e9a7b6f88"
      unitRef="U_pure">0.50</grtx:PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-5"
      id="F_6fbbe429-fad1-40b9-8534-e9f2838f6dbb"
      unitRef="U_USD">63700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b8b04265-e6c4-456e-b08c-93fe2b0c7f68"
      decimals="-5"
      id="F_a3eab5da-4d05-4280-b7a6-ad2684b1657b"
      unitRef="U_USD">2700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e00e7a20-1841-49e0-bf38-357903c57486"
      decimals="-5"
      id="F_91545752-ab34-4513-8d3d-1ae2fc952766"
      unitRef="U_USD">1400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_9d9a581f-e062-40fd-b896-d6dce0738d15"
      decimals="-3"
      id="F_d2e36a83-27ae-422f-a75d-4af55d992351"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_529a418e-ac29-46de-92f2-a6213918687a">&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11.	Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;IntellectMap provides IT-advisory services to the Company. The chief executive officer of IntellectMap is the brother of the Company&#x2019;s chief executive officer. Fees incurred by the Company with respect to IntellectMap during the years ended December 31, 2021 and 2020 were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="C_e58e8310-2bcc-41d3-91b9-08c841d3541d"
      decimals="-5"
      id="F_2cd19e8d-b1de-4722-99df-600896335a9e"
      unitRef="U_USD">200000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_8002ece0-6266-462e-8ed6-a5bfe859d9a4"
      decimals="-5"
      id="F_e17f804a-394a-4160-9f6e-a4ff25e292b9"
      unitRef="U_USD">300000</us-gaap:ProfessionalFees>
    <dei:AuditorFirmId
      contextRef="C_09c415d3-dc69-4465-956f-96ac5d96e0b9"
      id="F_105b19ba-e568-461a-ae34-32346ba67dc6">185</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@>*"OG,8N7SV0Y9L^,'$T !T.UY.QW]@G*H\0%LE@F4(ZP<TQG"8IE+#K1*
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M*=#>V],D#(<";:LLSD:X!7L$0#\#/IL55_4#XU1H[^WVCN4R"L>F3K__0S\
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M?%3G2?GB@R3J&81.%B>[)2-T2U/P)K@( JB8R8&J^3IR"6 P#0+S!\0*<UW
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MOKTZWKY(UIK+U$<F):O-XXI@)5H;J-^73.%Q]Z+O9_<7^(O_ %!+ P04
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M?FEV0MD6K2[4+:?:$F=U9>JC@\(S%HJB W&&"';)DF\GI[P7P!-*W_B$HD*
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M.8JS_L;W1*4K10XEAQCH7XQ%Y6P%=0*(3(2>3W A@\CE6M%M4=D E!!D@A6
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MWKP>"1>_>L0+S.C\I6%I0[ E_Z27<<K1 CS/+$:.YH(.Z#X]G?T'4$L#!!0
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M@2QY+6N#21:F-BUQU7?E&@4MKGZK]BBD$]@*@S\YDF%83&.SI6>D^2">F0#
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M6@$ZP1O@]Z6%R$>^X 3Q!:XO_P-02P,$%     @ +CQJ5!2VR[2Y!0  8@\
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M/_0ET24_3$8^]2A)X?8D,VYI<AJ$#3.$B 9CZE\A#J9.DW4:FJYT(0@[9-H
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M5B_0XQ@"-HY).]AA ;9UJ.SG:[7>Q"R7[,@*\[NC0L5/$H]F3]$IGQ21<I$
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MH232,D:&9PF@D_%SAJS+,C(N-GPG00-A6?89'$3*FYZ+;M*HWNVUDV915 )
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M6'%H&I^=1D#]$ND%9]HPN$OC> V$:\U[%\D[L+TRQNT%GV#8Y+,74$L#!!0
M   ( "\\:E09"IVJQAX   )C   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;)T]67/;1I/O^14H;?8KJ8JB2<KRE:-*ENU$*=M167'V86L?AL"0G!C
M,!A LO+KMZ\Y0(*0XH?$$@GT]/1]S>C'.]M\<1NMV^QK5=;NIZ--VVY?/7GB
M\HVNE)O:K:[AFY5M*M7"K\WZB=LV6A7T4E4^6<QFSYY4RM1'/_](GUTW/_]H
MN[8TM;YN,M=5E6KN7^O2WOUT-#_R'WPRZTV+'SSY^<>M6NL;W7[>7C?PVY,
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MC_]JJ>C$:T-H5)/2=#[@3"O"YL0K/I8RH<[.+E'7B@^>P%M<"$O/HM!4,=4
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M3D\M4"W=RZ$AL=>X;J_M;/LX'=<]^7%[_;)=,+7DQ%I@1J[#P?[8 U6_%O7
MR)7KT+$TU.^=F=,#B\INH/5,2K,=V #MDSW[!5!+ P04    "  O/&I4$I"B
MO<<"  #Q!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R%5-MNXC 0
M?><KK&@?BH2:&Q2*  EZT:ZTE5"[EX?5/IAD0JSZDMI.:??K=^R$+)6 ?0![
M[#GGS(PS,]LI_6Q* $O>!)=F'I365M,P-%D)@II+58'$FT)I02V:>AN:2@/-
M/4CP,(FBJU!0)H/%S)^M]6*F:LN9A+4FIA:"ZO<5<+6;!W&P/WADV]*Z@W Q
MJ^@6GL!^K]8:K;!CR9D :9B21$,Q#Y;Q=#5T_M[A!X.=.=@3E\E&J6=G?,GG
M0>0" @Z9=0P4EU>X <X=$8;QTG(&G:0#'N[W[/<^=\QE0PW<*/Z3Y;:<!Y.
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M4#L'.B^5L@?#)1@^TM5?4$L#!!0    ( "\\:E0D-]9PK04  'D/   9
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M&\5P*93VH6<G6M3F<347&IYJ9KB$MS&3* #?<R%T,T$%[6O[\F]02P,$%
M  @ +SQJ5#06J*GQ @  108  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&ULA57=;]HP$'_O7W&*]K!)B$#X; 5(T*[:I'5"I5T?ICT8YT(LG#BSG07^
M^YV=D%&I90_ V;G?QSGG8U8IO3<IHH5#)G,S#U)KBYLP-#S%C)FN*C"G)XG2
M&;.TU+O0%!I9[$&9#*->;QQF3.3!8N;WUGHQ4Z65(L>U!E-F&=/'%4I5S8-^
M<-IX%+O4NHUP,2O8#C=HGXNUIE78LL0BP]P(E8/&9!XL^S>KH<OW"3\$5N8L
M!E?)5JF]6WR-YT'/&4*)W#H&1C]_\!:E=$1DXW?#&;22#G@>G]CO?>U4RY89
MO%7R1<0VG0?3 &),6"GMHZJ^8%//R/%Q)8W_AJK.'5 R+XU560,F!YG(ZU]V
M:,[A###MO0.(&D#D?=="WN4=LVPQTZH"[;*)S06^5(\F<R)W+V5C-3T5A+.+
M1W5DTAZA*#5/J3J0@FV%%+3U\8EM)9I/L]"2D$L/>4.ZJDFC=TC[$3RHW*8&
M/N<QQJ\)0G+8VHQ.-E?11<8[Y%T8]#L0]:+^!;Y!6_; \PW^4_;Z5/:WMNR?
MRZVQFKKEUP6=8:LS]#K#=W0V=(GB4B*H!&Y5EE$?;JSB>WAA6K/<FK<.]S+E
M<T$D>$!>^K8F8ILB+.FBQ/2Q';\DK8+E1Q#&E!@#KZ6-EZX::;#*YZXDXWMZ
ME&-['+H#R'CJR*M44+!%SC)TLIH+X_H"2N?#X35R%(6%[?&5=&.,%844W"-,
M@5PD@OQD@AK+*Q;LZ%QWX8ER&[>M03P40A-.'."(3!M@B47M:44NK&#RY @A
M9A9-!YB!1$D:->;F:I,RC=2#IY2U%ASA:X-LM^G>(*U(BOD3=>NK[S1/'EJ7
MS=N"Z'K0&4_'\ 'Z@^XX@G$X"5U'4C!VP>3J7I7:IF]!1^/.]6340B=A_[K&
M4C3UX+?Z+3R[VAGJG1]@AEYHF=OZEK>[[8Q<UJ/A7WH]8!^8WHG<@,2$H+WN
M9!2 KH=6O;"J\(-BJRR-'1^F-.=1NP1ZGBAE3PLGT/YS+/X"4$L#!!0    (
M "\\:E1OGSQ&X0,  %T*   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;)U6;6_;-A#^[E]Q4(<A =+(EOPVSS80IRL6($&".-TP#/M RV=+*$5J)%6G
M_WY'4E;D5-'6 89%2L?GGKOGCN3\(-5GG2(:>,ZYT(L@-::8A:%.4LR9OI0%
M"OJRDRIGAJ9J'^I"(=NZ13D/HWY_'.8L$\%R[MX]J.5<EH9G A\4Z#+/F?JZ
M0BX/BV 0'%\\9OO4V!?A<EZP/:[1?"H>%,W"&F6;Y2AT)@4HW"V"J\%L-;'V
MSN"W# ^Z,08;R4;*SW9RLUT$?4L(.2;&(C!Z?,%KY-P"$8V_*\R@=FD7-L='
M](\N=HIEPS1>2_Y[MC7I(I@&L,4=*[EYE(=?L8IG9/$2R;7[AX.W'9-Q4FHC
M\VHQ,<@SX9_LN<I#8\&T_\:"J%H0.=[>D6/Y@1FVG"MY &6M"<T.7*AN-9'+
MA!5E;11]S6B=6=XBA:3A[(EM..KS>6@(U'X*DPI@Y0&B-P &$=Q)85(-OX@M
M;D\!0F)34XJ.E%91)^('3"XA'EQ U(\&'7AQ'6+L\.+N$/^\VFBCJ K^ZL <
MUIA#ASE\ W/M:QCD#M9E47"D.C6,PXIQ)A*$M6NH&^&[QI;?(W)F< M&@B?4
MENI_<]KPM*D\^=;-&I[4BR?N0S\P#?3;24X]J&<]RC#F&U0VRSV;99OJ?N^^
M0$408E\Q[+D6?2]W[TN-'HM@-!H-/T#TTYC^1W&_YXR!9VR3\<QDJ"^H<)4B
MFA"-IA#%TS830:PI>T?+0BI'?CBTR+TG:6.4-2'^&H!\Q_W(,1AVZ#FJ]1S]
M5ST]UVNI*4PFMG!O4LI40\HVX3K1[<8ZTP5+<!'0SJE1?<%@^90B)#(OI*#X
MM?7L@\1GVG#I>4"%)ZK]@4P!VB9KU<RO3BSO;]XJ7S-':)N[V&HXCGHWPI C
M36*(EBQ'$<2C-]1HH$4C5Q$3Z)!B7$LQ_E^M=<UT"A\I%=_?5IT.V]4Y<9U8
MUSOK^OOZK%4Q%T?!LBW9*6"Y+*W\F4AX288T "HXR FQ5([ 2VDTE&E(7+/3
M#O&53+K69S@<G79TU<MR8^CP]J[Q.4F9V*-#\D[EAF=[%_'KLM(PZ<./[Z;1
M(/JY2_E)K?RD4_E;)$((K[8AN*VB_@IWS)2*!FT:=T*W:WQ??I.MD^)GKBN;
MFZ4[DNB$YIS.8.*"%PV]X>Q%3-)0EIJV#WT^L]I'KMO&=AB3$%5'Q0.[>VH]
M@RPO2N,DJ+KQ#*9PWO.;7%MJP\:1GZ/:NXN-IO8G O[TK]_6=Z<K?V5X,?<7
MKSNF]IG0E( =+>U?3F@S4_XRXR=&%NX"L9&&KB-NF-+]#Y4UH.\[*<UQ8AW4
M-\KE/U!+ P04    "  O/&I42]UKWX8$  "^"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6R55FUOVS80_NY?<3 Z( $46>^6 ]M TKK=!@0-DC3%
M,.P#+9UM(I+HDI2=[-?O2,F*W3E>!L011=X]]]RK.-X*^:16B!J>RZ)2D_Y*
MZ_7E8*"R%99,N6*-%9TLA"R9IE>Y'*BU1)9;I;(8!)Z7#$K&J_YT;/=NY70L
M:EWP"F\EJ+HLF7RYQD)L)WV_O]NXX\N5-AN#Z7C-EGB/^MOZ5M+;H$/)>8F5
MXJ("B8M)_\J_O$Z,O!5XY+A5>VLPGLR%>#(OO^63OF<(88&9-@B,'AO\B$5A
M@(C&CQ:SWYDTBOOK'?IGZSOY,F<*/XKB.\_U:M)/^Y#C@M6%OA/;7['U)S9X
MF2B4_0_;5M;K0U8K+<I6F1B4O&J>[+F-PWL4@E8AL+P;0Y;E)Z;9="S%%J21
M)C2SL*Y:;2+'*Y.4>RWIE).>GLY^U%R_7!C'<O@H2DJV8C9>9P]L7J Z'P\T
MV3'2@ZS%O&XP@S<P_0!N1*57"F95CODAP( (=BR#'<OKX"3B)\Q<"'T' B_P
M3^"%G=>AQ0O?P+M?,8FMT[?LA8I,PY64K%JB7?]Y-5=:4L7\=<)8U!F+K+'H
M+6/42'E=((@%-(:O_QWMV;-9X[%@GT0W37NIUBS#29^Z4J'<8/_ OVS?##9F
M8,L4T-]"%-25YBE!KQ!>D$D%:+(&%',LYRB[N .K<K/PX(Q7)"YJ13OJ_++W
M!ZDU6CTK:(1Z=T2&R6QEU7+<4/^O;7 _0.",_)%]1K'7^X(52E98.993C7,3
M>].L$#DA%5/H>&G2^P!#)PA]4HN=.$S@1&;B+C/QZ<PTD\@F1HOL";ZN;92N
MS*B@MCB6C9.(Q[/Q0)%M(LVK)6C35NT0Y'^CLH%GK46:<P73%'TM0%E*HJ&T
MI.+4_S=1ESU;" J^V^%$LKO%1>]KK94F04.):?B=5;4)10/A4<SC<.B,HL3$
MV_6'O2^& "'XE(34B8<A^*&;I+W9,\J,FT([ S^)Z"2&<PA=;]BCL;E KINC
M*'72)*$CWW?CT<_F?_;!H]1'"25^F,+0C;P]\TD<.FD<@.^9_7WS\8C(Q4.R
M$;A^=& ^CB,G&:7&?.!2S?V'>9_,CX8>_6+R/W6CF%CXO4=4!LZ$%QN[-I='
M 0(G]3TG&D4$D+CD1NRFAP!K^C UF=[0]OMIG*K\I*O\Y+V5_YEQ"8^LJ.V
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MJ.P">K^6%%XQL!N4G?;X'U!+ P04    "  O/&I4E)KH99@%  #N&0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R]6=MNXS80_17":(%=P(E%TK<L
M$@-.G* IUEUCO6D?BC[0$FT3*XDN2=EQT8\O*2FB',FTL"[\DNC"F3ESX9DQ
M=;OCXKM<4ZK :Q3&\JZU5FKSJ=.1_II&1%[S#8WUFR47$5'Z5JPZ<B,H"5*A
M*.P@S^MW(L+BUN@V?383HUN>J)#%=": 3**(B/T]#?GNK@5;;P^^LM5:F0>=
MT>V&K.B<JI?-3.B[3J$E8!&-)>,Q$'1YUQK#3T]X: 32%;\SNI.E:V!<67#^
MW=P\!W<MSR"B(?6544'TORU]H&%H-&D<?^=*6X5-(UB^?M/^E#JOG5D021]X
M^ <+U/JN-6R!@"Y)$JJO?/<+S1WJ&7T^#V7Z%^SRM5X+^(E4/,J%-8*(Q=E_
M\IH'HB2@]=0+H%P O1- \(@ S@7P>PO=(P+=7*#;%%(O%^@U%>CG OTT]EFP
MTDA/B"*C6\%W0)C56INY2-.52NL L]A4UEP)_99I.36Z)Y))P)=@)JBDL2)9
MON, S-DJ9DOFDUB!L>_S)%8L7H$9#YG/J 178!P$S"PG(7B.LR(WPA\F5!$6
M?M0K7N83\.&GC[<=I:$:@QT_AW6?P4)'8$$PY;%:2_ 8!S2HD7\X(8\<"CHZ
M1D6@T%N@[I%3XV]\>PVPUP;(@\,Z0&[Q"?6U.#3B"-:(3YJ+>S7BCV[Q7Y/X
M#7RM]2>W^)3LCQ@_""4N:@ZGZO 1=?.,Q<"7Y<DB^_.SE@7/BD;R+X?E;F&Y
MFUKN'K$\$YJ2A=JWP28T)DV=T[\3MM%<J=J:D30[^RPKXXBJ-0]D7:K=1J02
MQ/#9E7F1JW%@[Q78>TZUS]&&,&&  L7!BO-@Q\*P#EZF9Y#J,9UE.])9VY:+
MS;7B %R_ -=W@OO&E68!LA*4!H!$)H^&5 3?DU#MP281_EKS/]@(YM,ZS)GZ
M7@D11$.OCSWO/?;JRC[&_9ORP@,7!H4+ Z<+7QMC'500] 8]SZM"K2Y$GG>X
M\ #JL( Z=$.E09(U9ET)AK>)AIP6<T"W>EA(RQG05SU^R%H/AI7\=^OP#ROX
M!P[T-P7Z&R?Z"5WJ)P%XT 0MV"))'9GI_=@&C]$FY'LJP)0H?VV8H+RH#694
M^-JU.I?<-J'G77O>SXYM"#W;,3TWB60@]-QE&"R'3,%CR%9L$5*@)QX-.S+!
MSYADK!-3>%9VJ+:ON8UW3[E1:OSP[#1,F/0%37N\YNN#E>-TD]=Z "O5A>NJ
M*U]7W1[UY061]0PUVLEC0T=F*^@^,J71@@I7#X&V?<%+]R]H&QAT-Y=SB?8^
MUU_.SM!)2M V*.CN4,T9%%8;$(3O.?00A>U$T-V*OB1**LV%)@_5 )&WFJB;
M@G+-@\:$#6US@>[N,M8V]2 *JK7I*@O;$.#PTB5IZ1RZN?7<DGS*]?>:5P.R
M9(W<?'E&->2:R["P&Y7E7N3FWBF+691$36@)6=I#Z,(U@"PE(GS.8$VE8OK7
MH:Z/1-)E$H*0;6GM:'W"#@9[/>RX]@RR5(K<5#HEKXV38#D0]2Z=!,M\R,U\
M_U\2W'9ZIY-@>1&Y>?'E>GX-O@E*9**C-J=^(IA*H],@*Y8>T:7I$5EZ1*?&
MW84J.=8&XRUA(=&3XM62BRM)0MH&+[$.0<C^T<GYS&5]4FZJS:E?G:I.+CO\
MR6Z)%+N)](DMU5IGBL3^FH)_:QI9DY1A2Y$87CAEV#(I=@^0/]XT'G/-S4<(
M7#HU<7/?^PS\T$B!+3WB[J438%D4NR?),[HVKHZ6)Q)@^16[>>^)":G.WP*6
M&_'@TAFPC(E/'#$T_D&!JX<)1P+>*1U31U2LT@\*$J3>9 >QQ=/BH\4X/:I_
M]_P!?IIDGQZLFNQ+R)2(%8LE".E2J_2N![H:1/9Q(;M1?),>AB^X4CQ*+]>4
M!%28!?K]DG/U=F,,%)]X1O\!4$L#!!0    ( "\\:E2#.<H7[P(  '\)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;,U676_:,!3]*U:>-FEKOB"!
M"I#XZ+1*JX:*MCY,>W"3&V(UL3/;*=V_W[434F# UJ?VA=C.O<?GW!-\/=H(
M^:!R $V>RH*KL9-K75VZKDIR**FZ$!5P?),)65*-4[EV526!IC:I+-S \R*W
MI(P[DY%=6\K)2-2Z8!R6DJBZ+*G\/8-";,:.[VP7;MDZUV;!G8PJNH85Z&_5
M4N+,[5!25@)73' B(1L[4_]R[GLFP49\9[!1.V-BI-P+\6 FU^G8\0PC*"#1
M!H+BXQ'F4!0&"7G\:D&=;D^3N#O>HG^RXE',/54P%\4=2W4^=@8.22&C=:%O
MQ>8SM(+Z!B\1A;*_9-/&>@Y):J5%V28C@Y+QYDF?VD+L)/C1B82@30@.$WHG
M$L(V(;1"&V96UH)J.AE)L2'21".:&=C:V&Q4P[BQ<:4EOF68IR<SJI@B(B-+
M"0JXIDUQ>4I6;,U9QA+*-9DFB:BY9GQ-EJ)@"0-%/I(%*VIC EE!4DNFS>K5
M4U+4*:0DDZ(D<U%6=8N)>]@$?'=GBXN#Z2-(_%C(*J>XO0G!C!*#5UHD#^3=
M C1EA7J/FRD;,G(UBC;4W:05.&L$!B<$^@&Y$5SG2(TCKWT %ZO5E2S8EFP6
MG$5<0')!0O\#";S /T)H_O_IWADZ8>=@:/'"$WA3]"5]J1-75')T4Y$ER*;Z
MY,<7!";7&DKU\PRM7D>K9VGU7D@+]F@E^[1@2ZM"6M;Q8X8W&_?MQN:8>IST
M^X$?A='(?=SUX4B<YX=Q..SB]I3U.V7]L\J:;_-K94BK,Y6*.KSH+1D8=[3B
MUS(P_LN8WC#VAG'_P, C<;TH].+!<0,'G;+!665[9\P=E1*/N'-&#CO<X5LR
MTO>>SWCOM:QL=][_,WI1Y!]8^>^X1IN[T\I*D&O;X16Q[:<YHKO5[A8QM;WS
M8'UF;A>V13[#-%>3&RK7C"M20(:0WD6,I&33[9N)%I5MF/="8_NUPQQO2"!-
M +[/A-#;B=F@NW--_@!02P,$%     @ +SQJ5/O3'O5T!   6Q<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&ULS5A=;]HZ&/XK5K2+3=I(;(>O"I!:
MJIY3J3VG*NW.Q;0+$PQ836)F&UBE_?AC)VD<6'!A2Z7=E'R\WT_>QV_?P9:+
M)[FD5('O29S*H;=4:G7F^S):TH3(%E_15+^9<Y$0I6_%PI<K0<DL4TIB'P5!
MQT\(2[W1('MV)T8#OE8Q2^F= '*=)$0\7]"8;X<>]%X>W+/%4ID'_FBP(@LZ
MH>IQ=2?TG5]:F;&$II+Q% @Z'WKG\&R,NT8AD_C,Z%96KH%)9<KYD[FYG@V]
MP$1$8QHI8X+HGPT=TS@VEG0<WPJC7NG3*%:O7ZQ?9<GK9*9$TC&/_V,SM1QZ
M/0_,Z)RL8W7/MW_3(J&VL1?Q6&9_P;:0#3P0K:7B2:&L(TA8FO^2[T4A*@HP
M/*" "@5TK (N%'"6:!Y9EM8E460T$'P+A)'6ULQ%5IM,6V?#4@/C1 G]EFD]
M-;HB3(#/)%Y3<$N)7 NJ,5(2? *3'%C Y^!<2JJ?D70&;AB9LI@I1N6+P@P0
M!2IV-#CW-%H+P=(%N""22?#^DBK"X@_:[./D$KQ_]P&\ RP%#TN^EMJL'/A*
M)V-"\J,B\(L\<'0@\$L:M0"&'P$*$*Q1'Q^O'NRJ^[J$91U164>4V0L/V+NA
M&QH#"+[<TF1*Q5?P ]SRE#Z#6R*>=#=>K766604?6Y,6>!!9[9[!O].8+8CY
MHJ4C"EQ&@;,H\*MH?GP5M!V8C-0_/!5[N'VYT0[ M:*)_.H(+RS#"YU%&A.Y
M!/3;FFU(G'UEQJV@4@D6*1U2M/>^[JO(/70S#X:C-B.(<-@9^)LJ^#5283_$
MI=1.^.TR_/:I&#].P%]\0T5JN@:,N5AQD:.9Y7:^H&EDJCXQA<T!>-%VU+-3
M!M1QPIU_6V0:4R!+!V<.P]W2<->9::WA.C1R,^U*G8,]))R.S"%U)E<DHD-/
MGT*2B@WU1L"10:_,H'<R5CN-=QHB_=)MOUE$8&").F@&D\).%92PW0_;>\#4
MB+5A+T3U/0(K!PH\HO+HC9@06D*&Z$_D0FBY&N(W9\/"A:L!G2*[H5L>AVXB
MK\'X;9@06FZ&[88[S[(L[#34>9V?6RJ$>!^0&JF@<ZCO+&5#-V?78?(;C <M
MT\)>PY6W; K[#56^_WH?.%V=?A(AR]S(S=PY,OB-&!%99D;P3V1$5)FAW4-T
M$XQ8N'!]"4Z1W= MF2,WF==@_#:,B"Q)H[#9OD26;)%[$CZZ+PL[3C2<KGZA
M+RVO(S>OUV'V&XR)+%6C;L/(6#)&[KGW>&1ZKR/C=/4+R%C>1V[>GRRY4)\4
M%0FX3C>: /*E1 6H_?G>]<^S)6H<-(L+MMR+W5/Q U<DKL.AT'MM6J\1<TSK
MV%(N=E/NL95&1U6ZLJ=P+RI.K[2E/>R>30]7.CQF.JN3.CB=8<N8V,V8Q]89
M'U5G2W&XX0T!MB2&W?/FX3IW?UJ^[#.+V_0)S.)7-I]F[:SS73!]P,9TKBT'
MK:Y&1>2;W/Q&\56V#)URI7B272XIF5%A!/3[.>?JY<;L5\M]^NA_4$L#!!0
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M;3N]7;F-F:OP'1$SFDC$8*JCG(M OPNQO%TN)XJG^05MS)6^[N7#2-_(01B
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M!7XQ0)H 7,^%T.\3TY3Z;U#R!E!+ P04    "  O/&I4&YTJ^K $  "J%@
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MZU4CJFM"U5&\L$?S@BM]T-MFJJ]6*,P$_7W)N=ITC(/FLC;Y U!+ P04
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MTTS4^PJX-E#S,6/RT-$!JA>;_Q]02P,$%     @ +SQJ5/M+4O:( P  HPP
M !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULE9?;;MLX$(9?A1"P0 JT
M.OF0I+ -)':+[46W@=/=O5CT@I9&%E&*=$DZ3MY^AY0L.UV:ZM[8$J7_YWR<
M,3F>':3ZKFL 0YX;+O0\JHW9O4\27=304!W+'0A\4DG54(.W:IOHG0):.E'#
MDSQ-ITE#F8@6,S?VH!8SN3><"7A01.^;AJJ7>^#R,(^RZ#BP9MO:V(%D,=O1
M+3R"^7/WH/ NZ5U*UH#03 JBH)I'=]G[93:R O?&7PP.^NR:6)2-E-_MS:=R
M'J4V(N!0&&M!\>L)EL"Y=<(X?G2F43^G%9Y?']T_.GB$V5 -2\G_9J6IY]%-
M1$JHZ)Z;M3S\#AW0Q/H5DFOW20[=NVE$BKTVLNG$&$'#1/M-G[N%.!-DTPN"
MO!/D/PO&%P2C3N!6+FDC<U@K:NABIN2!*/LVNMD+MS9.C31,V#0^&H5/&>K,
MXI,H9 /D*WT&3=Z1QS:;1%;D0U6!6V/[D*RI 3NZAD**@G%&719PY".4H"@G
M)Z?VY:L5&,JX?C-+# 9JITN*+JC[-JC\0E!93CY+86I-/H@2RM<&"1+VF/D1
M\SX/.JZ@B,DH>TOR-,\\ 2U_79X&PAGUJSYR?J/!52<KI@LN]5X!^>=NHXW"
MPOX6F&+<3S%V4XPO3'%,B\$Y-B"@8H900[2A9F\DIEAADGRI"=OF69RFO_E6
M\/_K7G%->JY)T.C1V.)"JK=$X"Z'!5AUI!VECRELF<43/U)8-AD@FO9$TZ#/
M'Q9CAPB&B2W!6M"DH$J]X!Y]H*K4/J"P8WHI1T.R+ ATW0-=!WV6-15;($RX
MXKM49V&/;!K?^AG"NJMKR_XF0''34]R$"XURM^,I^4*Y>4$< PJTM[["3E>I
M)Z869E"8AV%N>YC;H-.*X6ZN0!0N+5A9>+R)BZD)>Z7QV)^9L"R/;X+5E:6G
M(RL-.JU! U5%3:@H\<A^PEYDAYV%-S,#5I-XZF<9T.%V]I_R?$US=@!GO_AK
M>:)\WQZKE&-[13%;7J2P'Q;-Z$*U#2L'RBW+3U1Y^-=34P7O;(-5$CSKL.O4
M#LT+%+:Z<ON2'VA0.; 99*<3.QL%O;Z8&I0W^K N\.,?4'IV\3;VY*S=:T!M
M71>,AX;<"].V1/UHWVG?N?[RI_%[VX&[-O)DT[;OGZG:,J$)APHMT_@:CT+5
M=L3MC9$[UU1NI,$6U5W6^"\"E'T!GU=2FN.-G:#_7[+X%U!+ P04    "  O
M/&I4T.=O=7(#   #"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6RM
MEF&/FS@0AO^*A:I3*S4+& C02R)M-[JVTMUIM6E[G[TP"58-IK:SV?[[CH%E
MLT"2_7!?$@PS+X]?/&,O#E+]T 6 (8^EJ/32*8RI/[BNS@HHF;Z2-53X9"M5
MR0P.U<[5M0*6-TFE<*GGS=V2\<I9+9I[MVJUD'LC> 6WBNA]63+UZR,(>5@Z
MOO-TXX[O"F-ON*M%S7:P ?.MOE4X<GN5G)=0:2XKHF"[=*[]#S=^8!.:B.\<
M#OKHFMBIW$OYPPZ^Y$O'LT0@(#-6@N'? ]R $%8).7YVHD[_3IMX?/VD_E<S
M>9S,/=-P(\5_/#?%TDD<DL.6[86YDX?/T$THLGJ9%+KY)8<NUG-(MM=&EETR
M$I2\:O_98V?$48(?GDB@70)];4+0)33.N2U9,ZTU,VRU4/) E(U&-7O1>--D
MXVQX93_CQBA\RC'/K+Y4F2R!?&6/H,F,;'"9Y'L!1&[)AN\JON49JPRYE<JZ
MKNW]-6Q!*<AM$KG6&HPFK,K)WYS=<\$-1Z6W:S","_T.-;]MUN3MFW?D#>$5
M^5K(O<9HO7 -XEL(-^M0/[:H] 3J&K(K$OCO"?6H/Y%^\_IT[V6ZBZ;USM'>
M.=KH!2?U.AL,VL :&\ZH!KUJT*B&)U3_Q<K%&E7,\&I'A-2:9$RI7UBP!Z:F
M;6L5XT;1ENW#*@Q\'RUZ.'9G(LH+:-A'O< ->]SP+.ZF8 IFMHYR@@L)FXMF
M=J%,8;9*T1$ 3>)P0#D.\J,TF(:,>LCH+.0=:& J*\@?K*S_Q")_P.Y58R\R
M),,/R(<?KL6-1B1Q0N,![D10&,?3N/,>=WX6]SK+U![]A$=K)[3%)4T!:@IS
M/B880HY#TF0:,>X1X[.(GY1=F/FE"F@)X]'KHR!)T@'D."I,PY1.<R8]9W*6
M\SL3>]9N%P(W+%9E,$68C-X]BVB<#'V<" N3P$NG&=.>,;U8\6,GIS#3<6WX
M'AU 3@4E)PK(]YYW">_US4X\-_HS'<\_VH+\_W'!=V(O5CP=NC 1-$N\4S8\
MMWR?7B#]N>?6!E[-:B4SP"I03]W%4A_UEDEV.L::1\$0_D+42_CGG<6_O+7D
MK_J.'>QXQYC1> 1[(:J%=8].*/9X^ ]3.X['"0%;3/.N8IRL:D]<[<#(NCFT
MW$N#1Z#FLL!3*B@;@,^W4IJG@3T']>?>U6]02P,$%     @ +SQJ5.H6 .>*
M P  HPP  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULM5?;;MLX$/V5
M@= "+9!&HN1K81MP[%UL@!8-DEX>%OO 2&.+*$5Z2=I.@/WX'4JRY#:VNE@D
M+S9)<<Z<<TB-QY.]-M]MCNC@H9#*3H/<N<W[,+1IC@6WEWJ#BIZLM"FXHZE9
MAW9CD&=E4"'#.(H&8<&%"F:3<NW&S"9ZZZ10>&/ ;HN"F\<KE'H_#5AP6+@5
MZ]SYA7 VV? UWJ'[LKDQ- L;E$P4J*S0"@RNIL&<O5^PL0\H=WP5N+='8_!2
M[K7^[B?7V32(/".4F#H/P>EKAPN4TB,1C[]KT*#)Z0./QP?TWTOQ).:>6UQH
M^4UD+I\&HP R7/&M=+=Z_P?6@OH>+]72EI^PK_=& :1;ZW11!Q.#0JCJFS_4
M1AP%L,&9@+@.B'\.Z)T)2.J I!1:,2ME+;GCLXG1>S!^-Z'Y0>E-&4UJA/+'
M>.<,/144YV;7*M4%PF?^@!;>P3S+A+>72[A6U27Q9K]9HN-"VK>TY<O=$MZ\
M>@NO0"CXG.NMY2JSD] 1&X\9IG7FJRIS?"8SB^&C5BZW\)O*,/L1("09C9;X
MH.4J[D1<8GH)";N .(K9"4*+_QX>==!)&FN3$B\Y@_=I@X;L4VOXH*V%!3?F
MD2S=<Y-9^/,#[89KAX7]JR-7K\G5*W/USN2Z09.B<O3B@5[Y^R&*;4'#E:5*
M(,C?E5#"(4AZ9S)_S=$8&CC^0$O\7DCA'H'(@:+]NB$NB?BID^TF,XHNH^AU
MAZI^HZK?"42W$E+B*1RD1^Y= "_T5KE3S"K 80GH2]AN-DB&$1WG[@2/0<-C
M\-P\N@'[OW)HV# ;=@+-T]1LZ2"%<FC0.J!W$:C$<^D$GCRZX1.#SI@S:BB,
M.BG<HD5NTKQ,O<0=_3)LJ,Z[#G7C!GK\XF\0B]I*&#WW*=>(_2,W6>_<;6-'
M-9G]+TOA'[ASW&&7W+A-$K^\N6TM9,FSFYL\,7? SIK;5DK679TZS*7&@'[V
M59?@MG2Q_LO;VQ8H]NP5JD8\MC<^6RE96Y!8=T7ZRN6V:AKFDGI$KE*\@ XS
MNN2W)8B-7M[LMBJQ<:=$ZIFH8[;H&Z!=(Y<?Y)XT>_RD[/;Z1V97_<F)76P0
M/SF3\*C=*]"LRR[80NI/NNJ6FM6FTYZ7_>5/ZU>^ R_;R!:F:M\_<K,6RH+$
M%4%&ET.Z)J;JB*N)TYNRJ;S7CEK4<IC3OP@T?@,]7VGM#A.?H/E?,OL74$L#
M!!0    ( "\\:E0)'KBUF0(  ,P'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;+5574_;,!3]*U<1#R Q\M6D!:611BHT)#80A>UAVH.;W#8629S9
M;@/_?K83LA:U$0_PTMC7]QR?>^Q>1PWC3R)'E/!<%I686KF4]85MBS3'DH@S
M5F.E5I:,ET2J*5_9HN9(,@,J"]MSG- N":VL.#*Q.QY';"T+6N$=![$N2\)?
M+K%@S=1RK=? /5WE4@?L.*K)"N<H'^L[KF9VSY+1$BM!604<EU/KJWN1N(X&
MF(R?%!NQ-09=RH*Q)SVYSJ:6HQ5A@:G4%$1]-IA@46@FI>-O1VKU>VK@]OB5
M_<H4KXI9$($)*W[13.93:V)!ADNR+N0]:[YA5U"@^5)6"/,+39?K6)"NA61E
M!U8*2EJU7_+<&;$%<$<' %X'\-X+\#N ;PIME9FR9D22..*L :ZS%9L>&&\,
M6E5#*WV,<\G5*E4X&5]7*2L1'L@S"O@"\_8T@2TA(9R_J'O2$)X)';C"##DI
M3F$NB40@50;*2>53!3]N;X0)*!Y(.&94"CB>H22T$">*]W$^@^.C$S@"6L%#
MSM9"98O(EJH$+<1..[F7K5SO@-P9IF?@NZ?@.9Z[!YZ\'^[LPFUE7.^>U[OG
M&;[1 ;[.D@$FOV?R#9-_@.FV5D225BNX84*\,?_WC<J&:XFE^#.PUZC?:S2H
M.F'E0H4R?6R[.^T[D)9K;+AT4]C$[BCPPB"R-]O&[TGS@V#B]&D[4H->:C H
MU5RU@9+#GB?\='O'_5[C#[2WY0JV?0O'7N"]L7=/6C .G'"_O9->ZF3X_K;_
MWX&BSWNF\T\WV'7^-RWG RWNR';N9N"&;QS>F[5US5NI]E:KU>_<=\)7M!)0
MX%+!G+.Q.B+>/AWM1++:=-\%DZJ7FV&NGEOD.D&M+QF3KQ/=T/L'//X'4$L#
M!!0    ( "\\:E1W]*S%$P(  *D$   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;(U4RV[;,!#\E8700PLDIBPE;1#( AP;10VTA9'T<2AZH*6U19@/
ME:3MY.^[I&3!!>(F%VF7W!G.K)8J#L9N78/HX5%)[29)XWU[RYBK&E3<C4R+
MFG;6QBKN*;4;YEJ+O(X@)5F6IN^9XD(G91'7EK8LS,Y+H7%IP>V4XO;I#J4Y
M3))Q<ERX%YO&AP56%BW?X /Z[^W24L8&EEHHU$X8#1;7DV0ZOIWEH3X6_!!X
M<"<Q!"<K8[8A6=23) V"4&+E P.GUQYG*&4@(AE_>LYD.#( 3^,C^\?HG;RL
MN,.9D3]%[9M)<I- C6N^D_[>'#YA[^<Z\%5&NOB$0U^;)E#MG#>J!Y,")73W
MYH]]'TX XZLS@*P'9*\%Y#T@=HYURJ*M.?>\+*PY@ W5Q!:"V)N()C="AZ_X
MX"WM"L+YDNQ+OC*6AZ8ZN(1I78L0<PD+W4U):/?;.7HNY#NJ> ,,7,,MNH)Y
MDA"(6-4?=]<=EYTY;H[5"/+Q!61I-GX&/GL]//T7SLCXX#X;W&>1+W_9_1YA
M:BW7&Z09]0ZXKN&KT9?5N1+X1J'C5=>X7Y^)&A8>E?O]'V'Y("R/PJ[."E.*
MNDZ?O]I>0,LM[+G<X7,-[XAN(E&XL_LR':4I-7=_VM>7JCJ5[&20PB7^PNU&
MD#N):\*EHP_7"=CN8G2)-VV<K97Q-*DQ;.A?@C84T/[:&'],PK@.?Z?R+U!+
M P04    "  O/&I40<N(P<4"  #7!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6RU5=%NVC 4_96KJ)-:B9*0D% J0&I!TRJU6U76[6':@TDN8-6Q
M,]LIY>]G.Q#1-D3=PUX2V[GGW'//=>S11L@GM4;4\)(SKL;>6NOBTO=5NL:<
MJ*XHD)LO2R%SHLU4KGQ52"29 ^7,#X,@\7-"N3<9N;5[.1F)4C/*\5Z"*O.<
MR.TU,K$9>SUOO_! 5VMM%_S)J" KG*-^+.ZEF?DU2T9SY(H*#A*78^^J=SD=
MVG@7\(/B1AV,P5:R$.+)3FZRL1=80<@PU9:!F-<S3I$Q2V1D_-EQ>G5*"SP<
M[]D_N]I-+0NB<"K83YKI]=B[\"##)2F9?A";+[BK)[9\J6#*/6%3Q2:)!VFI
MM,AW8*,@I[QZDY>=#P< P],,"'> \"V@?P00[0"1*[12YLJ:$4TF(RDV(&VT
M8;,#YXU#FVHHMUV<:VF^4H/3DULT'B@XAZLLH]98PN"&5[O#VGPZ0TTH.S,1
MC_,9G)Z<P0E0#M_7HE2$9VKD:R/#DOGI+N5UE3(\DG*&:1>B7@?"(.PUP*<?
MAP>OX;XIOG8@K!T('5]TU &E$,$9 3-4J:2%*_W7K8F$&XVY^MV2)ZKS1"Y/
M_TB>;P5*XRE?5:DZ<$O)@C*JMQWX*GA:2HE<-]E9\0X<K_TKGR?]_LA_/K3L
M?4@X3.J85WK[M=Y^J][*EPZ\TSVC*A4EU_! -#;I;>>-NU'PJ<7/N-87M_*X
M ^=<+,]+TS?FND>,8MVX(^-6?RH/JYCX(":.@F8/DUIC\L&>L\H[MN]YD\CD
MG<@H"-^(?!\31_UFD8-:Y*"]T60AC$HAMS O2(KPZP[S!<JV37]1<U_\UY]K
M6.<9_IO1&F4.8@FIX%J:NZ+)[W;*'N0&NX8$,K)531K]@V/77GEW1*XH5T;"
MTC &W8'92[*Z1JJ)%H4[B1="FW/=#=?FYD5I \SWI1!Z/[&'>WV73_X"4$L#
M!!0    ( "\\:E0-(TT!?P(  ((&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;)6576^;,!2&_\H1ZD4KM87PD78506H33:NT2573;A?3+APX!*O&
M9K9ING\_VU!$DS3K;L"&\[X\Y]@^I!LAGU2%J.&E9ES-O$KKYLKW55YA3=2Y
M:)";-Z60-=%F*M>^:B22PHEJYH=!,/5K0KF7I>[9G<Q2T6I&.=Y)4&U=$_GG
M!IG8S+R)]_K@GJXK;1_X6=J0-2Y1/S9WTLS\P:6@-7)%!0>)Y<R[GES-IS;>
M!7RGN%&C,=A,5D(\V<EM,?,""X0,<VT=B+D]XQP9LT8&XW?OZ0V?M,+Q^-7]
ML\O=Y+(B"N>"_:"%KF;>I0<%EJ1E^EYLOF"?3V+]<L&4N\*FCPT\R%NE1=V+
M#4%->7<G+WT=1H))_(X@[ 7A1P51+XA<HAV92VM!-,E2*38@;;1QLP-7&Z<V
MV5!N5W&II7E+C4YG7]'40,$9++ME!%'"#6&$YPA+MXUN>;=7;-'OD1&-!6@!
MO?!X@9I0IDZ,Q>-R <=')W $E,-#)5I%>*%27QM.^S4_[YEN.J;P':8%YN<0
M34XA#,+)'OG\X_+@K=PWU1E*% XE"IU?=+A$/Z]72DNS[7X=\(P&S\AYQN]X
MNM-R)LJS5B$P^P$@2J'>6ZW.ZL)9V5/YG(6?IJG_/"[);DP2!4/,&\9X8(P/
M,KJ\@5&RHHQJBGO9.HMDS)9<;K'MB8DN][,E UOR?VRGP,U>-9LW;Z5$KJ$1
MTF[9?<S)#D\<;R'OAHQ+_@9Y.B!/#R(_"$T8F/8KS5GBZW[5_U'>Z<ZR1D&X
MQ;H;DT3Q%JL_ZA"V.W\C<DVY,A"E407G%R95V76\;J)%XYK&2FC3@MRP,C\)
ME#; O"^%T*\3VX>&WT[V%U!+ P04    "  O/&I4H87ZUX<"  !O!@  &0
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M[ ':SZ0TNXF]H/L'Q?\!4$L#!!0    ( "\\:E2.7ZGG80(  $$&   9
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MUZ-%>B71;&DMP84 NJ^MQ;,3GLJ\Z,5O4$L#!!0    ( "\\:E2=4^AQ70<
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MRV1D]2T4PPH7J7Q@Y0^H PHT7\1289ZHK&T="T6%D"RKP4I!1FCUQJ]U(EH
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M<O\%:C]=RY=*KMV3[.O8P"-IJ8TL:C J*)BHWO2MSD,+$/;. *(:$!T#DC.
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MF"*V&(1#B:L!>!& LR/ :4:NE;0MLD@$>2X08_1C"K+'%"RR-Q574)V0//U
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M9] N /<KI>QVX@2&AI__ U!+ P04    "  O/&I4(V/'9%$"  " !0  &0
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M"  O/&I4IW[QA/$$   ?*   #P   'AL+W=O<FMB;V]K+GAM;,6:6V_B.!2
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MSN?FZ^4ORZ^=>+]H+S@G^'?G\2]02P,$%     @ +SQJ5'32QF+> 0  6B,
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M\UG_2\WL#5!+ 0(4 Q0    ( "X\:E0'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +CQJ5%3TPXOM
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ +CQJ5)E<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  N/&I4\,+US]L&   <'
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ +CQJ5 T),QWJ!0  S!<  !@              ("!'0\  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "X\:E2I% /@SP(
M &4)   8              " @3T5  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  N/&I4UG&;4-8#   N#   &               @(%"
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +CQJ5'8_
M]V*G @  ?@8  !@              ("!3AP  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( "X\:E1V484*_P0  (H3   8
M  " @2L?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  N
M/&I4" 5$F$$&  !I&   &               @(%@)   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ +CQJ5-_9#.Q="@  AAH  !@
M         ("!URH  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( "X\:E2""11Z7AP  ,Q5   8              " @6HU  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  N/&I4%+;+M+D%  !B#P
M&0              @('^40  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( "X\:E2SJ?O+\@(  '\&   9              " @>Y7  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ +CQJ5%Y5:@I_
M @  4P4  !D              ("!%UL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  N/&I43(/-;\<)  "D&0  &0
M@('-70  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "X\
M:E3[$[<I=0@  "46   9              " @<MG  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ +CQJ5#&"59D> P  M08  !D
M         ("!=W   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  N/&I4.2^73QX$  "'"0  &0              @(',<P  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "X\:E0% [- %@T  '$F
M   9              " @2%X  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ +CQJ5+A#\/60 @  U04  !D              ("!;H4
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  O/&I4&0J=
MJL8>   "8P  &0              @($UB   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( "\\:E3%BS*[W0(   P&   9
M  " @3*G  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M+SQJ5+[QHID> P  O@<  !D              ("!1JH  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  O/&I4$I"BO<<"  #Q!0  &0
M            @(&;K0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( "\\:E00NX>IBP(  %0%   9              " @9FP  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +SQJ5"0WUG"M!0
M>0\  !D              ("!6[,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  O/&I4-!:HJ?$"  !%!@  &0              @($_
MN0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "\\:E1O
MGSQ&X0,  %T*   9              " @6>\  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ +SQJ5$O=:]^&!   O@H  !D
M     ("!?\   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "\\:E3[TQ[U= 0  %L7   9              "
M@4?5  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ +SQJ
M5$:%DJY' @  +P4  !D              ("!\MD  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  O/&I4X3!XF2P#  #O"P  &0
M        @(%PW   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( "\\:E28#D1?4P(  $,%   9              " @=/?  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ +SQJ5$KT!CR* @  CP8
M !D              ("!7>(  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  O/&I4&YTJ^K $  "J%@  &0              @($>Y0
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "\\:E0%])1,
M"@,  +@)   9              " @07J  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ +SQJ5%>V+K:/ @  ;P8  !D
M ("!1NT  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  O
M/&I4OO)4'NP"  "]"0  &0              @($,\   >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "\\:E3[2U+VB ,  *,,   9
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M970T-2YX;6Q02P$"% ,4    "  O/&I40<N(P<4"  #7!P  &0
M    @(%R P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M "\\:E0-(TT!?P(  ((&   9              " @6X& 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ +SQJ5*&%^M>' @  ;P8  !D
M             ("!) D! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  O/&I4%%IA,JH"  "/!@  &0              @('B"P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( "\\:E2.7ZGG80(
M $$&   9              " @<,. 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ +SQJ5(TR<_+Y 0  ] ,  !D              ("!
M6Q$! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  O/&I4
MG5/H<5T'  !J(@  &0              @(&+$P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( "\\:E2&'6CXW@(   ,)   9
M      " @1\; 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ +SQJ5&?!D7A'!   _1   !D              ("!-!X! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  O/&I4/P#'6>@"   K"
M&0              @(&R(@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( "\\:E3-XZ0SLP(  ,(&   9              " @=$E 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ +SQJ5%8WZ&]W
M @  UP4  !D              ("!NR@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  O/&I4&9C:@@@"  !T!   &0
M@(%I*P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( "\\
M:E1_)6#B> (  /P%   9              " @:@M 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ +SQJ5"-CQV11 @  @ 4  !D
M         ("!5S ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    "  O/&I4F3/J-B<#   ,$P  #0              @ '?,@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( "\\:E27BKL<P    !,"   +
M  "  3$V 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "\\:E2G?O&$\00  !\H
M   /              "  1HW 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  O/&I4F!M:GOL!  #+(P  &@              @ $X/ $ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  O/&I4=-+&8MX!  !:(P
M$P              @ %K/@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..1 !$ ),2  !Z0 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>118</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization and description of business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and description of business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Royalty Purchase Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiability</Role>
      <ShortName>Royalty Purchase Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Equity-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation</Role>
      <ShortName>Equity-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Royalty purchase liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityTables</Role>
      <ShortName>Royalty purchase liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Equity-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables</Role>
      <ShortName>Equity-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Organization and description of business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and description of business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Royalty Purchase Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails</Role>
      <ShortName>Royalty Purchase Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Royalty purchase liability - Schedule of Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails</Role>
      <ShortName>Royalty purchase liability - Schedule of Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Summary of Company's Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Company's Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Summary of Company's Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Summary of Company's Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Schedule of Significant Portions of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Significant Portions of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail</Role>
      <ShortName>Collaborations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Leases - Summary of Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Summary of Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Leases - Summary of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Summary of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails</Role>
      <ShortName>Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases - Summary of Operating Leases Liabilities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails</Role>
      <ShortName>Leases - Summary of Operating Leases Liabilities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Commitments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Equity-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Equity-based Compensation - Schedule of Equity-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails</Role>
      <ShortName>Equity-based Compensation - Schedule of Equity-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Equity-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Equity-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails</Role>
      <ShortName>Equity-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail</Role>
      <ShortName>Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100700 - Disclosure - 401(k) Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail</Role>
      <ShortName>401(k) Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="grtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="grtx-20211231.htm">grtx-20211231.htm</File>
    <File>grtx-20211231.xsd</File>
    <File>grtx-20211231_cal.xml</File>
    <File>grtx-20211231_def.xml</File>
    <File>grtx-20211231_lab.xml</File>
    <File>grtx-20211231_pre.xml</File>
    <File>grtx-ex10_6.htm</File>
    <File>grtx-ex23_1.htm</File>
    <File>grtx-ex31_1.htm</File>
    <File>grtx-ex31_2.htm</File>
    <File>grtx-ex32_1.htm</File>
    <File>grtx-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img187335194_0.jpg</File>
    <File>img187335194_1.jpg</File>
    <File>img187335194_10.jpg</File>
    <File>img187335194_11.jpg</File>
    <File>img187335194_12.jpg</File>
    <File>img187335194_13.jpg</File>
    <File>img187335194_14.jpg</File>
    <File>img187335194_15.jpg</File>
    <File>img187335194_16.jpg</File>
    <File>img187335194_2.jpg</File>
    <File>img187335194_3.jpg</File>
    <File>img187335194_4.jpg</File>
    <File>img187335194_5.jpg</File>
    <File>img187335194_6.jpg</File>
    <File>img187335194_7.jpg</File>
    <File>img187335194_8.jpg</File>
    <File>img187335194_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="466">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "grtx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 118,
   "dts": {
    "calculationLink": {
     "local": [
      "grtx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "grtx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "grtx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "grtx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "grtx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "grtx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 642,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 18,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 22
   },
   "keyCustom": 30,
   "keyStandard": 334,
   "memberCustom": 17,
   "memberStandard": 24,
   "nsprefix": "grtx",
   "nsuri": "http://www.galeratx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property and Equipment",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Expenses",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Royalty Purchase Liability",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiability",
     "shortName": "Royalty Purchase Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Leases",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Equity-based Compensation",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation",
     "shortName": "Equity-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Related Party Transactions",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_87179a00-f82d-4ea2-a1dd-b16211dad274",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grtx:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_87179a00-f82d-4ea2-a1dd-b16211dad274",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grtx:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Royalty purchase liability (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityTables",
     "shortName": "Royalty purchase liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grtx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Leases (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grtx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Equity-based Compensation (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables",
     "shortName": "Equity-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Loss Per Share (Tables)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Organization and description of business - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
     "shortName": "Organization and description of business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDepreciationMethods",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDepreciationMethods",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_d5282f06-c797-4fe4-b19a-c3d0534f9f5f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_a8e23883-6f88-4b3e-8a59-993c4b0a8e68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_a8e23883-6f88-4b3e-8a59-993c4b0a8e68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyGuaranteesCommitmentsAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Royalty Purchase Liability - Additional Information (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails",
     "shortName": "Royalty Purchase Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d4c5149-766c-4bc5-83f6-bf6032eb2088",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Royalty purchase liability - Schedule of Common Stock Warrants (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails",
     "shortName": "Royalty purchase liability - Schedule of Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "grtx:RoyaltyPurchaseLiabilityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d4c5149-766c-4bc5-83f6-bf6032eb2088",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Summary of Company's Loss Before Income Taxes (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Company's Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Summary of Company's Tax Provision (Benefit) (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails",
     "shortName": "Income Taxes - Summary of Company's Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails",
     "shortName": "Income Taxes - Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Schedule of Significant Portions of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Significant Portions of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "grtx:PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "grtx:PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_ef60c426-c561-4135-a8f9-593afe49a453",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails",
     "shortName": "Income Taxes - Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_ef60c426-c561-4135-a8f9-593afe49a453",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Collaborations - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
     "shortName": "Collaborations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Leases - Summary of Balance Sheet Information Related to Leases (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails",
     "shortName": "Leases - Summary of Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Leases - Summary of Components of Lease Expense (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Summary of Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails",
     "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grtx:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Leases - Summary of Operating Leases Liabilities Maturities (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails",
     "shortName": "Leases - Summary of Operating Leases Liabilities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Commitments (Additional Information) (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
     "shortName": "Commitments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Claim",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "grtx:AggregateValueOfCommonStockSaleUnderOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Equity-based Compensation - Additional Information (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
     "shortName": "Equity-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "grtx:AggregateValueOfCommonStockSaleUnderOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Equity-based Compensation - Schedule of Equity-based Compensation Expense (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails",
     "shortName": "Equity-based Compensation - Schedule of Equity-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_3286eeb2-2aa4-477b-b07d-a1e64579ceed",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_4c5d124b-43a8-4a57-b934-4599e22a52e8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Equity-based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Equity-based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Equity-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails",
     "shortName": "Equity-based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
     "shortName": "Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_9d9a581f-e062-40fd-b896-d6dce0738d15",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "grtx:EmployeeBenefitPlanPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - 401(k) Plan - Additional Information (Detail)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail",
     "shortName": "401(k) Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_a526bee0-eb97-448d-b843-ed2b8330aa57",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_2a9a3126-74c3-4629-800e-3c042fa2b51f",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_e58e8310-2bcc-41d3-91b9-08c841d3541d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_e58e8310-2bcc-41d3-91b9-08c841d3541d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization and description of business",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and description of business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grtx-20211231.htm",
      "contextRef": "C_09c415d3-dc69-4465-956f-96ac5d96e0b9",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 42,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "grtx_A401KPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401(k) plan.",
        "label": "A401 K Plan [Member]",
        "terseLabel": "401(k) plan [Member]"
       }
      }
     },
     "localname": "A401KPlanMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_ATMOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering",
        "label": "A T M Offering [Member]",
        "terseLabel": "At-the-market Offering [Member]"
       }
      }
     },
     "localname": "ATMOfferingMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_AccountsReceivableBilledForLongTermContractsOrProgramsAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable billed for long-term contracts or programs additions.",
        "label": "Accounts Receivable Billed For Long Term Contracts Or Programs Additions",
        "terseLabel": "Amount receivable on cost of construction and tenant improvement"
       }
      }
     },
     "localname": "AccountsReceivableBilledForLongTermContractsOrProgramsAdditions",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of redeemable convertible preferred stock to redemption value.",
        "label": "Accretion Of Redeemable Convertible Preferred Stock To Redemption Value",
        "terseLabel": "Accretion of redeemable convertible preferred stock to redemption value"
       }
      }
     },
     "localname": "AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AccruedProfessionalFeesAndOtherExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued professional fees and other expenses current.",
        "label": "Accrued Professional Fees And Other Expenses Current",
        "terseLabel": "Professional fees and other expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesAndOtherExpensesCurrent",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AdditionalTargetInCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional target in cap.",
        "label": "Additional Target In Cap",
        "terseLabel": "Additional regeneron target cap"
       }
      }
     },
     "localname": "AdditionalTargetInCap",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grtx_AggregateValueOfCommonStockSaleUnderOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of common stock sale under offering.",
        "label": "Aggregate Value Of Common Stock Sale Under Offering",
        "terseLabel": "Aggregate value of common stock sale under ATM offering"
       }
      }
     },
     "localname": "AggregateValueOfCommonStockSaleUnderOffering",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AlbanyLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Albany Lease.",
        "label": "Albany Lease [Member]",
        "terseLabel": "Albany Lease [Member]"
       }
      }
     },
     "localname": "AlbanyLeaseMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_AmendedRoyaltyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended royalty agreements.",
        "label": "Amended Royalty Agreements [Member]",
        "terseLabel": "Amended Royalty Agreements"
       }
      }
     },
     "localname": "AmendedRoyaltyAgreementsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to licenses to targets and associated research activities and evaluation plans.",
        "label": "Amount Allocated To Licenses To Targets And Associated Research Activities And Evaluation Plans",
        "terseLabel": "Amount allocated to licenses to targets and associated research activities and evaluation plans"
       }
      }
     },
     "localname": "AmountAllocatedToLicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlans",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AmountAllocatedToTechnologyCollaborationAndResearchActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to technology collaboration and research activities.",
        "label": "Amount Allocated To Technology Collaboration And Research Activities",
        "terseLabel": "Amount allocated to technology collaboration and associated research activities"
       }
      }
     },
     "localname": "AmountAllocatedToTechnologyCollaborationAndResearchActivities",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to transfer license to develop factor VIII target for hemophilia A.",
        "label": "Amount Allocated To Transfer License To Develop Factor V I I I Target For Hemophilia A",
        "terseLabel": "Amount allocated to transfer license to develop factor VIII target for hemophilia A"
       }
      }
     },
     "localname": "AmountAllocatedToTransferLicenseToDevelopFactorVIIITargetForHemophiliaA",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_AreaOfSpaceLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of space leased.",
        "label": "Area Of Space Leased",
        "terseLabel": "Area of space leased"
       }
      }
     },
     "localname": "AreaOfSpaceLeased",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "grtx_AtTheMarketOfferingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offerings.",
        "label": "At The Market Offerings [Member]",
        "terseLabel": "At The Market Offerings"
       }
      }
     },
     "localname": "AtTheMarketOfferingsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_AvailableForSalesSecuritiesNonCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sales securities, non-current, maturity period.",
        "label": "Available For Sales Securities Non Current Maturity Period",
        "terseLabel": "Available-for-sales Securities, non-current, maturity period"
       }
      }
     },
     "localname": "AvailableForSalesSecuritiesNonCurrentMaturityPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sales securities, noncurrent, maturing beyond year five.",
        "label": "Available For Sales Securities Noncurrent Maturing Beyond Year Five",
        "terseLabel": "Investments that matured beyond five years"
       }
      }
     },
     "localname": "AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and consolidation policy.",
        "label": "Basis Of Presentation And Consolidation Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_CRISPRProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "crispr Product.",
        "label": "C R I S P R Product [Member]",
        "terseLabel": "CRISPR Product [Member]"
       }
      }
     },
     "localname": "CRISPRProductMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_CoDevelopmentAndCoPromotionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Development and Co-Promotion Agreements.",
        "label": "Co Development And Co Promotion Agreements [Member]",
        "terseLabel": "Co-Development and Co-Promotion Agreements [Member]"
       }
      }
     },
     "localname": "CoDevelopmentAndCoPromotionAgreementsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_CollaborationAgreementExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period by which the collaboration arrangement may be extended.",
        "label": "Collaboration Agreement Extension Period",
        "terseLabel": "Collaboration term extension period"
       }
      }
     },
     "localname": "CollaborationAgreementExtensionPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_CollaborationAgreementFurtherOptionExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement further option extension period.",
        "label": "Collaboration Agreement Further Option Extension Period",
        "terseLabel": "Collaboration agreement further option extension period"
       }
      }
     },
     "localname": "CollaborationAgreementFurtherOptionExtensionPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_CollaborationTermExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration term extension period.",
        "label": "Collaboration Term Extension Period",
        "terseLabel": "Collaboration term extension period"
       }
      }
     },
     "localname": "CollaborationTermExtensionPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grtx_CollaborativeArrangementObligationToBeFundInDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement obligation to be fund in development costs.",
        "label": "Collaborative Arrangement Obligation To Be Fund In Development Costs",
        "terseLabel": "Collaborative arrangement obligation to be fund in development costs"
       }
      }
     },
     "localname": "CollaborativeArrangementObligationToBeFundInDevelopmentCosts",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_CommissionToAgentAsPercentageOfATMOfferingProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission to Agent as Percentage of ATM Offering Proceeds.",
        "label": "Commission To Agent As Percentage Of A T M Offering Proceeds",
        "terseLabel": "Commission to agent as percentage of ATM offering proceeds"
       }
      }
     },
     "localname": "CommissionToAgentAsPercentageOfATMOfferingProceeds",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_CommonStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuance costs.",
        "label": "Common Stock Issuance Costs",
        "terseLabel": "Sale of common stock in initial public offering, issuance costs"
       }
      }
     },
     "localname": "CommonStockIssuanceCosts",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability additions.",
        "label": "Contract With Customer Liability Additions",
        "terseLabel": "Deferred revenue additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_Covid19Update": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Update",
        "label": "COVID-19 Update",
        "terseLabel": "COVID-19 Update"
       }
      }
     },
     "localname": "Covid19Update",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_CumulativeCatchUpAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative catch up adjustment.",
        "label": "Cumulative Catch Up Adjustment",
        "terseLabel": "Cumulative catch up adjustment"
       }
      }
     },
     "localname": "CumulativeCatchUpAdjustment",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_CurrentOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Operating Lease Liability",
        "label": "Current Operating Lease Liability"
       }
      }
     },
     "localname": "CurrentOperatingLeaseLiability",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accounts payable and accrued expenses.",
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_DeferredTaxAssetsAccruedLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets accrued liabilities and other.",
        "label": "Deferred Tax Assets Accrued Liabilities and Other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedLiabilitiesAndOther",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_DeferredTaxLiabilitiesAccruedExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities accrued expenses and other.",
        "label": "Deferred Tax Liabilities Accrued Expenses and Other",
        "negatedLabel": "Accrued expenses and other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAccruedExpensesAndOther",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_DevelopmentBasedMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator.",
        "label": "Development Based Milestone Payments Under Agreement",
        "terseLabel": "Development based milestone payments under agreement"
       }
      }
     },
     "localname": "DevelopmentBasedMilestonePaymentsUnderAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation net operating loss carryforwards.",
        "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwards",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation sale of royalty interest.",
        "label": "Effective Income Tax Rate Reconciliation Sale of Royalty Interest",
        "terseLabel": "Sale of royalty interest"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSaleOfRoyaltyInterest",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_EmployeeBenefitPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Benefit Plan [Policy Text Block]",
        "label": "Employee Benefit Plan [Policy Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "EmployeeBenefitPlanPolicyTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "2012 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected payments to be received from royalty purchase agreement.",
        "label": "Expected Payments To Be Received From Royalty Purchase Agreement",
        "terseLabel": "Expected payments to be received from royalty purchase agreement"
       }
      }
     },
     "localname": "ExpectedPaymentsToBeReceivedFromRoyaltyPurchaseAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_FeeToExtendCollaborationArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee to extend collaboration arrangement.",
        "label": "Fee To Extend Collaboration Arrangement",
        "terseLabel": "Fee to extend collaboration arrangement"
       }
      }
     },
     "localname": "FeeToExtendCollaborationArrangement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_FifthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche.",
        "label": "Fifth Tranche [Member]",
        "terseLabel": "Fifth Tranche"
       }
      }
     },
     "localname": "FifthTrancheMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_FinancialInstitutionDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial institution debt securities.",
        "label": "Financial Institution Debt Securities [Member]",
        "terseLabel": "Financial Institution Debt Securities [Member]"
       }
      }
     },
     "localname": "FinancialInstitutionDebtSecuritiesMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche.",
        "label": "First Tranche [Member]",
        "terseLabel": "First Tranche"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow On Public Offering",
        "verboseLabel": "Follow-on public Offerings [Member]"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_FourthMilestoneWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth milestone warrant member.",
        "label": "Fourth Milestone Warrant [Member]",
        "terseLabel": "Fourth Milestone Warrant"
       }
      }
     },
     "localname": "FourthMilestoneWarrantMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_FourthTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth Tranche.",
        "label": "Fourth Tranche [Member]",
        "terseLabel": "Fourth Tranche"
       }
      }
     },
     "localname": "FourthTrancheMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_HemophiliaCoCoAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hemophilia Co/Co agreements.",
        "label": "Hemophilia Co Co Agreements [Member]",
        "terseLabel": "Hemophilia Co Co Agreements"
       }
      }
     },
     "localname": "HemophiliaCoCoAgreementsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_IncomeTaxBenefitTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Benefit [Table]",
        "label": "Income Tax Benefit [Table]",
        "terseLabel": "Income Tax Benefit [Table]"
       }
      }
     },
     "localname": "IncomeTaxBenefitTable",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_IncreaseDecreaseInDeferredTaxLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deferred tax liability.",
        "label": "Increase Decrease In Deferred Tax Liability",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiability",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_IncreaseDecreaseInOperatingRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating right of use assets.",
        "label": "Increase Decrease In Operating Right Of Use Assets",
        "negatedLabel": "Operating right-of-use assets",
        "terseLabel": "Increase in operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingRightOfUseAssets",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in research and development expense.",
        "label": "Increase Decrease In Research And Development Expense",
        "terseLabel": "Reduction to research and development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_IncreaseDecreaseInTemporaryEquityRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in temporary equity redemption value.",
        "label": "Increase Decrease in Temporary Equity Redemption Value",
        "terseLabel": "Accretion of redeemable convertible preferred stock to redemption value"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRedemptionValue",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_IncreaseInTargetCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in target cap.",
        "label": "Increase In Target Cap",
        "terseLabel": "Increase in regeneron target cap"
       }
      }
     },
     "localname": "IncreaseInTargetCap",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grtx_InitialPublicOfferingAndConcurrentPrivatePlacementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering and concurrent private placements.",
        "label": "Initial Public Offering And Concurrent Private Placements [Member]",
        "terseLabel": "Initial Public Offering and Concurrent Private Placements [Member]"
       }
      }
     },
     "localname": "InitialPublicOfferingAndConcurrentPrivatePlacementsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of operating lease right-of-use asset and operating lease liability.",
        "label": "Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability",
        "terseLabel": "Initial recognition of operating lease right-of-use asset and operating lease liability"
       }
      }
     },
     "localname": "InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_IntellectMapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IntellectMap.",
        "label": "Intellect Map [Member]",
        "terseLabel": "IntellectMap"
       }
      }
     },
     "localname": "IntellectMapMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_IssuanceOfCommonStockWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock warrants.",
        "label": "Issuance Of Common Stock Warrants",
        "terseLabel": "Issuance of common stock warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonStockWarrants",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement.",
        "label": "Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement",
        "terseLabel": "Issuance of warrants in conjunction with amendment to the Royalty Purchase Agreement"
       }
      }
     },
     "localname": "IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC.",
        "label": "Jefferies L L C [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_LaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory space.",
        "label": "Laboratory Space [Member]",
        "terseLabel": "Laboratory Space"
       }
      }
     },
     "localname": "LaboratorySpaceMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_LegalAccountingAndOtherFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal, accounting and other fees.",
        "label": "Legal Accounting And Other Fees",
        "terseLabel": "Legal accounting and other fees"
       }
      }
     },
     "localname": "LegalAccountingAndOtherFees",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_LesseeOperatingLeaseExpirationMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease expiration month year (YYYY-MM).",
        "label": "Lessee Operating Lease Expiration Month Year",
        "terseLabel": "Operating lease expiration"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExpirationMonthYear",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grtx_LesseeOperatingLeaseExtendedExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended expiration date.",
        "label": "Lessee Operating Lease Extended Expiration Date",
        "terseLabel": "Lessee operating lease extended expiration date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedExpirationDate",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "grtx_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease lease not yet commenced annual base rent per square foot for first year.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Annual Base Rent Per Square Foot For First Year",
        "terseLabel": "Base rent per square foot for first year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRentPerSquareFootForFirstYear",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "grtx_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease lease not yet commenced base rent per square foot for last year.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Base Rent Per Square Foot For Last Year",
        "terseLabel": "Base rent per square foot for last year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedBaseRentPerSquareFootForLastYear",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "grtx_LesseeOperatingLeaseTerminateTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease terminate term.",
        "label": "Lessee Operating Lease Terminate Term",
        "terseLabel": "Operating lease, terminate term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminateTerm",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_LesseeOperatingSubleaseExpirationMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sublease expiration month year.",
        "label": "Lessee Operating Sublease Expiration Month Year",
        "terseLabel": "Operating sublease expiration"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseExpirationMonthYear",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grtx_LesseeOperatingSubleaseRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating sublease renewal term.",
        "label": "Lessee Operating Sublease Renewal Term",
        "terseLabel": "Operating sublease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseRenewalTerm",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses to targets and associated research activities and evaluation plans performance period.",
        "label": "Licenses To Targets And Associated Research Activities And Evaluation Plans Performance Period",
        "terseLabel": "Licenses to targets and associated research activities and evaluation plans performance period"
       }
      }
     },
     "localname": "LicensesToTargetsAndAssociatedResearchActivitiesAndEvaluationPlansPerformancePeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum offering issuance and sale expense covered in company securities.",
        "label": "Maximum Offering Issuance And Sale Expense Covered In Company Securities",
        "terseLabel": "Maximum Offering Issuance And Sale Expense Covered In Company Securities"
       }
      }
     },
     "localname": "MaximumOfferingIssuanceAndSaleExpenseCoveredInCompanySecurities",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_MoneyMarketFundsAndUSTreasuryObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money market funds and U.S treasury obligations.",
        "label": "Money Market Funds And U S Treasury Obligations [Member]",
        "terseLabel": "Money Market Funds and U.S. Treasury Obligations"
       }
      }
     },
     "localname": "MoneyMarketFundsAndUSTreasuryObligationsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New accounting pronouncements issued but not yet adopted policy.",
        "label": "New Accounting Pronouncements Issued But Not Yet Adopted Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements \u2013 Issued but not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_NewMilestoneWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New milestone warrant member.",
        "label": "New Milestone Warrant [Member]",
        "terseLabel": "New Milestone Warrant"
       }
      }
     },
     "localname": "NewMilestoneWarrantMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-exclusive license to regeneron under certain Crispr/Cas platform ip.",
        "label": "Non Exclusive License To Regeneron Under Certain C R I S P R Cas Platform I P [Member]",
        "terseLabel": "Non-exclusive License to Regeneron under Certain CRISPR/Cas Platform IP [Member]"
       }
      }
     },
     "localname": "NonExclusiveLicenseToRegeneronUnderCertainCRISPRCasPlatformIPMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_NovartisArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis arrangement.",
        "label": "Novartis Arrangement [Member]",
        "terseLabel": "Novartis Arrangement [Member]"
       }
      }
     },
     "localname": "NovartisArrangementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes for BioMedical Research Inc.",
        "label": "Novartis Institutes For Bio Medical Research Inc [Member]",
        "terseLabel": "Novartis [Member]"
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_NumberOfAgreementsEntered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements entered.",
        "label": "Number Of Agreements Entered",
        "terseLabel": "Number of agreements entered"
       }
      }
     },
     "localname": "NumberOfAgreementsEntered",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grtx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grtx_NumberOfRemainingSharesEligibleForSaleUnderAgreementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of remaining shares eligible for sale under agreement value.",
        "label": "Number Of Remaining Shares Eligible For Sale Under Agreement Value",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "NumberOfRemainingSharesEligibleForSaleUnderAgreementValue",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_NumberOfUniqueExVivoProductsCommercialized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of unique ex vivo products commercialized.",
        "label": "Number Of Unique Ex Vivo Products Commercialized",
        "terseLabel": "Number of unique ex vivo products commercialized"
       }
      }
     },
     "localname": "NumberOfUniqueExVivoProductsCommercialized",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grtx_OfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office furniture and equipment.",
        "label": "Office Furniture And Equipment [Member]",
        "terseLabel": "Office Furniture and Equipment [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office.",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space [Member]",
        "label": "Office Space [Member]"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_OneTimePaymentToExtendCollaborationArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of one time payment the entity could receive if the collaboration partner elected to extend the collaboration arrangement.",
        "label": "One Time Payment To Extend Collaboration Arrangement",
        "terseLabel": "One time collaboration payment"
       }
      }
     },
     "localname": "OneTimePaymentToExtendCollaborationArrangement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale Agreement.",
        "label": "Open Market Sale Agreement [Member]",
        "terseLabel": "Open Market Sale Agreement"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_OperatingLeaseInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease interest expense.",
        "label": "Operating Lease Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseInterestExpense",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards cumulative change in ownership interest of significant shareholders period.",
        "label": "Operating Loss Carryforwards Cumulative Change in Ownership Interest of Significant Shareholders Period",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsCumulativeChangeInOwnershipInterestOfSignificantShareholdersPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders Period",
        "label": "Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders Period",
        "terseLabel": "Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders Period"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholdersPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_OptionExercisedToIncreaseRegeneronTargetCapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercised to increase regeneron target cap.",
        "label": "Option Exercised To Increase Regeneron Target Cap [Member]",
        "terseLabel": "Option Exercised to Increase Regeneron Target Cap [Member]"
       }
      }
     },
     "localname": "OptionExercisedToIncreaseRegeneronTargetCapMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_PaymentOfRoyaltyPercentageOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of royalty percentage on net product sales.",
        "label": "Payment Of Royalty Percentage On Net Product Sales",
        "terseLabel": "Payment of royalty percentage on net product sales"
       }
      }
     },
     "localname": "PaymentOfRoyaltyPercentageOnNetProductSales",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PaymentsDueFromAffiliates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due from affiliates.",
        "label": "Payments Due From Affiliates",
        "terseLabel": "Payments due"
       }
      }
     },
     "localname": "PaymentsDueFromAffiliates",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of likelihood of realization needed in order for the company to record a tax benefit.",
        "label": "Percentage Likelihood Of Realization Required To Record Tax Benefit",
        "terseLabel": "Percentage of likelihood of realization required to record tax benefit"
       }
      }
     },
     "localname": "PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PercentageOfEmployeeEligibleForCompensationAndEmployerContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Employee Eligible For Compensation And Employer Contribution",
        "label": "Percentage Of Employee Eligible For Compensation And Employer Contribution"
       }
      }
     },
     "localname": "PercentageOfEmployeeEligibleForCompensationAndEmployerContribution",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds from common stock as sales agent cash commission.",
        "label": "Percentage Of Gross Proceeds From Common Stock As Sales Agent Cash Commission",
        "terseLabel": "Percentage of gross proceeds from common stock as sales agent cash commission"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromCommonStockAsSalesAgentCashCommission",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Maximum Offset Indefinite Lived Deferred Tax Liability For Net Operating Loss",
        "label": "Percentage Of Maximum Offset Indefinite Lived Deferred Tax Liability For Net Operating Loss",
        "terseLabel": "Percentage of maximum offset indefinite lived deferred tax liability for net operating loss"
       }
      }
     },
     "localname": "PercentageOfMaximumOffsetIndefiniteLivedDeferredTaxLiabilityForNetOperatingLoss",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders",
        "label": "Percentage Of Operating Loss Carryforwards Cumulative Changes In Ownership Interest Of Significant Shareholders",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "PercentageOfOperatingLossCarryforwardsCumulativeChangesInOwnershipInterestOfSignificantShareholders",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium over volume-weighted average trading price of common stock during 30-day period prior to closing of equity transaction.",
        "label": "Percentage Of Premium Over Volume Weighted Average Trading Price Of Common Stock During30 Day Period Prior To Closing Of Equity Transaction",
        "terseLabel": "Percentage of premium over volume-weighted average trading price of common stock during 30-day period prior to closing of equity transaction"
       }
      }
     },
     "localname": "PercentageOfPremiumOverVolumeWeightedAverageTradingPriceOfCommonStockDuring30DayPeriodPriorToClosingOfEquityTransaction",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grtx_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based restricted stock units.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance Based RSUs [Member]"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_PerformanceBasedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based stock options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance Based Stock Options [Member]"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_PremiumOnSaleOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on sale of shares.",
        "label": "Premium On Sale Of Shares",
        "terseLabel": "Premium on sale of shares"
       }
      }
     },
     "localname": "PremiumOnSaleOfShares",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining common stock available under Sales agreement.",
        "label": "Proceeds From Issuance Of Remaining Common Stock Available Under Sales Agreement",
        "terseLabel": "Proceeds from issuance of remaining common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRemainingCommonStockAvailableUnderSalesAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_ProceedsFromRoyaltyPurchaseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from royalty purchase agreement.",
        "label": "Proceeds From Royalty Purchase Agreement",
        "terseLabel": "Proceeds from royalty purchase agreement",
        "verboseLabel": "Royalty purchase price"
       }
      }
     },
     "localname": "ProceedsFromRoyaltyPurchaseAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated useful lives.",
        "label": "Property Plant And Equipment Estimated Useful Lives Table [Text Block]",
        "terseLabel": "Summary of Property and Equipment at Cost and Recognizes Depreciation and Amortization Using the Straight-Line Method Over Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant and Equipment Useful Life and Values [Abstract]",
        "label": "Property Plant And Equipment Useful Life And Values [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract",
     "nsuri": "http://www.galeratx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "grtx_RegeneronAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron amendment.",
        "label": "Regeneron Amendment [Member]",
        "terseLabel": "Regeneron Amendment [Member]"
       }
      }
     },
     "localname": "RegeneronAmendmentMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_RegeneronArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron arrangement.",
        "label": "Regeneron Arrangement [Member]",
        "terseLabel": "Regeneron Agreement [Member]"
       }
      }
     },
     "localname": "RegeneronArrangementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_RegeneronPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals Inc.",
        "label": "Regeneron Pharmaceuticals Inc [Member]",
        "terseLabel": "Regeneron [Member]"
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_RegulatoryBasedMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.",
        "label": "Regulatory Based Milestone Payments Under Agreement",
        "terseLabel": "Regulatory based milestone payments under agreement"
       }
      }
     },
     "localname": "RegulatoryBasedMilestonePaymentsUnderAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_RemainingTransactionPriceAllocatedToCombinedPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining transaction price allocated to combined performance obligation.",
        "label": "Remaining Transaction Price Allocated To Combined Performance Obligation",
        "terseLabel": "Remaining transaction price allocated to combined performance obligation"
       }
      }
     },
     "localname": "RemainingTransactionPriceAllocatedToCombinedPerformanceObligation",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_RemainingTransactionPriceTransferredAtInceptionOfArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining transaction price transferred at inception of arrangement.",
        "label": "Remaining Transaction Price Transferred At Inception Of Arrangement",
        "terseLabel": "Remaining transaction price transferred at inception of arrangement"
       }
      }
     },
     "localname": "RemainingTransactionPriceTransferredAtInceptionOfArrangement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development services.",
        "label": "Research And Development Services [Member]",
        "terseLabel": "Research and Development Services [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_RightOfUseAssetsAcquiredUnderOperatingLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets acquired under operating lease.",
        "label": "Right Of Use Assets Acquired Under Operating Lease",
        "terseLabel": "Right-of-use assets acquired under operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetsAcquiredUnderOperatingLease",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets obtained in exchange for lease obligations.",
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_RoyaltyPaymentObligationsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period under which the Company may have royalty obligations to a collaboration partner following the termination of the collaboration agreement.",
        "label": "Royalty Payment Obligations Expiration Period",
        "terseLabel": "Royalty payment obligation expiration period"
       }
      }
     },
     "localname": "RoyaltyPaymentObligationsExpirationPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_RoyaltyPurchaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase liability.",
        "label": "Royalty Purchase Liability [Abstract]"
       }
      }
     },
     "localname": "RoyaltyPurchaseLiabilityAbstract",
     "nsuri": "http://www.galeratx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "grtx_RoyaltyPurchaseLiabilityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase liability.",
        "label": "Royalty Purchase Liability Disclosure [Text Block]",
        "terseLabel": "Royalty Purchase Liability"
       }
      }
     },
     "localname": "RoyaltyPurchaseLiabilityDisclosureTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_RoyaltyPurchaseLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase liability.",
        "label": "Royalty Purchase Liability [Line Items]",
        "terseLabel": "Royalty Purchase Liability [Line Items]"
       }
      }
     },
     "localname": "RoyaltyPurchaseLiabilityLineItems",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_RoyaltyPurchaseLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Liability [Policy Text Block]",
        "label": "Royalty Purchase Liability [Policy Text Block]",
        "terseLabel": "Royalty Purchase Liability"
       }
      }
     },
     "localname": "RoyaltyPurchaseLiabilityPolicyTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_RoyaltyPurchaseLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase liability.",
        "label": "Royalty Purchase Liability [Table]",
        "terseLabel": "Royalty Purchase Liability [Table]"
       }
      }
     },
     "localname": "RoyaltyPurchaseLiabilityTable",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_SaleOfSharesUnderOpenMarketSaleAgrrement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of shares under open market sale agrrement.",
        "label": "Sale Of Shares Under Open Market Sale Agrrement",
        "negatedLabel": "Sale of shares under Open Market Sale Agreement , net"
       }
      }
     },
     "localname": "SaleOfSharesUnderOpenMarketSaleAgrrement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_SaleOfSharesUnderOpenMarketSaleAgrrementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of shares under open market sale agrrement shares.",
        "label": "Sale Of Shares Under Open Market Sale Agrrement Shares",
        "negatedLabel": "Sale of shares under Open Market sale agreement, shares"
       }
      }
     },
     "localname": "SaleOfSharesUnderOpenMarketSaleAgrrementShares",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "grtx_SalesBasedMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential sales-based milestone payments available to be earned under a collaboration arrangement.",
        "label": "Sales Based Milestone Payments Under Agreement",
        "terseLabel": "Sales based milestone payments under agreement"
       }
      }
     },
     "localname": "SalesBasedMilestonePaymentsUnderAgreement",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grtx_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second tranche.",
        "label": "Second Tranche [Member]",
        "terseLabel": "Second Tranche"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period",
        "negatedLabel": "Number of Shares, Cancelled",
        "verboseLabel": "Number of shares, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "grtx_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options.",
        "label": "Stock Options [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_StockPurchaseAgreementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement date.",
        "label": "Stock Purchase Agreement Date",
        "terseLabel": "Stock purchase agreement date"
       }
      }
     },
     "localname": "StockPurchaseAgreementDate",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "grtx_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement.",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_StrategicCollaborationAgreementAmendedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic collaboration agreement amended date.",
        "label": "Strategic Collaboration Agreement Amended Date",
        "terseLabel": "Strategic collaboration agreement amended date"
       }
      }
     },
     "localname": "StrategicCollaborationAgreementAmendedDate",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grtx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grtx_TerminationOfAgreementNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period under which the collaboration may be terminated by the entity's partner.",
        "label": "Termination Of Agreement Notice Period",
        "terseLabel": "Termination period of agreement"
       }
      }
     },
     "localname": "TerminationOfAgreementNoticePeriod",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grtx_ThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Tranche [Member]",
        "label": "Third Tranche [Member]",
        "terseLabel": "Third Tranche"
       }
      }
     },
     "localname": "ThirdTrancheMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price.",
        "label": "Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "TransactionPrice",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_TransactionPriceAllocatedToCombinedPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price allocated to combined performance obligation.",
        "label": "Transaction Price Allocated To Combined Performance Obligation",
        "terseLabel": "Transaction price allocated to combined performance obligation"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToCombinedPerformanceObligation",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_TransactionPriceAllocatedToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price allocated to common stock.",
        "label": "Transaction Price Allocated To Common Stock",
        "terseLabel": "Transaction price allocated to common stock"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToCommonStock",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grtx_TwoThousandAndTwentyRegeneronAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty regeneron amendment.",
        "label": "Two Thousand And Twenty Regeneron Amendment [Member]",
        "terseLabel": "2020 Regeneron Amendment [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyRegeneronAmendmentMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TwoThousandEighteenSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen sales agreement.",
        "label": "Two Thousand Eighteen Sales Agreement [Member]",
        "terseLabel": "2018 Sales Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenSalesAgreementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TwoThousandNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Incentive Award Plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TwoThousandNineteenSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen sales agreement.",
        "label": "Two Thousand Nineteen Sales Agreement [Member]",
        "terseLabel": "2019 Sales Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenSalesAgreementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TwoThousandSixteenRegeneronAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen Regeneron Agreement.",
        "label": "Two Thousand Sixteen Regeneron Agreement [Member]",
        "terseLabel": "2016 Regeneron Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenRegeneronAgreementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_TwoThousandTwentyStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty stock purchase agreement.",
        "label": "Two Thousand Twenty Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyStockPurchaseAgreementMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_USTreasuryAndOherGovernmentSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US treasury and other government securities.",
        "label": "U S Treasury And Oher Government Securities [Member]",
        "terseLabel": "U.S. Treasury and Other Government Securities [Member]"
       }
      }
     },
     "localname": "USTreasuryAndOherGovernmentSecuritiesMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grtx_UnderwritingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting agreements.",
        "label": "Underwriting Agreements [Member]",
        "terseLabel": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementsMember",
     "nsuri": "http://www.galeratx.com/20211231",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r48",
      "r50",
      "r101",
      "r102",
      "r241",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r265",
      "r384",
      "r389",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r581",
      "r639",
      "r642",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r265",
      "r384",
      "r389",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r581",
      "r639",
      "r642",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r169",
      "r302",
      "r304",
      "r583",
      "r638",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r169",
      "r302",
      "r304",
      "r583",
      "r638",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r265",
      "r331",
      "r384",
      "r389",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r581",
      "r639",
      "r642",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r265",
      "r331",
      "r384",
      "r389",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r581",
      "r639",
      "r642",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r101",
      "r102",
      "r241",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r302",
      "r305",
      "r641",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r302",
      "r305",
      "r641",
      "r668",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r550"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r20",
      "r623",
      "r671"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r19",
      "r99",
      "r543",
      "r545",
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r37"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r213"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r53",
      "r54",
      "r55",
      "r627",
      "r647",
      "r648"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r62",
      "r63",
      "r64",
      "r110",
      "r111",
      "r112",
      "r483",
      "r643",
      "r644",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r428",
      "r429",
      "r430",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r391",
      "r393",
      "r434",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r393",
      "r424",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Equity-based compensation expense",
        "verboseLabel": "Acceleration resulted in additional expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential dilutive securities excluded from computation of diluted net loss per common share",
        "verboseLabel": "Antidilutive Securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r179",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Other Asset Backed Securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r158",
      "r161",
      "r167",
      "r186",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r479",
      "r484",
      "r506",
      "r548",
      "r550",
      "r603",
      "r625"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r47",
      "r94",
      "r186",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r479",
      "r484",
      "r506",
      "r548",
      "r550"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r175",
      "r193"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain",
        "terseLabel": "Unrealized gain on short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r174",
      "r176",
      "r193",
      "r609"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r394",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "negatedLabel": "Purchase of property and equipment included in accounts payable and accrued expenses",
        "terseLabel": "Purchases of property and equipment unpaid at period end",
        "verboseLabel": "Purchase of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Costs to obtain or fulfill contract capitalized"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r29",
      "r83"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r84",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r512"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r91",
      "r94",
      "r124",
      "r125",
      "r126",
      "r129",
      "r131",
      "r140",
      "r141",
      "r142",
      "r186",
      "r226",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r263",
      "r264",
      "r268",
      "r272",
      "r506",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Initial Exercise Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r287",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrant, shares issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r287",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r223",
      "r611",
      "r632"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r225",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued for common stock",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r550"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value: 200,000,000 shares authorized; 26,458,767 and 24,976,142 shares issued and outstanding at December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r68",
      "r614",
      "r634"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r145",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r289",
      "r290",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, Balance at End of Period",
        "periodStartLabel": "Deferred revenue, Balance at Beginning of Period",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Outstanding amount of royalty agreement",
        "totalLabel": "Contractual Obligation, Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r332",
      "r374",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Expenses incurred to obtain collaboration agreements and costs to fulfill contracts",
        "totalLabel": "Cost of Goods and Services Sold, Total"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r459",
      "r466"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current - Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r459"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current - Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r459",
      "r466",
      "r468"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current - Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r459",
      "r466"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current - State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r13",
      "r14",
      "r93",
      "r103",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r522",
      "r604",
      "r605",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r39",
      "r255",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r93",
      "r103",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r258",
      "r259",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r460",
      "r466"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred - Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r460",
      "r466"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred - Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r95",
      "r460",
      "r466",
      "r467",
      "r468"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred - Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r460",
      "r466"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred - State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research &amp; development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r442",
      "r452"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "negatedLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.",
        "label": "Deferred Tax Liabilities, Derivatives",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount",
        "verboseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution of employee contribution, percent",
        "verboseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r156"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total",
        "verboseLabel": "Net loss per share of common stock, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r97",
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory income tax rate",
        "terseLabel": "Federal tax benefit at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Difference in foreign rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfReconciliationOfFederalIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted average period of unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized equity-based compensation expense related to restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r110",
      "r111",
      "r112",
      "r114",
      "r119",
      "r121",
      "r139",
      "r187",
      "r279",
      "r286",
      "r428",
      "r429",
      "r430",
      "r462",
      "r463",
      "r493",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r643",
      "r644",
      "r645",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Recognized at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r256",
      "r257",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r374",
      "r496",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r495",
      "r496",
      "r499",
      "r500",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r246",
      "r332",
      "r334",
      "r339",
      "r374",
      "r496",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r246",
      "r256",
      "r257",
      "r332",
      "r334",
      "r339",
      "r374",
      "r496",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r246",
      "r256",
      "r257",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r374",
      "r496",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date.",
        "label": "Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect",
        "terseLabel": "Changes in valuation techniques"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r256",
      "r257",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r374",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value on Recurring Basis [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r254",
      "r277",
      "r492",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r207",
      "r209",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency gain (loss)",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "verboseLabel": "General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r199",
      "r201",
      "r550",
      "r602"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Acquired Intangible Asset"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r81",
      "r200",
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r96",
      "r469"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r599",
      "r612",
      "r616",
      "r636"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r96",
      "r469"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r445",
      "r448",
      "r454",
      "r464",
      "r471",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r120",
      "r121",
      "r157",
      "r443",
      "r465",
      "r472",
      "r637"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Total income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCompanysTaxProvisionBenefitDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r440",
      "r441",
      "r448",
      "r449",
      "r453",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other liabilities",
        "terseLabel": "Other liabilities",
        "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "periodEndLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance",
        "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance",
        "terseLabel": "Acquired intangible asset",
        "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r155",
      "r519",
      "r521",
      "r615"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r72",
      "r154"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities",
        "totalLabel": "Investments, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r600",
      "r619",
      "r667",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs and Other Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Operating lease, existence of option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend",
        "terseLabel": "Operating lease, options to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee Operating Lease Liability Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, options to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Operating lease, option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether sublessee has option to extend operating sublease.",
        "label": "Lessee, Operating Sublease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating sublease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingSubleaseOptionToExtend": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend operating sublease.",
        "label": "Lessee, Operating Sublease, Option to Extend",
        "terseLabel": "Lessee operating sublease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r94",
      "r162",
      "r186",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r480",
      "r484",
      "r485",
      "r506",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r94",
      "r186",
      "r506",
      "r550",
      "r606",
      "r629"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r94",
      "r186",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r480",
      "r484",
      "r485",
      "r506",
      "r548",
      "r549",
      "r550"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r14",
      "r605",
      "r622"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Letter of credit",
        "totalLabel": "Long-term Line of Credit, Total"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Long-term Debt and Lease Obligation, Current, Total"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "periodEndLabel": "Loss Contingency, Pending Claims, Number, Ending Balance",
        "periodStartLabel": "Loss Contingency, Pending Claims, Number, Beginning Balance",
        "terseLabel": "Number of pending claims or legal actions"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses on marketable securities",
        "totalLabel": "Marketable Securities, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r58",
      "r64",
      "r67",
      "r82",
      "r94",
      "r113",
      "r115",
      "r116",
      "r117",
      "r118",
      "r120",
      "r121",
      "r127",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r186",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r494",
      "r506",
      "r613",
      "r633"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r128",
      "r131",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss per share of common stock, basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements \u2013 Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expenses):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r533",
      "r538"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "totalLabel": "Total operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease rental expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasesLiabilitiesMaturitiesDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r526",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Combined NOL Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Net operating loss carryforwards expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and description of business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r489",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets [Member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other Liabilities, Total"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments",
        "terseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r331",
      "r333",
      "r339",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r374",
      "r376",
      "r377",
      "r378",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r394",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r550"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding.",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expense and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from the sale of common stock , net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Purchase of common stock through private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r427"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r650",
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Advisory services fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r58",
      "r64",
      "r77",
      "r94",
      "r113",
      "r120",
      "r121",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r186",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r478",
      "r481",
      "r482",
      "r486",
      "r487",
      "r494",
      "r506",
      "r616"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.",
        "label": "Property, Plant and Equipment, Depreciation Methods",
        "terseLabel": "Property, plant and equipment, depreciation methods"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationMethods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r218",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r212"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r215",
      "r550",
      "r620",
      "r631"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r215",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "verboseLabel": "Property, plant and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Unaudited Quarterly Results"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResults"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.",
        "label": "Registration Payment Arrangement, Maximum Potential Consideration"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementMaximumPotentialConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r357",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r357",
      "r542",
      "r545",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r540",
      "r541",
      "r543",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r437",
      "r582",
      "r687"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r601",
      "r626",
      "r669",
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents",
        "terseLabel": "Restricted cash equivalents, included in prepaids and other current assets and other assets",
        "totalLabel": "Restricted Cash Equivalents, Total",
        "verboseLabel": "Restricted cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested Restricted Stock [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r286",
      "r431",
      "r550",
      "r628",
      "r646",
      "r648"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r110",
      "r111",
      "r112",
      "r114",
      "r119",
      "r121",
      "r187",
      "r428",
      "r429",
      "r430",
      "r462",
      "r463",
      "r493",
      "r643",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r159",
      "r164",
      "r165",
      "r169",
      "r170",
      "r172",
      "r301",
      "r302",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Aggregate transaction price remaining to be recognized"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation",
        "terseLabel": "Aggregate transaction price remaining to be recognized, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r535",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]",
        "terseLabel": "Royalty Agreements"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Royalty purchase liability",
        "verboseLabel": "Total agreed amount of royalty purchase price"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Cash consideration received on sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Common stock shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommo",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares of Common Stock Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Company's Tax Provision (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Portions of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Effective Tax Rate of Reconciliation of Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r393",
      "r423",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfEquitybasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r393",
      "r423",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Company's Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Results of Operations on Quarterly Basis"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureUnauditedQuarterlyResultsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r394",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r402",
      "r412",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r91",
      "r140",
      "r141",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r272",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r287",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Lease security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Remaining vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r392",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description",
        "terseLabel": "Description of stock options granted under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested",
        "verboseLabel": "Number of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility of underlying stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "verboseLabel": "Shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of Common stock initially available for issuance under the ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, Forfeited",
        "terseLabel": "Performance-based options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r404",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options, Outstanding, Beginning Balance",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Vested and expected to vest",
        "terseLabel": "Number of Options, expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r392",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Weighted Average Price Of Shares Purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of cumulative increase in number of shares for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Share Based Payment Award Terms Of Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r392",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Anniversary of Original Vesting Date [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r394",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "periodEndLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Ending Balance",
        "periodStartLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Beginning Balance",
        "terseLabel": "Options exercisable, number of shares exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "RSUs vested number"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vest percentage on the first anniversary"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Maximum term of stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r418",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Performance-based options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock, exercise price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r12",
      "r607",
      "r608",
      "r624"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r663",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentAtCostAndRecognizesDepreciationAndAmortizationUsingStraightLineMethodOverEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfCarryforwardsOfFederalStateAndForeignNolsAndTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r91",
      "r94",
      "r124",
      "r125",
      "r126",
      "r129",
      "r131",
      "r140",
      "r141",
      "r142",
      "r186",
      "r226",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r263",
      "r264",
      "r268",
      "r272",
      "r279",
      "r506",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r62",
      "r63",
      "r64",
      "r110",
      "r111",
      "r112",
      "r114",
      "r119",
      "r121",
      "r139",
      "r187",
      "r279",
      "r286",
      "r428",
      "r429",
      "r430",
      "r462",
      "r463",
      "r493",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r643",
      "r644",
      "r645",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r139",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r248",
      "r279",
      "r280",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r279",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock in initial public offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r279",
      "r286",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, Exercised",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r45",
      "r279",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r279",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock in initial public offering, net of issuance costs of $7.3 million",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r279",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r24",
      "r25",
      "r94",
      "r173",
      "r186",
      "r506",
      "r550"
     ],
     "calculation": {
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r264",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r286",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits",
        "verboseLabel": "Summary of Carryforwards of Federal, State and Foreign NOLs and Tax Credits"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Tax credit carryforward expire date"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r226",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodStartLabel": "Balance",
        "terseLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r254",
      "r277",
      "r492",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r100",
      "r332",
      "r374",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to operating loss carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]",
        "terseLabel": "Valuation Allowance, Operating Loss Carryforward"
       }
      }
     },
     "localname": "ValuationAllowanceOperatingLossCarryforwardsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureEquitybasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityScheduleOfCommonStockWarrantsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant expiration term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value of equity classified warrants"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/DisclosureRoyaltyPurchaseLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares outstanding, basic and diluted",
        "verboseLabel": "Weighted-average shares of common stock outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.galeratx.com/20211231/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetail",
      "http://www.galeratx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r688": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r689": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r690": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r691": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r692": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r693": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r694": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r695": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r696": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r698": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r699": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r700": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r701": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r702": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r703": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r704": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r705": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r706": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0000950170-22-003292-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003292-xbrl.zip
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MH#!8X?8,+BN6W Y\$H)9 #I [!&P04P2<"NV7!<THS5,^+X4Q&(G (4[(E:
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MI(?#05 \-V4,A-%'POB&H-@!+?@I\B<?Z19-QV.4"=,E5HB153<2)+1]2IS
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M.H&5Q=-"-:%N[J$&$*5I?HU,$@=HWFAF 'Y VXF17)%<#"!\6"Y3$MI0ES4
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M5Z3C5;AXG6C=_*/Q"U' *U[D?,8QQ*8<Y;J46)4;(15E2:7U*PJ@TOT+<>V
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MR0&YTF&9E=FT%FZG@DNS+^3:_>0L6;9C*SI R3FILC%^=/CTT#\IJHY@N"%
MV:3^+!>O0MD/3Q^' &M4=CN8.?^X;I)T05/*OV",)'L:@!]RH8>$H$?)XX.?
MDBN\42.=IH)70-/:RXSK);@49!DMX/?CJ1D$SB!PODGIGT&!MYPW)MU,\Z(%
M!>.F:LYM67-2YV< %W_.%G3Z\A4?TK7"KLW5&B1%N&-WZTIB22*,DBG)J$_,
M[TTGXV)=>KG)<2#E5&M6:CI'JZ1IQZ@]B<IFL?X#6\[7+O>C@2WG>[#E##II
MT$E;II,^NG):YMBI6D9W;KM9;#UBDO\@3]GCVEOF-/7:(Q5J$2GOJ<C I<5
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MQ0F*UV<?SL^3?R8O/[Q].Y+$:7TA;/[M<BH4;L)YK?$D%T5:0A)FY+O-6Q*
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MC1&GA&<F'0"77[?43P; Y?< 7&[-_MNM!/JY/>#/)>-IZ5G^TCS/=\Z:#\G
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M<RXY4'1IQ'5D_A.:)DR/SXA5(9@!BQ3DH3CK=I%.N>HI*]L:V4)W=WNKZ^Z
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M*8Q)1&-,NN.6 -6=T!^#\=9+UR*6#_Q*N].T/XXKP.*.,3&5,OK HA/?59F
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MLD@_9XMV$?0NX'61AX5TJ+X%2OS<IE3,>,1H<!/)V"YX)\/1O['T?XU^C=Y
M$/\>.^2J/?$&RSH9IZ".:)=:R>^V6U@52A\"Y1'O-$='AZM#$ >#M**BZ5&P
M$?NJN&TZ'T3-3).V5N;Y@ ^0>S]Y-C-.)Y.6!)GV;XN:YI4"_^5RU8=TRB8T
M!WC7-4Y5]R9X/DU60&L7O[.#MO#<!:.XZ8>CY.CI3_31+IRS^QT%N&.>[=&0
M9[O7>;;M%O-.6H5U$!\<LT_:5\E_Y+E4"L!,D]Z;A%069W'OS$X/)6E/OL$^
MP?5 LE:H\S #X_FN;K1W'>!Q8 8[R&@/,C3E8AP!>R[+NMF+\: ?0T3RJ_?G
MH^3YZ[U998QB.+&UWGX0^"9;]R?!9F73&W'TM>?J8QF,*F-\>OS32/[GB3*5
M\S\J4R_%P,]I-'&W0M@([C4"F QLIHO@NQ"U0Q974PIP6HF :27;:2:]?^=S
M4S>NVB:D7"J-G!)KB@C->@$G#$Y+%77P[6U6N,WGZ3Z+[2^/Y/9%.-X'2[KW
MLI#*WE]I>URD\ZS)?F3@>0C(?,/C$JUSINML_#JC:B-UJ47X6H9C"-I#Q^8:
MF41<I(C6F]11CQSO?L3]HH/$I3)2YVTQ']D1&'B*,%A10HD2P524>V$FGQ(1
M1%P[R#]<+987]%;[R6W>*2MF>;I8J*-GIF:1TG^J%?T,?W&[G:JLU4#A'&L[
M*6L2HW5;S=*))?NV]VUK&D];"P]5K%*"4X,Q@XL[SV9F#YA&4B-%AA=F5Y/>
M@+:08QA+N$;'QFS@LUVE4&PC<4I1[(FP3)M/C ^=8"'X3])#9&D5<_5YF>([
M1RH)_UZD-$KS[S:CNUR4]9(/TG_X)J(#0[>W,W5SV&$H[+?EJV]LQ^YS40TO
M"U(J3=L8[N_]YOSE"(@J;*"/'#RBW3U?)>=T>WI$RHL7IRM'VO*#]]Z,=.&>
M,/7AR>S"DCHS/]\+1;/CV2^!#?2D0]*V*9^-RVIJ*GXN+=O/!\_X\KT\79&M
M\O,L^VRFSR3=='C ,Z4_H%7,TV5M?JX-<'B-L>]<\0SQO?^!Y], G'-[F=69
M')6?[>_U(KIJ&F>W#H_WGSY]]!.FZ9_-=--%^P<')S=<\^04PPXNH3^J[LAT
M89_P)*\/Z09E<$5S(D[[S^*ZXX-NI8]L!CM_;FN<'M CD[K,LVG?%MFT9>U>
MX,WQY#9;]F!'0BH=:^/)+?8]NYW!MN_=#=]B#5&M=<T")GS+H]/3D?T_FD=Z
MYYU;UQN$T6W69$T6?;M%6:(-1C$7*7:P3X(I*X;3]I>=MN>FGE39$@9%W_)>
M(UY5MWX?^8JS>=<EO9W2WY4UO6-0^BO/:CB_C_8?H8SUUNL6KE-HHNA]?O32
M_67M9+Z;XE)QN$WG8;N=;A>Z3#GU*6Y?"@@"Q\C9%Y[0='#83J)Y[&+5@TB\
M/R+Q:!")@T@<1&*?2%R3B&E.1QE!/ D[HIV?A,(X=B9"L^+8W'*9,_=DS>0Q
M$Z3]!J%Y?X3F\2 T!Z$Y",VNT#2?+[)QUFA> -C2:P2F!OXY>M^.33*3/ 'P
MG4V*OJ@5"P$FW6JJ3$ :53=-,$C5^R-53P:I.DC50:K&4M7F1^NDK>;,![?D
M-.NE45I:8-K+XAEP-=(X&?G*;F9W$)/W1TR>#F)R$).#F+3((5.WN< OIR3M
M+JZ3=/1?9/[_OCB)@>SB&\'17"U9OHKY[W-Z;5,E]/:?T!]EN2RKIBT8. 6N
M8X#&7Q:,+E/@6/*@;"NEN6_PX\;^&("DX)D/N4\I(O7XO^6R*C]G"U+O-(*C
M8YJ.@X.DH%=P6+>T*%H>GP*3_Z!1  /? #,\ J!*T$WQK4[E3G@&%T#9'KD]
M\&3P,N>YI= 3"&[02O>"YM]4,6KK1BB>0)8O3%!]17<-IPM@K,Z(?Y(!52H)
MT$^&IK1NR3;B01V>'B1_['_8YR<IVK_ ;IIG-5VO^..@#&N57&8TE>";3IL4
M/--C(QZKKK387^! <36%#HB,U@W^G2V&[,I#J!$=I%TA18DSDUJ\$&/</B]I
MDUM$FS:M"0#1=GI\S\\8&+>UL.>OK5'_FR%B^\#%YUK6^]$=C5=I,:TGZ5+*
M#S/:4J^R!8-B@R3=4*V^VUN!J9=4[&ME-TF]HDQ>/#_;8U&(&HMIU<YK6[=$
MTHSLG*R^H"_F;38UF*NZ7[96-ZBZ_6"_E4OAQ<=04)7!&6*Z-<.N(1'';2,-
MQ%@-HBUVD$(AP5BD35L9396@ FLB>U7E:SI=9 6(^2NI&B&7]L^VF/AR<*!T
M)VW-;0&FI'908'ZQFFH)%[^]C16R3JA54Z+$RL-Y%=9\F599V6+2TIP40#:!
M*H!"),E<+CGIG6?3<I)RG3G=6[N4"4J:8Y8TH>2$5RDYX;B3"V%.2YX?GFB1
MY+2[JWS%K7_2=KTI:^_,;ZLL_[L([F]3$_*6;)$/9=YB4_X<5@SB. [U+;NV
M*>YVEOXH\NR3(?,NTT*W-9DJI6\D6*WH7))QG=E GY><WHX,S,*+M$MQ >J+
MZ;0RMM""-M/<TG%4)<FFVXNAY!?X.(M2RO;;I8'Q/:6QA-P=-7G?GCLAY--(
M%^ +C(S\LB(Q2=(7^"(,H[:U@VOMOWP!CA:^C"Q_=V50X>*?$_7>OOF=_G7[
M>1P;+IUD(A-E=,4S)FEE>NQQUS/F"X83.49"SN(]GD$-[&B<]O#QP( P,"!L
MC1UR;I&<SZ4RTCH '8MDQXV/+3DD ^G?=DGC7L.\F)<P:923>"/SWROH8JTI
M?7#VZX>W[^3*AX,Q?&<*KO^3%FU:K9*C@Z,#:3M>D ?-_"IB/9'\<;PLJ5\B
M1['W);1X_$G(BP<:?OLE_;I=PLQ[=+#9!@NBN)69F4J8Y7BHLB%X7([K*OAL
MI)T(XR$S]<8\ _55$]#,C U)8".=?U'7O>(H!%G)QP>=*'F52HO"_6$/?@6=
M>94ML EM*T=;2R^;+*L[_($AU4B\_=CZMT'[R/*_,1\B?"IV!^R$K3]LI_6)
M^Y=ACJA)(]XO\CL((F(")(>DS2(CV6!]14G^7:3YC%FH#HZ.;G6L!Y.WJU:8
M(PCG\ P,0:JR?PV.[?N(()'_59NBIL,H:-)!I=]Q_Y_5-C\[,7DN&8(%@ND+
M*#2=8Z:/HM'+(_1*<,7FYI(SS0CEEW-2BC[&=!513T&+@Z'#)CX_3R"<?4P*
M=UN[":A0D!">9O6B;6!(+&C\#>+]O?&>K/A2KBE$D_#&RCG#J6)$JZRVM_TQ
MYN47/ 'Z@F0'@F13)N7M/#6P22[22Q-V?>;D"5Z95M@5\"G?UGYR%GV,A'9:
M(>T!'%(NQ'3+UJ:/Z$9].FE;=EZ?7?]APDQ]9*2G19U;4IC7R#;1>=SFMR$%
M3//].F6[^! 1U4F5C:UA4:\*4\U7#M] QT:R;CT;N\\F_O#+^X_XXE.6YX*Z
MI\-9VZ[8A>5Z=7MP4K;Y%#1!2]X:;9Y62/<MH-QHT^)6M6D0S@8G+/,^7[@4
MY:T.3I+F8*/CQ]<M+F+$*\RNR84[\P@L(R&HQ'([82,-NOFF4_I*Z<?/+/WX
MNY2W(#+%JKG?DJ@'$&<7XU"#D="':'<K'("Y(+Y8&9(\$8TF/#,BGA"37#AN
MS:RN6TLY#[DD0HO\[D9N%4FJ=#Y'_@L2DF_".1M^+%)( 6I/.KMFU70O-\+L
MY9)C^@-&ECJ*SPA)I\"$")+VR,/QIEDZ+UA]XZ$G3_@+O1U(+Q=674/B[R>_
MY>48QV)D7RZ8K'1"$KEHE$\TS9FTCI0U3>[*WO+!R<DC/.(AOHB?_^#DJ7XE
M3SO8YP.6'!^ 9AL7P]+0RX,V]VQ<%&6Q1ZHEK1L>D5TR3EK2S+<%YG(B-%S3
MUMA\'GH,- %YG?6XE92T8LQ2941)UQ?9TOZP)BV"+8O%(%<;2XK\IP#]Q%]B
MWPKW=:G4F*4<RQ*-2S<4Z.^" -!^\H)S>&7@AH/BO'8_J,PB190HO)=0N_)6
M">XU4AV+Q4[,PN"LKN=Z]YE>+M#)*5\O7XXZ;["^#<H9V:JR*K3A2[PSV;NT
M: PV5)0,R.J8Y!4HR.P2=AZROS =@-F)M^LA$)1G.#\"H;1 4WEQAVJE&: M
M0!M%<KR1$>L@0 4,<O#?ZPZAS9G.N12:#P#Z9^A3R9  =,GSQ8;+-RCY>Z'D
MWY#8^+  2O@<U-AA)'U0[MNZ]'>, )!VJEA>JPAGPLT.<IMU0K^.W6,U0*)E
M ?>"\=!]ZE8T -W;:4^%SJ@*5=$EW3PZ(/E'3BM/4G6H(R#^&)V8WWPX?W4N
M/*B\<1&E""][V&\%,-=[+%6/CP)E3P(V_O;Q*7_KX?J('SCMRW)<AL+9 );E
MFQ\,W\LE"R+<?@WH2N@*TDO7J"2L2%O%X80H+<* XL6B+?SW4[,THI&U\4E(
MSDK_SBHK]06D$^K" ) :.8"Q\N;!PE;CM>'7#Y4EED/BY=;)7(-1C732K.JZ
M9L-=9]2Q.@08=*1JROK@:WHNW$!^-#)[]H>ZQE[3114C0$UE\(_I"J]A!P5X
M+Q1@#/Y\'P0%'_QV?O+X\/ A;_R;0M=A3OJ]*YS! 1O4Y[9MG#M6G 5;@V2F
M!/A0TKT>W8.]#[0AQ,XTFY*\<@%H-&U@60(]T!^-AFQFR'O924J/.G%J^C+S
MV_*Z2#7VX7[R"T</2PD\T[0CYG]IHEBS5%.AY5VI^0"?&Y-P=5G.]NC_(UEO
MEDVRS/*R25Z=O3NWV?0@'Q"&V+]5(/\7],.;=@/X"$@6HL\J,Z=5*#"004+O
M*"[SR8#+''"9/VS[^70FFO'TYB4M_KV3[KPISXEN"E\L\] 2R)K3G&<<($7?
MNJVPP 7K85[O#!=\3C;O8DR[F([%XTWM>A,8*KG9X_9J#B@8U.=QL]N@PC!4
M\1DZ B-[GF<IX_A><U+<X1/#YZEAUGEL6D_4/78-0;E=\')M2.%SHP&-5\GA
MZ1Y]T#8F*BS,BEE;2YE0B?8S>7.Q2B[)KR!-B]XST>AWP2YYM/]H.S@GO@L[
MS/:_]E:=;HGI\/&H1S%R)@W:R'$I5J?'(H<#;;RO*!5O>3Q*3KCISZEO#:4=
M?;1".OXXR>7V<("F57J5Y@ZOYP;&/A9W5FIBKHGP(O8ZL-+9;!7W!J[1Y+'-
M3??\RTL)-H?S@+,6B2Y[/^UBK901\$)>DD50<S$?_"?,Y/.JG2.ZF&LU-;_Y
MRS?/1\DL8Z#'K%.F'#X?M>&7+'PNLS22/B)QME::#(027V^>!*ZYTB@-I!'W
M8[D9D<PYXK +I[5'DL\D".85N;C:\*T@/\)D$\W++TH$RA<ER08.4#=5B2!W
M6=E,/8FLYLH8;7_N((K6M?!L#(J'KRR^H]<A$=[L&Q!M^\F;$CF$U6B]<3H#
M(&Q[O&S"74[Q-R/NZZ9GA'%I2-H38QN;2;I0"  W7EWG&"J,\$5 >*]&'K["
M0QB;E&E\)!WAY]MA"K1_^M%)LIC_\U.W0$2&#,$]DS#9J@XK6+0_ [_/3'S(
MV<SP5]V&[EQ\+4$KJ#]&J2ZS"2Q9\D3+*\$_F,\I[-L1:<S?5LEG^@]C!86Z
MO/;]Z?G=W.!U;!%$E3^C>R!M93DXHC'9P8C.EC7GP7!^1J*092N/0RS.9JUZ
M7>61I,?J"\8J2F"4&Q:"-/,RS85 ,ZS-YAU.1_2JD>%)"+(R,XQ#WU2@_/ 0
M% \QUO'<;B^'H^83LK:[['WJ,/N3KZ*-6UT'_MU:M?RC=? /ZRIUJVG[_?#H
MZ=/D]Y;^I9+AHX*2R.&DH_4#LSE#?>U6O;3?Q]EBGM35Y+__07\</GE\?'QZ
M^/3D_SL\WO]S.?\'&-8W?&-GBAM$/CHZ67Y^9L?VZ)#^@9CVMPC@?L]W_W&>
M^OV677=,G#P=$B=_6>)D8&7M"Q6E@D=:*VQ"#^_0[%Z'S:Z9X!%,*M4H;G)X
M!..5?86HH"I-%B8%D_JLS>D;;P:*08E8++D+5Q?D%(5UWH#V3J=F.@+(MVMX
M_RNL;6/3+ZO5Y(1%>U5?ER,2[VXMYRU%0C2E ;X8):GI,IN";HD32LV-J21N
M/ XNTJR)"OM<9LK7"]GB/FT.OGXO5+A7Y8)&&=Y*X%?WPXX=;)Z_QN8YV6CS
MG/38/"='!][F.7KZ^![:/ ,1^/=&-:LKCX9$Z[6T(H,9YCE%.*2M6#F92R6
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M5YF5$V8P+8N =*DL)MPOH&[J2 '0 R<9MQ_6.&D),Y^C/G07VH>FVK,WM,Y
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M:M-F$G,Q_BQQ =AZ Y]'$".5:;6;9"G.YKA30AP#%\/4PBY(WP'(U -D>CH
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M@P^[4R0S)LP!L\-*XU;=)L[)1R$<H!GA"BN)A\^ -4;CRT^:/NOX;NRC!@G
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M$!C#G;J0"-DY:=KSLI!VR[[#75_\C$FYT=C,$_&DREE%VHE+CN6K /_AK-\
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M:&QGTWKG0_ Z!^:%TD8<0<8H'(#]>'0%"B"S45KK/FHF^)DD=L","P3& M1
M$T&&HFDC?E\U<9FW;\&Z1E9Y0L-D,2%W"8".7$#_"V6U+>)OQ1R[71A:%?P2
MC@TBB5;"J.BA)A^";'FD^<%)PAE'SD#Q $7NI\%7\>E)[\4SV?Y-4-0[T:5]
MN7BJ1;UNT&.GKP*06O$M\BV 2L8/)BF"T+72JDV63L<J)VD^7."_2&65](3_
M&!C^(0+2>%?8..H=3CVWA(?6_\Z6$6%5V:[Z+?!C5@S[<N!9&,Z6:I+B!7CD
M93A&T@HIEA)]]-NG5Q<#AAI-VB'7P#->/%1E_-Q;OB*WOEN'3)2YHU=OB^39
M+/I++M9-DZ!P&V[+SK=&Y9B<\;?(M)5)AE7T1[#.;;?* XX,3#3QY-HM.P\L
M#BR$_K9".16(T-2#X&,61O_IUJZ5P7^M?9NWE6E0+-/NL;A8I)N^(L/O\AVP
MM$7(>^,'9#16.3:T6<_V_)[V^CR>>WW.O=?G5^R"0%EMZ/L\9%BN6'ECMG"8
M#?;5*#((5S[N01S6.=)-8[UE#0^^F7K?N6IM2)1[DNJ]!4',9E/TW!4:S8%%
MTU$\Z11G<26'#U,DGU=ZP1PH(:9I%^1)_<^@U?L5R^< J&_DZ$@O\8K$J6,2
M,Y)"$AK)KT3B**6&8SA^@IU']IK]G3#D$,H3G)$JZ;&OR]49&?W%1QU?>U[I
MS.-\S"#IIGA^P FL<D#X=%)8-A:X(E#ER:-T^PNMW/ U0EP0B*]X74;[QC3
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MP(4DF3<]LPJ\GRKP6['(,/?6,R(=)N1'Z6%6Y(%QAK5&A:OED5E+8<%RDTI
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M4^ZQ1+SVZ,&#+W__\,'OGSWAQ'"8!\A2"?96C\OZ)8@F2.YT_I]^N"%[8T^
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MFJ_TG@*A.7%3;7$R98R.'I]UDX/;YL*$U[?6A3#L"Z,3FPW?$&]CR*#D!6,
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MU_R-^5S,Y^)<M^XW_X76B98=<0YG HD$_0I O)AG[+K>*455-*J7+QLP5H0
M1RAR]WYNA$[4.N>!>JM%2)7BG0WA949A)G?(-,J*:B,4%Y&9J:^MYJ%HY(N*
MXAS JU*XT=Q>]#LFO/7LLWJWI%KX$[?X&IM:3-\FAQ[-(_IWAL4I9)"1X5#<
M1*[X\J,R:'//[00C!(#^5D#9%;\"WC34[KK<"S8MTO6@(.-"E\ 51=,.[&IC
M*K//A^W_TTT0"M]LC?1QAZ]VU&,VM=3V4Y.TWA )0[F-@?07+2,_"(@-RVC:
MOS\8NT!Q3I;EQBC]&,48,OX=:]2SP0CI%!F-(F0#=E5%RHTK*60!*OGW86J7
MCI5+IF\6YI^MS7YB,.5D*IK[B3&@UM35P4"(:9LJAL]M#S*M)ARQ36?L/LB6
MI+,28=0ADI?A)[&RC,4&=5%ZP*+)HF]ZX; 1"Q898&-&PN)J!BN"7[S:E/1!
M+[0\*C+/ -Q3??2\%DH-1<F^=4I '!_[DV=/4@(\'/Y!XT>9XJ&*J!G=N1^.
MRIALE9R0;-'O%&.QX]FFF$.^LR-#EKIE M+A&;X^>GK9BJ\P#.<*G6<?<$#J
M9T9#4'S2,40ZXB[1YGZ% J#;\VCZ)O:2%ZW PZ]M5MV6#FX3>;8P6<-#6()C
M(V-).ITC[/%[Q@F+#B<K)- QEEL>RA-4/D]D[VDK ^WBD&86U\W;MKEEY <2
MU%L;=_#)6!X5$G+=9J?XY='W^.K"+:V@ Y[8DXQ%P[ !;721Z[XLV"OO,C^S
MU9RV5(/9KP$YFNDW>]I9)=U3E?2-6^5]YT^\I_0X!@LQI%:>"&(S4VQ];?.
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M(S/"^:QY?Z6:-RH6#L8>EHX]CL&\P^Q)S/)\SO+<,*.V8NM'Y;D->ECBS$I
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M$\VGQ-+:D'2HTC<A!9,];  AE2']UJP;X+.Z7#GN!D45\0S9EPYDH]Z#)2\
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M[ORRGDI,9>DODVR3AP@+H%-1@BR0X$[ 3\THP^<F?G?3-;#)'I+N5(IMHFE
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M=!PK<!4_T)'?*Q=KMEJGK-;4M)R^W<Y*]!3E\J@#)PPFOI"H!QFH"^79N*N
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ML;+2<_PT*\,PAIR#5%)T+@G@M5\,4ZI0#A+:"@PQ1&T2]*5Y/5-B-HH(: !
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M4!>H29X8_1G8,**E:[4P6B$_UT/9"/' W>9'5MJCX/U(8H,[OU;GLO9QR9M
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MSAWIW75A3.9GI_/Q3R6=B#$KQ0]K;_.I[=XE)6".;,/]<N\=_50CR7R.L*>
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MXDU-,LD/PM$H7+CS?NE<V;;85$.@L 4NTOUE%#P*RPF6==J^M^^/NXJ024I
M0CO6_+NO0[M?5"*-F"%3-#8<I XN7!?-5PR\#4$?BZGQ%G1YGPY.1++03TT:
MJ2_8C01<FEVSZE-M)U(S:DC4 W=LUVI*/KQP@Z2 M*%KM8T,6O?HK!);8"-X
MG&31&8!SQOW&%Y>216O[F#B6(ANS0)WB392#TF[87P;*Z(DHIV4>*S288\@U
MWSG<[2W""[IWW'SGUV1S;+-7BJ!(9\%!HJV;XF]3C!%Z9$' 4?&X*E-I=^-,
M(@.@[3WX= EJ!C*W&<#$[?=M-V3@[:<'WKX_YN8?_O,[,%M^%R$?;]OCR0TB
MZO:=4V'O_^/.FR^/I[H]._%#7VNH]5^@;OZ$R*$K?OFWA5'S+AE('5L4V=K]
M$%U0%*IB57K6-?1^"&RS$HL@$$]]!OT5RT<*&3!I8='_)\<-%)V\>]RU&9%V
M=7OMP_SS#R_EI28M ]XA$)VL6M*EW0*5>_"_S\$(;TD)([!GS3[ET\KOT).$
M4,Q"VHF,UR*/<(2I7;K0"\+PWKEW5I%JLO\#99<J,4K:^C.5%5,U2\"?&QS]
MT$ I:Q\[K'U&%PO$![1D9_-O3VU7[WSZY'#J=QSLE,0_3:)@I(OM=Y:;7OO2
M%;E7&P3-A0B<-2']0O+[\X\47Q_D8L:N'Y6ZW&X&5J1A@':4>7?UKH]2O!*C
M(28AD??=W>9[ IGS=WMGM\6*5@PN< _P$ 4NWL&!?SW2LO5;JNM";2;5=P/_
MN_S-W>;;$-SI;[8DG2TBM*0NZH-%'X@>JVV.BCYU5/2!XTB_S^-(?[=QI-]R
M9/:A,#!6Q*+DOK"B1W[O-5OU]SSD<AKO:]%-/775(RL3]*[LO--LNP?OL/^:
M(FQXYD8_4_"1174#/AZ55P33F*KV:14J2#>IZVCRDJ4)]E!#U*L9OUX8C6^E
MX)F=^3>1..:(;KYP7XMB!D]GA3A$"B#)H2W')*<#LT]0V,2?F$1'K!25ZLGI
M]$ L:?BMYX]GR%"7G$N$70NB'+\S9U2IHD6'#_]"U"!4PV$A5#8<J%VL[F0:
MR',!Q],/XRX,XZ0C$(54DB;*'CHIUR^HJZ9R[RH &B,:DQMMOG8^;NM$:73[
ME['BXDZ(H=*(KIB$<ZSH43XTK7<V-'"]&WN>;DPS/$QM8*W"4OOLC36%&SK(
M.Q0/6&*DW/1^+]7^#<7P4@I'&BGYP$T^0F,1&*[T+^S![B*4YRB>PM-3!':?
M; 1[N=F<9H?J[06'A;">8][$R;E=O 4MD,TB/-VIN,C8\Z[9=F,5B*F[4#61
MA.4OH[=G'\_N3(!9J+Z*>=<LCRB-+I+:Z=NF<75ZDUCW%$+FW[IL/T$FT%X3
MD;L67,+S?5F2)@T-VN )L'G@H\/^X(H@\7-CN!2@9$P[-HX2=?H+?^$@!_?0
ME<?;* )F7[XLB&5D"**LU#G.J"KU&!DM]1X:6'TU,^]$C#G-?:T3&U@(L=R3
MGC5[8IWN+=CQ[]T3^PC,4O4DY41.8*>?I%WL_P;?]9[(>ZE*"M<EA!_]ET*_
M@=TFG5B<FVK*+DHCT5G0 R3MM#^(#L.:"%%'J2RY)JZ?\BIM^#5L_+G2C^2_
M?JFVM)C(]KMR5[6<E)YA4;8Y ^$K[R)>;:GOT 5!IV)2?I](?Z6,'*NORO[T
MYNB&0[OC1ZB.<LZ0,]A0/QTKQ!?JUQX'/0*^\7[MKC$>346=- V7]25-<,0!
MX>63"Z<S?B.78F>-:3K^CW8<5N[G;O/-9"MB0>AU2D/G3W]\$_HVJTI@_A\K
M,P[.)Y^_\YVI3)IK)M^E44.MDRJ6/51*)S>7N'1_;@X=': J7Z[$*5$T;7&O
MHI0C72ODU";*P1FV>>>2DMF&)](MH3Q]0\6Y:%ZXOBB";F3)V0"AV7J60YH7
M+[Y_UB8KHH&2A"A4?IDY83;2+R>P?_(8F^",>ABKG=XM#'(?\*91ZUTK49$B
M_YZ*9N?>;Y"R20Y)47C%8#[H:?PM^/M*"H!*&BIL -R_:Z<$ K!JFZ2%W,PR
MTIW*,P4_MW!$_I83\H\N7:J6P[J1_8)<) >$,$3WB]N.M-VE--D2C(E(K K]
M%"<F R?R,7(,T6#NB%S=EOK@&7V$.66@%R&22M;V//CH'><2)7:4"',BP5L,
M04XC@/NU?%4#_B*1EZ*2O@(#; $^)L&2T'L/W1"8I/91 J5Q@6TE)BA%4BY/
M<E]7'N\V%D>#!\7QA!"#SBHTDZ6FU3F;F='/!#OQO^NO[^A4=255M'!_1QS
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M-79:[W:-7ZZM,U>+5=:<]=SHD9N(Y#R%>O+#6':E/P&D5!0/NSZH5TD5!9:
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M N/'MGYTH8>$ '*FY+J7X/HOH^OY#LADV>%X!^33 W*'''R*4FP-(EHJQV/
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MP DK/)\8\H@3JQ P;5@7BEV&;K2$.1$3+*;.'%NU,"?'=?S5SXX\.C*GM.R
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MFZPNG:WCRJVCH_W@,XK^$ F2^W9;0>^5XZ^T;6YF@I2O6J>F1':FFY.71/*
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MB.@$JB64PWYC7K(QL/MC;<;$PI:;,$:)0#7*"@$#ESTEV]L"")\S69L8"LF
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M@@'+$Q/&]%4!^[(\,!'^D.)2 @6VA7O_FM%F8C3OZ,&L:&+ Z$>5*,M_?E6
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MR6J%W>[>B3HO*Z\V#GWR?FQ53Q90C)'Q 8L*&FWLOS61_5HG8*?S&5/1G1]
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M:UF@Z8*2:>'3H]O3<:=,&/%F]$C&H?@E)8)(4/;LN:141=?O:8%2/WVB'WH
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ME).H4P*J3W2+69DK5*5)U7ZCRE;8/>6U5@2 S@\5/N+AR.3XTELF\9%-W=\
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M%] ;^__Z';E#:=JHR@)_+Q@"RB/1\ PA;.I/T*LBNR(OB"I,PT?D5T4764(
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M)7ZJ4_?)U\,<V\#I(QNN2(8<Z=EEP<B#?'U=M&#<N:XYESR]!U@E<J*,KV#
M2_R:(+;YZ@I2:[O\P'<63>5K89_D+X*IY<B.FA$M=Z\($1%LP$(1$9%_H7F
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M.A6W1G#G34N[?\#2W1UH27Z#M*#80:K> _1G$PR,5MGO/#8%*\M36H4+$)2
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MO8W*3"7R 6WQ=RR9TN8J>(@-0#("QU8%%X-XG3(+2/(1*V=BM4;)Z^?-X3^
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M&MTAP*CN6V8LY/W^:S:%O4<YXY#OO0!^&<R*5/^,6 8?%Z#"\*\Z=7"19,M
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M81<<F:C5)P[$I&5AITK3]UZ6>(]^!7D$DQ19S#X0;*GGJ99Z2JFO%7CRZV"
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MCWI#SQ+E=EW57 M.OV-?Z\(U&89)SCW,+>495',H,F?4HWR)XM"TA&&D0?]
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MLO@MUM-0Y+$2724K Z;$-/&5G[:G6CA;<TTD?B&YZEZ%G)(2[HVR/YJ;#*!
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M?U/D?]=%_EWD_X%<X*>JH,0>.G^>QIB)RR+I5<X)CFX.X2VTIDE#R_$[G22
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MDS6;*&O0.'4RQ?&Q]@#5\;&-PO;V\+&NXV.;P\>NT8V5?W%5Y;C?/?3[>UV
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MHHB2$:YFW2!L*2OAD,N.CKTEU&F?=CN'!F1A24"M_FK HX'RYN.KT[.='IV
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MRF3OH')+=KP_E=:<I$">HY0)$=9$-0FX VB*K!@ &O+ZOI>7F#B1>WAKS,U
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M,7RE2H*C[U](T)QE<@/-'7WG\JNU@-PBH*[!QNX I ! _,L_GQP\:4L+K<W
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M3M.4"WH(^I8WK"'5%C>G,VWMU%ZP8V:4]6JEVIIJ$OB[!DDM;R,=_$=2ABS
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MSMJ2]3U/>).VB!O*D59Y3I^GNYQCEKTZV8 1ZF:YNU"'H:3.NC.< * "J,,
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M#%L)2S$1VS9K@/9 T"X)6Z 0Z-2 ]@!7Z2#O^!'=YU';H6,S7QE0F.(5PU@
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M# 8 %H =)+ 0FMIJ:"IY$C2G2&G+$'<N(<V81U;:)(345O);YSU]2SX;A*:
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M[MUX./@PA1_29KQ[VY4*,;K^+\,)H^L)ROD0(06U& 3XH!:@%C"Z0"T&0U@
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MFI=EA<GNCR=+QKRFTO"=M2:%(;DW*LB[WUGB & !V&$!"_':+<5K83"4-Q@
M6 !V6,#"3&6KJ8%&1D$81T19V]9)E$C'%!$7RD4:M=+DUAE!ZZ0&?F&FTL56
M[Y^HK%VI:D2EA,G*SG('  O #@M8F*S 9 4& P +P X26*!OH&\8#,, =B!Y
M@KO; ,/MV1"3VF9,BFAA9%NT57CB$$]8(6VE089JRY.@R6O>1\X@Q*2>*'=
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M./Y=Y1*W*&=J9#@&2=LIL@!( =+R(87,&:BJ]:0' $ *D)8/*= TT/23'@
M*4!:/J00(-KJ>H<DGFBCD4_,(AX%0\:2@+@12C.NDU7R>Q(4MQP@@C6/H><E
M[FY>:#',L&S%WR<9SW%^3ZC&TZ:I,D4TY]/9'&5*OKB9E'CS9SUY%U>U2HM-
M^WV:.8J[.VZ>XEX,F)'"EKL=&PP +  [+&"!OH&^83  L #L(($%^@;ZAL$
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MN;JF/8[IO:]A]W\.W3/WO 3O&?J8ET/N>]'M"]KN455W].]2)MEW$^80B],
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MUL\P3=#?V^T;" 'BD@&;Q.]W#1:)T"?:58-U.<^N*JI]RFJ+UJ& !UO7)2K
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M\Z/9R'>^@?F@H;KC:V#FN<Q5E.5$4FW 'M89 5]=P$\1TU'(=10GA["AW\S
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M5W;6DFT&6V!I[TEP:A/&+;@V0H'9/KJR606+[%@NQ$=L@LNJ1ERM/S&<M[B
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M#E.5A*!)<TZ82B7A46C@%JF)\E1E*M;CU(\LC2=AEGO].![I<C?A@6\+^/C
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M%H7M60".X<&\G%:+3OQM"-0-T08\K!U^O+; ZMUX ?@<Y'<-+!W0G"@X;Y?
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M?CU"&>3K"XXO0K$;>7<2G.-I]C&^D>IR3]ZQDM>;00\<9J A+](\(J*0TJ$
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MF[9]OA8P&(?39@9/F-(@JF  ,M-":.QA3=LN;"T@XGB<A LG_(>!:X#Y6\0
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MH2_C&T#W!'/1U]'M4Z3A9G;5<)%CT:4%7?'.FQ2,#*H_[CSKII>BNX>YYJ>
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M$FOD-7:(N[38(RXMW&S$5'GK:[J3Q=Z^BW@*36"ZE/IA/8/Z4L3S"#&HB+=
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M]!!QCFK]%NM:<:<=XM%8Q F3R JN$9%8<:.HM\K?7K]IKXU0)** Z]1"*<+
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MI%XPBS.#]3V$3>K!3GNM%KSO.RP5P1X>*HH.#J^#8X?K.\(C$5:YD42-8E2
M>)$*I&JND0.\](%II^+NRGD](CQR-TK>%1XA_0N/B(':>7BD('2/ R-ET\E>
MPR,7P:4_9I/J,WQ<-J'D,[5R2:(HFLA%$\?.U_(QD9O=*YI1;^M:(AR50UR:
M@!1U$FF>:@E8&C0-.;A7.@-_.O9O%N;]XR1]5/:F% )70/R(Q'M$()Z/Z2][
M4PH+^$XI/T]KIBRR3GG$N=%(:X!U9ZE4@ABKW5IV;9XLH&Q9*?2@T(.C%>\1
MT8/GHXEC1_<[8C+<BA!2)$88'6%IS1RRD0/&&L:BLJ$F?G?U^1X1D[DWJ!Y1
MJ*;L9#D".[<:L('?4W!Q@SK]\//=DOKQWH(B>Q<4?9"@-KZQ'N!:YO#.^5B"
MTZ::Q+L#17D^]$DU.PNPJID&-_DTAM-21<AK#( _FEGUQ3357S:]QU$M837
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M8>/F#9BSRH;1Y$M6\P_$M7R$Q?1(TZ"=@>+'E_#D%R-S^2*.PM=M9M__G<.
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M78YRQ> GWC=15'!P%12J=%BJY+FQB@J,>,0<J!+%2&GOD(F*1^F#4;[>97I
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M)'R:SKZN,ZN%65XIEPS4JJUGOQM2M4M&]933H%2P+P!\3.(M -P[110 /BP
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M-E2?PCA)"(9R,[=-^*]Y.A &\7^8\3S-1G*2)ID:;'K%?;Y# :#["RV9]0U
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M! U4<2I@$8@]Z00/@'<'DS=_:[WBO$%>U4W("A4?1906<5$NN]G_*D:Z\*D
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MMU(I:[B4X??V_:]-UY-Y,. /2.\+&M0=^M=F8)Z"FLSX]D5;H=K/(-<T0!S
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MXHM1PWD;OJN22\;_-,_C,H8SGMP$$YI>,G+$%ZT1,7S+'O"R(PHG"EDX$%^
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MZQI3;.4;4^(3MB7V6X'SQ;<_^(*&P&1+$MR;:^)O3(M\/),H69HN86;PPHF
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M+.*GQTTW+J0WH%O","04?4 @3?B)^74PFM.QM^[#]1.FZB9VL3_DWME$=VH
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M_M4)_OD<Z?5A<5F;O_P?4$L#!!0    ( "\\:E2M;9X*@A   +OG   5
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MZ +-2:Y5/+6H:W_7)^B5 7P*!OJ"681\@3PTQ\%>)5#/7P_^Z_D<\2@?/IZ
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M%HK>)Y#84IM!B8A,*(>ZH_V)_>Z^V)OAEPNKOG@)'N>%Z,8O%[XPQ"77OKI
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M/G<'S/E4SN7QY^S'(W#Z^?]02P,$%     @ +SQJ5.T<@@0W/@  Z4P$ !4
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MR\1/)4E^'*UU\G"$0/VM.N?H<SIH# IK/,)OS([^5^ZN'#3D*Q"F/,/Y>O^
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M(+#:8GVL6V6<4F:L5:Z/K0\:G!_FS'%_ Y[@&O-Z&+/"5=&ZNAZ"B\CLKHU
M7NI^*DF<#A;Z4(0TE*IVR=$#S#1G"OM+.C6<1DXHNBYA)@C"J?1Y"E*5?K4R
MMO&@=>34UX':#-PI8RAJI6U=2@FR%D)I_BVO-UGK@1AU>XFK;];BIWIOB2I]
MUCIUQMIP@IJCM;A-MM$:>J>U+K*Q-QI7>;46M<';C*W\6NMC''LG#:F,9[XO
M<N%Y?C;CZQ!QE5U6_>35YSA;GV,,D\KTT7\UITXM+9A/L_[;]%.BFK6:OTXZ
MK489PM;$ZK\;M0_O*K)KEB%=>$NVNDZ+>;T,41OSVN_*W%W-NS2NO#J.PKP
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M8$3-6%M*3<VNH$?K6%N[2I'HS+$T6%L]2!$TX^(QX3,617C4_,365FSI 89
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MX=@DSR"Y>':@UUKBYO/DX0/K>X#M;H&7EHFO>53$+#)XN:_4C?^:*>LU4]:
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M30WORF*0-%FQD?8W[^SS888%*-45Z;*5CPV*=_4$;"NUAO)OQ_.D97&('@_
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ME;XK[;-5F^H#G3?O-';]A%;UK!N:^YA](<P@:)Y R-QIZ:_238<>:0=/31-
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MW?'D1M2M4I^W0$' P;:JN\J'QRU<OG3<7ZF7>X0:%<*F$>.9QEV;;DZIVR;
M3_MI@W6K/3#\Y?S(## G^+_^[BKRJF"8&A[^&FZ10>[D>GZ3=S+U]"X-VY1"
M@,'DP7M:'>UO?G:\_ :ZA>K#>,^=D1B:@E G[Q*><L!;] !%CT[#X7<\G4EM
MPXI^+5 <ZX>'=4DGDSF_DF]FYM$ Y*.>P)MK5X"-\C&7LBG> M8SJGS:ARCU
MFYJ>=!@UY@U_@*!R%_J S%3,H*I7 #J./[\KE^\>]LH4:DC'#MTV.8X7 95Y
M_,T0):6GQC,;#G*%G>KTX&93XD@J9Y"]U#MKR4ZH%C,8]--$!V]*!& 38+Y
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M426*XA0T"JV16W,7QOH!@]S;]X"S^+B)0EJ9^5#YB#D@6FZ^1_'^>>>X#;
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M6"KCZZMYZ+L5R[1YS%=HU2A*?%"YQFUP2Z=M/M,J#5K5%]QT'U<4"4:3]VW
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MQ5Y$JXO\Q9Z1L+_GPH9T#= &!R?H(,)A'B@O>[@73:Y.W)>""I%D[!V0#7[
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M>65/<P[@ZG_C3YR=D(5W+< OW6(79MF(F>RRE\!WV1-,/T<,AI!'.%1#9A=
M\6<"OL%BN8G6?!KFG!_G@$^3_^OD8$XCR U@NIZ?;-68"WGFV1E*I-E;'5Z9
M-8L+*Y,Q\VZQ>H1*81%>X-9*$@6^A__F7;7YGZ:067G"'_8ISAGCN>OJK,D.
MN=HJ1!]*>/%]<J$7*Z(S%(DQNM"BC;KLJFX?7'6H=2AE$O,=\%C> 06^5I%B
M7$J]!%3X.W$1+%:UH".GQRF1"U?3)1^N@(\ /&)9Z%*?#$UR7Y/<U23?*<D3
M.Y)C!$\DIR9/U*7^*QROEWX04.@(=Q^%:Z@XD9ZO!-O KF-GF\P]IOV!#[_G
M82>YDUBQ)R_(GV?-LQEPQ#17S@'\!CLQ"^+(:=@*XPZ\.N++4*N2LR6<+Z^F
M8)RQ!DF5E;&C$[OH\E51[+^.1=&_'-'Q2MLM[&0$%55\/$D:"X@/."Y3&H*G
MR=^R#?-J.?]+7!2ES'*CUR,XC!3YF;H$Q7\'L=CM2-EZ^5GLJBLV+&B;<+'S
M]FI8.Y0G)IY<]:ZIL_?J*$/%%K8GKZ72,T8%'^N1!*M2!\<+?*:2ZON6RS9,
M7V4GV<#_(*OKE9E!>!2SD\]WF?T'OV""%G^@/=DK!,9(L7?&_B0:1:CVDLSX
M+^%=EW]6&& [4#;D @5&U^8K693#(+<2WH6_T)PT!+E?]""WW2K)$98A3V9H
M7 3*DQGLBJ^7?O7JA%$JZ++6"$. Q*&W4K3LY.&D8K4OAA(7JR\)K_ID+[%4
M#=PSO4;,@&A3 '=%N3R:1S39+]A$>-(X.C$.JJCM)>6,O5[ZG2@7+=86C>WP
M<@%^#'.YB%87&?L')J/C-W)0I__U+MH!)*65=;/E*[Q9K:B;*O3UI?,.7;MA
M'4.7,4:A %J]-JIUXC>I^&K-Y+'7.2GRQJJ-IJ#GU[(NA08'$,?)=P+(['Z-
M,I<^G7Q/^'Q/0($+='S'CTG;$V'+^MCR*!V%PFVTY9NJ"ZEHSDOH(6;WJY4.
M;T,O0NYLKB^*J49B'Z2#V]#+49,'H):G6"WEI-@471@MHE]Z4NQ>C;B+VRA.
M_;_R'WR!MAHDW5#RG,8.WE'WD.'%&TR3Q2N-!\>^KPFT8YB4N_@3O.\U=W_O
MF'-3DH& 2<E9E\,>.?>O9%&*B9JZV'&..-\0_F#G>1H5TACL+0R_NS #!FL6
M^M7C">5$D;-:;%<!&']RF88I:)#^53 #X-^,M5Z5@/NR,R_":C4MVN6^\.#
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M]G.&2H(<75B0M.T5E9'G2QK2E9^"/]PL;J<*S0L.Z'(?!IW+DH#B?7U]@A6
M<ZNDLUK+P?TZ4/BN;(9EI/E:-U'@L0F"E>#V*%\1[J-O@=%WN6D$KC/=JRRX
MS;!^QSU;P<L-+K&@WTG3V'_)4BFW[FL6S,Y6X&*:OQ(9E2"L""R!?L] W_9=
M/',]W@/!+L@2HJT5T)-4T=NUG[ALMNS8[P&VQ0%Q#_"VM/R>G,T92EK(5#Y
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MHJE_Z#(BCR&<.;8D+06V=ED*\3DIJGW!3E!N;]Z9UA'%S!AQXOU=2K<)N$I
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M(E6^!;CP>U67-I4!Y\3/2*X"B@U"8 8YW/$,]R_;W((XV47Q4'4AAZCNQLM
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M:_*JNQWE+.5)$LF#Y$S0!CH[,8OYDD>]4VNRKIU --W@B73HW(?F/[WW[!H
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MJW_:Z[1'^;$E$/Q%HVK198\GOT3"9;_?Z-BA'(GH9*C),K2=A/T5;+1.NX.
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MFKBQOU-8%B:2].'B452%&CU,DGY?:2H:*-P+E,$!!;H*G"01)VG?#QEI:;?
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M0)H 'V,Q>V3H_$L+&9OW7>(Q6F!JG^^T3:58,_)*$I*EZNH[3#G.33G'^!^
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M3A$2@G&"?B<,E$SA3TNJ!1<^5K/^E8 /AK9Y(YG_2@2^R2.]0AWZM220#F.
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M[F<3:+13)X&VM\#JO>UBK2K(I)Q.@.5OUGQ1,JN*CF2$YP<4PRIF*E]0$IS
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MXC!V?LR^ (>14%XWO9OX6"_G7T^XJ\5-7C?>UZJ.H_\?BHWKOV9?:FX+$;1
M)9OA$+MU<QNM_ J9V5!6BR2A7N1L;>A:XF2:A^%AU0J;K3V<"UTM)>"8P*27
MM(YV<_T4I^OBW<<4*/%/9:98,KWE4>[:^?QNRIL/>D&D61A!F3O,C'V@X\"U
MD<9TA->V=][B<#-(E(&(]+I74?UM'F$N9@M#I8'SC2E%J+N$"U$LY *D](8X
ME817)(.(HU7F@U^1J:L=XQQLC>445R/=9\6FHR6WK;%KW8[> W17!NC6R@[F
M&U?;T*GCJ_3)8$ 4"L:\3(=!8CG>Q;5IG;!HQ@XU?R& -"0,"PCM8EI;^P!Z
MKA7;RNP:'+8TFX$WEJXXSVXK <@ )?<Q2\-]@%%M1O]LE[[.9=)7#M>4)@*_
MJ@1CX\!JCVE!_T<$>FN21R$70/2R:F]RLXIFD7H<2%!F3\G13JX%\[+42B,<
M\10SY['>KA$;1D!P;3-2C4G?M1D+.6AS_JD-YI*57!;:4&H+2Q.:!'+ B&.\
M5;OE+?<GZS1M/W[QDP/>. ;AJ-'"]36D#75GTMH"#-GP.$9OA 7H& TA/<@X
M_4[2]LMBE=#ZV_Q6NE:NX\)5\$JVOF9MPMC8N62C,YLITHBPWZY2KDS<IAF&
MKN27![!!F/-/1R#L6E?DHO8M ?$K/L'"VJWG'"Z< ;7ME7S\CK7M?S9>6--.
M8PX+WP?>&28/-9;@W]WO_A,).S?4=3YE\SI68)V]H4]K<8!Y93N>D0XI'RSL
M0?ZI;M/MULOU<U=+.$7L+[C=(6=5CWEQI(OS:$=Z"EHUFFH+USK)L/S@RX.>
M@.G]MCB<ZX5L!2W%BNS?J5KJQX#-<F^HY'XR$:<R=FVR>3G3T@CSS2\PL/R2
M'-(DA'RU6_KEFI)X?UIS TQEN4>8@1R5MVZ#X^Y=W3+XZL=E\4418 [!YAJ.
MC&W/53)B3K4RG#E'CE8;GVN^L#G!*4?"A[W1QS[5X"X-1O^;K*EJ0D_K_?V5
MP7O7;#(3/4R&#7<KY]>CN^M0GCI(F*+;: -Y6MJ[9H6]!)5@TE."D]H[SF=#
MJM %!!,2H!SBD6VH[^3ZBS% )NZL7V:(P&(.[FAI[MJ3&ON)+IM5]_LYR:)?
M#5_B9"*NF0X"5NF+A-=DEY& %56E_XX)MU+ST@',0VJJ-*-=BY%HNPZMDO6/
MXCA]!^]+SD 12 ;%5EOLKMUZ.DVX?T]7FW2?TV?J.:)R-$G*P%KA.3*X;+IW
M/5<YE@N,]"2OB2B[V,SRMCB,2]ETM8FRL+UV4[.)ZR^M9#E)',HWHM:-98[N
MP/"S"L[9H4SM6*.X7C8&@062:R6^Y8D$A,X\7";*C+4K<@H!]TZV*KI-#=-&
M_U>S,W$(O3D643I6=*-COYDH!3W<A/-R9.!3>YN"_+!,'O<O=)&7:!%(7@WO
M<EMCQU\%;P$Z'[@?63$!2 ]8*P5SI=4&A*-<_U-+<=(1Z;N6R]NK>962M<:\
MS=(LZ X^74'I2-CU@S50U#)[J6\^2!9$.6D4D)UX:/>%BT9 '#Z=BM.DBFA=
M;(X5*ZTW<>XV;0%V88Z?XG \;+8'F=G$/M>MQD:Q_4B7.1K\*E>"_#'GO^9?
M.IL"CQ$ZT\<.[&=6'KL*8<>+4R:KE3-O/<VM'686N-+V?)C:GJOP<4WR((MV
M1B5Z!+J.4^)$QM#Z,2/;:+]=4LGFES2F8G5-UN')E?PZ4CQG#$_O3W^\]@_,
M!$:;I-DJO8K3'&5YYMXUV"-<SF/.DH "\0;Q'ZOW]&0IH$G"O8A:)IP;I,^R
M@>L[0YH,]1#DHAP'<Y"<DN=T.CW7@HYRN?'J1XB8T/82'.OCG"7,X^ VSRC_
M[2HC853 O_3<&)N[MXV:<3M:3:#'NLT P(%AO[/;_);^K7)IM#9TJ956KV.!
MA\'7MJ&@MK9V+>3+&#<T%1^K5F1L[?JP\TH"# 3JE"@:4Q?WWT5H01@J!Y=M
M1C9T@O)5@1>4/J?+M4G-.HV$\YR 11C2<Y'S_[J/$O*E?AD8&[J6) ;:'X4E
M0/J85VD!UN^"RKMY%!BA#J88]\R75C'M6HAK-0TR1Q_B$6B>4_O.0ZN]CWXC
M<;1)TQ"2K\%.Q.51J@E")"'6U,L@HE#S% REY5PP+")6!@NQ5%M3374M73]Q
M$&E\Z0>_D; TB9GEV9;FKK7\3H6G9U=Q&A#WH\*DJ)>_SD4P>*3*I1__GVAW
ME88-T#=SRQ_G_;(O#Q@'<WW".AK!AAC0'!89XCA.98 $T813M#9T'4)"MI"#
MFQV8 1;]>.!*QHJKBX)A?J.]*WWT31?DR41FN"DU];L@<3Q*:FES?6G,X3+K
M T1 =5$2 Y,DY)"71X3Q,0=Q&LK-OQRF ,L([(>TB(RUJ8YW<2\X-*"/[I((
MD-BJX6T&N:);YSEL]3Y/*=MS],M)0!Z6>+;8%YLT S_VJ"_W\>%<.Y=%PD@+
M]$^UB6N]I!$R[NNCQ%MTE=-(N'?:=8P(&Q9/-@^+P7*-827J/:2"M>4<H WP
MEZ **_TIPK)DK2[M?B1=6HG*6:Q2G-HB5QE:K+Z)BUBPU3 6G4["Y0Y0G&!X
MB4KL9:$#(#R?%O"O3W_7EQBOO<:2/4!JIN>TQ:53;>AR8X(;!A(WQ+*NTDLB
M4E;@9-5,E&:$QKZ$W*,[U0HWH_=&WJ>\](OA<W;O[?(L+A.RBK;BY(@:QTKB
M5D7T:1S%T[K/PU%<#V^]8KXYNAFOL!QW3K_4>T*R?!/MA(MXN7Z.7I-H'05^
M4J!8MTEC>LGD3<W!_FBNY7% .\ (!F8=D 733#;OU@[.30>\AGF7*'!M4]?/
MBXKN>[SH<*VA<XNR@!=G13WUMN1J&Y>7B!X6@V-IB_JX J*H<2F<U-NUKM@A
M;HXJ4U3-V =8L(#/OWM]S7%'<%MM3'WNA/""3R&(Y ;C4J=>SF_'BE'T>4\_
M@]XNRA[^#H;5HS2<OV[T3N?/+7NO'M*"="RFT[FS\WL710T?S]^U7_@:;^FQ
MMLY9X"[&*_K/9;9*WPU0I8UF+J\*5C2YKN=HH?S,39UB^"MF!4M";N/=G&!,
MUY=.7T>+6L=BOQ6A9$S;!N^%-@7.WFCS?*YZOU&S>)C@)N-Y.,^'[4L:UZ^Y
MRH\N+S?A /F>1/_8TP?^E^@M%7YRL%!"A"/+'VQ<=MV[S@0-Z@;SI$A2+2)R
M' JJK9_S(#:,4'[TLTKB5M="@B=TGZ>7A55"')J]WT)E7K=C-?SF>Q+2[P3V
M9U!% PCJQFB/D^-X3(1<GEO,XJ:72R[*/04LCA3]!%4^&F?WA+XNY;*FM;D6
MQ'.L(.&I!%P7"&/)(D<K8^K:.1?VTJP <4DIO=I23-G8VJ$\@D"WCYLT(<W@
M(=WO+D_&/3.RI-GA>><')N@2;2O7&Z5A3>AF<W ];9E\^^][*@R0+#XH,%)8
MX_74+-X3",T&> 4N4>'PU'&G;SD3\7:1A*MW.I]#B5E*IQ=VDW&/=G8>-:>6
MI65!6A  IX\',[>>A>='ZN2EG&WV_F@:N]QP?R';=+<!8_]5>I5*;<A4(;J]
MN<.H\2<PG-2]GY4?G!M+G[=^'%_N\R@A>2.S6]-DAD?T2'V!(UU<OPO9JY_P
M-#; @$WC*/0YR#>=>0[V319G+)\XZ39O54-'(3P+S915L&K!5^W0W+56(NY7
M7D(8%UG^\2\1??&S8',P(W2>1,#U^Q/^?<\5DE5:!CT_^E&()4\ANDEO:L8\
MSCPJ"$^=8;Y.</V^)I%619UJS-F(SHTZ,-42U:<(SR>1FHT?'53>DUSHF@ZN
MXP>W.WIR8;,N,RIP[=+<CY?K^Y2*_!#YR#Y&A_NN#QWGMF06I'$<%&<F&H&A
MM,;WG*SW\7VTUMY&';HY9NS2CR&MYWE#2 %&&10,#&%ZIK9.+;<\,IAIQ\N7
M.'KUA=N1%[,SW V=>[J^\ONF&ZF:J)6Z&[H!W,/64^V$,I*P'%3XB'33\H+E
MV3>_"#:BA++XG04/+-?XHVZ!!A-U?=>RG?YU[T.()"'H,(V8D&1VXASO-;<2
MF#+U%O[1..]'>[C^2N2-)/NRS#<O) \W;GDYR6"*:(LHFL_TK_F:.5+I;W17
M-FHRVZ _EP C?@3)#9U_Q%"**W<8?7'Y(54/9VO\4#^2<U$KF:C'=<-P"05D
M]AD6K_7SJ!WU^%0:<W\6\R, &E\1P5N\6Z.7,1AO>/=/JK;2(_LKC[GFFC7$
MW^C#KQ%NU/"XCD7>]8XLBSA!&L)RK02YF TZQWNY#O1'EV$KSGBEA?-G5!ME
M=$\EN+N"; V86^U]7"N?O,2G>1-56\S'6*L@JQO+2K0T=XU4RBI!X-ELW3_:
MAK/X"K48+/B/A[3X&RDP9I(2"4^.?>U(R?6WDSF$.OOF$:CLHQU=VPU%0A1'
M#J&7K\%DHV_I^C[+TC5!, (_OB5ZJ(IZ&]?>.6-606DMJB=IG-IWAA<&J,50
MUB$Q'I?CO1RSU2PA7#_5+!OD+C&;0DZEX5IBZY X6:E(+]OIS^(0>DYM1#)D
MKP78J+VET[C$B,XE[%!1U-30M3X$XA"S#K-J,$S511O# WG'7PQP !TZ.DW2
MZVLQ9YJ24BH3,[E7]/+@5H$KN%SB6&^PGWILQ_NG-::SC$]K$^9.)#&'W"BM
M639O;(/VYL[E4V.5#4,3YQ,.P<<3%00=YG1R]#2!]9>)_3<?0;R'&+&O:1J^
M1W&LY^@T&G,Q&2M6-Y/-%ZK^E1>'E(96)-A@.EXNQ!_Y%WKPD@+3:%EH&1,A
M6LW.$\[#=5Q4 \=+,4 9H/N.]7&:6L2Q0<NZF'<0:?CW?8)FM%^C8B/CNU?I
M:D,ZXX*-1MGU8>-)1@B,$*@V1BB4>;3D] G=7<M\6NFDNP/%N66"[/Q(>!T$
MTDX%&$EOK#C:S;E5G-Z:$7AV(2451,$W/S8EGA@;N[;IE5X@85P OP\">FI-
M>2WM79\3&7RI/P>H G&YG.<)=RA#/9RJ\_-GB)>#.B@M[H_CW9R?/WWN>YOR
M<JR/Z]/(B[*1D&1^?%(=-T.7,S";L8N]C#'O:RZKTW']+34USW.$$@+TU5\W
M4;"IESSG(0HFK]XPBJYOYW%JM2%"K[5"9HU!Y@F:P2TO/:')-;U='Q4E"C)!
MN8+.CDKE$+32R29U$@'7SU85VV+Y4O@0"7N7W'P$J&I3S<0 \Z%]T?J3<PIS
MW<7_@6$\7/T4QJV&/MN;DDO+I)PK?Z8;D1SF5JX-+:B!:<TI^(MKJX P?=TE
MNWV1WT,XV\\M2"7FYC-T';<'F[;W<+G;%4]!7D0%1O>"W;&M[N%)'5W+-GKG
M&LOE4!5$$8.JSQDYF8ISMGE*\WU;(%>SE>N3I<! )V$WO)=C?6:8<696[<VM
M7<N!&@6G,(5A&1N?1\&#2>L=G%VY Z/UJ4T+.-II+O?E<@UZV6V<OK<:J]K:
MN]SDB]?7C+S2N:'D!%%ILM@3"-H,I$]3 ^_DSJY%73W404O=L[8.+K^8J:YY
M0^TXWMIY5 %7B6X^?%$F\I'0%>=/L[C>>($'?5#!220<H@AQ,??PY>>7553$
MC4H=]=]=/]_I=D>?$0"#$-KX Z&7E\$#V]+<::F\C&RC_7;)C09,_&YH)MI6
M9V!L%_+ 3>)C3BIKT]?DKJ?F7+Y/X%W)2*CWF*B_S]!:\:?3K!5_<OJZ<#.5
MIGXML\,&S#OUF$5O=&-0P2QH!9OK3<DYU-NO)([_FJ3OR3/Q\Q0,L*#(-S!:
M6QO/-A^C5;_OT,VQI55 *_O9*WA$=CH[:[V-:U6A=RHT_@?XZ &*[FB2HXUQ
MYK!TO>JGPW_PRNG,>UIB&!C7;NR!YO(@71Z: 'CXWIC,,=UZ.I=0)7;9&U&^
ME/G);>]QKEN]#<AI=.+.-48!X<X$69TC\5C;N5K#6OU!QWO-Y;)1Q-DOITF_
M7]S;5JB8&@6D#>:^T<)U!((6[D,YV2*R<Y7R5!B((8#HJKP]9G 4PBZ%Q<6_
M_?'+7^&\&/23VN]GI.\WTNZ;^;=#C0 =AG"_\7D0-MJ;6W$RFPV=RRX95(8I
MR#'/>:<.+F_,)@0$L[16G:Q'R_D>ZSL'X6Q +"(H" 3*.DC\N!3^I*"KCXZO
M975&LX3<TBV3ON69[Z8J-)HQO</",,Y-<SQ"_HG0VQ +319^L3>48]"W=0K&
M*[ EE70%/$_PJ 8^GD+ZK5X@Z%.;N-P08@93G(U"A^8G(TI/O97C:7_SL]](
M 2[4\BTV G@9&SN7H#H GNHEJ@X=74?;TR9^OBF+22:AC)5'.W9K9<JNG9W?
MA[^D\3XI_.QP&\6URL_&1DZ5,L3_42XGS$1/X_3U4*E%0%=<*J#:O(CAU!Q^
MN^LT8! CH(EQP3Z\/#R!L )0<5I3T$D=SU7".0K"T@H+BS]B#I4P+XTJ%XT]
M.<<?2>27P>E SX4B_'^CHA)$HY@PV[KV=1T^H FC[P?H."OPQAL_@W<77$VX
M4SN40#G2Q;U"U[."@$'IZTG-];4I\],%RCJOM62XLMC#A\ MO [3/U',IY</
M CYW3(8?>3#GMK4*&OT3*2)6!JQS^F'7[DYS[OA;!+LV>B-Z.W=[RQE\IWU!
MLA;LP2--W:KRHC)KF^?Y2%/WMRZO]ZC#ICP.5W!*_QDJ[$^$89\(C*"NNGN]
MG^O(]B!@&2*$F<HUH;@M4>Y=.SO4EA;[,"K2[#;*MG<5>:WQHW-C%JQ7F2-W
M-'FKM8-K640O!6"D&+W&J/"P3%HVU@G=YV6/ #LJO=;NJ2!$;Z]5RIW?M_2]
M3[-?[N[N6%CA;9J5U907'2P3O>BZ?J)U:7E&.Z>YM?O+ R(:#5<'_.0\)JA9
M>9D#TO^S>TWULH?KX.,2W<U\030:S?.^ZP,W,[4OM^/0[E_'C!4Q$0':37>_
MX9$\VL\1:U"A_EN41-O]MKG1&S_. X)4R=$41KR&RMC:>@[GM$\H:]_ !^GF
M$@%O>S^&"@Y?C$=Y%K.;2SRH4H?]-B/_V - ZVGEVVO=7.\_GJ=Y379IKM>+
M:TU<3[BE6L!0/!,S$9="_??G58;;YP#A8U3,^)K2PY+ 7CJ*4G-"7]??=2(W
MEDL7VDP\9 \I_?A%$1,0L0 *(-_(BZHT"[?YR;I1F*.Z)PHIE+O_RH<B&)>'
M.CYE9YVP.TG7BDSVZB?1/UED--V<:1R%PC% -; <TKR81T2"6TECC@)6V.J&
M&7N,&80U+)*$2B$L[LX4P:"V<?E6F'+"RD"F57I);O< )=%6KG4P,?=I+ZT9
M+[-X\GHF/LP_F:$[NFMKV-K)5-R;!-(M 1\*@!XSJ-<]U%5GH1?T-F1U&Y1Z
M:50'@)B\0,?_ '+.-[9:N,44!MMLY53*!G2G=WB_Z<X2=42,8G5+8\=K+^H-
MW6UW5")C?AB],U#?TGD,*$9U7E&1X#7-#O7W5M-D%H>>GKX.44NFMC,0<FZI
MZ.7'?R-^=DO_THB\-31S[2NFNR&,XCW()Z7TS4IOD9#=FA!J(:I!U8+&[MNP
M0\:B?:YJ=6<+GCW(^ZYCNUYB&7DV<,\879'CCN!2-%^]IZM-NL_IYWN@)Z0@
M))'A>F!W$\!^+0%@IY-PO3]&35R;-D;\+"/!GP@K-"!VOQ(5!+&T@=[,?;S7
M7"2-CJ:8MO;.I;R;#PPAB?1 +VWMYN()*E>U58MM:^\\3L. PM)Q@YW2?Y9W
M<#W0!-4ZQ?\#C.65H(,GN#"%P5<)5.#W9/>[=_2A7;[JM^D^*S8\$,[P;&O:
MN QS\#]:PAS4'UVNZS. F83MZZIIX_QROR+@O(^A1/+'7XE!B:\U<NTL\G/
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MG38G:-H9.%[N[\]EPH0 +8;7&BPVO(I[%[SC'F1F@0;R2#_NECY0^X**XC'
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MM>S(9)Q?=[K"O89TL\Z=2J;^OS^4/%$!Z[?_]7^)O]#_@,?A?_W_4$L#!!0
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MH)X<?>N4'J__4Y!-94>%Y:<[I5GE43J/4=9<F>!U?&5P+,C%'X59U#W]*=<
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MPP01MD82E3F)DT^(.V%.\T$FG']L?T+X1Y[;=$!DKWRX/,_AH\L(\VFUVFK
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M>E*YK/4-/B))D\J A!G3DER)HFC)[CT>8P60($C[L 4!;!>IM05_W3#VM\4
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MN $!ZP[C?IE%J'LYROW(E#QNM'[#86SN9S(1-WMJ\C>VTA"FSZOT%M9BY!5
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M5Z5$CN<(%/O?AI\2$[SZKX-.ZRMHG:#H<"=6_=U<V6N81@(*W3.Q^B0 %O'
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M:N.V']<2A EM1#VTO0TL97'./R1(7\)O;"[##9.N&Y,%-7;3ET:2H#6G]Y,
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M44_;>SK549ZLR[W>2NVEM E!:00;9,0A3,:&\MY?.3ZFC[:_4O-9]H1B_XR
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M@;2M;LI>D99*VUH@//F"NHI@S*2S!;RVVLC[M3T(LN86P-IJ;>S;VJ"6S[=
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M6BG-78<)]L/8=_O$6.K3QP<LJ<]!?J@1S1WVW2)L+2YB&K3?T6H?MX\CEUU
M@TN<Y6\?']WF,R^9S/NQL7"_<WR0'3[OZ#,.)?^"N>CUW"5YA:-UX9*J.(AY
M(>V-_8Y/4ZAH]54#K&YE0?0I<_I"F/B>'Z0D)"FO-N\CN-'=(/601W::K#+-
MGH#.%Y<.#H&"X^)Z$B:[T3/V\7&3?*-!DE\@G_A]>]/D!5\Z6MA*]\D@TBO_
M>T?+S7*!G+C=JDL2AE?V\T%32028;\5)<H"#%]N6IW"2>OI=SIK >6#=!TS!
M.!!JRT%N1)7.VAL5A>^:;:?6IB?-%8@E'@_;2[;LYUB[)+E*[X!MIRKI5^;[
MFJ.'3Y(M!XGUJ+E\VNKT9CD<C*?3931J3Y9/ XS#L])PA[*?15L.EO:WTQ6Q
M-2-(RR%DOJV6H+>.+YHM1[4?T XWA_-JVE)T.2G BD-;>Y-M*0C%UNMYVETY
MZ?JXJ>78"S.CE2%E/#F?U"2%M^^6IK!N8F35]_.6@M"K$,=6M6Q'LF>I0SG+
MPJGCW=Z<J2L#@_5;T"?S:##H]U$KX"AN<D$V#LOK)QC2Z^KY0OI ^1GAI^AH
M<![64728NN34Z7S8FZV:%Z6/PB/CX+N]WF85,WLOQ5N.B'XU\6E!.IM31UB)
M0[1(Q*.UC,X(\>V3%=2,_K9#:4(M9N5CLAWG7G4Q?KA*'T6C1B(/Z&>R;;)R
M#5&5RUJZU;"%.?Y_M!7_<2D;E61L$_0MH&^1[BW'^4\3SD.0N%2.N7Q+_CQM
MR1!;(I.M+M^1SY/9;Y@]R7:@GOJN\*C8&MPPLDUH3*I7[(>U+JY1[\<A>_IH
MH4-L9'N@GO2OV!L;C>9'MC?*Z5J*O;/6;J3?RM'?[C$2#Q;[H]4^,LEE&C,7
M%CND58T_@1TRF/JPV++)(C".(U5/E%CLCU;SP D<J?:/E;F9%HNMT&H7L/ZH
MR.9O+")]M*K[)T#H0Z>0+/9)JQG@!/:I:U:7MNK,IREV;LAMDLM:6>S-%+4T
ME!^&_B"9^++8G<D0,(J+J)HYL]@<:Z,DQG5T^+DWBXV8?/:#OSHJ,GH66S I
M[RI;()$MM !V<LH/HG,+<Y86>S&IW4IJMYXTJ$5T_>2$'_*V929:+;9B\K\;
M$GPX2MS/DX(]Y"4A2@5;[$BO:O5?WQ]L""SX!_V)^4L.PL&^+!UJ9W[]R8W6
M[XNB;N\3YS4*H_4V^_@^^TSF.3@ ;A]4S6F0&U@O4.+XP7Y'_(3,IC[5MQ6Z
M0J\)"N&V>&LJ;?!U"-"@W?/P&_(IOY[@L);Y5]S'6 9D$I,+1V\U"[T+](R"
M:$-FEV^.L#2[3$]SB9WWY">C_N?. "IRU"W--)-2);Z_GM.YEV\9@XY#J.7\
M<'*D37N8K#G.S(E5SX!56TMCMW%7@&DDKH,[L+9^W5^9ZK/UL;@O*(0K.@#6
M._/6?N@3VB0:E0S?ENMK6LB3NF)K*3.:+S++\]+U>NN5P1;>$9:#+'$_2D!U
M(HE096]A=AY*K51L.=(]B0<=0F9L17HP+JM]2RU/!J<L,TB*44/ -C+K3;I>
M.WB;IUG(+%PS%Z"!QD=IL=&3+;DF27<<U(;"85/!RS91<E]P%&LO?"GXDCG8
M"/O('M!>I'B7ES1SH9;C9XKP-&[A/O6!CI96IG*&Q\65OO]RO*"5O%:]@G;X
MG:.%+(L& 9F12(DD1>MC1/XT%/E)?_YH 2XMI1886S!W&B#;__$6?GV\\'*3
M5,E$[&N!6.,,CA?F@XA[$TBK3>)XP69(,B;@5IW&> &W@4=___CQ>!$N24P&
M$);]^M'"VRQ&&4"]XZ2.MHPZ?X'WB-ANX>_G44BM9JD3D&SPGT0[,/!,CA9V
M_B'G+7: LO;2,SE:V)5/^="[H7&"IEU"/51)[.W%FE9_Z2:SCR8.3L;AG!O?
M3C!M\I:[2'O8A18F?JW5<SYG((>T=(1G+<Q]/MV9]L$<^__^2S^%(;(+X#*<
M=D+>]6%YH8/Q[8&\+\7R1/SCVQII2T@?J?LGZ56O&\?R7/XCW!U%[T\?J?VG
M#=+J,;(][__17D'$S=-/%8!)AM;EI.JE-L!T>'IT</52,<#^'1O:"V9[<8#Q
M;5,KKUDO-0*F;1K(R]9+_8 C>0&TR]Q+DG&YJPQ=JGM>QHF_)KO[N,)1NEQ%
M:?(/Y.!O,6!X%CCNC]A=P;?BK L Y\(/7R,/!=,3(BN>$+4YG3MRFL5QNBXX
M:GY"^_!I-W_P^&*81&OZ-0+*\0,XT_= 0;H#E12^; >L]W[\XPHCDM,+ 7]*
MA@*5^5T[("WHY<)_]CW@Z4/3:>6[D^"DPIHM?]D_(BU>A<5/,2LF=X5]0V@-
M<9GV1,L5HS7<90Q:W#W\7VDK;J)XERAYGZ0$ /-=DA6+9%U&WBU*RNTR5>RX
M-+&#I-!B'8O;W)@X!7N0Y2JYX><!J+8Q-M6:D:22!+UD2ZD1&6=-+0<SEW*Q
M1CERJVSJ99IW-QV?,E>N4:KE\I\*,FT/AN7"F@J$C<=K""%J+!?V702W:N([
MP85\=82#*_T\*Q9RK!<[NSC$K;-&PM3:C=U,9M=.L$\D41H)_RWTD_C^X5M3
M7FU!GQ%DU.Y8PD,NE;:6CYA+/MQM]F=;]@""'-Q]?G$T\M?1"?H==^6F(5FW
MMN&/%:"B'% ?Z.1CF\_WOG]#);PW^.U-RX2RUWHMG;?HYK1<$>GGLM58ATM\
M0UF^.P/<[LU;53X^EN.MHE/J/CF60ZM;0.FOU)^M.S!Z5G]S,OG#V\@I BG-
MNK3A->L57?(J"F"5<19%./,\/UO7=;B(\)I^]1@-4?ER&M3-:J,16&;HCIQM
MSP,GEJQ8=MC#W#+2IQB.GX.W#\YN:@*+![^]N27L)T*XQGSQB)TP!N+P&XH#
M2G147]02)Z_OBJ-,YTG^\OTJ"H+H91[>I4^![\X7P'U(7"Y+M6QN;PSJ1_@"
M7)G[\  !I;#;FK-YE!XISD+O%OCE_B^EC8^%ZK[J*-KHYQMP9OQ"[L9P.5MB
ME$V!3S_"]KHV(<9):0/@O^K@PY^^WQ-X&'12_6WX*3&QJ_\ZZ+2^.J_^.EUS
M)U;]?2I5V<LRCK&<[,"%"?L^!^=$!4485(=D2RYF#O-@-AN6CZ!-BMV5$Z,=
MBZU/BDE.:GVUW2'W:$DV.PKO0,-<.RX"G<MU@ABHFG^1-'<R5VR6R,^Y -?D
MM&&W'6>)EEOT0G_BRN!RG8>]NX!U".^NRN\FZQ.34 T"X)V#YYBR<H\&LA:6
M%QX!2?34=E(?7Z+'593&3NA=TH G%!)E)=ZQ"OYYE>UJ; ONL/\,T-T%P$NX
M2VEHW ?0M\ 56@(M[#H&6C]W-G[B!!F'(#5[\3/RKB)\E9)4+(1?."$WO[;Z
M.'ULS^,+0+K-SE_]XI3:)(D!S+[TBC.63C-!-# C?GN#QSIR$?)B8MDN"(&^
M4BAHAWO"F_IIHR8 R27FSR5\@":>+7^[],59G!]D(I,Y\8K\Y,<Q"/HL$M,P
MJK85WJ EB/*N2P1)HOB'WCQ9(7R%#F2)QN;:YE3$Z.Y>^F?$>QGX2_\I0, ]
M""[47K$[C_1:9<VX_6!C,$^>1V'L>\3B3Q_MN CT+&\>ENQ&S99*B3'&L%0I
M+L9KWLN)O\-H[:?K^3/"OT9!NJ[G$0$$2>@XG4F% 64R]L\?+IQM)FC?$<?2
M8W0>1"3IPGR1N23XNVAT*F-3<>AI;*GAU/J:]ERR_57LN B&D^AD7.Q<!UD%
M*KXCRG:@FEQP%9@DG%VVXR7M[R/ 27C?+,=+Z+2KA*RHNL@L!ZZERW!'=6*?
MG:7@,5U^!)(#QYOM !Q2!</)9RD("K[",@=J\,F=)EC\,#A)OU\?L(&B\A29
M!J[)6;AC._)^.DM)K)6W<G>123@.+<5-RM4H79BII/;V@5=@GL0$]U[506AY
M4+,TO4@Y)"T'JZN<+>TMM1Q'18L+1R^T'20EZT&3T]IRL#2>3+%[W?+$;9(G
MLZ8[6PY*FSM2-I#!<N@4.;U0"Q\B/Y\=+$PF!,5R-.7U('Y$RP21=,1,'R5*
M1V&Y:7$QL@T]?2 T(F)29/0<VK.\PFKCB=,6_34!V11D9GG%6#F$.H2\]5'7
M]9CP:QDU9WFIU3:PL:4N6VN=JM\!@\8#VE[&M*M_I!X5V$MAT4/)UV0BCU\^
M?/S[7>"$UJ3ON$ +V'F/%G+SGU(R2[*^4N+=AC=Z"@,8BVKES#%/2(._.@F<
MDKR:7?%[QG34%BTSX-A $"4_$78QF"DX\3$5O^ADX'N"5^R<QB.:O/#M.K>Y
MMFC[6<'2^.^QZDU,/H[;ESL)O3TX>V[3D(A(982QG50)[C)?T!^U<ZUBW+%"
M0G8/(WHAXVVYD3#K;<=!38MOZE=W6:;K<B=:'C<D<U-6$_"R+R3+81+?PV*
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M"C!S7R6$1&V4&O@\4'>A6VLCBG &,)B4>\-$4C%H.B2+A+M#L'EY$EB^%O)
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M*IM!\8FR"_[Z!WP3#(D%X-JFDWH3&0K2:-3B4DPOM=S,.":/E_M0]?X!F["
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MU?I=_7&-],?&>J"B$6!D1?L6:.T(K.R4X4"^(-\:;V\=;/OB?)O[TA!=#7/
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M?]"F:ZY-#WJL3:6+A@' =HC.YH9W@GA"\30F;^Z(8W.8^I'Z8[4(]VI@14"
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M54K_Q.] ['!(/8USPNFA_&_3T5ER+][/K2\M:IHV6['(JD*'WBT/V8%X-6_
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MU/DW BA'1GHXNKW;/$MGTRKQPT)B_,*]CO,O3J>)5+12 Q2AYL/;2M2ZJ"7
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M#D?O8UBU.+#EQ<[.%_@E,3B\Q) $\IW1,+('Q5@:A*?C+*(/Z;ZO^;JT#Y'
MB(FF_L7VG.$V(EH[0\"(BU)P[PFYRD-$=45LM^P6<3E2COG!.^<.<8/!$SX5
M8D>.55Y@>IBB][DF@8\WSK-4ET++9!H:@*"((UP[84VE>SKBQJV ,0/V4MD/
MPA2[?,@WLQ_!K 5&^V$"K.1PE:JX#(6"%K[OG#E;B8$09A#H!">=XA)(SP3A
M<R6+6[[@ S<$#84&H'(*%C9B=OR9MVN9@QI!?(U,7N;%S_ ::[19Y&N<FB9W
MQ + !2[Y.23#C-C+*$X6IY6T>>'S(J%C [6K1^(<3@GE_*)&6;]J',R&)@U
M:%@GYZ\NCOUQX$3-H[Q^'$6 WYTEL<UQH(CP@OB-U%B=8-1PC[D%29<6OE7G
MVV] MI %N(;8<D)'^,^$.K!CZ\*%C-C"KD#P7)D$)W.PD9R1LLT^/;Y8P^C.
M/'41;)%-[0Q, UCF3]^/T791&KH9=;,Q#B9<OTVXPSZ;<*?!E/F\?1A/)T3&
MVG74$D>:,DG.VC^SOKEWZCI*.?+CQR31:LE(UWOW 6E8 N(T,#C>%.M)2E*A
M=V3^6?[ W^.Z(6@E7AUPX)I@8A=W;00K'+BXL(WQ;!Y3G#X_#]INBQ5Z]WS>
M4@YQD[X+FF>]%C3IG>C$L..X8B=H [.,O<[PFEJ3QWRP%-K.9)MC5I*006 [
M@\Y.M=7\OJG-I$5S+E;@+M8Q'FR&-CJ4D"%272T0[7AF,!20(15R]9(30:/@
M_NGL/DKG.CM$B3>C42%O]*PXYZCY'-T@$ I=ZX,GB!*ZITHMK,1,=RMM][H7
M^U3ZWS6!421M6%39)4YQ;&C2V:Z%G@]C,2W^ZWDXV.N7'4,S(+#(8S(-";QP
MJY'7N>B8EO/U'O'=[I#T].U(9^7D]J4!3,FC[)TK;)*'_<?A"_"668$CI<<9
MT4S$MO)87U.X)N?22!$&$K5<AIJ^P ET:&'!HW)/^E/8;O1D;CZGI/=CH?5'
M_%G@4MU=+:G71M>S\&X!DZ+#V>G2"H4UO\[GEN\.G:1#LGY(UG]&LGYO2-8/
MR?I>&7]#LO[SC4$;!PSO,JVL\\3AO@1K32,]15 8:BW2P&PCK-"@5#5!C2>I
MQE@B4PO-]I#$LH7P7J*9K)K+Y0)?A8[5N-'<6%@O7=D%.Z&V_KG#$QW\KG[[
M7<][[7?Y!\*TI^CVP$RK"CA):5Q<2],V_$V[TJS["=8EBM"RC:1U?%'F&/R6
M8CFJKV*:6>E3QV']>N@U;*<PEH$ML#!'&3R /%MP45:5)NH6L:H8!:\FY7#L
M>G[L?MR88R=ED7!NIG  R?M7<\2D8Y7HDC(!C<2#GU]X?&DD^-FGJ-Z21*=2
M/70#.RRBCO'=2NK(E5\YKUD&C,4S+J3)39PI!(H=@:1QI'T;YDMG*K>E#OZ+
MR3]FE]D+'W]>.-,56GH>,\Z; 0 KZCS'6/YEAN9E>5875(7FZRW4DNNI;!62
M :CCD,@NX3"+YT1C6M0!#^4;M]_@HCS@YF!_>^ZWUUWCQ,6D\%'2>M&H+27E
M_.L7[:!!=O9<=K[8!-F)T@9%"^9Q)W W N;2>)9+NM^UD<*)J5S5"R7#@*OP
M&^5\C')HD)!89A+"_ACBD:[T]#IC9/GB>E]#(]77>=Q__2D4\S0KR>JD:*77
M7/B%J!\*4#..AEK1D1WYSPI1*X1Y2&N%K^0?2F_CHH62<1B+%3R1(4C1^1CK
M\R12/\ZPJQG*>L=C@[_G_F588P:R2PH@,2Y?^STC: IOT^:(5!"U0#B E@N;
M!1^U7HC2:32:0[LWCQD;%*?4*9F6"KQ3TQ<.=SZA>'CCCZLBIF@^;&<5YP^A
MSZF]5?@65*/AG-'B+102?+]LC. 6CM!WN.<K"(8L-0+J.!<[=^-TGYBM?ZS=
M+54Z(_P?!;O-3V$MLT ?458AM"P7B!S$C !Y*]<JD@II^)(4$O><EOLJ52<\
MPB?6DIK YXT1])ACH?2XBA-2\BB[:(]A=@C75"[X2+TM\2D5)KIQ?RP8;0.G
MI )CAQ%6**^R234WO$F88,+Z[FQ:8I@#G@"J(B/")55B>DS2%Z:PNE3;+IUQ
MZEEVL.+*=JQ<D&6"@XD%3XF5Q 1TD7Z.^:*DLG)L#ANSM.17P+-<\36=PB\>
MOWTV_FJP3GING>SM]MD\.6OG5>MJJ^ETB !CG%B^O#/F*<#I.(7#7URC94)@
MU&N3Q6,7:HE2F@G,.J WIA18BO=)8-K" G"L)BN@;M(QNA%T::!NI&'M< 1[
M?@1[3L.%:F.6P@WM=#]U*B:2@I),&+9!O"!^$1Q*Q=[!$=B6K?#)%A&!"#Q,
M"U$"'NX,K.IMJ@OT_72,!#!ZW/Y\ZDPX-<8&[7+8O/P_PAX*&<]PFOI^FGI-
MP?3;-:@B-'9-$4W(2"6OK?,*5(R-]\?$KP$&)!\T8_2EFIP>:2KG8%M(G81Q
MP16-X-&XCB59=^\88D0()9&\!-Q[?#!X9@G[7XS^]\ZG*%$3NW1\&8VVX!BA
MK-SU?MOVD"<H[R+N('E=S%D*[XU<3N"%3YWB9HNVUCP;710;,:U)%E.6X-U9
M']*XN@^GEFLB8HU"/RGCWN&^7*U%/7R_>%J;\!V+ZR:#GA3OJK'FON0BAQG.
M]:@FWVN#EQE@0M\9)K0_P(3^O1LRK+G=\=>?FDWK&TT(,+QU,7I_,;HT?=FI
M+SJUK'^Y&IOEMP02JV.P"-?0(GR^L[O_;/_YTQ>'NX>[NP=/?]P QN-?CG\=
MP9X]?AV<7@4GQQ>C-Q_>OOW]Z'Z?9=BT/=ZTO?9H3H,/9Z]'%Y=7)&#?O@W.
MW\#FO0RN1A?O+DGJ_N?9^6\D=$$>'[\+?C[]%27VA_?!Z;OWYQ=PWU5P<?KS
M+U>7(+#/3MY^>(U_?O7A*C@[OPK>GKX[O1J]#J[.0[F*WP</'($\'P6O3R]/
M+N"BL^.KT_,S>$(P>O?^[?GO[TCHGUSA>)@C\AB& []]/7H=!E>G5V]'1%L)
M?\9'G<"HWIHWN-N>^K<=T96C__H .N;]\>_>90<AC^?=Z.+TY/CL$ON*_X)#
M.WYU^O;TZG3D/1.9(7%9Z%DTU!&>^:O3BQ&-&=;@_-THN!R=?+@XO?+>\KP^
MF$$H;+10Z#ESSZ_G;S^<71U?G+[]/3@Y/R,3[.H\&/TZNO@=C#4XX7!23Z^&
M7;S9N[C7G#MBC[T:C<Z"X]>_GEZ2'J+M_.'M%<OX8_C3U=7YQ=GH=[CPS?D%
M"/7_!M%]15N<W0YYSNOS,Q#KY\'Y!<CQ-Z ?C85'%A]>CQ?CTT]!P9$Z"\V]
M)[^<PQ$BC0@C>'U.SWD3O/L]./_M# _;*5X^G*;-/DT]IS^@G?P+.#=@"J*'
M?A7L[P6OCW^_#-Y<G+\C@^CU\=5(-O;%Z&1T^OZ*#;2V=V].(IX5.&@A._AG
MH&U^.3[[&0RN=\>OX;B!-07__>'D%W[T;Z=@H>(INAB!Q7IQ12^] ),.K*_7
M,)PG,)S@/5AQYX.!M>&'J=\E_K[7);X5':]+L+#.^%"QCB$W@S42N$=W'*:+
MT:_G_SDR.HN>V7GIY2_'<H9>C<A3&;UY,SJY.H67GU\$HS/0@2>CXU?@7H$!
M"#X5G[!?ST_80>/#!8.]A&&]QV,W'+3-/F@]K^GB8W7Z\QE:?UT' N,;8+V!
MHX,'QW=\\&>R$BDX !;D"2DWTE+G'\ IPH=<'9^>L6')-F;P;L0W@8IZ#P<+
M_P*.$CYL."@;?5!Z7H7ELBNTW]]?G,-V!I%_N5+KO -CBQ6)B\S]=@R:!/Z7
MS;C7J%/>G;\^?7,*_Q[]]\D(+,)7>+*"T[/+JXL/$C(+?KLX)9=+#BI?<OSA
MZI?SB]/_#;^PB:!CUE02]3M_]QY/(QY4N.7=:-USY6M^>/[Z$UK9+UL=K-O_
M">@_]U_754SQ#:<3N/\,:=K/7,.__"7X.O]YI_*/P2LUN4YTI-;C<PQ@EGZ
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MV<Q!--;$SIZE-SHOC5G5,:A6*T%BO6,+C=U0HH[GZ5K+PO=%G=/9[32&S3>
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M>WJXM_OLX,7SWO?8,7F/@YT]3,^V!+U-@$0ZH1:+N,-S#7.;^*P';7:255K
MW^K/=Y[^[>A[JX4UW]C&[I\<X?>Q@H:_2ZXGFKI:8BXNF[ H,XEP0;)) AR^
M['\<',)(=W>#+4;L*_']-@&R?^'F_Y[GU1MG+L$2"Z\#*!XJK(V%TU2$@64'
MB+$C]M;![G80J67A3EQ0]^\1G.]M!OCL&*Y8Y/$<G;Q<H\[#C"]8>?+H@\,
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M;3!#N<:-"X'M@:T_J(6#6WO$^P902P,$%     @ +SQJ5.>*$?B*!P  >C<
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M5RZ4HMDP_G)N-@R_N?L?4$L#!!0    ( "\\:E3&_U,Z=@<  %\W   /
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M@ZD*$.,=,>^T4T4 1%M\-UNF)<E;KJ:Q\0OU-+2LX<!S?6KT))BUNYMX.G&
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MZHLNNM@4H%K.*6;G0.:>[$3JI5RY4(IFI_'K<;/3\,6Z_P-02P,$%     @
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MYWEZ(;^>_9W\^QW(VCOJI#'\#.7HZ=BI>:$QH4Q YG\PLLV"&'S4QT +3CF
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MIBJ;RFKD=3LLR26"LI$\GTQ?Z2 U^L*#<?#F5F-M/^3U%FFJHX$,# "=B7V
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MB 0D<C.Y?*@$@H)+6KZ?PH!PP""S$&QK P/.[AQ@ #@!8@V=&(<!VS?S4!C
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MC.L_>O@?O8F,WT0S;C[Q\IH0KW8NC NTKU,^7 (\_^O@@SRF/S_(^(F-N_'
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M&'/G$O?'VR5<ZD99_"V]2Q0Y)UV_L:OV^0H@,A]F6C@/?UEKYU,ZON"VWY?
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MPW<J&XS2&',P"O/&6K"ZM2X^@"FP3_5INTG+20]R%H;MQN>MS((_RIV2&JZ
M+]:M!6U%R-*Y$OD5I&]A."?-NG6KL!U)Y"2(4#E^E;Z%!,4 %NKA'P4)DU7I
M[93HA;4N5T\GB^B=PVO<D=B:R@5/!+?IY5E8FD'R9F 'Y]Y7NGE.:T<ET#HS
MZ> ,:M!^*]^;B<P'54*1E:;T?-K:AMVJ4_!Q7 D<-4H,VN$O<O/8P>KEX4 D
M#7W)00OGAK!C=IS[6XM;^A98"R+ $1K!U0-;]C?7Y!L,:^#BQH5[X&Q&EMZ<
M1R ,W:\8MTX%DK8.NE4P/D;8A$\^11"Q=X>&-CY_IMJ/@2@TZO\"W>&OED/>
M4:]\>S.U/YXZV9ZX)\6GZ?4WS,6<26DPH\A-3=1#:;T'-EA$C.FTE!A*Q+)T
M/=TI$.Z]')-'RIB.?@V E81 ;J>^!37^>R$!3F0%"N-J&WZW\T,D9Y!6 <[P
M-S?N*INYB&RT7I.JXLYX("C=%!RNUT$4+J?0 _'HQ2Y:UQZ8HF&9[.I6>"IV
M!7CW-%I[0<_6'4Z,Z4-0?<URO*O4\J9IN/?[O$?6,;W>23FF1R[X-%P.X%;'
MC4!%P42]AXE#[74+%9UBTL]\I3:AD/B/!#SS@%1.$)X,KP54J9" OFKEI%9,
M:\)V;*6*O*RJU9\U-E;L]?,=.='=#55#_D$^"[F(.%Z+B"!J;(#T!2 WK2P0
MDQ;K!?D7J 5HBQ9AE/L1/^=G.F'F5GB506)00/D;5)8*_&RHZH>W\A$OG^3Y
M1S#6L>VW,YT;D&9;1M%U+[8BN)NO3O#7K[/AB.EJL;\>-"/LLTHKZ@>7DK5F
MSE4?9L<4&(JTK7P\IHK6 ^>3"@@T#WU,WYPJ=/Z"/K!_!(A[13=09T:[Z2CJ
ME-0K@!3:T5^#M<(Q++.Z*(@0U0YB#](4-*X[LETFI4C6^>=,CT\HYC80,1FX
M?2>#IIT K3J859>_NK)-[B[%+9@4=J:V;</FK-?0C@ )&A/4Q5Y8_4ZFX+Z5
MH-?P^4,GD#I'I#K,34%U5&),:7^=[EU_Z9#'(-BD_1OJQ$Z#AB@J:?;-"+,?
M4[]W.QHR9HS,H@':3NG!%> ,%XU+E'\\.QU NT:KC.C?O7E.1IA)HI^!^/EY
MDOI::0%)I((OX::7DQ1R[*+:,<6X>L'I78#GT4[MRB1O0^.,>@I9PJPET<C.
M?9^G<A/R+_F5D^!1G/15_$H4YQ09S -<0AYM]T"4,AUQXHJ:^/,PJH L7-7O
MM35T21^:'J:/J\%Y^%I;#+L89RZX)2 H'S04ZK\"A BK!8IZM79<)KNV ;?1
MS-YPSAI%V LZ*'Q5(VOXT"Y<[7CL>+B]-IQG76A/'#W1J0GV:$1M&1;OFP%F
M_'BLQ<;GH3%\RM%([XZTZ>P61@EUG7/1#9^PFOH%U;^Q*[UY4%UM48DC]K)1
M3PO$? L7#(0WG.VBG2I+Z['*F0^CHU(EG!2IPLPY!PRP$(BUY!+,RM13Q1N!
M=C (U=30&Z#KR.5!_8+\;_P[Z6C3V4ZUM1?G48O=4ASD+-!9[GE!R."E(^$0
M@7#F>'"^H'.+_KQ)G$[URX@&Q[)'NQ?2&Y']MQDRS+ Y2IA.B8UQ>B$W]^%R
M4?*MYTC/X9 'GLT58*+C,A&5'59F?YXH<7D):1)ZE,<YEFA<XKG_)4W=F6W,
MQHN;4MV0;>!'2AG9S^J20\0S%Y[*J"V5WXM<_E'H\L]@5^9?[L C[-(?SXEU
ML+[HC\+LUXF_6#\)6=I'TO8OE@?*-5XSX'+BZ;B..ZD;62LM0D7<6C'O6CU(
MC5M]CX"-^/DX['O^:V,6LRCF&BZ^B*BDU.I ,J;WLM#N]-R3/,6RNDIO.>M(
MYM)FO\U'WBU$D0P849$Z#%AK*3:UP^GS,@RQP_>_GV[UNY3!4SH;-]\V5,8=
M'1I-VYU")WH7PDE5/]7DK-?=%0ZW41JQ=S\2"Y@+UH^,--%%N3%IS#7> "[1
MCGT3N9F)*ISWFB$0='=ZVERB/\6B:)]=VN,TBD&.B*G&N 8G@"/4)[&&<@HA
M]5'-=Z#.U(F@<INBTQ0;O2_^]V-6M12?]71%;(R:EES8<2</)V>VY.BJL4YU
M<I<_LQ>,&(N\X>)GBKW-W#0CLD@TX(DYN&U5*.AA$J97F>*EHO)]6"\#7A5*
MZZ[X;)'L,XTI*#E.?1\'>];).L;3N_8*X'/8E-T$-0-).ED/[W;A!;_]IA8O
M[>08,]$@[HQD1\L7[D)9^K<RGNW_KV4\_ZT/D"B7Z5-,("#/$HCWR6<NFI;L
M#A>XC:D,J;*SH3+XPK(V<F_K*?2IG!;G:V6F)!W[/V^;A/@#8Y:%B@[R,C[+
M'8'K3[2J=-#(Z>DK:Q0EK#&_OW[E;']?;:=@/?!I.V,H;+.3;0_HAUZ#^IFP
MGL/MY=0Y^0N.*4X4K! BB/:PO^>DC\D4P2R>02(8>$^>9;$;5_GM$/$ZZ$2<
M:OP^FL0',=RC%]=/R1NO '\UI*.H7D1? 2 C]0DP/W=-]<VT44@);VI;Z(V?
M#:GH!F$UO[,G<IT\A6#L0Z.=@KWTU,L'J=]3E^1+WAFC.AMA+&"7$Z-,?D[O
MJOV(E#P4Y?8O0E%-M*!R(5.49W\P8/'?,C#W=P9^-+@FJ$98?QIE34[R4H=R
MO=I/U?!*J)45PLN/R&=@).!)2-)X)DNIQ7CK1Y78>[#=-9[S,B&9/X/FC_Y>
M21;CKPN=7)M?\NLI,;A_5G(UT&]RQVIPI% F#.8'MP$G-4O_#W;PNWU9#_]F
M?KV 7VM3/W&-^^VKRQ\&JT.?Y1$*?LFP++9J.3@;J">>"YJ^ G#R+5I*<!:;
MEBD>T'Y9K"H*'";,\C$50-1<"P/=Y7?VZ;6,>@R:;A6R[M;0""H/\3Y"6S*U
MT76##BA(6&.\ROOS,'84O3](0S]M)?/!-%L]]:Y_9#<MI:%]P@,QD%6BE1;M
M+!J,*,W<.W/A+4T#O">=T54="-XC$6DE?E1E=T\S?NN[^"HV:WE<!@<(V3#K
MB7HY6-F1SAM-<%254K]C?VHE_WG]!H6'J6H5-&5:+.;M5!<I#GC4/$#"WT%@
M0NCQ^9,)U8'V-;ITP_=W7Y9YQ>Y3")0X8HSZA(I%K>EO0^U,G6VSN*0>/&)3
M+^?KDV8Z >[D1&D/Q"]6\&T%@IL_/V&A\F&+ICGS=E9IJ7!I]_ ,R>[*1V-V
MXL+'*9*<@XO%-]0)9?&SN1=R[[L+[V5@H1WSC)?2SI>9#HE;6B;1G_2%B5<4
ML+V:[C!E3]!L)_2+IL1];F(D:57'9Z.9:D,\-!M(?#S0>[HBLD0M37[ZNMO!
ML8U&T*EN/I3I:]F*=ZC-1,N3S)8@A6L?(S(J"+Z]P%\6)@BG.3B^>>9CF/%L
MF)6"UQWPPI@7_Q!ADT9\F#1B;8<M'2/5#_7A?9M+>_-8'!7MFA6,!B;"O8H$
M3M8M0O!\@L?O$)Q7@(>1@>GVN0C6V'%6(ZY%4BZS(C8:FF\BR^GO#$HCA2QY
MR.T6<1Y?@%9VO[%1R2U'4VESRXU[16&K=F\,^H$9O5 XGWN^!-"MTH!]] +X
M 0BKC=(CR71!C%Q94^&Z-V%W&;Z;<PV\3F(7IX",'^2YC>Q-&@2@NHJ)E.\N
MP^)PNC%H-A#Y@*>_0ME"TL%/E8GZ@TG3@GS>Y0HC7 CNRB1C-ZS<0H="^MKB
MX0'=03IBEF4/NCW%='O6W61$N ZC_(KN\!-@2[?)$HW5L1=MWUIL/U[CC/"Q
MYG/JEX!.2N?>/4]-C2>&<OWVM?' $'>QR@C';AR,Q<7A\+ 6L2;)"+?9Y[?H
MIH[\M2=I2!!1)]<?P<PWGF4@WGU_X!2LX$^+]\*)U,"7---YHFTG4T5_*NA"
MZ;VU*Y"E(#V*\\,;"F%68._1.J[$>@VGNT19\X;;-RD,<VO5A4A<K-W\9^;S
M9.TSHP+^(4$R03I,ZC=) &=8W=#EO!!@,_B#<(3'M W>A' G&)NI:3R(GU7E
M #UX3/&4P>GBM$(0IK\I/%'$N,:T\'9&#$(K=&U6)T%. ZI'@M<M,#+\1=_Z
M*4O)?DA=M#?Y!PSX,P<=(AKC2ZF\3Q *S&:KZSC/?65+#MA WOAL^Y^:0CA;
M^S7JT_F&![1A\)5Z,+UYMZ=+PZ*3R)I">57>RK/X'<>]KJ2#M3<]Z@.9-JRQ
M 2S!($_B1K]K.F2*T1K2'"3><LXCA4*"CAX!!O*<JSILIB\S].N6L &C$DBL
MW"XA\G/F7>^9'2*WDJ$8.9F5[X\4,0T.NAU[V-Y\.Q#T'="R&(LO>:VP7V5)
M@YN"WS:[WV6'O4NI 8GZ: #2L\L]@DH^4K9,.9WTW!WH3U>H4222Q@EQ VH!
M4.L/DXS#$D4 IEF.PY$R+C>.Z[9/</1UU]=($QH=?-QA^2LT/0]7LB%*9MIG
M&<@Z 1$5W_O3%@"#B*2H31C'X/F]]_K<EV%.[B3UEJ]@[B6GS-V)U\("9LO]
M)ZV._<')2:_F&I TK7(DN)#X3^-1FV7C<@\Q][Q6MR0'6-KV\/;,0)BJ8EH5
M ]NHGI46C[U;8$#)K77G)E.LT#+>_K+#0>U3%^7,:+-]7N[1NYLKF<JVIO/*
MVM'U7WG,^0$T2,)(OI1W.>M6RI5I*NN9M*]NNX\)V;6HI=!#5;(>,H366%84
M*GF-KN?:L.VSWHP4_@(' QA"H33/VKILQ"5!7IEP449$4D'G%^[%4W=79IF>
M^MOA#?.&>2$4JPKQ>XN\;9WQ #)\MJ+M;;4/A29E_4:.2DU:0Q?W<N6=F!ZF
MT(DP.[7!&W!3U0]Q:L-DAK>$MB1>;-&/*_1,A]020^T*_5V[O![Y3WOA<]D-
ME@B&7><H4-4-/@0=%>KTE^:IT#6*B8$;Y6K5W"20$EVVLLJ+7GKBG*T:,V.G
MVS"6+;1KBEOSUX&F^?., _Q:PN;?*&/3,W52,*!:4^M_)*)E''\KJ.W],E3O
MTSXOE;0X ,:1"PE]'KDC37"*!%GH?J<"\?D17B=>Y,%^+U]H_V3$#J?O4&Z0
ML&M%L-$$B[CZK1R/:J(N2BA.G#CKBV-K[(V G&H\"I[N:E,#YEA4_*T%AC<'
MZ3DD]G1K)38XC<@$VYSOZ;Z:+E9'><6&"\!E@"\XVR9ANMC^\]3$6I5=YJ"P
M&]+Q7J)+7]MYT$6.,'D2FY/H(+4D1O^FT'4OQJZ%^KB"SYMQ!B+A))37D>+%
M;-,%ZRDWPA[7)VR</U8OTP_0QI\KCZ RE^4.CLQ\-P/DD+WK,YCFM4OXH-17
M(VM>WZ_T7$.J2-+,,*THFP:$@[T SA>#4%KKC'>LD:MPS'!9J'$H&/+C"/A*
M88<T"<5"FKI8[.Y[U4ON\7&(0A7:J.XAEI(8JRL!QA12"*PRO8&7M*99M@A=
MY6KD"X4H%FV5#*3OXIPT*!HWTK'7V/$ASKHDE[>HBFG70 )[Z2HP3I'K-;Y6
M\H=P'(=TZ\7#@SPZG<#GAQU32HQW%>Q-2@+OZ=W\P!N1"D.NXHV+'>?IG%W+
M2F<=Z!S <B9RD&S%(@C6-0V%FVHD<_"4&QEFE,A++-XA_,I+C_F]X2D8(G*X
M)2\E<K"K7="/-!Y723W*3F7@^_24^BVU7/@[[WBBS^]N8@TY#J>D<-6%6\=R
M9MXOUW$"$5=M'$_;\FF3?S2*NX4=J3!+(:H9DX+GW_-0&33L>I\E7-F>S^IM
M.)B($!-('X0C5H'3;=WKP3$^H%%66SHDQ$Y<HTSP@.Z>QL>ENCT*0B9=7_R+
M',S6B'RCJ8T;3]S2LIOL0.I<"\C*?3=."DSDWNO"5@=\;/?\]:9><<$Z9@&\
M0^7STNB@KX8T/=VJRA0Y-!7PVQ7_5D4"RT2&5^R)+P/A7\/H0R$A&_);O+ >
MCRO =K&!?2ADX6@ !4]=,<@'>*Z,&U\!4G:O #,F8:4-5P")!33Z;H$R4F)L
M6,Q/^A+MSEX!RCG>C7*)OWT[5:P[8K*L'E[98'!&'M9>TQT(.( +3@GK!JLX
M/-!C?:3$"^]V/$W-?JX!LUS;$'?B6MMK XEE($%8H:CEFN% P"%^OLN$?W2F
M5?PBAW(LO3]?,-,4QZUL:Y^A!.]S/5H9E?!JYU+2%RK03$J,-77K!#-IWY[D
M;[F=Z5G]]6W]Y:G9_!S>Z4MRM_F6,:^+= L<"BU_>(2;(V/W[%I;\ET<*>,<
M<WH=QVM%$FVY(YOL-'*]M^=\'_E!X@K9/[V6D-D\DE1.JR3J;.CT5Z]V:"7Q
M+N*H6DMP><XD]MK,(/RIX;=(/-#9Y4(+M!9-?/C(C7KK>8=HU N?Z_RD#RU'
MAB-MN26=4.9(CHD -3$_+EZ%@W68Z#X'.]9 74M624D'?V<WC4BDE#LF8&6'
M2IRE'X>D@J 3J'LL_CH2QS'UE6U[SD=2@_.'S/O3D/--]:,XR$H-['BT$(AF
MS?G/R9'_:S9J0M'ZZOEK2IBMWZ"\$&@$'[@GRHXU(CF >W$<ACJGHJK9R;CU
MQ*H!B>);MVUG_Q\A0NF=17JZS7QYQ-FV^@N!QZR5?FFNU^4C,TB3=*+4I9C*
M&)L)Z=X(0@%8^X'N_RDJ_ZX87N_3(J?Z+ **&8CG,W]VUHGHDV*"_QPA_<_.
M3^5E_Z7MI_[)XI^*7G1YA%OPDT7V_SV!G.64&U+45LCI[.W09KH]S_^<=/_C
MZOLW3"U^GC..U%_(?D8>?<(ZPVA0<X7"Z64 V-78?P%02P,$%     @ +SQJ
M5%7\KL =R0  #_H  !(   !I;6<Q.#<S,S4Q.31?,2YJ<&?LO =X$]?2-VX@
MU-S06T*QZ0%A5%?%@+GJO7<9,"MI):VD74FK5:4E(?000@^]A8YI 9MF"*&7
MD #&-CVAFQH"-F#:?VTE-T!(>]_[W>?[/]_=QUZD<V9^<V;.G)DYZ[.\*'WQ
M?5ICF4@J2JM1HV:-9(UD6MJ+'^0^#XX'L\AD--P+= ;L4"]' "''P2"9VHM"
M3NO3+QX$'3X(S[!#;ACMV_'NMIT=,V!GWXYF0$E1!OF0!Y8D,4B?5!D<29^#
MX^S8+[M//"N.!!$(!S/BB!\-9\7[=JS&SB(^5S63.V94D^"^OAVY51T9%J4F
M@Q_ H R@%SW30:%2,YC,7E0&P&12>V;0*%0:F4+\,#.IC"R F45C9?Q\=<QN
M0-S[8$Y7EDX@^ED<\:UOQY_5BL5BO6+T7@',3:9R.)PJ&!HMDZ#(#"=0'(QG
MHN%.*9!?< 10V('!01P.H!E5WT%[((+W[=BQ0<9+5TJ0T_$O.<$(YJ^6XG20
M(3^$0"@>)DQ()?\+O K?Z<AR!3 $Q+/!8- /.\ J*>1@((RG9/8A_TKQ*AL.
MXWXH^Y4Q5(^6Z\=?;?VEPP]7#3++#Z+NOAWCF4[(!4;\>,=L-XN.TNA]R"F:
MUQ#)OX6L'M+KTJM&Y/S53O^+<6%0$(2QCME&M%J&,Y/:M5.<V]L0@3*4()9!
MI57-/B>#RLQB<+)HG RQTI!)85$HU53ZZ@%D1&F]&+UH/3.D?G\DC&,@'L R
MHE1F+THO>C69& .#'MB1@2>"4%8&%\-C <Q7W5-]Z]&CA\$#93@#CDC5M&5X
MP'!&$ R'(6=&$(-<?MCMP7L11+]R9/YOKVJ4U$ST N&4QIY(2F/&SQK3LBB,
M+ ;U_R&-V5D,1A:=_G^'QE7DKH#?'XC!J)OX1*SG#) (4 1YN H!1C/PEQ"S
M,G(,4!P7$709!AB!PIF\@-\YX#]O02 +H/S7@K]O04<$(X3]8D$1!J<L"*0L
M2.%DT5E9]&H+DB@ _2]:D/+_D@5?]<$W6! @+,CXKP5_WX)_,_N^(=.F: 5O
MZ/B;)0Q1A?VKAGEC"?@[3&(IXOYC1C<91MROEC\$7Y:2J/^<( X*0!S*KO*8
M3 H]DPH84G[#8!,^0ZR_/N3?T+Z.$W#"KL1?0OF5\C4,/@81K;^#P7H9XR7*
M-V$$,$,@X,].U;(O.S=?S\QXWPRCSD LW/TEJ)\97L,BXCEB1T'8'_Z;%575
M/T$0"T,&8N'T[:B#PH$(YH Z_H;A9TE5LY<5@YVX)YL&,*O']5+3'S%YH*I%
MELUF_\KT<],?<?U<TLHT0O&O?+^I<W_+!R.@&\HF<[QD!I>KU?ML,IV;R^.Z
MA5P]ER?E<@5DEI8;-HH]4:>8DP3%G)A4H(PHN5R&UN=7<4D4;O7%XQ+T59>0
M6[W^N-HJ9N+2<GED$H,K\(E\=IK,SQ4;4@PNLITK)3K=6B&/:Q3RW$81S^T3
M\[16&3_F%O/<;H6 &Y#S8P%Y-:" QU4*N+&J7ZV R] (N6RU@*<TB'A:@S >
MLXOC88<DSG;]ZS<FE/!B#I6 2[$2$JQBCU$GT@6J^ZH!7R'^F[]D-J&HULTU
M$^IR8T)=2F6N5,?5*G6$:D(N6*V]A%NEG5;(_?72BK@QJ9@PBX3/]1'J$7UN
MJ>!UNI]MR.43VA)V<4CYVH""Z.83 @1<MY9/M!$6(8!0)3%92AUA?Y%4)XUK
M34*QD":$'5:A41D4>WAQ<UP+:WC5@$9<XE'&;3";KTNXHT*_-JDS^$+RA)6N
MX:N,6M3'5"=5'J?1)C$(*!&I5!90RO@>M\TC(TP7TE-,N,HDYV$)!EDCK :D
MJ@T4F\4L\H-F:MQI\7/,-IHG"")XV&X&HE:ZCNI$G0S($F2Y)%22BZX6>JR@
M!)8B<IB14'D#)+X/T)O\0<B*V*H!0W941H-00.X-RLU(D D'0Z%(& .9T8".
ML"^AOE3 TQ+NHK4*^81#V*MLYA$*>'RA7FD4BHPZE4?JML7=-F&B&C!@E\1$
M2HF.H5?Q1289[(@*DS*!3N#V@'ICP@Q;60H^CZ[1JR"9T!UW&GTQ=[7*,J]-
M)(:=/J?(2&>'U,E8PAVL!J20-$F/3._#E08CH-'YG5:S*6BWB*B0A:KSVQ!G
M #0',;N8&K'3_DS]:D"2P"\SF_T ;$."$0=J8[I\(;4O"()H2(Z$0LP$CH5(
M43)(.)J@RB.$52XF8',Y1D:();)87[ZERH57V_[\YL'U5'&"0HNA41;-J*7A
M$0]DUD5B$F;*AI!;X@#D0H'4+4#,RB!?&HYRR6H-$"59G3;$YZ8D3!PE)8$+
MS5*VC2Z!V6ZZR 68:"3(*0B2D@RM*,$QH@8;QRDWIVSH=,?D>K/>E&![_72[
M(QR7R4@^ '4;&3J91J7F<-DLR,;A(R:.)@J(O$:J"I?&?1XKQ//:[4Q=U*^V
M&*QL-T=K#Z=&&$ %/DLTZI,D.5;(KN#!(E$T9(KP.'9<3F6R>!09,^"*,25A
M0Y*&43R$IK#%";J, JE&Y3=;O3YUW$231ZINU8"1?WW]6[>HQ)5D4TDV,X6L
MM29,7J<+\Z=LR"-1V3J]TB45F34D*L)DR>("R!5S6FA>'Z C*>(D.6$1G31
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MCU_%<@3E%%6 8:$P@""5$39(Q:$$9O2YN'(2S>JAQ-5*:S(A84H4X@ L0ZR
M7^Y2B3TZ4._4\+464X1#!:L!,95*Y'0[W( 5#AE-&H\-4ACI 4,\I!?X:0)%
MG)Y020(4@*WU6#0.IQ&!8<ALD@;B"9_/*H>](;U!*U# (*A5J#2II>=*>LEJ
M?I+MH0F=."CUTP%/U*0PX^$XB2^34SB@V<,+6FPZ$L7E1V6,L$7$0@-AFE4K
M04@&C3**D),* (F:HRI'*J?P08Y?)M/9Q&1GT +Y'-8 +* 9;6C<+66C%D-"
M;%')V+X8!+O\=)*3C@H2+D=<IW%H0@ALXOHI-,"!Q\U1$E.24CD(J\E:%Q]B
M)%"91QB% +'&J/<FZ0(FAXV3K+B<'6?*0# 9-$8QLXJ!JE7><$RC\SF<B,FC
M]<:3E@2L!15A:X(G2BT]99C_>A3UH0#@0I4N&1Z)P$RYR944.>/LI%PK-E-A
M64 B1P(*W, P:9(:$"=)!'$[ZF.07*IJP)A=@)",*AU5853IHS(%W:A S*P(
MX$WX(S)4Z0V[G(A,;6-P)3(J)2A$$IZP7*PGZ35)'CM),CCU>C8%9-JD<$R5
MK :TJ?74J#+ Q*1^T*FA>=A:ED1JB,-:NET)&>/J)$O%]D!.0G6 9&:YS!Q-
MR.W#) X:2RABV/PDNIBJ08V2"%^ 1*H!46Y<):(Y9+ VK/0D!*HWK]XPCZP6
M).P:C.:)T_U>"1,),$&STQKGA/0BM\9HA&02H;(:4!-D.V@2&RTH5CLE?EF,
M8W<S&#2UU:51.\5,634@4T RD'T)!M5K8>!FU"NE) T2H<?A);S:R:!8X@S$
MJR+;D53$9NFH4H_ (Z'J24 2%[B508<.X#%< (>=I&L05](50O!DV"RBJND!
MN<$HXWH8<:F&8^(J8PX')#32 !O;"!O#86<JC5+5)!Q#F'B 3\5L'H/3HA!9
M&0&RT0Z[05TBY Z[PC!N\'FE/%@J#,-LE,FSF5VH0$]ETTA>&VA,*" ?W>W$
M($9J4R\%Y")(B/K"J%:)ZRP87:Q%Y?$PC<$P*:@.GY>=-".H&8G2J=$@3O@/
MC9_PT2ALKD,G$I.D/(U1H=&!;!>L<J:RGE^(X+2HE"L3HS@Y)DC"'B" 6HPJ
M"QM+1,UT'TS$G)"/;'.*S7*C7,/&+5HR2Z*TFW2 *('+-(B$XD7$ !'5]*DD
MQ6(GB)5@,&CI*HH4P4-DL\1FX:B5L#1IA/0HS\"T D899I '"5^D&$AJN]_*
M$?D1KC4>A0$'IB8+PFJ7QJ9#V"F529: %@U9!!XZ8J:;%1194L;$XHA-I+0:
M$+41]/M#*K:79//0R59S0F.+6-D>2I09H)JHR4@$M-&< $C',8&3%DY%[*29
MPN3KQ2:!R6SR&(6$:EII6"WSQ1,>HD"0^]0@[K$2N9RM,= =+A1ETX0N(^HC
M84Q6B.TD?$3)D_J$E$0L[DFE49M%$M/YN"8+CB2X#*O=R65&=(PP0C8&XR$+
M8 =%(&@@64U,F<(=!8Q1J<*NCRD0NH^CDV$X9D4 DY2DM?+41"RM!F2K:3JQ
MEBY)VB1"KDP2L0+!J%\L(TMQ,A")RB0JW$X/FQ$:%1=J,8V2"858ZB2/) _Y
MY7:[CQ.R*9,<DU(:D_!MJ6B#):F 1N*/ !2<8?-JK$QJD(J'<%_2S==967Z0
MA,H,=I^7"P>89(^7[R3S'!&-)Q3107X7FQ&"K#;,GK2'U)XPF50-Z 6]("D"
MVUUT3B06U$?)(GO4C!+KA:IT8G:.3.'P<'2 1^U@B<QRDA.AXDXM.RJFB9(D
M-QGSH4R(%("-=$F0; )2:UE+CFCH]" I&@/8*K($C,C#:G8<LFN2(@H30"@N
MK4H6#7+4L%#GH9H9N"+$B*@523.FU@,JF89N9#,8%$#@T9)3B5XI#[I"=!1C
M)P&GRQ,1LJ-,CX28!Q6D$4EXH"7FC?A((3K% 1KB;K]-Q_0I!3(MRQ\WB(R)
M,"&5K (A6C0HB\KCU8 PQ(OY>*H@% H:+0ZC0A_&C(1UN(X():"7F4,:6BAD
MDF-4B2%H#]D-++.91=@VHA>K6+!:@\;,.C_/H6#" 0XW]237X MH8)[;)*P*
M_B8^A\@<<9PH*Y@^H4.I]R.@1T83@7(B2,397)Z1$Y;R@ZX ##(X5(B.D]6N
MD)-B5!.F3$A3?HA3M!&^V2'W"A-8W!&BTS1A3LB'^'A>"RI@!U1<HJID)2@.
MICVD8$5EX@ H2S*B$I,SR0CI6-2DFD(&A6QK@!10RU(1F^*PL=AP3&U@N\DJ
MMP-6D\)B0SBI409)#)V*%%6RG9B5Q+307)A#RD$-3*&,&I  O+@N@2DPG"3S
M$64W!KI#XI3;.# CB"8L3$<@P0FQ(+=+%8ES4*[+: EQ/$&./\A!13::46[F
M8'RUTFBT!@(23M0!A&Q)I==&5X0#<:Z(1W*)DO94M*%1XT3)J(@C'F< $&F(
M[6I QV$D06X$E08HB:@^JHP@*I)%'82,+#=,C01QK8<JIT7%)D07\]E@2)0@
MMGH&EMYNK 9D<I1N*PKCN%?IX,$)C3\H0>@)3C#BB9EQ%J2#C$Y)!)#AQK O
MX([8$&7"0?5I(Q1Y)!2,QM0LC5$>X4!L@PLRTWY.]%Q74LL.)Z4.'8M'3GIY
MP3"5#I"B-I$MP BHE*C0%Q)[Y3:+5P?)6*J(7N-'-"$#TR*GN#DZ3I)I)W.5
M*C(',Z1&J"'IR&15Q&H1 ARY/QJ0!))!!<EG9QK<,3L%D$7T*D,XQF!Y);#9
MYZ.2V1',8F:16!$B#RDMU(B*8=-H#11 [ 6EJ:(=UN-)N9ZOBB?-(1.&FQ&K
MVJ!W.&"]Q<DTX(B9+[3&O2Z^UIFT1E@R,16.AYU,DIS)9GLMSF1(#H:<.J_%
MJ'/24D4[C8U2'8B2;++*K%**T(69)!Q2DEB!=B$3U*GH4:M&$2')E2[09XVQ
M-6X-+Y;P<LSDD%^L4[$U'*' %X),&JD)!U+E7-1EP3$\:.79%7:^B$H/!;P\
MG\*'>&1>=<*CBU)"<H9#[!>K36Z.6!UEF?TAJTFNDL ,C 1171+,9I"0!2XR
M5XRGBB4M&9 0V4X5L46%3,COCP(6H3IL)@51DU/K5T4E,K%"KX?P"#ED),EU
M:BD@ EV"*.Z-VXVX!I:KS21V@.3PR*5&J!J0'./QHB2]-NF!4<SLPTV 1ZR#
MU7HGDK2Y3!)Z)*0)^ED^FI>LM!L!#^##;40.\+K9=+I#10U1O$&'R$J'4243
M2=4V"FF<S]<EXB*Q2A66>+SVA$V@2-+$3'+2 H0]>C819U1R*!%U<J.N4#@<
M5D7M"1H>IB;M<;Z2+G18Q#101B=)(Z*4VRC8)E6,ZQ!*G8:D02-5:P$%1\ZF
M:D',"7J=D)6%Q$Q$'4O$$SMH4>$*92C@TWG=,.XR>/T<8=QE%XC\,JM18;1Y
M4_'0:DJP*/$$U\<V.1 #F:M1*XE:Q4D'R!%%@@MKF!ZK02FS&"-NGU\>UWG\
M/"/."2"HU*F.:*DRCD*A%U"%T2# 2FT>DPXS26#D:/ALD4A@-0A) 2E32=5!
M H9!P=9:PM$85492*!6V)(>"4UU&#D0)F)D6! ==$I53K+-#,I4B @1E?%_J
MZ9R2B&58')4:X*32Q4<-(8O-22$V"R%(2[.YV0G0I$1"B2 O&(0I)(9?H#?$
M$8;'1-.SI1(Y7Y8T150N>Z"*B97:!1!%F=\;I\IC?!:%%Y;!+E8B0"=%!&2G
M*T:.\7&VQ<!P./UTO2ZJI 5T3 8-UH-TF\1H=V(V>T3FE$1A-PGW)_F:U$,,
M48*BAP(AATEFI5C%47: 8#;X%98DS&-#(=!A(&H0 Q"G\  7VQ5DXEIOC,.D
M"JP6IY&$02!D(4MT84@3I 0YJ>>'",9$ VS(Y,)<-)>9I/%2&2Z>.1IGL!21
MH)C"!M@Z@TFE%KA$1M003&C"7B_.<;)41C0NXN'ZH)W/PA#<I599&,S4QB<8
MX\DX\@B:1-P U^LG!P. T1Q@V5F<D"BLB/C9$H4A2(EHE#Y[,J&3<.@AEH:)
M8V(])2@0RTQ>/4VN8ZD43"LMM=<3)E1TC<:'R;E:+5]@E 0<[I?V\6QB&PR(
MR/Z@DRD#O B;8E8:- $:EA#K 9M6+U7@'+H XB=0AE_C33DV)+;1T(19[A 8
M&2&-4.*%; J8*-\<L$;*C!,%F#,ATHE$>KW3S>7!&$M EAK8..9-V &++Z+2
M>SD:,\<B-Q !+*5R+"X5,(TR<L*34*A8"&I7.=&$0T<#U,F8E22$[!06D:!>
MV[BP&<3 )62NS&#Q1(,:=02.B4&^J1I01T+LD-(E$C.Y<H6;ZS39=&R7VP6S
M$,069$?9,H?&R+!SM"X-9+.["3!+V"YF1UD)<2(<L$3L$89#%]/J0F8GW9IZ
M]L4/\:@Q(<7']5$D- M)3P= 24(%6)0J>MQNQG4V&T?O-)A,<C>L%@KM1,GD
MC:B#,I8Q:;&%4:%+1D,DDA@?#:A3(U2%=" ' 'U4B0F74V%*Q(^K]!2W16YF
M)70(* TZXQX9EV*%I-00'!8D6!!)'E4'R22'4\$%99H U1MBN'%;4&KSIR;%
M3!%2 CX/)6$Q,/T>A5A@"KK,XA@#Q^DAD9%.(;.Y,I O,2L,1CO+:*3R[! ;
MB2I@.4CW6>G\!*:)>WT 7>BSIG**C.4+>PD8G8F':24",!@,N0 'W4\',"JQ
MA>6%0EI52$D4QI";&F&C?#5?#:KB%BI%YY4JW"R_'*,Q42XFQKGD5-9+6+2V
M@#UB,$I5=CALM7 (-U8H=2J5E!J4V-4:,^B,14-\%=-DAA%3,N*,F8Q638)K
M8LF3)EROIT-R?@*&Y&::,/7(U&UVQF6*N!).Q$.040C36$:+TT0'3'&32$'2
M"1"Z7FVWT)&(4$_36GP^):;GTJB(/Z2+@8!2(*4'';&PSVX,Q4*I:,,(<:PQ
M.2418OHE7)N9)Y#KC$))B*\TZ0UZ3$^F$,, R5&K(:#4"A&4R_9#=&^(E0A*
M64)W("K3^@7A0%!K3#@=J5GF.F@:!9J 3"1'-!FAJ@'4A[L4* DV@U0+D\GT
M!(-JJDG ]? 8=A/);,<,3D3'C4  "S79.) >]+!IW"3)KE$)V:F\'$J"44A-
MANVPQ0ZX1#@2$Z-QKY]PL)@715P,&$7<+B0))"F(S2"#5"%5U.A@*,*(U@=1
M/"2EI*H29 I$2D=J:Z;QT:T<8B.25$6=&AD95>BC*C5"-K.D1.IA*IQFC&R'
M'=Z 2V2@V:.(ARI&_+!?1WAG4I?@QU 18*/Y66""Y@=2#]/\23 9,B)NOU'M
M#4$!FYDP7SP&VF$);$&29%3D2G!<%@%=XT\:;2J9PDXV GY5G"]@2.,VFTB2
M5-A\<2JQXXK;4L'!+ /L2BL>)3GT9*7 (%>@%I9>S8_&HR*13,J0A#&Q4D)V
MA\-DE2!B=?G(*B9&LD0!$<G@DH43ED2(%&3&$":=0TG]/46O)"F56I)(@X X
M"]#YDGH?G<%66J,Z1]"._N8Y.\,M% I-/*979$$T")V,2H@MB"*9Y#GTEE2Q
MI%1&?!:?1Z'FP E,G)1 F#8B-I#=:K5%FTP(#!I#W!<WT\E<-:&"(I24V[T6
M+*(72A@4+PQ[K5Z:E13@D6.R1#(URQ0(P,A$$$]PE&R_RV\'%&PD9*:8X]RH
M6"+6DU%-B"X0Q "4)65KW=P$ NF-$;M+(!%K9'[$%*:_-/[4,]A7GWI% 39D
MLP448)+"ISL"BH#+K$@@=+G*'!1'$XJ0WN53TL@VLU"(V)@.U,P)V$ NK,82
M^@1%D?J;%(MNP))&H@ PAUG<.,SR*WT@A#*3#BLSQ)+' 14>)FJB<-B:$!J2
M&AG51U2W1'4E,(>9JI#92^RT@K2@CL]GP_Q4&M5+U3Y4@A"2$&4XPO1),$\<
MD":]<1T@35B37 H$!NC^I-EO]&,F=R+F,B-P*!J"!1C3 V-)!D4%4IAVCM++
M2)V8@,B801&S.>D(X@(@0EV7@L@5H3 KH-)3$8>9PXA:XWHAUT=F>@(QDMD$
M)OE*1.G%*':5PL^0>2,*IBOI1P,2:VJE_*T_SOSVYI8 S* \BJIE*);:WH()
M6&GCN-ENE2:(H5J.'^50V18])T"FNSD)/<GLM%&8"7: 2%%B$/#"45RG\BG4
M8KTL:+)39##;8V=(M"X^C>J(ILHY!J!/:*7B6(0,BS&!DB_T0$!0[5(:U3X2
MZ%)9$(49DS#C$$TIPB0.K47(5X;!A$XKCXJ=-J,IHE!)#" :HX*1U'-L92"&
MF!42OBP@)E,X8J;#"L@2/B+(,_ DY.2()2C"8-.)39O!C(J<*CF>Y%AIS!B$
MF(-,E\"GMLBC!MPB86.*6.HQBY=-<L5Q5U+H$JH-"4"C,9H0ITEKLL'<@(1@
MLH5A!M=E-3NL'.V?6;0:\$\MSZ:0U?2$7Q6"?%IFTA8DTHI2P&?H="8$I]%E
M1 T)V>@DG=JN23V=2QKYRHB0'71!#'$TQC9"4D>,+4X&)/K4LU(*68X1<%@4
M ?F07HD:<+7-QD*T7H8^@80=KJ3-$]'P(U9UE)J*AW%&0L.  <0;8SM83!Y'
M:DL:HO]#)WI=9:&)IC&(+'XZ*F'[[ JC M9S*'R;0@QIV6@8X+JT"DG(**>"
M&L H9<MMN%-#0ZQPD$5RF:@DES:U]'01==PJ4)$,*.".)QPB"D=F(G97))F&
M*R+L(W&:R0*56TUQ:%P<CT/*E"CH,B @ 80@X#!(23A=Z/3;N>ZH2.A*93U$
MRH(#))X+-9(5<F44#',U6H7"Z66I?08FS/%1#%J.DF(P6'$UA2;4TB@6>RBI
MA+"J'V)CH? G$J@"]B>=07[*AFZY1$;F^/K^>D0B=?[A-Z<^_L;QH3<?*_EW
M'A]2*O_X'!""O/$,41C70:X_Y@Q7G68A_W*8A2#O]&8@813_.T#"*(3BG5X_
MF*149DG1, ZB#D@JR"8:>L&P,XO"8?$H3$#$9S.80@Z5RN53Z1PZF\K@ P(A
M0&55&_A5UM_ "GX^7/8SK/-OP+[$^AM8-0:[813TOT03B1#8@(!&87-H# Z=
M)Q+PJ%0.E<%E QR*@$X%*&P^^Q?L-_#_1H8.0IUPE1_P_6 XG/WS(?)?$%[K
M_:WB$ 9'(:<("R!_\812GVJOR(+?,!'L/[/8;UC?A.Q\PUS\163GF^ST*W+@
M?SP=O\O_)C'8[\S(&WM?"P2O3LEOYTL"A_$ EGC#V3,]%/KWG#VK7JQ9H*,Z
MYH2)&M]9-?27VGZ?Z0U.P:;0>#0>GT'E,8"JJ>/0*3PN12"@"V@B'H_&_07[
M]YSB%?R8!T)_/09(,Z1>.6 P,BFL+ KE%ZAJJM\'"0=<> S$(*Z;F,(_/P_X
M)J;?!W=X0-0-.;/)OS#^TO#7$L3_'7/VYZ'O?SQGOSW^^?_[.4NUOKK\?EG+
MKRW7?UM.AW_5_<UI]26"U!'AEP?W4F>6'@<Q/!+48 $7[(>R-1B,$J'J#RC^
M#Y0G!LV?G%/&R4'W[U0H ACY*X4%00:A86(XX=\I4$3H7RI0JHZ=OQ&AJAS\
ML\/6K]<SA-Y9$C!L@L.PW0^IHQ 6K#)_M@&+0-4>]'L$?P1CP$ T3 0."'4D
MLD6@/_PFJ%>(?HNFTA U;3B;^B_.GQM^2ZD$XU5=>C@)_?7Z@9B,K%@V0!BE
M^JI:=JFF-Q%ZLMF,UP@];R2,H#">K8$=8/@7NNJ6UQ;E:X-^@TI54_RFP]T\
MT/WO"M:$LV55O>B@ A$H^]>7&*K&_4K7'W.+0 3V)U+\+[/^W/YGS XH^W6A
MU8U_S%>E8';5+8/Z,F=U\^]S$IY;M?CT..&^[FP*I7KJ?^%_M?/W08C%% R$
M81SZQ:U?;_X3C8GHE3*XE)=;=?72B'B],U[ZIGS%%K^0_YTL\*J/_,OA7G>I
M7UQ-XP?Q:B%O\K<_*.BR^0D0_;,*(EL)5B4^\$_IK%#5RS=_2L;S@P[?WTR!
MOZOD+Q;0QT#<X1%C@4CP;]K@[[]0D>6N$E,]IX)439Z1$I]1+3^UI7^)Z(]Q
MJCV>\C+3&]? _\!@;[+)ORW=!IV_LZ,G.H@T17\U21&-643B=T8<$/9SV:41
MB#+\L!T#L40&E=*+0H2!5ZC^W0,6QO&JS!VN6D-ZXA/TRGOCT,^]U2I4O[?^
M+[I7-?D-3%;8'W&_P>7^;6'^MQ*K/LF)(C5;$PCC^I_?)O\#LK^(^DH:^-W^
MOP:FCN!^&(6J@E]U>J1SF"S.FU!?)_RK%HB@3J(>5L!HH.H%P@RN^,T62)']
M-5!3*G_\FE9^G^2O <HA#"52$=\#.7SA")+]1LC7B?ZZ"U1_RJ7VHN7^BYG&
MH5"8##J'!OR>0[R!Z:])_(LR_B;JKQ[\FQKF3XG_-PGUCY?QFX-.JE4G$&4W
M(&+L+__OQ9L4_?=?_Q7R7R'_%?)?(?\5\E\A_Q7R?Y60!K_^QUD0ZNS;,=:Q
M7_:+,VG\M!K_RZL*Y'^+4>/%5VE-ZJ4=J3FH5HTF:36;U*C5I,:+/6GI:372
M:KQ5B^A/^^6J7Z=NO09OU7Z[1LU:! &O<75_6HU:M6K6JE.C?OT:;]6L5;M.
M6HVZ]>HW:=JL>8L.#5JVZDCM1..:/R\%6W>E,WA:G?W#SEVZLSGZ6#R_@,!H
M1Z#7J/VRC+2Z-=^J7:=>K1KUB6X3,9Z:-0CXVF_5>:ON/^K63ZM1,ZW66[6;
M-*W3H1F56[=Y1RW8B1;ZL$5GGGW20KK.,+4> ]M5=/+'EDR^WC%YRJ+%ZS?<
M:]4%$. ?':O?.AR)CMBXZ8<7I]/^00R[9I-:3=+ZI5VXU*3UF#VBCM0F8SX1
MV#O]'_ZB4)77W33D1=KEN""].//@R3$_F QU^Z[I,'/\N0_?._W=#/ZH8[4*
MTML7M D5*M6MFKW]V!;$YVUX,*FDX,%:?GDKRWG?<<J+-%/>UTZOM<N*$_<F
MVOD7]DZ8GL;]D7K\YJ//]JV;O:ZX<L3*!P-G+<]>,J7BSO857R]X.]RKW;Z;
MYHRF&[CM,[\9D//1PL-#N@TX^NS^X.O//Y >FR-K6;B'U$ _X>U.E9H[!1=;
MGZ^8>$"Q^GM?WO[;%3O&GVBR:7YQVL6BZ:Z#NC;#!W0X<?[KK6Z5[79)X& )
MMF_OS:N/LI(%\PZJ>G\RFSUO;]ZA'P:ES<'/KOYXTUJ?[:JO;U)I@-G7@OFA
M_MN/]RGP9>;68+7[2C%,HO;E#'(.//^LP_7V\_A[\/8E17DOTN;*=*/F;"\]
M\FE =OYA_MYQ_4??_I!:?KYBTNXFHYJ57SA]?L<6TB"\1%4F6[7,DU2U:E+0
M<\@_;+?ZF3<:+VX;=G\;M9R6?:0DDL<=[[IQ>I3J^?0KYP_4>&![_,BS<^O*
MNL>MA8U%\YZIY@\6#+TP_-J)52<N#'^1EG[ER8X7:=M>I,V^4_DB[=+,-:3]
M$YOL1S;?8M_^Z<QA>-SE,S]=3B1^.GOWZ9 K-Q<FW<?:;AZ5>^W<SA5%#[Z>
M_,7H)HGUU.9WINQ<F=/K7?&:SE<CA;[A'WPWWSVXN"#_X8/B0>4-9Y056JV1
MS+>E1WK68^9^^$G)._O.+'G>>FO^F8+.ZRW)=Z?M+BDO[#-BY"IOZS/^^,D9
M\=6WKY\, YLK:4T>3)YV[>Z<?ERMM YI6\F@WDJH![)HZ8>MLY1/7<.VBB[X
MEW^H-4Q[^L[P^=QI R:^?TU?49B5?59_>FSE^%*QROLV=+J.2C1ZVOKN_"^O
MP4?/?=MT!N?PLDFWOZ'Y925W+N7O<HY>]"2G>-TI4O'[RXS[;[U79-CSC?;*
M9N]4AW5/[&)1)\Z3DG<>SFZ:F%\ZIUGQM&M=M]3>M1A*:[?L5O-$_IDQVXO[
M=3T^ 1U8.U!8\-;35?+W9X[IJJO]\&%^G6F)!^S3G&TKL\C+D_TZ:U?_T'SI
M/M*$^5S6( C9\J3M!ZN^O/7V>[UD6(MA79<8/G(]J[62@7ZQX,Q2J.[ZYD#I
M] ]-KNQG.XHGJV[N!!$EU+DBY^V:=3175S'K_<?6*?&E::?GLFS9Q2%S6]_M
M>>5346G?6GW?FW%R0]-CWSW=T;EBV _=W'O/%QTK[F2U2=>8#A2?>MH&Q2*%
M>WMD9>^B#J96@#'S:0"QY$PXL;GB7HV$.9J'(%]>NK2YM&3<Q\T/'N(?GO[H
MT>7^F07O,6X>+5R[C)05G>/;:=M:>+!W7UL$S6ZS9N //[5N;W 4(/E;O_<!
M)<,6/>R=5[#H=%>T8%O;P@VG0.K!^JO>*ELKD1YH?NU$[N#+.Y:0;B$;%TXJ
M#=QJJYWM 6=YHK/A=F-'CAB]].*Q$1].4+5O3VMP?=_^/._*C>W'C4L[.]GZ
M^9VC5^8>IC=-K"*1NO7N>';UX=L'#Q:./Q,Y.G"_XX9U;-]1N_YY:V7-Y0W2
MINX8((^G3#1M0JT%Y[9 6UL^/GKK?O,G(^,;9S?J5\>VARW6/S<N]JI/;A!T
MR5L=_B"S8-=G3?:/8&"U$\5F:#E<FI7?KG+8DK$JM*4LN"V]0ZWB2T?2>6N6
MN=;L(4%HK>)#-UH/ *]>*7L,N 9=SAD_A8^MO&%9O**\S:='5K/,HMKMI&:3
MCGOF_J41EX?5*ODNO;35,U%QWUK6"<\44ST7/.O;U<DP+'S+YCV2.;CT6J/"
M)::LBX:K7YT9.^43_7K59WO$[SV15[@G'=N2_@5^MQ5Y&99WR9AW[]S2L]<B
M>PZ##U>AE]J0!O4\\_7&MS_:] SXKC"BUNOO6'>TS]XT,9=$RAVU^O2,]0?V
MU[VSH>+>];-3N^U9FSR<J5LVB3'I/^"*/W^AOGTV>_FHG]+GWV[WSZGC(JOS
MEJ[_YOL&IN<'#^]9=QFE=F9.Z["_X\+];;<\SNNPSW#9Z;A(>>*:WG7&%CQ=
MFEL\0#A^2??DC]^U+51WJ)ND='>VO->Y<:_"N=3K9QMG;AHP=5'VZ6]-Y2T&
MT!==]KZS]Z><\B$-<@[=.MQB OA!QJR;1E]>Z82;>5,I+NOBVOLNN*ZW7/7.
M^6LT9%2)=T96=!>KX]TK-)E.6/Z9E4RRR9H]W%Q8EF_C^QL6?_;5;<9N)'_>
M@Z]W[SVQGKHNN'QMFV9-9]V[=WVU?YI1-U*02XO6VM;4^NFM/>L[_]359!*A
MRL<)4^'C=YF%);9KT<%MI[NZW>O[0>G[I6EI-?6)2)]?K3)M=+^=.0FD^,OO
MKH>%)<B#QZ%N&5UKYI[^<72=:V?G9C:HW"CYF%50NT_3QM^/_NAQC=:'O_[L
MOOS+(OQI7W-=DK+H?<6<GJ=STSN.3G^[^-+.X4"D=]]H]T8#QN5W(JV<%!DY
M<\JR*Y>N@:>+(/OI KTWL7C%[=([[TK.#6C= N^YNL'DAN7G.0].#BZ>TW1^
MR<+/V$WW,2]WN;I]]^SP$]?]QF?JS1M;<G[)MDI6],<3C0\G<H8^>E=2<.!X
MO4CQL:_.P<=/]4TOXFP%KJQ>4F]GK2ZCSI=_&'),C VJ.V:[;?S7GY(F*0]M
M6V[J._AXY;-V\L4.;Z2VO$TRW+WN\%JT!3N H0?[J+ODYQWL.IN4>:]I':UK
M!;/U?R@TCET^^IO @OIE.^:G3]HW9UF/_AT;QT<V/#%;L^=\7L<1O3W]GFX[
M;OH^='-MR=212V2--R<ZY^<-6W(NL+YP-'X#'MKC]-Y-'\Y<>QDX.^;1C%I-
M+J0WW;E@<!V5ZM+=)>5H=NTYQV[GV/S/%[R'H"KF1-G)/>U.;OBI1:\#P_=J
MCG'K;MVD+CA/:[/!.PDGAD+^IMF1H8<7ZP]?WW2(M"B\(/=9]W8MR_H9KVY_
M4CY\AM\O"K1[#UME?'_CCKGKU@NG)RK.G[;FP"&IJOSI\Q7?X6>+3F#AW3>B
MY"XG**&?RI7R4;NVY->9*1IHZZ _T/OX2C-6/VWFY[N_ X;<,AU=W'A- U:S
MN=.&,>NTRJRX2+N_9M]^UUEDK[]G(Z2@MXHLO#_<?P4X,'[)\5'!!]9R>+/J
MP]S)'VX/'S1'"]I(OL]=?CP_*]0Y;]\\N0-@+FI[ACQTPJI[G(J2I>7,T:N<
MYT:.7&XZ]>C9W1,;O >^*EK1IJ;MF][9J_TG-?6Z?--6= EC-;L:';D*+C)/
MFS'JYNB8]TMXPYSMI(:7B0%.SQUW1)+Q?D%X?6F4=L 534V8=/.CO@_J,_KQ
M2MF&%8>4[DU?->W/7K-EY]? \\E-PC6RCL[8N6?_G4U.RV[RK2=MV>N^GVDZ
M6WJK4\9.]%G6K-$JQ\UR<V7QZ,_&AC\\M_'6S::C36>VQ:WN%B>&[O4\?N?,
ME'=[/NE</+M1SD[Q^A=IYI.P:X7TUI;-XXI7M*G(;=9Z8%[^WE/=ZP[KT?74
MNP?"B_]#]?7CPK*LT],*NW0OKE@22!9ORO/=++P[^#F0YWM\_N%3GV7LM6FG
MUCK+&VXKRN*B>=?NSJWY ZHK*;R;%'XTY+$H1UWRK'BF<_HIJ'!HTQ/*A1OA
M]V61M<?.M5(K2>+C&_?4,*M/K/OQJ_0^_N2-SD\/M^BY_\ADZ1UW,^_,"<N]
MR5'A=D==J$EU[?G :^L:?54GK=$_TZ:7T+"OJ<UZ;!?N=O1-O_$I9_^UZ)U5
MT9QWN]F:[AX/'B>UD%A[#_VH[Z*<T_U;G+(L[[CH\^Z%9;LN  4YE9L_OIF<
M,<!7_.!;Z4W;T>SS]\=_LF*,E5_[T.$=J_OX&K0_NFG 9],WM#^RG'M+4;I5
M+5D[X$8F6;%M>,TGAR^GQ:?OW[?RR.SO6+-FDY:L^D?O%8/$H<X%UVA7+XO5
M/^Q(K%[7IR[KVIPYO9V0Z=WIEP9]/'7^G/FK1YT)?;1D(6.,I,&8$8*;RJ%I
M[4W"A</?4W13B=KO6C?RM*FP:*;B5-;2):M.C44'W$(*;^Q?G-[]X*:'0^\>
M.!+;MO,T8*0'=D4O#%T#Q6VC)BURK#PQ8L32-<IX></F>3/.11K4]FUX-HU]
M:%/%H]J?MD*5A8$?!P]JM$B8S#TR]*TF>6</[;>,*KBSA#FQ6-#!.;7<?G+I
MOH'/)_1P8C?ED>+\,[NGU'O7OGG7^T^WK:^X^TDE4D@^:8M,&+WRXI4!']/?
M[].K@P:ZB)Y?-$JQH/F=U5M:=AK%W[BM0HI=,Z_UO+M\2];01^7..3YQCUTN
M]N,VW7^Z9US>><*X39+#7\8^.U;V7'"A]H-NN9=K-;X7*NI==);17;!*]OZL
MB@//D,C]YE.7] :N=[QTEGY+-:ER2>^*X5-N'UR[)#*BJ!UGL:_GRNG>ULUS
MD^2SBGE]:$;6W5U8TZ]F/[Q8Y]GEG*+W/,?*"]4*4^; ]M!)PS?G9GW:?WGF
MDZO3>4^B5W8<W^,:!A(K8^S@I]\.Z32C,GT,WN2\_KT5D2S&+J\L?V[OEGW'
M]=/7Y!0.93U2CK,NW)D7R#E#WI(7R,U=,VCK?/4 \S+@'&?&C!TPYT'&_=/%
M^[[<%7IR\FR3DF\O:FF5=1QPY?DILY8%HD6A3/1)P%+8Q]CM<OD,_8.NR7K7
MKCEO_X>R1=;; ^>?LQU>..QNT9V:;OZSG7>'#3\S]FF_P(LTUN4GP^8_NG(T
M/7WPWFL/^U[]-(>()'L'YAY.7)IT^-S=2P^WMXF_2)NV*_]Y^.C@?M)K#?=U
M)!93'_G9Q=M_N('V+G4WO;%JT^QW:]B:[Y8/O=JC8CF<->'C"E% %EQV\:);
M/K6MJ?QQO0SFK$#2=J+0.S2RX$S1N6YYGHW(78[ET*,Y8XS^[?(;1_;E?5XA
MS+^%KYA38<34@UQ[C\\J3+;2E"67G'G4^N&T Q?K=TKON(JZ-KAX&Q#I7]SC
MTUN'TNY/-MZ?I.Y_0?O#\]&K&O<=/_/!0-D[MAYG&MS'-%T.?:4J]3NZ;Z$R
MK\_W[ZF]KJ-]4T&D\NKBSG/:_.3IN+.YXU8Z1?O%S4+6]+P)*\NV[IT9 \\O
M7?WQLD[I;=XM6%$QM.S GO6];E<@"#>?2<Z\?_IJ]VV:XY'M6$'9X]->1\D4
M;4M=L3[R<$7+7C<W;;R\V'SA4GUPP"/FR;5?_R.C_WGZ\>?SKH^>H+YR<M87
M #=:MLDOF3'04^+/-WS*F_(B[72[,8-ZW%3](WM.Y\G7'%^_,_GMF.+*Z +?
M!7W!DDJS,N_+B'_UX?MUVM6:NTOI:-5\P\2MO=P'.\R&#/LW[.\Q_M" P5U7
M4$@E6T=P2EJI]N]?U?SRZ7BQA;/CQV45$V0;:Z[:1N\_;N'GMRF-M[:=<2!]
M>5:)I,VB<$.@_O$D_D'1[JWETX)MYF5)1NU9KEM0,XW#OWK+S[WQ3C-Y<Z=(
MU&=0O9[%BED?U9'Q%96%<Q^LF;@T>_;*F[&R60.4LV;U(F]_U*)HY/WPAO;[
M5VZESGJ1UO:[=D]SC#W?_V2JTVKZO#0:6:;Q6@_/7586<=]H^0]ST4_O9--+
MSX;6PX*<@6>*Y[]E,PHCT_]Y- _I[LJ(#I2&?FC'*SNP]M(H8.MXRN8$OK]%
M9>G%%OFM*=WK79QZHF&_].YM-=@_-S^ZU&Q] W<Y[Q/17+#PL+"8LND9J:[E
MQ,PSC;(G1;([!C>)NXK7%)W[Z)1Q3+FEQ=S$XE!LP.<WLY;.GK;XQKLVEW?E
MY1].>PM&8*);[P[,[R WVVFE'Z\L:-EVFNK[G)Z'Y/7VJ/XY?S[TSL)A.U<\
MX_=;]F38SMBUIV.?Y@9./*Y\KBXH>_!\V!9YZ.+9'7>;'1Y^X_:%Q[(9P^3[
M[V)MA[=[,IQS_=[\6?0MBZM6G'KV^4UY=P<322\P^/S#!\6;UEX;7)7T;"65
M=YMTGW"N#"8]D!6<?! X5S%L2OA>%NGNB[3OGV4??KHS]B*-?*K\1=INTH^W
MS@Q_I^+Q/63GI\<GMBRLN-=L^ S@PJ- #WQ%#]74N652T\8O5O0N/O[%W=P!
M@9R2>X6!W*,%:R\EGT>FRJZ=_:M!8>^.A[>_[9B(].JTLY(^Z:>RSK3)S7(V
M]%^DQ[J,[/13EQ_AM!W0#F'>8MA\N6;CJ</GIG][<L_0DM*MZ,+9STFC)R4?
MAV5G=M>]C&28^C&;[B8;3JSKMY\>NG<&>63U/OIX2/$"Y83'W2=-"#[_(GW<
MH5VJ\2V*L]H]SNPN.65XSAHZR+BB=V7@7J^R5NK0GF?#MLK'^I"UN5=Y4R>4
MY7QC/E9Y:>*X<=Y*ZQ1IOPKEH.?#/SU1VVV[WF)RJXXWAVVZ-*#@RL7,\,J\
M%VFZ&7N_*%-.[#;\9O/BZ7E=Q%;VE>4+;<4/'YP^J^2;%D>GODA;\R*M\:?D
MLN=CS[](^V1%)2M'N_7D1/!Q5U[-X65]J$\E4TN**VO-G75KW(Y\AT7\;,:8
MX5,G#:O_D_"'=-7TMKF-R_ME;+%T-GPL+JJWH4!7V'99]BP9?]& F7EG91=*
M8-F#/>^]2'NO:"JG(D^J^O&Q+7O%QV\[O[]L&G]MD+KIPD=G<K/V7ST!C,TK
MX^SIU6OA!%_!-->N <M^7'F^Y8NTHID%GY^:^G>">'; =KX@[V9.<7DA,>\E
M.<4OTB;<3%ZH<H";JP7WO[EMH"4"X(TAI4L-NXNR1X96#!U77%[NK?G5D$%W
M%@]^D39TQOYWEY6&^AFR#D_8/.'VVZJ'E9Q%WK=7>4ZKEH^.%#%N]3QZ?G2W
M]MNLZ@.KJ*;V'S<I8\\V[D;ZZ8LHK?W!^]CZ_'X]T.2N= KOHT:3WFI2>AB:
M*06)$<HO"1[,0*^6Z]^/#+[W9$'[%VDWQE\K]I22+O3#=QXNR'<M+UF^JIWV
MRY85+])(2X#&'[4+2_6?=B?J_P^_+9O[MOZPDD]2KWTPP;<+:)N#,9X)NIZ-
M#WY>>_.ID34KZJ$]ZGR?5G_F$&7,M&N?/XO>_P?.Y5)K?96K"?+PRIV9TRY\
MTF;8E9'<L:532E7]A _4\(WOM$#OO<]MO-EI:P_6%8YOWVL%=W1,%K)UI(W7
MU6RXJ$G6F37/OICPCU/U3ZSQJ7PJ<LY:95EA,\F.6]O?R9YU'QOL=)\NOG*#
M->&#2^C"F2X1,O;'M5^53+O5\,R'W8\6EP\0S5J_X;Y_B&WPB=&VD@DCM7?O
MF4=_,O52IUB_ID5MMMP]>V3ZCQ,G)_?'\@N+O#BK5XN&?:FMF$]A4VOO!ZR<
M.>&+,J[6,G\>I</H=TLV-I] [#(>KV^!;*DTO4A+3/_0F>=8NW6WI.PI</Q+
MH!%VI'A%_LA-U+7??%FWP=[D!J#._OUB%]3VQM?B2P-.#0YGU^;TG'EG8EFA
MW'(P:Q3SW4/[CM]><R(GUT2#H XYW7>WZG]]H?0'E[X[V93]5#P>ZI#7:,,/
ME47]%E>*']WK5K]#Z=5&-;\9WGYK3K?=7)EUT4=S/LW[P+-F1YM+7YL;CJR?
MOR=C>AJOV;N+QEOD7<[N%PY8?.Y$EOO)_)65#VR^+UNI_%.]=P^L:EFROZ#K
MH;.D5;E3!E0TO3$!S":_U?*M_F[#R14GUUP;-G/#LI.9^(%O;-:!*_T'5O1:
M\S'>I<%)?M$'G6@+:NY0:-;OO75ZZ<[68X<\W<OKM+R2/#I\KU3[WJ9R61_M
M6%DT#VAZY>.Z7<?;(GEW_2,:']O7[T'Q\T_6%3YC/:ATU5T9J7U\:V!@D77S
MG+[=LB]GYYS=7-R@<6*(J;]/>">[:S/R I"Y> W,EK$>SA4WS;^]X^3L[T[O
M&3)YP9T+_W0O0(=%CQ[[1#!Q;>3IG$2W2\4;SLZ([1@V>/N"ANUTEZ8NW;LN
M0LJQZ2=LU*QK0Z$N6-@NL6S6R5FG.M3*#?UPH+&TYN4<22]H8V&K?J9A[$V(
M;N[J P7XHIT+@_5=I2.^WA0K_>B?[:ZFFTKPV^^M.Q5]MNJ=F_N6U]VQZW[]
MS0UFWR549+U5,V?CB2G$$BXZ>7O'=_XYW>9<ZO'<LF!KP>?_V/S9I<JZ1@80
M0&[K8FT4.=,>%:0'I)&-)^%C3;6?LB\AEH:GVW3KW+/A)R="'^4[K',#R^WP
M@G054'SVZ(6=/A*RL\9928GV9IZ^\P8P,]Y\[E<]:I]Z:UCY](9O/_CQAFYG
M23;6(%FPK&^[<XJ,Y]^>'US7D+%D!>I]=BPO?^&4)8'!)_@CZ3TMW$\NE-QV
M<NL.<C7)8Q[.7)BERD]2UMW[9^O2S0^0%VG-E)'Y1Q9]I#XR94OYK*6B8:BU
M&XG<+6/NB[2E6P_7'?Z9*Z/1@K2A728<G@F3Q9D/AB]D)U9+0FNNE'"TCLTS
MVH3G/<B)<'N?+R@_W<[5H'_+>M#P.]LY[VS=?>#T[,2FA3+5[;6[]QQ\R^EP
MG&\T?[PR.IRIXSYN<C8I7TG_,B3Q^[?/P7I/K'.35'YALREMQ(UZ&94CNI$.
M#B_:>6=>AM_9;XAK[8V5M4C0Y!/P/][KIVK</""M%%Q8.0G9/ZM2ORFS9 U
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MN'_#N?O**OWMR]<X,[?4:X2?6#>@E_VK6&X;BB/3>:NG#&NUL^5I6X5T4?[
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MW@2\IQPQ#05A"L>URMD9.L#W"!:20[P6@1Z:%PM19NXL=.$];J9&]<]O@I\
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M\;D5B@:;R5JR0J1IB/##$Z!L>S;TLM-\]G[D-7WC[_L>531U0,W5-%.68=&
M](+%F,>I@T)24Z1-<OHGE:,L;V893?.WD&0GVSW-G3:4N!)1&XX%<[AGHE D
M$VNXJ$E*-@VE-!EV+A?E?OOG#6NKH)@K;?Q8<8H!ZDL068YD?_5KF1R\B4YG
M^OK;9D6*?Y^,=!O"AAA^-VU7THN0,"3[R.1Z2;X#R9!FM9RA/X<V*\G;U:=H
MU(88D;$)BOZD&_0T_DH7]B+5'$^O8? MNM*4?D3BC&"CU6"7'G=63(07I.U[
M-?6J&D+?N)=1V7\I73"1_QS\:;&>??TWV)\W=[Y >7ATX"2'^+"_HL_6AFQV
MM>NP>:V(Z!EI<"+?74G#8[ZL0=R"B"3HPF1%Z? G=B*V=*63=E4PW.M\6H"B
MVBF4=]O&'=@UO?X$B+"5&/*?0!>..E(20M/]1%_(*R:/3ZHLR\8/5P[E/JVK
MPZQ.G#%98M-E,=(W\CC<&AD*O_$2[7%IY5NIMSES@7W<O=5._U5^JGGP0U&&
MNH]W?L1DLRZ;&;NOCT\(,\5M=0QB51N>^>YOT?.!,5>SC^=>IR>!R.YFW!)W
MC\//%\6I+X8MU=RK/#Z '7SF]B+)*X",YI-Q9?1ZS^XC[Z0=K*:]1P"FN_X7
M%>U-[*P(^ZW,5U4S]R@\<'^)^O/,',D]!CS-:VDQD]+WE3%W&'N89FPW"6L:
MHN;=9]EAM[A#J?]OIRL-'9DK4CB+&W H0A:2!1782ZMU]D3B* A!8@E6I^-P
M(\C9B-KMQ&31N^K#%M-7KB^4<@G:BR:@IQS<L!L3(:U?>7,IQA,DD[XQKDP-
M%?[[*?@Y9T\ @> ]X?62G?GY5YX+UB=65 =2:35E.@'>-5O=CY_/NH8ZQ)W5
M1%GN&08>/PM947A KMC#!@69)@GD]77E,#+GJM_-$WDW.?5]><EJ!!UN&]48
M":?:#H'A<'&.UU&3NG8/>C&NX.G-<'V,-DHS$!%X%R:WQ#,!#/P9CQZH7L'Q
M%>L :WLPD!N)FA13N4G&PN70WU8P#Z)CLI.R0=?FY"U@\:"UK2S$_F"QOL'1
M+^ITXE$^?':WG%3OVHPN=E6K;S#.P5PT)Q/[;%T^MKFW5OI%;!95*UD2SODD
M2.RZ9%\\SX%,Z(5PK<K^(8/JR,P':8?6]2G6+49)OUC9JAX0J7)0&PKSDF>8
MZ.?#CN[*W71!I5Q'D6WFJXH> 7;./?'\A=09_.=>6TOZ?)O=/O&O:=H"D<>K
M0F,&\J=L,HMUC]4':8(6TM%;TI-[G'JX>:3&PK&UAHK9=;WK ^YT [\^THKF
M^%M=&:1H'V/7!G_=;%J 1L*027QB:O6*>F^\#PJ7V&KK*IE?8G??!,:UXBZ^
M)&^[%K+C)HF3_[.[H.]=8$VL.><\:0UVLL92DG 1W]AP4B%L?0NR@P#&[,X=
M?WQ.BHLUC+*'G;WG=,D,K!$_HT ;UM;)<NC0[Z>*' -"Q/6:.542;..?'?(:
MY64Z6^XLRTGV]7RV2JKDGD0FA-AK853L>RY(S%95)Z0$6'-:4PE=HQ.G!Z_F
MF?3R$9C;_:)QLA=8)A0?GM6=DU&P5?"_)4X-LJF&4I>VQN%V%61RT&GH1[4X
M*^D]FO5T\/AP^(2=MSNT(XV_C_5/]J&'[&)L8O_,&J=GXZ(OIN^DL]AT.G><
M70#R#C!#B'"!=Q>CT?QG*(2F41'$S3(F_OI)E29K$-#:JJY-Y:(]N?L2E!EE
M*(6#>6;>F/TN[C5^9'Q(A(IU :'$T(@>[<A$J<[7XI_[5D6E'L;XQ*<]=(V:
MAW#.Y@R4ES,R[+P6*T\ RN7S]=:Z)\!WOWY!X6)Z%&^7'%?FD1!"^9V4XO '
MECI'J=0/15'O2?X./3T&B416EA++Y/8-G_6B/U9FC:>5KUG#'T\CQT[B(=-_
M,)C\H&M=N*]$+??D:A!#P<P+>TA1\YBDHWFY5T;CF4DNP*&.OOCX5\P^@A_>
ME!C+$&C:4HPF]TE3>[/]E1"/(H4C,0J B]7MRTSS<YY'C]3WGX6@"NX1C(-S
MNL3L%3Z(!4969078V@*2X61@FLA&]DXEI8IFG_5]3 5I/""CD>VA+:3B2C.N
M+Q(<[:<8=H(G\WF;K)W8TJ4]G1<BYK_]RZ&Q\!' K5DPJ?D"SL<CT/1?!]\0
M0V&*PGT<D=;U@'58^K+M_:_6(X=/,\SZX]=R:8*-3AZI&3 OJ)AWBD%=7TMO
M(3]$[-BJP+;P<^*;A.<24I*/8,=S[J_IV2G5Y@Y[P="T; 3-7[6PV\AT/XZA
M%#%D2F8T$  &G]N59+JR*[L&UY\V'1]@PO,$^J[J;9.WLUCE?.);=C4J?/6(
M5<,DEX'\'USHPFR,BA0&BN82O_E>'S?1= 9P0A[NPP\1NYP.ORFYG1Y]2KWE
M:Q1NLS<,L<Y*RJB%VV$,%F N5_\<DR0>>*[BCF]8SIB+5ID(5OS2S^S%<,T[
MLA>];5_LM5_%AD4+D@_1EJG4 G":2>,,!^\[Q4K&5<G1EBD*TVZ;_X@*Y79/
M+9V?9VLG'7O'+3\Z0P)DHMI:[P2/TO@">FZSHNC&?S\7C53^0.1A8F[(<'V[
MWX0V)".CKMKKN(GPUPM(?0*(7=W*%=3XSG4[62NF-2W>S[M$G\]P+'+YT]?#
M2P[J+I4&,]_Q#[N.%X'6S^\GY2ZK,\&SAO"X?K=#97Z.U7E.E.%B.1(VE-<'
MV,YMD'/*T#^WC^IX.VEY H27)/<1NN2H@W:"":=!VZ",HJEOU&H2SDJXRF-)
M]69:>Q*"@^=\5K][:;].3>&\YZ;717/,:M&=+40&%!B>18^S6YV=8<;5>ZJG
MNHZC,(UVW6)NSU9 ,3,(SNF,&H"TS-_H57Z46&]#1$W&XXK2':NXR%S'=$UR
MQ3-9BW9H(JOR>"WP5I7&:A$1I(\^U^03PQJ/JK>Z8.\+S_UC[NV+ZR8??<(:
M6(M4 GFEB1 V2L79PIQ"=L1NUGY80%B0?93Z3J%+U_H^"UHN?':8PXUPS(E>
M[/V[9[XL4)..C6="[D*'&P%B:3E6#DV$8V$T1YK8C)E5OLM:23X6I6Z/\EW@
MJHOPH:I8D;CTT:%/GU+@ ACXN5KCU(+)R>\F7:'K]G,NI Q7(HK!)*P]H=(E
M4]\)*,I1Q+)7.G.V$>>9K'+_?=/S$2DJY]SW:@)KL_V@ V.'HL"@F72$]?<[
M2Z6$]Z3ER=(YR76CLZP?U&N"U58W:/](I/W(6**JDE<0GRU@D*[3SI-BOW[#
MS#G<^<[,6&4F:M]&-WZ%QK:T*KK2]FL54"MAK>H@!">\=LS"C:CIU@*/ZZ)F
M<E]M1:M'?V$ /).L492@D_EM8R>R>QGEWG,V9,XK)ZVI2*A3?UN0PP$U\5V:
M+@1>3):=*)2G\X5^P@8%-Y;%TIN^D_.#OGO'8(0Q/R-1^F3!2UQAIU"KTL4X
M=WO%]!0V_OY?C&#";_A4K\+B"@1+/1#-[L:RM/V9FE)$1(WFNG-F;'+.K.Y;
M_=O+!V3M0.)(^D5 9)XXX'62@!E',;NWQ0 9QFS\J_#]Z:WHM!<6:-4KN4OV
MU)>ZL$RUQP3U0:/#-HHLW16-CUU3-1RBU=-B!.N[=M-V?ARS[9)3Q*B'I#R)
MF42\2CF>_WHK4W-GZ]P3%?_LYH)' +T3?>E=O-MA0-&%?6$AL&PMM/$=6, U
M0=.,],B]Z@_6;C/#KT;;0FBO#8,QS]HQ HWB6R&N;0E:O58KCX.<TV\CV@BL
M!'_RZJK9A-G16MFRX4>")\!\Z:PMIT/ZFO]6'MK]#RL12EC'BJ"'B%IV;M_@
MY)D/:D>C[X-(7,+7Z;S1DH3C[EJPQE\OLI@NKW,E S;FGB_84"W_O03FY5HS
M1UDZD (?S=KRDO5=IHD".9*C1A I?FRCX7Y1"-1]_(;8(CH+4JE: :SM^7LF
MB?%PE+?]?-5/ %=)A,VC6 ",SDZL0M!$ V@G5OK1-W\11]\[E"^6[PP[=I;M
M,F?9>_J!UB\#UG*%0L,M,UWZ_ J!]01X=;C=ORFICEW>C#MFW?IUGK)P^EW_
M,/*ALWC:J)7F"/D@FA-VXJ]</7>#].LTK#[-J/8<6)\8* G+X<#G?P*,;T+/
MTZM1#V]N-)W/UKNACZ0.''880]D_=S>X^O "+Z.>4:JI1:!:GJ])T%@C?@O1
M=].^=32F,SS1<7Y3X#U[?>W'T[[_LM0M0-Y*;JS4#2LA6JL97'^Z<@[-(;->
M/J,\D8,_ 8A3>W;; U2^?KBPDSL)L',\U@U]U*MRU4T[M7@FIY7S^.8NI3?>
MK/VY?> &SW(95+Y*')=\%BGIO9+\I]43+44I=+$4L; 49%XI3S[1:M\C5+C+
M'"D8M3@>_!VB#FOR(AE7ZJ57DNC RBX9%)UE'.LT69JU['\C7$UZ1"M".$]0
MG3QBWIBDE"']I_%=G=G6ATO2//Y&>^&<OK;@;:T)(P3?+<UW+[F&EFNRHJBW
MJI5UTP\MLMXI+0L$$[]E]0XCKB8E*ZV6[:Z,Q6U?4:V 8E'>T2^Y'&U3E.Q3
MY.X=Y"6!+7B&0'AQ82HGCDXHAQ!1KL0\R(WB+*DSN3B!WMUKWAU]GH*++8$"
M^3[=^2Y"4[BO0EN0B'W;MR^()O SM1+GE*HMTV+K<Q&BB W0P7BQH<-E9['@
MZO?2(E?1_6DP"EA^86KT<]:X$?R#CN9U^V,J+^$%3G>)S\HD8V7!?B=TO_E<
M*=?DJ]'Z-[3@*"D+!TW=:8%[':C));U+55F\<R/90:+':=VQTX6ZC2-E4,E;
MT2 3)0-YHE[9'S>&-W4N&]5-\V[>:>D5M]O1KU]SSM!3:4Q>8="F!)XG:&TW
M%D1^35@?R_K\N?=[[VP?MV--@GT>A#0Q+=Q+\%AU/R>O-ND7T+<M<42B8Q-'
MW0%W#A D<:92T;0Q*CRCK9A9_!$;EJ'I.3JSNO[29IX7ZV#CQC6/ZIL>"S?O
M0&1U&KTZTQ- QX<PR?E8&>'5F>R;M6')P>NT.#H@4JWE39C3?&Q:=QF^H%%Q
MHN:>.:&SF\!KT#9510^P^A-@86"U];F;D$S0<&FP3Q[/ "O'#PX$9>5DWV;@
MTXU?;"['IA\:A^'/2+&F;_>\8/%LU"4.IFR2B'0CEZ>D%%WX^""DI$<&TDV6
MK]D=JJ?26"(9J>/0&KJ3*(S#6AC.([^U'Q#TEWID:^*IZ/Y9OZGU*R6"PF."
M;7HAI![B=>O"Q1MNS5O9%V?X\T>^O+RPW@)J,6+9'VKYG2J)AH^\\XA10RM_
M-38F@+#0Q@NXE[;C71!5537"TC^RA@/^(Y"_D/MR91CBO018O,<<K;%*F6UX
MPS?%>?E 1_+#MKR5JV:$)THK7();8U0>!=@[9YRHY1#CR1SO.+<NM.50?F_N
MXA\UUOP$(-M>9L2*\2 X<8WI-QX@,74*Z@IY%O_='G]VWM&L#I=2;65V&5:A
MYM99KSL:VPAKL-%2=VLFF+*JG'UI'4U$P-:\B? ;AQ'G7?)*ATA-J\<HKNU+
M%55ZJ!52*7XS6+3E.Q8(H$-\?##9Z$E6N15Y D2?C]N02NY8[A@-P[9L$V4H
MG%E<&MMEDJ=A55CP3 JW-?=U71@B(S3I\NY=N\-6#"S9<F[13X=/;Q;V)Z56
M59QLYIK,Y[@E\&S12[-YAIAD2T1[SA@F,>/8QF-_((O?[OO%?M%VX_X:E^#<
MY$>;,=WJ^82J4/AU!\,\C8%3L)>R]G;[6P^2A8;JEDS;B!JF]EVQ8\@9S?3(
MF,->6(:3'1NSQ'36XN8DEY.STX23O\ATUA-@D\7T$72$G7?<E,:O@X;'3<BD
M-$!)G1F*.'-G2;@-A*S4P_$Q),/E8\I8[*SD)AL<Y.0FP5:R:L#JJN04&^\5
M*/CX7_?]+,3&XW(J_[/G<4BY$"]RSQ1[MLVCY:"/%287W(%04[CWTWW6B&]!
MF\JB\@1H2A3.../-Z)?T%]<^7?V-1>NQBTBOZ6NRM.T,J=?6G#Z><JP=-S"G
M9]/Q\EE(5I?RJ$>WWNJ>/V-#UU?19-%8LVW&8.1*I:QG*=L185B0T;#>ARUS
M3^L^YL&R^&>LF@4["LJWK-[-F%?\Y+2NQZ,DE8&M(&OMAZ \]57#IS;=,&Y"
MBCN6 LHK*$?%R5'("G)#JCYJUJMQMF=BNP*:8)S=W&I5321L<8CCY!9A=7/K
MPD";K<:":) ??$E'>&,Q[7B*X9M@%Z?^5;5HRWHAQHO$C$A'RVA122UOB&^J
M6UAP/^](GF1.S&05OG-YZ,&IP]J\]Q#DYEY]B%;L]]-5TSYF[@<4:"EHH;;[
MKROZZ3]PK4BR"#;OC@S,J\.*-U952]9FL4J.X=K0-7,7F+1(<X6^ECI4V08Z
MU)PEV7QESQ:PK6>PI.^6R,8B^&S =/L]Z*=1^?2 5N&OY-44^/HRXWM916.E
M4QH\:D^G.J=UDJ-YF5AE=4PQ-%+@=,-H&QOW^S),+V_[SM?.K]Z!2HVG^\ID
M6"-7GF_JZ,<VPB,'K)(F18+$=-W,H0?7>8+GQ<B<ZH]R;O+,4X24:E,-566=
MGT&DP.Z=Y0#1Y!+UX7XY9_;"O9LLD:C,J!A_ WK%!BKW523?2D..$,CSI>GP
MR];\D-V,#T;-;.5A'++,[3PT5&;:G+BR7%=?H%( \-(?=%P=2$0L(_7/]_E\
MQ1I9L,I+<_:XA$(5>(9 %!B>8G5+E&K<R-O:B-[V8V2?.>:8AVN^5EJ3%=OJ
M^*#UGJSQ"6"%Y&C(THTM_"UH\ 0PO?$B?K JN*0@Z-0L"8R(DJ[VV_I1TU#9
MVTJ=,ZF;PK?*/9.B),6B/M,>:1;P\@#+O^. X8<WF__BP!W9!L<U/C76R;+?
M#47*FYQ9?^=2S;V&RR "A3P^,F_T[ZGNZ+TIH4H+X5[%D*.CO3UA[O*JB PE
MZ:PRD%9,E*9*X4RF5E^KL:G)LIO22/<MT*C\. 12^4UA]A+;6$1.) MQ:%C,
MPT8(1I(J3SP03I.$*?,6&11-96QWG>SN*1)JP1I&[^6JKRM=E/*^_XA-E;IT
M&0<OT8ZPPFFY_V.D?T"? ,"BC:8XHA,2P 13:E5'+(6SY!=-6%U0X7E%@17.
MLI]_%*4S0>X;-8_JAZ_OM<#[!X\>]J&EO 4I5N?5;TJ1I.S5G>MU.#=X'SDL
M"5)@'W;1C.PMS9&195#H:ONW1RK%UV=J";0Y<;NE3X#++X5/@'M)>, 30'#<
MNMWL"5#+^@18XWP"G&9 +\0>5RJ> *%#3X NNKO;[O4.OL;['T@*GTH?B:'!
MX^*0 1X^\;BSP_K"UZB!GA[\N&QV>L9(LE=JB);/-6]:(\Q9[0::O-?U%H]"
MZ\@;=W_&2+23XEC"DJASY\GL!!JG0+Z9\GZ9&IN>D/WKV#N'12^/&?X%LQ]'
M-AO6<3%.1$N[1 0K>+9RSPZME_*:&37O"B+L1:Z6AF7&_J@D=#[/UHJM'!>R
MJ)(Y'NC6.JCN;0<\A+XU$&'LU5B?_(QK];9J!+"(UHQ[&]).5L=+6M@!T=@[
M:?^H?2GMY?9G^R+0%7.4ABR%->\;2E/6 %OHG4/-BBVY&HZW_$O5^\^4!1("
M!B\G3>*K5!*UXN&GM*<(NW'89X6D0GF^Z?,E6AF:Q[21T4YA21I9 ^&A%5;-
M9A6W0D(F$7_((C,D"-,KIU$)G]@ Y.8JU/XH39,;3 Q"[#:V1=7-UPG.%D&=
M&\W7\IG.@.4M!^)H0SD>B]/-HG6@'JF!'7G=[#%[5!!\9&O"+I7N>TZZ<OUM
MB+@(?>B;MI.)C^)'3=W/6Q9'18>G8:-M4Q>0+*M>.Q:[_MED,(;T12&+KIH'
M>!\T)#,QT71+\>>1ZG8P'O<532UY-S*BP^*22?P30O2#\/XLF"82(?%]W[<T
MW(L!9(?VX,W !A%S_F8$4DH.+%R.C,[XZ'Z1!=YK8F?9"82"^Y9)#C4;,V(S
M;Q3C_C9#*!RA#8[+8R9.IDS*^9F*7,8]1,.F'@L92HC5N%JZF=99HT*2!\>+
MK0WD_B T+:#^TJO8]@0HA)RI^*G/"\\YL'R%>UTSMQ6ZL?A(FJE7NC>A45B1
M(GZC>V7"+/UD9R%'Z:3R*T\ C #[X+F4Y])9[LM3^WN(76,:NR> V>)Y(E_]
MR)?!Z1U$/2S.'J&[THLX)[B^?[$\1Z/#])\YE%;IOL37JO/8T@#CMU?(%4<B
MLF+PX2-6\W9VR-<H9N."NS]JER,H;BR#.,,*5?O.YQI[E8ET^5-ZR:]/P**L
MON'%LC(D*15.2UZAI#B;MW&E&91JZ=<II^6]='?9)V(BN>K4E#L>Y<J@6@]9
M':=U6?+;<'M]I9K3*@]\7!%PL2%FIMV9M?BP8\BQW>1A\6[]=SD?/_\LR!-
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M1P6[&K\'BDU+$&GJ0((Q[PNGI2.VXZN)5K%MA\3.79?:@!4L[_.I)T"]Q1/
M;^ )()XMS&-X*!AP399S&1U@>U?_Z'[+\I@F1/CP9ST[[2%3[.Y(#/G"<2:@
M8?<)L.0<,,OY4'\T<;NX48W4.S"\#H[U-KRR?0(<-ST!=G!Z@(^PDB> TU]S
MI3WPWS\JL!LP7_\$Z%A_ N3*8&K=*>4\## \F' <BV 7!H-,_:N-"Q;8D*R-
M8FP35DG3@@O=:I<UVN:=IAVN7M)19IWE\DSN%AE,/E/S;S[O6RZ#^Q/O)E.+
M?+!#]W'G$-/G<F7Z'9*AZUMFR]0GF:8BRN;;[L70,MX+,HK%3*<]KP,_0 ++
M'H(4_C>\>8*$_J=A?BEKHK7K]IH"<S+1C'42E4M7EU@E/N6/;>$S%):?<C3K
M?O5U-'L2(QL#=WCZ$UYQUPS($1+N/_"Y@RO-K1^X*W2*+E%_6/:,@S,2H\&G
MG&>UM\E;P^ X-V .;H73$8^C=?+T%9^/#]G5=M$=[Y4%3'2LO?6.K^<J\,"B
M*DUS+S9UI/A']4P#!;E4Y<51[=',YAMKCDY2[2F7<Q8BW=C,2JN(4G:@;DA9
M3ER$@JD/887'$T#1UUL%R6!<4B>, %P!DWX@489'+==ZYTTK@-WO 3MH:/C7
M?>\A"AGT(314SR/#G7N/$DCB>_@]3S_Z%T[,-([']8Y..P4M%E[2P76;\_!M
MVG?RK!7Z/Z^T!VL[D4_?F!\-XNNK>H_ ':3O>*X4'_'T96#DF%4B/P(:JHUT
M#8%W//I:S(OUKI7Z((U6E<'=<H[1]1_C%U^!T^E-\\S-%44EK)".>Q]G^TS*
M%!L>54.R]C/]^5=GJY6-@B">?!(WJ$P:E_.AJC=DPP+F\Z"UX60RQ GY",Y5
M7>*^KZQ9#T]J0=X'7!-7:.N35)R>AKQYQ6("2HFU8GJPN^-?O/KD\+[MC\.)
MX)1;PN,[_[&3BOZA$C&Y6;>Y&6M3UWKT&#'QV20-A?:_X5VKL*<+^L77,E/0
MGLK<(.&.#)D-&W]$M6Y_Y2(!D;HHW20GIPW338A E\P[N>4G,@GST?646*W8
MZNN+QQB2S!6D#G:#S/Z*3S]6'QCN_76E&I=.[(PG($!S1-'@.\:Y"YZ^UBQ/
MJX*HH4BT?7FA-+^#Z?!IC_UOTA\2S7J;C_I<Z'4DC1+=:H<8$G+3D!;[Y1I;
M"\"O\G@02NY%<1D9FE)F273LA 5<<*(MOB%AVFKY6XR;L;SSC_P6TB5+&TBI
M9M5.8)K>-M5*<R_T&,9LL5]KC(:>Z:&NRV%7X]+B+-(Y>#IHM1P'MJ[GJQ2D
MP7M!,-H_Y+L4E+7P\^/(K_H^J$.K;A6OTA+DC<>G9KMH\D?TEE!*N8!@CAOM
M2T)-KM]3R*W@L*D6ZLV#AKTL]038,C ,*?1"[*(9@JBZN'%19N&$Q:H[*KB[
M[=]8R.S?+T[=5T7L+LQ,#5,:'O()A:%>#G#MXM4+WU7U+>16;FMZ74N46\ON
MN.]U?9+[>*CVVKA?0)4>B_BF?&4].+D^22DMLW35QI/HQZ8 7U5!V<:&E;YD
M2*9=DW>,QXR/:EA&W. LH^Y/,F](Y3H/D&3W9';DQ_H"H;RK#/".<1^KX$JV
M?$<0^( SZ8T5=D@*K]9TK<H*GE[&RRC8$Y06!4\O<U?^E#O/T1J:=ESF 4O9
M#Y/,Z(;ZZ;24#@WV3C'_Q)B$UC/7!;L(M*0X'VWO!)AFM .+V5-4'H?>+B4^
M3-6C..:.#/GGOV>(Q-YEJQ4K2/ 50'L"Z'VHELY@U[#&*MZLW3L>LG8#3YA
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MW+451KW$X&Z7/L,LGZ1F_2:74S0WD>' Q0!J.A-N\CK*=P*G^P8*V>2Y+]?
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MV#W ]<XV*@YJXM\QHW=)*^!Y[2KL^MN,Q:&LL*XDC YBR0\%OTY4\>3EPP_
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MI>Z94[9/;_?0(+/K$QI4L"C*]LGQ&X!$J<EOJYSV/3%U(1%R?JU+' X=YB-
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MC:A46;[6PI&T,-]$1X&6] Y^@IP*? #D#]^>A-U7X05?FNEU'9W),2]W'3T
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M"TH>=;K^_+I+$MG%,6SOVO8 4*G^3K-R$]2%NG8]0JK<K:C=Y<\$2G3U+ST
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MVG;&>OYT*<^--@F>=U?%'XWG4C>!]RUI]Y=Z5>85OH):QW,416X6/+#%M;5
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M$J_<G#6YDE_\&N:O)Z3,;^5[RXVA^+*9^GSQ2O5Z:DVBZY?6C\J+!(/QX/
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M%-K([8=HV.C<IO:#]%_O*")/\4J>KRQWE-!N#@//<ME?$7D51+;Y0A;3#1X
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M>>,>Z;7A=Y<GJ^+$6%]%$C)9_F_1_)\B3,Q.UT!MDR<YNNVCZLGJ<)HZOJK
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MRHBOV:&81@)'"+7>+*JKI3_'\.+V\&HY*'764,=01Q\[K1 1+9;V4JJ<]AV
M*()ZH=^?ZN#\+9!H=T2)]W:0Z9\7E-GYGV$/ $%JH0< JC?E 7"MQC' ??M:
M<CD\XP&PJVSV *B:6:_=\[\[V7H 7-'(/0#&IVR:+[2WXOK.M@(MKT;NZ+@_
M.M[Z.1/JJ Z/?G,JE0]*E1Q ?Q!K>EDST!_1$)CU;E-%02S-P6B>;;*Q>/T:
MDQ9*6>3G6R.@FEF&NS.3XU>'5E%C8&3?O.&<G8)9Z5A='0S**-UTE@Y7'NR
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MKVG00(=R,KMO5TU2"V\F5;?U6P24F\^7FL?Y[QES*;REP-\HO_!J).NX^?&
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M PB[259T866H(4=F+=^[.(%\&(H:D+0+Z*29T%;JX/=XCUV*"Y+@.=R/8"_
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ML-7^$]5 VT8E%2'N2URV-O]<3]Q(ARZ_CJ@>+!8%04L$%[1Q@#"J6)_?KIA
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MFSNE\G6:_]!_K['[?E'HB]/[ZAQ)P]> \-B>3Y,SC90R"-+K6\EB+TPZ-J!
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M5$>T=5$U'Z<>,YV0 -91 IQ]#W;:&-UIT]8:ZA5'>-&_/>.F!IM8+W9L22
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M+NV2#D>,W*7Y@*\_]*KOF"G7XV8OV_$?B=-[G%K)OIM)J5JV0CPH\JO)R\*
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M0^ W2WITT P%@DJ_+VT5RZD&K2U,WJL >65=?4ZD*GFMQW5K9H?>-SC\K[-
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M$LQZ#]VG!A00 T@3W]'601>CRWT_N5>AT4<A6OYYX_N*(+_/'J+<9*N(MP^
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MVJ<%P=6/G6*,+S-^'U/B\N 4_M!]1KUF.X/15)88S6C*X *.H@P8+3>:QGX
M(SPGRM@,VYLA2DW3=36*S]#VK<M1WG-3XC@4>LWY@5"^50U4"[X6/>6%=G;'
MI[#=,FKU;ZF<UG\*=OZ^)]?_2!',DC=T5UU2.?'S-T1([5HPU3[09<G_I'VD
MYKZ5S4B$WY%J)K&'FN+[!"O+C_TUP9_PTBA*(!OG-&<9N4'DH*B8W_C6FQQY
MK$HB,WQ,1/7SA+5??8.4ZCD"H[60:NG#*?>/R44H;=6 Q)7*E%9,G/QJ;]1R
MZ8L6^X>R'\\,6EFVMXVVR96M?CM<N=GYX$;Y?YTUO9$+5O<R>*#8%>*.0WE+
MC/B+M_;0^.[KK\T- ;BSHGWQGK+L4QU;@1;46;RG3/C&3V:*_QLS30LM6HD:
M5PQY Q"- R0*<TOX(YC)BPX]'+*$R_P(O6)\]XVKS>;4T^;@(=,!.R^B.Y+X
M^GY#(T^;!\I&4DMLY#D7%JILCAUNPDZ+$P^-AU&#O(QI7J6,7ZS4>9,5D9P
M<74+B"T5OQN1 'D#2WK\6(?.7BL53&(IW64_4+.Q9TKOA-\Q-SO 5&IJQX%
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M>X=5L[M=N80MD9O_ %M^C,&;;7[#E 9ED#,R?PX!Z09H2GX)&*#.3#H<@*@
MB-!%BE3]'BQH ^Y.AF6RG2#!?_/IU'^B%MUD32#)#]C\/2 I3\HPNXMU&!FO
M &Q-!X]"><"EBX,=CX+O-3N,0&:GI0]*)VJ&-<UQ##CB(T4 TP2%N5DRAUIJ
M_)EE?Y(9F"(>GL3D-D"/;QCK;,B 70^\U'G<880B\-,C0I%SDZ?4UI*.N">"
M6LB-:GCDUE'7+,OQQ>#'!H\%5>H<QU+\C7/('#9H],L@@T@;1G=\RYGYA^4Q
MZ@H4K$2IJT1'P=$7[*?@OLZD.'(Z@L[3?Q/!NYB8Q)D$RP4,VM_X@=]PGZX&
M)':\0(=>5(W<_U 356Y"BKIQ_4H?+A3S&'[+GE"^ E)(T6CD*3CODE,!Z@CA
M_NHCF_+&8["G;E-VW0<5-"0C$D W2Z]^9.#V#AQEQ(8 Y^;$_A;BKA*\9*;N
M[/]>OI!(J1*^7#Z1CC]BW>?G'P4WGN,W:*ELLGJ'PJ__NG\D#?)Q">P@3%D(
MZ,/] <3>^E/IWZS4;K#IH2.@%G\4;PR_9*6>X()-C]H.**@'@W+9]##\4UL$
MI<-Q5E:J"W.B[=&NYUMTZYN"_?:H]XMYN/G?Q+@016T>QC'V)+KK2AG/OW"V
M),8A3\.<C,PV%VUDE'U>FA\9^SJ.C1CG_F/T/@Y<Y"?2P^$Q68[*@S5IA1\J
M-G,O@S[?>4+J"TTF1AT\V>,9U2#VCXY]8E:9='!+M]./4#/+_'.M?C,Z29F%
M3Y1?X[2M8;&W47*%J24'A5\_,ZO-+NL&/><7"G1W\08[95Y;=;>D)QC-:L.Q
M"S88%7%9CHUP3/M&^O F'_.4HB)O/O]H)\;P<%K?W,]/ P2EZ- =Y*UC=EA$
M6]M.>FLK!D\&%F*SVU4B@L>%3J<CT7R'&A4#WLF'>LB(F)KCQG[ES*-I?O6$
MB GFA0I1+!S/_1*^GHX?%S\>BCPK.9);3#W4 R*,.?@:#F^1O_X/QVGY;!BZ
M.0H'U:F$=E,:9Y['[W;4_"@U58C<P,K:L0-<QZ#K14SX/@K U(:N,U>)RP9X
MA0@UKC#>GW[_9U8L#,G/!!V#M@:3GA4N'RC.@*/B_*,(AJXBFELSI$(!4\U5
MHM WICW9%TRC7-Z?T+G70"H#IG48VJ+6R(TJ>/N^3>YLC>P.H0B-48=KV::_
MT@98I+Z(!!>22*968@[3QL&.NL_1)!H*W2AU$90CE:,SE#[;;X.Q$,ZT2I1'
MDP-57'\.V;4CJ>#-<S7[2_$GQ(/+A"K;NDNN3*_ <(!R$0X^<>PM>C*9\ 2U
MR':(L!P;"[PA*]CJU=>Y.O*6G&]^R?,<TJ:\ASMX_/MFV< QX7/BA8"#!:<6
MA@9;E)%456I[BM773[#_NJ-DSG![V=.#20 MJN']RRW_GRW#XNC"M0?Z@9VX
MO<6;0/YC(K'@P6E1]DS-T=Y?[7:]9^[JX&0VFZB))Z5;G]S2[7L-A!1!)PQ[
M\O#W G1K[@H2TY/'1+)GSC5(S[#/'99XTMG3HQZHBS9VPM  %Q626(:B;0>$
MOP/THKW>(-9;;<B+9'>#*KM=4T(0 I$Z^.1A8B6L[Z86Z=NC7!E:[HFS:_#Y
M:&=YA4*=8V+;KL.Y"[^CRGSHZYR$>0%;W*EBL;PYGKR'SO9JYY<<8A4YFH&H
MY1 <VLO- )SB!6Q!OX M*?-0S* W[5SO!8TZN-@-JMYUE*[U[34VO6</@36L
M"5R#!R@ZI2Z+(>G-*9$U"6"A1-<7B5-URPAA=+C-J[L!I'3NHXB'NWVGW^"3
MQ4"Z%6:;6"U^<H59 %I!>W9JN974)?OKI O9N_^UY2^=GW]_/_C.(FZ>SYPE
M[J+6"[>3R'_0=Z@ /C=X_5=,4]P7%^Z1$&&Y[+7TENO<DGY7%P%YS_V&5[3I
M2*P(QG4. >"ZEHHW=$ZC[S**8<LW!DK5!Y+7YPA!MS=B%8-F+-73>)6Z@/O5
M^1NI4/16\UTB%>!6.P)A$[?>]F/'X2T[;?1PA;J/;\D%S:KNQ!\;3;PM4P.B
M7<GW^!U&D=_13KM3"J'F[)ZVRV8Y+=8_YT[73"[7FT?PBN:T5>Q0P-1?X7O.
MX$P)PM,V_I &)$[Y M#EC)8)"*!!7;N"^,0( T$_"Z,.!Y*2NT]W5!)=:<,5
MQ/N?W(;W83VC1:JE)CNUI\[EBA^!T[7F8L@:C0NR5%GJEKNA!>J1#_P?S=MU
M>^T?-X_0_]JJWE&$OOG=EZ!ABY+7"V1:Y"-D?X=-S'\(F]_3]6I=95+OQ5BZ
M>\0?&TR$_UR%)71O>E,MC)\T3HX+_FP=@C?WI)Q#JB]:+3E_B@Q\2]\JD(3?
MY=^Y4-8P^:6LX64XE&_T-3'8;VI6L:^E"]]JCQ#)HAT)XW4+/PH%1;@YP1?N
M</P]@(K^"J":T6  ?7010&T++@)G1H3A(=U>)D]N;U+^5I=UOP),U-AO9CC&
M=.35HO\0+WQ0)/>+O.U0I40?TJGD2*6K&+I#_IOB5[3'"]8"WT2!H\-DQ:A3
MNOQ[R+7XP_6:'T&_C1K BH\V'_QGY_QU!O@F'U76MVSO5EBD_D]>W0B^5R?G
MVB12D F^6@G*+1V#S8\W[Y""%I<+*9YM0+JJ2&%*"R0>01A!AU@[V>HM@U@G
M5YM.?8[E47O,_Q,6=/NAO\*"_^_ZUT Z6/_Z:Z9M>S?^T&ZE1N%G*SSP#-H<
MZ/<P]Y.@!WW5Y$G$B9+?99=C8"KP'/*W2%!-!<"/WZ$@Y0B %&Y_08J@^MQC
MDE!DU;USR%/G,UIZL!W_KAWJPZP014IGG)3,Z/9DRE].YI!>TL^R3&*-'7"&
M=>3'=QFADQ>L&7N.1@2P(S\^Z#L[!GF)^CJ4&D??]@U[Y(\HEW#D1/2,_O9&
M0E#@/HCO5Y?\&8 8$&K A=K_0@R.06TR-T) N> 7G@!$J"8%OCCS B(\E52&
MTGW=VD1\T#D VWY$\KJ<"&#]P7C7!1DFVYIE+V>T 9S:&KO0W28:O$<N>1RP
M>M2S=Z:VQR.[I;]Z0K$G!ZJ6XZSC(T77V<Z.H7L:"BX7'KSPMP=W) <]>#PN
MXL8):=/[FCGEG_#57ITSR.#;[^Y/]G*=@2S;;Z3DS!D #U^(MKBQF@7#3^SE
MMIJ/,)L<0\%JI';+@J9F?Q3@!/SBQ8'XM 3*:BA&R0( 7^R"SY+@UX2-H'-F
M4X?6:Z=VSR;CW Y3:8Y_]@_4TQNP<PA%VZ]61_H*1OSQ;9U?"%)$1M'S0H14
M'G"X4O"*OSM2S63@CR).5)3^%#!2S$\*VX8B CK^@Q'H-]^#6H*6X.<W,GR7
M=8@_ _>N_20+_[3R:J(?@^\*9?0&T:HKD,<_Z->YU$=L!KWM!!KP8$R83U9!
M?;V#;SHS;7W[8I^BX3<%4ZFW=9#"O+(7G8VZW''<402H2!T8BEP# (/5:F^-
M9!M\?'87T>79> XA# 0[\A6!3[Z1AU313I,CW@# ^<SR#"]\X:\5N]\K!O&U
MQ[%#6#-D_B(X*EUDS7_3V8."5W*5ZY(8-90%OP?.K5O^ZC%W/3TT4?<CKY!7
M^J69_9C^EUN[%,/2<@?Q C%XHT)!]D.S*KRY[U\_#9?U.B%2./JXJ R.!B\K
M*#Z&@\*A.M>[\E^)X,A?*?U'W[8S#3Q,<SYD#<5%G^/#KS[',/.6_HHC3PF8
MG,T:(I,%PTTR@!V1?@$9/I$&>4;,7&CN/=$%W,"U\-^-XT3P'3[5]OD@EU(2
MM#(01?2 O%,=*.#M<)W)&G5^80;'O]TGZK%#AY'=Y8B2$+6FJ^4=5/D/V I8
M*,0ZKT/,J;9#FRBKQU^-USKIYE:GFNI3S\%&'[&*W4O\]BU$$3%WY?8,%@\!
M"1&OSU.BU7J'H.3A-L:5Y6'\&QP_$H/[GDEF0+Y[$+RU[I^%#&Q\<G%*DR66
MY _S1L/']B+I;"7(Y?\ ^!OA@R2I@O)>?GY=[*S#FLK/C0$05CZ\QN?<:+."
M/[TRCRR.HSB\L8K*BNE(3L/=.VST,/MVGA"N[LPA2A,L#0$[<*L]@^L,PHH2
M@Z_@7+&QEA1] ER8W'\G5H%3Y?^PB@7V*7:78J@;6FB1&A>LULWJ3I_*"ZI"
M1NP]F4>JP_42/%2!*1X\T,)D<F/)E4"OY'NAKV[#QY.1/X# LMA(?KH0VZ ;
M=BJI;/%M>F_U+;34M!+XJ.;BDW=?C!]=YW5%(_N2C8^!=ZF6E,OS4YSL03^P
MFP4N^]>OS(D"L!YC/:&$?U .?=9'\_%K2"OMQS*#5R'N*:7Y0RKO4[[$%I4-
MOZM_)"#&F9NPZ/[ZI&>!.=OYQM9!L//RP"(2!7 OU\&BC] J_'2F,G=- LX"
M>$53L6-9Z"[^0$+9R^YB@5O.7 !(@)ZA9I]#-OV@TV0@49+4$BR!(QL^[:(?
M5,+#_/\6)MRI < 0?QDE<D7TT; ?O4@2(X+@8C=#G"&WE,JWD*$N7+$.J;76
M3)R;X0[% JPN-J;+6W;*9"8RVDU=KXU/C0H+RZ9<TAU4RN-O.KKN]V35;#8G
M(;&A6(#1$[4A$7[[T*)/.S'DPUUETWSI(3L^N)O0+3]'.-)C0.=P3@ZXJG@?
MX%?> O(U=Q'RD;;CIZ<\ARSN!/#F(&,D AR/_I814:X?&W %0_QJ)4,(I6^8
M7&CH]\/TO_@FE<XA"]&?8+V>3J\_O?Y'?3B3?]'Z\_B?+;/P_QFYJ&-Q=#E&
M9%)'QM+49G<523S65%&/HCR6G-4(.%_$_[@T&+F#L)S,4W1@P\9?AV]&Z:PQ
M,B-=P;?P&)6JSG7\N",B,=UU3%2S#K97V7/B_W-F".F#'Q.RK!AZ?M+F8Y$*
M0=)^3'@/'6N0(IGQ&6!+G[4\;54[FN-#5;TH77<;X4I@PQO$C8R:K:!EZ![6
M.^1Q+@/IITH9$6H&-;((+)*\+6N30\-XI\Q5L<_514OD6T'@&/OM$N"'T,&G
MR7JAEU:B@G] 5?-Y%3D0M!/G!IB?%)"9-(\"H>6BW@:D<G]:U$SW7BFUVJM\
M;Q[\C7*FZ[,DV!HO6O4EOQIV%+!E1S8F\SS]9,,,9/+9F?#!&!#X7/&<1CG(
M39PO>.L81Z?T]4.MLI@]Q9N5ZUT/"FJF<;JA2U@7-N"FC$60MYR2"UMDX394
M2W4+NCDN45XU")H4_-*B=(Y$^*' 3C!E/MUA*#A5@]-UG,6<QN&6)_?"YPQ[
MNLZ@%T'W$.OH&>+W>70]1SK"?HHA C0=5**86?D0Q4!/LL;$%*-4?#*M5F^4
M1HFQ =*':=6=<=_^RV.OA/7^;[$>ZB][?VB\%:1F72YSNQ1C9$^&P.<O>CZQ
M@+T4[;GQ2A")%7Z(+7LT%GK4]]PK.;0C@!:)^GPFO]4M^>&II(K*F1?P5+H"
MH(<=M =X8?!YT!'Y>P6R[HB$X#4EY)34D>\P+E]"J.OI-7FVN<=;@%%DLJ@]
M09/"D>QI3+J9M@8A\S#PX-;!(7&,O)3ER=ID<3/M,>C96XWD;UFGC)#6A2&:
MR"(Y"/]R0MHTE/3A)M_2.\K67K0G24:]"VSZ1Z-Z> [QO"#3V=6<;:O"7TL=
M?X 7)2%2X\1K@V<JL*[ FXOP?S63C('$%1P*[.:=1!YE<IZX96<),SA6?JZE
MHC)3A+5,$6U\G]^\Q46S:6NCR]*&?14GV\ IMR'H^/HR=*,#K%'>O'W5Y6SB
M?8H)Y@<7?=PV&OM([YVRU8"])?K\K52?+BVRYG/(*+:.K'<[+I$DWM#QR1&7
MLH4#/ZT=<>9XS?2]+2"=0OEO3FL2M*I/![ -QZ<[J;C+.M=KYC# LN8J?*DP
MI^3/,TL,DY9/G%G5U)O, D8C7QVC"+!:3[[1',JRR;VMH3J)Y6F;VF&S_D_J
MB!P+L5\+%?\[T:L;[7^R6A0T S^&7+(["O]B]T4RAE=N?UYX^H L8T,<^H8=
MI?YKZSO"U+-DADQD71]TL96\-?0_SL8!-U!EG4YLY&YYS5\.RAAZ834^R./$
M:=W@OF;!AWW7?]53Z\!ZZBVPGMH"\N]LG3EC,?VIE#]^]6_]%H#=R,W!'Q'<
M1BQVWU"40-_P]?4]2@Y6S9;$Q+4^_FH\#**Y US:*,!>H$-$LF>H4Q?_U#3I
M7WY%I>L< MA+D.6I-K35Z1SRN;K0R5_['1C]/OZ*?J%(;"!ZO1DXAQPVD ^%
M(%]>."S;5-Z<&#$$\D*9?9_AX@6*)E%+1)*\Y<M;#'287YFN4R:0[5N-BM:A
MMU-V-T_.:J>@7]_JMK8XY$<84+^F^1J>Y3IIC$S *E(=UU[CIYO>>LQN>A^Z
MZOLWRS@)6M>K;MD]AUP$M+1Q[?7_$L*VWA_]#FYG635AT()XV(\U^!PTF?R2
M \7HA@-VS<+B\+IU/U+)/.C0(F#]5H\BSX-&UEA8W?GN,C.I1&A3OZ;Z&A[8
MSH$NRJCY+SJ0<[PWC/Y!.!(<[%2Z^05SRCFFMQOESPK[WZKMGXC"VW0D#%/5
MJ>OS//KX^PB2I/<TO5ZK!EH'Z*:3&#[/4QH5&6">CYJ8D=(85)-7I3#V*WV1
MK/8"C^3A_5E2)Q*]*_.!^:0=_1%<#XO+/>'.XU]O5>I2 #GPW?U%R'8SKO'F
MVHR?L5[%&\HWQ>WK]Z^P-6'":N?L]G';=$;&-2<Z9E2S<M BJE\4OS.@CN)@
MK%Q?X6((1JD]%A5*&3?FRELF>K9F\31YN*+JE/W5G(K5Y&-1Y?'"/():;D+2
MAZBIO,51C'?75O#B#6R$91:9&AMAWIVW'\,II4,U>E\YAFC)MQ#I8Q&8>E[M
MWZ.,>W*08\'(UUZ55_:!@\_335J&<D(H?X?B5>6#C'7"FZS?]8)</[N*,^?<
MTR@*Q.AGI:'P[JU_7'Z,WD&5K&K=#,&E)"#D_G)K=H;$I.;5*3.BVE\&:9BE
M;;"FN]4TJV(G([2\]4S7IS/.29D@B3D/3S"[\QJ* %8>1WN=H;U=\SQGP1JR
M3P*#H)/S[)/%9HIC5RYN]^I;SKX#3>/X$;RL*=D[6FN99U.EQ[[<4[ Q&Y:G
M/7!MH2)DU;-WBJ52G]XI%DH)XZK12 0$5S_OKFC-(>8^MNX495/1KRXL,5#+
M^?(AF.[E#D1(UZO3319UH+1B56+<.JDA0S#ZNI]$0KF:Q%A($M9#J=U%([,W
MM=^;V,^4Z>S<A ^,LIB))D2^">D7VT[@V6C,O[P-X9_#TH[I4Q_BB[7+27[E
M<J_-V,6<W_AP@D[IQYDXO\(]A6(7KR=V1KH?L1,9K#!XS&8QEJQKT1;C)>NW
M<3],]T.^^2G+R%,8VBRQ/D#Y1G+BZOTD7JNP0THBRDU6#F^K_-B><]UD6ER'
MD\M>"7T'?:AW%X,4Y^3#A[2P,6V-NCDO5J>0C+5;/T)#&UT,LQ5#-8N84\\"
MQ2UF*DH?.^6U$BIZ&G2*P@ZM@YR_-QP.4?9/]!H9UE2QMC9V=S'&O+J90DG(
MEP?IO,U%=DNE+YM90TE"&^,@8 5I%;$ "6@V;YX03H/<:Q)R1NW <(&NOG2!
M:QN^2M?)B=7K"V/ET1>?1;\FINNE4_]Q+Z//Q$'&<< >S[J+7S*;3XHGD+N%
MA&DJ2\KAM+1)GOL:^9UT=,F8;1Q>3W.*/316+(131)**.;YJ382IRWM&2RU]
MB9=>*?33PN'Z0JI67]X%V,U9?X3K>-Q$/C#ZF3WWC2']1@B*F3ZQ:K5DGJO;
M#U18P);HV+;REYI^=;7U#=N&P.G7NP^,%I@Q8XL_/>0L=M%-I>0?$&B7<8(Y
MI(\O?=,<>IZO<7Q7+!+31"V@6FUNIPZC#L(6L*W,[C@BH'F+[U3$MJB$@5[[
M^,L-%&+[&^[NT05!GU*=\??/X%IO # YN#\VDE<5]"+?;^6QDAY)IIT\-[U;
M+1IYLEJ6#N85V]7W'O4*$[*/=#;PN:%!.HW%:;]?&H%ZDU%'N=*TN*#OT02#
MT\0=O2H]0WKGJ6="70/9ZH[O9,H+"S^/UZ%J/6"WZJ#/G"_'- P-%B.U,F66
M[J8H1_:9_JR6Y3S0S;=(>:]U8VI=&?)N-="DGLC:IW[PP]62T#M]B6_1%4?\
MO>%A9#&NE5@F6OC[W;PUJ^G9MY/TK>T8L_ C=L9$D-^HPM7Z2NZ3^)DYY\0R
MUFDTP4UVD\R,(O0?9;?4$G8Z\KL0S6>M6QB\$\[W;IT9V)15P;];*9T67Z'/
M;?/X]/.[G= 5$P).!D?MAL)37XMUC 9*?LR,U!:K6M4 P1FV\.;9N,3HWBD[
M_ZQE2YQO.<D&/3]PDZUY@]^4X_',"A3((OO[D+4'FR7J9T%(=_[YG9/934-2
MQQS94]8-9HPC2S,'J^QHAC$J[&OA-^2YS/3-@INH7L;-?E3(#KN"7LF<>W<P
MSJJ,,WV!X5B?R]?3:42LK=60?V_!)^FEK4RVL91!B7GZ,(:AN3]+K#W>WJT8
M@Z^!)W0I)7=DS!\IB/8R//I>@!*HB+)[VXEG-DA][J.%NG)U*7[$(:6MU0IG
ME%K[]PS##D]O*YLJJS*,6D+"P)DZQ?X',L48F+W#$VDLPB]5'K44YE&%&:!R
MTPK Q/:/4 ;K,HT'L64>$7EEY=<BBWKU7Y&?UI/QDA6NFDLV[AA3%%45QZG6
M#%#)9^*<> !7J>BG)4\<:6:[FB;/^,#40:S$J(W-?)0H'5+\>"P@T)%_X&N$
M"O:JNER!KS!EW[RO>'>$>*?N2!8*F4] 8!A<)_[8G>+,76=!NW^?(5-JE8%/
M2MPP8DG\213L;MH+K!<?XJK#Z76JLJ[)O!P:FL_SU+)0:)1]E-Z)LC^EK(2,
M='#*,L9PW7SXA"?$E(6Z5--KY(8*%7Q2LS\J(H*RK(?2F^]]HM]IAWV(V.?4
MC4FT@KM"G7S=UZ)-3EY+H%FFC3",0;K38Y^$D7F).G45";I)_AA8X#/U'S4R
M_$2F*2^9T17ZQN.Y+$?+I*HD!ZD)<=-/1,6B M&P!E4F*\Y-G+(/Q7>>G+9_
M,:0L2]$T+A"QR]30ELK&J:3+4Q]M>AC+>?6F9J/]X_O[^J@\I!T8)^>0^[SK
MS\_8.WA-2T2M"0A$[N-1>5R310VA+\0_>3LA9@E/^2I%'U*@(=WWX&/+;4FF
M2=UF:*?&5(_1QMOF%0*A7$L*K5YFE(*X&XW/>>^I*MMO)Y_%...HAU?E33"]
M*I,(P15.15&6\W#0)>8SY']QXO,T&3\BFX05X[.D+#+=\]U=Z_BPPZE[3<DB
MEIG+);!CO)$/7_MT!35A#)PL,5,D>PME4D^L!K1)\DZOKG3HTHR&#*RE>3Y;
M/?2MN^*,VXQH4'W;Z *]NG2(K=9QT,$C;UF0<6>]D4K3KD790L#Z:7'"G"W,
M1+GG\96%/I-FW;#*:<D[R;Y-/&:P=X$\Z5$KX](4.0_('$ZR2H^/NMI6F_CM
M<_39,SV+NI]U\X>T.![B.\H+%S11F)U 5)GGE<RS[-#\]JGRG 8E"D,&.GE"
M&6"E(5BG3U^*"'[-2WK)M<$OELH4[>*@[V3J?)!7V('#=;,)XM!HO9_-$2Y3
M&NFKQ% ZMW6-31ON=G5_+I27)MGV=C@,;_D1O]=M^X]$3-U#LQ_J3^_"M"*2
M+3F:O'/6$]$[0SIZQ&0_)Z#N)S,^F-SO-U7^M-^=?%;CP'5@5= W8U]SEU_;
MKC;@^B :RP\NJCO6@0(F#/%WM4>TF>(YHR'53I38&>.A]Q@VZBQW=JX_?$+L
M1H]?**-N>:O5W\I<I#! [ZU8D(6<=83P]1.#^$Q']^&K(2-UMHT:1U%.SW8J
M*X3S6H+S7Z(/H@KNRZB-=NU3\S4B10-.8@_B=:T=TH8U$D6O-127L>*_MD)O
M]T6G@D6Y52$3F5^75/<I4X=+2)BG&'\47YM+7.^R^'(.X1Q3$WN5/):%%[IR
M\VC2TMIFYY.V)];CO.4X[FO?"H]T_17RM6XS/I_X*>6601P62:':3'553135
MHI'3OM/Q:PGY4Y?GU:=N%05B\S(X'W!Z+#J;R!!ZV&^QK$0TL[1P\'_NMW2[
MSV\HX1P\RD_3/=X^4OY)>N>J_,\BK+4J3JDNAHXA1;/Q$K[/S)KDZA6J2+I
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MD(NH[[=@,2<^+)_*B^LEG)8Y9*.2S&22;;>.B[UF$ECDE#F^NK7D+#*F?.L
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M>'B7\# +( QX3WX>UA?$^>*9P\O'/U=@WOP%@N""K#^@.3R\O'/X>/GY^?C
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MJO4BE78*'LXN%HUT'\MC(17[A@L IABRK!X%+=B'"'29:*WWL''9G/\!$$Y
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MZ->%2D<]V6^0;CR(Z&IRD4WC '&W&DE$],O)5R9"F8L#22U.I^+542PS?I'
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M4NC3L]UBUZIDWM'::^ZH79CWL2-/&'_@$ NW-Q%W'!!0^WW2FZX*GEI!0G(
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M61FGTAEUE26\QNO:ET,Z6-J+L;1@7K@D6Y1QD00,>]Z)2B25(6>>O[3H[>H
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M97AXR(@RLS3@">J1/9=P/;)<->I]U111[QL"O"^ZODI2;\;[KAY3Z4# LT(
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M0.\4A/<--DKP.2I>]"_9D!S=;2;6,M9;4:#V'LBL437PYO=/03P,7U:UW'P
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M"F7QP/C%F;$JC65!(K+EHZ'C\%-0E\9L##" (/BX/#QQ-C#94>W>57'S9%E
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MGTUCL@U3:Z:8+20A6RC7#JP@28'J,($#8U@QJ" )]'MYT \_Q=+C%B2!3:1
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M+N3@%5N,L?16YC=.;-&9 C;> A?"'5I_YSVC]$Y.49L;,9CF@P7>_+H3E_.
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M;2$Z]]5FR+5SN[@AP3O9&0V8TY>T<>O+1!N'WRK=FT_78VQ)30@9B_PBI[5
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MT)-&VT+6@$Q%^U^[M(D2J!S+^\BI/:X-BJ%]:S>S?EW.2@";/=I.V'PX;X!
M=37H%"1H#T;MN_NXKU""0\CJ*8Y@]P.O?;WU2RHSZ+,N==%^4M.*<H^TXTMD
MW+95AUR@8*^=]B6;%6,F1)^C-2[>?9H+2GO+$+8E&3Q3P6N;8F$&G%GV:2:\
M"1^(5G.JU QFP%S$Z._H3\*CE^4$RXWM"U0O.0LF3$^0C"\6.24-QB2;6*8,
MW\LW"Y&FM"*R?\H##]+I-59U"G\U([[1E) JDZJI-7(2WS9M'4E$/)KIO -Y
MMYOP?:FJ/"A.E[(TOG0DA_S L'T5;#R@YS_2-;A%%["/2;0.>A :I!"\+DT3
MZ,)&&$&1>%0!-@CSI00UOB47^\IE&3Q2DK9G_4/089^7A-X[.&NI;#=N>*>]
MH-233YKVMN>B4"W&BGJ93V %6](R]C/'#%'RMIC,5^H><<(/;[M1A[R.SA.9
ME]19$!$U6HJ:C\RL;%L:@EKN&6W-T>)<V*-Z&F09K('NSNJ 'P45PYQX&E_J
M'/2F"J^P#.IH^Z&BD4^V96P(LDX??#08L_"6W0\+2WK%KY\PPCRWGI6!MYQ+
M5HG,1@"@61LB=N>H F7H\;$9:QUTI/61RM?L0S*/EX*>H<I&FSAA9@F-&5HZ
MB9RLJ<9S[_%'<2FOBCF2YTI2[Y'WLB]FVTLCN2%Z(/_+@%[(U(&2\1@66*CD
M6E1IED.<V,:B_W+QYD@DC^CM_!LKA4+<^RFM#,/#?E&<E9VF#"QBFQ3!T[?&
M=I!XIN< RF!V,I! 5V:2;M8A[F71Z-I7\>7SXM97,AIVQ?GZOUK[SJ HGZ_+
M49 <1 E#%DD" @Z2E"Q9!"0C0U!R1LD9 8F2)4D:R2(,><AY@$$RPY"&G#/,
M($,6EM^_=K?>L/5NO;7[X7Y\NI[N/G7/Z>Y;Y\I>V:ZE[#O)WWXZ'!Y=T-26
M<R&Q,S:OS!FB,"X\=@4W#U%=S7GFO6M8?:6 R2(G^5VF1-;''.2Y&2+T_.BJ
M/>[)VV\S>,GZ>]M;/Y<;PC?F!1ZE<(1-N?;%D%3B"!J;_\\+-YK/7<V8!*[Y
MF?<KR&[Z!F =9!=0SEJY]T?R[ZKUHO$D?UHW)<D.7:F=4YG"N(33V[XMX,7=
M#LK),&*IA!><S2^-^&0,)H^'2%#&.UZ)LPH:U&VNB-$[OZ]XZ[ZNM%)VO]DN
MM ?-O22K_I#X&8?N8/(;^U^YW''L'4-\U+')X[.9';IM%_'0_7LF8!93STUQ
MA%:,C?2$_@!"FA[%?V!3-[$,FA4X5PN/^;5)#P=H<E!(*=Y2Y)Z [;Y;;EZ5
ML!F=K31;CHIPJR)W*JCQFP4;XB<9@3*R;EMXO(;!;B<D>JT<1YIM@4C8FDQ[
M(&]3]*BIU3:K)'%D+B9Q-KO;"\IX"#P+>M/84M>*2J(O._'IZYMSIG\K?A[%
MM&1=FGA,]U+L25DV73=:+#)5OM ,X6IQN7-'7VL7]ED\3Y/:.Y"'X87(/(B9
M6%^_.>:^\ELE.]?^D\KSU%.1GV67ZGY**(%[K:G0#VX@_,CE1F5S0M,[0ZZG
M.40YH$]>@K$B9VPFR#:!/EW38LS=C.C6@CUN 71V#\W&#8!\98)+[ +76_)K
M?CN&A>^)0)&=D2+^0RY*^O./H!WE22?N5UBZJ'VK"0^HBP'2*E7I_CNCJB^O
M?BPY$WX;;]<*S;'/YLA4WWN=:?>.)4SQ4R Q"D>N0>ZB,.%LY!<KZEDG]BD[
M9L?U3M\6G#"G56*BG<"^7@AZ'5'R!KGS\LV"3O^\=<Q17$#?[IDO,D6T8DU$
M>'_#0UA+T=KP_[/+V)W8%=$9)]N@[?6@8]J?-P#8B?PZX7E5[$)*D"YR90*:
M1%R8^JR<25@!+XMJCM7H]PW@B]#X=0A#_-^_9M=<Z9%70M?6]:60"YM_'.OC
MZ46+(+3"!&/(F<.>S',U-\A3+)=;".6;:_'R0Y51IUH[ 8YPARC3C[F#@Y2D
M61: (.])_?SETH'VR SE2/;4.W8VSEB5&,0@1VEP<(S%!C/"%YF<#':I>9SG
MQ!'S=9<RLFF](", A>:". DEIX*#GC7J=.)QW  TH7*KS(_)";MRZ)#[42#P
MSLD.?5,5/$D3E>0PMIN%#0_V6"$U$>)395."H1XW!8E$WJ,6E>V0/.+-U5DP
M&"-Y.S:K;WF6= J_<(G9%W1^CQ*1LN+OE[-P "8K%?S]V_(>MRD3\;H#)2+Q
M]3!R@;8U#7[*H"-9K;RA(>O3"UBCR/3RVFU&-YF X0QKTOQ!5-Z>1[\%N+_(
M?[IW5*6$!WST<^3#-K)$;>F0:M$[367*@U]CV&>?BT"%75]E-7Y,G#.SPMBS
M],N/I*G<!]HNSGEG^D0XF<@<7I3+?54W.V'/D\L.:6U_./NXA+*,F8Y1_45@
M2K[]17F-E6OESI'=0>^$I2P'"3%E#3TWW]3T)8H!$H;S,WN@7N%M?81D_%I
M[.'D76:>QLS(UR?S-]!'1#1TV6$:YM?JTBWVUM3> .1SA^W5XW#IG<:US:L
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M/>=G9.'@Y.'AH600%!7@$F'CYN'Z-0D<*BHJ!CH&T=.G1%S49-1<_^D#U@;
M00&<PBDAP-$ X''@$'#@8%T RL?[? +WUP'XEP,.'@'Q"1(R"BH:^N,%-=@
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MF/(9F7C 4\"Z/OL& [2\@0%"L_\\+6,+%2M5_NJE?2FL?*7((KXU?OEPK?S
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M=Q%>K<$DBN%9S"E>DXY-[V?RH]J_%6%=:3=BW9T^<JI5ZI%3Y6+'YG>![V"
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MO]E,--(FIR/HU';G>X#*)<\.5S7UV_S$>X7!#\\WB(2.=K P'[V^;"Y0-/5
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M>AN]2N$>8M_VN"8ZA'PR@DFU(T'A&VG^\5'H]<:D_A^9D*597NP+$&T>.L,
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M=G?+8[,H>R8?]3VJ)^,$O08&*(^! ;Z(>N0'GSME6X:Q.$)E12IS.'DGWG&
MUBOZEI\;3]=XFH=G)^@+C0O06)I89P:JPL$ &@\Y:*L;W\L9&NL:XD!)N77S
M[^R$Q!/MV]=\A31YD6^+#7IJQ/@S^^I"V<IRQJ13I,G<+DJY*ZICUXOALVUQ
M@I"TUM.1F'Y,A]+ZH.LT5X5,*8H"53:Y*%--'#-##&1E &LU5OS^$C% ?9(3
M!IF8^,R6D[Y34J>H!)5VD;5<EL6GR;JLDO.6;AZMP=TLL?HLI>%DAM4? ;9
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M+,F+^DR',AZXEF:WJL7-15^0YX%/E >$WJ78WO!>9FKK&B-!2+I%2[@L$ZI
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M8;_\U<"D^&_7GD+V11X]Z:-M&/UR<TAY'>GU:/W<>9]*"D^=+ >MZT"#5SR
M,5V2LBL2(DAG^U9W.O<??MI2W^H5VQ>,*1!\&B5^^CT1M=IEBR'RJN3JCL';
M!1HV6\+6G%%S7[F@:E%)GGF2RL$Z < )6(*F:(CAU%0$#<L&W5V7C.$R)XTO
MY)**[2PT%?1:'1;&:%36"!H,6MO9[6[B]$I=)ZYJDMS?6-5-:9+X9(4I*%<W
M5RSA%L=*%B=$2*XSXSK:(_LR?:M[=,<E9[?M8#0)OAP;4T;J>')?4VT:;XQ"
M^^:8O?-2=V?F0;-)H/^$2N3JS5LNT-V@JS/5$SA'N3:$]Q(EG2ND5](Y&A>:
MCM23,$ U.WVZEMM NQ('?N!MNS#<>\_D@O6:I;N&VJ6$;UX'UP@]4M<C"?\<
MSM&'SB'QK8D[\:&EO7K(I@ ,\'L3W3L?Q;(6BM]5Q$S=+2:2I-!J'P'M+YX_
MMET4UT>C(D9Y32+^P-2JVP<#."2JYJK/@:S*O",%!5<9GA?G#3%UA+W%[CC1
MD^5I2K8$1&A>.M >; $]S5MU#EM7,*=;MSIA -I?ME##YBW&N;IV@K[XL.:I
MNFQJ<0U0.,D=8G"^/5F4HA?[UN.#X<.X&:XU]K"O339 WA&!V)B6ROSPX\*-
MKSK!MX,S_[M^T?Q$VUO$AS=,_DAZ,?7KF&FR4OK)5]P&ZF@L @@(E_V/JZCS
M7SD5@M[9I"B(F[/6%S2HQ*6N1\_N#3.H0(1NVZ5A &9!:T7)0_/Q=!><^T(@
M%I$!%Y)ZD <90N\WFZGW5UYEK O563\&=(L#->LUZ5+($LP9WF-1G+L]8!]X
M/7B+G_! [M2%7-XE?J.[O*:6?[H?SG1)^2@^^E+R(?5+-Z2:\8\^C;P<,OKQ
M02;JE\'3/++ATKU2'4"-,XFY#MZ+MI?Z*LH<QY%J"G)LVGLPF]&J>:,^<1=R
M/M((N??.N">@,[82^E";G! #)LE4&$P,E6Q;A\.(Y!S5^W+'K2NT["KD'LD7
M\S!N7_2"X5+5,YJ9X<WWUIKQ)TT3Y4Z(Z2;*3Y9BMZ'RZSR.C-M=+C\-G'WQ
M7>[SS VN&CO:;;UG;),.7BTZ.WQAR>+58 T_HY$[GO]I@&RF>]7(:-?2+Q97
MJ%,?_\4UZ1U3;' X%%6;%-C#;V+B"$=UK($5B%AW>?F,Q*>KW\V:O# B1^^#
MWA;KIDE"7__>27FN;HK$:4[LV_V&#Z.<]4N;Y;A$S6DS2U$-/4)N>\/BGXFX
MW7^D=P@>.!=WQ2_^R YRB7(^&KJ5HI^FPAM=9([D!S!-IG/4*4BG\2S(:*@E
M'=)(1[DT=FV0M>@A!&D027:MA8<F@HY,A PR[&R=H0WK(89#X_.'P.X!8^>/
M5D']*&(J<=W*+BO,NM6H;#&N^#PYP8=WWQZ,$UU\*I\.:,755 KN*&P^<5@=
M5*YK?FKI7KO#^&$Q7IG9/6H(&@%]^"D(#3]._4%*&:RCD6LLVIWZC+M958HR
M!KV3MB*IMG>@3\W$GV,(I9<*;:SF*+2S6'^76TM?F64B*8;$:$/V<Q=D]VXX
M\"O*0OA*Q7B)[M4[9HN7C/E66$0)@NIFK9:27&1E"R=I7R@Z$>8RAC":HHBA
MNI)UCA),DM3Q.4%O,!1)>[DZVOI.2HPQY'KD1*6<D9WD)[],\32!):%N<?9^
MDYR(43:%5/<2M-^3"QU6A'6C^7>>60V,<S5K^NH6>HCT4">\D& ?18;F$V2:
MY@WFS_9:@_/F63C#GUO&C^J=:/>+>B6+&2I+4ZAOW5TIP@ ^O;^>EFP80$8_
M+%W./[)95/B]BFR\QV.BXT&6'&" 8S4/S8S3%?[[2TH8@$ FK>UY]D S#)"!
MVOJS'@:X*A(I'KT^2GFX_47O;*5E_-_G^G.1?'M!OF.*'!%UU@^68+K&IIX8
M#YN2#:-%3K[5P$$3#R\W #H%DI*- <=4AO(D<BS)X2S5IX:QPS>#VOP;K^CJ
M6C#<YW.P/E.N\/Z =+##34)5'@::;R6<J"BM[^<:] .GQ+G?U8[++,.MG_;G
M!G1R0&?G=<KBW8!N0.*A2U_K 60SM^@J-B2^N'!<3G\K7V,F=TB7PU[< A6%
M=CBCW) 2.IN@X3K8*)VCH:W'7FGLFUIIM7BEU3/^[Y9NS Y.#U^3?B0^P.=>
ME'FF?3$Y<=+T_BWN_%/L?X*9\G^ RO.]9YI\.J(+PZE(UL%K+,'8+<JWQ8/&
M96/]/<@Z6ZS-TD6+%D*!0V]FNT4#!Z6!ET+>QRP!@YIPAN:81(GJ&XWA[QV?
MN-01:O)KG$C01<SEA%5_SM>:P3+31*2TMV9ZBSPW;/HDV])MCXR;](/%SUD@
M%YG_ =4G;GZ&6$6&722^W-5A!?E)>+V9@X@#!"#-G ;]+_FNTZ *!\179W\O
M-PHX%_*9=YOS?J;2!]3&YCLFE8U;VK#53.^-^3Z)Y^[!1GV2/WZX06E^RV'>
M@+$B("(89_].,G9V7KZ0P2],(]E[BB]&![HSC8YO72,E'^Z;DPC,4%52I.2@
MSXIB.GWP?A1N+6N_GCR?E(MO==C='CYVE_3_B&8$\:NL,FNOQG56IP=/PRMZ
M<M>XC)T <B^D! %Q-4I*'%SN0BV_PZRN+P7R49W>G]8!CT4YUG/.L]B68$IH
MRF+D;\OF>XH9.DS[LO_('"]AH[6&8XE1! X9FDE5OGC/@6LV;TR7=(G2QS0?
M3OKL@:-YPL5Z3_<S6D]9%CR+&3@L(ZF?^#1(L /._\4[0:-R=O]]L[I0Y+&?
M(M6:JH1GY<GD=0*?0IR>&\>Z'8XH%Q:[M9"%O09-K8$:Z-\%I@O'D$9D.#.S
MO"\@%H%''EI:%,SX/'C<%]M3*=,>TV9J]#W@^T1A!51?FJ27(HTI"U"4F=V&
M\.5V\N?OL!55'U(5)S^[\^^]=\N  62^O?D-QS(+B:#$(-72K=%X48G3MY%,
MYD?>,, 0[3'$X&7B(T^O<V& Z4'(=A(S<W?R^47 ?<*%Z]@\RZ6TK8H?^WJ)
M,NWG(]\'[&6R]>,>1QY>CY91MA2V'I\ZAHU7)@^[RJI/)!S<K%T<K$7FP!,*
MEM0)A/,!UO@F#!^W-LS(;B8%:N-#%>F'WAQCCHP0 5NE+0[+\^O\M<P#X5XF
M&H(KY<BOF)2Z[?*I-'+2V2LBA^;#O.HHS1OKT8H:F.UH>M82VH!?:1F(^H$:
M.E=>G3&=^!S;B4?2I,(HRTT6/^I:+C (7Q.[.>*O8[:I%>985"SHZ77G[58,
M"_4%9K?&N**2B:1KX;T3'?J2EN(4JA=+R87C"]S.F/-TS:!RWVS!P1_N;@)S
MU<[T$*J^92#K(</PE]LBT1$/LW$IM7X];A2QUE@!E,,XDL,D>G0:FK0$@N1D
MC%OY>J]K)WC"!)?3H<H_C&+Q,F+OVZ(/69.04T) +%V)\X_6J7H/S UJ3M@=
M59PDU(9[LZE/3" ![E;1D2S@GGV![R@G&#,QIMT*17CPMFT5^$5L\5KDNZL%
MW[^JQJ_A7&DS&, &Z_JX\>ZOK'B8H3Q=<[G^JU;T4VW*Q!.DW'\5W^K9._TK
M%6X-(:,1TUN_ZHPL,"")1$W#[J+MUYN,\I''_8\Z\/OUV/]MZF/9(8O%-+%4
M^6^M#1X^;$(./2C):IS8JDH6-'>7_N2OE?4:,)1N^22L\CT?1L3,;4T@>/7
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M&./F,%=AFQ4TE-D0ENO;4_X(&F,]Q-C)V7URUQWS,M%F-_"M^TPI(PH"P+4
M ?J79<K,<2]:TIQ4S-)ZJQND/4><KX8J$"1!%NA:811D=.F_)4A,\$WOO/S"
MY]/70;M<?=J.*A9SSU14/9&TMTW/Q6;6X,O_L#7KT4ZT\J'#O[N;WRW5HV2,
M8&+F_UV _29G(T'(7!QQW>ON61=3NYO,HD)3LA]0G:_[/Y<8&'/4]X4XG'I_
M-O[ 0"M _/KN1>-D=83.WJL4I71=RVS.TA*PIU%@- <74#G19D-I'#[U' VT
MH MF=8DK?LIV>V!Z-V++3>23@AY\-^SWV#W]MQ##3ZP\(@([#("-ZA.L.V_L
MFZ9Q#>'\^<_: )$?3+ =+1Y#H6[Y?\@$;5%VZ62[F^D.^L@LZLXP< YD=TY[
M(!L:!B%0Q0@%?(N<Q^GUA#9_JYUDR:]JG+ UJ4O#<*1^SI5C>$))4]E:>1;S
M#DPXJ",W]X8GBB*?:9#Y #TQ6O';P^ML##D W,PODRK-*M5S>>.S;WM1\2WG
M@IF%F:"YDB66RQ]MI$%&+Y:/*9'*EK@/N6+"CG:2!^I5GXN;4Q&T2&MQXG47
M<<HN>*U,FUD"*CU+.KC[.';X4A*Z'URPFZZG1U[XD52(G3G@L54^[VYB'O01
M&V%6 (L=&(6X%IAKBJL.K<=ZQH* YW^1I^B?DH>GH&3I-T I?T/RESL8+WF+
MOX=GD<S84!OETQ4GBPBI]_!/-$3'C]KRQD@K_JNI&O\VO3HO\0&O-7UU\T0Y
M"<W $C"+3T,5A6E@Y9,_7!_5V"] 7DZ7KW\=*P-O5C:&>K56+0R!<_VJFO-^
M!(:84&T)?XY^0ZJT7V;[']L?UGE+(=[A^-P4R[E**:L#H"2YI%R(*WAHOY^#
MK;O2C9,!F'KB9/Y_MP72(*SP\L"8XM/Q\&,K!YKBZ5$[1Z@KX%5S)3  X.I=
M&$0,#_?R*6>WK/EO0"OX%3" .H/1L/&ND$]9*9JTFZ6G=]TIK7MV,B.M#4Z\
M<R=C.ZT_%RKY4TN"PRS?B>?]JPQ?$X1UH:#\!'%&ML-2; \<GH@:)>*Z$WO[
MS-J _I^O\\-+]=GT=N;\93'>#)-6]H9,/4.E7\H(YZ2$6%!M"?07BQ]%6AHX
MX][[PP#.U #*'5*]S/D\Z1&@H<?\<NIIZF2^],1=C715:Y25?.@8>O#LRS+R
MHT%_K@%,IQX.CN=5Z-ED5S]RG_6P<JT2L9Y=E2<<I!-__\@&F(L]?2A9#MI"
M%B!BS1-10+?Z:<C"[EJR"3T0B!K@NO8U&VUM.KS\]=YC0K.31+*X8.+G,1!I
M\85B_REVE>#2Z)";<%HO:X+(B66TNU4_K^ZPY"HZ-,26P3*>A/&N>N@=]VUK
MO2X@8F:$%%\[<"S#^AA^225]@%7\57W#K?36K GG/%0@[%*1RB:G)/^#B#D5
ML]L<R>RQC?TL:D3:PEK1*'#)+.390*0@,3KVN)<S8D4[E2M>YTH$/6*$ZJ@:
MO:"&2<Q&H[F&.A/'>D+/E%'XLK\$_E[4TQU^%5G\9)^CEZ=(,P_?4SIKMS2A
M$;L@!FL3+Q7+)]\E5L.L(PRUZ-*6I01K=?/43I)5GJ54>T,?-I5<UVJ=NFTU
M''=J00)I-FPOP^QM_4Y,5Z6(PVLY[SMDA'QYO8;$3SOV8 "X'!@ S=7(62S4
M_#-D*W#Z 0'T@._Q\<%='[+,D[$B_>$?#;SWP1_E@ %&T<OOD.+NGG-ARYVP
M*;?./DZW:O$5*RMID_)ZQ>71PXQ# BF,8(#T9V^OGC)<J1@*[H&M[N\TW?+U
M0>3-\%+D.7;YKS!@@$;->0;6C8H1&. 3QLI3L[H0E\]GWZ0_=8H.5\<$QC@7
M?Z F(DNH93.A97IA\]Y165IP6RG*Q(6[X%M+SB61L$+-(-"#B X[K< A)AYP
MXJ/(]119L:ZNX;WV+E=NGXI@/3\W3Z@0HSE=Z(FOWMJFK:"@AG$C]1$,$+PV
MS=#X0J2*2#7F<RJAGF-[WURGB)&37_AR6K9G56DU5%A1<O,&7;B[O@$&T'KE
MQ 4#M*G=_:LK^_EW !AG [_?,*;_%NEO !!B_^,A^/0Z%S?3S+<+6E);BU((
MS9PVYHO+N$@_UD]GG/3V'X"303&(M1.]/"U>W0X"8VQ1L9*':%,KS=T,M)L,
M1%1K,?J*':P_FJ-!3T]^O1C)3N9#F/T$CU7/F^ MF$>*8'JAKR8Y3@SLJI/8
M>,?AW8OLG&IH%$($<(8/^GP8_NRX>]_:TO5"&EQV=G5(';9?&6OBC"'NR94#
M+_<<OP6.5@1A9N?28<GR2%^6*L;DQ=^>I,4W&'A1R$JIESD7HU>;)"HWS!G>
M"J!C%%>*!'QH(Q5$'UB^*[X?"R.,[C:V)"C]5C/WRY)]'^C=!2'&[8+Z,^F?
M21?]<Z1ZO,,R\O]&I5.LNZ/'CMYF*=X1!KCI.Z8O98O*(0USOQPYZ<6 -'A(
M)ACRXRLG?>5RC53BC$F-4/[[EC"5WN>VY%M,36O411";VL4R9IN:4OF7?"&@
M\NNC">.<WZBA))?(M[P@GCR;<&$V,Z^7J8%#;")#2;O\."*#NF:-]QU^;XEH
M8><F]Z#Z:)5J@'76Q@Q<F)'4KW?=2;;*P2&'&*GEK+*3H&)9G$\7L30;7W=@
MD0>LO;\-PZF/7>($KL<ZI4ZP5WL]E39_QJ>9^\N.:8\]*#<2)#YYT;^,+6;V
M<#SP6-&4!'&UIN1FN 0P2H2P/4E<I(BULK76:AO47A"HZ8+>(TM<6C[\':PW
M5=@W#9F0/A;(]*.M/[/^@?5;P _^3KD(_N(0<43#J,568WD(\NA=+V78S0FP
M];&Q#+,_M.C" "_[M=-9COGO:%_/B$&QSIH"D),@7A=:QEVVU^8S"ZZ&&"XT
MY;M5=,TW-I6V,W4,PFK_TB746^(4)MELS-/*0%7QN=*$/VO"9(ZCV\II,2%D
M&K:LN:;W>CGCMJNZ[D7#V1/=^\\2N!<E8_?3QU7(3!.%2?2;"()0VJEN'9G2
MZB+V?]8PEAZ\@]!PFH<<&B=@<<R#: !%8^LP0#$B_P)X089;6WF%\NE@@=:B
MHE/!*YL5.5IML'K_RSZ$(4Z/]T;!U%H(D^&QBBF*6*"ZZ'ZQXA(#A937Y0XH
M Z5-53W9)@H]^I5*H//"]<1W#8E.LJ^/>Z+R2M*=/9/<MT*1(IQG._& Z5JF
M3Y#.^W<;]I$4GO-1=O,1[@CK56VP151*VR%.R!]\%;^IB7)](2B "#=YCI 2
MU4%!$61]O=HRF9U^HO9Y(,&B+#(.-;X.Q7%=*-)D46XO=2IUSC5YY%1W-[FT
M%*J7DE'=:8L>9#'%1V21Y!K]Y>2;Y[M(D"NFZ?SWM\06["Y@._(]N6E4].S<
MY@@BW+0*6_NF-P[+MK0,D=76OHQ58^/GA(R'; ?@B$Z9K_T;:ZE(GQBE&9#]
MG0ZTO^\($333/,]M17GR&=#UB%@V:).!CLO1][+<1DUG,21K[^9#HF9=<A#%
M;&ESP0'!"QE$G*:!15G@@1ES*ID)!EGL/ME@0S%#F'/!4!SOY+L>84M;@^40
ML7V;HJ%L,V(QNV;2]+;P&.ICUO!&\HM\JU[3])?]+OBU!Z1/GG[44-P[J<QH
M=$2A+35N^9@IVIRP9#FIL5!J6A5)C0[V?V8JC'?I_62&+R 5(?(]G.?NDEQ3
MU11K3O(9?='M%C/"AG)"S%TK YF,T%:LQ7JBX:;^(.3HDZ5B,2@WY] .9XZ&
M!!71UU"9HW<3/-MD/ER-ZS#"V.@6ZCPLI5S=J/MIN!.E3=JQQ>CC*!.J.M"F
MOQ_A2$3#Y4=M>@OX1[9>ORO;XHW !@B7+_X+QP%01DX_7Q1UM%Q^:.R.-V_G
M^TZ'HN8;N\HL;EVZ%BK+P+K9H0!.NPWNGGWS5)5^MO:AIC3RNG >A6)N-X+)
M+"R@4BE=2>&FC-+W/F()>Q 1-'7=N*!T8,VV>D%(6T203%7QPH<JT,P=> J,
M4'=E0 VX[5MUFOC<[0R!$D(64Q[;ZOJOXO6W&,_4L0["Q'\J/E:X$\@Q#\1&
M&P;PM+M#CH,!0K)C]0.2W-C'U,1K66" ;_P/"(\RKFOLOL+\?J?UB$+Y@?YO
MM,E9I'(])AH'EW2%;,@I#@[6>$^B>7_E2SU:8X4*M OVL/Z,J&%E@ZK'J8R?
M]2E^B.XR(2GV(%U0B/<@(7@N^4G<>;TON_694OR*RBJ*2]<$391*>)/'\<XZ
M=]4:RW 57;W(5L-Y85:8PD=0_<3XWFMT)V#L,$=(5YE^&/\07GA M3$BAC$1
MXM_(8RYU3)?>*KKN&BNI6"AM<NH7C<N=(#%0Y@@G[H48R:'TPTD(7!:3:^7&
M7WNZ"(YW[;4%!T?"I7Y]08N,^-X>U&N#R?SV]MWH[01D623C3O%OD_J&9OX6
M=-3O@#DJ?'5BV[AA^GC1G7&9]]@+/,2ODO_$ZZ\=C)@^5]X7Q[(2*H^EOR5O
M&MU(G*&TBHN8$=B91JJ$K#"E7NF[!(.=;_<'*UJK:G!X4!HVPG/Q4YW;5-VP
M!8B-\ET*H<K60)4%?:AP&:%%Z>=&2I4&M*U=E!)BYQ149^LT\5L[;1#;H=B8
MBVMM_^8(5'(Y /4%1X&8.J6S9VKJ7U'P5:P5Z^/I-TP<9M?A=%J9]3>B,_,3
MW<\2X:2N#;$ !$< ](VZS)^^5?CO"E+'T$?H&Z"*],W@I!9#L,]$]S)::B9<
MGN.P/59'T\BE@4@[JB#9-6X +723#-/!SQ\ ]YET#CR2D6?Y?;:7=3(,NS>)
MKNG044F!C(H8&->&\!U-D&Y&,-')[+\/9>(>:3?)SSO:9%(K,?VF58LL& !4
M?T+SEDM:<>16URIBE@$Y5^=AINKA;.D*BP$&P%,O__FEN=K"<))]WP2((_JM
M3,_KG=RLQ\W?<BNI[H$U>:!3ODGKS,O/^P4J9H&"/ B!<&W@_KI]] BB4^IR
MC#;2JS994M;2C35K(A>3TX+FV(LX' ]/\$ % G=^Z4?3 %,JILA&@4A:RA($
M')QPH86WVJXLFY)&0$*6)?L\?H=(3F.-BO$:MV1M=A<B6TK#2/<O=%_4=PM(
MN.IM:O?]E3SOBJO_RL>1'.P75.L4'U2G3%NR\^>@TG8XJ;*XB*_!ZP( 0\A3
MT/^2>ZUJSAE7IW$/+;;B9T[C?Z1OSIB^R<3LM+#.JB,7A\-FJ[%R?$%3^9ZJ
M;6I\:VFPR[]]Y69J8 4_<M&!'/SY<-WB9<-M)'ZEORB*!O%YVT^=QIW>"X^Y
MX8=8=VD6R _0C)/67$L&155>ORF7%0YSO!$+AU CUU=#M7C1WEQKTI,LRJX!
MOD6V"5,%2#6WY"4BCQ>M!S9M@Y;V/-OD(L>+=T++YJ5\RF3NOO31HO/+LJU.
MZ(*A*YCD 3;MZK08;2M>,<KU1^?-E]9,8H6(E(VGK#1U8FHMV@.V0Z9!'&)[
M&._AAOF4,69!9A?=+JP18#<;.;^JVI7.AMLT"96H:1[M*(G3J[R1\1MFT%K:
M>O)U23;?]WX.#9SK#+%G&VL38@UM[PH>V,9+#4-^FL^,T-E(X5<6Y=A5+ 0K
MQTOT:+]'$'7H=Y[#P%6JRK:R'ZJ# >PT(^=C*0=.0E>B(W)1*9K7<;I?+A)5
M6FN7#NSJTM4VU!BO\TF.W,Y'Q16(BNN-F9$\2^PB<=H3GV4Z36F.7YUZRTXM
MA?/8+J)1^A:F(YLUTAQN?/T*==Q73[7YMA,NG]0UZA+&3[Z'3VTC<_P" Y0:
M]:()0*>N_\W&*.KQ4$IS_^Z%1#IA !&VUB,2Y:.LCG\RUO:_:8S^%+#_4/<B
M,-;T@KTM$RZR7I[DT*_DS+6\.Q &M(]B<'DYKV\17?IR3/) ?>05[OF5/LR*
MJ! CY2PJ7>IWZ\]1J07.^.[TQ\CZ\BI_Y#$JDR[)"Z=M#6\XC5.F3DLA-@,G
M,02,>&7H)+,R/:_NWW]S*\?:%04<#]:3VYBI\FYW'W$]]D?B#(<G^'P8M+U(
M53VUV10YNTH_4V!R*O&KL"L5<;<Q_#2,Z4&=+O$1EZZ;<"$-J\>% 7 C"N%J
M:01D5;$1'\NZ!P/Y5V;-/SWEE_^J'RJ$&&]KWF1\HKL%8O$GO+4 ?TDU1R87
M6IXR/'ZROTC^,%E5-UZ.EFAN[:/LTYCE#SKU;H[KX:P[+BWV UZ<2%-"2Q<2
MX;5*M2H?"SC*Z"1)1V+''FM(W</8-*%LXZW>)?RLPLB*9,2N$>-[ GMXOY.
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MN71'\P;I#\(<G6H4*,]57<FF7*MK==HK729=F(GW-[FE>$MKM7##/^  E7+
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M9H)7R.5>8)/APJVGNK:5OOW]/4]0P#_2Y/]0K",MZ'6;6[,.#6D(3%9A<T$
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MH6+5)X< STI_/X_V)*)(@G*[FC=/]5*TWLM\_&[DE56>1I?-!1=^]BR.IK"
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M/VHZ9UH[_QR@FY+ 3CH+_NTQKRK"]  _P[.",[9.(8B-8[RRTXE/2+J88,J
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M0[(Q2@UPM9I>U[XSL[P+<B(B38-!NMIP/$9'%4PS0-/JDQZ7I3'Z7PGQJ2'
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MCW)9BPM6?(ZE[V4#O /"G8!-AO?; <Y](ON40E1XAJ(I&&,6I'J-58H)HU2
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M_^TC<?E[0)!RYAU=S"40>@^X0O'X+[T!7+5TF1>DQA.4!>-7: &]3+(-J_<
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M\M$NU5R=("_/+XV#G^/TT\+=$KW[!O)=Y,\J$X\Y5*?T5E^LR3.S2Y_OZG.
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M]D%[OWJ\:GVZ(,<$J"%G,PTSVC$V#9$"6!:7RO^A[Z,R\?RH2<IZC/T=)GE
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M*/??8Z@YEUL?*W#2P^E)1?,A;!TP)+U$U4+_P?J=4XS8'9<KWG&,)R75U=K
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M RI-/1^&LW"/(5V+B7I(J[O(6G;3C#B2+#2,=";K]LFF13)!PM)3?U_!PM\
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M;6<Q.#<S,S4Q.31?,30N:G!GK+IU5%M!NR\<K&AQ=RLNQ8NFT&*EN'L+I4B
M%'<O4-P*%"CN$B@2W)U2H'@;W!T2B@0+E[[KO$?><]>]YW[KF[6?/_;:F:S]
MS.SYR3-S_^M^%4#\2DE5"8"&AH;1C=$- -PO %X ,-#1_UX/#?/APL+!PL+$
MQ,+#QGZ$0X!'0("/AX__F)"4^#$A"2$^/C$E,0D9.04%!0$1%34E.34I.07Y
MWS]!PWCH@XF%BX6%2_X8_S'Y_W.[[P:0X*"QHV5AH+$"T$G0,$C0[OL!3
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MKK>N&ORBOLH8\C409\Z?UT,LY\*%_VA1A+TV0@NOH-\5EW[5?03217/+B,Q
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ME%%DT-IEVHW^U-DF@B)EQ7*7$B)7[(2S[#_J5-MB2$#FAL4Y^@<P\DRL$_T
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MCJ=Z=G%'OZ$!8@(S2E28RSU9G*"JZ!VQLI:R;W(&O3T!B-ZAG#:XHN(I@ %
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MP^X^Q0>\8TXRR^WM"F]D)$?FKYN6=+;/"CJN)XSFG(QBBHW;9-%I$1?/LXA
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MM6L U#0!755IQ8F\E0KF[MH@U\Z^<(33+?1,<@,3*OVB#'0F/<<L?+=-&]C
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MLD\BK?^VFVG<YQ6K^81J[N.N*FC9+&=9,6L/^:D7:HT6B9)4HG(^]VEGGW2
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M]-)9[RHJF&K:O&3! U?(.:F=:U71BVR@J,<^M,N+YL\>CS8R)[</WTOTDMU
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M&ZFT7*\3%MR)\JO,*K__7:S[9Z-S6@ 3>:X^V0&.*>W6!W_H$_:3^?"*N(0
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M*G.936HW[C8LW96J6UN0:TO3F)_FFFE!F_2>?VR@=4E5YR7I%]MSR&UKE)B
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M\08I/^S,L.26D9M%E0^>P$XY^QFBFT7T[(EC!\9U7C\B:Y%>DFYC)LH2HF?
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M8;*Y;4EE)&=_'Z@ 54!?KBR'T+A/[DEE(8Q6$9(<OR,71"-S<4TJ!O!Y?W+
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M]Y^V&S1]W#C-^EGAA6SMR #K(+%&2_928[YM7-O-)DM%YWVIVJ-]+F.36U/
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MO]>N'6SQ)W'%J[\8%3OSA?W<O>.<'(XNLL3]:641;H[3@:>)ZJM2^2,[/6[
MTJU8K)\IB=Q**U7/740':L"F.4/?7HB8]2246B:^_"Y0_\1:=^1Y$E9]-C&S
M(#@B0WP"_-]:^<ZH)J-NS2!2%! IH1<5!*5*[PF"-)$J/4!0>@U%)'0% >D"
M$A20WB$@)71"[R#2)?30!"F)M @!QN_.W#MWOKDSZYNUYL?SXZSUOGN=O<XY
M^^SG[-("_;JH=5-Q!FV3,NB=4^/!(7U+78,"Z!+S@/0-X<_:K\2(93*B,S9#
M@FV'S2--LM[!>"';2;">L[OQD%5<L$_H4FDGBQD'CC]VQ*_@B]^_RJ#4J8\H
M@UN[WUA+]S=AX1>\8\[[ML!3YD$?R3K;&7/_&>R]%(QBQP0-G,X95U090-H'
M^@*R@+XV\U:4<NJ 7)X/+$D#0&R6,($*>P6(9UZZ,Z-H<R8:<?Q041[#E ++
M6]0.2=+T>-E\_FQ"B_'^&\02377$JBIQSH,DE>B,C^T#UUZ,10L%Z91#"(NS
M7:;6]R;V05V(9R+(C1CF>B_6SOCTS6O%!P]NW?"@\5T"XIGC6QGPMLJXT+B@
MQZ[83XI:^8O+\XNJQ<A\"RN+UFM.;YY'1B-6@(L(<HGDN372'N@UHCD^#T:W
M!+^H<[^VN=4UR\4VF?O=H[#-+,N?!P&I=[[W/AQ-*=U'TF$RS(&?A&MT7,K.
MHOF<+A_ACRR <<WD*5Y%9A8__7PLD3VSM#>R-D:2-#;B('D5MB$RTF9X9:[\
M2E>F2Z[Q*I1VIUA=S=M]OG-%6L4,.FWI']^9?=YXEMU0 O"AX3C1OJH;1+N+
MLCKS5D%_?S_.J'"I)XTRZ5;328:G&"_+&UB5Y5<7"VMMP0_4_U**T#\*W/\I
M:R'Q'R\(I+3]7)(3(9P$#5.\=(NWT%&\R-Q^I0./@H&Z+H5W ,G"!\'^4+M$
MBE]LL$BBSIJ5;1\5=FTMW@ U_U!XI-R=)J/D-Y/LAK&= N5 1Q_CZU%O[@:*
M'ON(5@G<I#[.:.DAKCB&2KMJK-F):6F)62-.3=+NI:U *4FC@DI2U$"L$>$S
MN >V"XN8J0]?77%$/9NW9'T-$6""!+V#/CPINRVW'9Z0.JM*)3_\.4C0;[Z]
M]./. ^>I T6I0F=H'32:'P]JR+7L+G1*&;8M+)R*&FZA.!C U815%-SRF0T3
M3]U98L9Q1:S\6)0,EJ8"VB)^?Z2>J?&7MPH[^%#QJ#^<-SX%I6&H9TUA<7@%
M8 SYGG435Q7^ G^_KV#RA^6S[Y#"&@^$P_-(3$$"A:$>=S1@U;H5TC(A:#\'
MI)S7WKE\DLT%XH,$B>'(]LY'JI<7!"%SQ883J8H7S*5GICU0\DM^/4?\=191
M*:V-*3Y7?Z00)X],R\<]LC$ 0E;(TU1N0>'U5W@LEK^OZK:5966:+S:1!KH?
M6HW*3H-1_OGXI&88]<*F<;AGQ']'1V;5<;>_? F^OSEK'G7.HXM*97,2VGBY
M'_4E6EHBSK=_"RICF(E/M34U0BQO'2HU;F7/3=F'#6/+?(@^]8DZC!YI70?(
MR_N!4KD#1'W<ZW*D.3K%MIA\:J5%1D;>_LM1<P;DCB'CPFCV0TO[-U2#@P-(
M[KGS5=IXC\VI#ARJ<"FE9"Y#^Y,OI,G=T.X0V+G(9&:3LQUS/MP-HAI7Y,[K
M+W1JMD=GV,0F\BT^HF49YJH(_J:%U(;(5N32=;UE? W\J4JF*W^I$?Y\'ENT
M@]V1&RRWFML^A*:V5@31X/-70LKSG;Z.473_<K_&;DF>/F8IX^2]\*'F@1L]
M?)#7%!4RPEU[41SE=F<V2-5I<@<_,.;H*GC04'O=UEO$TS*APG_%%GAD4EPX
M[S*#)!O1%G*?-G_,C=2#P3@KM#E<@,PYP%8G=?%-N=RPXAN'!Z<AT?1DI#F]
MPHRF6DO_U^J<M(I:(8RGX8K41'C-CQ%*S*(>L99[+_O%$DJ0!V)W;O*1,]_0
MXU+Y-)Z$?_C#JG'H3*;CJ7L?B4?9 U(SPPG#[R1J_JC3?AWYOA/L_"4=C%7W
M15*^^./57U$:G7U&>^L<GJZB!A?Y0FZ;7^.#[JZ1GGPF)MM_K^2YX^]Q!7@@
M>-@P #*8YR>X@IW)IK;@,=K^7"UJ_J%$T3V%RPAN]M!5.9\K0,_T:""V$$,4
MQ-/&2G+?@NH%%G8*E1:Y)@T6U>[JC_0TTS.*Z*ID[MWQT=$5'Q=?,V%X':M$
M'_,GK?<*@)K)7T7:KJ8F.[$%<C,[6S@4UF/QXU_VBV/X(_DH#9ZI/.;;_JP:
M)T"<JZS%GO:/JO[U$-IPEXG.>3WINDFW4.4NE_?:TI=FEAX6)3^P-: V5)"0
M-*3O(5/..<PT3L\: \;7,3]?Z(<Q^DE$T(^4D [6W6Y)?!Z7Z5CD$G#(31GR
MW9H5_[JM^"?3GLS)WNAH;_Z\>L:$="1&,"K-O^_%0R_RP4<R_J4=@[W+U$1_
MG%X<B.=7",7$\2]V9*B6L7@GY]0SNY>6FN]S8YGB^J.NTQ0BWBB1Q_Q9T[XH
M%9&BO7U_L;<^O! ."KQ0[QO>2W_7;82&\'WF2W^ 8.!>#M.IKHT4**P![>F]
M.'],: :_.T'+3P<)YW=RO]]#%N+J4US+M.Z/]C3<M'Y0J:U2]BGVM'( XE*0
MR=ETAUO9 "JSG8VJ.QM9IKQ3^]U],Y2YLUBG8O"DMO:IZP"7YCV]M-.$H-*$
M6X]*"BZ.2WUAF$"K<:(<]KSE"D"]C3$^B<7^"J4^:)ZRVMW+0U#R,?L95H3>
M*\F@9K21)M\-FB(YL@)BF\%[JJL_0AVU83&7?(^<3MS)!EUE]PWB>WMHQ"6E
M]^[JB65V;)!T\G#*55;UM+,3A7/@IJJS>R+V>"E$2T!SR$<TEP'\=)*.!QCK
MC%&I$*^6ZZ ,Q"MS7@ /^]^"W81IC7#0*)3H[1]+W:'^SC#_,JTB<P6,L\&"
ME9:[QV2M]/HM_->.!?4)3=+TH\1(*+NB$M[EW+SV>WX[,YO@1;:A=@M,<+?A
MFI:MJ]_@%< ";?"27-E4-?N3/D4HE!I>U9G^+1Q/:UZ=LOHM98TN)(NGOFFF
M8'J7)TK_\GMS0_K\7I9;F-&YN,I+P>JO/'JB<ET78U!F0L;*S!>8XU]61NL*
MK;T"$/E"A/&WBDL7,? :S%+W[B1R9$*I-='[MU!]$>\K$Q*?3\,T&S6/L\V"
M0!.;WXD4JZ/B:P96UIO]N@VH-'V3!1%KV6FV9Z<+C\'QKX!8:&UHM\(5(+(A
M1."-T\G9K;>/JA-F9L:&M0/+2U;F_0*IQ;Y\[9=@[%K5^CT,9&\ZP5S_#T/P
MSX_O5995/#/@]=W6AU> E[I55X#",W= P(;!K%0&^-;/AK/*?'G,#[/Y05\O
MB5<)DH8C_3])I/A*R\Q_IKO/Y)98J=K;NK+K*(UVOTO@-4 XV'8 KFF!4O'\
M?>V)IMSLK5ZAN$L%6;U.]D79_D"LMG^!.<I\Q%71P&(HBFZC2]VOU+#H&4[-
M^:9/R1Z9E]R#?9OM  6B/D@8WY8=MSDKBN9SH?)9=1<VL8,$LJMT""75O.5X
MFY2B&+X1QK)O:P7N@D: 0#.*L.(%UQ,>W;K)2LQ.X* <8L<R!:VQ,WI(EPSG
M-M3SRMW)XB90X=K/GU[.:U\!WLUJ3""^S6M7?Y!$2#LHWVW@>0VR6O/)_G0J
MY ^6AC-C^1,4[9$N((:)XX$*AE[OYJ>B["Y,-MKV8=6&"XEIL\ O0:.K;%WZ
MIU6!;3+S>J($G\(7SNJQ/=CB86$Y'H<-D<KAR?*)/4&D^1'MGB^^6[ME_"[.
M+TKJ;6#)@K2'P^0^20PO*QGGU&\]L*B;3\S*%< 63+'MEZ78I./-KJ2^PZYS
M@IA\UYAPM]4^38[D+(2\;4OC(DGQ/FUW&[@;$Z?M$\BRZ%NJRI( B1(:'>Q[
M&M\C$@ 0S"- SF7AD%61TON7<;5_=J4W-<: 6X$W:\O9:I(G"^.<5&]N#\'3
M=8VYNRN3,!B(2<7^ 7+,V&R<4:"L["_K7#'RPO1RC-[+N;6HHZ,6P/N_U1O]
M.X"JEC/(('#!HHM,S7MW9)ZSW6M9$B.[61E<-[8H$0]Y+(](W>RM'O&&+)#1
MJVL\>Z-'@7+8>:SS'&;R2H/6Q*C06BPHR5EF7*9Z;ES'A"9)%WG+,R]F.)1A
M6^R7:[YTOEMSN<8F,BGU244KL=,G61:<RC>Q4-)GV"[0%O_TX4/G9&!:.>S<
M <$X0-)TM[4E]!'=AJ;GZ!5 J,_K,& U- 8E"+:>=6N5RE]R"7C71:5@ENX,
MK62DSKRUF>(L6)//+)T/?#V\EE-8L7R+$-G?:R&<55XTNC5GI5[3RR>6RJ.8
MT(^I*]'1LKJ>_T"K[^GH#>,#R?/ ;>$L)X1&?=JWB(PRT(Q.][+K5Z*.>=[G
M>R;\\:T\CFMC5"[RY+E*&VT)N=PI"C\LI5I[;[!_E/]-0NI\?#WAN$D- )\/
M&0)=1W#RL2:@O,BS[=V+)0UW)FL6,?.64KUU$O'+K6;KMG4!0<5W7C:@[Q/)
M< V].JKGJD;R7Q)R3NB=GR\ZL[VKA_G:K2/J,UY<TQSD77W;:1LF[CI>DD,K
MB(-U*/%T+K/Z9G-A_ U0WZ+L<S 6>=(_7T8=M+2(+7VC7_1Y&_'6)_V('4RS
MW1S24NHJ?=*EI&>8P%)9*2,F7@$A5H=YBFV"E>4/+5[I4Z16[4ZN1."# LXZ
M2]ZD?VSNVN;&2'!*6@\E)%M2O9PGK1GF\WRD7=VG57($FPM=/4G+14?X%NI@
M16E+#!SS"0D;QX)*L@]L\C /AX6>4-BPT'1X97I95ZL!_(&)NQFX;-U:7*;T
M)>4$3T:W^/SPBP A[+F!DW&8?\W>XIUAIKO1PR\2>:1\GEYDU0G37M)+3QXO
M \T7X&';,%CERUE^^KJALHSIVLX'[Z,N4@U^F):,*W,@J[K^7D@8HDPH2=&G
MXJX:L\%BK9<338=W? 7O.,O A.8_(18;$?QRFRE8_FX=;JQ'1K&%RVB@QYGO
MC@N3:;K[ J*!:;*L&:9U.TP\6;-X2JZR,@: 'P#;+4<AJK<].QU+'SO:PV"N
M]S,#,K'L/Y#[7-CK35;+:+JA_6X_?B\*GIAM-$<0PS\R1#2,T+A=9NE9^;+2
M*39(6MJ>=S3OAS&^M9$*AZ!V0^GPKCB_.GT2Z'7XV HHJ=*%K?\]:BPR;?FV
MHSNT)\"Z-#A_&+C1.Y>UHO7"BXY^ _2-AVFD_6%T;%BAM^M! *$R^(4B_UHB
MJQE<KV^9T>W(KWGZN)Y-)+%@U&92U8]MN=>A5L4N5$ [,8/T>L4GD3\#$K_
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M[G'"PJK],%8&7Z;BI/@-KZ73>]E&WULB.L<L-+23Z&YX>@4T&HR9B-8$TN.
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MNX#KR[ZV!?C9O>%(>:KMS2H1X3^\I1^<-1P_4JF"'BR=,5]FR#?).A,O69]
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MU%0=M4#LZ"N.Z.HYJJMVR>MS*7*IN;*+7!-?J'0FF,V@^%)'/SED;ON@ P)
MU-GFZ7Q5?B7?_6SK<<";-L%0C]'@[B1UM-+B>PG2/?&8CP$GA62SLNJUPDFH
MYA[J=EI+W67(<5^%=W$]>2#G;G0HC5T,/$+*E7\LA72X0ES>+6*!HGXX%>(%
M\9C9O;16L:MB7U#>=RUN4Y#.^ZITE%M4O""5D;I Y:0G\O$(4V1:9?_A^LM>
M\'(3JB>S,9')JALB\GE.*Z7&EV J-H!,L[0.43'$OU0N<8.73SF%Y>.#PW63
M3._P?CGN->J^O.CO'=3RCJ[LO@];Z*\)_5SF$ -O+9$+/BH?*!&K"=#:/;RS
M1:><+<Q_A[2#W]=F<"K%A=:,U]Z]!N\F][*ZR!3<##>FG6#+OQ80/1+GS$8U
M@[73$AO;9=WH2B_@H @S,AIQ[U;5;F"N6&T^OX:X;G\EWS6*8#TV^X)/R;GT
M AM1JKL1=AU*]J5_\X]?G4UEBK95F:)$_R.E^^* 1K-3ZD/!,VP<#E!0,I5-
M.F(/1N[QK($.+WBP'Z)JN]$G9*,'-G#\:=:SP+S=&DOL>\H+-[-%K:6O%:"5
MCSC@MSKTGGU_6&/T/?LIR]^G$'LRYFF?LU-?0_<AV_ZUB6S=PLYMM/#EV)]I
M\[FFAUU+$4,Z0?ELA@ZVJDXI59E54QUSZWS3&R9V>_I2]; [AC,-:%'HM-DL
M.3;@+FKYO?O1^Y"$2C=A8Q/./AHZH4;+Y^CO1DZ&;9:GHP1)(@;\7**#FZMK
M3KOQ3+:'AP?;8P>LT.8DO<R,"7FQ;JG(^>J !*MR(34&0IMNI^#YZ,3P\9%#
M<DKYW:*SYN-*GN>A8[?'2>OUN>Y38#\WK/B-QMD0YU375M7_$)GLX]R_#W1P
MT'%2D(BQ:T6]EQ7#.&(5/[ *&*F>&2U"02*E%</NY-KJ_<CR[2U^)_=BF1^S
M]\K(QYF5SW.C<C*&_#5L\FW9.!?38<^KPY7->9]I.E-H/)W19TP2 5^ Z>NF
M#[9/OUPX>2(23U<A'6E!,MHODG(29>OSQ<KDL[G*.F].!3T:-E'N,/-8*A*,
M$%6#7$=-\"HEEL=.[:V-3&30.5SOC.QHE6S?-G5,$GF^XS[MFB">@9H$D4%C
MAKP+]2MK*LJ^EP^S8>^H29I;)^SF@R9U@0LW[=7 NX[,#1:HQMWTH1 <D/KM
M;I-2N<>#5F$I_5MXS0),6<(I7V[_ZEH7678S0DU"NP^N(&#7[-@X*D<@G-82
M=,T:$'ZG5<(99V4LY_K/_&(9_:R+LB;A"S@WMB]-WOD%0N@.^:^"^=QU4[<D
M$<W#![:%@UC*TZ0+SYQJ >@,-&:5KO[6K]D*Y,"H_EZ&?9,/+=IV3C=@VD?\
M_H.;!V*MWF^UL,,C6_=:FBNO-O-V"?/6 />O7 5HXY-$]-4HF5R7C##(]MYB
M;@_+SJ-3' #[O-&?Y/2JQ\GM'VFO-#.='5\'0?Y1!V7S+<%)L(J.S-C&O[T0
ML0H^Q4R?= T>V@R\Q $-O[\2(?B>?>^YA^#?*Z.C6K/6>H91,23+6B*3==+Q
M_;P0QA&#4?+%M]%?WFSQP03SF3R&<C:B(EI3"IZ[!-7\FA%1M,_$ 2'0N>TS
M C5\JKJ. W;=H8W(7:\+ -_'_7P'/:D^KJ^2/^W?QP%:S5 .R>[^I!4<,&MV
M4H-]C6_^9IZ ,";L.R48$QSP\"YTYS8[]EYT\7.L._O?KS9AQ_#A 'KHKZMF
M&-(P'/ A$TN+/R)7B 2QA/(XH*7_L).]]^V:0?2"C:2"._0OHD[TL?=PP%<:
MY D5)5Z,TN@=J!1EO@4H)F61L3CZKZ)PP%7\C^F#2XDXX!*>D[F5LT7*Y4>'
M_$I[(BD9U:"_2ONK:NN?0*DD0Z7L[;VNX?\%E)U\_RF)<G@.?P6H46$BEN_\
M%_7N^:\"_:_?8'L"P2I.4F.1,SC@5\NKO^A>F74":O8U>^?^H6N36UD@$_G6
M/_35YVOMP*Q!6I9G4>'<2N>GV-BZ+Q7L)*9BF3PD+_O]YK;_L?0S'#:,%O@_
MVBDNF=-@X+!U>3A'1MJ<YH 6^L+9^D!RQ3X)SYS)W/3IX7?\;$ALZ[<&BY7!
M=(9./>B.^NZ8U"%?Y_/(4<SECQG5..!$=TH 'SI&@A@R'+#QZB]W5M<CP["0
M[@5L7S,.X%EPI=$WPZ.N:4'NKUOAK0*]B&3?*:S%!Y=<A=D)/0X8ZS_$@/8#
MS2]@[[$:[0MWBI%86J\/T.61+CQ%.."<"32K[UV)#7! [@CB@-+,]1/H$J;I
M'$2-@<6T:YI ,;S;^,#L@R=BB7# D2BTL7@7@CD;A\[@I[54&MW! 3VG84>!
M/*<@CG]#^^B261R0O$^Y@='8"U2ZI>"! _ZB[5_!F#7A (DE]O$3V (FZG'X
M.MY?_Z3O7]#(_<X.J&P7U''*$D([BE]#_Z3P7^ $0"DQTY^A-G/0N#W)JWPE
M?U7W+VC.L.RGR/O_OU"O7^K/@0-BI#7_]NC)V*/US]3C8[0)SKLOOW,$-\_C
MMW6A74^@JM]]>^VEVYNQ46++]]EZL1%<7M!]699*,G"D_MW6SND%;ZM*C"^>
M3^/14QW$X"H.(/?7=LM!]=$BOD0I:PXE%[%<)\4RE?X%E&<;:YC*/4CW3(+9
M.U?(O\.3W=]\%/;?5OZ_.\ 8F$@P$6<2%\%XA0[L1@<.9RL"@5VVF$+;I)#-
MN@ST(ZA#K]:RR^6>1S]1(B-UG;4.K>6\0UIOJTLW%\MM%.,BAE-Q0#L?NRH.
M^+A4@P/,J* KG^#A;0/(!<G?WK?2;';&Q=<G2VT1?N?KI7]W_^Z/7PK8])#X
M0MT>!V3&(@IYFD&[B_C?S8Z09Y)W@#"L(GKZ;*<27TS$Z2%>XN%S.&Y?>/]6
MCW04@E]?O9/Q[^\M^& QFV,_.\<!:.]"NU('Z.A)&!;?#AU-\0*EL].G=.ZP
MLWW\JON0-MNPGA4?T#8J^(!^ #T@ .L F@HT_^Y.$#\G>$K$<Q& PJMYLJ[W
MO58!!]S,PLNJ,;M@9[7[16!PIH\)$YL^._F  YYD.^C)Q>. 6SU>V/K;>*!W
M'S+3:"H _]CEO;R((K,J]85)9]ZKU:3]U.=B;XZ\WPZ7#<V&6"\0U21<4W2;
M@*FNR,C;6P5\G439T5^!. H[V)H$A4C.+.R.TK;V"(9C!'(VZRJ_CY0;7+?Z
MH6_0]DPVK'35Q-O7?9G5Z[!R<LEECG<HN&Z2/AN+K9"E,A .U;H:\U')%SQS
M&/G$Y"2S(6Z\ZS9X(LPY7#4H6^?UPX-""3=5.0';G?<OJ5@EWT<(H9X9I;CG
MG]547#"??SCKK(,/"]:QIM(NUU.6.FH;XHO0$@BCHYC$7CKUMZ<+AZQMSZ2>
M)\7WAN#]_\:JHVBTEZVDVN,-M>\]V!+6$TZLSA3SE,NS3:-=+HNZ84D^'FC3
MF8TM%"J0<A339N[B6M91.G53B'1^R2$--JM?V'>(]CD(W=$-G^@V=.KG@MS'
M[F"J^DHDU\$6*RN!#Y!&[V$;^B-0NPCI&[3SYS.^+CT402[/!#-/QR,MF.*T
M3+0.JJ50?&]*$S>FB.TWM76JRY)U?NP?-ZNIA4(21%E]--$C90?G^>5(IE='
M1RI%:)3IMJ'E4!9/S[STIQO*+6(AD*0^>RQA+=BXT@B].[9YL!E(KF8T=/!C
M-H;S&R\KFL%Q*K[$6",$N?#5N^SB!!E3C/I>0G1EW-,L7'',IZIQ;PL'$#>&
MWRE2#_K?$A/A:[," MQ5<5Z)UQPY'!D?7.:A%:"Y&:A$C0/(U)HFR!-/94G&
M\?7[8?\*>#/WG0-XK\.:BC]49"EG\"/!ZLFHQ!ST]$X@S5D/)L1P9'MKYB1D
M=OU!L96:;>:GKAL5M#L4PM*C#OG:G_1OE]G6G9MUM<^$V,7$+7NI9%?Z^9RF
M>M"V=4"]Y7CJWE5] D>*=BQLG7K9%,O:?_Y6/7I/CJVON +IRUT>@Q(EO#[V
M0LY54<,TE9<CQ)$G8/-D8L"@/%E5 H%7%/IE[4 _Q<R.J?>+Y=?U[<(^D6GU
M&^KVB">W6&P RY)Z-["C2YXWK$4J+9DXUR778#6=JK[G#6?QQ+(+"\%;^<;R
M$@\G;-3/4MN:.S5'A_K2JGQAY2,>#.:[<I%>GH,3JQ6;G/0O'%VSKS"V,8>Q
M#",OM01X9!BNC:+@DUT]5S3)OHTAA9:'*EE5\M-8&^^I'YU.&N=9Z"QD)$+C
M4[\,FIJB;8]B34RZ/S8P=$FG$!A/EC2;49B8"ORHCA5HYE7A5]",'L6XZ&+<
M,^8U=X8_K3%U^NTNWY41%WH-%3$ZFPR-<<M4HRADX7OQFDY@+[AAG@3QH#'%
MDEYT6L(I5<[BTUJGZW-;U^/UT04[36//4JB;7%76"42E5OQCGY.UWZ=3=.?E
MUUG+Q5+]MA[0KR?U@X]_#'$/"0A^M0E7>WTMIGKAHS)+$(FOF;YGW2%B<T%_
MA%X,GKT)%2DMJ [-MLT&7^0<>80+-#R2'3L O,26?2F/IN S-3W/-*Y/*W$5
M=N\2WMSB%=F_(:R$T-L5:VFMFM&@6*ND%^'_;LSI].ZAHL.WZ>AM\MH =4<6
M]FU)*P%!:W-^R-9$)JNCNV\=;>-)RIJ455_( 5H6O"$Z*D 35^-D2]+5Y?F@
M(Q]A>,BLKJ2T@XC*=>:JH>0<'31?'*MZP&(I0[79\O+;L4IN'78Q0#V-NR>G
MHG)J,W?.,SXY>SW!MZX%0U=O?7XW0GC;F+Q)5E:)MD_!#3J+I%U%J;=FRV5:
MY64&VZ<PWO98WB9HE]Q^NL.#"?77QP'FW%A']5^J-^*\^L6.Q]2N3RJW\-D-
MGA=[#FDJN*8^,J@ K6/PT68&/8?0.NH)1)_A 'RK-#J-1;<\I).1Q@&W>^-P
M@*DS/K0NE1=*-"'W^%=!A\N4V-=\JO^QL @AHFE?H0AW&_)-3F\HUPSY.(PS
MMKVPK=;_<,!JMV T9B?4(=G+P:L#^WK3NDJ#L4N&_;JHK4#YXI 5W7='A 4
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MCN" ]-[5>N8J=5-9,X.AR(L-S<^SZ.M1#]ZL/8[*.ANJ9]\Y7ZFLKFN:X,_
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MU='\"6(OZ>=X56,Z1A0Q8*"3AQHK=+DH8E<6[Z86B'K-3T<L'IY'62@8^CD
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MW!2U YZEW9775Q#I%;GF$J+/5#+[\*IV)]E>KTUL3,?;ZB=\S-@MY%94&C&
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M+#,8L.A#TUL$VGPH7S=;5<'2%8W]1%I-G89^V*L" YGAN,3CU-F,\V$(\9>
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M'^EG@86*QK! N*4:E.YF@8O;4E!,C"]SZ;]:'=U%SX/F9?>"'PM+L;K&J7S
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M#JG:A8(0&01S]&U#^%[WYOR4I(-U"4NHG[!<MU44W^WCF.#&][?UK2*GIW>
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M'<+$Y6/D;^O&88\;U?$2= ^:(T1/5]]MQ/V VT-ZH%.50$2W$;8"BE!3\3L
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M7VT)W9Z/TT\:61L_(^:.JQ3,W6@69JX[Y(+,C7U)VYT^TL>,\BHBK9X;>@P
M?'=FB G'Z#/G\>7R3 .XI4F9+0; K]3CX(#^![VIAG4!M.F/[0=D3M[^17(H
M17NXY]A#)Q'!R_&T56%O6]L=_6/>.P"V.=G.M7C#(5%>9G/.C$).AT5YAUUT
MRO;%AFWU)MIP^J%^2[Z7T<I)W5AQ:YW8%LN][DIKMXUC=G3 AJ^"3C#LN,A#
MT\=6PME6EJUOTZX1<@O-?2K@!)RX?KEVZ";;-BY,,.*D =[$TM)+GS>=- V?
MVD]OGGD"O:[TNMG[?#FJA6"?=.XY4 XC5^Q,RS6(_!U1D1ON-PQ*PIF:@4.#
M9/7"/QGCBL@'0"*=?& (% 3L/2;71W$+[S:#&)=]6O84>3BW_=S@[ '*H4R&
MJI\#<JE2VG ]-;(9SZ68)7%=J)*V7.%"X\9DAO>.#3HR>2!J.+O4"E?]+\9P
M_-4-:8DY((*ZC>O6C>6M\>7:Z8Z<WD"K2R(\*B\WL\?R:3(\UQ[3VD1-7<V&
MEU$4K1R4_#MS^;Q:TCH[#F[3BC;KGE:E#KY^.OIC>=G3]R*8-*7'?Z:%?:VS
M<[?I=( :RY+_ML!1:"_,/*,!_FY&7V=F-DAXMC^) (:\5W 1L)]@)V19^[_H
M6KBE!"(] )9LJ7N,IZ%^UA('1ST/7Y2%%^@PQ@%P8P'*[AN(V(@QX)<H?MTN
MK'U*S!-#6;RUHC;$=K)\A3K7$&ESN[=&*P)R2#0.#&(]M6;=5QM>@N@2#6L,
M2CI5>%>HJ>J44C]94IC?8!9B*OB]%3D]Z\) VN1#9O[Y G/"AGF"LC&KDL=J
MEN9[L53C/NXF?%A90NI1?A-/RIQMT7::.<^'![=Y1*8*3.T]B7+A.;.FPHC\
M,*[\."HBJ13D@?-[.RE2WP^LTOOG8A._&CF!V"T/S_.Z(OFZY)-V+*G^OEBG
M^A>G\_+VCKU$Z\F;1CG"OUT)JD@[HS?YI^'< 3HKLQ&V(EGD$@!B;!TRKE?
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M5?5X6\K<2C:<--N=!+T*L1RR:CGF85%0C)1?QLPJX'ONJJ6TBLRR*#D$IN0
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M-RJ> D!:'0#I[@^OTD0B"+TL5TPR@3$Z68=>95MQ*8P*)&C =\3F'#"=6N"
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MW,'"@JI2="=<]!=.2J%90Q-L=!HUC T\XZ2]AMLW7CCI-+^U$ED".G6QD&.
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M[D,-(5RII>?6<!75'/6OS@^_%3%X)Y85!MA%2PZWQK0S [!WHQORU[CIF^1
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MO?<[2R<[CON#.-X&<)4*NZ_? G?Q,2)^G#9YL/.>,Z O#]7BSDOB$&U2EM+
M'J!K#])QQS7?@I=V[]QC2W66/M 5?\OW7,1CY>!I8),/8P)FR G*ZK"I(K/
MNS&E8CE.1]+^02%U#9^J;J-MS1:-<!9O?C5-B\ S:^56X&*);Z3"7>FB^_X7
MKCF86=68C1SR(5BAOTQ&F"CIKL3GT!E2VYC4QCF)!W+HHATCAMZMH0_^2.!*
M:N.[BK<@O!J<*_4.,QO\9Y%&"V-:V6ASYIXPD(OHG"H,9&RV%#4FX87B,9SY
MXF"A&(M!D[I<DJMR5W(T+8L"5"D#%G".Y;1>[G>J2"]2Y.=<WT'.,=WBMP9[
MK*.%7ME='18^?%[+SN!Q]K[?=VTC1*IS,WKS=3\\^SHZN\!$PN\<.&K8'UK/
MP/.9X>H,WI9[O>%=G_2/FX00_^1P3BM7WU\QR>4+VMJZZ^'@-MM\K_Z2OY<9
M/*NI:Z?SQX<8\Y4%/_.,S_H/Q;D U9H_]ISYSM*]IH][77=\EQDZJ"1)F/EV
M^3N^T'$="#+K.58=:;<4:,<^_O'W+;>",AQ--YG2#P:W0M2AQ'6NCA:H40^4
M/ ."[0,Y2/"YM5DZ<B<BZS7VNCH9=0NYF]7<:3+N_8,L\Q)]NZ2,+I0W4^D'
M/L>JYC\EE?(.7VM6V$2QHYNR5SWDM)N(4^'O**\=$30_LJ<S9)6OFLGC_\KD
MY2LU[&!B9]'O]!=NV&K^+=N;?@9&UHA^VBC\H8*6\DO&#34\/ >^Z_ZR+6ME
M^2!*5BMTWXBF8FDZS<1&8L.II)>4KCR6KCRNRGENL=6>>EDY5\4+PCN>(W%4
M,)7XP',S^L6@)6VH=4_^!4AQL8:,^UU.- U>X2ZKKL.&0MM6C#$B+]S\0\76
MK$F=P16!+]H9D9ZV8M^:F[W%1:O/G[[F])VLK.Z%+X45HKX%<DKRK-D(;=UA
M25L SX^[.:I.XS1\6Q?GC/%!K4U6W+G7S,)&?^%XW #1'2'*/- #/1HH*9<>
MF*6.)9?(9  6@CH&&U>2>0_/H=J"342"08"556(B4[ ^[YC=M+10?["VF"@J
M]-H(I7#&ZK[+XNR6;G&HX([F<1!-LM*7BUB_$F#8!Y13'A&>L'JWE/_&D":/
M3VE4_8TFO0NP#,,AE[\Y\2/51"M%M,QX6!SU\]E^8-6[-V!"DP257OBM!/&>
M=:_)-B/?3,-L1J,((ZK%$P2CIT _0VC7>8"\\P0*;;HB.94I;&#[K69ZY;@6
M^U> 7NRH+\SXLCU!B'I8T*88:1]B;4'1A8^#:9 P$<JV655-Y4M]060_1$MZ
ME*8DZA'?[G#A#[-@^MF.,B4K6E0BG/[3D'K>6D"-_-?4N*X?_4=D6@>4]B?O
MB""8[LC>TZLYY)>O]SL9FQ))'?\UCX?]-Q)G)3*9?*2821I'G=1P/OEXUVXA
M99=8,Z#)8+:*,N9/YMUTL ]%_4!S(J\CE8!BGP83%AH"BMJ&@ , Z(42X")5
MLFM$SGBP8.XXV&XO8.Y"UF&_4.5@ACA=\X90N.QRK0X;Y'NRY@%]G/1;NE^"
MY7V::4X"OO9NZ?JZ)3U ')V>;"(*Y>[X22EW25$<$WLCIDJU;IH4R<C-9;7D
M%!5@@^>W.NS%J33)&VP!A@T]1W6Y]L<O[!8,B?49+09*#=P71IXKAN7EWQI!
M852B5H6X9P'>+6&8#I8$8=+"49:\^,<U4/U-(6"I=W<S2IJS!""IY!8^S8FO
MH,K4/ ZU"F7<JC"!S\&$FK33):\EX?"W1V.A>$#@56$?3]).N)OJ*'2Q,2XB
M/02-%AU&3AHCQA83DL@%!5YV(S *VK>)V  OBPT"F_.#7M"K6KL 'PI\0N/5
MI(.!55^OWI\(6"+6:-;R6\6M_( ZZ=4>K\EC=3Q?@[UR5K$)UM,C<0131=Z?
M#54\FE/UDS*O6'Q&[)):UB]5)<IICI<" QR V5#2;;XWYF"DOE=%_[]PZ\<$
MAEV=P9OIE8*X6G*T;_)B?/9Y*8TR75'\U)#7$(<Y2W[T-.\H-49!!N[/'/FM
M$KF?<YVS5QWGY6YTGS*IIZ4K2W=TXWBA@M(4BR91Z:XTUQN&[JAXJ3._Z77'
MS-4NZ0ZP8^"E&[9L@9?PYQ]RV%\#>R#X%E%\KF>3G:.!*"5]VSS0,7AW&*V&
MC 7VV[B>1&%H,\=TY-=15BO2(OWJ,IH.FE9QS1ZG_N]1WTU%-G)>$\>$@1ME
MC68JB&U!-W"VYR3XOC(&]3]#:B& B1 /]8?\]%-W1@4?RH^(C9RNR?N?HEC8
MV4=BSV5EQO#3T]!(""^76A9(MT+VH%(\6J-U**+.*WQ:R]P\]6#5,P'#9Q2*
MMG,08M.IRG&FJ? >F9$LQ7#H& PIN^EK&0U?64S>%X11Z*LG6O]E4("@ADMI
MVTU P6H8W&PY]2W*R_*TDN8#).$1QJ/;=<J\X4RD_IK3K>M57=?^TRPVQ(^)
M2':Y#:E.DE?TA*:0P@8^+BVM\^/,<[JA@.5^[&<?V["RO)K4#RQ55;3E78>&
MF=3-@/QA>[7*@C5-HFAU 2139G-;GV&65N'A&;@487)&,)43-VQK8OJ<CA[Y
MP=X%&3L\^>1*+KZ-_=B'UF!VBH!ZJRG$=:(\(H\G()CP,$";^KRUQLSKC V2
M,@!$?G>9CL^[.TBEE&2I*^C-/I*!*]_$(8M#+-&50($9-#,;*^ ] =72<CQN
M.JZ(/6(L5CANRSNKDU""F4EJA3PRJ/^F)>\/UHYVH2FQE-ZJ.XT(6;U/\B(@
M5EX@\*_8'^[+8&KR$KD=G)4C\.7JM3.;,"I76)5HLLJ_-RD@YQK8_=\@7\??
M1%^W+8":7 QQDX_> J]Y#Q_]O#(#UX^0R'/DA[\8[V#WMOU"2(]T8TP7 #7S
M"2LQ!YY[D2;W1.?ABX*I[Q#VF.C% 5NE/QIBFUQ&#&W($48]D77:QG<62TX7
MTN;B6GR# TW6BG 3 !Y3=*=_57S$^LIC9:"SU]Y'_;#,%->%13GL7.M>W__,
M?M OSM7CO;MK18]/O!!$;R.L\6#**_J,1I&Z7+7#F]?K\L"MH$HFTZR@0?$X
M>!^ZFP!''*2=O8]<B%NZ[,6QN7'M(O8S2]8V**TX$)R@-T61Y[+,.+'SV]SE
MHN@1XX73;A3\@W,CLYIOGWTR>J^P3D9^Z(PY17?L%"XI?]!O@-ES,Z\DMKD\
M_+"R\*K]MI"7@#895[>5XG"5?2#7_1=.G?<["SE7!I]S8WO1'90(X8K@_);I
M8XI8M IU%++P.ZZP25D(GS8R2T*J,K9DOI!Y-X\$N7-JJ!4@5>+ S9W>@CX\
MZZO5?X/".D>8>UNYQ<0DZ_&W[.0LU61L%AU0S7Y//*S79PIE6D9(D*")*+ZF
M7!/,>277T(Q-@P8]&$7W[G,MD*$S4KLGL&1],E^P0]2LYR1V-K_61E T:P>/
MW-O \V/<?%5&?2-#HXR.K6O-C_TZ<B7JF*8AN%F*$.8I4U#W.T5W*UO=.9&O
MD/'J;OG>]?\-;5ME5^]U(<H,$OAJ+79[(V8\NH^2Z@;8O< F<?8?ZXC70D>>
MQ;3JU@^/LB?(]!N=/_+8<6'F(>2BI+N,]77U!1U_X;(Z"/-.1?G7KDM\UJZD
M5CM_Q/,^V]?.*0]%E88?QP6ZQ7<W,KHR]8.E;UY4XA(C\#7,&WWZ\QMY+SM;
MA$;C(O,^T7$]UHA)+>GLE@',3U5"V.><[E5_(V<0=V>JI*U\6996*FW;D/?,
MD#"TK?(_KB3C^2DI/9B9*J^$EB3[">.KY3$TG!CU ^ZGU1,1ZB^-LC !<Z#'
M^^BJ8]A:7/%&M6>ZGI>GJG+; 'UA_$9@[UNXZ&E7YLE2TN1Y$.A*+G!CG0H4
MF.ZB_YS;E*S)1\3;4_*BXIK\;.P^HH/)0M]Z)#+*QB3H>GA\<?A^#P\U6OOJ
MDYHMNBVK&!F1:?8 H.+R;F\HUKP Y!).U.10;/OSG+FXCD!S*<.P4\]&!5=K
M<+*Z$VW.Y"_<67//7[A;O'_5PWV-""N$3-1JNZ,BJZGR'5I027)K33<J$4%1
M" Z?+K,DAV@\OROD+2-B@=06DIJF\.A35P#$AA H'=Q"S#'WL=Z%$M!14U S
MV&AD]>;HS6)*EG$=:B5 WDEGKDI+V3U)H2!+/,45<9MA O.\E1V)RS6:!?(^
MUWPZ!?$%-]LL/%)6Y#^@U^&1D;7W1U3RY@VQ1/_RJPUC292 [)($0":4&N:/
M;@(478QC[!L1#@SY3)>45]1Y-2>GCL]K_MWO1$N9;QWO8N_@\.M?N S8, =?
M1,#A=>6ZX@FS4UBJ$_^SX^^2(K*.A%G:H/,.=?[4*:,S(V*7/N@^UR[^L)]3
M'KNAF.CETH3%JJAC/2SF0R: @)M%X\!WQ&WX?,HP3$\ZM@39WZY[]VK$((F
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MR@I@/^%6N=J*5]$J83,W1WI4[/;;M\*##4[> JAO.?2B-AM(H=^&+;V>))S
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M03HU_$]*8ZN%I=FXRJE92$*TD>GIYV*\:&,D2J9_ZG@X[>M/7)=LZRY[%7Y
MNC;'LJOJHY*PL*!OQQ#=:VC&3<3Y%*TO3*IS*W!<];81*'-&].N-^,]D]@'6
MB#4?]>U?WIEV<$QXSL]?3>"RA7L\G>S6%0IE;OT'(YH"[38EXRA3%W^AUX]C
MAQ=36BVCNC0($0X1I)XNRE;V=CQQ&0&)//5*$; &D EW^YGXVPR<Y:^J7HEO
M,9?40HRO:+8]$G0RI*SR]AK$GC2-?91W!M,]'4 :-/S^SM(C!N;'-]E4+2$J
MXSUSY5J@M^#U4KDI<(&AL:E!)L,DQZ]QA)]?(V+-*FM-8W_VG4.Y>YT\KQR-
M 40>Z_D"?8-BW!R%1PU70-J.H,;B1"/?I(BX?[G7RJ;.$WGVDIP@5E?[#$D:
M3O%&>1HOD[N<C!<)D%_"* O9*K,0(>ITPL*X:\:M. \#[K5#=17238'GE%,%
MOF!@@6,_Z$'Q62VX58F:D9Z]PX6_1B]QLQ^Y?^20OM!(DI"V@A0'0^=N2UID
M@;!.<02E^?YHP>Z-;-"BQLF=QRF48,^EKG2LG;%93->T#_U7V3?[]&YJW_'A
MHR:P(;A?T%T-W@Q.7FE!D3$;EU%6'X?)\;913VK4RQ-0?.G^7 T@188&RD(-
MJ!/SY6V<OZ[, W>%7)0B&%)PY',A:A&]\BBDD"'[]5\$<ITPWLRO<WL>[6@G
MY05Y;%)Z2?LKG,[4(GLN5TE\@H/,R@@ RQHJ)?;C\OH+8U\2Q8PZ:>_@^[8$
M..6I4<W[JO(V*U>A+M?,U44B\5THV<C;)QH _\.^<F4?K1JYF9C:+H($]4W2
M+K,4-4^=BSN)$F$?.$JMFO2KQ\S9'_Y#6%2%V5T0A0)MX&7O [,MWK@3JNDE
M$:I) _ZGP;OWP?NA&^RXV=.;SOG++]+D(P^>R62QT_.KOL(Y"XJ]"H.]>R]M
M-@KI/M+,;A$^NPFI<"\P,!#2RWUD\*P"Q:R=>Z7F@(=5\6JK^;.1:/M];'8"
MWIAYG%>/9&F9!S#_V-PU0?MLEU.V>$E_:): S82+#3/)R5]5(MJGPRYWP6:A
MNTH\9;U,Z3,IRPLARML;?.69,'U,]=@!-4-"(96$$[T?9\L![O0,MGP[QR9/
M^ZCO;5G3B:?9CH9;ST5[2L/B'-X253OW^;R?X:]L2UWZGMT<>O<B5E^^KH!;
MEAH!>)5X-A?EA.:)UYL5+3L)J)3?;B98D<E%6?S0-[69QZC_\MVM(/N(3]B>
MV*"%79:Q],N4"5DG,XX/+EU'", W?[O4XHCK"E,+:L/O8<PE#,S988#?P%HT
M!MYZ(@Y]" ,9R_6;T]'A$LCP%O$S_=Z.[W:*&SR%I1T$=L^[X%3MT\&E$)D9
M^N=QGU"KCH,"EM(HL:?>$\^"UYE.II.J+@79Q2:"6Y-Q%<YDT9%I-VG7S/$-
MPC6RIC(P'++BL#['Z9JK5U"&D>E29P5U$L*TWF"$$6F: %X!"LOS;WG3SC?%
M#.RO8-^&O?/COEZ4(7?K9R34GZGR$(B5X7P/[_/& ,CQF7SOJ=_TIE,XX?S
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M<CCW:8SR1E9 ,^@_R30V-"5]9^H8/W)8]_7*Q7$PTV+[>'P=BM<5V4@OK*H
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MJR8(W=^YB87DMI]R0 I^Q"KR3/2/>R^"V/.:GG&/1R>5U:D*/ >L;>81*][
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MN7\UUSG/_[(-JPNF4T8V>!MU%_ANAZE=,C[MZ8?]V">3>R$C@1ZD\-9YJ7!
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M$KI74@T3]>CYJ8U9-(4M:C5,\V#F@ZHX:BQGUD=KSCJ2RV>B7YT)(@!4","
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M&9R2,W#CAQ"QW[ 5 5@#)^\1ZF"BA_$*.X8*)67ZON +3;6S?O\:^^D F<4
M<J+?JYT<$'+9LZL:C9!5G0@1#:/V=K<V$:4O<IV/9=8:V0@='9H$>F7UB5O
M^GDW6>T0>+WCA96WM&O57@9]96M-"KN'L@I3#/L6R;@T>3'^8+=II)R)#QH;
MAD"_R*ST_VU;W90(0$3'%OI#>/#.\,$;5'Q7'MB$ /QSX 30GF)C@REBEE8<
MYC35)7L,$)8TZ?J&G;.S]K3S0>2BN\F-/[F%WK&5#^"F6QHZ:J.8MB3X?_<:
M&;_H\X'9_N19%NZ"/SEEU9N[S\>$S7K/3!%;$XT1>ZB-8RY?")!2OFV =U1
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MZC/.Y#%]'%=\'"DF[>U918;LN/SM4M39D']!%%J>3N':>>@ORA9AI7U7#40
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MCTEC>:KHF.9]EC9E,T?JP9DN*H&?&'9FW<;>WT!F 6; ;)'@U]/M,F6J]'3
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M$,D7= 9O;W41F\Q]D-G2;>3]QT'<U@@+(:MB)\5+@I3[5@S+[+!?O?]5)7E
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M.<DIM5+>U#*_[K[0!DT)#37)]"UM,.&(/"8*6YHI+]G%U7R8&I,&LC8RN&V
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M:PSX=[<+$C]F3)'W+T<V?QE^*]/3BGL#%QFXV:6SN/-$ )*=!NX%'QJ^%X<
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MTUQ1S+0X,TBF2FF;0J1F3"HGP. 7*SDV>$RCU74[*(KZ]"CKD;U7-#!BY$+
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M0=BJ(D=".UU4FG_O^6;N]T=A#'SF'E"J"EEZ=VC7XU6V '>RV![B-;K8'EU
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MEV5-G69ZXB+5#-F@^).^;F%[0P#917$=/TYT7B_-Q'DJJ33@T_1%'PE)MR?
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M.>3_%OD/BI3E_A'J4S'[:YY37.4_&_O_[->F'L$8<>7OO)+JP7E2;LE:MJ#
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MW5>?\6S[:I!JKVV?SJ><G[)C;&7*K;^<\#&RR%?*01^O)35Y0>^*-9?LLT(
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M%T)U-D+:1C1N,0JGS;/B824=L;(BP^=\E\!4$A@@R@MGV,A.:('HQ9;4PA$
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M7+'=>NY-VG_5(5C#V?BCHD(N"0( -BE54> .Z )5Z"  ([F4E_N@(,H/U0A
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M78T KEM'U#$=A/0WTL\#Y5F>^ XOYN*H++M6(>Y-#$/_/1)9G'15"*E=K5'
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MV5]DE)\/BN]>=A[B,PHW/=\LO(A3DA^% 1;2(7518QLL?XXW5DS:+S:G[+V
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M>7NH%?8_=QK]*F7UAF/UBQ!MFQ(!YPC;:WCY_@/]%+VQT@9!R\,>,_!3Z?K
M'Z_?9'25-9(Y&B0GGC1$;AB>B!9+[/@K:(75Z=4-(/R7H/+>H"]M]Y0-03XQ
MF1(LX&-P5C;RZ4:R;%D:<'[G82X&\#D%?>@M.5Y?<O0'1ZL[I[_+"<W9MB]L
MO+A(?==A^W/Q3.M*1O! K#+S]AS-UVZV:<&#,LC2F^V]40)T.E97RSO,[_5!
M.KGS$5?2=Z]XL?JMMGLL]0@#S-MN1/,J[YW ;$B#99%-M96JI[)AP"7O:K4<
M ;NRVZZ.G1SS:-:8B/"\8B!MS;S;BE*YY,N%)+G#-Q\?KM/NF'T'=T;PU_5[
M.U$>AO+>2%-EBPRZ[XOBZ>^?A:>^MNGO>%H $HVF=!49O=1)Y,FI<W1?#LTO
M'9GJ3C&V\^:72R*1(CF);[?R</&6SB1F@S+CS&:D<'*Z'9<8)$K!UW\^C]"L
MKTR<?Q3W75TX])K+IV>,1\MOS&; "9&'A)8-B#A=VH_WU'*W91GHD+L*]&FA
MHSI]+OY.?*YQ;*\2C#AD562T^9[,[:-0&. [:U@(/._<%Q+;HI5#G$%B/OWS
MS-S?) $1I#*029=&2TU4>QXM<NC=KRH>Z\T]FA>AEFI4G>4D#?:U)/G!]XR*
M^,?"\NI)I^<X^DYU0X,/_Q,/I1CZ\S[A':?%F+Y!-J<-R1+[$ON*#Y%^H27O
M2=EYA3/XUED>R'AL:2SQ*&^C7UNLL+_+':YJJ/.%C:4^.+G9V?,&S:ZCF-\'
M9=O_68>SJG K[(7VJ;RSVZX9Y]MM]I',L3N.7HAWETHO$(_N-QEWB<=HPA%.
MWD[^-"F.;I3[*U'[$I:QH]9Z8U%/%')3P6(%[R+!R9#QYC5*;46/-,X_RDNQ
M;I9SSC@L?6,[M^%XLS<"*[QQPD*Q#YGYE\D8'>J:*@52<C7XQ(LXXT)F/AZ*
MNZ5&NZ4'&2BNQ2YA -+VJQQ70>C'KQS6-0-D3I.<QS"]D==,=LD&4)<B,'PB
MC9@:9X4D]Z.RC/_0/HMV=<6>YPJ%Q*%S4#C;K^X[\4>XR2?V2PMY1'JLKT[K
M1O<=GFU*#,!]C:&E1[P!,ONOT*P5R>.7^">CUZQQF9\SO]O:,O<H,?4I=31<
MHO,LOU4;_Z)=8+8^6BAZ; C%,K+Z !R=J_<^A)#RQ"JM^Z %M37N* 7/"NW0
M>,1=<$:ODR-C3D_J;@_K./]9UF :;EPP0?6PEST/(!K>,\\KVY3C'\FFN0CM
M4.?R_32PG46@\U.BT]."$J5S,E3VQO:N,;O9*5_!QX+LU[):B/$Z%L#',D V
MBRW^#LW$0U4AU@2F^#VT]83B$S4C9U]%3O[F[VMYH2X4O3>J<YK/&6&=LN[[
M<'4S_'&O<!I%W^I4FA<2P"6)+?-QQ)(&_M;BZEJ:?_ZF3F5?37Q4L_#RG>!1
MQE-L_TS%QUZY+Y98QFJ%]S[H*[*1U&VGBP<6@]*P6?KYJL3I[HMDA=D$H8_J
MXC\H2=?#2X4#/GVBJ1M9PP A?.JFQZ;S#<FK&"#('S_%KRXLP3'@/K6/@289
M+JO8ZNV8,R.+VUZ!5P*#,5;TZ9#=_"O>G/T7^0'L>Q<CZE'5<QK7I@7(>*Y%
M[5R!Z.OWIK%M_.0<@\F'>*>Q7^P!T?J04(@ A'XQSX%RU=CY*.8\;<S%/->N
M,1';_[&6ZQ-EZ0% "RY<>WQ E/<0Z8P!+FZ4'*?!4GW\M>42AR$;'#7V*,?1
M7R4H23_&T_;/\SEF+!<N&* B?& \  2=W4QGK:U,_T68\:VSSM)@7]SRTX.G
M;K%G8QFA@\V/ZT%'^[]=NL4VYL0_!8'/F$RS:56)QA?.'H3X[T]D74QX^L45
M?$@);SZ*9N27&&UK59V^L,4IM*,Q!&>ZV1:Q5U6?;+VXAXA*!W(2^-:%/OKV
M;&E.'#G6LH^S!E(O'9PL;7([P;1QB&]-'ZQ+TK8'-!XF'TG^&N8EJ(_,?4_A
MEW&?YRN6<?<(&L7$>&GJJ"-\G9U]KWH2U/<G(M<JC8H_:TY#6K P&(86O( U
MHZ@N-EPGO*3"36<GRSY[WOEL&GWTI)#DM8'>NN2FT##4"/F"W\^ZZ<>+V@9_
MI(T)6IR/C]"TVA=PJZA#C$%)1!KAG8WM+8MLBFE*;9KW-7WDNK+K)OB@L,P*
MXYSD->-$Z@]L.D,K%(E,;MU;ZM-ZC@G*%S^<HT3/4YNAD.^+KZ*(M:-EY0A%
MD:6_+*L:0]>$0K5YK:RL/0=IY4;/JASS*S\9VR&H.63OF3CF60,SWQ].1[*D
MKE#4S]6?'6O(&:19-55[(=:>510)88#&098HXF+DH(M8F\54U:U4]3M):EFG
MDBWY^_H,S8+KXQA@/3.1.OG2XK,Z)+% 9/&*ZFB0'-Q[\T,UPHE9]$OQXI/6
M=S<W)\NZBM6+D3^FNCWYKXI->D_9[3^Q!I*Z.AC_VH$Z]7=V=CQMP7\2)Z&/
M&J0:-- I_#74R/4HN<I8S&H2 _2,8)-B@@&R<J2UQ*LP>G3)X!V^NBOO:9T&
M$(+>>QSZXVP$<I5CY58!MJJ5B6. WDUV&@:+HEQ;.O.N3DIM'>T$[ #=Z \8
MP*(;V_:I@^'__$$5T-L\VHM&HO4/=X,PP(KO</-6"62#WT)> YVO=:IU ,L(
M(,"&=R !2Z FO]7.8W<,L#!V=$6WL@;JRMFZR-E08O@4HQU^#M,<9AMM4*3^
M&(?G:RM$PQH<XNYV1G]AT"#=>1&X_E;&5<S1;I^D,C"?H+LO8^GQ!1H_T5AG
MP-4$GGFHYOTT!<P)RY'B=UQ4RG#*GC$U,C>]*J;]GM%TIV3!.A(0,IJ_<>SK
MA'K,\<4TQ;^F#T\6MW! >3%C&+:906UPJ)@\/O_$IRP_LLMLY3H-*U[T6@F*
M8XCSL\%GHU?WI@B_:Y>S^ Z:!N)#I)!7FVVC%X,]:^:=2T57)FM^_3NA^3G.
MSQJKPY=8!WHI[U\Y)"1&9)^]YG;FYW."4CVM_%;2H]V[7L9KT'"YE-_T\I7/
M4807R*[Q<M'O?2NZ(&:@(9D\S;A8VT]DHD.3,G.SUR&2C/0Q9_3KNS..#P@U
M$G((])V_,"HUYR_K;+Z^NT\0$6 A_B';/(77)^F'<+E&JU\E^:!YD*''0AK@
MX]_N:E(7["&X:XMMH>>#6E"\WU$,?%)D'1%?X#<2@7P[]>]>D>NL;!=+C1(#
M8IR2BA:Q8-":K_O;HK94ZYV!7<$#<13_4J"+VG[PWGBMNW,[Z%.%T(Q^><*=
MXSN7%V,QD3>KV[&%L*P"<M?T*(H9L1_%7A'?'[%CMZ1RCG<O,O4B(!\A)RH^
M"U+]WQ<]CK3ZD,=6.E5_&=K/;<G369^[W718?\"\VY9A^QZ7K5J:AA.7_3XO
MOXST?0Y=/&;(],[Z;6OGR?"@P[,'5%"LW'VQU^'-$.[K97EZ?3:2PR-:Y*BX
M_"Q]9"=V2O2!==)MZIH#MUM>3[_=&*3K@8F39C??1?;KVGO$;9UX>VL_7@&#
MYSIRSZL1!%A&53)HG6J_2.Z'#\%-3.R<LU4,EN:\XQ@XT])N<SS-!]V/7(]\
M$XG;K5:#9@_Q9^C-#/]%NQ39X"WH].DC;B2,%?0X<M00S4GL?QV:*O+1Q:K:
M/^S=J4)B.]?+8Y9$A\SBO)[/QU<!G0]4F[PP &QK=31\77T,KBTV.W/+Y+N.
M1':UL?>B0O&V\5=AS3F J1')=T0\*;B8K,4?1]SP^-"]>M'"[F+UPI^HGB#\
MZ'PU5E\ S](L)^DC7LHS]FK&"]P)NOSVI3ZZ9XFZ+O[D"M$*T2KW#WE3.5KG
M.:-'=XUYN39XM5V2^BRV+BZC-GFI76Y/RSOBP6P#UP>^%SE8=M1:-+9*M!P/
M2$)Y>7L\B25^02>K=$@B(\DG0V3EEVIGV*F\HD-UA+V>E"M2ZE%;G96@%9V4
MT37)QI 5ERJL.S<PP)&U7CH/EBA,M+&1Y4BT.&?8 6VU0:[HJ( ''1>4K^\-
MI6@E(J&Q::9U07X>T8XI/YIH[;S27R+B( [.$AKS/(47N+W]%F<165K0,YNF
MGKQ?3A8#"N9E0F&X>Y(HWL$ IOWK*!'KB\#9'-.I,'[F+J(-+>U!;?-TYC1[
MR_GRSV;-"^GF]_)HG]-4QVBPH*X-=C03(>MN5-2/6!W<7DQ^\/:VWBUAPD&U
MC8 ''@*PO? + G=SPA=!0NM!M2Q9UVHR:'RJU[N\Q[^:3(FZ=JF$D1]*E__"
MMN(3 9R9D.<^.O,:-3BY-B]2/1E2"E%2KZF:[ND4A(64[)NOT=IUY7,X?VYW
M9.9<9"&#M&F5=3\;H7U.:!,;U#LEU'*Z8FBRS!)V N8(%2@H,!V8D\<W6K^+
MX);HN4/"K/@L9QXEM9]3_NZ[WDPQ0["H<C[9ZEGX^+Y%1^Y$E:KHM#I!\ O6
M?E]39AP"7.9EJ*>>SX?QMT4@#ZTS3GZQ=Z%T;<6G8UBR9& A]/2U030-V[CW
MDG*\95DD"&-YLGPHMB$5'5/@L$]X3,SEK/?JD(8MD$S;E+/-[+:_.C'48$DX
M9,OA$>VS3W2]%Q2HDF'>GFY5OB>IH'Q_6EI$6'AAI/K;81F6K-DYDY^M3B2J
M->]'KZUGXAVSI?.&G'E:L:/SBGR:=?M\;;[=EBJG>R[W)OBX2(YCL](A&?XY
M=%O.E[A$C< ;](HE<WV_;/$5U[8,G4"$?3H_\YV^L2]%O1=QCGI7"62^ER.H
MYH4DL1W'RY+9@G,,T"(S-ZB[;QL#-ZG,WU3J(@0\HZRYBH6](@M[.>?#Y\Y\
MEZZ4GXXZB\J:H9!+!G:K$K,'J<*IGA?C9&UI.MWJ#6.LS77ADPUVA@//,G?X
M8P=?^^E!R%@?S).7N5C.6&K)Z;2XA;&1H"%YGA,%#'IOPM6X3;1&E[-T# O$
M.%8Y=F$;GAG4)BZAT,$K64%TR-B/,R.:/><O!+IV&=]J,R)V$&U>Z^CTB=_*
M%#+@3HN/B.H+B6M#-SB1Y@'SEVR&*;)$CE<56KUT0F?@]4OA)4FGG:E5Z(Y5
MU >\-RS\ Q+0*T--QTNH6*1;+R4-OC'NQ<MG$KN]5%^:>$S2=(;N(&K5)>\E
MZQRT**<69X;%3" CTR5*Q,WYOC:^4 Q?>Z":$SJL0*=S/J5YHX7-:F(J__7/
MIA?-!04;IDR4J;H'E_"K)X-GBASBU'N*C-0'P5X5:JFWV$AH"LRSBXW/#'7%
M$8]>Z4-X)(8ERZ@5XJW"6HGI%S6%!K3$Z@4C7K+61%.%_;(-[#[5#FLKH>2/
M7(E\,\(Y!7, -TC9QN431WS(Y^P+FY,=F*3CQ L"3F61E^ ^=:S&).54BQB_
M9$1),1>P'R&<K.Q?V-2$:5.Z.Q/#F51E2%*_HGC%I]O\B@Y#.TOOR%:TM,P0
MD"H4=A-17C?%#3X?/_0)<9RU4D6,+'\"SY3TB4;ANU4M9/4RJ,AJDDH<%\(#
M+;3A8S8Q.XG5MSCF67?$MWM=5=:%KUWSZ(;YU0Q =[(O+^P4LE1+-G>0$[HF
M3T:BHM %][H976?48N@+F,CU]J=CP9[![ .P(@L-_ Q9:#+X[>V&6+J(GF\,
M=BN6#UG3SXLCEM07"^V_]I/PP-B^FE_OG=K<#/YT<;L=!O6HTTTYQ K^5SQ?
M0PZP38"GGH% 5(E6D4-RJF8A?Z;U+2K&K^?!G/NZ,0Y3I7DT-"\<Z;AY<Z)!
M!UKL6!;<Q0!Y'/7TRS&H^%[(5CT&0*J6-<Y:1>6Z4^G=5MV^KJID^!ZE;+,(
M%8()3//YA%.!1*,V0$4[YB!;&RA*=9]BYLGJ'=UW\2QL-Z[&F 8Q0.FX5GB
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MOWVU9JX/#?D%VDW(05,U?D9A@!G(/*\RAP5J\.*<H&H % >:^#Z$ =X>RF.
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MSNQA@'=W]\YJ;LVH"J8AI%MHNP+EX EV"Z,L%2XI%P=2]RN_I^F5=/'(.F$
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MZ]:'V"?"L-S19B['%Z^%V^HF-JYMQM$+=!$YB[;;=DL3W]_?5T:DM[/\@MF
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MW(IY-D2)M6\@ 9&X8G65W]$=30P\TKPCP+I[Z3@0+FO$0$NK=Y%'@)XW1$Z
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M?+$X6GA#/O^7XIE@QKM#C^+,!#Q%<@KDBJ):E4J*8@FM:'X99"HV:4IR_LQ
M'TF9K"17ZHHF9FO)#+^S<A"]\"YP5NP?[][]H'"]3$>YMJL!RURG+6397^OV
MR 9I>V\:G5MFV>GI )04)*ICY^R#58G2[DC=FQ&O ,O-!KXNAT7];\)$9HBW
MJ:!ZFR5=@Z*WK#:>[R9B#D!.C_.JC*K\-;P8'B]WQP#>" ;*[>[J>%GI6M N
M",4>MZ.8F!W=/8F=$]0QH"09E__4+HZY?A6MMB'4JW[E]T($&]P-I._):G]<
M -;FQ<<S;, 4!:V(SN@TS]7(O;K7#-IHF0+:.7J?^Q%(/-;X]C$*%TTQ*[S+
M&3/;_7I[/3?%7UIK]79:85#1_%&A&<.OM !;H^@T217'0NV>CCC+=:8Y]OYX
M29/VAG5:E91V4X<'!78J>>+%3Q+?0'GD'^+3P4@"V1O(0FKCE51'&LN?"$J/
MX>6+OWZRL66_T^XR]GL+H/Y&&XRZ\&I>C#\L-_=5/9S>*^M@A/?[E87J*Q^>
MJKKR'<2!(NNC&!'\;^>U(_X^ 9UT=CO=,E$IWC8EA@6'<R9.@&Q8*O+,QSZU
M%SGTC^-MB<1-&:7O^&]AUM?T0(*@[^6EGN(1=]O":#4-O06O390#;LP9!&^D
MJ:U!?HY&D#IX;7P,O"QQ]SC1HGD$:%7+J";)"H  A3F 3LJ#: (?5T"Q@Q?Y
M;Y=I5GG=3_*@ 94\_JF$H7/9NX+% @Z]-^\93,Y_=MWL"E>@KRIJ/XU<@&.:
M;)0I^?Z=MU;%%YU?FL&BF+'"%>X!)'S:A3<-KG=,*:Z>IR*RD8TS(_.^Q+!#
MO8*X-5?"EH3WT717WWXRUNXK=#X-(WY;0_K\K7PW<J_-/;7OA\<D9LWR"$"X
M04>@+:57NM2QN^4H@+LK$-:[OOCXK(DUI_"N_$'B9N\10)?\VVL&6Q+!#FB5
MDM#UH6N_O88' @$E;*VWDI?.",/1$FF+]T@;2/<!'3@2B6GJGRY:G,Q?LU=1
MBQWGW6.-#FRK]%.S;(4GHG"6B$%(WDA,I05IW2Q4>7\,^24ZNM7,EMG?V(4W
M_%P>%BU6R)2"-"FS)47K&JGAXHZU*WOPNR<3;UF3R1978GL/^2^5%")[,6<3
M=U)O&GU=!.D;<,![<@>J!FW\!>P'6$8\R(]/Z(^ 4)9D4#. X5::,H&59X=B
M9#_W>!6DM5];9:6<6M0X= __[4H$QAT^7?C6K)/?#%ZN]J[B2]^YQE,[1I9-
M3@$1,/@.I*J<X+<(] 5,-0+S(BKK9J9.;4^F6E1 K<A=+LUI5^/%YBU*HS\?
MD@FO%9[=;Z!==&*RW/T  3*TMIH9MC'.6&FV&4,&I8J_C"DQ&*N)K&W-.'7U
ME]49$7\AGA$8OCFS;T?2?\^,9-0]HN^ /K*PA>I^$"AO.: LT-7NF4;T$# '
MLN'I#?C!PGC'VPP[[TM.6+UN&!=*G'-L[[RYK<<WR)Z#(YH3"TI,O.IG9*%J
M6T+=^WQ'P*.GY!H:)V\08%5=N)%S$&KH-%(1;#-HBK_DWMP \<8MNH%9LZCG
M6I"%$CP<:6&$V80DSCA80%=[,&4)=^0HM/L@;,=DS*/Q"^\^&5?U>/01("N$
M1-)][Q&TQ]$E_R0^>P1TM;M4W8*/YH:?P,<AT0E\,"JS9]*PMP31N-QWIOJG
M=$9#[5J$V+ 2_RV0SHA8--H? 7>U\\<.9EM7RH,I**6L;//C0A2^>XL1.3K"
M3 (!V*7.%@JT*OOOC@IB+Z,33\/^G;1=Q)XVNX$3NN& 9L9#'0NDCE>3MM[Y
M]GB+%?(_,(H4(YV"3JH>LXW#!9!N_":+KL1$'V: U!GR/?F$(*TE'S,DK/];
MI1^,H/SI](W0GK]RG >]"O:$-P6>!<O?I.]O/O65W)8K^5?%J&#R#H>\U'OI
MHLN(V35ILG@CM7,IHW4X5T*?C-=".Q>UKGSRG[A ]&$/0*5)D(7I)'Y'5 33
MM'7O,V>VO'V=YS+J0^O;\2T"R9BUJ'?CP+8MR,Y5NAF3=6&W/ &.]JIDPS$,
MA+';3QEOI6QTHK;@/=[D?^)3KG?DGP1 'Q\!S@?N)QI*#[3(<W^ S <A#P7J
M_OO43!%-!S3 M_3W;I88=^BB0A1\/AGS"CA@3] %92[B0&,V<1_L_53 ;>T4
MO'R#7(JV>VJ\"9JP\AIF6AN![)E-7%V>>])@C=G R$^L&R93YV]<)#B38L*L
MT[=BWL1,R1RBB!OF8T.Q3H>R=O>N+_X.C07]^_',=$^^54ZU.4DCI#ACA'-0
MBA3>= &TQMRW1T#2N?6#[;5GA.4W^KPL((M,:8<^GT [<MT0YZ_>C=R49 FT
M_/6&"9I$-R%;N;%2<9X_6ZL '.?&L?[3GC/E@V]D^T^32LGE!]F+G((NCB+?
M8XDLKS0E$2MS7FN\5]#W"UF-3AXK=4T3W<&6Z,&A5A@#440@P)8R5CT&B:=%
M'G[93"+1^Y-DB@+?L_SZGN-OY)-#P]NS4FG[-(NNN;O/YZ7]WD6X@_WBY6QO
MM$;:X7VQXLLT*\I]$;+=8S13M#A\7#U(4AIDBGJNRJ!GJIMA!;Q'@!NB<T.D
M +)K#3=0 \D9YQ+IJV,(DIR>C$:]B#)::SW^:;OE9<2>18L$H7DX?B<O'*0:
MAR>5G8*&*U8I1&EO\==3LTA\_^G/"V%[6HWD1(@/W>I6]GW(]B9@A]*PP2-Z
M8)7)-?*5_5B0E": X+WLBAL[^,Z;IO[SOB8DHY[%'#,%DATCM(TG!=:%F&O"
M3970RB-@X-]1"[/!:L8M2#UX1!I(27B/$_L#J6K;L"V*)5P!T'%_D]?1O\GK
MC"UU/+N\+)9@&%'/<+N "G]-6 V627MO!N5K"=LT=.R0*<PCYFMH6I2P?,NP
MKGY"4C^"PMI5+SL[2"NHJ7NLGK,I"$<^6=0X82HE[WM5M+4Y9<7 HOMZ 33>
M.7!5-V1.M)%:*K*;U"0IKN13)_3!7-^UO+ CX*Q\*OA$\+*E"-.!Z<9T#/MO
MNCX8K19MD,R3+YGR5/ZB4Q8RQ'G'TL06M<Y@SZ\F5(Q*N4SD,9<+?<:=J&LK
M;6C $=/>54(DD7=MM/S 4F0E3M.5GLAG=4XTK<_^7N2+>SFSV#,-CJFE$_.]
ME%GFUQ>KQI%+YFS(PO"UM,4#S[:WME.5>I[&IA<'$# '!R=;>RHN9M+S35RC
M5QT6ZYGU2@*VQ24-6Y#?6#"##2\%@7WC-VOO=="STXD]A7<^%W?;W#94\'R<
M5)@O>]ZXF)J9RM)0(/%6?S7)G@>&;-FB&*%>^LEWC_RN3.%,N"/ '+?;3IXA
MQUG/N=C;QJ1:$)DRFG.P?ZEP&HZ.>6!?9_$]2>#,I*R'2Z;HO\9$F];559PQ
M*YPFM7D_4GI'%/-JB2U%X&?IIS+=9)^+4=IG:8@*Z+W5<1:R>G,&O8.RF3)K
M6<Z8LLY*"FQO93XJ"35DMZ+*#S*;"$D6.>C"W0(]3>&/Q!*)3_E7,%:/'>\9
MS2%PI@ *P:\I/>1!GE)9?>R*FC8[P4? %0]X!D;>6YSC&"[!A\3R-#[*FPNZ
M#!(=,YOUH1W>(,@&\!'$IUQT6&8C;-&Q<]=E4\I4$/1!KQ>@ZZU)3.3>WY,\
M AA4%#!5SS'>G(W+)Z!&^@>H38!!;;QIR_$$P^@#V8YQBY.^$2,?;X0I'3X"
M6+,#3W.@!1R38_F;;82!;JD=8* 'C'I*@E2I/&LNHF&=/-=\2W#):CXW,5OF
MJCY._>ML7JLG7GO.NU*#IFZ1^Q1$#EW.V]2=AA4#,4#0>8)=4&O1SJ;M7MI(
M;E5;Y9U5?><M>C.'9ZYQ=WB_[ZX0$N4%NKP![7Z?(-&QYBM( UP(9*BIH4W(
MFR=GY=BK@AT8!+V#"G;N(["/2APQ:D%P0TNK(\4"@5\_5C1.DW\86J12A[KQ
MRGPK6J(\S75RVJK1<U!HTU0;?#05[2*1 /9'NI3Z\=5VX?Y6V1/ZC)H7J@R3
MT04&KB?U?>(]I8M.H]=;2M7KWIY^8H&<.$F-_P:G,B3^S?I@ )FE(K4Z9^"U
M2DTO2^Z_KSCY4'Z,KT%&LF.UPJ1X(0DO[Z'77?PE!Z4_\G0G<D@E>(-7;0V^
MG?DJYQ-FVI/843(= $DJE;J[ALRB-)T>]37>IDK\==#RO_Z>]LNX@]9#GQ%[
M2O1'"E3>[%] "+0UHT&(JZH^Z*\U?*+5DY5KQVWVL8(7-YB6<MA'<V(ZT68M
M<R[8 R//?0=3=4+RW*F]:.+=E-3>SEN(Q+YBND22!I*9VHD>Z +$<Y_U^*\&
M"'W!'D_RW)U)G#84-:!,B#;G?<;#:W9KE-TQMV+=QYM49O>-#[^'<ZZRFQ?-
MN15HQ:;UG$A,.4O5=!=\\J$U9(NT"A6!LH)2"3X40"<>5XH,N2T\"E7._=8&
MM=R-.0)L3,1S2P^\!A9SODU\4JQ12M:E$'#$HIX/?/-[*E.S&SJ#DP9'9L$/
M"#+[-_.U(A1ZZL?8@V_/H%J '=$T#3DEA=-+/"3E?L@D47WYL@Y/S@JF"*NG
M>4M,,+*'2U22)LFA(GY#Y=K*?(@%QP+%^Q&B7>B$N-E -@4P( >O2)H>B&A&
M'+[<O[.01,#JSX>;R'"85E+T,/GO,U UMEJ O+S:AI!\KM7XQJ62@\09*YQ<
MD)!/833=^(Y## <X1)T@;^>=58B @$Z0UBU-[[#N1B9(2/P!_T#;?I>FPJOR
MY6G<.+A7@!Y]TOFZ'3IF] X$EO).$4YDU7G&JH#T575XCX+1[ADW8@_\SVO[
MV&#$W8)N8=T#HUCY/GV(-F:CRO+=;U?&Y?,-]14\X)Q#I/UCG?0NPB#\6OBU
M?"F3N)5-F?U'4:(BDQ\%2D:<;B^=2A+W1LODZSOA69KQ&,W%!.#.2\Q+S/@N
M2Y_7>1PRMC-YY>M,8=#U_>"@D/& K9WLJ/O)7 \YWBQJA:M&"%JZ7[TO2]9+
M!9'Q=EC6ML)*<(:/&W4@Q*!KN?-JQ\CRCGBDSIGG[W,X;H3PLZPXT"ZDTKP"
M>ANU'/<GDH1-?5*VL)F,.< X@[S\UYI!:+F0.;1(JP,9N]F[4+0D]#^'%GO_
M<,8]FB8!P/57:E2Q<.QP\8YPHNJ9&R!>>!FAB9!&1K\$8B30NCM41A.RW5ZR
M6C=,_>ZK_&^#"XPP,T.HM=3"1-UNR#?E/EF)A O#C-/@2=*7A[0E"51)PJ#I
M2R!/9@..K34^97"\W#!Q#/SX[Z22]37>5602AA=3).Y<O=E^XF>_:Z4W( ])
M@/TZT3#*B]K\%6J.LU]E:OMSOT)8%0P)GS'IVSP"H(Y@ RRJHG-CA=;VJ8K4
M#@Y/!.4W<\AE!*WH'M.29;<<Y2H]<.+U>O*':8NW2%,+M2(."55K>:3:(>OP
M?,D/F$7X?.RO0);Q#MZ$#X:'XZT_6V3:F=.LZP(K;[^__7 O,4::OE%PB2V#
M[?0R>&NBJQ4^PJ'I'774K(/:S#\@ 7"_=4J#KO ..KA%PJIQGEKKH7+&SL3,
MSF[FD%TNR7L#T]HR0/GB_J?+ZXL) JHJC!VBQF%D3_VP&<8<:AC(Q4//SH_%
MV[[7&[I'/7D]YXXEEV*CEZ0JGMH3]3/Y+94ZI!DIFQ<.E_=[0DG5B6DO'29O
M)!&DA4EULG94.^_NY)QWIAQ3?;GC)J6QJV9O,]$H(TUX/->A7>B(EXW%BL.Z
M3Y.L7>@0KS=^S.2!;Q)UQX;J%@ :[>(CWEV%6?EZS (J'>O?E.-T5/'F%S\U
M]L='<X)>;9S9F#GHQ9M.<\8?@"P:'3)I([3_I*_0YS7D*,?</AM6?_>,=%91
MX,(_4%^"#U+.4(+#BU\CQI(<2GJ@#H:%,P]!DKPVXRYJ=-BRGQ \Q[J+W$QN
MDT7!]GN^&:TB6H(ST=W[VNT05>[_<]6DKI9MT( \NV,5-O7Z@_\3'Q_)F3AG
M9G6\6<JGIE.7$I9$[+(Q'6:BM)%EEVWIQ.:KU3I* H;XG?:(NK"[;VUJ'^8>
M 4]H)/HQ8!/&\;Q%7^;NH1(Q9<*;Z3;ZR6\^(0XM]_LT3SA(41J\21X"DK0R
MFSG!S9=[:I(>I*8&K+'5H_##B:XK6W=^KP0A!"\[ G8_)^$C7S\Q X'0@ E3
M=A,552G0;K1:C?Y^G/N]"C-@ A!C-_O(OOY%1['_>QT5LF<U^830C,"^FE>.
M=:_=9<SF"' Y M9\?P",A?>9_B)8U92,\3IT_W!5$5ZEF;Z1@<H4YTMKQEAQ
ML^<SQ/04H8/<Y56>DIF&@0",#_\9]U8]R^]+1< 81"9>W(#N==Z&3-]+=>G<
MI5V A:V<S+K4^O8$DBH#2]W#)IC%,I)IE/7OZU\BH?VY77?2S[?_O@Y&_D_U
M$?VVHD9HTQ#T3Z:+:>!0_^] Q):V_3=N\=T'\.[D56B9Y-+.[]?X$,N*\G9>
M.]A&' $RE.Y5_/ +4D.0<S19=1M^GLT4?\&'AM+IT^N%L -;*OMR5HI(V;D#
MGK?NW\O8'_'UPY=PID/H641FTRZV5ZR_>$^X^^AC*TFENT,(J:0G&\BD88H9
MP8W4[_=!4N3N??9734!ZK DH1U4$+<Y*V4]"6THU_LC1TF*N@S<,$ER-S"%1
MP@\U2C7-)P*! PK&-0TP+BT!X8&(#L1AG]M)C1*'/R@&TI<]G L7:57A/=4[
M\KF0W-16Z"BR;3^H%SU[P #:6,6F3Z7OQ"[JJ1#DX !R ("'&.Y)+\6R))=.
MHYGA"]BE)SD/R<NYZ-DGG4KODL$HN,T6R_^0-G8_>;%QX$^SP/J4"%-PJ%1!
M9[IG>P1$=.']97.&HZ=4S\S5V#%AHLEAIDPL;S@/1P)X..2 %0V'H,FX;;K.
MN'XL"K\;N3+-@ZC4"9$UI49]J*<X"3KXG*"10R) E)#'N!"K_/G#7S*>\?^:
M?P$;R0:<GEAQ]W1[WJ"VM]T#74[YFQ0&Z[]WO= ]T$\8?XD^W#@VQ;*#?2[M
M]?FESH^U1P V_<L-\)1_/"-"[-Z87P$+=IRCJ-PT?<FQ_E&C*/\JA<N$)?-W
MI:EBMB2\@O./Y>W?LQ\OT8+_ND0K8+18>/5-6LD>\M^$Y4>#U65VOKV_NAKT
M1U=+_-W5U/[;KF:<M#A>;HH)AJ3M*E0:'E=[!(#UW@$%82A)/,A2P/"RP)BK
MW: V93DL.RE[-T BF=0IT(5"\]5IIGWOU,KK+EQBRP>[,.>NC'AYG-V4D(8!
M]KI%;*X/J;)83;@SF"*30. 8FT-.^'3OKQG( C ^5"2N0F;OG5]@P[("O^;X
ME\).[_^78P&/-$$M?IP8<T.>SC(:44%GL(S!SCB.@2'(OXN!G[][8*3=$6A/
M4C2@C?C+S,/G&'AY==C"+'R-<\Y=DD+#2-!31.L?>4PAK,1)3[^AN\V82)\'
MD/#[13MLQ!NJ+ 3? W$:N@P^+P3 M+Q%H_M=.#EG#W6X"<OB,X)R)FNWT*(2
M'DAE53QIUL';X!AOTH*6L(@1= L^MH"M(X#&4\;- Y8V+-0^L_X9.Y0H_!K
M/.'UWILOK==NIC1L@(<Z ')U&S3C_%SX?"C(3_U@>LMBMCOC^>/Z+;IM-N32
M2O>%3>E+YQ>UTW'>8%HJ08.2Q1Q0P,T-CX#.*R#O.[=@'B5BXF;NHMA]4X"O
M1ETL0CDDO"%?_G.8M_E]1P+)!1SR3K4RGU510]Y(554J=RWDZQ.+43LQRK^Y
M85#X\%7/1V 2I^\)UR%(;:J82GJC;Q5NWN*9W57,])9NO+-BD%%9=*G5S([Q
MDBWU*]D*>S828=,<@08;]X%@W=NQ&73=D38:V?BJ^@*?H9-Z>[F8IZ!2?4IV
M\J>!V4] O2(-4OZ:%T= 0^5JX"IF(/>K%W3N(=Q,'01]T@V)"QC*W$"PRVD2
M]\@@Q[KV'+(>OD6LAB) H&!C"\F'>M7FX)"\_OT$T5Q<ZY(R5C_;+/OLEGM,
MHN9:6CA<BC,068-+_VJJH:?2I^;V;4F:A^H^/E^)M9@G?O.)?_QC1; !R<B5
MNK*^[X*ID4_:NVTA99_5$XZ J\R;B_4/-*2)+3A.D$2BX=CW#TZ@)#@^,&P6
MRC2,@B7^,824/5IFADS=EC%O7VH66E]ZI*D,?2Y>S74930Q8_FETH7\8AK/B
M(A>,^0$U%9X6/H/O6+STY?&=NVNH#<AN5_(AQRYDZ3EZBS,I9(HZ)9(IDF[*
M-IPC[I4(/G[7A.]>WRLLFO(S0!V*U'X]]?<A/Y98IO!.5C2T ?';@!_+ACEA
M$ %[4;"Z(OOG5:QE _8YQKU]]=QUX5<$&O@)R<61A5\\8$X2WV4<*"+T/^J&
M7;X8%!9*]6@Z-J'LX6#&Y/##)2>3AQ_KF-,\27&/ #_85/4!7AH&5^'XK_**
MUHW0.'= %&<"#6VWC#/SMZ&,:4:'R9:CH$W?U?:TJCB/@"0;^,0-^+2B%\U>
MEN\10/Z'O6P$0HLR=XP0^\]WY$C6OH-A(N1U^+#UM4<;M;6*23?N$XA<D99<
M&O_3N,-<724%L[*$=")\@B0[V/LT%"U_^F.<P8")T9*V@TVB10E?A-_=@.=<
MNCJKG4D<^%/69?(%0NWS7WF0#\I)KB83R8A*7#AP^#Q7W*81<\./H@D/QS14
M4D"1,?B>6,-3[R$JM@Y)-BS=P*T?K<%?RS*@[\8^A_0B1J@EF%2C!ET#CF_]
M(\IHT@#!FP%TC/VV=&&Z+\A#7NXB)L>\^: ?MR'[$]"U/(4=>A#T)/#1.YPY
M6MKJ+3*W^0E6V:UP0C%?^N#SWL>5Z/469@[;7F=/>4Z0,D]":I_MS'=/5EPY
M3SFD6ZH9.V[E 8[OPD.%^=OJ.'_<$?UO1I H!PBTV>^#DCUMK_LW*[#>)AX=
M+?++BM9V:CQ38<K+E46IZ1'1XRU*^J*,/FV*CK%G7*6(7XFN88=HJ916<=5S
MN0-^VN,]NJZ\X@^5F2$;BRI/-UWJ?LY\.^^+$6^JX9,-NWF?'TSB![3P&*7,
MW2GR:ET_ @0@WP+IQB<Q"C^>LF7T7.QBVN0HSP:Q,K(U7/=+NBYE_K6G@X?:
MMG+F1A"M0E'FR.!T\ZUTM03N$<O?[2))E!6MCVA%66]IGQWY(3P,U)_^W4.L
M/##HXVF=(E#]Q+=K/<;S)8M:9(0*,8Z%86Z!7O*WSE,]<AHODMVQ]<#XQ,(Q
M /0(H$LBUN/D_#:TBSXC> 2@ #A&7.%KT=K!.>LC8 \ 2QYY"\%(ZZ-*M&,%
M'73Q-C%(N\E(X0?8=W_)&P<N[&D> 1;(Z@5VD"Q,X!P!ZT-2[;GPKCL@IZG!
M!UEM(58[K(P^U9K?1FO.4U8]+*YIG>VE31;/!X!.:GT^HP/?)M74]@.7UUUT
M509+5/2&@ *Y<E!WX<W9%=J@-SAKTZ+XN-Z<^8?70$B240'O%H < 2'=I^_?
M522S$FJ0L(J"E& O,SR]=5OJT.DL(>TUM/=\[ID2IPZGV[HZ2V1?KW_46^JV
M5B[.=+/GA,:UX;CYX;F:LDBL3$Q,2R!-3U69?*H[I/WW;,2;MG0&OM_*GE,T
MT1WFY]+OC*(Z\!M&)AK"#/.K3K?8\PT(C4GO05WE30J2#RL<K<"6GS> Y/::
M\L!<7\HZPU-7[@G"!TSVA;0:KP-]RR_[])C2.=R=+5@GU,\WJ'^R2.'S6='2
M=KTAZ\:LQE.3;YJ63&<<'^=T_FST(@L_KO7-<#,@B<HD-AK3;[K;)BF13YK)
M$/I=&7<O_M+)E47B02^G7JY_J ,&UT*6/+J*\&$YKRK3YPD3G\8+XB*91(<_
M4V&7KQ7 QK<H>H^ [UA@U2M"WXH^75OK<QX8DN59D0PA34>OZ7G:,;WH,UZG
MRO>S72FZ,AL5U4MOVI0Q/ZM1=1^'H*8#_14?L!2R5R]$GAE(+W,T;&9^)R_0
MQ!P<]J1>'+\];^.-3^20/+[[\G_JST!/5IU2?_7<C,*SL,<["SXZUVX60[F
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M?HCQS&?D"&<2+U%Z-O*H>I15PG:Y7FRYKDN?(Z,H/NWQ@ RDM<.AT?#K@<-
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M3&UU#2Y^IOAPHX6 :3;,'S2X>419=23AV\66MW(?APMY>NI\O15N;7^A]US
M%BUJX@['D;A$1OWF/CD;[F5O@4Y)A5N]^O?\Q]7RR\KDC0H_)$;@LHML2Z$_
M9=!>[QUI, M4,%LPM&3>(&65V,#7>S(DY%<K'2ZM7%-^'M_8;V)B8K.)SI,-
MN^!Q>+MM:ES]0W*)"Z]P.%R!+ZQI+?#F-'U8URWF34I_"-G*;=>,^\GTJ*"0
M?JXR^GA!&P16K7<R2<V$W30#2.G'XQD7!A9=;9GO,VO-?C4%PG7]!<+=38N
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M?7V;:A$MN3*X6ETOWAJDGV6PE%156[+"5OZ[2/#_R0-Z]/5_ 5!+ P04
M"  O/&I4N/<&PVU"   04@  $@   &EM9S$X-S,S-3$Y-%\U+FIP9^V\!515
MW=<OO&DE!0%IE%!:NN$@2BK=)2(B)=UY0 24;@211KH[) 0)):21[CIT<SAQ
M#S[Z_/5Y__=[O_>.]]YOC&_<XUB#O==>:^\UYYKS-W]SK;U%3B#G@6N*L@JR
M !HZ *"A_@'(*> ^< 4;&P<;ZPH.#L[5JU=P\4D)\/'P\"E)KA.1TE+1T]%2
MT=#<9.*Z<Y.!@Y&&AD6(E8.;AY^?G_Z.B(0PKS@7'S_OY4W0KEZ]BH^'3T%
M0,%[B^86[W_YAVP%B*^@L:+;8Z Q .C$:!C$:,@.@!XU3BRT'S_@YP\-'0,3
M"QOGRE5</%2#ZFL .AH&!CHF!A86)B;JJ@_J.H!)C$5RB^<>]G4U$QP&!U)>
M_^B,*XS2Y6UDZH-[3'Q/'5]>Q26_04%)Q7S[#@LK&[^ H)"PB.C]!S*R<O(*
MBAJ:6MHZNGKZIL_,GIM;6%HY.;NXNKE[> :\"@P*?OTF)"8V+CXA\6U2<F96
M=LZ'W+S\@HK*JNJ:VKKZAD_M'9\[N[I[O@P-CXR.C4]\GUQ87%I>65U;W]C<
M/S@\.CXY/3N'7LJ%!F"@_?K]6[F(47*A8V)B8.)<RH6&[G;9@!@3ZQ8/-LD]
M-1P3A^L,O/Y72*6C,\K;KC+RJ>^1/74<Q"5GXE]@WK\4[8=D_^\$>_F_)-G?
M@OU+KDD 'P,--7D8Q  (.(6R9/KA_I\JGT;%S=+7QW?-?#P'IQDX8MC:F%X*
MB+0]+9 ^DI#?,*C^+#=_7JUDH-\R8E<M)K_+Y>J3,+N@+I+^0--H@KJ^W9DQ
M0(K6:Z8UNOTVO(>/K;,[)\ \5WD6SF9UF+.W6O[BC8^-C?W=)+OGK">1\5?Q
M:_;R9JI8B%)!C3UYV7ND9?!,,? V]@3'4I!L<]1.E-"N+=' Z<L4<*NG*DZ.
MVN-'SL8W^A9IY50%A;B_,@DY).H%=7((=I F*6MB-,8;DFWHCWE*&9,;6NB;
M]4;FA+HSC^1</!1[H_;N]-ERU,!!PL9!:5T&AJ@U$J!8][3-AOKTC;1815HX
MAXSIN290 G'J:&TXI9XSD,=.N;J0JXM?OX:&&E^7JJ6*??C.8SLP2Y8[3Y=\
M[F5!?6L?]YFI8<CT)GFH:W+'R;AC[[:KNP<-Z9M[-H6!G"^QT3"210U%)X[N
MUDS!6[8D+2Y4XM<\W$6^IY@?YD.Z016VG-5H5.NBV=>,IAF9_48P#!7L\%_T
MNU%> 7K85MS"#B'::WO]#38W*^N&[6ROM2*![QOD.=7\&_IR-[NG B0_LV 0
MS#F'.24#QU?6(O28'W VW)X\5Q=I%;\^_E)47<X%<[@/WY%= 0V/+7*!Z1G&
MV34PU:&'.&NQE6#MD!6[!W.K?V #7A8%GP+K^5Z1Y&+1,XRNVPVE>)9W5!K&
M=CY4)N"]:SQ][L%$L)JY%\:MC$9_/V5_R$]4]/^D'?X_%%X7'Q?^=Z$&X'(C
MHSY'FDP#ECLKG9[1$"W0 DL=$LBPTT<"+:Q(X+-: 1+H7EM  M U)R207NPL
MT+@<9NKB53J:=-'W4=D+01(:"24_+KTX2(-I\8C+,)GU^MX8_=9H^[3LYK2/
M2E]/24Q(JCOX[F+75ZXU"21P5:8+CN<Y#C]70;!%GBER@=8-QEIVOX#WM;X-
MRHF#$O=-4.V$O1_RV*^U4[4]N4*P_$%* ASR_F=/_7$X%-6S@8IE+?@ P2%B
M-MTQW"1;"\T]\4ZV.4Y99>2%YY#=4Y5:PCP5J#4\:CE0W09O4=Y!A.FO6VHJ
MZ.4T7!$J_A3"4O3UWRJFLV&?,^=#%G-*E%'T]2Z:RB*]<,K]JNLIA]%3'U^,
M8<T%<MI6>P@8<Q=O)+ RQCX1$P1PYX\Q?8WD%(<2F>'PL,W#J5.OQ-6QJK.W
M+/41VH=C,PFW\=4FYK';%C/?=22+LP1?2,]*7\"J(V2>KF#K$CJD>(XII?D7
MO\B.7VQZQ\G[)3LR2;K<IGZW!Q+R8$^TZ!&U>OR*JQ-3,<E*@,Q*VC>,-/WQ
MF.!#2B<=A$:FD6)/ELZ%)AL%SWDV!K6L08LM(O[QH5%E5?G+ ]Y3AX&;(7<K
M%J6WG(937 7>.\Q?/(SU6C54"BUT(!ST8Q2W-=F9T@$I,N[YO!VT.>K)YOU,
M.S#Y[,L^NU.4K#L$JJZ6E?7">[2F/,N\U/+47N;6>YM9!2JRH/E7/IOV.I@'
M]XYRC-R4?!2V2#9O)Y&2M[\D39@D3=G[+L%.#,.QV#5[ER_>**UUK11;XN)3
MBFD4.#1_=X!_94^_BRE&)E\Q[ HW/2L?.?.AK/MY_<#CD7,+,'=<X?&;>J[*
MG%:T1-5JPRQYM'A'+:<Z_U2'@'--U;. A\G705,F\KPAE0H,!?5F^-P*1P*)
M=O,3V]_!P\O.%B>/BDFNW_H:=8]QY6(M5S^\B:08,-ZF%)_/P$]5O*;QE3BZ
M:C\&6*O&)06]M75IB5O/&N'(:;26WYGWBL>L8K_)Q;,I.IK\J6SO8TV:#]F(
M>CF/ J.?YK,@&</K(_,LQ9.=5JP7):MECM:SVBA+2:]@?_?VQ;99?5VT:1 S
MU\X,0&N=&-"E.FWA8$5L><@_?D/)VL[*$-N5MD><I>N.!+M&1[)$?ZT)677U
MHL&+]V9@WKL\S_"ZU>LI*=M@[.%T>&/OY%1J9&P\.)L_G$H/OI9)HA9K?B)/
M77$%)U<1DH'+)?1N;(W9,SZN&"LGPA]FQ1#1VI=C*,/<3B\H9(^O2&LZ3;0?
M5M<I&F$-5FZA"N-5CHY_K;C?V;'6B^M0YT5"M&)8'!FT\P+&-?C0Y&JST%WF
M%*DW6*^C_2A,X8.Q73D&>S,)I2;%CPVFKW:^(R$-]D)_A2[X B/Z8,WMHVC<
MAG"STOC;_)&"[/H37SD=&5(=R@E2-1G@LI %+MZ]/N7N4;3H/ND5FJ_-_\8
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MVC(GL<GN\E=,/$]S*;I$!G*>ZKD_7=B.';B0J-/#Z[+]8HLI%=B-+R\>98#
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M/ZYKY&7SO1\E!B_P[IU-@D:G?^Q1=-9E/**6HO?*75"U^K$,@ZB?1H$(N[;
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M^N_2JJC=>^<.ARUFSD=L/NCQ5WP96]=7O;^6,8 3D219A7;_0G&5':^XCWJ
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MI;A);%C\]_U'(&PSQNT6FQ4X7_'#LP3>Y5L[Z<T]Q'PZ?6[/D<%DVJS^D*
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MH""$3 H7&Z -Y+S4(>DD"]J(AL7ENQR9?K0R_Z>K0,CO_P-02P,$%     @
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M<B)P*(Y[XI(KI:2CV/T+*& 27_Q,^<K,96CU!<(*$$#I?ZT:F;L1N197-!Z
MF*-?K+#*Y4K7WG/T1F?XBDYA:69^R"=W(EL^3/%\CHZ.O76\Y6&F^/AT7F3B
M$Q[^G69N;<\O=QYW6Q?&3GI+:<K9S'P31/^$/B%8((\]YHQM>Y^6C#R .9_T
M<^:FDV!#F]70!R7?T!_,LU,Q/ 8!4V]N4S8!*,IKYPJ%<2N74?>41)6X&@S=
M#RG?&._MB 6[4?KLIR'B4]E"T(T "%Q)DJ."V^0U.AB'0).;93=[],E4MURT
MZ[<WN#RB#Z L.KHJ:M?U2A93^\@7]1O55568JJKV]K0$&@* 615->AFLJ9HP
MG%&<E8&PY0&1TZJ#N AG5Y^BA2SO\7=A+N)4.1I3C1\ZA;-810:1D4E)95(K
M3813%C=U)N5*.D]HM.-4L/SX'F,<1\FB^C(DI>WFTPLYBBB^;Q3.DYB@PDU_
M;JFKR>I1;B- C3L=WZ<5;UTJ$#,O76%.4,X=6*):-1MR- N3JD*,93#6F:QV
M-7N(IE_A6P;>/K&3:D#O) N&W'@9<1])_>ZN9IESU/0I)DU$+0>=S2)RMXR^
M'OI.DI<[V7)6DF[GHK_18^E/I=Z"T].RF,IE#!UDJ_9)[XXJ^J<'M=,Y95'%
MXNEDY=&^=?3BFFB[L14T,U;[C:6.2:1KX,P".M[--P0W;SCV6FB#L63-4RU&
M[AW*G6R<=!*4O340ZN*B74(_7 L26IH4NCM6;,[ASR&V;^QC']%4O,@\T<I=
MR2!$1D16R\W^=&:+/U,*;^S6"A+ %IW$B;&ADKD;VC+5[4JHEZ^WANU@L!^,
M9LME3'OWC8TX&6V6&#Y]B1M]1D"S,VZD?KX]G74YUW[$;789,O%6^Y WZ%I7
M#=*.C7CCDBS;X[" 0@;.LI4[U'46J'U\?$;7F4>/19,1 \ %V#EX0?/<U)?>
M+P.G):*-B >WJX9]OYTLO+O;;>Q^DBQ?G;1PC3^=!Q&D^! Q.3VA.AFX6L:\
M?E(G"=K?!D5N*L/:AA SLTG(C/3%"UC;U2C '@YX4NWE#2OWL<]U4+90;7J"
M89YMEX>0UO!?Q<_*/YL =<=I":M'C_/'OS0-8"&6T:RX89@70KE(63E[2Z%L
MN%; @[D-U69S/;^>-O0'M=&Z $[8C_/O$W5XRQIE^%\L*!^-#N5U,,3*$OAB
M+WF3$GP3]HFLG/_T=3=7]X<D$?=#,]8G^1;'NS$@ J\FFXF0$+/3<%['KDH'
MZ>*<RW#$<*FO$C$@#S\=N'[R/<\M@?Q%JOD=M4=8QJ_SQ5J5JG(85^+L$96D
MH51*?R),NW[R&]R%Q7##\&L<2U\KJV>G)>DV18D$@<?.(1?0<.@J' BE&CNF
M.M@&[Z3!^%X&_10O[2^AD+<?!K-T64J7N2:MT!-C"B,C,20?^]JH*1:G02Q*
M7A\+#C-)W;O9BT2]1)6;)-)60?037 Q[UB?M'EYU$G7.4O8 :)KM/&K8V^.G
M;?V>DE;::^<FPS0:!?MO(S!9>7Q"PEZJ0,:4^3(VN:OE3M39[(RCJ"<POY&B
M5V<#5%9#I0IDA\Y5#]WI&^793[\?0,LVA1@.O\W:(0BQ0Z"%_*.X_YH_F^"?
MB6)Q]'N<W=K-P=:$N;.H  Y46<G_\A%D.WQ)TJDBISW6IX N@4UTLCQ]+P=)
MG?F-<2+ ??][C$><F>IPNFG(FUDZXT(I*;>%H#2^H/7G%/QOM\QI.\$G((K.
M&1_ $F?UY827G2;)\<K)8*TKFMJTX9DA^EXX*S/^B><&$]C](T'0DK0:'+ ,
ME1=-8<Y>EZ.FZHR\LRPA8?&4BT(B%?0ZJ;4*;;>W&)7IV'W*]++=<#3,C<!0
M,:MF%KK 6^QFI*RA-?EZ'1CDIM'E) ^(L[1S._N()U*7ZUX;M*3;VW3[C=G6
M@1&L*NOT*00Q:>J7L(4>)\_I5/@7'&$<+5N651I1U.;8V^V+=J1S(Z<SS=[\
M%!(V_7UDJ+)*F>I<[Q*5'C'0,H<1_:RK=U7WJ;)D4PP!'/AU1?K*\-YOAL3T
M1#I"/VO>NU[3]G^K:?O?KDEL5FMI/?WZRY(U@!@&L^I3(@E1[$*8K;2\>WE(
M*J->I<"D B[29RD_8L[>:?+$5D-,2[2K@^8QZ8?98HG>(8=E>=@/SS(+D*Z;
MGV?Y&P>95/7/RV0&\6&0M0Y56+PAVL7[CLX0DCL H5Z2?@B+NUK4K=\9A_A2
MK4$.;WZ 72(8;%H^(SA;>CR!_O[9S[4PT6!_9EK$[.=J=7GF9 O<&'Y8?XZA
M  =>#UTPRS%6.J2"?UU@O&Z8GOK?J<K,M)WT(TWS*)PI_8$1'NW3E7YCQV'5
MA/;OFS:%-I^2>C1M:$.CA)J74!^51,DYV?NNG;NFSG4&FSU192?7$5-NML*6
MW"]>S0K+&LQ2J[*36W_*B>KS]F'[^GUU-MLYS:_-(R?,>IV!3_EY%FN]/G D
MY?KJ;7N^SC*3*!\N8%OQ>?(BGE""K=.(7D11Y.5!KV,".RA[X-\-G4FLA@[2
MW/B;C$H9>K6BI0B98ZP*CC4<:6\5.]@)S0=Y5ER\;(+-PE1^6V_6*"JOM\3
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M#\Y1U '!@I<-2 TK-C+638)MJRSR2I7#:"%8P192W3BQ/9H"6A&"+"_ M^$
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M'KE7%(N='6EM0_M>DM7#;RE2ULY!5#_ES7G21XM1A/WV^%7#]1;#X9*E@G
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M[:DS*W>]'BAVV]5S6B5&AABFPH&W/BJE?MC0FJAC[L:W;P) !N](6@$R(?+
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M!-F6=TMXRB'/,_2?V,R5MO!2/?ZVZ+OLO+6ES3.B1-L\GE$*/_<LRBZBM_F
MW+?9)K7T:6_C;')NZ>OL,"8)]NPP!N ^E8VT0\43,T][- E_^_US-[)@KZ.Y
MM6K45F<;NH>FZTK%7=6#@^1!3!^6KJV/D(.D08Q(%L!$V&E ,'ICF%V;5,B]
M@^(:(XR)/Q[B&"/M)(!<:F5UQFZ5XEH35)0 J@TUCG@4AW\7.(OK%9?^6)#'
M&'<E<DFGVU>N&XJW09-;='TLY<"4.7)Z*[6C&874,+QOS-BUA\8'[ROPK@?7
M7&IA4&U);0.9_-G8H48"*VA)0?7E.W^>'U7=%"O^C606,SP!PZP5OI]U)ZU
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M0H*S)H=B%)T4)WC^Y'/8])D2RE8&'G2PF22A= Q>.V.N@[&BCZR/MJL+D0W
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MMDO.5]0QLL>>0=FF(05 X.#4'J:7EI:.+-^-$9*EON/:!CY);2>K+4C7KUE
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M8QR_XB#T5 _DDADK2YI*-X:@S\:*$E]PM)%+;]2?L/F&7^.H3>[U:^/UG3X
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M:H'8;N<CPQ?!RL:\,1>1$/B;@RWI7JN)C>= XMQ8P588,V/[9_R CJ[#:0K
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M/NO[(LQ;@!-=-X!X(F:E\55)TZP%TJS@:#SP:ZB0:]2-]/0@MQS+V-RC\S2
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M!;5R&:YJ5[4/MAZCL:>8B=.](T^R?$=B==[MPF1B'VGT(CY7]2"S!E5H>5_
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MA<TD6,NY37%,]99$_ETPPS6C)FP1Q6V)PY+B@TLP?D;D7E3G*+HXAI9MXE'
M11A26^+XT'V"Y9LJ$EZ@<B6JXDR<9";F 3V<"G(-!<'6AD[LM$BN+F<-C.*$
MP6329E9#H,%&Q'I4/+"=/9H_/#_T0"'T$\"%9\4>UAQ_]P HQ+B] W6/E4^E
MCW-4EU:*4$H9D<QI/5V[^KJOI5>CZ'IK,V V17*\)&'QIJV$H=\(^KZK.S+4
M<$;("4"ZJ%D(:@DZT@[CLDR=NBACN(4UO\@(ID/]XUSQOZ9_'8[A#%WWP80=
MERYQQD#GU83;M(!B/-6).W=W X>L[3K+<$95A!24PA-N#22X>-<GZ;Y&&]S<
MY&?:$W9-E!.,A*,>'/QJ!IFZ&\^C<B+Z0_4Y.<M(),A$90H(HLE6<UP"6INO
M;O<> $'%\T;PW$/N:BQ@9U^)<?L@,"._48[)E#S$8%:K?>.M"+?B- \@HK/.
M >J;=#(UF?I.K!C4MG1*?&)T[Z?W !AET-S^MP/2WLF_K8]_=H; A%,O)T!@
MRTF\$-#Z\P> A=KMY+<F=C%Y[Q^5"F)_WJ[S/YC@M@C_/LY2':S(T^XHTGZM
M)5E0X@6WHPRJ>M.\M:L+W6V4U(TEQH*PT2NH/@#^^#'B0.;HYC8>=ELXGHS\
M3:7YCZ^94$4HS#/[ ="4-\[^USDR/P[GBP%AXX\=>6H^Z*A Z ^*,-%WV3A6
M?S+XDX0#[;^SC']8_,"[S+ZZNY=Y 'BH:1O8\9E,]AO8?O@4DU(U$"C;0:1@
MPFDU\EAOQC]@KI MB5GJ!T *^&:*AH+7)2R8@>S@)6A(]6X;^G[I;**9EP??
MC@A;5>AWHI'+H.:M0D][V[>;G+1%H$K9!X  \"SS]RSKG_O-%?Z-\4AWV_?I
MC#+8"-?=A=5@Q!]YH@)8RL3T[C.L;G:7DLE^ST*!KO<EN.OWH@7_EB-<G+BS
M R?B]Y(]_I:!.)3G_\KZ_X^LD\FU3)9?DZ)Y$^4X"9U8^/_S&$8OCK/Q>FME
M,7]MX-U9.^[QM!FI[LQFZ93%JG(DPV?J=\L^DOA$P*AP[J>-FOFFO.()1>]*
M=UT=LO>E;;$V<:)$;M^RU\U[,-HD1MS1R[Y>R&VH/@XUS72<@$"<*&:4<86\
MB@O;$E>= R1EQ1E0^KBUO[^'V-R8;V.@X_$@2U!PYQ6YDZPDLZY8,KH+9,_)
MY3(PJD85E@Q[1P$=WOW7*_,F<,._8HKJ/\2R@S]CG(G,VGOE:X)Z,6Q5 S]L
MQ9=^U%ZXP9L6'&^OIDQLM=(2?%YT;5R"R2IG'MOA ^"H L;1P6BN1PTNJV_K
MH80F5JJJS9H_MO:EJT<"0L$QH_O+QV]#UZ.WYVXHTS(5T#!-!H8#3M 2"+K_
M  @C,ZF 01\ 2T9WQH\$2*7Q1E>$?[!X /P+CY&+[4N,S\Q#AQS&126_"=#\
M6#Z[1\[0+\CLD7J2N3>R3_I3.W7>=$1#]T_.4-G4JR485&A-8BI]6N!KO5#-
M1$9YTXC1_=7?V%Z&"!U![N]^_9\Y+1#: %M3#>Z%BOV1Z9^$:41OW3>8N>\$
MX\1>_A Z:KZ_!'5&_&D,]J9FTM9]JM\(8OZ2P,-3(. W@JI'@I#?">(/<$%G
M(X\$U;_*:";]>8FU_X<4=^<@Z$%S9\PCR1]&TXWX]!N!9G#//XC)^*>8()V_
MI/@'173_Y-'[IWW^6=6_:_+7JL)^$?QOVN*O"1YMX?N?^\3=?^P3?ZN\L?_(
M;0JI]CILJ:H,]17\P[Y'KMT2XO+B3:!]7K_DVLZSL,RH]Y)Y:2"/0)IV2YA8
MKR2KC5]E@?_8*MK_PYUYJ@ZNP]<*6WVKG\6P5;#^LPEJG%EU4#?K&*P6>76O
MLO0!$&F0>V^+X^<1544R(X"MH)6S(B;J9!OG:+<@B9_%4AF*EP_07SLMMG<>
M49.)4*D==G"S8!DQX+):9\VR".6CEQX*)4ZB:\FX?]*E("9!F<VT:+QFTOVN
M-RHJ?LV+5;CGBMQM;#Q.6#J64C^_4P*"#:C\1WG4&/#"VF^E)C*/+TMG;0MY
M:LB,R%]'$U0'.46^=49)X56311B9G^OB9R:EP^9]N]TK+I)NBO!-09G]7G-)
MH7[<(ET*9Y_FA;06  5;K7?YO V])@WE7$'EC0.1AZ#,^Z12L]J.!A%QVW7<
M.VY%$#( (B:!6D)?YDSYM;#<^Y6B.KQ7FPD_:2;_K;?B1S@Q'"+I/1OB+\\)
MB%E8?>J5\%MX?KW_0AK O4:.]1O,47XU =Z<8J[TDT+LJ,0<W!>>5>F#\TW:
M6A=HI+]_5$B%9AQ\<,&@+=#GD;%#Z3R.SIG#A05:%CU+0[%7=CQMF-RAC)2"
M+^T)?I<=/WU Z?E^_-O?\).&:UQUHL-]6/#,@O;\HA5+U].A6"6BA)!RKZ<K
M\RG.3W,G.&0\7@\=X#V1F-_#5GA?GZ*!OZ(@D2]8 Y]/;B?64B^FIW$=9#3Q
M4K9AS*IR+O]CSY,%%_T/2(NS(_6AX<\1?'VC4DSIW#^F.+14C#KP0=T,Z3@&
MBHP5U(G?PB6Q184[,MAUT00S^W1>X SI7(])EGO@;<8Y.P3,6/#3([_Y@->#
M@%I*PGM1R#L5Q%C),, ZND'CXD#DC?":"LF$$FT@^FU:+,%67B8,'RV8]I^W
M#OU3^JO7&/KE_WF[^[^MG_27%INMHAUFYSJCJ->/RH#W/QH0<LQWLW*])4VW
M!2'OF*6<= 5:\C,M0P\,)Q?Y@L!WC662DJH+KTMTKW'HS)6=)$))7/OD/!PQ
M4*^+;R\OMZ LE5UNU2EF"1 6AT\N74*LD8!M";USWBWCA2GBU8:ZK<Y;P>25
M!2/5\F'S\R7LG6W"S9^[B!JVZD]:XY^^YUGQWHK0O$#X,E)(F@6O,CQ4<K'.
M^Z]]F%G:O\)W,9+_7;"NR#4O)*TI#@W8$2:F-+KG/(+55VD.*"F%[#7?'D[H
M.;@O.$%G7"L6<YJ=R-Y+);(I'&8Z&-CN__X)#P5C@"#'\M<'+,/0<;>\!;&?
M[0F9'*2[7 K69=3& Q)U8>-:C'^G_O^<*%8K/P^B4!<20.>XN"FCT7#-0W.O
M[[+2=3TE86&',_]$'4CO&KY\2^:ZKM*;6&;E0%6TZ$X<<[4VA"[4M5A?^KW9
M\,8 LFZS^G;^MLNN*".]JB[X%(Z=*9;_A6O^N> %AYM43G$$4T[R]U_A\G\P
M5 :M>5!H3MYQ4:5X%Y#P7G>'4I\1\N?Q%V_<Q!^?=[E.CWVJK1X](&^H@<J.
M6V?("K)L<@-PNVHWP0I:A3(W/QK-C?::3]^8@BYVWL"\S.)&V66--(X%DS\[
M%<[D_+#3PY*,NT2MP ]&S8O*_O2<^&5%;0M)O0N%E)[QNIB]M4JLOPA2WNMH
M6CV(WRM_]G#:<?K7M,AIU@#XM*RXDK]M=GH#&3KGWU(8+0+"<!'G9MO/YH#?
M($X?.S$O.9 ^"SE1^(:GH9[G*XF/547@:U%GF^#,*VQS=GQ)<"*GRKJI3N%"
M[\KKZ=(\(NP<F%SG*$)E]F>&"R7CUK,:NC_DWH)@YQN9$7?J5_L9&+>+M7]B
M$4EB]G@J3WJ>9'7OPG$;.Y"3.EEX%_%VQ,*B\IZHI:Y!816V^2F>"^1J$MGV
MBK[?Y?-I,=Q.I5ZVF/Y[UV;?"TEPD?E@IJV-4.KFXF*F^'I"$GUX/6OSVQY\
M"@"9@C9GQ^OJ($;P))]2W0*"- (-@L%309WGQ*X3QG<\Z3]/^5TYD\(H0QC*
M9],8=VWQ3WH0HC%T3)LF[HYNC&5F%U7O!DE)L)XW\*RB:<Y.<DX<5,D4!M+0
MHB8$VZZ^77B77-,E__UV2G[EN7\^#JPAJ](UMM7X.?Y]+UK0-3$;J*509[-C
M\J<S>V=U>9PJH];<D7:_;;\R3A^IRY".G*FL8"\)EUQU&41+U JKW>L6SEN:
MOG=1!H9R]V+]\&CS ;",35-[\GJ('#)JG_ *]1U_8E)@?V.0@J6PX(R0YG"E
M&Z12M<D?WQ+=20*A4YGXQ)\^ZV2?O@,;*//LU$SB!*WDYS2-_^'P#M,FTVB'
M?N<FD1W%<Q+\;I7OJ*EUW$-:=IE.^F_NE,QR6G-V7(MCGT:]5!?)T\8.\J9D
M#T:P)/%ZQN;M)7%5.)Q>40VIPBV=:\.I07@6]20'0\&[BX=#$82Q#5'].*-E
M@HLU*P++><X4E1EQ/T$!?YQMM;?^Z$1.L*8U_S$+SPF/-!/>C8Y8V'?%LYYP
M/E\[A&B&DOB7;'";K*^LX4B44S(Y4G,D/NL5-:@RIWX)Z0@BM+#H3=W.=O2=
M?LHG?.#%,)8[:C\'YF&'A@F. BF1<6<E53(_-@(4W[+,9A*BAU>S3H=1MVO*
M5/98,HWUN0.>JN%S(]?<8DB;28!V=E-W/C7%P:K-+O@?  J)1,U8IJJGTD2R
M-5,'X"-K3_$GTYX'0^F1]%%+Z7O!S277H+87IHE45<6IN490;83+W@)5@>$>
M[XUSX3GE9;B://X4LXH(L=&,BKA! =8>)L./Y3]+:24  'CFM\( =#?D,'>!
M#.;42\21\Q.#YGXH=[7\&]!5]1K!53H#<.,:>.==?S]Y]VB;E2"T3'#E.AKG
M5OO5V\6-ZOS0/FJ<B"N-2SJ2L_ +W7;5N,F8O5OQQ(RE#_"R)N35-UC/$]?A
M2]_,?_&6ZN0CO2F1YG6(T1PP-3\8:-@(+?T>K^]7^Z4-G^<HI8J8D#/>0N\2
MGWV.&\P5 .6WIN^J>2$R^Y0M$MU#C+9S\A2R'K]C;05\  "78'!#V[,>.1%K
M ^)]LI#PT9'S;1KC5Q^#-EVBZ2PR0R,!-$WTG84/ (I#[P> CE,S5+P.TPI0
M:Q:%^F4E4MQ@E@L'(;)V+S3:YM"$=/8Y,T6-LYY))FK^JX\:HGKDI&G$J/>(
M:-K J9/F&[^+YHNR34&RT:+S>[R6V=@B!IR+CMX.@98'@ 8]NR)6Z()T6*&7
M,S[^CK9NJ&,/IY^9HTWVO&[@$1RW!"GPF\2%JG6:;^NR$_AB;#^:R%EQ<.%+
M]:=A\B#A0"]A>I;3)"SN"PZJ@4J\N%&@M@CQL21G@V*:P>=MD>7@DK/F=;2%
MI;Y?9C^UT!F3&:U*Q6[+*7H[]RX1V(?-_1S>(Y?Q23BV'JKP!4VC\?7$2MU4
M52#N1^F9G;)NS-*//WZZV7.3PS@6YXQY!9*P6LVRIEM1RVX4)7#JZ.OL3B.1
M*#8M!8; E*1D(Q9?6( [N)CB[\*BYEZ'/IWGAJ]P;UM*E#)M"!AH3FZ6/^4^
M<),=^Z%4,PJV]Z"=G3;YJ0H\Q9H<T4Y*H/!3V@1]BW:B$69EE54XOFC,R;99
MYIOK_E179T%OM]7O/5_NXB:W-JC&%/$A\9ROD>+#./.GVL8Q,+.1UR:!H;=V
M)L]0KV3WNE&PU25U-"XBH7;<G MJ:41%SFM;6PWGY9A!"?9:>UC#HQ%D'P"Z
M3C?$3R-0N6;EO2L/I+DW1G,KHU((0!,#O'XLA?!M-@U^ E,"!03F!\4..*/*
M>"/I)_1B".2P XF9[SU8#X!2XE*&L6B6<(91JE'VF?.57-G<6:DO:7#FQ_F!
M<-TWDEW8V^=SSSY!?!@8]/UG("*$[>E?N"E^5=/+L?&Q:LC9O=(](]JC&#0P
M0Z2O!^EC%ZE8.Y=119S6.N*??5BJ7B\@LR$JM"!$6PN8DH@/CJF=')=.6BS7
M5D3(O]0$SM,:+\JN2\[)H[:8$W3!->X5AB\^RXY37PFC_.X?.R',+-S"Z'8,
MV"K-XT!CD)M(5W=@0 %.1T'HM7Z6(PJPPL,/X,[UW17AS9^!,#0TEJY]V\;F
M@6V.421B%LPT(A3L"A]2I%!MY8;EQE*S'77>>C":.)[L#O"_E;(/C(^L$35Y
MPT?)+-_GV^E"0([I8V:N,??\523P)RD"W4MS@C Y5NQ+)'CO;;HS49QV+!%^
M$T9%.HFP<=;RE&?D%]C ]X\AQKHI]\UE(U#LA#0Y1[: N= JK\%;U3B*^1,*
MZ<%-A&FYOM[A$Y1P>6E=A(6Y&6=./K?\-7^+M_QJBWIKO0Z495]<X:_*77T3
MY\8J96DD64G89,K+63_Q5$,DK_1R'+U3<J*/WHV^.:)H:!@MLK3,[.S)@4@X
MM':W84;Y#CSA'V'/=^!F)U)E>M'LH6JFW>)+**A)X3M64)I?7 6W*A/&IMV"
M@IOYV3#HOH>5]//C<)8U_P%@VRARD!;GG!O];-'8;D.R&X5:'!U#(6H*!WG'
MU;6]C"FL-,SP[.<SM2<?MCQ9KBH&73>_%HT=6+4^HAXN^RDWF-"QC/T_OJSV
MWX7M13L@MW*YF7N)JKEZA3(61NOL#P!#R!>#^=Z^#<RK8^&%\-BI2:0PA[E4
MU&L^Q4G&@[C5U=FW>F%G$"J?C;(["AX!;J0HJ7#>>E*WU06S5D_.JF 2W39!
M:M9VB5@[W+@=>K>G7:+;MD*$%^< \30C?/P!:QOC):SU,%)YO!W:?CA]639K
MI>WGEA*-3IG<!'N+A09?K-Q8S!)'+,$''$O8(0FK7YMRB=*B?A[JELVAAEX0
M('@^K=/<L#_@G5*9:O@P5>:2@R;V.F*3H<JSQW)Z.7R_ZR27% AM.1I>@HV/
M/0"V8%.P!\";ZY'[_-P'P-!]R3U,]Z0@]3ATA^QLYP$017;WZXDX(\D'0*K\
M7> #8$T%VLSJ\0!XO729D_H $+ILOKH!=98UR'N8V&29^^\2D/4K55$B7)T7
M+OT##S.*=EX.O[!OK$"1LD2'=TYEW>2WJ::CJ15;JK4OMS:<>'4A,X^ESY-=
M'8/"R*PJ'DNK$3I:?@ 09CX G@U&/0 $4V\P'P"=$=?B]A$WYX]0.0+&D9Q_
M90"%B1W]0U[E']ICJ[50MGE:*B<D!)Q;??N=#_\B/_5Q<LB"2T@=]Y,'0(&B
MG#Q_M-1E3BPS.*@NF=$NO;6QGMP'M5\$1\_AH^0:I+XNF HYB T1ONJ3\V/W
M!/MY[+"_?5V3X!X(6K1DNT9-_=DD!][048A0NTV5EZ429_5H%HT<:7!RL3L1
MES*H^;[M%-T85E<!V^8]:(,;HUR#04M$)]T5#-)--2UBU]7(3M[&] ;K?]13
M[<;_(B>A*ZI#YY1^/3C5.GDY:LQY>:F*1;1B'_TF"?TYY=U6-?=<ZC=7-;=5
M+E*.:R!IOJG$;+I8_0<'C9<!9+=X.]JQ.V,-I$G-*!70A"YQ!S+6W8F)QYKM
MWC,\4?FFP^C;%H+6#REOV\(+4^L+<X&V)X4G>^\R8*A<%Z[<4ZC]D$MA$EGW
MOI2AM'8/]#@5N0L8XX@ZGLB=JF)2ZYC*KW;SJ1Y!7:?/(RJ[]KL+LX4(4HQS
M-+)IQRN=Z/.:,<C@7:K-X(2&A"(.(:76ITAVFG$/1_#Y;L?>ZV88U(U:;T:H
MY69<&%\DJW4F4D>EB8#E;?4K:[JB-I@WOT4EP5V3UG0H'F^U:^.US_JJ:W:Y
M($XK_F0(M)8DD5..%,)B&)(Q/CJN;V/(WZW8F7K.UUATW*E/*UHMI3"(1,(S
M2'_U]4XB3RC\@/W:87WJ@ KRF:FUXG3Q!1S%)@5WM\ZZW9[R\;!"<DQ=\\II
M&9EZC+7E;/;U(_9.%B\[T6MS%2RD3GU57Q--/4,QUTF Z=V*$$?056VFIW"2
M$IM[K<'_GA#X VFNLB6M;-YF)'#;=>K;MNMES,H<!IZ):[?QT2%EK +AD\X/
M/H!N?.*S020.QF%9J^/GN/H&2]:4PDL+K-8@TLJ- )^-D2,<SZM]#AV+1M71
ML:IJO@&&U=0 !P]#-$YX)^)X?$P9=A&%[P\ =+NDK?#OW7MJ#?)K S0_XU\
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M?;$Z\FXKV\[31X;9QH<F"F(XVTG_;\\*_/VEU&+F^@/FH<%1"V(I[PWTB:%
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M4NCV8F?9!XZ$3S5L@2#=[+]\VB.?=ONW-T"0.E)/T1]5*8F%R0(G?%>';I"
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M-4O%2KOE-=V]"^*5W&?\TA1]R\=@WQ!IX>87]#Z4>[F:U16C6[DVDR.BRF/
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MG-66)1Y9DLIL:@=Y47J2Y6)Z0VA^R)=01'MKPT\//(",4(L@S<_JJX^[Y[<
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MG/U(8FN<A-HL#U,VHJ=+OE!KH8:IWE5UKF-'FK]@"T(J2 &$D/@XRTR8C;
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M7P-O>\'../SF*ND<&#V6$_>ZXB,7E4[6*3&B7D]8[H?)-(X/%,.C:VH,NW=
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MJO#\TO)2/C_['F69Y_E>%YFA4.4X6^WB'WZ8!J>[JP#C6>XMP"3F%K"!6=K
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M(^OH'WK8&*!#WOGT?16R9CJA\XMM,Z$BRY@U?G^T>&$ET>VMJP= 1\]A_ #
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M@]TW>RL2L9X1;W9U9A384^39(SHZ#ZV)#ZV<$YIC :SA7@$GX*GBJH>>7_[
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M=.Z[GB*\_)**BO+W&- P]X2BD?@)@<:"BTQ13/,, 3$?0)@HC6LA)HYWXH:
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MV@E<,7\P2U!SK;UK._>;4'%W^*;7Q[WT\^6=2:>'LIU#.9F#U/?0>-RJ?F]
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M.E-W2FPEMCR5!6I;@G+#OZ.XY5(PSKX0HY:M)<>04/F-AEQ+->BJ#YHZ]_^
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M>RUGV[H]&8J=,HH='1\!6K\XOJB4TSS[E %>^W9Y.7FTT6([5\/3V6%& ST
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MM0#XGX@-K-MI:RL!5+KSCCR8&W8B+8<#PK+B3*3.C!/RHC54JAM;)X]VORB
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MXI;"Z.$)<F?ZMI557$%XQA66U14_9Z RWY@ZI<Q]5*KW:?P2H%/GQ0![D\$
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MH_('J,VYQGK@$V$\@?\4)0/*U"-H\5)8>_=5*OK( "?G>.4LFNT3UZYUKC!
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M 5\FKD\HKVYNIF",[H3\XH^&?F"HEFBY *E<,:E-\:3;3)C8&GFS),YD_,G
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M7;N>_3Q[5U4W]4.6)G?11WIH]L(O*W&CE8'&Y;5FZCY?[#_EVS!=:)O,AW[
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M5:NJ_K^:W: GT O 724Y13D ZP8 8&%^ /0T( /@8F/C8-_&Q<'!P</#O4-
M1DB CT] 14)*3$9'S4!/1TU+R\C,P\KXD(N)EI9-B)WK\1-^?GX&5A$)83YQ
MGJ?\?+^%8.'AX1'@$]PG)+S/]X#V =__]H7^ =S#O<%\*_,FUD/@QCVLF_>P
MT.T  T;/VUA_N8"_75@W;MZZC8V#BW<''S.A^BYP ^OFS1NW;MZ^?>L6YFX
MYCYPZ]YMD@=/I+%)-<QP'KJ0\;V/R<1E>E[>0JXYA&!^^L8U$.\.!>5]*FJ6
M1ZQL[!S\ H)"PB*B,B]DY>05%)6T7FGKZ.KI&YA;6%I9V]C:N;E[>'IY^_@&
M?0@."?WX*2PV[DM\0N+7I.2L[)S<O/R"PJ**RJKJ&FAM77UK6WM'9U?WSY[A
MD=&Q<?C$Y-3BTO+*ZMKZQN;6P>'1\<GIV?G%Y6^[L(";6/_M^C^UZQ[&KANW
M;MV\A?/;+JP;7K\GW+MU^\$3;!)I#1PS%]*'?.]QR9['9):WX#$]U420OW$=
MND/!S+_(<O#;M+]8]N\S+/ _9-E_-^Q_V#4%$-S$PAS>S7N %'!VR9;U[L[_
M]BACZ$R7@"$&/KJGD;Y$;-M3)G]Q%;>!OB$1=)7GD%YF+=B4/?GND]9!_F/#
ME"1WE.?$\:DNXKHSNF3S--+G5-&:A*O\?6KQ.[&KM_[CZ\'^AC@?&REMEY0+
MED>^I5'-6J:21V!S]G[& 4G+9YS D5_IR,G55,:.^]Y0I"B/.O)F:56GCWO$
M2Q^S*!:8'5!\<BD43,&NS.]]FQ-2K9QC*TTG_<SM4N,U?T')*=S=8TPN8:KT
MXZB:LHQS.@@RTP]6^I'8=:J3+CHJ+E; W11?G99L+)CIXEX0Z@*PWP(DSXSG
M@^G>;6\40:G3@O,RKC/= AP)$P;G;6*U]1"^=.W+V.&$2EW:U90&'KO5JW7,
M>(ZK^G=C1BT5R;#LPMB^W?A_9!P-4/BKISR'[U4%L+9Y&8R.4[1N72]_E:O9
MD /7N[KT"V_/IRH7(U^-[#2R9ML;>*:Y%<S8JS*5EVO>FSP*O'\402^,D^JY
M%G]<ZU$^KV'D%2CN[:_O4;@)KW]Q*5>:5U_:D5/A\Y4P]>X$U>;FC+E(6=29
MX7#5Y#C^KFK/N%5DKMYZ[:LWX6/O6+]U/4H9Q!_5T3_@":P9A[,:CL@VC3A
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MK5_$#*WF?K!=GN9407L1*F^SA^;7+_(O]=91-P(24?<<W7:D#C:O*X5B(M!
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M/4OE 9FKP4_N^<E=S:?Y/3G A\P]108A<=VG_XX:7;I/G!)IOB11!LGSUM)
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M@\5^\U)P9+5@U4 X-7V^2V[!R$F*O:-*@IC]-(8&[;)OTB-3:[R7F>8R<*)
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MM(#HJ* )15/HJXKZ=#\WALNKC1&IQE1*2\Z8GJ 'VP/=5:Y=Q2A8,>J&+9U
MWVY3]G3.H8/])_^O(<->DGA==,):\.$B-<AFPD^F7M=G4<L[);<<U%*@SL^
MG\SN79K.(DL%6R8,KHY[[IMT>Z\;##-X#@]U(Q%42H$=-<[K>U%M83T-W\>X
M*/ ,=QQ]/$JY6^7H&K\3O'#@CL!P)IKR#1<D?S89&H"HG3-5;%Z#T "PM2-
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MI M&B3; =@M/2F'W-N/L+CDGIZOLF53P@QXPFK'H2F#MY&4GW$L%%7G"!E#
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MG2!*[Z'PM/;_D7'102NF ]8%^H"8D!/-Y/\V*O 6O@8JWT(#;0FP[O?S4)D
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MFFDKYO7(**A&F.-75>?P,/\Y#'TM-*NX_SD53P]$A'P934 ":NBO702G%NK
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MX*6SK/<] V^[:^/S7,OAF_IHF-T<R*&O6#KC+G"D,>?D*@*%%8CQ/G?Q^J.
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M+N?AQ#K;R85Z'[#A=^Y>=][)T;A2G]4^?NQWKLUW6N&\%EQFI\P.'C_Q,BY
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M'?)]X4:XQ!N:&!$$*Z2[\$]8\%1$#PC.I4*DP,^ >R'4QJ>V 3X!DJ.7=&V
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M2SB/I.>FS@RH7CC=%Z1;9+5H?7EKQ]3%O07EZ!Y3EKVL6[TU'TC7-S"_UM3
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M:TRB$_L1]E;)ZL16ATX3F;;T]#"DM)/[0!BEX>G<W_9$9[,,U6ZGVR@H=ZN
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M((KW*:"+F=W=58Z2VDQ(1X-^@-8,%YS?%2O R&AHG0(<G3X4[>8+0-XZ@)
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M4GO_='[SO=A22]05]ZW],YV@G60W0]T5Q22%**-.:T%I%^P1H*FB'F_R,M1
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MVH[AFLOAAL#:'#BSWN#[OIUX7OQBAO;V'R5.AN;7&B>QMQ'&:C"W<[8EV/O
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M9=M#_;DIB4>L1'#_&X-?6T.S*A @?<NBF4'+8885[M-469&MKM]WBSOWQ?<
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M:PYP^/FQ+& C$IU #'[W6-A.^!Z)+3L""]Y.ML<N2<V(LU,Q@C,^(:^-_:5
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M+ZFWBDUXJL_#FM9AX?ZQKWBD:/_HM_X5^OU+0Q=!K94,W>X06R9 /8R60E6
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M*Y;K9H;V4:?^(B#O#G1MEWH;?1=9E<AJ:U&K.0HMNO<#]<X^ 1*\?%G\"R_
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M6&-1:5ED8X3>0E$F6T"\3-ONJO<^LT0'H-ZW_\(R1K"S5-1XC/K,=#%N/''
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M;.G#'R;!^"Q'T)/'K[@LY O;[DT/E@_Z[ TFELP(UY]KPX'LH-J'"_#3M5L
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MKC4H'*)T_D_2[1"]G?Y?4$L! A0#%     @ +SQJ5 )20L"EZ@, C)(N !$
M             ( !     &=R='@M,C R,3$R,S$N:'1M4$L! A0#%     @
M+SQJ5,F'+$Q-&P  83(! !$              ( !U.H# &=R='@M,C R,3$R
M,S$N>'-D4$L! A0#%     @ +SQJ5*UMG@J"$   N^<  !4
M ( !4 8$ &=R='@M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( "\\:E3M
M'(($-SX  .E,!  5              "  047! !G<G1X+3(P,C$Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    "  O/&I4?7Y.DD[<  !/Q D %0
M@ %O500 9W)T>"TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ +SQJ5&$V
M[<=]8   D0T' !4              ( !\#$% &=R='@M,C R,3$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( "\\:E1UU*^M"W(  !N( P /              "
M :"2!0!G<G1X+65X,3!?-BYH=&U02P$"% ,4    "  O/&I4D9:\ 3X"  #I
M"0  #P              @ '8! 8 9W)T>"UE>#(S7S$N:'1M4$L! A0#%
M  @ +SQJ5.>*$?B*!P  >C<   \              ( !0P<& &=R='@M97@S
M,5\Q+FAT;5!+ 0(4 Q0    ( "\\:E3&_U,Z=@<  %\W   /
M  "  ?H.!@!G<G1X+65X,S%?,BYH=&U02P$"% ,4    "  O/&I4W 0:$Z0$
M   9(@  #P              @ &=%@8 9W)T>"UE>#,R7S$N:'1M4$L! A0#
M%     @ +SQJ5!"'PR6*!   ^R$   \              ( !;AL& &=R='@M
M97@S,E\R+FAT;5!+ 0(4 Q0    ( "\\:E1P4KO2%V   ,!T   2
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M;6<Q.#<S,S4Q.31?,3(N:G!G4$L! A0#%     @ +SQJ5#9TWM7EG@  (:\
M !,              ( !=<L( &EM9S$X-S,S-3$Y-%\Q,RYJ<&=02P$"% ,4
M    "  O/&I4J?WMOS!E  !R:P  $P              @ &+:@D :6UG,3@W
M,S,U,3DT7S$T+FIP9U!+ 0(4 Q0    ( "\\:E2QZ -!PV@  &=M   3
M          "  >S/"0!I;6<Q.#<S,S4Q.31?,34N:G!G4$L! A0#%     @
M+SQJ5)-)&CD?CP  [ZP  !,              ( !X#@* &EM9S$X-S,S-3$Y
M-%\Q-BYJ<&=02P$"% ,4    "  O/&I4'I5 N<E<  "RA0  $@
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M-S,S-3$Y-%\V+FIP9U!+ 0(4 Q0    ( "\\:E0%S*5'2-,  &3W   2
M          "  8W*# !I;6<Q.#<S,S4Q.31?-RYJ<&=02P$"% ,4    "  O
M/&I4;8K]CN9\  !TFP  $@              @ $%G@T :6UG,3@W,S,U,3DT
M7S@N:G!G4$L! A0#%     @ +SQJ5'J)E#>) 0$ M'@! !(
M ( !&QL. &EM9S$X-S,S-3$Y-%\Y+FIP9U!+!08     '0 = #\'  #4' \
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
